[{"article": "\"Adoption of the clinical chemistry score algorithm would standardize reporting of high-sensitivity cardiac troponin test results, how the tests are interpreted in the normal range, and represent an option less susceptible to both analytical and preanalytical errors.\nThe authors suggest the score can be useful for standardizing diagnoses and improving safety.\nIn this international study, researchers from Canada, Australia, New Zealand and Germany combined common laboratory blood tests available at many hospitals around the world to create a single laboratory score, or clinical chemistry score, to diagnose heart attack.\nThe score, published in CMAJ (Canadian Medical Association Journal), can also identify patients at risk of subsequent heart issues after discharge.\nThe researchers validated the clinical chemistry score as a predictor of heart attack or death within 30 days using data on 4245 patients from emergency department studies in the four countries.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the score is based on commonly available tests.", "answer": 1}, {"article": "Dr. Sonia Friedman is an associate professor of medicine at Harvard Medical School.\nWhether Xeljanz should be used as a first treatment is still not clear, said Dr. Arun Swaminath, director of the inflammatory bowel disease program at Lenox Hill Hospital in New York City.\n\"Treatment with oral tofacitinib is potentially a new treatment option for patients with moderate to severe ulcerative colitis, pending review by the [U.S. Food and Drug Administration],\" Sandborn said.\nIn the first trial, nearly 19 percent of the patients taking Xeljanz experienced a remission of their condition in eight weeks.\nXeljanz targets certain proteins involved in the body's inflammatory and immune responses that other so-called biologic drugs don't, the researchers said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear both that Xeljanz is already on the market for treating arthritis and that it has not yet been approved by the FDA for use in treating ulcerative colitis.\u00a0It would have been helpful to note if some doctors currently prescribe Xeljanz as an off-label treatment for ulcerative colitis.", "answer": 1}, {"article": "This is in line with some of our recent studies which indicate that the GI tract microbiome in Alzheimer's is significantly altered in composition when compared to age-matched controls, and that both the GI tract and blood-brain barriersbecome significantly more leaky with aging, thus allowing GI tract microbial exudates (e.g.\nEven though this increase is moderate, and all patients remained severely cognitively impaired, these results are important because they are the first to show that probiotics can improve human cognition.\nFuture research, on more patients and over longer time-scales, is necessary to test if the beneficial effects of probiotics become stronger after longer treatment.\nBut prior to the present study there was very limited evidence of any cognitive benefits in humans.\n\"In a previous study, we showed that probiotic treatment improves the impaired spatial learning and memory in diabetic rats, but this is the first time that probiotic supplementation has been shown to benefit cognition in cognitively impaired humans,\" says Professor Mahmoud Salami from Kashan University, the senior author of the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release provided a thorough description of the probiotic milk intervention, but did not mention the fact that it was manufactured (in Iran) specifically for this study and is not available for purchase. A brief discussion of what it would take to get such a product on the market \u2014 in addition to its cost \u2014 would be beneficial.", "answer": 0}, {"article": "After one year, both groups experienced minimal body weight, triglyceride, and HDL cholesterol changes, but the walnut-eaters had significant reductions in LDL cholesterol (\"bad\" cholesterol) compared to the nut-free control group.\nWalnuts have long been touted as a healthy, whole food, but new research just upped the homely nut's reputation another notch.\nThey're rich in fiber, folic acid, and potassium.\nWalnut oil can be a good alternative too, in dressings and for light basting, Politi said.\nWalnuts are especially heart healthy because they have more polyunsaturated fat than almonds, cashews, peanuts, pecans, pistachios, and macadamia nuts per serving.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Walnuts are widely available everywhere, so this is not applicable.", "answer": 2}, {"article": "\"It's only been relatively recently that energy surplus has become a problem,\" Wu said.\nAnd because it is already used widely in the food industry, it might be easier to convince patients to stick to a cinnamon-based treatment than to a traditional drug regimen.\nNow, before anyone goes dumping tons of extra cinnamon in their egg nog in hopes of keeping holiday-season pounds at bay, Wu cautioned that further study is needed to determine how best to harness cinnamaldehyde's metabolic benefits without causing adverse side effects.\nResearchers in the lab of Jun Wu, research assistant professor at the LSI, wanted to better understand cinnamaldehyde's action and determine whether it might be protective in humans, too.\nANN ARBOR--New research from the University of Michigan Life Sciences Institute has determined how a common holiday spice--cinnamon--might be enlisted in the fight against obesity.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release strongly suggests that cinnamon is not yet ready as a weight loss aid without saying the actual words. The news release warns that researchers have not yet determined \u201chow best to harness cinnamaldehyde\u2019s metabolic benefits without causing adverse side effects.\u201d It also cautions against using cinnamon as an obesity protectant or treatment at this time.", "answer": 1}, {"article": "\"We know that art therapy can work, music therapy can work.\nThe researchers found that tablet use was safe for every patient, regardless of the severity of their dementia, and that with proper supervision and training, the engagement rate with the devices was nearly 100 percent.\nResearchers loaded a menu of 70 apps onto the tablets for the study.\nThe apps were freely available on iTunes and varied greatly in their cognitive complexity--from an app that displayed puppy photos to one that featured Sudoku puzzles.\nThe tablet, however, gives you the option of switching from one app to another easily, modifying the therapy seamlessly to suit the individual.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that computer tablets are widely available, and at ever-diminishing costs. The release explained that all of the 70 apps used were available for free on iTunes.", "answer": 1}, {"article": "Most are still of the opinion that sunscreens with an SPF of up to 50, and containing avobenzone and oxybenzone, efficiently protect the skin from both UVA and UVB ultraviolet rays.\nOur two cents' worth:There's no reason not to take a flyer on Fernblock \u2014 actress Reese Witherspoon gives it a hearty endorsement - but keep slathering up, too.\nIf you're squeamish about vitamin A, there are a number of alternatives.\nAs an alternative, there's a relatively new product called Fernblock, which claims to protect the skin internally by systemically inhibiting the absorption of ultraviolet rays.\nCreams must also be applied.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0It seems clear that the product is available and being actively promoted.", "answer": 1}, {"article": "George Bray, an obesity researcher at Pennington Biomedical Research Center in Baton Rouge who has also studied this topic and who wrote the accompanying editorial in JAMA, says that other studies \"show that you can do well on any diet as long as you stick to it.\nA new study is raising questions about the age-old belief that a calorie is a calorie.\nThe diets had the same number of calories, but the fat, protein and carbohydrate content varied.\nParticipants were fed food that was prepared for them by diet experts.\nOn a low-glycemic index diet, you would avoid highly processed carbs such as white bread, white rice, many snack foods, prepared breakfast cereals, sugary desserts and sugary beverages, she says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the 3 diets is not question.", "answer": 2}, {"article": "Rick lost 20 pounds, and Nina said she feels 20 again.\nLike many on the various detox plans, she couldn't stomach the all-liquid diet and craved solid food.\nBecause of that promised quick fix, the detox diet business is booming.\n\"I was drinking over 20 pounds of vegetables a day,\" she said.\n\"Since it's predominately water weight, you'll regain the weight very quickly.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The \u2018treatments\u2019 mentioned ranged from concoctions you could prepare yourself with ingredients in your kitchen to products you could purchase on-line or at a local drug store.", "answer": 1}, {"article": "\u201cWe want to alleviate the suffering and get them back to their life,\u201d he said.\nIt\u2019s also a drug of abuse, at much higher doses than those used in Zarate\u2019s research; while patients in the current study received about 50 milligrams during a 40-minute period, a dose too low to induce anesthesia, recreational users of ketamine, known as \u201cSpecial K,\u201d may take hundreds of milligrams per week.\nKetamine could improve treatment of bipolar illness and depression in a variety of ways, Zarate said; for example, as a means to jump-start standard drug treatment, or as an anesthetic before ECT.\nBut, according to Zarate, more research is needed on how to use the drug in the safest and most effective way.\nRight now, medications available for treating either major depression or bipolar illness can take weeks, or even months, to work, notes Dr. Carlos A. Zarate Jr. of the National Institutes of Health in Bethesda, Maryland, one of the researchers on the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that ketamine is not currently widely prescribed for depression but that it is available for other purposes, thereby lending itself to off label use.\u00a0", "answer": 1}, {"article": "Antidepressants frequently prescribed to help treat bipolar depression do little to help patients recover, according to a new study that adds fuel to a long-running debate over how to best treat an affliction that affects an estimated eight million Americans.\n\nBipolar disorder, also known as manic depression, is a serious mental illness that involves dramatic swings in mood, including frequent and lengthy periods of depression. Along with mood-stabilizing drugs like lithium, many physicians also treat the disorder with common...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It's clear from the story that the drugs in question are commonly prescribed and available.\u00a0\u00a0 \n\u00a0", "answer": 1}, {"article": "Bipolar disorder effects around 1 percent of the population worldwide and sufferers can experience moods that swing from one extreme to another, and have periods of depression and mania lasting several weeks or longer.\nScientists say the drug, ebselen, may be a swift answer to long-sought after better medications for patients with the manic depressive disorder, since it is already known to be safe.\n\u201cEbselen is an experimental drug that has been tested in people for other conditions, and does not have problematic side effects like lithium does,\u201d said Grant Churchill of the department of pharmacology at Britain\u2019s Oxford University.\nIf the drug could be \u201crepurposed\u201d and licensed for the treatment of bipolar disorder, it could reduce the unpleasant side effects of weight gain, thirst and potential kidney damage that patients risk when taking lithium.\n\u201cNow we urgently need to see if it works like lithium in people.\u201d\n\nSome 60 years after it was first discovered, lithium - a mood stabiliser that can protect against both depression and mania, and reduce the risk of suicide - remains the most effective long-term treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the drug is not available by noting, \u201cEbselen is an antioxidant originally developed up to late stage, or phase III, clinical trials by the Japanese firm Daiichi Sankyo for the treatment of stroke, but which never reached market and is now out of patent.\u201d", "answer": 1}, {"article": "\"I would say that hearing better kind of completes your personality, and I think Ethan became a complete personality once his hearing came online.\u201d\n\nAfter witnessing Priddy's miraculous results, Naberhaus was inspired to shrug off his image as the hard-of-hearing teacher and get a cochlear implant.\nEventually, he decided to get another cochlear implant in his left ear.\nBut Priddy adapted quickly to his second implant and can now talk on the telephone all he wants.\nIn the meantime, he hopes to inspire others like him to get cochlear implants.\nWhen Priddy's implant was turned on six weeks later, he couldn't decipher the sounds he was hearing, but he was definitely hearing them.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story fails to explain whether cochlear implants are an FDA-approved device or widely available, or if trained personnel are widely available who can identify appropriate patients for the devices and surgically implant them.", "answer": 0}, {"article": "The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has more on rheumatoid arthritis.\n\"We would therefore recommend that a future prospective study should be performed to further assess the impact of alcohol consumption on rheumatoid arthritis, a study recording alcohol consumption at the time rather than asking about it later.\"\nThis finding is slightly different than what is reported in the current study (that the severity of the disease decreased with more alcohol).\nNor do the study authors advise drinking as a cure for arthritis.\n\"What's been reported is that people who drink excessive alcohol actually have higher levels of the cytokines that lead to the inflammation and moderate amounts of alcohol actually may lower these levels.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The availability of alcohol is not in question.\u00a0 In fact, we need a drink after reading another story that conflates association with causation. ", "answer": 2}, {"article": "Close to 800,000 people in the U.S. suffer a stroke each year, mostly older adults.\nHe said that larger studies at multiple treatment sites are needed to determine how helpful magnetic stimulation can be in stroke recovery.\nThe researchers said that it\u2019s not clear what the amount of improvement they observed would mean for patients in their daily lives.\n\u201cThey\u2019re less likely to become completely independent.\u201d\n\nMost of those patients can improve with therapy and exercises, she said, but the process is often slow, and keeping people in the hospital during it is costly.\nThe ideal option might end up being a combination treatment that involves stimulation in certain patients and other therapies that address a range of skills important for regaining function, Barrett added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states: \u201c\u2026brain stimulation is still an experimental technique, and not ready to be used as part of normal stroke rehabilitation.\u201d", "answer": 1}, {"article": "[Watch how the body\u2019s \u2018serial killers\u2019 stalk and attack cancer cells]\n\n\"This is a first in class agent, a brand new therapy,\" Harrington said.\nWhen the latest trial was started, Harrington explained, there was no standard of treatment for melanoma -- so it's compared to a treatment that no one expected to outpace T-VEC.\nThat means it's just waiting for a final okay from the FDA before the Amgen product can hit the market.\nBut this is the first time a modified virus has been successful in carrying out that treatment.\nNow that other therapies -- ones that target specific mutations in patients' cancer cells -- are showing more success than what was available when the trial was formed, researchers will have to see how T-VEC compares.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a bit too much crystal ball-gazing as to when this drug might become available. The start of the article refers to the drug as being months away from approval. Later in the story, the Amgen-affiliated researcher says he expects approval within the year. But his optimism might not be shared by those outside the company \u2014 the story should at least have asked for an independent take. While it\u2019s true that an FDA advisory panel has recommended approval of the drug, the researcher can\u2019t know if the FDA will in fact approve the drug or when. One analysis suggested that the FDA does not follow the advice of its advisory panels\u00a0about a quarter of the time.", "answer": 0}, {"article": "...\nMore than half the trial sites were led by doctors who practice chelation, says Paul Armstrong, a professor of cardiology at the University of Alberta, chosen to discuss the study on a panel at the heart meeting.\nUnder the best of circumstances, that's not a strong result, says anesthesiologist Kimball Atwood of Newton-Wellesley Hospital in Massachusetts, who has followed the study from its beginning.\nElliott Antman, chair of the American Heart Association's Scientific Sessions program committee, praised NIH for doing the study.\n\"All of these factors call into question the results,\" says Michael Carome, deputy director of the advocacy group Public Citizen's Health Research Group.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Another mixed bag for which we\u2019ll give a satisfactory score.\nThe story is not clear about exactly what chelating agent was used in this study, or where one would go to find a practitioner who can prescribe it.\u00a0 (But, to its credit, it mentioned problems with off-label prescribing.) It was relatively easy to find out online that EDTA was the agent used in the study.\nWe give the story for credit for reporting that \u201cthe Food and Drug Administration had taken the study drug off of its list of approved medications.\u201d", "answer": 1}, {"article": "Early menopause is often a side effect for women treated with chemotherapy for breast cancer, but a new study reveals some guarded promise for preventing early menopause breast cancer patients.\nThey conclude that using assisted reproductive technology \u2013 such as storing eggs before chemo, is \u201cthe most effective option for fertility preservation.\u201d\nFor younger women still hoping for children, these treatments can cause devastating short-term or long-term loss of menstrual periods, and loss of fertility.\nPatients were randomly selected to be treated with chemotherapy alone or with chemotherapy and triptorelin, a drug, called a GnRH analogue, that prevents the ovaries from releasing eggs.\nThey also stress that women resuming their menstrual cycles does not mean the same thing as women preserving their fertility.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is no statement in the article as to availability of the treatment, although the information is correctly identified as arising from a \u201cphase three study.\u201d But are readers really supposed to know what a Phase Three study means?\u00a0 Want to do a reader poll to test how many do?", "answer": 0}, {"article": "In an outpatient procedure under local anesthesia, doctors funneled a catheter into the patient's heart and removed peppercorn-sized bits of tissue from the part of the patient's heart that was unaffected by the heart attack.\nMarb\u00e1n says when the first patient data came in, he and his colleagues were relieved to see the procedure was safe.\nNot only did this show that the procedure was safe, it also showed that the cells can help reduce scarring and even cause new heart muscle to grow.\nFurther research will hopefully also help answer those questions, she says.\nShe is hopeful further studies will confirm these early results.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear not only that the treatment is experimental but that it has to clear many more hurdles before becoming a clinical option.\n\u00a0", "answer": 1}, {"article": "In contrast to photon radiotherapy, in which a dose of radiation is delivered all along the x-ray beam as it passes through a patient's body, in proton therapy the dose is precisely focused on the target area with little or no dose delivered to normal tissues in front of or behind the tumor.\n\"Proton radiotherapy is still not widely available in the U.S. or around the world, but it is increasingly recognized for its potential to reduce the side effects of treatment, particularly in the pediatric population,\" says Torunn Yock, MD, MCh, MGH Department of Radiation Oncology, lead and corresponding author of the report.\n\"At experienced centers, proton therapy has a proven track record of treatment success and safety.\"\nThe paper from a team led by Massachusetts General Hospital (MGH) investigators describes patient outcomes an average of seven years after proton therapy for medulloblastoma, a fast-growing tumor that develops in the cerebellum at the base of the brain.\n\"Our results indicate that proton therapy maintains excellent cure rates in pediatric medulloblastoma while reducing long-term side effects, particularly in hearing and neurocognitive function, and eliminating cardiac, pulmonary, gastrointestinal and reproductive effects,\" says Yock, who is an associate professor of Radiation Oncology at Harvard Medical School.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that the therapy is not widely available and not often used. The first quote says, \u201cProton radiotherapy is still not widely available in the U.S. or around the world, but it is increasingly recognized for its potential to reduce the side effects of treatment, particularly in the pediatric population.\u201d", "answer": 1}, {"article": "By far, the lowest incidence of colorectal cancers was seen in pesco-vegetarians, people who eat fish at least once a month but eschew all other types of meat. Compared to omnivores, pesco-vegetarians were 43% less likely to be diagnosed with these cancers during the course of the study.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. Vegetarian foods are widely available.", "answer": 2}, {"article": "Adults with arm or leg pain caused by a sprain, strain or fracture.\nThe drug industry\u2019s triumph over the DEA, even as opioid-related deaths rise\n\nShingles can be intensely painful; it may also mean health problems ahead\nMight non-opioid painkillers work just as well as these addictive drugs?\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nResearch has shown that even short-term opioid use, such as that stemming from an initial prescription for pain from an injury or surgery, can make people predisposed to a dependence on the powerful drugs \u2014 partly from their effectiveness at relieving pain and partly from the euphoria they produce.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story doesn\u2019t explicitly state that the relevant drugs are clinically available, acetaminophen and ibuprofen are both sufficiently well-known over-the-counter painkillers that the writer can assume most readers are familiar with their availability. Opioid drugs, meanwhile, are generally much harder to access and tightly regulated in many states.", "answer": 1}, {"article": "Trisha Bradbury was one of the participants allocated to the FIT study, and she explains: \"I lost my mum at 60, and being 59 myself with a variety of health problems, my motivation was to be there for my daughter.\n\"As well as being delighted by the success of the study in the short term, there are very few studies that document weight loss past the end of treatment, so to see that people continued to lose weight despite not having any support shows the sustainability and effectiveness of this intervention.\"\nFIT goes one step further than MI, as it makes use of multisensory imagery to explore these changes by teaching clients how to elicit and practice motivational imagery themselves.\nIn addition, users of FIT lost 4.3cm more around their waist circumference in six months - and continued to lose weight after the intervention had finished.\nThe study showed how after six months people who used the FIT intervention lost an average of 4.11kg, compared with an average of 0.74kg among the MI group.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release describes FIT as a \u201cnew motivational intervention.\u201d Is it in widespread use? How difficult would it be for someone to find a practice that can provide FIT for weight loss? The release doesn\u2019t address this.", "answer": 0}, {"article": "Nighttime and morning BP decreased more profoundly on average -8/3.5 mm Hg for SBP/DBP, respectively.\nIn conclusion, melatonin can be of great value for aged people suffering from hypertension as an adjuvant substance complementing basic medication as it is able to stabilize circadian BP, heart rate profiles and their phase relationships.\nIncreased blood pressure and reduced robustness of circadian rhythms are frequently reported in elderly subjects.\nLuckily, as we show in our research, melatonin helps to ameliorate both trends.\nThe hypotensive effect was dependent on time.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Melatonin supplements are available almost everywhere.", "answer": 2}, {"article": "According to the FDA, \"Testosterone products are FDA-approved only for use in men who lack or have low testosterone levels in conjunction with an associated medical condition.\nThe findings may sway the ongoing debate over testosterone therapy's benefits and risks, especially for the heart.\nBarua and colleagues say they don't know the exact reasons for testosterone's apparent benefits for the heart and overall survival.\nTestosterone isn't prescribed with the goal of improving heart health, but that is a consideration in many cases.\nWhile the new study results do seem to advocate for testosterone replacement therapy, Barua stresses the need for \"appropriate screening, selection, dosing, and follow-up of patients to maximize the benefit of testosterone therapy.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that testosterone therapy is available to patients.\u00a0 The narrative does go to the trouble of noting that \u201coff-label\u201d use of testosterone is a no-no.", "answer": 1}, {"article": "But an electrolyte imbalance caused by dehydration, influenza or other health problems that deplete the system of potassium, magnesium and other minerals also can cause cardiac arrest.\nHe said a doctor at Mercy Hospital also is using the therapy on patients.\nDr. Ashis Tayal, an AGH stroke neurologist, said trials are under way to use the therapy to help stroke victims.\nMr. Beck said he didn't regain full consciousness for nine days.\nThat's most likely what happened to Mr. Beck, whose heart arteries were clear.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that this treatment is not available at all hospitals.", "answer": 1}, {"article": "\"We compare the colored glasses to being like a brace or cast but for the brain,\" he says.\nThe goal is to help the concussion patient feel better as the brain heals.\nPhotophobia is so common that many neurosurgical intensive care units consider it standard operating procedure to keep lights dimmed in rooms containing TBI patients says Clark.\nWe believe the use of the colored glasses that provide photophobia mitigation has added benefits superior to dark sunglasses, especially for indoor lighting.\"\nThere was no funding used for this study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "These lenses are presumably available at optical shops, but it\u2019s unclear from the release.", "answer": 0}, {"article": "Nerve cells that communicate and control the voluntary muscles of the body (such as those in the arms, legs and face) degenerate or die.\nIn Pharr's opinion, this and other stem cell studies are certainly fair from a participant's perspective, since beforehand, \"patients are presented with all the risk factors involved so they can make an informed decision.\"\nImportantly, one patient showed some improvement, though he and his colleagues noted that this outcome \"must be interpreted with caution\" since the study wasn't designed to measure effectiveness of the treatment.\n\"People who do these studies should be considered medical heroes,\" Goldstein said, adding, \"The selflessness of these people when they're told they're gonna die.\"\nThe results of one new study may be less than hoped for, but the science is sound: The study concluded that injecting stem cells into the spinal cords of patients with amyotrophic lateral sclerosis is safe in most, though not all, cases.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story quotes a lead researcher saying, \u201cwe are just now getting started with testing our hypotheses about using stem cells as therapeutics. \u2026 We do not know if these treatments\u00a0will work, and it will take time\u00a0to test these therapies in a systematic and safe way.\u201d", "answer": 1}, {"article": "And for the test to be useful, \"you've got to find cancer that's going to otherwise be lethal, and not cancer that would otherwise be destined to do nothing,\" Prasad says.\nThen the researchers will need to show that the rate of false alarms remains very low, otherwise people will be sent on needless and expensive medical odysseys.\nOf course, the ultimate goal of this test is to find cancer in people who haven't already been diagnosed.\nTheir experience will help answer the next big question, which is whether CancerSEEK will pick up cancer in people who don't have symptoms.\nAs for the cost of the test, Papadopoulos says the research team has tried hard to make it affordable.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s mentioned the authors of the study are \u201choping their idea would eventually lead to a $500 test \u2026 but they have a long way to go.\u201d Future studies of the screening test are also discussed, so it seems clear this test is not currently available.", "answer": 1}, {"article": "The researchers, Drs.\nBut the findings are not likely to be practice-changing, said Dr. Richard E. Greenberg, chief of urologic oncology at Fox Chase Cancer Center in Philadelphia, who was not involved with the study.\nThere was also a benefit in men whose tumors had low-risk characteristics.\n\"The management of early stage prostate cancer continues to require further randomized controlled studies, which are underway, to determine the true benefit of treatment versus expectant management,\" said Dr. Marc Danziger, an attending urologist at Lenox Hill Hospital in New York City, who was not involved with the study.\nThe earlier study also found that undergoing a radical prostatectomy lowered the risk of the cancer spreading, as well as the death rate from prostate cancer or any other cause.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "An important caveat about how the prostate cancer in the study differed from the way in which prostate cancer is most commonly detected today in the US was explained.", "answer": 1}, {"article": "God watches out for fools and little children.\n\"That's huge,\" said lead author Fran Weaver, a researcher with the Hines VA Hospital in Hines, Ill.\n\nShe said the best drugs provide only one to two hours of added improvement, or \"on time.\"\nThose who got the therapy also had significantly more improvement in other measures of symptoms, according to the study that will appear today in the Journal of the American Medical Association.\nNausieda said much of the benefit found in the study could be due to a placebo effect.\nThe hospital has done about 300 of the procedures since 2005, said Brad Hiner, an associate professor of neurology at the Medical College of Wisconsin and neurologic director of the hospital's deep brain stimulation program.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the article does not make a clear statement about availability, it does imply that deep brain stimulation is available in at least some hospitals, has been in use since at least 2005, and is applied to a variety of conditions. \nThe story says that only 2 percent of patients get the surgery, while 15 percent are eligible. It would have been useful to know if availability played any role in this discrepancy. ", "answer": 1}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe story does not report that this trial tested a specific type of exercise program known as Jaques-Dalcroze eurhythmics, so readers have no way of finding out whether it is available to them.", "answer": 0}, {"article": "About the Society of Breast Imaging\n\nThe Society of Breast Imaging (SBI), established in 1985, is a professional medical organization dedicated to improving the practice of breast imaging and the quality of medical education in breast imaging.\nThe SBI also provides a medium for the exchange of ideas among those involved in breast imaging.\nThis approach saves many more lives than screening started at a later age or with less frequent exams.\n\"The decision whether or not to get a mammogram remains with women.\nWe want them to know that mammography can detect cancer early \u2014 when it's most treatable and can be treated less invasively \u2014 which not only saves lives but helps preserve quality of life.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability isn\u2019t mentioned. But because getting a mammogram is relatively routine, we\u2019ll mark this one \u201cnot applicable.\u201d", "answer": 2}, {"article": "Trigeminal neuralgia (TN) is a very painful nerve disorder that causes an electrical shock feeling in the face, usually in older people.\nThe authors, from Cleveland Clinic in the US, say considering radiosurgery earlier on could make a big difference to patients' lives.\nIn the research, radiosurgery helped improve the quality of life for patients with trigeminal neuralgia and reduced their depression, which is often exacerbated by the side effects of other treatments.\nBy considering it earlier as a treatment option, doctors could help improve the lives of patients with TN more quickly.\nImportantly, the benefit of treatment was strongly driven by improvements in pain and discomfort as well as self-care.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The authors suggest in the release that the radiation treatments should be used more, which implies it is not in wide use: \u201cit [radiosurgery] is often overlooked or delayed as a treatment because there is a lack of capability and experience with the method.\u201d This statement highlights that this may actually not be possible due to lack of trained clinicians.", "answer": 1}, {"article": "Myo-inositol is also found in fruits, beans, grains and nuts, although Bild said the finding does not necessarily explain why people who eat more of these foods have a lower risk of cancer in general.\nThe researchers have patented their findings through the universities but Bild said myo-inositol supplements are cheap and freely available.\nAnd, they said, a natural supplement derived from food that is being tested to prevent lung cancer appears to halt the precancerous changes.\n\u201cEven in normal cells or premalignant cells prior to cancer development we see this pathway being turned on,\u201d said Andrea Bild of the University of Utah, who worked on the study published in the journal Science Translational Medicine.\nAnd the second group was taking the natural supplement, myo-inositol, to try to prevent lung cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This genetic test is not yet available, but the story could have been clearer on that point. The story suggests there is no question regarding the availability of myo-inositol; however, more information on the specific formulation used in the study, as well as the dosage would have been useful. ", "answer": 1}, {"article": "Aside from hair transplants, which can cost about $10,000 each and do not always look natural, the only current hope for complete replacement is hair cloning, the act of producing entirely new hair from the DNA of an existing one, which researchers have been attempting, unsuccessfully, for years.\nThe result is an enhanced, refortified hairline rather than a brand new head of hair.\n\u201cIt was a noticeable difference.\u201d\n\nBut Latisse does not appear to be a silver bullet for hair loss.\n\u201cWe keep on moving back that time, but I think there\u2019s absolutely no doubt that it\u2019s going to be done.\u201d\n\nHe believes hair cloning will be commercially available within 10 years.\nBut the fact is that many men \u2014 and women \u2014 simply do not accept baldness easily.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that Latisse is a prescription product sold for eyelashes but being used off label by some doctors for hair loss.", "answer": 1}, {"article": "Labor may be induced by breaking the amniotic sac or by using hormones called prostaglandins or medication such as oxytocin, which can set off contractions.\n\u201cSince we don\u2019t know exactly what triggers labor, why mess with it?\u201d\n\nHausman suggested learning from countries such as Denmark or Sweden, where midwifery is the first line of care and where fetal and maternal mortality rates are lower than in the United States.\n\u201cThere are anywhere between 25,000 to 30,000 stillbirths a year in the United States.\u201d\n\nLockwood and Norwitz\u2019s support for induction at 39 weeks not only surprised many of the doctors at the session, it also upset those who believe less intervention is the safest route for mother and baby.\nAs with any change in standard medical care, extensive research is needed before it can be safely and widely adopted.\nFor Dekker, the major benefit of spontaneous labor is avoiding the risks of a medical induction.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Since the discussion centers on when to induce labor, it is clear that treatments to induce labor are widely available.", "answer": 1}, {"article": "The scientists, meanwhile, collected blood samples from the men several weeks before the race, as well as immediately before to the start, at the finish line and on select days afterward.\nJust how nonalcoholic beer eases the ravages of strenuous marathon training and racing is still being investigated.\nBut, said Dr. Scherr, it almost certainly involves the beverage\u2019s rich bouquet of polyphenols, chemical substances found in many plants that, among other things, \u201csuppress viral replication\u201d and \u201cinfluence the innate immune system positively,\u201d all beneficial for fighting off a cold.\nFor that, at least, the beer can be full-potency.\nThe beer was effective only if it was nonalcoholic.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nNot applicable.\u00a0 The availability of nonalcoholic beer is not in question.\nHowever, it is not clear from the original abstract whether the type of beer matters, as the brand and/or the characteristics (such as calories) were not provided. This is not mentioned in the story. (note: the brand was provided in a press release)", "answer": 2}, {"article": "Some doctors say the increased rate of Caesareans is partially attributable to maternal demand: busy mothers may want to schedule their deliveries.\nBut defining medical necessity is complicated.\nAnd some women are scheduling them early.\n\"There are certainly women who want timed, elective delivery surgically.\"\nDoctors such as Stark say we need a better sense of what goes on while the baby is still in utero.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly Caesarean\u00a0birth is available.", "answer": 1}, {"article": "The women were followed for an average of about 3.5 years.\n\"These findings really emphasize how important it is for all women with a family history of early breast or ovarian cancer to undergo genetic testing,\" said Dr. Virginia Kaklamani, co-author of an editorial that accompanied the study.\nTUESDAY, Aug. 31, 2010 (HealthDay News) -- Women who carry genetic mutations that boost their odds of breast and ovarian cancer can live longer and reduce their cancer risk by having preventive surgery, a new study suggests.\nKaklamani added that she hoped the findings would encourage more women to ask their primary care physicians whether they are candidates for genetic counseling.\nHowever, \"what our findings show is that women who choose to have these surgeries will reduce their risk of dying of breast or ovarian cancer by about 70 to 80 percent, which is pretty profound,\" said study senior author Dr. Timothy Rebbeck, a professor of epidemiology at the University of Pennsylvania School of Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not mention that the type and quality of genetic testing, genetic counseling, surgery and surveillance offered to women in this study may not be available to women in other settings.", "answer": 0}, {"article": "Exercise, and in particular strength-training routines that develop muscles of the trunk and core, can help reduce pain and improve function, though many people avoid them for fear of doing further harm.\n\u201cMore participants in the yoga and stretching groups were very satisfied with their overall care for back pain.\u201d\n\nDr. Sherman said that like many other therapies for low back pain, yoga probably would not work for everyone.\n\u201cThe smaller studies which hinted that yoga might be helpful all had problems one way or another.\nFor those who want to try, a weekly class and a few 20-minute sessions at home might be a good starting point, she said.\nThose in the third group served as \u201cself-care\u201d controls and received a book containing advice on back exercises and ways to reduce pain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\n \nThe writer probably assumed that yoga classes and stretching programs are widely available across the United States. So we\u2019ll award a \u201csatisfactory\u201d here.\nBut it is not actually all that clear that similar \u201cviniyoga\u201d classes and intensive stretching programs are available in most communities\u2014or that physicians and patients can easily find them. And it is not clear to what extent they are covered by health insurance plans.\n", "answer": 1}, {"article": "\u201cNot everything that is natural is safe,\u201d she said.\nHer lab at Emory is doing additional research to confirm the safest and most effective way of using the plant extract.\nResearchers would still need to conduct pre-clinical trials to test its medicinal benefits.\nIts leaves and bark are used to treat wounds, ulcers, burns and skin infections, Quave said.\nFrom an ecological standpoint, Quave said, it makes sense that invasive weeds have a chemical advantage that may help protect them from diseases so they can spread more easily in a new environment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the product isn\u2019t available yet:\n\u201cHer lab at Emory is doing additional research to confirm the safest and most effective way of using the plant extract. Researchers would still need to conduct pre-clinical trials to test its medicinal benefits.\u201d\nAs we noted above, the story also could have mentioned the need for expensive follow-up studies involving many patients, should those pre-clinical studies produce positive results.", "answer": 1}, {"article": "Politicians started giving scary speeches about rationing health care.\nSo perhaps it\u2019s not surprising that the company\u2019s PowerPoint presentation to the FDA included the unsubtle phrase \u201chuge breakthrough,\u201d or that the first American patient to undergo 3-D mammography \u2013 Laura Lang, a polished 55-year-old Boston marketing executive and breast cancer survivor \u2013 did so in front of a CBS camera crew last February.\nThere\u2019s an intuitive argument for why 3-D mammography might be more accurate.\nOnly a prospective, randomized trial with mortality as its \u201cendpoint\u201d can say for sure, and that\u2019s how long it takes to conduct one.\nAs Rafferty says, it\u2019s not a panacea.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Early in the piece, the story mentions the limited availability of 3-D mammography, which received FDA approval in February 2011.\u00a0 The technology is currently available in \u201c\u2026at least nine states, three of which have multiple sites.\u201d\u00a0 The technology is clearly available for the paper\u2019s readers because the piece focuses on Massachusetts General Hospital, which was both a development and\u00a0a test site for the equipment.", "answer": 1}, {"article": "Although the use of NSAIDs for arthritic conditions such as knee OA has potential risks, including heart attack and stroke, existing evidence indicates that naproxen has less potential for adverse cardiovascular events.\nThis new research analyzed data from multiple trials to determine the relative effectiveness of various nonsurgical treatments for knee OA.\n\"While the information in this analysis is helpful to physicians, patients also can benefit from these findings and use it with their doctors to weigh all possible treatment options.\"\n\u2022 HA injections did not achieve a rank in the top five treatments for pain, function, or combined pain and function.\n\"Using a statistical ranking technique, we worked to provide evidence regarding which of the most common NSAIDs are most likely to decrease pain and improve function, and we attempted to fill in the gaps in evidence for more inconclusive treatments such as HA, PRP, and corticosteroids.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that all the treatments noted in the release are generally available.", "answer": 1}, {"article": "At the end of the study, the group of volunteers who had used the dapivirine ring had 27% fewer HIV infections than a control group who had a placebo ring with no drug, the study found.\nBut it\u2019s now known that, when taken properly, Truvada cuts new cases of HIV by at least 92%.\nOne of the new studies, published today in the New England Journal of Medicine, tested the ring in more than 2,600 women in four countries \u2014 Malawi, SouthAfrica, Uganda, and Zimbabwe \u2014 over nearly two years.\nBut 1 in 3 infections were prevented overall \u2014 and that\u2019s huge.\u201d\n\nWarren noted that other rings with antiretrovirals are also being developed, as well as rings that could offer multipurpose protection, against not only HIV but pregnancy.\n\u201cThat individual control of prevention is so powerful.\u201d\n\nThe dapivirine ring has been in development for more than a decade, and the the new studies are the first to show that it prevents HIV transmission.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that the dapivirine ring \u201chas been in development for more than a decade,\u201d suggesting that it is not yet available. Some comment on when the device might become available would have been useful.", "answer": 1}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of these different diets is not in question.", "answer": 2}, {"article": "\"The disc is made up of mostly water, and it get tears in it.\nHe says his intent was not to put some orthopedic surgeons out of business.\nWhether you have surgery often depends on where you live and what doctor you see.\nBut no matter where you live, surgery is not necessarily the best or only option.\nThe operation was a success and she's been pain-free for four years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It's clear from the storyt that surgery for herniated disc is widely available. ", "answer": 1}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story fails to mention a projected date for or the next steps in obtaining FDA approval. While the FDA usually follows the advice of the advisory panel, which in this case recommended the drug\u2019s approval for treatment of dementia associated with Parkinson\u2019s Disease, the FDA does not have to follow the panel\u2019s recommendation. There is no discussion of when the FDA might approve the drug for this indication. ", "answer": 0}, {"article": "Compare that with a decrease of about 7 mg/dL for the low-fat diet, and about a 8 mg/dl drop from the moderate-fat diet.\nWe asked Kris-Etherton if she would have published the results had there been no positive findings for the avocado.\n\"I was surprised to see the added benefit [of the avocado],\" Penny Kris-Etherton, a nutrition scientist at Penn State and the lead author of the study, tells us.\"\nShe says she'd like to do follow-up research to look at the bioactive compounds in avocados, which may explain the added reduction in LDL cholesterol in the study participants.\nAnd given the reduction in funds available for research, it's become increasingly common for researchers to carry out these kinds of industry-supported studies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Avocados are widely available, so we won\u2019t ding the story for not discussing availability. As with the competing stories, we would have liked to have seen some acknowledgment that there are areas where avocados may be more difficult to find.", "answer": 1}, {"article": ".\nBy activating the bitter taste receptors in the uterus, the bitter substances relaxed the contracted uterine muscle tissue more completely than the current drugs used to prevent preterm labor in humans.\nThe researchers first exposed the tissue to native hormones such as oxytocin and chemical compounds to make it contract, mimicking normal or premature labor.\nThey then exposed the tissue to bitter substances.\n\"The bitter taste receptors that we have found on uterine muscle could be one more piece of the puzzle to understand the onset of labor, both at term and preterm, and develop new therapeutics for preterm labor.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does not mention the name of the substances tested, so there is no way to know anything about availability. After looking at the research paper we found that the substance was chloroquine which is readily available.", "answer": 0}, {"article": "An epileptic seizure occurs when large groups of neurons in the brain begin firing uncontrollably, disrupting the balance of electrical activity and causing changes in mental function, motor function and behavior.\n\u201cThis is a novel finding,\u201d Dr. Vezzani said in an interview.\n\u201cThe challenge for the next few years is to find out the limitations, the boundaries, the real mechanisms.\u201d\n\nStill, whatever the role of inflammation in epilepsy, Elisa Moller says that anti-inflammatories were a miracle intervention for her son.\nBut there are dangers to this approach.\nReplacing anticonvulsants is not merely an end in itself.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "By leaning so heavily on the William Moller anecdote, the story may confuse some readers as to whether anti-inflammatory treatments are widely available for people with epilepsy. But the story also makes clear in several places how one particular treatment being prepared for market \u2013 VX-765 \u2013 is progressing through the various clinical trials necessary for it to become a clinical application.", "answer": 1}, {"article": "An 18-week clinical study of CoolSculpting in submental fat treatment found that 77 percent of patients showed improved appearance of lax tissue and 75 percent of patients reported their chin looked more toned following treatment.3\n\n\"In my own patients, I have noticed the improved appearance of lax tissue when using the CoolMini\u00ae applicator for the CoolSculpting\u00ae system to treat the submental area,\" said Jeffrey S. Dover, MD, FRCPC, Co-Director of SkinCare Physicians of Chestnut Hill, Mass.\nDUBLIN, Dec. 12, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the CoolSculpting\u00ae treatment is the first and only non-surgical fat reduction technology to be FDA-cleared for improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments.\nMillions of CoolSculpting treatments have been performed in more than 80 countries.\nCoolSculpting is available through a network of CoolSculpting Centers worldwide.\nAllergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release says the technology is available through a network of CoolSculpting centers worldwide. It also refers readers to its website, where you can search for a list of clinicians and specialists offering the procedure.\nWe rate this one Satisfactory.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe drug is approved for use with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML.\nThe FDA granted this application Priority Review, Fast Track (for the mastocytosis indication) and Breakthrough Therapy (for the AML indication) designations.\nThe FDA granted the approval of Rydapt to Novartis Pharmaceuticals Corporation.\n\u201cRydapt is the first targeted therapy to treat patients with AML, in combination with chemotherapy,\u201d said Richard Pazdur, M.D., acting director of the Office of Hematology and Oncology Products in the FDA\u2019s Center for Drug Evaluation and Research and director of the FDA\u2019s Oncology Center of Excellence.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While the release doesn\u2019t specifically state the availability of the drug, the FDA approval for its use suggests that it should start to become available in a matter of months and not years.", "answer": 1}, {"article": "The Harvard Medical School affiliates share a clinical staff that delivers inpatient care at Boston Children's Hospital and most outpatient care at Dana-Farber Cancer Institute.\nJoining senior author Orkin, the study's lead author is Huafeng Xie, PhD, of Dana/Farber/Boston Children's.\nEpizyme, a biopharmaceutical company based in Cambridge, MA, recently opened a pediatric trial of an Ezh2 inhibitor for children with rhabdoid and other tumors.\nThe new study grew out of efforts to discover whether different types of cancer are susceptible to Ezh2 inhibitors.\nAlthough adding Ezh2-targeting agents to the standard drug regimen for CML has the potential to dramatically shorten the treatment period for many patients, ethical considerations may lead to the agents' first being tested in patients who don't respond to Gleevec and similar drugs, either initially or after drug resistance develops, Orkin remarks.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes imatinib-like drugs are\u00a0the standard of care for CML patients, implying a\u00a0diagnosis would grant access to the drugs by prescription.\u00a0Though it doesn\u2019t name the potential\u00a0Ezh2 inhibitor drug, the release does note it\u2019s part of a Phase 1 trial, as well as other clinical trials\u00a0\u2014 implying it\u2019s not readily available. A\u00a0lack of absolute clarity here isn\u2019t helpful to readers, but there\u2019s enough to mark\u00a0this satisfactory. A statement that clarified that it would likely be years before testing in humans would be complete would have been appropriate here.", "answer": 1}, {"article": "Currently, almost all concussions in children are diagnosed only by symptoms, which are either observed, like vomiting or balance problems, or symptoms that are reported by the child, like headaches, blurred vision or feeling groggy.\nResearchers plan to do more studies with the blood test, but they hope it will be commercially available within the next 5 years.\nAs expected, the high definition imagery from the CT scans was able to identify which patients had suffered visible traumatic brain injuries.\nThe biomarker this particular blood test looks for is known as glial fibrillary acidic protein (GFAP).\nNeither scenario gives doctors an objective indication of the severity of the injury.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that the GFAP test is not available for clinical use, and that the researchers hope to develop a test for clinical applications within the next five years.", "answer": 1}, {"article": "All of these study participants \u2014 largely people in their 70s, all with a diagnosis of either \"mild cognitive impairment\" or atypical dementia \u2014 are living with the unconfirmed suspicion that they have Alzheimer's. The study is underwritten by the Centers for Medicare & Medicaid Services and the Alzheimer's Assn. It set out to find out whether knowing \u2014 getting the costly test that would offer either confirmation or reprieve \u2014 would change the way that patients with cognitive troubles are treated, or the way that they plan their lives.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was a close call. In general, PET scans are widely available, if costly. The story also made it clear that Medicare doesn\u2019t cover this scan. But, the story could have gone a step further and explained without Medicare coverage, it\u2019s unlikely to become widely available.", "answer": 1}, {"article": "Knee surgery for a torn meniscus is done about half a million times each year in the U.S.\nOne study participant \u2014 Bob O'Keefe, 68, of suburban Boston \u2014 was glad to avoid surgery for his meniscus injury three years ago.\nSurgery costs about $5,000, compared with $1,000 to $2,000 for a typical course of physical therapy, Katz said.\nThe therapy was nine sessions on average plus exercises to do at home, which experts say is key to success.\nBut those who stuck with therapy had improved as much six months and one year later as those who had arthroscopic surgery right away, researchers found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the various treatment approaches is not in question. The story could have cited stats from the study:\n\u201cThis procedure, in which the surgeon trims the torn meniscus back to a stable rim, is performed for a range of indications in more than 465,000 persons annually in the United States.\u201d", "answer": 2}, {"article": "Those most at risk of developing such cancers are of Eastern European Jewish descent.\nThe prescription-free test is the first to report on three specific BRCA1 and BRCA2 breast cancer gene mutations, according to the FDA.\n\u201cThe test should not be used as a substitute for seeing your doctor for cancer screenings or counseling on genetic and lifestyle factors that can increase or decrease cancer risk,\u201d he said.\nMore: Breast cancer: Study finds tumor risk increased by use of oral contraceptives\n\nBut \u201cit has a lot of caveats,\u201d warned Donald St. Pierre, acting director of the FDA's Office of In Vitro Diagnostics and Radiological Health.\nStill, the company, which already tests DNA for other health risks as well as ancestry, said this cancer test is \"a step in the right direction.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t make it clear when this test will be available.\u00a0\u00a0The company\u2019s website notes that said testing results will be available \u201cin the coming weeks.\u201d", "answer": 0}, {"article": ".\n\"Future studies are now needed to confirm these results and to determine the best nutritional components of the DASH diet to prevent depression later in life and to best help people keep their brains healthy,\" said Cherian.\nCherian noted that the study does not prove that the DASH diet leads to a reduced risk of depression; it only shows an association.\nRegister now for the 2018 AAN Annual Meeting Press Room in Los Angeles, April 21-27, 2018\n\nThe study was supported by the National Institute on Aging.\nThe odds of becoming depressed over time was 11 percent lower among the top group of DASH adherers versus the lowest group.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release refers repeatedly to the DASH diet. However, while the DASH diet has been around for years, many readers will likely never have heard of it. The release appears to assume that the DASH diet is common knowledge. While the DASH diet isn\u2019t a secret, it\u2019s not something you can assume readers are familiar with either. This could have been addressed by simply noting that the DASH diet has, well, been around for years. It could even have referred readers to a description of the plan on an NIH website.", "answer": 0}, {"article": "Melanoma is one of the most common forms of cancer and the most serious type of skin cancer.\nThe study was published on August 5th in the Journal of the American Academy of Dermatology.\nThe test, which analyzes proteins in cells, could provide more reliable results for clinicians with patients who might be at risk for this deadly cancer.\nThe study was supported in part by a grant from the National Institutes of Health.\nThe researchers found that in nearly all cases, the IMS analysis was a more accurate predictor, both of benign lesions and melanomas, than standard microscopic examination.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While IMS use is growing in different fields of medicine, the news release doesn\u2019t explain how accessible it is. Can a patient request one from their local dermatologist? Would most dermatologists know how to interpret the test results? The news release makes no attempt to inform us.", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nHealth care professionals should review the prescribing information in the labeling for detailed information about the approved uses.\nThe most common adverse reactions for these indications are injection site reactions and being more susceptible to catching colds.\nApprovals for the new indications were based on clinical studies, including safety, efficacy and pharmacokinetic data.\nPatients should not receive Ilaris if they are allergic to canakinumab or any of the ingredients in Ilaris.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since the drug has already been approved for two other conditions, it\u2019s safe to assume that the drug is already on the market and generally available.", "answer": 1}, {"article": "Cannabidiol, or CBD, is a compound in the cannabis plant that does not contain psychoactive properties that induce a high.\nThe study included a liquid pharmaceutical formulation of CBD, called Epidiolex, which is manufactured by GW Pharmaceuticals and has not been approved by the U.S. Food and Drug Administration.\nThis new, randomized, controlled clinical study eliminated those concerns as participants and their physicians did not know if they were on CBD or placebo, say the study authors.\nFor the study, 120 children and adolescents with Dravet Syndrome between the ages of 2 and 18 years were randomized across 23 sites in the United States and Europe to receive either CBD 20 mg/kg or placebo added to their existing treatment over a 14-week period.\nThe new study confirms results from a December 2015 open-label expanded access program led by Dr. Devinsky that reported reductions in seizure frequency.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that Epidiolex \u201chas not been approved by the U.S. Food and Drug Administration\u201d yet, so readers can assume that it is not yet available to the public. The FDA does, however, consider cannabidiol an investigational product for treating children with epilepsy and has \u201cexpanded access provisions\u201d that allow its use. This would have been useful information to include in the release.", "answer": 1}, {"article": "\"Now they tell me, 'You never say 'What?'\nEven with one implant, Merlo called the results \"surreal.\"\nIn March, she plans to have one put in her right ear.\nOften, it meant only being able to do one thing at a time, explained the mother of three young children.\nNow, thanks to an implant called Esteem, Merlo can multitask.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story mentions that the Esteem implant is FDA approved, it is not clear why Dr. Marzo is the only surgeon in the entire Chicagoland area authorized to implant the device. Is this typical of other cities? Why is the procedure not more widespread?", "answer": 0}, {"article": "That 1.7 percent difference is not considered statistically significant.\nAbbott Laboratories' newly approved Absorb stent comes with one important caveat: it hasn't yet been shown to be safer than older metal implants.\nAbbott said it does not disclose the price of its stents.\nDoctors who studied Absorb said it may take several years before its advantages become clear.\nHe says a \"perfect storm of events,\" including safety concerns and the economic downturn led Abbott and competitors Medtronic Inc. and Boston Scientific Corp. to slash prices in recent years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The news peg for this story was FDA approval of the device for patients with coronary artery disease.\u00a0 But although the Abbott Labs\u2019 press release suggests that the dissolvable stent is available worldwide (\u201cin more than 100 countries, including the United States\u201d), the story does not mention U.S. access to the device. The Reuters story covered this criterion better.", "answer": 0}, {"article": "A complex and expensive pacemaker-defibrillator can significantly improve the chance for survival among the tens of thousands of heart-failure patients with only mild symptoms, according to a major, multiyear clinical study.\n\nThe research, regarded as likely to change medical practice, showed that the device to \"resynchronize\" the hearts of such patients lowered the death rate by 29% in such patients over 40 months, compared to those who had a standard defibrillator implanted.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story makes it clear that the device studied is in clinical trials for the targeted patient population and that a similar device is on the market. \u201cJust over a month ago, Boston Scientific won federal approval to treat mild-symptom heart-failure patients with such devices. Medtronic is seeking such approval, but already sells it for more severe heart failure patients.\u201d We would have liked to have seen some estimate of how many people have these devices implanted every year.", "answer": 1}, {"article": "Men who had the highest levels of lycopene in their blood were 55% less likely to have a stroke, compared with men who had the lowest levels of the antioxidant in their blood.\nTomatoes are not the only food that is rich in this antioxidant.\n\u201cThe results support the recommendation that people get more than five servings of fruits and vegetables a day, which would likely lead to a major reduction in the number of strokes worldwide, according to previous research.\u201d\n\nOther studies have shown that high lycopene levels may be linked to a reduced risk of certain cancers.\nDuring that time, 67 men had a stroke.\n\u201cThis study adds to the evidence that a diet high in fruits and vegetables is associated with a lower risk of stroke,\u201d says researcher Jouni Karppi, PhD, of the University of Eastern Finland in Kuopio.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of tomatoes isn\u2019t in question.", "answer": 2}, {"article": "Heterosexuals who are HIV negative can significantly reduce their risk of infection by taking a daily dose of an antiviral drug, according to a new study by the Centers for Disease Control and Prevention.\nIn fact, an interim review of the Partners data on effectiveness was so compelling that the trial was stopped early and the placebo arm was discontinued.\n\u201ciPrEx provided the first proof of an important new method of HIV prevention that can help slow the global toll of 2.6 million new HIV infections each year.\nThe CDC says the next step is to fully review all the data and begin to develop guidelines for the use of these drugs in heterosexual men and women here in the U.S.\nThe news comes at the same time a second study looking at PrEP in heterosexual couples in Kenya and Uganda also found significant reductions in infection rates.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Unlike the competing AP story, this story didn\u2019t make it clear that there will be issues in getting this strategy implemented in Africa and in the US.", "answer": 0}, {"article": "It's a barrier between enamel and the soft tissue that contains all the blood vessels and cells,\" Celiz explained.\n\"We're trying to provide an alternative material, an alternative therapy,\" he said, because the current method involves the dentist removing all of the infected pulp tissue, \"scraping it out, and it can be very painful.\"\nThe stem cell procedure is in the earliest stages of development, said Celiz.\nIf successful, a treatment like this could someday offer significant benefits for millions of dental patients each year.\nThough the work is still in its early stages, and has not yet been tested in people, the scientists won an award from the Royal Society of Chemistry for their idea: regenerative dental fillings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the research is \u201cstill in its early stages, and has not yet been tested in people.\u201d It also quotes a researcher saying, \u201cIt\u2019s hard to put timeline on it, but we\u2019re talking years before we test it in humans.\u201d\nStill, the story could have been more skeptical in its approach, pointing out that the therapy may never pan out.", "answer": 1}, {"article": "Mark Thomas, who researches addiction at the University of Minnesota Health Sciences, says that a vaccine like this could help a former heroin abuser, \u201cforge a path to abstinence.\u201d Thomas, who was not involved with the study, explains that he was initially wary of the vaccine approach.\nThe compound, created by chemists at the Scripps Research Institute, works in a way that\u2019s similar to other vaccines.\nImportantly, this vaccine is designed to work against only heroin, not other opioids.\nAs a result, those molecules never reach the brain, preventing the euphoria that may have otherwise resulted.\nA vaccine that blocks the high from heroin has just moved one step closer to reality.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that research has not yet taken place in humans, indirectly inferring that it\u2019s not available.", "answer": 1}, {"article": "About 35% of U.S. adults take calcium supplements, alone or in multivitamins, according to a recent report in the medical journal JAMA.\nTeen girls, who are in crucial bone-building years, often have diets that fall short of their needs, 1,300 mg a day, Wallace says.\nSome people do need supplements.\n\u201cIf you look at the overall totality of the evidence, there\u2019s a lack of association between supplement use and heart attack and other cardiovascular events,\u201d says Manson, who co-wrote an editorial accompanying the review.\nLarger doses are poorly absorbed and rarely needed, he says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not address calcium supplement availability. However, given that these supplements are not new, and are widely available, we\u2019ll rate this as not applicable.", "answer": 2}, {"article": "\"This is quite good news,\" Fauci said.\nThe report from the Centers for Disease Control and Prevention Friday also came with good news: Testing of vaccines for swine flu show that they work with a single dose and take effect rapidly.\nAustralian and U.S. researchers said Thursday that one dose of the new swine flu vaccine looks strong enough to protect adults \u2013 and can begin protection within 10 days of the shot.\nSupplies of swine flu vaccine are expected to be available in mid-October.\nHealth officials say influenza is circulating unusually early this year with cases in every state \u2013 and nearly all the infections are swine flu.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story reports that H1N1 vaccinations are expected to be available in mid-October and that seasonal flu shots are available now.", "answer": 1}, {"article": "National Jewish Health is the leading respiratory hospital in the nation.\nResearchers hope that using the bacteria-infused cream will offer a long-term solution where other treatments fall short.\nExperts say there is more research to be done, but that the goal of the trial is to discover the best combination of bacteria to clear eczema from the skin and then make it available to patients as a prescription cream.\nA new clinical trial is testing a natural treatment that researchers hope will provide a long-term solution for those dealing with the dry, itchy and painful skin that comes with chronic eczema.\nThe trial uses a cream containing beneficial bacteria to fight harmful bacteria on the skin.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release suggests the benefit of the cream was already proven and hints that the treatment would be available soon.\nIt would have been helpful to note for readers something like, \u201cbecause this lotion is in clinical trials, it is not currently available on the market; furthermore the preliminary results have not been published or peer-reviewed.\u201d", "answer": 0}, {"article": "The F.D.A.\nThe review for Medicare said there was insufficient evidence to judge whether Provenge would work if used off-label.\nThe analysis is part of a controversial review by the Centers for Medicare and Medicaid Services to determine whether to pay for Provenge, which costs $93,000 per patient and extended lives by about four months in clinical trials.\nThere is only \u201cmoderate\u2019\u2019 evidence that the newly approved prostate cancer drug Provenge helps patients, according to an analysis done for Medicare that was made public on Wednesday.\nBut the analysis for Medicare said that there were issues in how the trials were designed that made it difficult to assess how effective Provenge really was.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story reports that treatment with Provenge has been approved for certain patients with advanced prostate cancer but that availability is limited by manufacturing capacity.", "answer": 1}, {"article": "\"There are many gaps in the evidence,\" Reiss said.\nExperts agreed that the findings held promise, but much more research will be needed.\nStill, Dr. Paul Wright, chair of neurology at North Shore University Hospital in Manhasset, N.Y., said the research \"is still in its infancy but very promising.\"\nBut that convenience also brings its own problems, Wright added.\n\"This is a very preliminary study with a small number of subjects and the results are far from conclusive,\" said Dr. Allison Reiss, head of the Inflammation Section at Winthrop-University Hospital in Mineola, N.Y.\n\nShe believes the current study lacks information on possible confounding factors -- things such as \"coexisting illnesses, medications, hydration state, tobacco use and multiple other variables\" that could influence what's found in the saliva samples.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "At a number of different points in the story we are reminded of the preliminary nature of the research, suggesting that it is years away from prime time.", "answer": 1}, {"article": "The combination of Yervoy and the newer Opdivo also reduced the risk of disease progression by 60 percent compared with Yervoy alone through 11 months of follow-up in previously untreated patients with advanced melanoma, researchers found.\nTwenty-two percent of those combination patients had a complete response, meaning no sign of tumor.\nBut after 11 months, more than half of the combination group had yet to see their disease worsen.\nOverall survival data was not yet available.\nThe complete response rate was 22 percent.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that both drugs are currently on the market. However, the story doesn\u2019t make clear to readers that both drugs have been approved by the FDA for use in treating advanced melanoma. That said, it\u2019s not a major oversight for most readers.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "A reader might reasonably conclude that the treatments the story describes are generally available. Whether the same outcomes are equally obtainable at all hospitals is unclear. The studies were performed at some of the leading spine centers in the world.", "answer": 1}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that the highlighted device, the RapidArc, was currently in use in only 30 locations in the US. \u00a0\n\u00a0", "answer": 1}, {"article": "In 37 years as a police officer, Edwin Michel coped with a plane crash, a sniper, wildfires and three bullet wounds.\n\nNothing much rattled him until he was diagnosed with prostate cancer in November 2016. His doctor said the cancer wouldn\u2019t kill him but Mr. Michel, now 76 years old, wasn\u2019t entirely reassured. He felt more confident after a genomics test later revealed his prostate cancer was very low risk. The test, known as Oncotype DX, takes a sample from a prostate biopsy and analyzes 17 genes in it to estimate how aggressive...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that these genetic tests are currently available.", "answer": 1}, {"article": "increases at age 4, although no cognitive benefit was seen in infants or 7-year-olds.\nThe lead researcher, Dr. Maria Makrides of the University of Adelaide in Australia, said this suggested that full-term babies already get enough DHA in the womb, and that \u201cthere\u2019s no extra boost\u201d from getting more.\nThat study\u2019s lead author, Dr. Ingrid Helland of Oslo University Hospital, said that perhaps the benefit shown at age 4 existed at 7 but was difficult to identify amid other developmental factors.\nHe said more research was needed, but for now, \u201cI think the market is running way out in front of the science.\u201d\n\nScientists agree that DHA, naturally transmitted to a fetus through the placenta in the last half of pregnancy, is important, probably to visual and brain development.\nShe said babies in her study might have received more DHA than those in this study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The widespread availability and use of fish oil is clear from the story.\u00a0 Although the story would have helped readers more by reporting on issues of purity, quality control, and difficulties for consumers in assessing the quality of a source or brand.\u00a0 This would have made it clear that this not a straightforward choice to just \"take fish oil.\"\u00a0 ", "answer": 1}, {"article": "And is the outcome the same for everyone?\u201d\n\nPuigserver, who runs a cancer biology lab at Dana-Farber Cancer Institute, noted that addressing health and aging through metabolism involves a complex web of pathways and mechanisms.\nGuarente pledged that Elysium Health would be unlike most other companies in the business: It is conducting studies of its pill in humans and will release the results.\nSzostak said his role at Elysium Health is to scour scientific literature for new natural compounds that are shown to improve health and bring them to the company\u2019s attention as potential ingredients in new products.\nOne of the venture capitalists backing Elysium Health acknowledged that skepticism is among the company\u2019s greater challenges.\nMany products in the supplement business are launched with questionable science, but Elysium said studies in mice show a clear connection between increased levels of this compound, called NAD, and improved health in older mice.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentions the pill will be available online and debuted on Tuesday.", "answer": 1}, {"article": "\"And in that case, I see this as just a waste of money.\"\nThe study was limited to high-functioning males and so did not allow researchers to generalize the findings to females, younger children, or \"lower functioning\" individuals with autism, the researchers wrote.\nFor her part, Laura Bono, the Durham, N.C.-based former chair of the National Autism Association and member of the board of directors of the autism advocacy group \"Safe Minds,\" expressed a certain amount of hesitancy about the prospects for MRI-driven diagnoses.\nThis tissue, the authors noted, is known to play a role in communication between various brain regions.\nThe current effort, focused on patients already diagnosed with autism, used MRIs to locate areas of the brain where the left and right hemispheres do not communicate properly.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "MRI is FDA approved and has been around for a good while and is available to most of the US population.\u00a0Still, there is no explicit mention in the story of MRI\u2019s availability in general, nor any specific mention some mention of how much difficulty patients might have seeking an MRI for this use. ", "answer": 0}, {"article": "\"If you are an Asian kid, you've had these placed on you since time immemorial,\" he said.\nBefore the FDA action, pain-relieving patches were available in the United States only by prescription, said Dr. John Dombrowski, director of the Washington Pain Center in Washington, D.C. Their active ingredients include such medications as lidocaine, capsaicin and non-steroidal anti-inflammatory drugs, or NSAIDs.\nThe patches also deliver their medicine directly to the site of a person's pain.\nPain patches have a number of benefits, Rosenquist and Dombrowski said, not the least of which is convenience.\nThe main downside to pain patches, however, apparently comes from their effect on the skin.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that pain-relief patches have been used in some form for decades while only recently becoming popular in the US. \u201cThe U.S. Food and Drug Administration approved the country\u2019s first over-the-counter, pain-relieving transdermal patches in 2008. But the patches, marketed under the brand name Salonpas, are nothing new. They\u2019ve been sold in various countries in Asia since the 1930s, according to their manufacturer, the Japanese firm Hisamitsu Pharmaceutical.\u201d", "answer": 1}, {"article": "However, he said, \"I think it is becoming more popular, both from a physician perspective but also from a patient perspective.\nAlthough there are no large-scale national results, doctors say studies have shown brachytherapy to be as effective as traditional radiation therapy.\nCancer Treatment Centers was among the first to adopt brachytherapy for breast cancer patients a decade ago, Kelly said.\nNot all communities offer radiation treatment, so women often must travel to receive it.\nBecause of the burden, doctors say, many choose to have mastectomies instead.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does not indicate whether brachytherapy is available at any hospital that provides cancer treatment or only at specialized facilities. ", "answer": 0}, {"article": "The researchers found that 10.2 percent of the patients who received zotarolimus-coated stents suffered a major adverse cardiac event, compared with 8.3 percent of the patients who received sirolimus-coated stents and 14.1 percent of those with paclitaxel-coated stents.\nIn preventing major cardiac events, the researchers found that zotarolimus-coated stents, the new entry in the field, were less effective than the sirolimus-eluting stents, but better than stents coated with paclitaxel.\nFonarow said the study results can help cardiologists arrive at treatment decisions.\nFor the study, a team led by Dr. Duk-Woo Park from the University of Ulsan College of Medicine and Asan Medical Center in Seoul randomly assigned 2,645 patients undergoing angioplasty, a procedure to restore blood flow through the artery, to one of the three stents.\nThe study was released online Sept. 27 ahead of print publication in the Oct. 5 issue of the Journal of the American College of Cardiology.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article could\u2019ve been more explicit about the availability of these 3 stents, but the last sentence describing the study\u2019s\u00a0real-world implications,\u00a0suggests that all 3 are currently available in cath labs.", "answer": 1}, {"article": "\u201cI tell my patients, \u2018buyer beware,\u2019\u201d Shepard said in an email.\nIn addition, U.S.-based studies of chondroitin have had mixed results, said Shepard, who wasn\u2019t involved in the study.\n\u201cHowever, it should not replace other therapy such as quad strengthening exercises, and weight loss, which we know will provide benefit.\nDr. Michael Shepard of Hoag Orthopedic Institute in Orange, California, noted that the study had a relatively low number of participants and that most U.S. studies of this type would run two years rather than six months.\n\u201cStudies like this highlight that medicine is still an art - we do not have perfect answers, and we have to individualize for each patient.\u201d\n\nThe study was sponsored by IBSA Institut Biochimique SA, a pharmaceutical company based in Lugano, Switzerland, that makes the chondroitin sulfate supplements used in the test.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that pharmaceutical-grade chondroitin is not the same as the labeled supplement one might buy over-the-counter, but makes no mention of how else to obtain it. Can doctors prescribe it? And do patients need a prescription to obtain it? Is there a brand name associated with the high-grade\u00a0formulation?", "answer": 0}, {"article": "Severe obesity is associated with serious physical and psychological conditions affecting quality of life.\n\u201cAlthough gastric banding has been controversial and is currently less used in adults with severe obesity, lap band surgery is one of the most studied surgeries for obesity management, has a high safety record and can be a temporary option to manage severe obesity during adolescence,\u201d says Mr Khurana, who is also a Senior Lecturer in the University of Adelaide\u2019s Discipline of Paediatrics.\n\u201cThe median BMI reduction of 10 kg/m2 with the lap band is a good result when compared to BMI reduction using the few medications available or lifestyle measures, which is around 1-3 kg/m2,\u201d says Dr Pe\u00f1a.\nHowever there is no data available in Australian adolescents beyond 24 months post-surgery.\nLed by University of Adelaide researchers, in collaboration with Flinders Medical Centre, and published in the journal Obesity Surgery, the study is the first to show medium to long-term follow-up (3-5 years) of lap band surgery in Australian adolescents.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that lap bands are now in use. The question posed here is whether they would be appropriate for seriously obese teenagers.", "answer": 1}, {"article": "Functional MRI scans generate a dynamic map of the outer surface of the brain, showing changing hot spots of activity over time.\nWe show here that it's not measuring what you're thinking, but how your brain is organized.\nIt's exciting to think that these individual differences may be related to personality, cognitive ability, or psychiatric or neurological disease.\nAll of the scanned brains belonged to young, healthy scientists and doctors.\nAlthough the technique's potential to identify brain disorders and diseases was noted years ago, fcMRI-based diagnostic tests have yet to make their way into doctors' offices.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We are not told how available fcMRIs are to the general public.", "answer": 0}, {"article": "Airways became less likely to close off after exposure to an allergen.\nThe drug also improved overall airway function, an effect researchers hadn't expected, Israel said.\nIt likely will be three to four years before Gleevec could be approved for asthma treatment, Israel estimated.\nPhysical examinations showed that people taking Gleevec actually experienced a slight overall widening of their airways, Israel added.\nTwo generic versions of the drug were launched last year, which could make it less pricey than new-wave asthma drugs headed for the market, Israel added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story tempers expectations when it quotes a researcher saying it will \u201clikely will be three to four years before Gleevec could be approved for asthma treatment.\u201d Further, it quotes an independent expert: \u201cIt will take years of study to determine the usefulness of this drug in treatment.\u201d", "answer": 1}, {"article": "Researchers found that the hormones, known as cardiac natriuretic peptides, caused regular energy-storing white fat cells to turn into energy-burning brown fat in mice.\nIf studies show the same thing in humans, the heart hormone may hold the key to an effective weight loss treatment, says researcher Sheila Collins, PhD, of Sanford-Burnham Medical Research Institute in Orlando, Fla.\n\u201cThese hormones are involved in fluid regulation, but we showed in this study that they also play a role in breaking down fat,\u201d she says.\nThe study appears online in the Journal of Clinical Investigation.\nFeb. 6, 2012 -- You may have heard about brown fat -- a unique type of fat that acts like a furnace in the body to burn calories instead of storing them as excess weight.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable; there\u2019s no product or treatment that can increase brown fat.", "answer": 2}, {"article": "\"The concept is very simple,\" Lee said.\nResearchers plan to start clinical trials next year to test this technology in humans, Sen said.\nWith this technology, we can convert skin cells into elements of any organ with just one touch.\n\"This is difficult to imagine, but it is achievable, successfully working about 98 percent of the time.\nIn my lab, we have ongoing research trying to understand the mechanism and do even better.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "From the final sentence we get a hint that applicability in humans is a long way off: \u201cResearchers\u00a0plan to start clinical trials next year to test this technology in humans.\u201d\nIt\u2019s important to note that\u00a0potential treatments in mice fail to materialize as a treatment in humans about 95 percent of the time. The release should have been a lot more cautious and pointed out that this concept will require many years of study.", "answer": 1}, {"article": "Although TEPI patch remains highly tacky and adheres well to skin, it is not uncomfortable to peel off, unlike many traditional plasters.\nWe\u2019re controlling the dosage and we\u2019re keeping it there for a prolonged period of time.\u201d\n\nThe patches could help treat conditions like chronic back pain, neuralgia and arthritis without the need to take potentially damaging doses of the drug orally.\nWe\u2019ve tested them in our polymers with very good results, we\u2019ve been able to get increased loadings of drugs in the polymer and we\u2019ve shown almost across the board that we can get a steady release rate of that drug from the polymer as well.\u201d\n\nThe team says TEPI patches could go on sale within three years, and Medherant is working with some large, unnamed, pharmaceutical companies to get them ready for market.\nHaddleton says the technology has exciting potential for other medications, such as opioid painkillers.\n\u201cOne of the interesting areas that we plan to explore in partnership with large companies is actually using our platform technology to include other drugs that previously maybe haven\u2019t been suitable for topical or transdermal delivery - or drugs which may have not got through the regulatory filings because, for instance, they might have caused stomach irritation or other side effects when taken orally,\u201d said Lee.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story tells us the the patches are expected to hit the market in three years, but the information comes direct from the company and isn\u2019t independently verified. Given the stage of development for this technology, three years sounds like a very aggressive timeline given the need for clinical validation of the assumptions made and the need for regulatory approval.", "answer": 0}, {"article": "Lung cancer is the No.\n\u201cThis new information adds to the growing body of evidence that metformin may help prevent and inhibit the progression of lung cancer,\u201d Gutterman said.\nBut Dr. David Gutterman, president of the American College of Chest Physicians, said more research would be needed before this could be proposed.\nMetformin is one of the most widely used drugs for type 2 diabetes, with 41 million prescriptions written in the United States in 2008, the American College of Chest Physicians said in a statement.\n\u201cOur study, as well as other research, suggests an association between metformin and/or TZD use and the risk of developing lung cancer,\u201d said Dr. Peter Mazzone of the Cleveland Clinic in Ohio, who led the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that these drugs are commonly used for diabetes and some are available generically. Ideally the article could\u2019ve stated explicitly that they\u2019re not approved to prevent or control cancer.", "answer": 1}, {"article": "Nov. 5, 2012 (Los Angeles) -- An IV infusion of \"good\" HDL cholesterol seems to rapidly remove cholesterol out of plaque-clogged arteries following a heart attack, a small, early study suggests.\nThe goal of the new treatment is to reduce the high risk of a second heart attack in people who have had a heart attack.\nStandard heart attack medications, such as aspirin and anti-clotting drugs, prevent clotting but don\u2019t eliminate an underlying factor: cholesterol that has built up on artery walls, he says.\nGille is head of clinical and translational science strategy at CSL Limited (which funded the study) in Parkville, Australia.\nHDL removes cholesterol from artery walls, but current HDL-boosting drugs, such as niacin and fibrates, take years to work, according to Gille.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Significant omission.\u00a0 How does one get IV infusions of \u201cgood\u201d HDL cholesterol?\u00a0 Where does one go for this?\u00a0 Is it only the experimental setting?\u00a0 You can\u2019t assume that readers know and understand this.", "answer": 0}, {"article": "For more on childhood obesity, visit the U.S. Centers for Disease Control and Prevention.\nThe daily routine might translate into less TV time and more regular sleep schedules, she said.\nMONDAY, Jan. 12, 2015 (HealthDay News) -- School readiness isn't the only benefit young children can gain from Head Start.\nWhether those children were in another preschool program wasn't stated.\n\"The children may be served healthier meals at Head Start than other children.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that Head Start is available to children ages 3-5 who live in poverty. We\u2019ll rate this good enough for a satisfactory grade. \u00a0Detail about how to enroll in the program would have helpful.", "answer": 1}, {"article": "\u201cNow we know that electrical impulses to the olfactory bulb can provide a sense of smell \u2014 and that\u2019s encouraging.\u201d\n\nIn addition to Dr. Holbrook, authors on the International Forum of Allergy & Rhinology study include co-first author Sidharth V. Puram, MD, PhD, of Washington University School of Medicine, Reiner B.\nReporting online today in International Forum of Allergy & Rhinology, the research team describes their results, which provide a proof of concept for efforts to develop implant technology to return the sense of smell to those who have lost it.\nThere are currently no proven therapies for these cases.\nThe findings described in the International Forum of Allergy & Rhinology report demonstrate this feasibility.\nThis breakthrough in human patients opens the door for a \u201ccochlear implant for the nose\u201d to be developed \u2014 though the study authors caution that the concept of an olfactory stimulator is more challenging than existing technologies.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that a tremendous amount of work needs to be done before any relevant treatment technology might become available.", "answer": 1}, {"article": "Drs.\nAsher and Burri are now working on a new method of focused therapy for tumors that have spread to the brain that combines radiation and surgery.\nThe technique was pioneered at Levine Cancer Institute and they are looking to expand and further validate the approach with the National Cancer Institute.\nAlmost one in four of those patients (about 400,000) will experience spread of their cancers to the brain.\nFurthermore, whole brain therapy was associated with considerably worse quality of life.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the treatments are currently in general use.", "answer": 1}, {"article": "Coleman RE, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero JC, Rojo F, Gregory W, and Gomis RR.\nThe new study, which is published in the journal Lancet Oncology, was part of an international phase 3 clinical trial involving 3,360 women with stage II or III breast cancer.\nThe results need to be confirmed in a second trial, currently underway in the United States, before the test is likely to receive approval for wider use in patients.\n\u201cThe difficulty is identifying which patients will benefit from these drugs,\u201d said Professor Robert Coleman, emeritus professor of medical oncology who led the new study.\nWomen who do not carry the gene - approximately 80 per cent of women with breast cancer - were found to benefit from the bone strengthening treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that \u201cThe results need to be confirmed in a second trial, currently underway in the United States, before the test is likely to receive approval for wider use in patients.\u201d \u00a0A direct statement that the test is not yet available anywhere would have been more helpful to readers but the quote does let readers know that the test is part of another trial and has not yet been approved.", "answer": 1}, {"article": "Cytoxicity refers to being toxic to cells in the body.\nIf there is a similarity, it may explain why H1 viruses are vulnerable to urumin's wrath.\nThe urumin peptide could be a novel treatment since it targets the hemagglutinin, unlike current drugs on the market which target other parts of the virus, resulting in less impact, Jacob said.\nIf those studies prove to be successful, human testing could be next.\nGregory Chinchar, a professor in the University of Mississippi Medical Center's department of microbiology and immunology, said that he was surprised that the peptide targeted the hemagglutinin on the flu virus.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it very clear\u00a0that research has been conducted only in mice and that much more work needs to be done before it can even be assessed in humans.", "answer": 1}, {"article": "Nearly a quarter of a million people worldwide have leprosy, which causes disfiguration of the skin and mucous membranes as well as progressive and incurable nerve damage.\nThe vaccine candidate will serve as part of an overall strategy to end leprosy, which will require detection, prevention and treatment.\nBased on data generated in preclinical studies, the vaccine candidate, called LepVax, has progressed to Phase I clinical testing in the United States, the first stage of safety testing in human volunteers.\nReed, along with scientists from a variety of scientific organizations recently published \"Innovative tools and approaches to end the transmission of Mycobacterium leprae\" in , outlining what is needed to achieve this goal.\nThe clinical trial is focused on safety, as well as evaluating the immune response to the vaccine.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does a good job here, noting: \u201cEarly results from the Phase I study should be available in 2018, and the partners are currently exploring mechanisms to advance the vaccine through later-phase clinical trials should results from the Phase I study (clinical trial NCT03302897) support further evaluation.\u201d", "answer": 1}, {"article": "According to Kramer, \"This randomized study concludes that [aspirin's] use is not only effective for reducing the incidence of preeclampsia at term, but also preterm.\nThe reduction in risk was even greater for early deliveries.\nIt can affect all of the organs in a woman's body, according to the American College of Obstetricians and Gynecologists (ACOG).\nAbout 1,600 women completed the double-blind, placebo-controlled study.\nLow-dose aspirin can also help reduce the chances of eclampsia, which is seizures due to preeclampsia for high-risk women, Kramer noted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As mentioned above, aspirin is ubiquitous in the modern world so there is hardly a problem with its availability.", "answer": 1}, {"article": "Compared with the 16% of people who didn't drink coffee at all, those who downed two or more cups each day were about 18% less likely to have died during the study period. In addition, those who drank just one to six cups of coffee per week were 12% less likely to die. Both of these figures were calculated after taking into account known risk factors for early death, such as smoking (which is often paired with coffee drinking), diet and body mass index.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Coffee is so widely available that there\u2019s no need to make the point.", "answer": 2}, {"article": "Therefore investigators recommended that only patients who are younger than 76 years old, and who do not suffer from other health problems use FOLFIRINOX.\nPart of the group was given gemcitabine, the most favored treatment according to oncologists.\nThe treatments lasted for six months.\nThe purpose of the study was to record the overall survival rates of each group.\nOnly about 6 percent of those with the diagnosis live longer than five years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the drugs was not discussed.\u00a0 This was a story about a French study.\u00a0 Are the drugs widely available in the US?\u00a0 The story never explained.", "answer": 0}, {"article": "For more on stroke, visit the National Stroke Association.\nAmong more than 200 stroke victims, TNKase (tenecteplase) was about twice as effective as alteplase in restoring blood flow to the brain, and it also resulted in less disability, the scientists found.\nArora explained that tenecteplase is not widely used in the United States for heart attack patients because these patients are typically treated with angioplasty or heart bypass surgery.\nIn this study, patients were given the drugs within 4.5 hours after the onset of a stroke, Campbell said.\n\"Tenecteplase is likely to become the preferred medication for clot-dissolving in stroke patients,\" said lead researcher Dr. Bruce Campbell, head of the stroke department at the Royal Melbourne Hospital in Parkville.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story said tenecteplase is not approved for stroke in the United States, though it used for other purposes like heart attacks and blood clots in the lungs.\nIt also notes that \u201cfor either drug to be most effective, it needs to be given as soon as possible after a stroke occurs,\u201d and in this study patients were given the drug within 4.5 hours of the onset of a stroke.", "answer": 1}, {"article": "Why Biogen is breathing a sigh of relief with the latest Alzheimer\u2019s data\n\nWe already know Eli Lilly\u2019s big bet on Alzheimer\u2019s disease didn\u2019t work. But a deep dive into just how it failed has provided a bit of encouragement to Biogen and the many companies still hoping to succeed where their rival fell short.\n\nLilly\u2019s treatment, solanezumab, had no significant effect on the buildup of toxic brain plaques believed by many to be responsible for Alzheimer\u2019s neuron-destroying effects. The company had already disclosed that the treatment failed to improve patients\u2019 cognition and function, but the new data, released Thursday night, shed some important light on the underlying biology.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes pretty darn\u00a0clear that there will be a) no final answers to the amyloid hypothesis debate any time soon; and b) the advent of a successful anti-amyloid drug that helps those with\u00a0Alzheimer\u2019s is not close at hand.", "answer": 1}, {"article": "They were divided in groups of 10.\n\u201cHowever, much more work needs to be done until we can say with certainty that it will tackle the disease in humans as mouse models don't always faithfully replicate the human disease.\nBrough, however, cautioned that further research is required to identify its impact on humans and the long-term implications.\nOur research shows for the first time that mefenamic acid, a simple [NSAID] can target an important inflammatory pathway called the NLRP3 inflammasome, which damages brain cells,\u201d David Brough, lead author of the study said, in a statement.\nResearchers said that the lab results identify a class of existing drugs that are likely to treat Alzheimer\u2019s by blocking a particular part of the immune response.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It says that the drug being studied is\u00a0\u201ca common Non-Steroidal Anti Inflammatory Drug (NSAID).\u201d This\u00a0is\u00a0true for readers in the UK (where the study originates), so we\u2019ll rate this Satisfactory. However, for readers in the U.S. (Medical Daily is an American-owned news site), this is not the case, and it would have been helpful to explain the drug is available by prescription in the U.S., though it is not commonly used.", "answer": 1}, {"article": "Lung cancer kills more Americans than any other type of cancer, nearly 160,000 last year.\nJanne, also a professor at Harvard Medical School, said more research is needed before lung cancer patients should be routinely treated with Opdivo, Keytruda or similar drugs.\n\"It is early days for the successes of immune therapy,\" said Mark Fishman, president of the Novartis Institutes for BioMedical Research, a research arm of drug company Novartis, which is taking a different approach to turning the immune system against cancer.\nThere have been no other recent treatment breakthroughs in squamous cancer, which most commonly occurs in smokers or former smokers, so this advance is particularly welcome, said Janne.\nFor other patients, researchers expect other drugs will be needed, too.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Opdivo is approved to treat advanced melanoma. And Pasi Janne, a professor at Harvard Medical School and director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, says more research is needed before \u201cpatients should be routinely treated with Opdivo\u201d and that \u201cit\u2019s a little premature to start treating people today\u2026but I don\u2019t think we\u2019re far away from that.\u201d That\u2019s all very useful context. However, it\u2019s not clear at the end of the day what any of this means for patients. Could Opdivo, given it\u2019s melanoma approval, now be used off-label to treat lung cancer? Should patients expect this treatment to become available in six months? Six years? Ten years? The story also doesn\u2019t note that the study being halted by Bristol-Myers Squibb is a Phase III trial.", "answer": 0}, {"article": "\"When adolescent depression persists without successful treatment, it can interfere with achieving important developmental milestones.\nJames Stone, a clinical senior lecturer from the Institute of Psychiatry, Psychology and Neuroscience at King's College London, who was not involved in the study, told Newsweek that there is \"a lot of potential for the use of ketamine as a second or third line antidepressant where other treatments have failed.\"\nThe study serves to point out the need for further, rigorous, study designed to answer the many questions that remain about ketamine for TRD, such as optimal dosing and route of administration, dosing interval and treatment length, and long-term effects\u2014just to name a few.\"\n\"Although ketamine is potentially a huge breakthrough in the treatment of depression, we still don\u2019t know about the long-term safety, or about how to keep people well from depression without requiring regular ketamine dosing,\" Stone added.\nThe latest study involved 13 young people ages 12 to 18 who had failed two previous trials of antidepressants.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story called ketamine \u201ca popular recreational drug and a useful medical anesthetic.\u201d It could have added that while ketamine is an FDA-approved drug for years and is widely available at medical facilities, it hasn\u2019t been approved by regulators for use as an antidepressant.\nIn addition, Johnson & Johnson has said it is close to seeking FDA approval of a ketamine derivative called esketamine, which would be taken as a nasal spray.", "answer": 1}, {"article": "Premature birth can lead to a long list of medical problems and puts babies at risk of dying.\nThe test wasn't as effective at 24 weeks of gestation.\nThe test may cost $150 to $250, Graves said.\n\"If you are going to be alarming a patient by saying that she may have premature delivery, you want to make sure that's truly the case.\"\nIt would require several years to go through the U.S. Food and Drug Administration approval process.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that \u201cIt would require several years to go through the U.S. Food and Drug Administration approval process.\u201d", "answer": 1}, {"article": "In the UK, at least 40,000 people a year die prematurely from air pollution, with a cross-party committee of MPs calling it a \u201cpublic health emergency\u201d.\nBilstein said the inhaler could be useful around the world, as particulate air pollution is not just a European problem: \u201cEspecially in Asia \u2013 China in particular \u2013 the demand for such a product is even higher.\nThe best thing is that we have clean air because then we don\u2019t need any prophylactic treatment.\nRussell, who also lectures at Imperial College and Oxford University, said it might also be useful for the treatment of asthma, COPD and other lung diseases, not only prevention.\n\u201cThe point that it can prevent the lung inflammation induced by ultrafine particles is established \u2013 there is no more doubt,\u201d Krutmann said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it relatively clear that the inhaler isn\u2019t available but should be soon.\u00a0More specifics would have been helpful, though.", "answer": 1}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The text mentioned that vitamin B12 supplements were available in pill and injectable form; \u00a0a table listing food sources of B12 was included.", "answer": 1}, {"article": "No one knows why some women have this capability and others do not, but for those who lack it the Inovio vaccine is \"giving our immune system a little boost,\" Kim said.\nThe researchers did not observe any side effects.\nThe study was not done as a randomized controlled trial, the gold standard for determining whether a drug works better than chance.\nThis happens in anywhere from 10% to 25% of women infected with HPV, Kim said.\n\u201cSeveral therapeutic vaccines have shown great promise in phase 1 and then not panned out in phase 2,\u201d she noted in an e-mail.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "They did briefly discuss future clinical trials and did not try to estimate when a vaccine would be available.", "answer": 1}, {"article": "Breast cancer has a high rate of metastasis to bone, lung, liver, lymph nodes, and the brain.\nTherefore, they expect it will be safe if ultimately developed for clinical use.\nIt could also become useful as a non-invasive way to assess breast cancer treatment progress.\u201d\n\nThe team plans to complete safety testing of the imaging agent during the next three years.\nTheir approach detects micrometastases, breakaway tumor cells with the potential to develop into dangerous secondary breast cancer tumors elsewhere in the body.\nPrior to their study with this contrast agent, Lu\u2019s team had conducted studies to determine its clearance from the body after the imaging, which is essential for safe clinical use.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although it takes time to get there, the release does explain that this is not available for clinical use now and will not be until further work is done.", "answer": 1}, {"article": "Attention, memory, and language improved.\nThe Mediterranean diet can improve your mind, as well your heart, shows a study published in the open-access journal Frontiers in Nutrition.\nThe main foods in the Mediterranean diet (MedDiet) include plant foods, such as leafy greens, fresh fruit and vegetables, cereals, beans, seeds, nuts, and legumes.\nMoreover, the benefits to cognition afforded by the MedDiet were not exclusive to older individuals.\nThey envision that the utilization of a dietary pattern, such as the MedDiet, will be an essential tool to maintain quality of life and reduce the potential social and economic burdens of manifested cognitive declines like dementia.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The ingredients of the Mediterranean Diet are available worldwide.", "answer": 2}, {"article": "For example, children with Down syndrome often have flat nasal bridges \u2014 as do typically developing African or African-American children.\nTo continue to fix this problem, both the NIH and Face2Gene need help from more researchers who can upload more patients\u2019 faces \u2014 but that\u2019s easier said than done.\nThe ultimate goal would be a simple tool that any doctor could use anywhere to get fast results and better diagnose their patients.\nFDNA is working on establishing partnerships with pharmaceutical companies to start their commercial outreach.\nThe algorithm the NIH uses \u2014 developed by scientists at Children\u2019s National Health System in Washington, D.C., \u2014 seems to work pretty well so far: In 129 cases of Down syndrome, it accurately detected the disorder 94 percent of the time.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear if this technology is available to anyone or if it is entirely in the research phase. This sounds developmental, but it was not clear. On visiting their website, it appears that it is already available for use.", "answer": 0}, {"article": "\"We adjusted for as many of those differences as we could,\" Wong said.\nOther experts expressed skepticism, saying the study's design may have missed another explanation for the lower death rate among men who were treated: They were probably healthier in ways that doctors can tell only by examining them, not by looking at their medical records, which is what the study's authors did.\n\"For many years, the thinking has been that observation or 'watchful waiting' was the safest option for elderly patients with early prostate cancer,\" said Yu-Ning Wong of the Fox Chase Cancer Center in Philadelphia, who led the study.\nThe findings prompted debate among specialists, who said the results could have potentially far-reaching implications because they address one of the central quandaries about prostate cancer and because the disease is so common.\nThe research, published in today's Journal of the American Medical Association, is the first to directly examine what has become conventional wisdom: that many older men need not treat early prostate cancer because it tends to grow so slowly that they will probably die of something else first.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that\u00a0the study followed men who chose aggressive treatment (either surgery or radiation) or observation (also known as watchful waiting)\u00a0for early prostate cancer, indicating these options are currently available to manage early prostate cancer.\u00a0 ", "answer": 1}, {"article": "According to Dr. Anthony L. Komaroff, a Harvard internist and epidemiologist who has written a commentary to accompany the study, \"For many years medical scientists have speculated that the symptoms of ME/CFS might be caused by cytokines, molecules that the immune system use to wage war against foreign invaders of the body.\nWhat's more, the findings also point to possible treatment with immune-modifying or anti-inflammatory therapy.\nResearch findings from Stanford University released Monday could point the way to a long-sought diagnostic laboratory test for the condition, and possibly a first-ever treatment.\nThis is significant because symptoms in these patients and findings from other studies also suggest that chronic inflammation plays a major role in the illness.\nIn fact, they're experiencing profound exhaustion that isn't relieved with sleep, flu-like symptoms, muscle pain, \"brain fog\" and various other physical symptoms, all of which characteristically worsen with even minor exertion.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that both this type of test and proposed treatments are still experimental.", "answer": 1}, {"article": "[2] Quotes direct from author and cannot be found in text of Article.\nUse of this approach is likely to have major benefits for both patients and healthcare providers.\nUsing this test, troponin levels were measured in over 6000 patients with chest pain admitted to four hospitals in Scotland and the USA.\nUsing this threshold in routine practice could potentially double the number of patients suitable for immediate discharge directly from the emergency department, say the authors.\nThis study was funded by the British Heart Foundation and Chief Scientists Office (Scotland).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release never explicitly states whether this is now being used, either at the study sites involved or elsewhere.", "answer": 0}, {"article": "The researchers found that the risk for heart disease during the follow-up period was similar to that seen while the women were taking the hormone.\nIn fact, the women who took the hormone ended up being at somewhat higher risk for fractures.\nBut the Women\u2019s Health Initiative stunned doctors and women when researchers reported that the risks of the hormones outweighed any benefits.\nThere\u2019s some good news and some bad news for women who took estrogen to help them get through menopause until the health risks of taking the hormone were discovered.\nThe women had taken estrogen for about six years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nEstrogen is widely available, so the story does not need to dwell on this.", "answer": 2}, {"article": "In the study, published in the Annals of Internal Medicine, researchers reviewed 83 studies on the two methods.\nResearchers say needle biopsy has fewer complications and a shorter recovery time than open surgical biopsy, but some women and doctors may have concerns about the accuracy of the procedure compared with traditional open surgery methods of breast cancer diagnosis.\nA new review of more than 80 studies on the two breast cancer screening methods shows breast needle biopsy was able to distinguish between cancerous and noncancerous breast lesions with about the same accuracy as surgical biopsy and less than half the risk of complications.\nThey say additional studies are needed to find out what factors affect the accuracy of core-needle breast biopsy.\nIn addition, the study showed women initially diagnosed with breast cancer with needle biopsy were more likely to be treated with a single breast cancer surgery than those initially diagnosed by open surgical biopsy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if all hospitals offer women core needle biopsy as an option prior to, or instead of open surgical biopsy. We are not told if recent evidence has affected clinical guidelines for suggested biopsies following an abnormal mammogram.\u00a0 We are not told that some women may not be appropriate candidates for core needle biopsies.\u00a0 The article notes:\u00a0The location and type of lesion, as well as other medical considerations, sometimes dictate the type of biopsy, but in many cases patient preference is the most important factor in the decision.", "answer": 0}, {"article": "MRI highlights angiogenesis, the formation of new blood vessels, especially those that feed cancerous tissues.\nHowever, still more research is needed to clarify the role of MRI in this population, she said.\nBut it takes no position on MRI imaging for women who have had breast cancer, saying there is not enough evidence to recommend one way or the other.\nWhile the society recommends neither for nor against MRI imaging for those with a personal history of breast cancer, he said it regularly reviews study findings to determine if the guidelines need updating.\nWith the MRI screen, \"we found cancer in just over 3 percent of women [with a personal history], which was double [that found in those with a genetic or family history],\" she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story does not address the availability of appropriate equipment and skilled operators and radiologists. The story should have pointed out that MRI imaging available to women in general may not match the quality of the work done in this research study.", "answer": 0}, {"article": "TUHS neither provides nor controls the provision of health care.\nThe study is especially exciting because zileuton is already approved by the Food and Drug Administration for the treatment of asthma.\nThe study, published online in the journal Molecular Neurobiology, raises new hope for human patients affected by dementia.\nOther researchers contributing to the study include Phillip F. Giannopoulos and Jian Chiu at the Alzheimer's Center at Temple, LKSOM.\nTheir superior performance suggested a successful reversal of memory deficiency.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes the statement, albeit at the very end, that the research could \u201csoon translate\u201d into clinical use. That is at best misleading and provides a false hope for patients and their families, given that no timetable or process is given for what would be required to take the step to human use. \u00a0A plus is that the drug already is approved for use in asthma, but it is likely that even if further animal studies confirm the current work, clinical use is still months or even years away.", "answer": 0}, {"article": "For example, a normal-weight woman should gain between 25 and 35 pounds, while an overweight woman should gain between 15 and 25 pounds.\nThere was no clear benefit among the women in the diet and exercise groups when the researchers looked at other complications, such as cesarean delivery, but it did look like there may be some benefit, they write.\nShe cautioned, however, that women should check with their doctors before starting a diet and exercise program during pregnancy.\nWhile the new study generally did not show fewer complications in the diet and exercise group, Dr. Loralei Thornburg told Reuters Health that it\u2019s good that there was no increase in complications.\nThe review incorporates dozens of new studies to update a previous review that did not find enough evidence to support the use of diet and exercise during pregnancy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It might have been useful to give readers a sense of\u00a0whether diet and/or exercise programs are routinely available to pregnant women (either through their obstetricians or in the community). However, we won\u2019t penalize the story for not addressing this, since it\u2019s also possible to exercise without any supervision.", "answer": 2}, {"article": "After all, our immune system evolved over millions of years to respond to infections of injured skin, not vaccines delivered by hypodermic syringe into muscle,\" he noted.\nNearly all modern vaccines are given via injection, according to background information in a news release about the study, which is published in the Jan. 17 issue of Nature Medicine.\n\"We should also continue to explore the implications for developing powerful cancer vaccines, like the one demonstrated by melanoma vaccine results in this study.\"\nThey also found that a melanoma vaccine delivered by scarification was much more effective than injected vaccines in protecting animals against melanoma tumor growth.\n\"This research illustrates the remarkable capacity of the most superficial layer of skin to generate powerful protective immune responses after vaccination,\" study senior researcher Dr. Thomas Kupper, chairman of the dermatology department at the hospital, said in a news release from the hospital.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It was not at all clear from the story whether anyone still uses the skin scratch \u2013 or scarification \u2013 method of vaccine delivery. ", "answer": 0}, {"article": "\"Weight loss was similar but substantial in both groups we studied, but blood pressure improved more in the low-carb dieters,\" said study author Dr. William Yancy Jr., an associate professor of medicine at Duke University Medical Center and a staff physician at the Department of Veterans Affairs Medical Center in Durham, N.C.\n\n\"There are options out there.\nThe more intensive intervention was more successful with 31 percent losing more than 5 percent of their body weight, compared to just 9 percent of the Internet group.\nTwo other studies in the same issue of the journal look at the effectiveness of the anti-hypertension DASH diet and a physician-supervised plan.\nThe group taking orlistat received a 120-milligram dose of the drug three times daily and got less than 30 percent of their calories from fat.\nYancy said the blood pressure and cholesterol drops might have been even more impressive if people had stayed on their medications, but as they lost weight and normalized these readings, the doctors took them off blood-pressure and cholesterol drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that orlistat is available via prescription as Xenical and over the counter as Alli. The availability of the low-carb and low-fat diet options is not in question.", "answer": 1}, {"article": "\"To address inconsistencies in prior studies on vitamin D and to investigate associations in population subgroups, we analyzed participant-level data, collected before colorectal cancer diagnosis, from 17 prospective cohorts and used standardized criteria across the studies,\" said Stephanie Smith-Warner, PhD, an epidemiologist at the Harvard T.H.\nOptimal vitamin D concentrations for colorectal cancer prevention may be higher than the current National Academy of Medicine recommendations, which are based only on bone health.\nHowever, risk did not continue to decline at the highest concentrations.\nA single, widely accepted assay and laboratory was used for new vitamin D measurements and calibration of existing vitamin D measurements.\nThe study appears online in the Journal of the National Cancer Institute.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Supplements, vitamin D-containing foods, and sunlight are pretty much available everywhere.", "answer": 2}, {"article": "Patients lie in a CT scanner, which takes a series of pictures from a variety of different angles, and a computer compiles the snapshots in two different ways.\nThat\u2019s a bit of a surprise, given that not all medical experts agree on whether the virtual screen is as reliable as a traditional colonoscopy, in which doctors insert a scope with a small camera into the colon.\nAdd to that the aggressive public awareness campaign for colonoscopy screening led by celebrities like Katie Couric, who allowed TV cameras in as she got her first test, and it\u2019s clear why more people are familiar with the scope than with its virtual cousin.\nAnd given the relatively low cost of investing in the software and other equipment required to run a virtual scan, more hospitals may be adding the option to their patient services.\nBut in spite of those challenges, Megan McHugh at the Health Research and Educational Trust in Chicago and her team report that about 17% of hospitals in the U.S. now offer the screening test, up from 13% in 2005.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is based on estimates of the rising use of virtual colonoscopy and cites one estimate that 17% of US hospials now offer it. The story suggests that the availability of CT colonoscopy is \u201con the rise.\u201d In reality the study in question actually demonstrated only a 3% increase over a 3 year period.\u00a0 Is that high or low?", "answer": 1}, {"article": "Menstrual cramps, known by the medical name dysmenorrhea, typically begin just before or at the start of a woman's menstrual period and can last several days.\nGraham and Rabin agreed that much larger trials should be done before they would recommend vitamin D3 use to any of their patients for cramp relief.\nAnd since the study period lasted only two months, there was no way to tell whether such a high dose produced any toxic long-term effects.\nThe 300,000 IU dose of vitamin D3 given in the study also far exceeds the daily intake of 600 IUs recommended for American women of reproductive age, both Graham and Rabin said.\nExperts wondered if women with higher blood levels would experience such dramatic cramp relief as observed in the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have done a better job on this point. Although Vitamin D is available over the counter, it is available in the high dose used in the study only by prescription. Just to put this dose issue in context, when people are Vitamin D deficient, a typical replacement dose is 50,000 units weekly for 8 weeks (a total of 400,000 units).\u00a0 So the 300,000 one-time doses are not as outlandish as they seem when compared with a typical maintenance dose of 600-800 IU/day.", "answer": 0}, {"article": "And general practice physicians missed cancers 60 percent more often than gastroenterologists.\nBoth groups could do things to improve the detection rate, they said.\nAnd for this, patients should do their part.\n\u201cThis is very different from a population undergoing screening.\u201d\n\nColonoscopy would probably miss a smaller percentage of cancers in such a large population, Lieberman said, because the rate would be lower.\nCanadian researchers note that their finding should be a heads-up to clinicians performing the exam, as well as to patients preparing for it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the screening is widely available and is the standard.", "answer": 1}, {"article": "PD-1 or PD-L1 inhibitors work by blocking a mechanism of tumors that allows them to evade detection by cancer-fighting cells.\nKeytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer, helping the drug meet the main goal of the late-stage study, Merck said.\nEsophageal cancer is the seventh most commonly diagnosed cancer in the world, the company said.\n\u201cThis marks the sixth tumor type where Keytruda has demonstrated a survival benefit, and represents the first time an anti-PD-1 therapy has achieved overall survival for this patient population,\u201d said Roy Baynes, chief medical officer of Merck Research Laboratories.\nMerck said trial results would be presented at an upcoming medical meeting.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll give the story the benefit of the doubt on this one because it explained that the drug is Merck\u2019s top selling drug and has already been FDA-approved for use in other cancers.\nHowever, the story didn\u2019t explain that because Keytruda is not approved for use in gastric cancers, some providers including Medicare supplement providers, may not provide coverage.", "answer": 1}, {"article": "In devising their models, the researchers updated assumptions that have cast doubt on the relevance of existing breast-cancer risk calculators, which relied on the experiences of women who got an earlier generation of screening mammograms and were more likely to die of breast cancer than is currently the case. Here, teams of modelers from Erasmus University in the Netherlands, Albert Einstein College of Medicine in New York and Harvard Pilgrim Healthcare assumed that women were getting digital mammograms, which offer improved cancer detection rates at lower radiation dosages than earlier mammographic methods. They took into account improved rates of breast cancer treatment effectiveness, and changing causes of mortality for women older than 50. They also took account of the fact that breast density decreases in older women.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Digital mammography is available across the United States, so we\u2019ll rate this N/A.\nHowever, the news story would have been stronger had it more clearly explained that these findings were based on an assumption of all-digital mammography. Not all women have access to digital mammography and\u00a0may have to travel farther for digital screening. Travel is often a barrier to screening in the first place, especially for those who rely on public transportation.", "answer": 2}, {"article": "\"This is the first and only point-of-care screening test designed to identify infants that do not have enough Bifidobacterium levels to create a stable infant gut microbiome,\" said Dr. Henrick.\nEvivo has commenced rigorous clinical trials with the prototype to demonstrate the results from infant stool samples.\nIn a landmark clinical trial, Evivo produced rapid, substantial and persistent stabilization of the infant gut microbiome, to help set a foundation for life-long health.\nEvolve BioSystems' Evivo is the only baby probiotic clinically proven to restore Bifidobacterium to a baby's gut and reduce potentially harmful bacteria by 80 percent.\nEvivo's quick and non-invasive test measures the presence of markers that indicate low or high levels of good Bifidobacterium , such as acetate and lactate.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The Evivo stool test is described as a prototype, implying it\u2019s not available on the market.", "answer": 1}, {"article": "LONDON -- AstraZeneca PLC said Monday its experimental heart pill Brilinta was more effective at preventing heart attacks and strokes in a large clinical trial than the blockbuster pill Plavix, boosting commercial prospects for the U.K. drug maker's still unmarketed treatment.\n\nPlavix, which is marketed by Sanofi-Aventis SA and Bristol-Myers Squibb Co., was the second-biggest-selling drug in the world last year, with global revenue of $8.6 billion, according to IMS Health. Any competitor to it could have a shot at big sales.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that Brilinta is not yet available. It says the company plans to submit the drug for approval in the fourth quarter of this year. \nWisely, the reporter resists predicting when the drug might be on the market, since this is not guaranteed. ", "answer": 1}, {"article": "HPV, a sexually transmitted disease, can be transmitted through vaginal, anal, and oral sex and has been linked to genital warts as well as cervical, vaginal, vulvar, oral, penile, and anal cancers.\nThe vaccine is recommended for optional use in boys and men.\nThe vaccine is used in girls and boys and young adults ages 9 to 26 for prevention of genital warts caused by HPV types 6 and 11.\nBoth of these vaccines are recommended to prevent cervical cancers.\nThe Gardasil vaccine has also received FDA approval for prevention of genital warts.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that Gardasil is avaialble and has been approved for use in girls and young women as well as in their male counterparts.", "answer": 1}, {"article": "It measures the damage to the DNA of white blood cells when subjected to different intensities of ultraviolet (UV) light, revealing measurable differences in the cells' susceptibility to further damage in patients with cancer.\nThe research team believes that the test could be the first screening tool to 'rule in, or rule out' cancer in patients under suspicion of the disease, alongside other traditional diagnostics methods.\nIMSTAR's vice-president for medical applications, Dr Michel Soussaline, confirmed that the company will be working to automate the full test workflow further to take it to market.\nThe Bradford team had scored 100 cells per slide, but the Pathfinder\u2122 system is able to analyse up to 10,000 cells per slide, and uses Artificial Intelligence concepts in its proprietary software.\n\"I'm now convinced that if we used the powerful IMSTAR system to look at thousands of cells on all the slide samples in the trials, we would see a significant increase in the overall predictability beyond the original 93 per cent of the original 2014 study.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The text offers only a general statement at its end indicating that work to develop the test will continue. Ideally the release would have explained that a prospective trial is still needed.", "answer": 0}, {"article": "\"I don't think pregnancy should be the thing that tips the scale,\" said Caughey.\nNearly 179,000 obese people underwent weight-loss surgery in the United States in 2013, according to the American Society for Metabolic and Bariatric Surgery.\nHe also noted that some experts advise women who undergo weight-loss surgery before pregnancy to delay conceiving until 12 to 24 months after the procedure, the period when the most rapid weight loss occurs.\nThe American Society for Metabolic and Bariatric Surgery offers more about weight-loss surgery.\n\"The positive effects of bariatric surgery on health outcomes -- such as diabetes and cardiovascular disease -- are reasonably well-studied, but less is known about the effects on pregnancy and [post-delivery] outcomes,\" Johansson pointed out.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article provides nice context for the scope and nature of bariatric surgery in the U.S.: \u201cNearly 179,000 obese people underwent weight-loss surgery in the United States in 2013, according to the American Society for Metabolic and Bariatric Surgery. While various techniques may be used, the surgery restricts the amount of food the stomach can hold and/or reduces the intestines\u2019 absorption of calories and nutrients from food.\u201d", "answer": 1}, {"article": "Parkinson's disease is a degenerative condition that affects the central nervous system.\nHe also said it will be important to confirm these findings in other studies and learn the mechanism of how berries and other flavonoids appear to offer some protection against Parkinson's disease.\nBut, he added, it's important for people to realize that this research isn't applicable to people who already have the disease.\nPeople can include berries in their regular diet.\nThe study findings should be interpreted cautiously because the participants were mostly white professionals, and the results might not apply to other ethnic groups.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of these foods is not in question.", "answer": 2}, {"article": "An estimated 5 million people in the world have an eye disease called trachoma that affects the cornea, and another 1.5 million to 2 million are thought to have developed cornea-related blindness through other diseases or trauma.\nThe next step in research, Griffith said, is to create a \"new generation\" of cornea implants and test them on a wider variety of patients.\nGriffith said a German study recently found that donated corneas cost about $2,500.\nArtificial corneas are another option, but they're difficult to implant into the eye and can cause side effects, the researchers said.\n\"The patients' own cells and nerves grew back, and there was an overall improvement in vision,\" said study co-author May Griffith.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The only hint that this research is preliminary is toward the end when the story says, The next step in research, Griffith said, is to create a \"new generation\" of cornea implants and test them on a wider variety of patients. This actually sounds actually more optimistic than the comments from Griffith in the press release, leading one to believe that she was more cautious than this sentence implies.", "answer": 0}, {"article": "Neurostimulation works by sending low-intensity electrical impulses to targeted portions of the spinal cord.\nTorre said though patients may feel some euphoria in the early days, it likely will take about a month before doctors have a good idea whether the therapy is working.\nA typical heart failure patient is on seven such drugs, which Torre characterized as \"the limit.\"\nIf the experiment proves successful, it would provide an entirely different approach to heart failure, a chronic, progressive disease that affects nearly 6 million Americans.\nThere is considerable data showing connections between the brain, nervous system and heart, said Torre, but until now, no one has attempted to take advantage of the relationship therapeutically.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story is clear that this treatment is in the early stages of development, It doesn\u2019t give readers a very good sense as to when\u00a0it might be available to the general public. Paraphrasing one of the\u00a0researchers, the story states that it \"likely will take about a month before doctors have a good idea whether the therapy is working,\" which might suggest to some readers that it might soon be available after that. Yet this is a phase I study which is primarily geared to assess\u00a0safety. It is not until Phase II and III studies are completed and successful that companies will go for FDA device approval. This could take many years and the research may never come to fruition.\u00a0The story never explained this.", "answer": 0}, {"article": "Male infertility has a range of root causes, from low or abnormal sperm production to blockages to illness.\nThe researchers tested the device on 350 clinical semen specimens in Massachusetts, including both trained and untrained users in their trial.\n\u201cThe accuracy of this approach was very similar to that of computer-assisted laboratory analysis, even when it was performed by untrained users with no clinical background,\u201d they wrote in the study.\nCurrently, they\u2019re required to make office visits to a urologist for several months to ensure that the operation was successful.\nThe app\u2019s user experience is hard to forget: users can see vivid moving images of their sperm right on the screen.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers are told the device is only in a prototype stage, implying it\u2019s not yet for sale. More details could have been provided, but this is sufficient for a satisfactory rating.", "answer": 1}, {"article": "The research team, led by Cleveland Clinic's Eric Klein, M.D., conducted a multicenter prospective study of 261 men scheduled for prostate biopsy at five academic and community centers in the U.S. enrolled between August 2015 and December 2016.\nThe IsoPSA test was developed by Cleveland Diagnostics, a company co-founded by Cleveland Clinic, in which it has financial interest.\n\"Despite criticism, PSA has transformed the landscape of early detection, screening, and management of prostate cancer in the last few decades,\" said Dr. Klein, chair of Cleveland Clinic's Glickman Urological & Kidney Institute.\nDr. Klein has no personal financial interest in the company.\n\"Unfortunately, PSA is tissue-specific but not cancer-specific, leading to overdiagnosis and overtreatment of biologically insignificant cancers, which is widely recognized as a key limitation in its clinical utility.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes it clear that IsoPSA is not available at your local doctor\u2019s office, since this blood test needs to undergo further study and then be adopted clinically.", "answer": 1}, {"article": "Iron deficiency is the most common and widespread nutritional disorder in the world, affecting 2 billion people, according to the World Health Organization.\nThey said ensuring that pregnant women get this basic prenatal care could have a big effect on the educational futures of children who live in poor communities where iron deficiency is common.\nShe said many children in poor communities would benefit from better prenatal programs that include the low-cost nutritional supplements.\n\u201cIt had an impact across a range of function, including intellectual function, executive function and fine motor function,\u201d factors that could affect a child\u2019s later academic success, Christian said.\nChristian\u2019s team studied 676 school-age children whose mothers had been in a clinical trial in which some got iron and folic acid supplements and other nutrients while they were pregnant.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "One assumes that iron and folic acid supplements are widely available, but this may not be the case in some countries. There wouldn\u2019t be a need for this sort of intervention if these nutrients were part of the regular diet in Nepal and other countries. At least some nod to how hard it might be to get access to these supplements was warranted.\u00a0It also would have been helpful to include information about whether any existing public health programs routinely supplement with iron and folic acid in developing countries.", "answer": 0}, {"article": "In the longest study of Orlistat, participants who took the drug in addition to eating fewer calories and increasing exercise shed up to 12 percent of their body weight the first year.\nWhile Americans spend an estimated $1 billion on nonprescription weight loss products, few if any of those products have undergone the rigorous testing that is required by the FDA for prescription medications.\nAt the current recommended prescription dose -- 120 milligrams taken up to three times per day, for example up to 360 milligrams daily -- about 70 percent of users experience gastrointestinal complications, Klein says.\nBut it's important to know that the weight loss that's typical for users of the drug -- 5 to 10 percent of total weight -- will be less than many dieters expect.\nThe company says that 22 million people in 145 countries have taken the drug.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Article \nincludes the fact that the switch in status from prescription only to OTC is under FDA consideration.", "answer": 1}, {"article": "Breakfast on the diet might consist of bacon, eggs with cheese, and a cup of heavy cream diluted with water; some children drink oil to obtain the fats that they need.\nAs the first randomized trial of the diet, the new study lends legitimacy to a treatment that has been used since the 1920s but has until recently been dismissed by many doctors as a marginal alternative therapy.\n\u201cThis is the first time that we\u2019ve really got Class 1 evidence that this diet works for treatment of epilepsy,\u201d said Dr. J. Helen Cross, professor of pediatric neurology at University College London and Great Ormond Street Hospital.\nA formerly controversial high-fat diet has proved highly effective in reducing seizures in children whose epilepsy does not respond to medication, British researchers are reporting.\nShe is a principal investigator on the study, which will appear in the June issue of The Lancet Neurology.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that this dietary approach to managing epilepsy is a standard treatment at hospitals and epilepsy centers in the United States and abroad.\u00a0 So we get somewhat of a sense of its availability.\u00a0 But the story doesn\u2019t make clear just how many hospitals and epilepsy centers use this approach, or how many have the necessary cross-discipline resources to manage the approach.\u00a0 ", "answer": 1}, {"article": "Those patches of dry, red, itchy skin are at increased risk of infections, particularly from a worrisome germ known as Staphylococcus aureus.\nGallo\u2019s team took a closer look at how microbes in healthy skin might be keeping that bad staph in check.\nA day later, much of the staph on the treated arms was killed \u2014 and in two cases, it was wiped out \u2014 compared to the untreated arms, Gallo said.\n\u201cPeople with this type of eczema, for some reason that\u2019s not quite known yet, have a lot of bacteria on the skin but it\u2019s the wrong type of bacteria.\nLearning what makes a healthy microbiome is a huge field of research, and already scientists are altering gut bacteria to fight diarrhea-causing infections.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear that this idea is still in the experimental stage and hence not available at your local pharmacy. Ideally the story would have explained a bit more about the many steps left in bringing this product to the marketplace (if it ever makes it there; many experimental products never do).", "answer": 1}, {"article": "Earlier studies have found that women taking bisphosphonates have a lower risk of breast cancer.\nHis team found that women who had been taking bisphosphonates \u2014 mainly the drug alendronate (Fosamax), which costs around $10 per month in the U.S. \u2014 for at least a year had a considerably lower risk of developing colon cancer later on.\nIndeed, it found a higher risk of throat cancer in patients on the medication.\nAlso, not all patients asked to participate in the study agreed, which could limit the results further.\n\u201cThe lower risk of colorectal cancer risk seen among bisphosphonate users in this study is intriguing,\u201d Eric Jacobs of the American Cancer Society, who wasn\u2019t involved in the study, told Reuters Health by e-mail.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story is clear on the drugs\u2019 availability. It says that the drug studied was \u201cmainly the drug alendronate (Fosamax)\u201d.", "answer": 1}, {"article": "Medical researchers are well aware that the dummy pills used in clinical trials often provide as much relief as the actual drugs being tested. This is what's known as the placebo effect, and it's quite common in people with Parkinson's, a movement disorder that causes tremors, stiffness and balance problems. A 2008 meta-analysis found that placebos used in clinical trials of Parkinson's treatments improved symptoms by an average of 16%.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of sugar pills is not in question. However, many physicians would not consider it ethical to prescribe a placebo. The story does not convey this nuance.", "answer": 0}, {"article": "A total of 117 clusters (or \"rings\") were identified, each made up of an average of 80 people.\nMerck has also submitted the vaccine to WHO's Emergency Use and Assessment Listing procedure, a mechanism through which experimental vaccines, medicines and diagnostics can be made available for use prior to formal licensure.\nThe vaccine is the first to prevent infection from one of the most lethal known pathogens, and the findings add weight to early trial results published last year.\nAs part of this agreement, Merck committed to ensure that 300,000 doses of the vaccine are available for emergency use in the interim, and to submit the vaccine for licensure by the end of 2017.\nIn January, GAVI, the Vaccine Alliance provided US$5 million to Merck towards the future procurement of the vaccine once it is approved, prequalified and recommended by WHO.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release provides fairly detailed information about the next steps in the vaccine approval process, noting that Merck has committed to submitting the vaccine for regulatory approval by the end of 2017 and that the company has committed to making 300,000 doses available should an outbreak occur before approval is gained. It also notes that if an outbreak occurred before the vaccine is approved, it could be used, with informed consent of those vaccinated, through a \u201ccompassionate use\u201d program.", "answer": 1}, {"article": "Anderson Cancer Center in Houston.\nSimilar drugs have already been used to treat advanced, BRCA-mutated ovarian cancer, according to the agency.\nThe trial results are preliminary, as talazoparib has not yet been approved by the U.S. Food and Drug Administration.\nThis targeted form of treatment takes advantage of a weakness in the BRCA gene to further cripple the cancer cell's ability to repair itself, grow and spread, said Weiss, who was not involved with the study.\nIn January, the FDA approved the first PARP inhibitor, Lynparza, to treat BRCA-mutated breast cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that\u00a0talazoparib is not yet approved by the FDA.", "answer": 1}, {"article": "Dr Allan Pantuck, the lead clinician of the study, added, \"With fixed dose therapy, patients are often switched to other drugs when they no longer respond to treatment.\nThis new study demonstrates that CURATE.AI can optimise multi-drug regimens.\nThe research team successfully utilised CURATE.AI to continuously identify the optimal doses of each drug to result in a durable response, allowing the patient to resume a completely normal and active lifestyle.\nCURATE.AI is applicable to all diseases and all patients, and a first generation of the platform was previously validated in the clinic for single drug optimisation in post-transplant immunosuppression.\nThis calibration is then used to create an individualised CURATE.AI profile, or map, that identifies the drug doses which enable the best possible treatment outcome at any given point in time.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does make clear that clinical trials are under way. That\u2019s good. However, the release is written as if the clinical trials have already been completed successfully. For example, the release states that \u201cCURATE.AI is applicable to all diseases and all patients.\u201d There is, as far as can be discerned from everything else in the release, nothing that supports that statement. And despite the sweeping language used in the release, it is not at all clear when CURATE.AI may be available for clinical use.", "answer": 0}, {"article": "Spinal cord stimulation works by implanting an electrode near the spinal cord, inserted through the same place where epidural pain relief is injected for women in labor.\nDoctors say simple adjustments to the device may solve that problem.\nAnother concern is that patients who require high doses of stimulation drain the battery quickly, requiring surgery to replace the device.\n\u201cIt quickly becomes clear that \u2018weird\u2019 is going to be just fine if it replaces the pain.\u201d\n\nChronic pain is a particularly difficult problem to understand and solve.\nStill, most patients accept this vibrating version of white noise, says Dr. Richard North, a retired neurosurgery professor at Johns Hopkins who developed several patents related to the technology, although he no longer receives royalties.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that spinal stimulation devices \u201care not widely used,\u201d though it does not mention that they are approved by the FDA for the treatment of chronic pain.", "answer": 1}, {"article": "\u2022 Retrograde menstrual flow: During a period, when a woman is shedding her uterine lining, some of that tissue can flow through her fallopian tubes and into her pelvis, which researchers think may cause endometriosis.\nThat\u2019s not to mention cost: The drug\u2019s price is listed at $850 per month.\nSo it\u2019s no surprise it takes between three and 11 years after the onset of symptoms to diagnose endometriosis.\nSoon, it seems, women like Dunham with endometriosis pain will have a new option for relief.\nThe drug\u2019s side effects also concerned her, as did the lack of knowledge about its long-term impact.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The text offers a likely date when this just-approved drug would become available at pharmacies.", "answer": 1}, {"article": "\"Some will benefit in a very large way.\nWhy would a woman at normal risk of breast cancer want to get routine mammograms?\nSo should U.S. women continue to get routine mammograms?\nOn balance, this is about five to 15 of those 2,500 women screened.\"\nIt is not wrong to want a routine mammogram, and it is not wrong not to want one.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Researchers told the American Diabetes Association\u2019s (ADA) annual meeting that 13.0 percent of patients on Victoza died from cardiovascular causes or suffered non-fatal heart attacks or strokes, against 14.9 percent of those on placebo.\nMads Krogsgaard Thomsen, Novo\u2019s chief science officer, said the results should encourage doctors to use Victoza earlier, since they could now see it offered \u201clife-expanding\u201d treatment.\nThe Victoza trial, known as Leader, had been designed to show Novo\u2019s drug did not increase heart risk, so its superiority is welcome news for the company, especially as Sanofi\u2019s (SASY.PA) rival Lyxumia failed to show heart benefits in an earlier test.\nJefferies analyst Jeffrey Holford said market expectations had been for a mid-to-high teens percent reduction in complications.\n\u201cI think physicians will look to GLP-1s with greater enthusiasm,\u201d Buse said in an interview.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is already established on the market, calling it \u201ctop-selling\u201d in the first line and mentioning that it is typically prescribed as a third or fourth option.", "answer": 1}, {"article": "Research presented at meetings is considered preliminary until published in a peer-reviewed medical journal.\nOne expert doesn't think sufficient evidence exists yet to take statins to prevent or treat cancer.\n\"We cannot, however, recommend statins for cancer prevention without a positive clinical trial.\"\n\"There is little evidence that statins affect cancer risk or survival, but clear evidence that they can help some people lower risk of heart attacks and strokes,\" he said.\nAt this time, people without high cholesterol should not be taking statins in the hope of warding off cancer or living longer with cancer, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s obvious from the story that statins are widely available. If research shows they can lower risk, they are available already for that purpose.", "answer": 1}, {"article": "All rights reserved.\nThe study hints at the potential for widespread health benefits from an upcoming nationwide ban, the authors and other experts say.\nDr. Mark Creager, former American Heart Association president, said the results echo previous studies \u201cand are consistent with the thinking of most scientists\u201d on potential benefits of these bans.\nThe results translate to 43 fewer heart attacks and strokes per 100,000 people, said lead author Dr. Eric Brandt, a Yale University cardiology fellow.\nNew York City enacted a restaurant ban on the fats in 2007 and several counties in the state did the same.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story lets readers know that soon a trans fat ban will apply to the entire country:\nThe study hints at the potential for widespread health benefits from an upcoming nationwide ban, the authors and other experts say. The U.S. Food and Drug Administration in 2015 gave the food industry until next year to eliminate artificial trans fats from American products", "answer": 1}, {"article": "\u201cWe are looking for corporate partners as we head into Phase II trials,\u201d Kalos said.\nThe results provide \u201ca tumor-attack roadmap for the treatment of other cancers,\u201d including those of the lung and ovaries as well as myeloma and melanoma, researchers said.\nThe research group plans to treat four more patients with CLL before moving into a larger Phase II trial.\nFurther study will show whether the latest results \u201creflect an authentic advance toward a clinically applicable and effective therapy or yet another promising lead that runs into a barrier that cannot be easily overcome,\u201d Urba said in an NEJM editorial.\nThe engineered T-cells were detected in patients\u2019 blood for several months afterward, and a portion of them turned into \u201cmemory T-cells,\u201d which could provide ongoing protection against cancer recurrence, researchers surmised.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does note the study is a Phase 1 trial iin the 4th sentence and also notes that\u00a0researchers intend to enroll\u00a0four more\u00a0subjects. WebMD did a better job showing that, even for people hoping to enroll in a trial for this therapy, the odds will be long.\nWe wish stories would take for granted that readers know what Phase I and Phase II means.", "answer": 1}, {"article": "Pacemakers zap the heart with low levels of electricity when the heartbeat becomes too fast, too slow or too irregular.\nStill, he said, the new device will probably be more expensive than other pacemakers, and may pose special risks of its own.\nIt's also not clear when the pacemaker may be publicly available, and its cost is unknown.\nHe expects the pacemaker \"will likely be utilized for some select patients\" after more testing.\nStill, a new company-funded study shows that \"this is now a possibility\" that could reduce infections and the severity of pacemaker surgery, said study author Dr. Vivek Reddy, director of the Cardiac Arrhythmia Service at Mount Sinai Hospital in New York City.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "In the second paragraph the story explains that \u201cit\u2019s not clear when the pacemaker may be publicly available.\u201d", "answer": 1}, {"article": "\u201cC.\nThough physicians think they know how FMTs work, it remains somewhat mysterious.\nPrevious research found that while every part of this treatment was unappealing to most people, being offered the treatment in a pill form made patients significantly more open to the idea.\nDespite the FDA\u2019s advice, some people have set up shop as FMT providers anyway.\nThe 116 patients used in this study may have been selected in part because they were ideal candidates for FMTs, Dr. Elizabeth Hohmann noted, but she said the paper is solid overall.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Unfortunately, the story doesn\u2019t spell out whether the pill form FMT is now, or soon will be, available to the public. The story does mention that numerous other clinical trials are using FMT as a possible treatment for various diseases but it is unclear whether the pill form is an option for physicians at this point.", "answer": 0}, {"article": "\u201cHowever, we still don\u2019t know whether it will provide protection against Ebola infection in a real-world situation,\u201d he said.\nThe vaccine is being developed by the U.S. National Institutes of Health (NIH) and GSK against the Zaire strain of Ebola \u2014 the one circulating in West Africa \u2014 and the first doses for a larger trial arrived in Liberia last week.\nJeremy Farrar, director of the Wellcome Trust charity which helped fund the trial, said it provided \u201cgood initial evidence that the GSK vaccine will be safe to use in people\u201d.\nThe early-stage Phase I trial of GSK\u2019s vaccine was primarily designed to test safety, but Adrian Hill, who led the work at Oxford\u2019s Jenner Institute, said it was \u201cencouraging\u201d that the shot also prompted responses from the immune system.\nThat trial is the first of several mid-stage studies planned for West Africa and aims to test GSK\u2019s vaccine and one from Merck and NewLink.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the vaccine is under development and that clinical trials in West Africa are under consideration. The story could have mentioned the long testing process required before such a vaccine might be available on the ground in Africa.", "answer": 1}, {"article": "Scientists working for Google\u2019s parent company Alphabet have used artificial intelligence to determine a person\u2019s risk of having a heart attack from their retinal scan.\nFurther tests are required before this latest method can be used within a clinical setting.\nThe method\u2014detailed in a paper published on Monday in the Nature journal Biomedical Engineering\u2014involves analyzing blood vessels in an area of the eye called the retinal fundus.\n\u201cMost cardiovascular risk calculators use some combination of these parameters to identify patients at risk of experiencing either a major cardiovascular event or cardiac-related mortality within a pre-specified time period, such as 10 years,\u201d the paper states.\nThe risk factors include the person\u2019s gender, smoking status, blood pressure and age\u2014estimated to within four years of the patient\u2019s actual age.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicates that \u201cfurther tests\u201d are needed, but readers are left with no idea as to when, if ever, this new approach to determining risk might be available.\u00a0 There\u2019s no mention of when, if ever, clinical trials might be done to gauge its efficacy.", "answer": 0}, {"article": "A female testosterone patch showed promise at boosting older women's enjoyment of sex, but concerns about the cancer risk of hormone therapies mean U.S. women won't be getting an equivalent of Viagra anytime soon.\n\nProcter & Gamble Co., the Cincinnati consumer-products giant, has worked since 1999 to secure U.S. approval for its Intrinsa patch, intended to increase sex drive and satisfaction in women after menopause.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes plain that the female testosterone patch is not available in the United States but is on the market in Europe. ", "answer": 1}, {"article": ".\nA limitation of the study is that the motion sensor often slipped off the sleepers at night.\nNotably, carbon dioxide levels were lower when windows or doors were open.\nOn another night, the windows and door to the room were kept closed.\nThey each slept alone, and the bedroom layout with furniture arrangement was kept consistent.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Windows and doors are widely available, and the story mentions that opening them might not work if there are noise or security concerns.", "answer": 2}, {"article": "For decades, researchers have searched unsuccessfully for ways to automatically coordinate insulin delivery with real-time changes in blood sugar to essentially create an artificial pancreas that maintains target blood sugar levels with minimal effort.\nAaron J. Kowalski, PhD, of the Juvenile Diabetes Research Foundation, which was involved in funding the research, says the study represents an important step forward in the search for a clinically feasible artificial pancreas to improve outcomes and quality of life among insulin-dependent diabetes patients.\nFeb. 4, 2010 - It has been called the Holy Grail of treatment for insulin-dependent diabetes, and it may be close to reality.\nNow new technology is making this possible, and new research shows that an experimental system can improve nighttime blood sugar control.\nThe system proved better than a conventional insulin pump for maintaining optimal blood sugar levels during the night in a study from the U.K.'s University of Cambridge.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story did a better job than the competing Reuters piece in explaining that the system tested in this study actually consisted of a commercially available glucose monitor and insulin pump\u2013not a \"new device\"\u00a0per se.\u00a0However, it still left the reader with the impression that system was automatically managing patients\u2019 glucose without any outside human intervention, which was not the case. We also wish the story had resisted the temptation to\u00a0predict that a new \"artificial pancreas\" system might be\u00a0be available clinicially in 3 to 5 years. The FDA approval process is notoriously uNPRedictable, and this technology has a lot of hurdles to clear before it will be available for patients.", "answer": 0}, {"article": "In 2012, a federally funded panel of experts on preventive care concluded there are more risks than benefits to screening American men for prostate cancer with the PSA test. And in April 2017, the U.S. Preventive Services Task Force dumped the decision squarely into the laps of patients and their doctors. Some men between 55 and 69 years of age might well decide to get their PSA checked, the task force said. After hearing the ledger of pros and cons, however, others in that age bracket might just as reasonably skip the screening test, the panel concluded.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that PSA screening is widely available.", "answer": 1}, {"article": "An experimental drug designed by Roche Holding AG's Genentech unit against a new cancer target yielded encouraging results against two rare tumors, researchers said, potentially opening up a new front in the battle against the disease.\n\nIn a small study, the drug, known as GDC-0449, shrank tumors in 18 of 33 patients, or 55%, with an advanced form of a skin cancer called basal cell carcinoma. In addition, the drug had a dramatic, though temporary, effect on a 26-year-old patient who had undergone multiple surgeries, chemotherapy...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this drug is still in the experimental phase and the FDA has not yet approved it.\u00a0 ", "answer": 1}, {"article": "Critically ill children in intensive care are unable to eat independently.\nThe current standard of care for such children is based mostly on the assumption that they need to eat to regain their strength.\nThese findings provide strong evidence against current practice and can thus be expected to change paediatric intensive care worldwide.\nPrevious research by Professor Van den Berghe and her team (2011 and 2014) had already shown that early artificial feeding should be avoided to treat adults in intensive care.\nAn international team of researchers from University Hospitals Leuven (Belgium), Sophia Children's Hospital Rotterdam (The Netherlands), and Stollery Children's Hospital Edmonton (Canada) has now challenged the validity of this common practice.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Parenteral feedings are a part of standard care and that is understood.", "answer": 2}, {"article": "GAITHERSBURG, Md.\nIf approved by the Food and Drug Administration, bevirimat, developed by Panacos Pharmaceuticals Inc., would represent the first in a new class of drugs that uses an unusual approach to block maturation of the virus that causes AIDS.\nNow its derivative is being tapped to fight HIV by a small Watertown-based biotechnology company.\nBevirimat is being developed as physicians begin to use drugs from different classes in combination to fight the virus at different steps in its life cycle.\nPanacos estimates its drug could garner $500,000 to $1 billion in peak annual sales from a drug candidate initially spotted by a professor at the University of North Carolina at Chapel Hill who was screening natural products in search of potential HIV therapies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The drug, bevirimat, is derived in part from the herb syzigium claviforum. This herb is currently used in traditional Chinese medicine to treat diarrhea and stop bleeding. Bevirimat is a manufactured drug, using certain components of this herb to potentially inhibit HIV replication. The story does mention that the drug is at least 3 years from market and still in early clinical trials.", "answer": 1}, {"article": "Researchers from Leeds Metropolitan University in the U.K. steeped thyme, marigold, and myrrh in alcohol to make what's called a tincture, and then tested them on the bacteria that cause acne.\nThey all had greater antibacterial effect after five minutes compared to lab specimens exposed to plain alcohol, but thyme was the most potent.\nBut some U.S. dermatologists are quick to caution that while intriguing, this research is still preliminary, and thyme-tinged acne treatments are not yet ready for prime time.\nIn fact, the thyme tincture was more powerful than standard concentrations of benzoyl peroxide, which is the active ingredient in many acne products.\nLargely due to its anti-inflammatory and anti-bacterial properties, the herb thyme -- which is found with other herbs in the produce section of most food stores -- may well earn itself a place in the skin care section of your local drug store.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The bold headline promising that thyme as an \u201cacne remedy may be coming soon\u201d promises an imminent availability that is beyond the evidence.", "answer": 0}, {"article": "Acupuncture designed to treat depression appears to improve symptoms in pregnant women, suggesting it as an alternative to antidepressant medication during pregnancy, a study found.\n\nThe study, published Monday in the journal Obstetrics & Gynecology, is the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women. It was funded by a grant from the government's Agency for Healthcare Research and Quality. \"Acupuncture that we have tested works for pregnant, depressed women,\"...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While acupuncture is widely available, the story doesn\u2019t clearly point out that the regimen used in the study was specially developed for this study. Where could a woman seeking this treatment find it? How many practitioners are trained on this regimen?", "answer": 0}, {"article": "\"I no longer work for a living,\" notes Dr. Ross, who now resides in Westfir, Ore. \"I wake up every day eager to hear about how a plant-based diet and a healthful lifestyle is changing and saving lives in our community.\nFor clinicians concerned about spending extra time in and outside of the exam room, the study authors encourage time-strapped health care providers to refer patients to registered dietitians who can help with the transition to a plant-based vegetarian diet.\nThe meta-analysis appears as an online advance in Nutrition Reviews.\nThe 2015 Dietary Guidelines for Americans highlights a healthy vegetarian diet as one of three healthful eating plans to follow.\nTaking small steps, like those proposed by the National Cholesterol Education Program Adult Treatment Panel 3, which include assessing heart disease risk, making lifestyle and dietary recommendations, and assessing the need for future follow-up appointments and pharmaceutical interventions, could prevent approximately 20,000 heart attacks, 10,000 cases of coronary heart disease, and save almost $3 billion in medical costs each year.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that registered dietitians can help people transition to a plant-based vegetarian diet. It also recommends the vegetarian diet plans contained in the 2015 Dietary Guidelines for Americans.", "answer": 1}, {"article": "The condition, in which a person\u2019s body clock does not automatically set to the 24-hour day, affects a majority of blind people.\nThe drug is being tested for \u2018non-24-hour disorder\u2019 that has no approved treatment.\n\u201cThese results also highlight the importance of chronic therapy in treating Non-24,\u201d CEO Mihael Polymeropoulos said in a statement on Wednesday.\nVanda on December 18 said the drug performed better than a placebo in the first of the four planned late-stage trials on the drug.\nThe study, named Reset, was a 20-patient trial designed to test the maintenance effect of a 20 mg dose of the drug, tasimelteon.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story referred to the drug tasimelteon as an \u201cexperimental drug.\u201d\u00a0 And it reported that the drug company plans to apply for FDA approval in mid-2013.", "answer": 1}, {"article": ".\nThe biggest drawback, Whitaker says, is the need for X-rays three months after the procedure to confirm the fallopian tubes are blocked.\nOne for the Guys Men, too, have an option for a faster, less painful procedure than vasectomy to tie the vas deferens -- the tubes that carry sperm from the testicles to the penis.\nUntil then, the patient must use another form of birth control.\nEven the IUD can't stay in place for more than 10 years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story mentions that the Essure approach was relatively recently approved (in 2002), it does not comment on how widely it is available, how many providers have the special training required\u00a0and whether access may be limited as a result. ", "answer": 0}, {"article": "Novel standard for research in malnutrition may save lives\n\nProfessor Henrik Friis, the senior author on the paper, points to the importance of the collaboration between university researchers and humanitarian organizations:\n\n\"It has been a new way to conduct research, that we tested the effect of nutritional supplements used mainly by aid agencies, employing very advanced research methods in remote rural areas where humanitarian organization are working, and not at the university hospitals.\nThe results of the study can be used directly both in the treatment and prevention of acute malnutrition.\nResearchers from the University of Copenhagen and humanitarian organizations have conducted a large study in Burkina Faso in West Africa treating more than 1600 children with acute malnutrition.\nDuring the trial, 1609 small children with moderate acute malnutrition were given either LNS or corn-soy porridge for 12 weeks.\nPrevious research has focused on treatment of severe acute malnutrition.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release assumes availability of both types of supplements, though no specific information is provided about how much each is currently used for treatment of moderate acute malnutrition in infants.", "answer": 1}, {"article": "The test, called a liquid biopsy, screens for cancer by detecting tiny bits of DNA released by cancer cells into blood.\nResearchers said their results showed promise in the approach of blood screenings for cancer, but noted further \u201cclinical development\u201d was needed.\nThe test was most accurate for diagnosing pancreatic, ovarian, liver and gallbladder cancers, correctly finding the diseases in at least four out of five patients.\nResearchers hope the test will become part of a \u201cuniversal screening\u201d tool that doctors can use to detect cancer in patients.\nProf Nicholas Turner from the Institute of Cancer Research in London described the findings as really exciting and as a possible universal screening tool.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of liquid biopsies are not directly addressed, though it is implied they are not yet available. We\u2019ll give this one a just-barely satisfactory.", "answer": 1}, {"article": "LONDON (Reuters) - An \u201celectronic nose\u201d could be used as a simple breath test to detect lung, breast, bowel and prostate cancers, Israeli scientists said Wednesday.\nUsing the sensor to pinpoint chemical variations, the team found they could not only distinguish between healthy and malignant breath but also identify the four different common tumor types.\n\u201cIf we can confirm these initial results in large-scale studies, this new technology could become a simple tool for early diagnosis of cancer along with imaging,\u201d said Abraham Kuten of Technion Israel Institute of Technology.\nKuten and his colleagues studied the breath of 177 people \u2014 some healthy and some with various types of cancer \u2014 to detect the different chemicals emitted from the surface of cancer cells as they grow.\nWhile more work is needed to develop the technology, the early success could lead to the development of a cheap, easy-to-use and portable test to help diagnose cancer earlier.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Reuters posted just one reader comment before closing the comment section.\u00a0 It read as follows \u2013 typos and all: \"This is a terrific Leap in Teachnology and should be made available Worldwide at hospitals, clinics and Good Dr. Offices.\" Readers should not have been led to believe the simple, proven breath test is at hand, ready to deploy to doctors. It\u2019s years away if we\u2019re lucky.\n ", "answer": 0}, {"article": "But in either case, \"Something is better than nothing,\" Sayre said.\nThe CPR guidelines had been inching toward compression-only.\nNow the heart association has given equal standing to hands-only CPR.\nBut less than a third of victims get this essential help.\nHands-only will be added to CPR training.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Hands-only CPR is implictly available anywhere. ", "answer": 1}, {"article": "Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma in adults.\nArmin Ghobadi, an oncologist at Siteman who was an investigator in the Kite trial, said the new treatment is \u201cjust the first step\u201d and that researchers are working to make it safer and more effective.\n\u201cThese are patients who knew they were out of options,\u201d he said, noting that lymphoma patients who relapse or don't respond to treatment have just a 50 percent chance of surviving for six months.\nEven so, Yescarta's cost is likely to stoke the ongoing debate about high drug prices.\nHe said the therapy already has been life-changing for many of his patients \u2014 and for him.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The piece isn\u2019t clear on this point. It says \u201c[T]he agency [FDA] is requiring hospitals and clinics that dispense Yescarta to be certified after undergoing special training.\u201d This implies that not all places will be able to prescribe this.\u00a0", "answer": 0}, {"article": "It didn\u2019t work miracles.\nRelated: Too Many Babies Die on Their First Day\n\nCharpak\u2019s team found the babies randomly assigned to get this treatment were 39 percent more likely to live into adulthood.\nRelated: More U.S. Moms are Breastfeeding Their Babies\n\n\u201cThe effects of kangaroo mother care at one year on IQ and home environment were still present 20 years later in the most fragile individuals, and kangaroo mother care parents were more protective and nurturing,\u201d Dr. Nathalie Charpak and colleagues at the Kangaroo Foundation in Bogota, Colombia, wrote in their report.\nBut overall, the findings support the benefits of kangaroo mother care, the team concluded.\nThey found that babies held upright and close to bare skin and breastfed, instead of being left in incubators, grew up with fewer social problems.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that KMC requires parents to receive adequate support and follow-up. But we would have liked to see more information, such as how widely this approach is used to treat premature infants and what some of the barriers might be in high-income countries where incubator care has been the norm. For example, how many U.S. neonatal intensive care units incorporate skin-to-skin contact in their care? Which babies in intensive care don\u2019t or can\u2019t get this kind of care?", "answer": 0}, {"article": "The results were striking.\n\u201cThere is a body of literature that argues that the whole approach to studying acupuncture doesn\u2019t lend itself to the Western reductionist scientific method.\u201d\n\nBut the study\u2019s lead author, Dr. Maria E. Suarez-Almazor, notes that the sham treatment was developed with the help of trained acupuncturists.\nRather than proving that acupuncture does not work, in other words, the study may suggest that it works even when administered poorly.\nThe results came out with no difference between the groups.\u201d\n\nThe MD Anderson research and other recent acupuncture studies have fueled speculation that the prick of a needle, whether from real acupuncture or a sham version, can influence the way the body processes and transmits pain signals.\nIn a drug study, an equal response in the treatment and placebo groups would prove the drug does not work, she says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "      \n\n\n \n\n \nThe article does not discuss the availability of acupuncture in the United States. This is an important question. There appear to be significant obstacles\u00ad\u2014relating to geography, licensing, and reimbursement\u2014 to the widespread availability and utilization of acupuncture.\n\u00a0\n ", "answer": 0}, {"article": "In the United States, the Affordable Care Act designates HIV testing as a preventive service, meaning that all insurers must cover it without charging a co-pay.\nA sizable fraction of the undiagnosed may be people who have been tested, just not recently enough.\nAnd because the incidence of other sexually transmitted infections declined for these men, after the diagnosis, the scientists had reason to believe the self-reports of condom usage were accurate.\nBut if the goal is to let patients test as accurately as possible at home, the United States is falling behind.\nAdopting some version of the British at-home test could help Americans who have already been tested keep up their screening schedule.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly reports that this HIV test is now available in the UK, but not in the US. However, the murky quote from an FDA spokesperson leaves readers in the dark about whether the company selling this test in Britain has, or is planning to, apply for approval in the US.", "answer": 1}, {"article": "And Owens says that people with medical conditions like ulcers, kidney problems, liver problems or bleeding disorders are more vulnerable, as are people who take blood-thinning drugs and NSAIDs.\nBut for pretty much everyone else, assessing actual heart disease risk in consultation with your doctor is crucial to deciding whether to take aspirin every day.\nPeople who don't really need to should not be taking aspirin every day, says Nissen.\nThe Food and Drug Administration actually issued a warning against routinely taking aspirin to prevent heart disease in people without significantly high risk.\nAnd while many medical groups recommend daily aspirin to lower heart disease risk, not all federal agencies agree.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Low-dose aspirin is readily available, of course, and the story makes this clear. \u00a0The story suggests that the typical healthy American NOT avail him/herself of this resource.", "answer": 1}, {"article": "\"They do research online, are more informed and sometimes go to the doctor demanding, 'I think I need an MRI.'\n\"\n\nAnd while an informed patient is a good thing, Mafi says sometimes the patient gets it wrong.\nThere is just no single reason why people get chronic headaches, although we do know that migraines have a genetic component and usually a trigger.\nBut even a little can help, and according to Bernstein it doesn't have to be jogging for miles and miles.\nFor Terri Bradford, the years of searching for effective treatment proved futile.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "If the concept is that lifestyle changes are effective at treating migraines, then it is assumed that people can change their diets or exercise more no matter where they live. The story supports that impression, and we\u2019ll award a satisfactory on that basis. For extra credit, the story could have elaborated on why it was so hard for the woman in this story to find a doctor to prescribe this kind of therapy. Are doctors who embrace this approach difficult to locate? If these approaches are effective, why aren\u2019t they more widely used?", "answer": 1}, {"article": "Fish like salmon, herring and sardine are a common source of EPA-DHA, while ALA is found in vegetables including soybeans, flax seeds and walnuts.\nDaan Kromhout of Wageningen University, who led the study, told the European Society of Cardiology the lack of efficacy might reflect the good background drug treatment patients were receiving, with 85 percent on cholesterol-lowering statins, as well as blood pressure and blood-thinning tablets.\nUnilever, whose margarine brands that contain omega-3 include Flora and I Can\u2019t Believe It\u2019s Not Butter, said the lack of benefit seen with EPA and DHA was surprising, considering the weight of evidence published to date.\nThe margarines used in the study were developed for the researchers by food and consumer goods giant Unilever.\n\u201cThe results indicate that more investigation is required into the efficacy of vegetable omega 3, but do not question the current authoritative dietary recommendations and advices for omega 3 intakes on which our products are based,\u201d the company said in a statement.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story indicated that the margarine used in the study was created for the researchers by Unilever, suggesting that they aren\u2019t commercially available. But why not make that point explicitly?", "answer": 1}, {"article": "The second study, published in 2013, had a similar set up \u2014 37 people complaining of gastrointestinal problems, randomized into high-gluten, low-gluten and no-gluten groups.\nIt\u2019s hard to test for gluten sensitivities.\nIf you think avoiding gluten will make you feel better, there is a reasonable chance that it will \u2014 even if gluten is irrelevant.\nSomewhere in that gap, a diet fad is thriving.\nEveryone participating in the study was on a gluten-free diet.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly notes the now-widespread availability of gluten-free foods.", "answer": 1}, {"article": "It\u2019s common for people who suffer from irritable bowel syndrome (IBS) to also struggle with depression.\n(Study co-author Premysl Bercik, associate professor of medicine at McMaster University, says the formula used in the new research isn\u2019t commercially available, anyway.)\nThose changes in brain activity \u201csupport the notion that this probiotic has anti-depressive properties,\u201d the authors wrote in their paper.\nStudies have looked at various types of probiotics for IBS patients, the authors wrote, and a recent review found that seemed to work better for gastrointestinal symptoms than another common probiotic, .\nThat\u2019s why Dr. Roger McIntyre, professor of psychiatry and pharmacology at the University of Toronto, thinks the fMRI findings are the most interesting and important aspect of the new study: they signal that the probiotics may really be working on the brain itself.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although it appears close to\u00a0the end, the story does state that the probiotic used in the study is not commercially\u00a0available.", "answer": 1}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nThe full potential of food-based supplements to do the work of some drugs without their negative side effects is just beginning to be seriously investigated.\nThe CHORI-bar is not just another nutrition bar.\nThere is no magic bullet ingredient in nutrition - \"oiling\" one joint is not going to allow the rusted out machine to run.\nIt is a serious intervention to improve health.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "One can only assume that something at the clinical trial stage is not yet available to consumers. But the press release does not make that clear. Some enthusiastic commenters out there can\u2019t wait to get their hands on the product!", "answer": 0}, {"article": "The panel suggests that heart patients be screened by first asking two standard questions: In the past two weeks, have you had little interest or pleasure in doing things?\nIf the patient answers yes to one or both, a questionnaire is recommended to determine if the patient is depressed and the severity.\nThe authors said only about half of heart doctors say they treat depression in their patients \u2014 and not all those diagnosed with depression are treated.\nIf depression is indicated, the patient may need to see a professional qualified in treating depression, the panel said, adding that treatment options include antidepressants, seeing a psychotherapist and exercise.\n\u201cI know we can do more.\u201d\n\nAlthough there\u2019s no direct evidence that heart patients who are screened fare better, depression can result in poorer outcomes and a poorer quality of life, the panel said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly depression screening is available but not as widely used as it should be in the context of heart disease patients.", "answer": 1}, {"article": "But the evidence that pot smoking actually helps with spasticity has been anecdotal.\n\u201cSpasticity is a big problem for many people with MS, and the current medications don\u2019t necessarily work for everyone,\u201d said LaRocca, who was not involved in the new study.\n\u201cBut smoking marijuana does not appear to be a long-term solution, because of the cognitive effects,\u201d he told Reuters Health.\nHowever, LaRocca said, researchers are developing cannabinoid-based medications for MS. That includes a cannabinoid mouth spray called Sativex that has been approved in the UK, Canada, Spain and New Zealand to treat MS-related spasticity.\n\u201cI think this study shows that yes, (marijuana) may help with spasticity, but at a cost,\u201d said Corey-Bloom, of the University of California, San Diego.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that some people with MS are already using medical marijuana to treat certain symptoms.", "answer": 1}, {"article": "Scientists have slowed down the ageing process by implanting stem cells into the brains of animals, raising hopes for new strategies to combat age-related diseases and extend the human lifespan.\nThe work, described as a tour de force and a breakthrough by one leading expert, suggests that ageing across the body is controlled by stem cells that are found in the hypothalamus region of the brain in youth, but which steadily die off until they are almost completely absent in middle age.\nHaving proved that it was neural stem cells that were important for ageing, the scientists ran further tests to work out what the cells were doing.\nThe next step is to create human neural stem cells in the lab for testing.\nThe stem cells are known to form fresh brain cells in youth, but the process slows down dramatically in adults.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this research is preliminary. The story clearly says, \u201cThe next step is to create human neural stem cells in the lab for testing.\u201d\u00a0 It also states that, \u201cResearchers at Albert Einstein College of Medicine in New York hope to launch clinical trials of the procedure soon, but must first produce supplies of human neural stem cells in the lab which can be implanted into volunteers.\u201d", "answer": 1}, {"article": "Primary pulmonary hypertension (PPH), a rare fatal lung disease, has been reported in patients who had taken a combination of phentermine and fenfluramine or dexfenfluramine for weight loss.\nLomaira is anticipated to be available by the end of September 2016.\nPhentermine has the potential to be abused.\n\"Regrettably, many patients are still not covered by insurance for weight-loss medications and the low cost for Lomaira makes it an affordable treatment option.\"\nDosage should be individualized to obtain an adequate response with the lowest effective dose.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that, \u201cLomaira is anticipated to be available by the end of September 2016.\u201d", "answer": 1}, {"article": "\"I think this may be changing in health care,\" said Spears, \"but because migraine affects women more than men, there is a stigma around the stereotype of a patient who comes in with multiple complaints, calls frequently and wants to see the doctor frequently.\" Men, on the other hand, have been stereotyped as going to the doctor \"only when something he has is real.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does state that, \u201cBased on the promising phase III clinical trials, the drug could be available later next year.\u201d", "answer": 1}, {"article": "GHRH, a hormone produced by the hypothalamus in the brain, is linked to the insulin system, but also has a host of other effects.\n\u201cThey wanted to know where they could get (the hormone) after the study was over.\u201d\n\nBut that\u2019s jumping the gun, she warned, because the treatment is still experimental and GHRH is not approved to treat mental decline.\nIt\u2019s possible health problems could show up down the road, and the mental boost may be short-lived.\nStill, both Baker and Petersen said more work is needed to gauge the long-term consequences of GHRH injections.\n\u201cWe recommend commonly that people start exercising when they are having mild cognitive impairment,\u201d Baker said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We wish the story had included even a line about how GHRH is used in medicine right now and whether there\u2019s any knowledge of off-label use for mild cognitive impairment.", "answer": 0}, {"article": "In his study published in the International Journal of Radiation Oncology, Biology, Physics, he and his colleagues found, \"in circumstances where surgery may result in significant neurologic or organ dysfunction, patients can be treated definitively with radiation therapy alone.\nThe San Francisco radiation oncologist not only shared Dr. Kabolizadeh's research paper, but also his contact information.\nWhile the findings were written for health care professionals and very technical, Tracy was encouraged.\nEven with surgery, there was a high risk of recurrence.\nBeaumont's center is one of just 28 proton therapy centers in the U.S.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that there are 28 proton therapy centers in the U.S. and that the center at issue here is the only one located in Michigan.", "answer": 1}, {"article": "Smith also embarked on a new diet, cutting out dairy and red meat.\nBeim, the Celmatix CEO, said the test is already bringing \u201ctremendous\u201d value, in part by providing guidance that can act as a \u201ctiebreaker\u201d to help patients and their doctor decide which treatment to prioritize.\nBut the report doesn\u2019t note that just 1 percent of women have that condition in the first place, making the odds still overwhelmingly in her favor.\nThat patient is now considering an egg donor.\nMany of the other conditions that the test screens for are also quite rare.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The text is clear that the test has been available since January 2017 and has been utilized by some doctors.", "answer": 1}, {"article": "Newswise \u2014 RESEARCH TRIANGLE PARK, NC\u2014 Major depressive disorder affects more than 32 million Americans, and their first stop for treatment is often their primary care provider.\n\"Primary care clinicians and their patients may not automatically consider alternatives when discussing treatment,\" said Halle Amick, research associate at the RTI International-University of Chapel Hill Evidence-based Practice Center and lead author.\nSuch shared and informed decision making might enhance treatment adherence which is one of the main challenges of treating major depressive disorder,\" said Gerald Gartlehner, M.D., associate director of the RTI-UNC Evidence-based Practice Center, who was the principal investigator of the evidence review, which was also published today by AHRQ.\nHowever, the evidence shows that cognitive behavioral therapy can be just as effective, providing important information for patients and their physicians to consider when choosing among available treatment options.\"\n\"Bringing psychotherapy into discussions of treatment may also enhance coordination of care between primary care and mental health care providers in addition to addressing the issue of patient-centered care,\" Amick said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While CBT is in wide use, the release glides over the long wait times even people with health insurance must wait to be matched with a CBT therapist. In some states, the wait can take months. In addition, the release notes that most patients see their primary care physician first. We are unclear on what percentage of primary care physicians are trained in CBT and are willing to offer it.", "answer": 0}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that the procedure is at least 20 years old and is practiced in a significant percentage of hip-replacement operations, implying that it would not be too tough to find a surgeon who does the anterior procedure. Of course, learning a bit about what the learning curve is for this procedure and how many procedures any given surgeon has done are key questions", "answer": 1}, {"article": "Claudia Kawas, a geriatric neurologist at the University of California, Irvine, said a patient strode into her office soon after the FDA approved the procedure and asked for the \"Alzheimer's test.\" In one hand, he held an article about the approval of Amyvid. In the other, he had a document from a right-to-die group. If the test was positive, he told her, he would get his affairs in order and kill himself within 60 days.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story tells us that the PET scan/radioactive tracer approach was approved by the FDA months ago.\u00a0 It also explains some of the limitations on availability:\n\u201cRajan Agarwal, an Abington Memorial Hospital radiologist, did the country\u2019s first three commercial Amyvid scans in June and has had no referrals since. Adler also has done three. Though doctors think the test can be a blockbuster, PETNET, a Siemens subsidiary that distributes the tracer, said it had made 100 commercial doses for this region since June.\nThe tracer is made individually for each patient on test day at 15 sites around the country, then delivered within a 2\u00bd-hour radius. \u2026\nLack of coverage for the $3,000 test is the biggest barrier to it here. Medicare\u2019s decision on coverage, which often sets the standard for private insurers, is due by July.\u201d", "answer": 1}, {"article": "Infants exposed to partial treatment in the womb healthier than those not exposed.\nThe new study, supported by NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), provides strong evidence that even a partial course can have some benefit.\nInfants in the partial treatment group fared better than untreated infants.\nThe study followed the infants from birth to 18 to 22 months of age and measured survival and brain and nervous system outcomes.\nResearchers evaluated 6,121 extremely premature infants who had been born between 22 and 27 weeks of pregnancy at sites in NICHD\u2019s Neonatal Research Network.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release reveals high up in the article that steroids are a standard treatment for pregnant women expecting preterm delivery, or before 34 weeks. \u201cThese drugs are known to reduce the chance of complications and heath among premature infants,\u201d it states.\nSince the release makes it clear that steroids are nothing new, we give it a Satisfactory rating here.", "answer": 1}, {"article": "For the control group, 56 percent displayed a significant increase in cognitive capacity, while 44 percent had no change.\nThis study is the first to examine similar positive effects from college courses taken by older adults, said Lenehan, of the University of Tasmania.\nThe participants who took college classes volunteered for the study so they probably had a greater interest in continuing education that the general senior population, the journal article noted.\nThe participants' age, gender, feelings of well-being or level of social connectedness didn't affect the findings.\nThe research was published online in the journal Neuropsychology.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Not noted explicitly but university courses are widely available especially at community colleges. This is suggested by the release so we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "\"It is not inconceivable that in the near future you will see the I-Portal goggle used on every sideline in America,\" Hoffer said.\nWith these findings, it appears the I-Portal goggle may be a solution.\nAnother benefit for this research was that \"this next generation test has the considerable advantage of not requiring baseline testing,\" said study co-author Carey Balaban, Ph.D., of the University of Pittsburgh.\nThe results of the trial met the expectations of Hoffer and his team of researchers.\nThe research findings published by PLOS ONE help support their objective.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release hints the goggle is not in widespread use \u2014 at least not yet. One of the study authors says, \u201cIt is not inconceivable that in the near future you will see the I-Portal goggle used on every sideline in America.\u201d\nIt is our understanding that this PloS One article was the first peer-reviewed paper on the only clinical study of this product. We feel it is misleading and too early to claim that this goggle could be on \u201cevery sideline\u201d in the \u201cnear future.\u201d Not only that, the wording is also vague. What does the \u201cnear future\u201d mean anyway? Until that happens, researchers need to collect more data and gain FDA approval for the device, which all take time.\nAs a result, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "If the child said a word, the parent repeated it and added something.\nNevertheless, for parents of children with autism, even a modest reduction would be worthwhile.\u201d\n\nDr Max Davie, of the Royal College of Paediatrics and Child Health, said it offered \u201ca hugely cheering message for families\u201d, while Uta Frith, emeritus professor of cognitive development at University College London, called it \u201ca remarkably positive story, because the intervention itself was neither intensive nor invasive\u201d.\n\u201cThese results at follow-up are pretty consistent in showing the benefit of this early intervention for autism across a range of measures.\nMy impression is that this is an intervention that reduces the severity of autistic symptoms, rather than curing autism.\nThe success of the preschool autism communication trial (Pact) has surprised even the researchers who designed it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article leads the reader to conclude that the training program is a \u201cpotential breakthrough\u201d but says nothing about a) how many children would qualify for this training program in the UK; b) whether there are enough trainers; or c) how or when people inside or outside the National Health Service can find the program and sign up.", "answer": 0}, {"article": "Dr. Adolfo Llanos, a neonatologist at Nicklaus Children's Hospital in Miami, who was not involved with the new study, said the \"quality of this analysis is very good.\nThe antioxidants in human milk may help, Chen said.\nWhen they do, the screening and treatments are not as good, Chen said, so blindness may be more likely.\nAnd any breast-feeding appeared to reduce the odds of the serious eye disease by 46 percent, the research showed.\nThe takeaway from this study, Llanos said, is to breast-feed as long as possible, if possible.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We won\u2019t dock points from the story for not discussing the availability of formula and breast milk. Although those topics could certainly sustain such a discussion had the story chosen to address them.", "answer": 2}, {"article": "In type 1 diabetes, the immune system attacks and destroys insulin-producing cells within the pancreas.\nThe study was very small, and the procedure is not ready for widespread use.\nThe \"cocktail treatment\" combines stem cell therapy with drugs that suppress the body's immune system.\nThis is the latest of several stem cell studies to show promising results for the treatment of type 1 diabetes, Ratner notes.\nFirst, patients are given drugs to stimulate production of blood stem cells.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that the procedure was not ready for widespread use.", "answer": 1}, {"article": "Co-authors include: Drs.\nThe results of the study show that choice of sedation medication had the biggest impact on the incidence of adverse events and need for significant interventions in response to those events.\n\"The low rate of serious adverse events and significant interventions supports the safety of procedural sedation in the hands of emergency department physicians,\" said Dr. Bhatt.\nThis study was funded by a Canadian Institutes of Health Research (CIHR) team grant in Pediatric Emergency Medicine.\n\"We've been able to identify sedation medications and practices associated with the best clinical outcomes, which is practice-changing.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the different sedation methods isn\u2019t addressed. Readers must assume that the study looked at the common types of sedation used.", "answer": 2}, {"article": "\"Most people, especially athletes, when they had hip symptoms, usually they just got diagnosed as a chronic groin pull,\" said J.W.\nAnd they've found that it can be fixed using arthroscopic surgery, which uses narrow instruments inserted through smaller incisions than traditional surgery.\nIn the past 10 to 15 years, doctors have discovered one specific cause of hip pain: a tear in the acetabular labrum, a condition in which the cartilage that lines the hip socket is damaged.\nThis is a marked uptick from a decade ago, when Ochiai said the single course in hip arthroscopy was nearly canceled due to lack of interest.\nBut those experiencing hip pain or stiffness have had more-limited options.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\n \nThe news story explains that orthopaedic surgeons are performing increasingly more hip arthroscopy procedures, and are taking increasingly more courses to learn how to do them. Readers are likely to correctly infer that the procedures are commonplace in some centers around the U.S. and less common in others.", "answer": 1}, {"article": "\"Normally when you make drugs, it's hard to say 'attack only that protein.'\nThe precision of the process is crucial to limiting side effects, the researchers said.\nThe experiment proceeded just as planned, as biopsies later showed.\n\"This directly interferes with the genetic mechanisms that promote cancer to stop the production of a particular protein,\" added Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society.\nAnd unlike conventional gene therapy -- where the offending gene is replaced by a new one or overridden -- this therapy is reversible, said Adams.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Unlike the Reuters story, this story was very clear with this statement:\u00a0 \"Obviously the process will have to be refined and optimized before it\u2019s actually used for treatment.\" ", "answer": 1}, {"article": "ADVERSE EVENTS \n\nNasal pain, discomfort or burning (10.3%); transient electrical discomfort (5.2%); nosebleed (5.2%); nasal congestion (3.1%); headaches (2.1%); trace blood, dot heme in nostril (2.1%); facial pain (2.1%); sore eye (1.0%); sinus pain (1.0%); periorbital pain (1.0%); runny nose (1.0%); nasal ulcers (1.0%); and light-headedness (1.0%).\nThe new advancement is an addition to Allergan's current eye care portfolio.\nThere have been two clinical studies showing positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients.\nAll device-related adverse events were mild in nature.\nStudy 2 is a prospective, single-arm, multicenter, open-label clinical trial in which participants used TrueTear\u2122 to stimulate tear production for 180 days.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release says that the device has been granted marketing authorization by the FDA. One can safely assume the product will be on the market by the end of the year.", "answer": 1}, {"article": "Prostate cancer becomes more common as men age \u2014 autopsies of elderly men find that most had prostate cancer, whether they knew it or not.\nStill, he said the new test could help patients if it was used with caution.\nBut some said that if the test leads to more screening, it is not necessarily a good thing.\nIt was released online on Wednesday, a journal spokeswoman said, because \u201cit is a very active area of research with a lot of competition.\u201d\n\nResearchers long knew that the disease often runs in families.\n\u201cWe are just feeding off of this cancer phobia.\u201d\n\nWhat is needed, and what the new test does not provide, is a way to decide which cancers are dangerous and which are not, Dr. Isaacs said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reported that the company that would be offering the test estimated that it would be available in a matter of months.", "answer": 1}, {"article": "In 2016, he was ranked the No.\nThis large scale randomized trial will test whether Plaque HD\u00ae reduces risks of heart attacks and strokes.\nThese results, published today online ahead of print in the American Journal of Medicine, with an accompanying editorial by the editor-in-chief, show that Plaque HD\u00ae, produced statistically significant reductions in dental plaque and inflammation throughout the body as measured by hs-CRP.\nThe results released today from a randomized trial of a novel plaque identifying toothpaste, (Plaque HD\u00ae), show statistically significant reductions in dental plaque and inflammation throughout the body.\nThis investigator initiated randomized trial was published in collaboration with academic collaborators from the University of Illinois at the Chicago School of Dentistry and the University of Wisconsin School of Medicine and Public Health.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release implies that Plaque HD toothpaste and testing for hs-CRP are both currently available.", "answer": 1}, {"article": "First, help with work or school such as assistance in deciding which classes or opportunities are most appropriate, given a person\u2019s symptoms.\nThe sprawling research team, led by Dr. John M. Kane, chairman of the psychiatry department at Hofstra North Shore-LIJ School of Medicine, randomly assigned 34 community care clinics in 21 states to provide either treatment as usual, or the combined package.\nDr. Mary E. Olson, an assistant professor of psychiatry at the University of Massachusetts Medical School, who has worked to promote approaches to psychosis that are less reliant on drugs, said the combined treatment had a lot in common with Open Dialogue, a Finnish program developed in the 1980s.\nOver two years, both groups showed steady improvement.\n\u201cI\u2019m very favorably impressed they were able to pull this study off so successfully, and it clearly shows the importance of early intervention,\u201d said Dr. William T. Carpenter, a professor of psychiatry at the University of Maryland School of Medicine, who was not involved in the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story touches on availability when it says, \u201cIn 2014, Congress awarded $25 million in block grants to the states to be set aside for early-intervention mental health programs. So far, 32 states have begun using those grants to fund combined-treatment services, Dr. Heinssen said.\u201d That doesn\u2019t provide as much detail as readers might like as to when and where they might find these services, but it gives a general idea of where things stand.", "answer": 1}, {"article": "Followers of the popular regime eat during an eight-hour window, in this case between 10 a.m. and 6 p.m. And for the 16 hours in between, they consume only calorie-free drinks, such as water.\n\"There are also many studies that either report no overall effect or sometimes the opposite.\nHe concluded, \"So far, the consensus seems to be \u2018let\u2019s wait until more rigorous studies, with larger sample sizes that adjust for confounding lifestyle behaviors, have been performed before we conclude anything prematurely.'\"\nWe observed that fewer participants dropped out of this study when compared to studies on other fasting diets,\u201d said Varady.\nNow, researchers have shed light on what one type of time-restricted eating does to the body.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is an intervention tied to eating schedules, not a product. There\u2019s no question of availability.", "answer": 2}, {"article": "Legumes, beans, whole grains and some seeds have it, as do uncooked potatoes and unripe bananas.\nMost intriguing and surprising of all is that so many leftovers contain resistant starch.\nEven if you heat them up again, they retain their new resistant starches.\nBut that\u2019s not the case with resistant starches, so named because they resist digestion.\n\u201cIn my belief, that\u2019s what\u2019s protected them against some of the ravages of the more modern-day high carbohydrate diet.\u201d\n\nLuckily, resistant starch is found in a range of delicious foods.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All of these foods are widely available.", "answer": 2}, {"article": "The American Heart Association has more on heart failure.\nAt both six months and a year later, the patients who had received the new gene saw their risk for death, cardiac transplantation, worsening heart failure and hospitalization decline by half.\nAfter that, the only option is a transplant.\nThe gene for SERCA2a raises levels of the enzyme back to where the heart can pump more efficiently.\nThe study was funded by the Celladon Corp. of La Jolla, Calif.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that this gene therapy is experimental and not available to patients.", "answer": 1}, {"article": "The Journal of Medical Entomology is published by the Entomological Society of America, the largest organization in the world serving the professional and scientific needs of entomologists and people in related disciplines.\nThe effectiveness of the device came as a pleasant surprise to the researchers.\nSkepticism is inherent to the trade.\nClip-On caused high mosquito mortality and knockdown rates up to 0.3 meters from the device, enough to protect a single person wearing the device.\nA product called the OFF!\u00ae Clip-On\u2122 repellent device could be an effective tool for preventing bites from the Aedes aegypti mosquito -- the primary vector of Zika, chikungunya, dengue, and yellow fever -- according to an article in the Journal of Medical Entomology.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s understood that the device is widely available.", "answer": 1}, {"article": "Dr Gorlanova said: \"As research in this field progresses, we are understanding more and more about the gene-environment interaction for the development of asthma.\nThis is the first time that we were able to show the effect of the 17q21 variants on respiratory symptoms during the 1st year of life, depending on breastfeeding status.\nIt is already known that environmental factors have a modifying effect on specific genetic risk, so the aim of this new study was to find out whether this could also be true for breastfeeding and this specific gene related to asthma with the respect to respiratory symptoms in early infancy.\n368 infants from the Basel-Bern Infant Lung Development birth cohort in Switzerland were included in the study.\nOur study sheds light on how this interaction can be modified by breastfeeding.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Breastfeeding is indeed routinely available but the availability of genetic testing for the\u00a0chromosome 17q21 variant is not described. Is this test generally available and if so, is it covered by insurance? The release doesn\u2019t say.", "answer": 0}, {"article": "\"Our idea was to ask, 'What are the most important proteins we could find in Alzheimer's patients?'\nHe said it will take at least two years and additional studies before such a test might reach clinics around the country.\nMore intriguing is a test that examined stored blood samples and predicted Alzheimer's disease in 20 of 22 patients who developed the disease 2 to 5 years later.\nAlthough the studies were small in scale, researchers said the experiment proved that the concept of screening for chemical signals was promising and that the first Alzheimer's blood test might be within reach after further large scale studies.\nThe test initially will be used in research labs, where scientists are trying to learn more about the memory-wasting disease that is one of the most feared consequences of aging.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story used words like \"proves\" and \"promising\", it also included estimates for the time needed for further testing\u00a0that made it clear that this was not something that was currently available.", "answer": 1}, {"article": "About the University of Maryland School of Medicine\n\nThe University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine.\nWhile most cancer patients are well served with today's state-of-the-art radiation therapy technology, up to 30 percent are expected to have a greater benefit from the new form of targeted proton beam therapy.\nProton therapy is just one of several new methods for treating cancer.\nThis technique can precisely direct radiation to the most difficult-to-reach tumors.\nNew research by scientists at the University of Maryland School of Medicine has found that esophageal cancer patients treated with proton therapy experienced significantly less toxic side effects than patients treated with older radiation therapies.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There are at least a dozen centers in the United States that currently offer proton therapy for cancer treatment, but that\u2019s not clear from the information in the release. The only treatment center mentioned in the release is the one that UMD plans to open this fall. What\u2019s more, proton therapy is repeatedly characterized as \u201cnew\u201d \u2014 when it has been a subject of widespread discussion (and reporting) for years.\u00a0 Additionally, most insurers still consider proton beam therapy to be \u201cnot medically necessary\u201d under usual circumstances except for a small number of conditions noted earlier.", "answer": 0}, {"article": "Inflammation occurs when the body is exposed to pathogens, such as bacteria or viruses, which puts the immune system in overdrive until the \"attack\" ceases and the inflammatory response abates.\n\"We know from our previous studies that by losing weight, people can reduce their overall levels of inflammation, and there is some evidence suggesting that taking vitamin D supplements can have a similar effect if one has insufficient levels of the nutrient,\" said lead and corresponding author Catherine Duggan, Ph.D., a principal staff scientist in the Public Health Sciences Division at Fred Hutch.\nWhile IL-6 has normal functions in the body, elevated levels are associated with an increased risk of developing certain cancers and diabetes and may be implicated as a cause of depression, Duggan said.\nDuggan encourages women to speak to their health care providers about measuring their levels of vitamin D to determine the most appropriate dosage.\n\"We were quite surprised to see that vitamin D had an effect on an inflammation biomarker only among women who lost at least 5 percent of their baseline weight,\" Duggan said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Primary care physicians and other health providers are well positioned to monitor blood levels of vitamin D, along with dietary and exercise regimens. The news release makes that clear, albeit indirectly. As noted above, we think the release goes too far in suggesting that people ask their doctors about having their vitamin D levels checked. But we\u2019ve already docked points for that, so we\u2019ll award a Satisfactory rating here.", "answer": 1}, {"article": "When it reaches the area of the heart that causes abnormal rhythms, the tissue is ablated, or destroyed.\nPatients in the Medtronic-sponsored trial who underwent the cryoablation procedure \u2014 which involves using a catheter to freeze away the heart tissue where the problem originates \u2014 was just as safe as drugs used to treat the condition and far more effective, meeting the study\u2019s primary goal of eliminating atrial fibrillation one year after the procedure.\nOver the past decade, more patients have been referred for ablation procedures when drugs proved ineffective.\nA small pilot study funded by St. Jude Medical Inc STJ.N compared the two therapies in a sicker population of patients and also found that the procedure worked better than drugs.\nDubbed Stop-af, the Medtronic trial showed that almost 70 percent of patients who had cryoablation remained free of the condition after one year, compared with just 7 percent of patients who received drug therapy, according to data presented at the American College of Cardiology meeting in Atlanta.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0Towards the end, the story mentions that the treatment device discussed is not yet approved for use, though a device made by a different company (Johnson and Johnson) has been used to treat AF for years.", "answer": 1}, {"article": "Researchers believe electrical pulses can act like a sort of pacemaker in the brain, heading off the chaotic \"electrical storms\" that cause epileptic seizures.\nThe device alone reduced that to about one seizure a year.\nAnd she hasn't had any seizures since she added low doses of a medication more than 18 months ago.\nThe device is appealing because it doesn't require surgery, doesn't have side effects and is very easy to use, Rees says.\nThe device causes \"a slight tingling sensation\" on her skin, she says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story that aired\u00a0said at the very end, \u201cThe device isn\u2019t approved by the FDA yet. That\u2019s probably several years off.\u201d The accompanying online version of the story said roughly the same thing. Readers should have been told that they are very unlikely to be able to have this device prescribed for them unless they can find their way into a clinical trial. Nonetheless, we\u2019ll give it the benefit of the doubt on this criterion.", "answer": 1}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Good job on this. It\u2019s clear\u00a0that businesses that assist with combing are easy to find, and over-the-counter\u00a0shampoos are even easier.", "answer": 1}, {"article": "They find that there are real deleterious side effects but that they are manageable, and conclude the drug is worth using under the proper circumstances,\" he said.\nOverall, Avastin, like several other targeted agents have led to therapeutic advances in lung cancer, he added.\nThe efficacy of the drug has been proven previously, he noted, but this study provides an in-depth analysis of Avastin's safety profile under \"real life\" conditions, he added.\nHowever, several issues remain to be determined, including the optimal dose and the role of maintenance therapy with Avastin, he said.\n\"Today we have a new option to treat non-squamous lung cancer, incorporating Avastin in chemotherapy regimens and in maintenance therapy,\" said lead researcher Dr. Lucio Crino, director of medical oncology at S. Maria della Misericordia Hospital in Perugia, Italy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This piece correctly indicated that this drug is currently available for use. \u00a0 The story used the trade-name Avastin (as opposed to its generic name bevacizumab)\u00a0nearly exclusively throughout and, at the end, mentioned that this drug has already received FDA approval for use in the treatment of other types of cancer.\nThe story could have clarified that the use of Avastin in the treatment of metastic non-squamous cell lung cancer is still an off-label indication for this drug, which is more common in cancer treatment than in other diseases.", "answer": 1}, {"article": "Doctors in Seattle cured a late-stage cancer patient after tinkering with his body's defenses against infection, leading to cautious optimism about treating late-stage melanoma, a deadly skin cancer.\n\nThe surprising result, published in this week's issue of the New England Journal of Medicine, is the latest hopeful finding from the 30-year-old field of \"adoptive immunotherapy,\" which theorizes that the body can be taught to fight off its own cancers.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe news story explains that the therapy it describes is not widely available, and probably won\u2019t be mainstream for another 5-10 years. However, the story does not say whether the therapy is FDA-approved. Numerous immunotherapies have been approved for various cancers, but this treatment for melanoma does not appear to be among them.\n", "answer": 1}, {"article": "In an email, Gunter said she frequently prescribes high-frequency TENS (pulses between 50 and 120 hertz at a low intensity) to treat patients who suffer through their periods: \"I have done so for more than 15 years.\nHe explained that the key to the device is TENS (transcutaneous electrical nerve stimulation), those electronic nerve stimulators you've probably seen in strip malls that hook up to the body to treat neck or back pain.\nBut there's some reason for optimism: The device is basically a repackaging of another (cheaper) technology that has already been proven to help women who suffer with their monthly cycles.\nGunter's main question about Livia is whether it will be significantly different from the already available and effective TENS devices, which usually cost around $35.\nFor now, it's only possible to preorder the device (at a cost of $85) and wait six months for it to ship.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the device is not available at the present time, and it makes it clear that there are available TENS units now that are not as expensive.", "answer": 1}, {"article": "Packaged in powder form and mixed with liquid, alginate expands in the stomach to form a thick gel, mimicking the effect of a large meal.\nAccording to the researchers, the higher sodium content of the alginate drink \u2014 a little over one gram per dose, or about half a teaspoon of salt \u2014 could have offset any potential blood-pressure reducing effect of the supplement.\nFor Mette Kristensen, one of the study\u2019s authors, the message seems clear: \u201cIf you actually comply with the treatment, you do have the improvement in weight loss.\u201d\n\nHowever, effects on blood pressure were less promising.\nStill, the new results should be treated with caution, according to Dr. Maria Vazquez Roque, who has worked on alginate-based gels at the Mayo Clinic in Jacksonville, Florida, but was not involved in the study.\nThese supplements are not regulated by the Food and Drug Administration, said Vazquez Roque.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The fact that alginate is already available in pill form \u2013 and that the FDA does not regulate such supplements \u2013 was mentioned.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/29/national/w155455S59.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This article reported on what it terms \u2018the first human testing\u2019 of vaccine against the bird flu. While mentioning other studies underway, and not explicitly stating that this vaccine is not currently available to the public, a thread throughout the piece made it clear that vaccine against this strain of flu was still a work in progress.", "answer": 1}, {"article": "Anorexia has one of the highest mortality rates of any psychiatric disorder and is among the most common psychiatric disorders in girls aged between 15 and 19 years.\nCommenting on the results of this small trial, Janet Treasure and Ulrike Schmidt of King\u2019s College London\u2019s Institute of Psychiatry said the technique looked promising and would give hope to patients with especially pernicious forms of anorexia.\nThis success, in a small study designed as a pilot to test the safety of the technique, suggests larger trials will confirm the effectiveness of the deep brain stimulation (DBS) device, the researchers wrote in the medical journal The Lancet.\nThe devices were activated 10 days later and researchers measured changes in the patients\u2019 mood and anxiety to help find the correct level of stimulation.\nAndres Lozano, who led the study, said the results were encouraging because they pointed to a genuine therapeutic effect, rather than a placebo or hunger-increasing effect.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story gave some hint of availability by reporting:\n\u201cDBS is used to treat several neurological illnesses including Parkinson\u2019s disease and chronic pain. Scientists are also investigating its use in depression and epilepsy, but this was the first time it had been used in patients with anorexia.\u201d", "answer": 1}, {"article": "SAMe may influence the expression of genes involved in depression or alter the function of different receptors and structures that transport neurotransmitters in the brain.\nThat\u2019s probably the best hypothesis.\u201d\n\nOther studies have suggested that SAMe can relieve symptoms of depression.\nDr. Nelson, who was not involved in the Harvard study, said the results need to be replicated in a larger study, and that more information is needed on dosing, side effects and long-term treatment with SAMe, among other things.\nThe research offers hope to patients who haven\u2019t been helped by traditional antidepressant treatment.\n\u201cIn the last 60 years of depression research, all the treatments have focused on similar mechanisms of action.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We learn that this supplement is available and popular, and we get its costs.\u00a0 Because the story meets the lowest standard for this criterion, we rule it satisfactory.\u00a0 However\u2026..\nWe don\u2019t learn why it\u2019s been widely used for depression in Europe but not in the U.S. That claim of widespread European use is dubious and could lead readers to falsely conclude that Europeans have concluded it is an effective treatment. Following lemmings off the cliff may be programmed into our nature, but the outcome is often undesirable. \n And what\u2019s it used for with such great popularity in the U.S.?", "answer": 1}, {"article": "\u201cFor young people they don\u2019t want to commit themselves to a treatment which they might need to take for the next five to ten years,\u201d he said.\n\u201cAt the moment there\u2019s no state-of-the-art guideline (on) how to treat those people.\u201d\n\nPrescribing antipsychotic medications may be helpful, Amminger added, but these medications have serious side effects, and can also be stigmatizing.\nSeventy-six of the 81 study participants, or 94 percent, completed the trial, Amminger noted, which underscores the safety and tolerability of fish oil.\nThere are a number of mechanisms through which omega-3s could protect the brain, Amminger said; they are a major component of brain cells.\nBut while psychiatrists now know how to identify these individuals, he added, they don\u2019t know what to do with them.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not state that\u00a0fish oil/omega-3\u00a0PUFA\u00a0supplements are widely available. But we\u2019re not sure that\u2019s necessary, since most people are probably already aware of this. ", "answer": 2}, {"article": "\"What we found is that kids get home from school around 4 p.m.\nThe snack was administered after school as students were boarding the school bus to go home.\nThe researchers conclude that afterschool programs and schools can replace energy dense, unhealthy snacks with peanuts to provide a healthier alternative for children (researchers in the study ensured students did not suffer from nut allergies).\nFollowing the 12-week intervention, students spent 12 more weeks maintaining the healthy snacking habit.\nParticipants in the study were part of a larger longitudinal study on a school-based obesity intervention program.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that peanuts and peanut butter are available in every grocery and convenience store in the United States.", "answer": 2}, {"article": "They form when the skin is rapidly stretched, such as during puberty, pregnancy, and rapid weight gain, says Joshua Zeichner, MD, director of cosmetic and clinical research at Mt.\nThe study, funded by Merz Pharmaceuticals, which makes the cream, was presented at the annual meeting of the American Academy of Dermatology.\nHe was not involved with the research.\nThe new product also contains pennywort, a plant found in Asia, Africa, and the Americas that has anti-inflammatory properties and is widely used in Indian naturopathic medicine for ulcer healing, she says.\nAnd it has sulfur, which fights bacteria and infection, and a moisturizing cream to help rehydrate the skin, Draelos says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the product is available in drug stores.", "answer": 1}, {"article": "These forward-looking statements speak only as of the date hereof.\nThe Oncotype DX DCIS Score result provides patients with an individualized estimate of local (in the same breast) recurrence, which could be either invasive breast cancer or DCIS.\nPhysicians in this study rated the DCIS Score as the most important factor in planning treatment compared with pathologic features, patient preference, patient age, comorbidities or consultation with other physicians.\n\"The publication of this clinical utility study clearly demonstrates that the Oncotype DX DCIS Score can play a key role in enhancing cancer care for patients with DCIS, and we believe that these results will support expanded adoption of and access to the DCIS Score.\"\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the test to physicians, patients and payors.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There was no mention on how available the Oncotype DX DCIS Score test is in clinical offices and no mention on whether it is covered by insurance. The test is, in fact,\u00a0widely available \u2014 the physician sends a\u00a0requisition form either to the pathology department, which will send the tissue to Genomic Health, or to Genomic Health, who will then request the tissue samples from pathology.", "answer": 0}, {"article": "\"Pecans are naturally high in monounsaturated and polyunsaturated fats, so replacing a portion of the saturated fat in the diet with these healthier fats can explain some of the cardio-protective effects we observed,\" said lead researcher, Diane McKay, Ph.D. \"But pecans also contain a number of bioactive plant compounds as well as vitamins and essential minerals that all likely contributed to this benefit.\nThe study was funded by the National Pecan Shellers Association.\nBoth the control diet and the pecan-rich diet were low in fruits, vegetables and fiber.\nWhile a growing body of evidence has linked tree nuts such as pecans to reduced risk of CVD, this is the first study to look at the effects of pecan consumption on factors other than blood lipid levels and specifically those related to T2D.\nIn this placebo-controlled crossover study of 26 men and women (average age 59 years), all meals were provided to carefully control their food intake.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Pecans are known to be widely available.", "answer": 2}, {"article": "Also some fancier CT studies, involving multiple \"slices\" through the body in a single examination, can be replaced by simpler CT tests, conventional X-rays or tests such as ultrasound or MRI that don't involve radiation.\nPatients often expect a scan.\nChildren, younger adults and women are especially susceptible.\nThat will require hospitals to feed dose data to a central computer run by the radiology group.\nTo cut down on unnecessarily high radiation doses, Thrall says, the College of Radiology is also developing an \"alarm\" system that will alert hospitals when their CT scan exceeds an acceptable dose.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly CT scans are available.", "answer": 1}, {"article": "Try to eat a pound of vegetables each day, half of which are cooked and the other half eaten raw, as well as half a pound of raw fruit.\nBut while certain common foods \u2014 like raw onions, garlic, citrus juices, coffee and chocolate \u2014 are likely to cause reflux in most people with the condition, Dr. Aviv and other experts emphasize that everyone is different, and trial and error is the most effective way to determine an individual\u2019s trigger foods and drinks.\nA food does not have to be obviously acidic to be troublesome.\nLosing weight is one of the best ways to find relief without having to rely on medication.\nHe said they should be taken 30 to 60 minutes before eating breakfast or dinner (or both), but not used as an \u201cantidote\u201d to consuming acidic foods.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t address availability\u2013but it doesn\u2019t need to: lifestyle changes are not products or services. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "Thirty women each received real acupuncture that also included a bit of an electric buzz or the inactive placebo pill, 32 women got sham acupuncture, and 28 women received gabapentin (Neurontin).\nInterestingly, sham acupuncture came in second place for effectiveness, the researchers said.\n\"There is a component of behavior of doing a sham procedure, so it psychologically may trigger a different kind of reaction from patients versus taking the placebo pill.\"\nDeng pointed out that clinicians have come to realize that the placebo effect is very important in treatment.\nFurthermore, the effects of acupuncture were \"significant and enduring for hot flashes while gabapentin's effect only happened when a patient was taking the medication,\" said study first author Dr. Jun Mao, an associate professor of family medicine and community health at the University of Pennsylvania in Philadelphia.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Acupuncture is widely available and while the report did not establish the availability of the treatment, consumers certainly know about it. The story could have noted that insurance may not pay for acupuncture treatment, however. Gabaptentin is described as a drug that\u2019s typically used to treat nerve pain, and readers can work out from that that the drug is available.", "answer": 1}, {"article": ".\nThe researchers will continue clinical studies with the OCT device, looking at other types of solid-state tumors.\nDiagnostic Photonics, a start-up company Boppart co-founded that also collaborated on the study, is commercializing the OCT probe technology for broader use.\n\"For the first time, this study demonstrates the use of OCT for imaging tumor margins within the tumor cavity, in the patient, during surgery,\" Boppart said.\nThe interdisciplinary research team led by Stephen Boppart, a University of Illinois professor of electrical and computer engineering and of bioengineering, performed the study on 35 patients with breast cancers at the Carle Foundation Hospital in Urbana, Illinois.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release says the device \u201ccould soon enable reliable, real-time guidance for surgeons,\u201d which may be a bit optimistic, but at least suggests that the device is not available yet. Toward the end of the release it is stated that \u201cThe researchers will continue clinical studies with the OCT device, looking at other types of solid-state tumors,\u201d which arguably suggests the same.\nIdeally the text would have been more explicit about whether and/or when the device would be commercialized, but we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": ".\nResearchers at Baylor Scott & White Health in Temple, Texas, found that dry needling, which uses filament needles to stimulate sensitive loci, or trigger points, in the muscles, is as effective as cortisone injection in reducing pain and improving movement problems caused by greater trochanteric pain syndrome (GPTS).\nHowever, \"this study suggests dry needling as an effective alternative to cortisone injection.\"\nThe study demonstrates that patients with GTPS can get similar results from dry needling as from a steroid injection.\nThe results showed that cortisone injection did not provide better outcomes than dry needling for either pain or function in patients with GTPS.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no discussion of what\u2019s involved with dry needling. While steroid injections take about five minutes and are usually done in a physician\u2019s office once every six weeks or more, dry needling is usually performed by a physical therapist and requires more frequent treatments of about 20 minutes apiece.\nDuring this six-week study, the dry needling group received an average of 5.4 treatments while those who received cortisone injections had one shot.\nDry needling might be more convenient than steroid injections if it\u2019s part of treatment strategy that also involves physical therapy.", "answer": 0}, {"article": "Then President Richard Nixon declared drugs \u201cpublic enemy No.\nIn the past 20 years or so, a small amount of research has once again begun to focus on these chemicals, showing that they have promise for treating a range of conditions, from addiction to depression and anxiety, says Evan Wood, a psychiatric researcher at the University of British Columbia.\nThat said, when studied under controlled and supervised conditions, these chemicals have not been found to cause lasting negative health consequences, the Canadian Medical Association Journal review noted.\nAll of which adds up to a compelling argument that psychedelics \u201cshould be the focus of intensive study for treating mental illness,\u201d Wood says.\nHe points out that psychedelics should never be used carelessly, and that the \u201cset and setting\u201d (meaning the dose, mood, environment, company and surroundings) where a person takes them are of paramount importance.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Magic mushrooms and MDMA may be \u2018available\u2019 in our society, but hardly through channels that one would consider reliable or trustworthy. While we might want more details on how to obtain these substances, in the interests of public service, it may be just as well that the story didn\u2019t delve into this issue too far.", "answer": 1}, {"article": "Chronic idiopathic constipation is a diagnosis given to those who experience persistent constipation and for whom there is no structural or biochemical explanation.\nTrulance should be avoided in patients six years of age to 18 years of age.\nThe safety and effectiveness of Trulance have not been established in patients less than 18 years of age.\nTrulance should not be used in patients with known or suspected mechanical gastrointestinal obstruction.\nTrulance should not be used in children less than six years of age due to the risk of serious dehydration.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The FDA release announces approval and most readers will understand that this is essentially the last big step in market availability. The release would have been stronger had it noted that the drug may not be available widely for a short time.", "answer": 1}, {"article": "Patients with a record of pneumonia were followed for six months to see if they died, and the researchers found that 13 percent (109 out of 847) of statin users died compared with 20 percent (578 out of 2,927) of non-statin users.\n\u201cGiven the potential low number needed to treat to prevent a death suggested by this study, we believe that a strong case exists for randomized trials of statins in people with serious infection to determine if a simple and practical intervention at the point of diagnosis of pneumonia has a beneficial effect.\u201d\n\nDouglas\u2019s team, whose research was published in the British Medical Journal, used data from computerized medical records of doctors\u2019 practices in Britain to identify statin users.\n\u201cStatins are safe, cheap, and an easy intervention in terms of delivery,\u201d said Ian Douglas, a lecturer in epidemiology at the LSHTM who led the research.\nDouglas noted that since this study looked at patients who were already taking statins when they developed pneumonia, a full randomized clinical trial was needed to find out whether starting a statin at the time of diagnosis has a similar effect.\nPrevious studies have suggested statins, which are also available as cheaper generics, may be linked to better outcomes after bacterial infection.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Statin drugs are commercially available in\u00a0brand name and generic formulations as indicated.\nWe do think it\u2019s a bit odd \u2013 and unnecessary \u2013 to mention the manufacturer and the brand name.\u00a0 Early in our journalism training, we were discouraged from doing so unless absolutely necessary in the story \u2013 which is not the case herein.", "answer": 1}, {"article": "To make sure it works, though, the Centers for Disease Control and Prevention says doctors need to do a number of things:\n\u2022 Prescribe Truvada only for men at high risk of getting infected \u2013 that is, only for men who have sex with men, those who have multiple sex partners, and those who live in areas where there's a lot of HIV circulating.\nThe study makes that last point very clear.\nThat doesn't tell the whole story.\nThe pill, called Truvada, is already on the market for treating HIV infections.\nNow health officials are warning doctors that preventing the disease will take more than just writing a prescription.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that Truvada is already on the market.", "answer": 1}, {"article": "Although surgeons can also take X-rays during the posterior procedure, it is much more difficult, and they wait until patients are in the recovery room, where, Bollinger says, \u201cthere\u2019s not much that can be done.\u201d He explains that while the body \u201ctolerates an imperfect alignment pretty well, if a new hip gets dislocated, it\u2019s often because it\u2019s not in perfectly.\u201d\n\nRobert Saunders, a nurse at Alta Bates Summit Medical Center in Berkeley, Calif., sees about 200 hip replacement patients a year.\nMany patients aren\u2019t aware of the option.\nAccording to those who use this anterior technique, the benefits are substantial.\nUnger says that most surgeons have used the posterior approach for years, have fine results, and see no need to switch.\nSo when students leave and begin their practices, it\u2019s no longer foreign to them.\u201d\n\nHamilton, who has performed 1,100 anterior procedures and strongly supports the method, says that despite growing interest, \u201cit will take a generation of new surgeons\u201d before use of the anterior approach is widespread.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story spends a lot of time discussing why this technique is still only practiced by a minority of physicians, but it is clear that it is a widely available option.", "answer": 1}, {"article": "The incidence of shingles increases as we get older, because the body's natural immunity declines.\nThis is 12 times higher than other less effective shingles vaccines.\nThe full paper is published online by the Journal of Infectious Diseases as Editor's choice: https:/\n\nThe Shingrix vaccine is developed by GlaxoSmithKline.\nA new study has shown how the body's immune system responds to the new shingles vaccine, Shingrix, making it more than 90% effective at protecting against the virus.\nIt is the first shingles vaccine to combine a non-live antigen with a specifically designed adjuvant.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no mention of whether Shingrix is widely available. It is, including in the US where it received FDA approval in October 2017.", "answer": 0}, {"article": "In their study, published in the Feb. 23 issue of the Journal of the American Medical Association, Miglioretti and her colleagues found that false positives and interval cancers were both higher in women with a history of breast cancer than in those without such history.\nDr. William Audeh, medical director of the Samuel Oschin Cancer Center and the Wasserman Breast Cancer Risk Reduction Program at Cedars-Sinai Medical Center in Los Angeles, described the findings as \"not at all surprising.\"\nAnd though mammography did not catch all cancers in the women with a breast cancer history, the study still points out the value of the test, he said.\nIt points to the need, she said, for women to remain vigilant about screening after their breast cancer treatment -- and to report any symptoms to their doctor immediately.\nThe interval cancer rate was 3.6 per 1,000 screenings in those with a history and 1.4 per 1,000 in those without, the investigators found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 Mammography is widely available and recommendations for annual mammography screening after a breast cancer diagnosis are standard. So the story didn\u2019t need to specifically discuss the availability.", "answer": 2}, {"article": "When a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.\nThe research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as \"a game changer for future treatment of asthma.\"\nThe study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.\nThis is the technical name for the five year Europe-wide, EU funded project, which aimed to produce computer and physical models of the whole human airway system for people with asthma and chronic obstructive pulmonary disease (COPD).\nProfessor Christopher Brightling, who is a NIHR Senior Research Fellow and Clinical Professor in Respiratory Medicine at the University of Leicester, led the study at the NIHR Respiratory Biomedical Research Unit, which is based at the Glenfield Hospital in Leicester.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is fairly clear in pointing out that this was a clinical trial and that the drug, fevipiprant, isn\u2019t available to the public as of yet.", "answer": 1}, {"article": "According to the Centers for Disease Control and Prevention (CDC), birth defects caused by genetic disorders affect one in every 33 births in the United States.\nExperts say the couples are not the only people who benefit from these tests.\nA diagnosis before pregnancy may sound like a designer baby, but doctors say that\u2019s not the case.\nSpecialists now have a way to test the parents-to-be that may not only increase their chances of getting pregnant but also reduce the risk of them passing on certain genetic diseases.\nThese results have helped eliminate pre-term birth and hospitalizations for pre-term labor, and patients and families have better outcomes, he added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that preimplantation genetic screening is available, but it doesn\u2019t make clear that it is available only for pregnancies resulting from IVF.", "answer": 0}, {"article": "An enzyme is a protein that performs a chemical reaction.\nA new study, however, offers some potential for hope.\nFRIDAY, Feb. 8, 2013 (HealthDay News) -- For people with celiac disease, everyday foods such as bread, pizza crust and muffins are potential enemies.\nSome experts identified limitations to the research.\nThe re-engineered enzyme, named KumaMax, appears to be highly effective, at least in a test tube.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this is an experimental treatment and not available to the public, although we\u2019re a little uncomfortable with the prediction that a pill could\u00a0be available \u201cin a few years.\u201d That\u2019s true, but it\u2019s also possible that such a pill might\u00a0never be available. Why not mention that possibility as well?", "answer": 1}, {"article": "\u201cWe believe we can modify this test and make it much easier and simple... (and then) we can have something ready to be introduced into the clinic,\u201d he told Reuters in Nicosia.\nSince amniocentesis carries a small risk of spontaneous miscarriage \u2014 Patsalis put it at around one or two percent \u2014 scientists have been looking for new less invasive ways to test for Down\u2019s and other potential genetic problems.\n\u201cSuch a non-invasive approach will avoid the risk of miscarriages of normal pregnancies caused by current, more invasive procedures,\u201d the scientists wrote in their paper.\nPhilippos Patsalis, medical director of the Cyprus Institute of Neurology and Genetics, who led the study, said the results were \u201cvery exciting\u201d and the test now needed to be trialed in a larger study of about 1,000 pregnancies, but could lead to changes in clinical practice within two years.\nThe risk for a 40-year-old mother is 16 times that for one who is 25.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Allowing researchers to claim that a test \u201cmay soon be\u201d available after a study in just 40 pregnancies is not wise journalism.\u00a0 If the story had turned to an independent expert, perhaps this enthusiasm may have been put into a better perspective. The path to commercialization is likely years in the making.", "answer": 0}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\nLast year, the Food and Drug Administration cleared the first laser, PinPointe, for \u201ctemporary increase of clear nail\u201d in patients with onychomycosis, the medical term for a fungal infection of the nail.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\nPractitioners have been using other lasers on toenail fungus since about 2009.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says, \u201cLast year, the Food and Drug Administration cleared the first laser, PinPointe, for \u201ctemporary increase of clear nail\u201d in patients with onychomycosis, the medical term for a fungal infection of the nail. The FDA cleared a second one, GenesisPlus, in April. Practitioners have been using other lasers on toenail fungus since about 2009.\u201d This covers the necessary bases.", "answer": 1}, {"article": "They might be more health conscious or conscientious, or have other traits associated with longevity.\nThis is a screening test that saves lives.\u201d\n\nThose gains come at some cost to health, though: For every life saved, she estimated, five men will be told they have cancer when in fact their abnormal cells would never grow, spread, or harm them.\nIf the new analysis is correct, one of the influential PSA studies, called PLCO, reduced deaths from prostate cancer by 27 percent to 32 percent, not the zero percent that PLCO researchers themselves found.\nThe analysis, published Monday in Annals of Internal Medicine, drew wildly different reactions, as is often the case with research on PSA screenings.\nThe finding that assigned-to-screening men were no more likely to avoid death from prostate cancer might therefore have been because their screening behavior wasn\u2019t different enough from the \u201cunscreened\u201d (but in fact partly screened) men\u2019s, not because PSA screening doesn\u2019t save lives.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the article that PSA testing is ubiquitous in America. Mentioning that it is covered by most insurers, and for those on Medicaid/Medicare, still would have been helpful, however.\n\u00a0", "answer": 1}, {"article": "\"Obviously that's very exciting,\" Spira said.\nThe minimally invasive procedure involves using a small brush to collect a smattering of cells from the windpipe (a bronchoscopy), explained study co-author Andrea Bild, an assistant professor of pharmacology and toxicology at the University of Utah in Salt Lake City.\nWorking on the theory that cigarettes harm not only the lungs but a \"field of injury\" extending to other areas of the respiratory tract, the study authors surmised that evidence of existing or soon-to-develop lung cancer might be available further up in the airway.\n\"We're now in the midst of a large study to look at whether or not activity of this pathway can be used to pick those who could benefit from this as a treatment as opposed to just prevention,\" said Spira, who is a co-founder of Allegro Diagnostics Inc., a company that plans to market this biomarker.\nCurrently, there is no good way to detect lung cancer -- the number one cancer killer -- in its early stages when it's most treatable.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The opening line of the article \u2014 \"Researchers may have found an easy way to detect lung cancer in its early or even pre-cancerousstages, as well as a way to reverse the start of the deadly disease with a readily available, over-the-counter drug\" \u2013 overstates the evidence for inositol\u2019s effectiveness, and implies that it is available in a form that could reverse the development of lung cancer.\u00a0 ", "answer": 0}, {"article": "Among those 40 to 49 who had regular screening, for every 1,000 women tested, 121.2 had a false positive.\nFor every 10,000 women screened repeatedly over 10 years, four lives are saved in women 40 to 49; eight in women 50 to 59; 21 in women 60 to 69; and 13 in women 70 to 74, the task force found.\nThe guidelines relied in part on a study of records from 405,191 women who had digital mammograms from 2003 to 2011, which found that false positives were common, especially in younger women.\nDr. Constance Lehman, a professor of radiology at Harvard Medical School and director of breast imaging at Massachusetts General Hospital, who is not on the task force, said she was pleased to see that although its advice had not changed, the group had placed more of an emphasis than before on the importance of women\u2019s having the freedom to decide how often to be screened and when to start.\n\u201cThe science supports mammography as an important tool in the fight against breast cancer,\u201d said Dr. Michael LeFevre, a former chairman of the task force and a professor of medicine at the University of Missouri.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the use of mammograms as breast cancer screening tools is longstanding and well established. The story also discusses insurance coverage issues that would affect availability for many women. The story states, \u201cThe recommendations are not immediately expected to affect insurance coverage. In December, Congress passed a bill requiring private insurers to pay for screening mammograms for women 40 and over every one to two years without copays, coinsurance or deductibles, through 2017.\u201d", "answer": 1}, {"article": "The Mount Sinai Hospital is in the \"Honor Roll\" of best hospitals in America, ranked No.\nThe results, published in the June 23, 2017, online edition of The Laryngoscope, may transform how doctors approach cochlear implant procedures to give patients the best possible outcomes.\n\"We hope the findings will help surgeons choose the best implants and approaches for their patients,\" said Dr. Wanna.\n\"This study is a breakthrough for patients with hearing loss, and improvements in practice and techniques will allow them to enjoy many hearing benefits such as music enjoyment, listening in complex environments, and sound localization.\"\n\"This is an exciting time in this field, and the advancement in hearing technology and continued improvements in techniques and outcomes will benefit patients and their families.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Are these types of surgeries or cochlear implants available anywhere in the US? \u00a0We have no idea from reading this news release.", "answer": 0}, {"article": "In the new study of 24 patients, scores on a standard test measuring the disturbances of memory, language, attention, and other cognitive skills that are hallmark symptoms of Alzheimer's disease dropped an average of slightly more than five points in those treated with IVIG.\nIt's a form of intravenous immunoglobulin, or IVIG, drugs that are usually used to treat immune system disorders.\nThe IVIG treatment also appeared to slow the rate of brain shrinkage by about 45%, he tells WebMD.\nThe drug is called Gammagard.\nThe findings were presented at the American Academy of Neurology meeting.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told that IVIG is a decades-old drug. ", "answer": 1}, {"article": "Men with low-risk prostate cancer are currently put under active surveillance, where the disease is monitored and only treated when it becomes more severe.\nThe VTP treatment is now being reviewed by the European Medicines Agency (EMA) for possible license, but it likely to be several years before it can be offered to patients more widely.\nThe trial involved 47 treatment sites in 10 European countries, most of which were performing VTP for the first time.\n\u201cThe fact that the treatment was performed so successfully by non-specialist centers in various health systems is really remarkable,\u201d Emberton said.\n\u201cThese results are excellent news for men with early localized prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,\u201d said Mark Emberton, a University College London consultant urologist who led the trial.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the treatment is \u201cbeing reviewed by the European Medicines Agency (EMA) for possible license, but it is likely to be several years before it can be offered to patients more widely.\u201d\nStill, we\u2019re left wondering what \u201cmore widely\u201d means here. Is it already available to some patients? The story doesn\u2019t say.", "answer": 1}, {"article": "Unlike the 2012 campaign, which aired for 12 consecutive weeks, the 2014 campaign aired in two phases, from February 3 to April 6 and from July 7 to September 7.\nThe website includes detailed assistance developed by the National Cancer Institute to support smokers trying to quit.\nTips ads encourage smokers to call 1-800-QUIT-NOW or to visit www.cdc.gov/tips to view the personal stories from the campaign.\nThose new ads featured people and their struggles with smoking-related health issues, including cancer, gum disease, premature birth, and stroke caused by smoking combined with HIV.\nAn estimated 104,000 Americans quit smoking for good as a result of the 2014 campaign.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release refers readers to the quit line and a web site containing the Tips ads.", "answer": 1}, {"article": "\u201cWe\u2019ll also advance key parts of our tobacco plan very soon,\u201d he said.\nThe FDA is seeking additional research and data for public review, Gottlieb said, as it tries to develop a nicotine product standard.\nThe comment period will be open through mid-June, said Mitch Zeller, director of FDA\u2019s Center for Tobacco Products.\nThe move was part of a comprehensive plan the agency announced last summer to regulate tobacco and nicotine, FDA Commissioner Scott Gottlieb said on a call with reporters.\nThat plan marked a major shift designed to give adult smokers a wider range of alternatives, including potentially less harmful e-cigarettes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that lowering nicotine in cigarettes is in the proposal stage.", "answer": 1}, {"article": "Only 30-50 people with type 1 diabetes in the UK currently receive an islet transplant each year, owing to a lack of donors and the difficulty of extracting islets from pancreatic tissue.\nThe pre-clinical results have encouraged CGT and Aberdeen University to create a spin-out company, called Islexa.\nIslexa will use CGT\u2019s labs at Guy\u2019s and facilities at Aberdeen University.\nGrowing islets will \u201csignificantly increase the number of patients who can receive the treatment,\u201d Keith Thompson, CGT\u2019s chief executive, told the World Stem Cells and Regenerative Medicine congress in London on Wednesday.\nInsulin shots could become a thing of the past for type 1 diabetes patients thanks to a technology being developed by Cell and Gene Therapy Catapult, a London-based not-for-profit organisation, and Aberdeen University.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There are vague mentions of the need for clinical trials and reference to a \u201cfew years\u201d before treatment with the lab grown islets are available, but readers will not come away with a reasonable sense of what needs to happen before a treatment based on this approach would become available.", "answer": 0}, {"article": "A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.\n\nThe drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Good job explaining which oral drugs are pending approval, and which is approved. The story says 6,000 patients are already taking Gilenya, the oral drug that is first in this family to win FDA approval.", "answer": 1}, {"article": "Worse, Anderson says, \"I could feel the tumors getting bigger.\nStill, the study stands as \"a major landmark in cancer immunotherapy,\" says Dr. Bernard Fox, president of the International Society for Biological Therapy of Cancer.\nResearchers linked 14 deaths to the study drugs, half caused by immune-system reactions.\nFor now, federal regulators have authorized\n\nto people who have serious or immediately life-threatening, inoperable melanoma that has spread, who have no alternative treatment options, and whose physicians believe the drug is appropriate.\nAfter one year, the once palpable tumors were no longer detectable in diagnostic scans.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the approach is experimental.\u00a0 The story also states:\nMinor quibble:\u00a0 perhaps the story should have reminded readers that a drug company\u2019s timetable predictions may not be the most reliable. \nFor local readers it explained: ", "answer": 1}, {"article": "\"When a body gets used to having a chronic headache suppressor, the patient can experience a rebound in the absence of that suppressor.\nSeven of the patients (about 6 percent) failed to get any benefit from the treatment, the investigators found.\nThe researchers acknowledged that this procedure is a temporary solution that would need to be repeated.\nMandato stressed that no one in the study required sedation to undergo the procedure.\nDr. Richard Lipton, director of the Montefiore Headache Center in New York City, described the findings as \"very dramatic.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of lidocaine (Xylocaine) was not in question, as the drug has been synthesized since the 1940s. It is now widely available in pharmacies. The bigger issue would be finding a specialist every month to deliver these infusions. Is it a procedure that any interventional radiologist could perform? Would they need any special training? The story doesn\u2019t establish whether one can request this procedure right now or if it\u2019s something headache sufferers will need to wait for.", "answer": 0}, {"article": "Phentermine quickly suppresses appetite, while the controlled-release topiramate decreases appetite and increases satiety throughout the day.\nThe people who took the lowest dose of the drug dropped about 5.1% of body weight at six months, and, on average, gained some back by one year.\nOverall, people who took the combination pill lost more weight than their counterparts who were given a placebo.\nTopiramate also has blood pressure-lowering effects, she says.\nThe new analysis of three separate studies included more than 4,500 people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear from the story that the combination of the two drugs is not yet available. ", "answer": 1}, {"article": "\u201cIt\u2019s time for her to be a kid again and get her childhood back,\u201d Mr. Whitehead said.\nBut Mr. Hoppenot said Novartis was taking a different path with cancer drugs, looking for treatments that would have a big, unmistakable impact on a small number of patients.\nDespite the mixed results, cancer experts not involved with the research say it has tremendous promise, because even in this early phase of testing it has worked in seemingly hopeless cases.\nDr. June knew that a drug could lower IL-6 \u2014 his daughter takes it for .\nWith a pill, you take it, it\u2019s eliminated from your body and you have to take it again.\u201d But T-cells, he said, \u201ccould potentially be given only once, maybe only once or twice or three times.\u201d\n\nThe Pennsylvania researchers said they were surprised to find any big drug company interested in their work, because a new batch of T-cells must be created for each patient \u2014 a far cry from the familiar commercial strategy of developing products like or medicines, in which millions of people take the same drug.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that this treatment is not widely available and won\u2019t be any time soon. As a service to patients and parents who might be in desperate straits, the story could have provided some information about research plans for the experimental treatment and the possibility (or lack thereof) of enrolling in a study.", "answer": 1}, {"article": "Kalluri and his colleagues examined serum samples from 190 patients with pancreatic cancer, 32 patients with breast cancer and 100 healthy volunteers.\n\u201cSomething like this could potentially flatten that curve and change the epidemiology of pancreatic cancer.\u201d\n\nStill, Donahue said, the method needs to be \u201cheavily vetted and validated.\nIt is a good example of how this disease sneaks up on people and gives no warning.\u201d\n\nA test for pancreatic cancer could save lives, perhaps even Flippo-Morton\u2019s, Raghavan said.\nAnd even if it passes muster, it will take some time before a test could be developed to screen for the disease.\nWhile quite promising, the new findings will need to be verified and validated by other studies, experts told NBC News.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We were surprised to see mention in the story that a clinical test could be available within a year. Given that the test will need to be further validated in a much larger group of study subjects, we think that\u2019s very unlikely. The story does frame the comment as \u201cjust speculation\u201d and notes that additional research will be needed. We\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "\"Those same benefits translate to people seeking to fight off the common cold, flu and other seasonal illnesses.\"\nIndividuals should consult with a professional massage therapist to determine the best massage therapy approach for their specific needs.\nBy meeting or exceeding state training requirements, ascribing to a code of ethics and participating in continuing education, American Massage Therapy Association massage therapists are appropriate additions to any wellness regimen and create specialized approaches based on individual conditions, fitness and goals.\nEVANSTON, Ill., Nov. 4, 2015 /PRNewswire/ -- People looking to fend off cold and flu as the winter months arrive should speak to a massage therapist about prevention strategies.\nTo find a massage therapist near you, the American Massage Therapy Association (AMTA), the most trusted name in massage therapy, offers a free professional massage therapist locator service at www.findamassagetherapist.org.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Most people are aware that massage therapy is widely available nationwide. However, the news release provides a link to the American Massage Therapy Association\u2019s locator service, presumably\u00a0 dues-paying AMTA members.", "answer": 1}, {"article": "A qualified claim means there is evidence supporting the claim, but it is not conclusive.\nThe label warns that evidence is limited.\nWhile many foods like whole grains, nuts and supplements carry qualified health claims stating that they may reduce the risk of diseases like cancer or heart disease, this is the first time a food product label will be allowed to make a qualified claim that it reduces the risk of an allergy, officials said.\n\u201cThis is a very important claim for us to allow to be incorporated into food labels,\u201d said Dr. Scott Gottlieb, the commissioner of the F.D.A.\nA new powdered peanut product is the first food item allowed to claim it may reduce peanut allergies in infants, though parents of susceptible babies are urged to consult a doctor before trying it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the product is available for purchase and goes so far as to hyperlink to its website, where people can place an order. We\u2019d call this establishing availability \u2013 sure. But it also might go a step beyond and risk actually advertising the product under scrutiny in the story.", "answer": 1}, {"article": "George E. Jordan may be reached at gjordan@starledger.com or (973) 392-1801.\nThe study said there were still many unanswered questions about Pfizer's pill, torcetrapib, the first in a new class of heart medicines known as a CETP inhibitors, which raise HDL, or good cholesterol, and lower LDL, or bad cholesterol.\nIt was unclear what the mixed bag of data presented at the American Heart Association's Scientific Session in Orlando would mean for CETP drugs under development by Merck and Roche, and another candidate in early-stage development by Pfizer.\nThe study, presented by Australian heart researcher Philip Barter, who oversaw Pfizer's torcetrapib clinical trials, concluded torcetrapib caused \"off-target\" effects, including deaths, elevated blood pressure, cardiovascular problems and a possible link to cancers.\nOf the 15,067 patients in seven countries taking part in the randomized clinical trial, called Illuminate, 82 patients taking a combination of torcetrapib and Lipitor died, compared with 51 taking Lipitor alone, which was the control group, according to the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that the HDL-targeting drugs are still in the early stages of development. The story does not make any claims about when a new drug would be available, however whether it will ever happen is still highly theoretical. However, atorvastatin was studied along with torcetrapib and a note that it is available commercialy and is the largest selling cholesterol lowering drug would have been useful to the readers.", "answer": 1}, {"article": "Measuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting\n\nMeasuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting.\nThe findings suggest that irisin could be a marker for PCOS allowing the condition to be diagnosed more easily.\nLifestyle changes and different exercise-related signals that regulate the secretion of irisin could provide a potential option for the management of PCOS.\nThe group will next focus on confirming their results and investigate the biological role of irisin in PCOS.\nThe findings may reduce the number of unnecessary treatments prescribed to otherwise healthy girls.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that it is too early to say whether irisin will serve as a good indicator for PCOS diagnosis.", "answer": 1}, {"article": "Men and women with mildly high blood pressure who ate three kiwi fruits a day for eight weeks had systolic blood pressure levels that were 3.6 millimeters of mercury lower than those of volunteers who ate an apple a day.\n\"Don't count on this to be the complete answer to high blood pressure,\" he said.\n\"Kiwi is not the wonder fruit, but certainly adding kiwi to your diet can help decrease mildly high blood pressure levels.\"\nDon't start popping lutein in supplement form based on these results, he noted.\nSo, is kiwi the new \"wonder\" fruit?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story noted that kiwis \u201care not easy to find\u201d", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe Brain Trauma Indicator was reviewed under the FDA\u2019s De Novo premarket review pathway, a regulatory pathway for some low- to moderate-risk devices that are novel and for which there is no prior legally marketed device.\nThe FDA evaluated data from a multi-center, prospective clinical study of 1,947 individual blood samples from adults with suspected mTBI/concussion and reviewed the product\u2019s performance by comparing mTBI/concussion blood tests results with CT scan results.\nThese findings indicate that the test can reliably predict the absence of intracranial lesions and that health care professionals can incorporate this tool into the standard of care for patients to rule out the need for a CT scan in at least one-third of patients who are suspected of having mTBI.\nThe FDA reviewed and authorized for marketing the Banyan Brain Trauma Indicator in fewer than 6 months as part of its Breakthrough Devices Program.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release announces that the test is \u201capproved\u201d for use, so we assume it will be widely available. It also quotes an official who says the test \u201ccan be used both in the continental U.S. as well as foreign U.S. laboratories that service the American military.\u201d", "answer": 1}, {"article": "Anthony Cunningham, Executive Director of the Westmead Institute for Medical Research in Australia and Principal Investigator of the ZOE-70 study said: \"These data show that this investigational vaccine maintains high efficacy against herpes zoster in people over 70 and 80 years of age, the age groups who are most affected by the disease.\nThe primary objective of this study is the overall vaccine efficacy against shingles in people aged 50 years or older, compared to placebo.\nThe candidate vaccine was shown to be 89% (95% confidence interval: 68-97%) efficacious in preventing PHN in people aged 70 years and older and 91% efficacious (95% confidence interval: 75-98%) in people aged 50 years and over1.\nIn addition to older adults, the candidate vaccine is being evaluated in immunocompromised patient populations, including solid and haematological cancer patients, haematopoietic stem cell and renal transplant recipients and HIV-infected people.\nThe co-primary objectives of the pooled analysis over both studies are the assessment of overall vaccine efficacy in reducing the risk of developing shingles and PHN in people aged 70 years and over, using pooled data from both ZOE-70 and ZOE-50 studies.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the press release that GSK has not yet applied for regulatory approval of the vaccine in any country. Thus, it should be obvious that the vaccine is not yet available for use.", "answer": 1}, {"article": "For example, robots that provide sensory feedback could eventually help a disabled person cook a meal or clean up things at home.\nThat makes it very challenging to perform simple tasks like grasping a foam coffee cup without crushing it, McLoughlin says.\nOf course, mind-controlled robots are still years away from consumer applications, McLoughlin says.\nAnd there's no good way to control them without implanting electrodes in the brain.\nIt's a mind-controlled robotic arm that has pressure sensors in each fingertip that send signals directly to Copeland's brain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear this patient is the first to receive this treatment in an experimental setting, so it is clear that this is not available except in a laboratory.", "answer": 1}, {"article": "Testing cholesterol in toddlers and babies?\nBut many parents balk at the idea of testing children for a disorder associated with middle age, experts say.\nNinety percent of them started taking preventive medicines after finding out.\nThe work was funded by the Medical Research Council, the British government\u2019s health research agency.\nStatins aren\u2019t recommended until around age 10, but certain dietary supplements such as plant sterols and stanols could help younger kids, Urbina said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Are these sorts of genetic tests available for parents to buy off the shelf, or ask for a referral from a doctor to get? The story doesn\u2019t clarify.", "answer": 0}, {"article": "Dr Davide Pellacani, who began these studies in York, before moving to the University of British Columbia, said: \"Using this computer analysis, not only could we see which tissue samples had cancer and which didn't, but also which cancers were dangerous and which ones less so.\nThe team needed to eliminate the 'noise' of the genetic patterns that make individuals unique, to leave them with the patterns that indicate cancer.\nTo take this method out of the laboratory, the team are now investigating a further trial with new cancer samples, and hope to involve a commercial partner to allow this to be used for patients being treated in the NHS.\nThey were able to do this using a computer algorithm, which left the team with 17 possible genetic markers for prostate cancer.\nIt is now understood that to find the different levels of cancer, scientists have to identify genes that have been altered in different cancer types.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "At the very end of the news release, the authors write that the next step is, \u201cto take this method out of the laboratory,\u201d and that the researchers hope that they will find a commercial partner to develop the test for general use. But this should have come much sooner, ideally in the first paragraph. The entire release (including the headline) made it sound like this test is already available, likely frustrating patients who felt duped at the end of the release.", "answer": 0}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discusses the relatively new Center for Surgical Innovation in New Hampshire and the program at\u00a0Brigham and Women\u2019s Hospital in Boston. But it\u2019s not clear from the story whether these real-time imaging surgical techniques are being implemented elsewhere. Is it widespread? Do we expect it to become widespread? If so, when? And at what cost?", "answer": 0}, {"article": "Newsday's coverage of the Class of 2019, led by Mariano Rivera and Mike Mussina.\nFrom a Catholic school uniform to a hijab, LIers talk about their religious clothing.\nA hijab, a turban, a beard: What aren\u2019t you seeing?\nHere\u2019s how he got out.\nAt 14, MS-13 was his family.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "After the cap is placed on the patient's head, it is attached to a vacuum pump that sucks the air out of the cap, jamming the tiny grounds together to form a rigid layer that conforms closely to the shape of the patient's head.\nOn the strength of these results, Vanderbilt University has applied for a patent on the design and the technology is available for licensing.\nIn this case, the cap proved to have 66 percent lower error rates than the headband.\nIn essence, that is what a team of Vanderbilt University engineers are proposing in an effort to improve the reliability of the sophisticated \"GPS\" system that surgeons use for these delicate operations.\nThey have designed a \"granular jamming cap\" filled with coffee grounds that does a better job of tracking patient head movements than current methods.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does the minimum, saying \u201cVanderbilt University has applied for a patent on the design and the technology is available for licensing. (Interested parties should contact the Vanderbilt Center for Technology Transfer and Commercialization.)\u201d A companion video states that \u201cthe next step is to work with a commercial partner to make it an FDA-approved product.\u201d\nInformation on how long FDA approval could take, as well as a nod to the fact that this might never make it to market, would have made this better.", "answer": 1}, {"article": "Most of the time, concussion testing in youth sports falls to volunteer coaches or parents with little if any medical experience.\nThe pace-along-the-tape test was also relatively accurate.\nFor the greatest precision, you might want to have athletes perform the test twice and use their best reading.\nBut it had not been evaluated for use in young athletes.\nThe upshot, Dr. Galetta believes, is that parents and coaches \u201cshould absolutely consider\u201d familiarizing themselves with the King-Devick test and administering it to young athletes before the season starts, then having those baseline numbers and the test itself handy on the sidelines.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not explicitly state that one can purchase this test, but the implication is that it is available. We\u2019ll give the benefit of the doubt, but we\u2019d prefer it if the story linked to the sole supplier of the product offering yearly packages from its website. It\u2019s also available on the iTunes App Store.", "answer": 1}, {"article": "Instead, they recruited 20 volunteers who were overweight or obese and assigned them to a week of either egg breakfasts or ready-to-eat cereal breakfasts.\nBoth types of breakfasts had the same number of calories, but the egg breakfasts contained \u201chigher protein quality,\u201d according to an abstract for the study, posted online here.\nThat\u2019s right \u2013 the folks who sell eggs paid for a study that comes to the shocking conclusion that eggs are an ideal breakfast food.\nAfter a two-week gap, the groups were switched.\nThis place conducts some serious research on diet and weight.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of eggs and cereal is not in question.", "answer": 2}, {"article": "A drug derived from this bushy sea creature showed modest, preliminary promise as an Alzheimer's treatment.\n\nIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug\n\nA little-known drug company announced modestly encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\n\nA mid-stage study by a tiny company wouldn\u2019t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug \u2014 derived from a bushy, hermaphroditic sea creature \u2014 takes a novel approach.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains where the drug is in the regulatory process\u2013still far from being on the market.\nAnd it indicates how likely it is for the drug to get approval, saying, \u201cA\u00a02.6-point edge over placebo may\u00a0fall slightly short of what the\u00a0Food and Drug Administration would require for approval of a new Alzheimer\u2019s drug\u2026\u00a0the FDA typically wants to see a net benefit of at least\u00a03 or 4 points.\u201d", "answer": 1}, {"article": "The Centers for Disease Control and Prevention estimates there are 300,000 sports concussions among children each year.\n\u2026 It's like a sophisticated video game, but the numbers that are generated from the report are critical in helping to better identify the severity and recovery from the injury.\"\nBut for students such as Aldrich, who don't know their baseline, extra caution is the doctor's order.\nAnd new research indicates children and teens are more vulnerable than adults, because their brains are less developed and take longer to heal.\n\"The brain, in its development, while it is actively developing, seems to be less able to take these forces and to really rebound from these forces,\" Dr. Gioia observed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe report describes the widespread availability of the Impact system in the U.S., but fails to describe how an athlete would gain access to such neurocognitive testing systems.\n", "answer": 0}, {"article": "All the women had been successfully treated for early-stage breast cancer.\nThe government study found no benefit from a mega-veggie-and-fruit diet over the U.S. recommended serving of five fruits and vegetables a day -- more than most Americans eat.\nResearchers noted that none of the breast cancer survivors lost weight on either diet.\nDuring the next seven years, the cancer returned in 256 women (16.7 percent) in the special diet group and 262 women (16.9 percent) in the comparison group.\nHopes that a diet low in fat and chock-full of fruit and vegetables might prevent the return of breast cancer have been dashed by a seven-year experiment in more than 3,000 women.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not specifically mention the availability of a fresh fruits and vegetables for all populations, but the focus of the story is on the lack of evidence that a diet concentrated on these foods has any benefit for breast cancer recurrence.\u00a0 No preventative behavioral modification related to diet is advocated.\u00a0 The story was also suffienciently clear about what the \"treatment\" was (number of servings of vegetables and fruits, etc) such that if a person wanted to \"treat\" themselves in this manner they could replicate the intervention.\n\u00a0\n", "answer": 1}, {"article": "Autism is a complex brain disorder characterized by difficulties in social interaction and communication, ranging from mild to profound impairment.\n\u201cWe would hope that it would work just as well ... there is no reason why not.\u201d\n\nThe ability to base a diagnosis on an objective biological test, rather than having to rely on personality traits, should mean patients get treatment more quickly, he added.\nThe accuracy of the scan in predicting autism was so high that the results were strongly significant, despite the small number of patients involved.\nExperts not involved in the research applauded the research but cautioned further study was still needed.\nThe speed of the test makes it some 20 times cheaper than traditional tests, which can take a team of doctors four to eight hours to conduct.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although it is clear that this technology is not yet available to the public, the story\u00a0predicts the new scan \"could be ready for general use in a couple of years.\" Really?\u00a0Who says? It seems unlikely that any knowledgeable researcher would make such a wildly optimistic prediction on the basis of a 40-person study.\u00a0But the story\u00a0treats\u00a0this forecast\u00a0as an established fact\u00a0requiring no attribution, so\u00a0we can\u2019t tell where it came from.\u00a0\u00a0In any case, we think such\u00a0pie-in-the-sky guesstimates are usually wrong and should be avoided in health journalism. \u00a0", "answer": 0}, {"article": "Observational studies in people living with HIV have shown positive emotion is related to a higher CD4 count (an indicator of less HIV-related damage to the immune system).\nBased on the study results, the intervention is promising for people in the initial stages of adjustment to any serious chronic illness.\nThis is believed to be the first test of a positive emotion intervention in people newly diagnosed with HIV.\nThe HIV study is part of a larger body of positive affect research being conducted by Moskowitz.\nOr, the reduced viral load may be the result of participants' better adherence to their antiretroviral drug therapy, which generally leads to a suppressed or undetectable viral load, Moskowitz said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability of the training. In claiming this research has not been done before it suggests that the intervention would only be available via clinical trials. \u00a0The release could have been more specific about whether the skills training has been standardized or whether it is in widespread use in any context. Because we can\u2019t give the release a satisfactory score \u2013 because availability wasn\u2019t addressed \u2013 we also didn\u2019t think we could ding it with an unsatisfactory score. \u00a0Thus, the N/A score.", "answer": 2}, {"article": "The requested URL /usnews/health/articles/061015/23addict.b.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that rimonabant has been approved for use in Europe.\u00a0 When mentioning that the manufacturer hopes for approval by the end of the year, it did not emphasize that the drug is not approved in the U.S., is not available in the U.S. and that it is not possible to predict the timing of FDA approval or whether the FDA will, indeed, approve it.\u00a0 ", "answer": 0}, {"article": "In the 1960s sitcom Leave It to Beaver, Beaver Cleaver was so impressed by his dad's tales of ice cream and pretty nurses that he schemed to have his tonsils out, even though he didn't need it.\nThat's a far cry from the 1950s and '60s, when tonsillectomy was used to fight frequent sore throats.\nObviously, parents could use some help in deciding whether surgery is needed.\nBack then, it was the most popular surgery in the United States.\nSo the doctor recommended tonsillectomy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a great job explaining how tonsil surgery as a first resort has evolved over the years.", "answer": 1}, {"article": "However, nearly 46 percent of low-risk women aged 50 to 59 were screened, as were 59 percent of low-risk women aged 60 to 64.\nMONDAY, May 25, 2015 (HealthDay News) -- Too few women at high risk for osteoporosis are being tested for the bone-depleting condition, while too many women at low-risk are being screened, a new study suggests.\nThe study was published online May 19 in the Journal of General Internal Medicine.\nOver seven years, more than 42 percent of eligible women aged 65 to 74 were not screened, Amarath's team found, nor were nearly 57 percent of those older than 75.\nReminder notes to doctors and patients might help, one expert said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not say how commonly available the screening test is, but provides the impression that it\u2019s widely used. Since the test has been widely available for many years, we\u2019ll give the story a pass here.", "answer": 1}, {"article": "People with poorly controlled diabetes, for example, may have breath that smells fruity due to an overproduction of chemicals called ketones; people with kidney or liver failure can have fishy breath.\nCleveland Clinic pulmonologist Peter Mazzone, MD, who is conducting lung cancer studies, says a breath test for cancer may be a reality in as little as five years if all goes well.\n\u201cThere is still quite a bit of work to be done.\u201d\n\nMazzone says the breath functions in the body in much the same way that the exhaust system functions in a car, and what comes out gives a sense of how things are working inside.\n\u201cBut we are still in the research phase, and there is still the possibility that this technology will never prove clinically useful,\u201d he says.\nIn a new study from Italy, researchers were able to identify patients with colorectal cancer with an accuracy of over 75% by analyzing samples of their breath.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It always makes us nervous when a source is allowed to speculate, without reasonable justification,\u00a0about when an experimental device will be available clinically. And that\u2019s exactly what happened here\u00a0when an expert said that\u00a0a breath test for cancer \u201cmay be a reality in as little as five years if all goes well.\u201d On the other hand, the story did qualify things quickly when the expert added,\u00a0\u201cBut we are still in the research phase, and there is still the possibility that this technology will never prove clinically useful.\u201d Borderline, but we\u2019ll call it satisfactory.", "answer": 1}, {"article": "\"It can be extremely painful to pass these jagged little crystallized minerals and it's very common for sufferers to go to an emergency department for treatment.\nTrial leader and specialist emergency medicine physician at The Townsville Hospital, Dr Jeremy Furyk, said Tamsulosin was normally used to treat an enlarged prostate, but the research team found the treatment could also assist the passage of large kidney stones in the urine.\nPatients with kidney stones were treated with the drug Tamsulosin in an Emergency Medicine Foundation Australasia (EMF) funded clinical trial run across five Australian hospital emergency departments.\nEMF Australasia Chair, Associate Professor Sally McCarthy said this research had the potential to help millions of Australians suffering with this extremely painful condition.\n\"It may also have implications for patients living in rural and regional areas, where access to urologists - the specialist doctors who treat this condition - can be limited.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Tamsulosin is currently prescribed for patients with benign prostatic hyperplasia (BPH), or enlarged prostate and other conditions and is readily available.", "answer": 2}, {"article": "Phentermine is commonly used as a short-term weight loss treatment, and was previously paired with fenfluramine to make the successful but now-discontinued weight loss drug Fen-phen.\nThe study was funded by the pharmaceutical company Vivus, which combined the two drugs into one pill called Qnexa, and petitioned the U.S. Food and Drug Administration for approval in October 2010.\nAccording to the report, there were specific concerns about each drug's safety individually; specifically Topamax, which is reported to cause some psychiatric and cognitive side effects and may cause clef palate birth defects if taken while pregnant.\nThe Food and Drug Administration denied the request, asking for more safety data from the company before moving forward.\nAccording to the manufacturer's study, the two drugs, when taken together, and at controlled-release doses, were very safe.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that Qnexa was not approved: \u201cThe Food and Drug Administration denied the request, asking for more safety data from the company before moving forward.\u201d", "answer": 1}, {"article": "High cholesterol levels can increase the risk of heart attack.\n\"Overall, the evidence is inadequate to establish a protective role of selenium in cardiovascular disease or to recommend selenium supplementation to improve cardiovascular health,\" he said.\nHowever, the safety of selenium has not been studied, and the authors said the findings weren't significant enough to recommend supplementation of the trace mineral.\nDr. Gregg C. Fonarow, a professor of cardiology at the University of California, Los Angeles, said that efforts to gauge the potential health impact of selenium have not yet demonstrated any clear benefit attributable to the trace mineral.\nThey also noted that the results can't necessarily be applied to Americans, because of differences in the food supply and diets of each country.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t really explain what selenium is,\u00a0why someone would want to take a selenium supplement, or where one can find them. While many readers will\u00a0know the answers to these questions, selenium is obscure enough, in our view, to warrant at least some background context on these issues.", "answer": 0}, {"article": "Cystic fibrosis (CF) is a genetic disorder that causes persistent lung infections.\nSo far, the treatments appear safe.\nThe other trial had nearly identical results.\nIf the experimental drugs are ultimately approved, there will be the real-world issue of price.\nBut experts said they were optimistic the results will hold up in the larger, longer-term trials already underway.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that these drugs are not on the market.", "answer": 1}, {"article": ".\nThe researchers investigated patients enrolled in the randomized, double-blind, comparative, multicenter international phase 3 ACTIVE trial to evaluate the efficacy and safety of 80 micrograms of abaloparatide-SC in preventing fractures in otherwise healthy, ambulatory, postmenopausal women with osteoporosis.\nThe results of the pre-specified subgroup analysis within the ACTIVE clinical trial will be presented Friday, April 1, at ENDO 2016, the annual meeting of the Endocrine Society, in Boston.\nThe data suggest that abaloparatide appears to be an effective treatment for a broad group of postmenopausal women with osteoporosis.\nOverall, 2,463 patients between 49 and 86 years of age were randomized to one of three treatment arms for 18 months: double-blind 80 micrograms of abaloparatide-SC, blind-matched placebo, or open-label 20 micrograms of subcutaneous teriparatide (an FDA-approved prescription drug known to increase bone density and strength).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the drug is investigational which signifies it is not yet FDA approved and that the study was a phase 3 study.", "answer": 1}, {"article": "Dominic Gessler lifts two squirming mice from their cages.\n\u201cAnd other than gene therapy, there was no other way.\u201d\n\nGene therapy is well-suited for treating inherited brain diseases.\nScientists now argue it is our best, and perhaps only, chance at curing many diseases of the brain.\nGao did not always believe the drug would ever make it out of the laboratory, because the field of gene therapy has been plagued with seemingly insurmountable obstacles, including the deaths of test subjects.\nAt the time, only one gene therapy had been commercially approved in the world: a cancer drug in China.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told early on \u201cthere is no treatment and no cure for Canavan disease,\u201d but then later a researcher is quoted as saying: \u201cWe have the therapy. We are ready.\u201d\nThe word \u201ctherapy\u201d implies effective treatment of people.\u00a0Therapeutic misconception like this is confusing\u00a0to readers, and the story needed to counter this confusion by more strongly indicating this specific intervention\u00a0is and will be experimental for years to come.\nThis was made more confusing by the discussions of available gene therapies for other illnesses, including two that are in use in China and Europe, and one that might be approved in the U.S. How far behind are all the gene therapy approaches discussed in the piece? This is important to counter false hope among patients who may read this story and think that these are signals that availability of these other therapies can\u2019t be far away.", "answer": 0}, {"article": "It did reduce the severity and duration of colds slightly, but the researchers say the difference was so slight it ended up being pretty meaningless, and not worth the effort or expense of taking all that vitamin C.\n\nPeople apparently protected from colds by vitamin C, Senay said, are those who subject their immune systems to extraordinary amounts of physical stress, such as people who run marathons, or do serious trekking in the winter.\nPreventing colds just isn't one of them.\nIf you suffer an injury, vitamin C is a vital part of the healing process.\nSo, even if it doesn't fight colds, you do need a certain amount of it daily for other aspects of your health.\nBut, she emphasized, this doesn't mean vitamin C is useless, not by a long shot.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Vitamin C supplements are widely available.", "answer": 1}, {"article": "The difference could mean 50,000 to 70,000 fewer deaths and 100,000 fewer cases of kidney failure each year in the U.S., researchers estimate.\nIVs are one of the most common things in health care.\nSaline \u2014 salt dissolved in water \u2014 has been the most widely used fluid in the U.S. for more than a century even as evidence has emerged that it can harm kidneys, especially when used a lot.\nOther IV solutions called balanced fluids include saline but also contain potassium and other things that make them more like plasma, the clear part of blood.\nThe fluids cost about the same \u2014 a dollar or two per IV \u2014 and many suppliers make both types, so switching should not be hard or expensive, doctors said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does well in including this important context:\nIVs are one of the most common things in health care \u2026 saline \u2014 salt dissolved in water \u2014 has been the most widely used fluid in the U.S. for centuries \u2026 other IV solutions called balanced fluids include saline but also potassium and other things that make them more like plasma, the clear part of blood. They\u2019re widely used in Europe and Australia.", "answer": 1}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Like the WebMD story, the LA Times story wasn\u2019t clear whether a clinician could conduct the self-hypnosis trainings, or whether the patient needed to find another certified professional. And how were the hypnotic recordings obtained? Readers need to know if their \u201clocal\u201d hypnotherapist can do this.", "answer": 0}, {"article": "In nonsurgical spinal decompression, a patient is placed on a special type of table with harnesses on the pelvis and rib cage.\nI would say a quarter of my patients fall asleep.\u201d\n\nThe decompression therapy is used to treat herniated discs, ruptured discs, sciatica, bulging discs, degenerative discs, posterior facet syndrome and spinal stenosis/arthritis.\nThe treatment, which includes several 20-minute procedures and rehabilitation, costs between $3,500 and $4,000.\n\u201cDecompression on the West Coast is a dime a dozen, but here in the Midwest, they are almost unaware of it.\nIt is less than half the cost of surgery but is rarely covered by insurance.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story does explain that this treatment is available and claims that the treatment is common on the West Coast but not in the Midwest, this is not sufficient information on availability. The story doesn\u2019t give the reader any information on where to look for the treatment other than the owner of one facility. ", "answer": 0}, {"article": "Among other changes, they found that levels of human growth hormone, or HGH, surged after fasting \u2014 increasing 20 times in men and 13 times in women.\nThat\u2019s the finding of a new study from doctors in Utah who looked at the relationship between periodic fasting and cardiovascular disease.\n\u201cBut what it does suggest is that fasting is not a marker for other healthy lifestyle behaviors.\nHe said the group was planning additional research into the potential health effects of regular fasting.\nBecause about 90 percent of the patients were Mormons, a faith that encourages its members to fast for one day a month, the doctors expected to find a relatively high rate of regular fasting among the study participants.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 Anyone can fast.", "answer": 2}, {"article": "Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment.\nThe findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).\nEmerging evidence indicates that overall eating patterns may have greater effects on patients\u2019 health and longevity.\nThe article, entitled \u201cHealthy Dietary Patterns, Mortality and End-Stage Kidney Disease in CKD: A Meta-Analysis of Cohort Studies,\u201d will appear online at http://cjasn.asnjournals.org/ on December 8, 2016, doi: 10.2215/CJN.\nHighlight\n\u2022 A healthy diet high in fruits, vegetables, fish, legumes, cereals, whole grains, and fiber, and low in red meat, salt, and refined sugars was linked with a reduced risk of early death in an analysis of 7 studies.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of healthy dietary options is one of the main points of the release.", "answer": 1}, {"article": "\u201cFor antidepressants in adolescents, this equation will rarely favor prescribing; in younger children, almost never.\u201d\n\nTo be clear, Jureidini believes there is almost never a justification for prescribing antidepressants to children or adolescents.\nA comment attached to the Oxford paper, written by Dr. Jon Jureidini, a child psychiatrist at the Women\u2019s and Children\u2019s Hospital in Adelaide, Australia, goes even further in decrying the use of antidepressants in kids.\nThat\u2019s because the FDA has deemed that Prozac has demonstrated benefits that outweigh one of the suspected downsides of antidepressants in kids and teens: disrupting brain development.\nOf course, having an effective intervention once it is recognized would help.\nIf there\u2019s an upside to be found in how ineffective antidepressants likely are for kids, it\u2019s that pharmacological solutions are not the recommended first line of defense, anyway.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says all the 14 antidepressants studied were \u201ccommercially available.\u201d", "answer": 1}, {"article": "\"The first time those three letters were uttered in a group setting, everyone's like, 'Oooo, that's scary, do we want to do that?'\nThe results are often inaccurate.\nThere are several scientists who say this field is so new that it's lacking in good evidence that brain changes actually occur.\nRight now, screening for Alzheimer's is subjective.\nThey see the potential of these games to not only make money \u2014 but to save money, too.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that these video games are experimental and not currently available.", "answer": 1}, {"article": "The American Congress of Obstetricians and Gynecologists, for example, recommends that regular screenings begin at age 40, while the American Cancer Society calls for women to start yearly screening at age 45 and then move to screening every two years starting at age 55.\nFran Visco, president of the National Breast Cancer Coalition, said the task force's guidelines for women in their 40s \u2014 that they should discuss whether to get mammograms with their doctors and make individual decisions \u2014 come closest to following the evidence accumulated over the past three decades.\nThe task force first suggested in 2009 that breast cancer screening begin at 50 instead of 40, touching off enormous criticism.\nAs a result of the congressional action, women in their 40s will continue to be able to get annual mammograms at no cost.\nSeveral groups that lobbied for congressional action said in a statement last month that the task force recommendations conflict with those of other organizations.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the use of mammograms as breast cancer screening tools is longstanding and well established. The story also discusses insurance coverage issues that would affect availability for many women.", "answer": 1}, {"article": "He says:\n\n\"When I was diagnosed with early prostate cancer, I had the option of active surveillance but I didn't want to wait until it got worse so when I was offered a place on the trial I signed up straight away.\n\"New procedures are generally associated with a learning curve, but the lack of complications in the trial suggests that the treatment protocol is safe, efficient and relatively easy to scale up.\n\"The fact that the treatment was performed so successfully by non-specialist centres in various health systems is really remarkable,\" says Professor Emberton, who is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.\nThe VTP treatment is currently being reviewed by the European Medicines Agency (EMA), so it is likely to be a number of years before it can be offered to patients more widely.\nWe would also expect the treatment to be far more precise if we repeated it today, as technology has come a long way since the study began in 2011.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release passes the bar with this statement at the very end:\nThe VTP treatment is currently being reviewed by the European Medicines Agency (EMA), so it is likely to be a number of years before it can be offered to patients more widely.\nThe news release also quotes a researcher stating that the treatment\u2019s implementation at 47 sites \u201cwithout complication\u201d indicates it\u2019s \u201csafe, efficient and relatively easy to scale up.\u201d That\u2019s an optimistic take but we\u2019ll give the benefit of the doubt here.", "answer": 1}, {"article": "Some prostate cancers evolve to use energy from lipids (fat).\n\u201cThis finding may have a huge impact on patients with CRPC that had very few options before,\u201d says Schlaepfer.\n\u201cSince the drugs are clinically safe, a clinical trial can be designed in patients for whom enzalutamide is prescribed.\u201d\nPrevious work shows that metabolizing lipids helps prostate cancer escape anti-androgen therapy.\n\u201cWe had to find a way to block this pathway so that the cancer would not be able to burn lipid in the mitochondria to acquire energy to resist therapy,\u201d explains Schlaepfer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The key drug in question, enzalutamide, (trade name Xtandi) is already widely marketed as a treatment for prostate cancer. This fact was not included in the news release.", "answer": 0}, {"article": "People with hypertension have traditionally been advised to stay away from alcohol because excessive drinking can increase blood pressure.\nThe forthcoming study on men doesn't include an MRI component needed for a more complete comparison.\nBOTTOM LINE: Having one or two drinks a day may be beneficial for men with high blood pressure, but studies like these shouldn't be used to justify excessive drinking.\nCAUTIONS: The study looks only at spatial reasoning.\nAnd, one of the study authors, Eric Rimm of the Harvard School of Public Health, has been sponsored by the Distilled Spirits Council of the United States to speak at academic conferences.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly alcoholic drinks are available.", "answer": 2}, {"article": "He noted that the technology's cost \"is not prohibitive, and it is safe.\nHowever, Brenner and his colleagues wondered if a much narrower spectrum of ultraviolet light, far-UVC, might be a safer option.\nAs the researchers explained, broad-spectrum UVC light kills viruses and bacteria, and it is currently used to decontaminate surgical equipment.\nThe disinfecting success of initial experiments still need to be confirmed, said lead research David Brenner.\nBut this type of light can cause skin cancer and cataracts, so it's not used in public spaces.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We get the idea that UVC lamps are available and already used to disinfect surgical equipment. What\u2019s not clear is if \u201cfar-UVC only\u201d lamps are commercially available at this time.", "answer": 0}, {"article": "Charli Scouller \n\nPR Manager (School of Medicine and Dentistry) \n\nQueen Mary University of London \n\nc.scouller@qmul.ac.uk \n\nTel: 020 7882 7943\n\nQueen Mary University of London (QMUL) is one of the UK's leading universities, and one of the largest institutions in the University of London, with 20,260 students from more than 150 countries.\nThe new vaccine offers significantly greater protection than the current vaccine, which protects against only two cancer causing types of HPV.\nThe new vaccine, Gardasil 9, is not only safe but will offer greatly improved protection against cervical and other cancers.\nA pivotal international clinical trial compared the safety and efficacy of the new vaccine, Gardasil 9, with the current vaccine, Gardasil, in more than 14,200 women aged between 16 and 26 years old.\nUntil late last year, there were two available vaccines to protect against HPV related disease (Cervarix and Gardasil).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that the new vaccine is available in the US but not yet in the UK.", "answer": 1}, {"article": "What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors been all that enthusiastic...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that raloxifene is currently available for use in post-menopausal women to prevent osteoporosis and that use in chemoprevention has only been in clinical trials\u2013more data is needed prior to FDA approval for use as chemoprevention. Use as chemoprevention would be off-label and only women with an increased risk of breast cancer.", "answer": 1}, {"article": "Breast cancer strikes more than 180,000 women each year in the United States and kills more than 40,000, making it the most common form of cancer after skin cancer and second leading cancer killer among women.\nThe test by Decode Genetics of Reykjavik, Iceland, a respected pioneer in genetic research, promises to determine a woman's risk through a simple blood sample or cheek swab.\nAn FDA spokeswoman said the agency had just become aware of the new test and could not say whether it would take any action, though she noted that in August the agency sent a letter expressing concern to another company marketing a questionable genetic test for ovarian cancer.\nThe test comes as concern has been rising about the proliferation of genetic tests.\nWhile welcomed by some patient advocates and doctors, the $1,625 test raises concerns among others.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The focus of the story is a new, widely available genetic test. The story says that any doctor can order this test to assess a woman\u2019s risk of developing of developing one of the more common forms of breast cancer. The story notes that the FDA does not regulate this or similar types of predictive genetic tests, and there are questions about the validity of tests that have not been subjected to external review.\u00a0 ", "answer": 1}, {"article": "\u2022 Khin NA, et.al.\nEsketamine nasal spray has an acceptable safety and tolerability profile, based on the adverse event data from both Phase 3 studies.\nIf approved by the U.S. Food and Drug Administration (FDA), esketamine would be one of the first new approaches to treat refractory major depressive disorder available to patients in the last 50 years.\nIt has a novel mechanism of action, meaning it works differently than currently available therapies for depression.\nA bittering agent was added to placebo to simulate the taste of esketamine, to help mask the treatment assignment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is fairly clear that esketamine is still under investigation and is not yet clinically available.", "answer": 1}, {"article": "Floaters become more common with age, and although some people simply get used to them, others are bothered by them or their vision is impaired.\nTHURSDAY, July 20, 2017 (HealthDay News) -- A laser treatment can reduce spots in people's vision known as \"floaters,\" a new study finds.\nFor her part, Goldberg said that although \"there was significant improvement in patients' symptoms following treatment, and no significant complication was seen,\" these findings are early and \"it is difficult to predict the long-term safety of this laser procedure.\"\nHowever, Shah and Heier said there are few published studies on the laser treatment's effectiveness in treating floaters.\nThe new research was led by Dr. Chirag Shah and Dr. Jeffrey Heier of Ophthalmic Consultants of Boston.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t discuss the availability of this laser treatment approach. Is it available through most ophthalmic practices? Is the equipment standard in most eye hospitals?", "answer": 0}, {"article": "Fibromayalgia is a condition marked by fatigue, disturbed sleep, and pain.\nCyclobenzaprine, marketed in higher doses by others as Amrix, Fexmid, and Flexeril, is already widely used ''off-label'' for patients with fibromyalgia, Lederman says.\n\"Bedtime treatment of fibromyalgia patients with low-dose cyclobenzaprine was safe and appears to be effective,\" says Seth Lederman, MD, president of TONIX Pharmaceuticals, which funded the study.\nHowever, a rheumatologist not connected to the study does not expect the new drug to be a ''game-changer.\"\nTONIX is developing a lower-dose version and improving the formula, Lederman says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story makes clear that while this drug is available as a muscle relaxant, the dose used in this fibromyalgia trial is not available. The story also reports that the drug is not approved for treatment of fibromyalgia, but it is being prescribed \u201coff-label\u201d by some doctors. Near the bottom of the story, the researcher and company president predicts the low-dose version of the drug could be available for fibromyalgia treatment by 2015. It is hard to see what support there is for such a prediction, given the preliminary nature of this small trial.", "answer": 1}, {"article": "About Milken Institute School of Public Health at the George Washington University: Established in July 1997 as the School of Public Health and Health Services, Milken Institute School of Public Health is the only school of public health in the nation's capital.\nThe researchers recruited pregnant women who were already enrolled in an established text messaging program called Text4baby.\nAbroms and her team wanted to find out if a more intensive mobile phone program called Quit4baby would be more effective.\n\"The study's findings suggest a potential new quitting strategy, especially for those later in their pregnancies and older pregnant women.\"\nVery little help is provided to pregnant smokers who want to quit so the study's findings are important, especially if the strategy can be adjusted to be more effective, Abroms says.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although the release notes that this experiment took place within the confines of an \u201cestablished\u201d text messaging program (Text4baby), the availability of the \u201cQuit4baby\u201d sub-program, which is the focus of the research, is not clear.", "answer": 0}, {"article": "They include people like Danielle Denlein, who, to her total shock, developed a serious heart problem.On October 20, 2008, at 1:50 p.m., Ms. Denlein was driving to a drug store to buy formula for her 5-day-old baby girl.\nOne solution, being tested by St. Jude Medical, a medical device company in St. Paul, is to let patients deal with important data.\n\u201cIt\u2019s just a phenomenal tool.\u201d\n\nThere is a downside, though: \u201cInformation overload is a very serious problem\u201d for the doctors, said Dr. Lynne Warner Stevenson, director of the Heart Failure Program at Brigham and Women\u2019s Hospital in Boston and a professor at Harvard Medical School, who counts herself as a proponent of smart devices.\nIf successful, the smart device could have a big effect.\nThose with the nontransmitting device were seen in their doctor\u2019s offices every few months, the standard of care.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was a tapestry of information about devices that are currently available, devices in clinical studies, and the potential benefit from devices to be developed in the future. \u00a0The story could have been clearer about products that are and are not readily available to patients.\u00a0 We had to read the piece several times in order to reflect on which device, from which company, was at which stage of research or development. ", "answer": 0}, {"article": "From a crusty baguette to a big thick steak, some foods may be hard to digest, particularly as we age. Enzyme capsules taken before a meal can relieve discomfort by helping the body to break down problem foods, say companies that sell the pills. Doctors say some enzyme supplements work well, but others need more human studies.\n\nDigestive enzymes are proteins that work like scissors to break down foods. The pancreas, where many of these enzymes are made, can slow down as we age, which can result in bloating and other gastrointestinal...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study provides the names of products that are available over the counter. Readers should be able to use this information to track down the products if they want to buy them.", "answer": 1}, {"article": "According to the U.S. Department of Agriculture\u2019s 2010 Dietary Guidelines, most Americans don\u2019t get enough fiber.\n\u201cIncreasing dietary fiber intake in the general public is of great public health significance,\u201d the Chinese team concludes.\nThat was after accounting for differences in risk factors like alcohol drinking, weight, hormone replacement therapy and family members with the disease.\nSo to get more clarity, the researchers combined 10 earlier studies that looked at women\u2019s diets and followed them over seven to 18 years to see who developed cancer.\nFruits, vegetables, beans, and whole grains are all high in fiber.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that fruits, vegetables, beans and whole grains are all high in fiber.", "answer": 1}, {"article": ".\nAfter 18 months, the women who received the placebo halted the injections.\nThe researchers continued to follow up with the women for seven years after the growth hormone treatment was halted to monitor their bone density, fractures and perception of their quality of life.\n\"The findings indicate the beneficial effects of growth hormone remained long after the treatment ceased,\" Krantz said.\nThe study, \"Effect of Growth Hormone Treatment on Fractures and Quality of Life in Osteoporosis - A 10-year Follow-up,\" was published online at http://press.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Many readers may know that growth hormones are available and already used for the treatment of short stature in children. But the release doesn\u2019t establish this for those who might not know. Are these hormones prescription-only? Over the counter? Was it a new formulation developed for use in the study? It\u2019s impossible to tell.", "answer": 0}, {"article": "1 Sperling RA, Aisen PS, Beckett LA, et al.\nThese markers, including structural, functional, and molecular imaging are being used in the AD diagnositc criteria [AA/NIA], (1)\" says Howard Aizenstein, M.D., Ph.D., a psychiatrist at University of Pittsburgh.\nThe concept that cognitive decline can be identified early and prevented by applying quantitative brain imaging techniques is the focus of \"Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline,\" a review published online in American Journal of Neuroradiology (AJNR).\n\"Recent advances have improved the ability to characterize imaging markers along the trajectory of Alzheimers disease, starting in the pre-clinical phase.\nSuch work is already happening at UCLA and other institutions that meld these approaches into novel ways to improve patient care.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address the availability of quantitative MRIs of the brain. MRI in general has been used since the 1970s, and its availability is not in question. But since the issue is not specifically addressed by the release, we\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "\"This could be an important tool worldwide, and even here in the United States.\"\nThe test, known as the \"Xpert MTB/RIF\" test for Mycobacterium tuberculosis and resistance to rifampin (RIF), appears to be more than 97 percent accurate and is even able to diagnose drug-resistant TB, researchers said.\nFor the study, a research team led by Dr. Catharina C. Boehme, of the Foundation for Innovative New Diagnostics in Geneva, Switzerland, used the Xpert MTB/RIF test on 1,730 patients suspected of having drug-sensitive or multidrug-resistant pulmonary tuberculosis.\nTHURSDAY, Sept. 2, 2010 (HealthDay News) -- An experimental test that can diagnose tuberculosis in less than two hours, making only one doctor visit necessary before treatment starts, is being hailed as a potentially significant advance against a disease that kills nearly 2 million people annually, most of them in developing countries.\nThough largely eliminated in developed countries, TB remains a leading killer of young adults worldwide.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states the new test is available in Europe and will soon be submitted for FDA approval in the U.S. But this information doesn\u2019t tell readers\u00a0when or if the test will be available in the developing world, where need for it is greatest. In developing countries, which often have rudimentary health care systems, deployment of this test may\u00a0be hampered by any\u00a0number of systemic barriers.\u00a0Cost is\u00a0certainly\u00a0one important issue. but so are management expertise and human resources and availability of reliable electricity.\u00a0The importance of these issues is demonstrated in our experience with malaria and HIV, where fast and accurate tests are\u00a0available but significant segments of the population do not have access to them.\u00a0The story doesn\u2019t do enough to provide this context.\u00a0", "answer": 0}, {"article": "A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday.\n\nIn the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, dupilumab, compared with those getting a placebo.\n\nOther measures of lung function and disease control also improved, according to the study results, which were published online Tuesday in The New England Journal of Medicine and presented at the annual meeting of the American Thoracic Society in Philadelphia.\n\nDupilumab blocks the action of interleukin-4 and interleukin-13, two inflammatory chemicals made by the body that are believed to contribute to asthma. Sanofi and Regeneron say there are also preliminary signs dupilumab works against the skin condition atopic dermatitis, suggesting it can be blocking a biological pathway that contributes to multiple allergic conditions.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "In the fifth paragraph, the story says, \u201cStill, much larger studies, taking at least two or three years, are likely to be needed before the drug could reach the market.\u201d", "answer": 1}, {"article": "He is a professor in the School of Health and Biomedical Sciences at RMIT University in Melbourne, Australia.\nThe study results suggest acupuncture would be especially beneficial for patients who can't use standard pain-relieving drugs because of other medical conditions, Cohen added.\n\"While acupuncture is widely used by practitioners in community settings for treating pain, it is rarely used in hospital emergency departments,\" said study lead investigator Marc Cohen.\nBut he noted that more research is needed because some patients remained in pain no matter what treatment they received.\nMore than 80 percent still had a pain rating of at least 4, the findings showed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While acupuncture is becoming more widely available in most communities, there is no information in the story that suggests how available it might be in large hospital emergency departments. Also, would it be available in a timely manner?", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story focuses largely on the increasing availability of new sunscreen formulations that are believed to protect sun lovers from harmful ultraviolet rays.", "answer": 1}, {"article": "Cabozantinib, also known as XL184, is an oral drug designed to limit blood supply to tumors and to block two segments of a pathway used by cancer cells to grow and spread.\nThe study results were reported on Monday at the American Society of Clinical Oncology\u2019s annual meeting.\nThe drug reduced by 87 percent the risk of disease progression or death.\n\u201cFor the first time, cabo is showing dramatic activity against both soft tissue and metastatic bone lesions,\u201d said Exelixis Chief Executive Officer Michael Morrissey.\nExelixis expects to have initial results around midyear from a pivotal trial of the drug as a treatment for thyroid cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the drug is \u201cexperimental.\u201d\u00a0 We wish it had provided more details than that.\u00a0 But we\u2019ll give it the benefit of the doubt.", "answer": 1}, {"article": "\"When parents have a child diagnosed with an autism spectrum disorder, one of the first questions they often ask is 'how did this happen?'\nWhile both Children's Hospital Boston and Montefiore have offered CMA testing for several years, not all hospitals do, nor does all insurance pay for it, the researchers noted.\nThere are a few other genetic tests that can explain another few percentage points of autism cases.\nBetween 10 percent and 15 percent of autism cases can be traced to a known genetic cause, the researchers noted.\nResearchers offered about 933 people aged 13 months to 22 years who had been diagnosed with an autism spectrum disorder three genetic tests: G-banded karyotype testing, fragile X testing or chromosomal microarray analysis (CMA), which has been available only for the past few years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that not all hospitals offer the newer chromosomal microarray analysis (CMA) test. It could have also mentioned that genetic counseling services are not widely available in some geographic areas. ", "answer": 1}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story points out that the drug is experimental and is not available. However, it says the manufacturer intends to file for approval later this year, \u201craising prospects that the drug could be on the market next year.\u201d While that statement is only a tentative prediction of what could happen, it still gives readers the impression that approval is likely, even though the full data from this trial has yet to be inspected by anyone other than the investigators. Nonetheless, we\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "Philip Gehrman, a Penn clinical psychologist who was senior author, said the study proves that rapid treatment of depression is possible. But more research is needed to figure out why sleep deprivation works. His team is now conducting its own study. He's not hoping to use sleep deprivation as a treatment but thinks that pinpointing what it does to the brain will help doctors develop other, more sustained treatments.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains it is not widely available as a therapeutic in clinics.\n\u201cExperts theorize that sleep deprivation may reset the circadian clock. But it is rarely used for treatment because it wears off so fast.\n\u201cI know of about three clinics worldwide that routinely use it,\u201d Gehrman said. There are some studies showing that it can be helpful when combined with light or antidepressant medication treatment.\u201d", "answer": 1}, {"article": "Because this important step is out of the way in advance, it completely changes the patient\u2019s day of surgery experience.\u201d\n\nRadar can target abnormality within 1 mm, sparing more healthy tissue\n\nUnlike mastectomy, which treats breast cancer by removing an entire breast, lumpectomy surgery \u2014 also known as breast-conserving surgery \u2014 is used to remove only the tumor and a small amount of tissue surrounding the tumor.\n\u201cUntil now, a patient would go to the imaging center to have the thin wire precisely placed in the breast.\nUsing the SAVI SCOUT system technology, which emits 50 million radar pulses per second, surgeons can target the affected tissue within 1 millimeter of the reflector.\nThe SAVI SCOUT Radar Localization System helps to decrease the time a woman is in the operating room, increase the success rates of lesion removal and reduce the amount of healthy breast tissue that is removed during the procedure.\nI was glad it was done a week before and not the same day as the lumpectomy surgery.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the release that Rush Medical Center is now making the device available to its patients. Beyond that facility, it\u2019s unclear if the device is widely available.", "answer": 1}, {"article": "Adult brains contain oligodendrocyte progenitor cells (OPCs), which are stem cells that generate myelin-producing cells.\nThis work was supported by the NINDS (NS085246, NS030800, NS026543), the New York Stem Cell Foundation and the Myelin Repair Foundation, New York City.\n\u201cOff-label use of the current forms of these drugs is more likely to increase other health concerns than alleviate multiple sclerosis symptoms.\nIn the current study, Dr. Tesar wanted to see if drugs already approved for other uses were able to stimulate OPCs to increase myelination.\nThe NINDS is the nation\u2019s leading funder of research on the brain and nervous system.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the two drugs highlighted (clobetasol and miconazole) are available and adds the important precatuionary note, \u201c\u2026are currently approved for use as creams or powders on the surfaces of the body but their safety administered in other forms, such as injections, in humans is unknown.\u201d", "answer": 1}, {"article": "Side effects including shaking, headaches, vomiting and swollen gums\u2014as well as unwanted hair growth.\n\u201cThis research has been tested on human tissue, which is promising, but not on humans themselves, so there is still some way to go.\n\u201cIt is also important to realize that this is being proposed as a treatment for hair loss, not a cure as such.\u201d\n\nThis piece has been updated with a comment from the British Association of Dermatologists.\nAn existing drug used to treat a common bone disorder could hold the key to the cure for baldness, according to a new study.\nDr. Hawkshaw said in a statement: \u201cThe fact this new agent, which had never even been considered in a hair-loss context, promotes human hair growth is exciting because of its translational potential: It could one day make a real difference to people who suffer from hair loss.\u201d\n\n\u201cClearly though, a clinical trial is required next to tell us whether this drug or similar compounds are both effective and safe in hair-loss patients.\u201d\n\nA British Association of Dermatologists spokesperson said in a statement the results were interesting.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that this is early research and human testing hasn\u2019t even begun yet.", "answer": 1}, {"article": "This is a way of getting closer to an answer,\" said Weiner.\nThe FDA says that Amyvid \"is not a test to predict the development of AD-associated dementia\" in those who have no problematic symptoms.\nLast week, the FDA approved an agent called Florbetapir F 18 injection (to be marketed as Amyvid), which will allow physicians using a positron emissions tomography (PET) scan to detect the presence and extent of amyloid plaques in patients concerned about declining mental function.\nFor now, says Weiner, there is \"no consensus\" on which patients should get the costly new PET scans that use Amyvid, and large insurers such as Medicare and Medicaid have not made decisions about coverage for such tests.\nAnd on Monday, the American Academy of Neurology released a new study showing that an agent called florbetaben also allowed detection of amyloid plaques when used with a PET scan.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The product\u2019s approval by the FDA does not mean that testing will be widely accessible in the near future. The statement from Eli Lilly explains why: \u201cBecause Amyvid loses over half of its radioactivity every two hours, Amyvid must be distributed directly from a radiopharmacy to the imaging centers where it will be administered within several hours. Beginning in June, a limited number of radiopharmacies will be distributing Amyvid with the goal of making the product available in more areas as soon as possible.\u201d", "answer": 0}, {"article": "\u201cI don\u2019t want to throw cold water on an interesting thing, but that\u2019s what it is \u2014 an interesting thing,\u201d Gallo said.\nThe patient, who had both HIV infection and leukemia, received the bone marrow transplant in 2007 from a donor who had a genetic mutation known to give patients a natural immunity to the virus.\n\u201cIt is possibly a cure, that\u2019s for sure, you won\u2019t know for absolute sure until the person dies and undergoes extreme PCR (genetic) analysis of post-mortem tissue.\u201d\n\nThe mutation affects a receptor, a cellular doorway, called CCR5, that the AIDS virus uses to get into the cells it infects.\nIt requires destruction of a patient\u2019s own bone marrow \u2014 itself a harrowing process \u2014 and then a transplant from a donor who has a near-exact blood and immune system type.\n\u201cOur results strongly suggest that cure of HIV has been achieved in this patient,\u201d they wrote in the journal Blood.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that it is based on the findings in one patient and that it couldn\u2019t be applied broadly.\u00a0The story shows that bone marrow transplants are available and points out the unique aspects of the procedure in this single patient; that is, while bone marrow transplants are available, marrow from recipients with the CCR5 mutation is not.", "answer": 1}, {"article": "Pernilla Wittung-Stafshede stresses the importance of finding ways to combat these neurological conditions in the future:\n\n\"These diseases come with age, and people are living longer and longer.\nNow, new research from Chalmers has shown that the protein parvalbumin, which is very common in many fish species, may be contributing to this effect.\nWith the parvalbumin protein so highly abundant in certain fish species, increasing the amount of fish in our diet might be a simple way to fight off Parkinson's disease.\n\"Because Nathalie had previously shown that parvalbumin passes into the body of the person eating fish, it made sense to study its interaction with human proteins.\nMore About: Fish and Better Neurological Health\n\nThe link between higher consumption of fish and better long-term health for the brain has been long established.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Fish is widely available. We\u2019re told the protein of interest, parvalbumin, is found in higher concentrations in certain species, and that this concentration is seasonal and tends to peak in late summer.", "answer": 1}, {"article": "\"They would probably be a lot less scary than hospitalizations.\"\nThe disease also affects the pancreas, making it difficult for the body to absorb food, which significantly stunts growth and often leads to early deaths.\nHGH therapy can be expensive, but fewer hospitalizations should balance out the expense.\nAlthough HGH not a cure for the disease, which afflicts 30,000 people in the U.S., the researchers found that it reduced the number of hospitalizations among those who have the disease.\nBut with antibiotics and other medical advances, the median age for people with the disease increased to 37 by 2008.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 2}, {"article": "NASHVILLE -- Sick with depression, Harriet Bruce spent her days lying in bed for months at a time.\nIt's an alternative to electroconvulsive therapy \u2014 shock treatments \u2014 for patients who have not responded to drugs or psychotherapy.\nThe devices cost around $100,000, Cochran said, who has treated 45 patients with the therapy.\nThe NeuroStar system resembles a dentist's chair.\nThe cost, however, is less than an extended hospital stay.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the device and thus the treatment is available. \u00a0The story does provide some insight into insurance coverage as well.", "answer": 1}, {"article": "\u201cThe goal for most practicing allergists and for most parents is to get a child to the point where if there is an accidental ingestion of peanut it would not be as risky or life-threatening,\u201d said Dr. Amy Stallings, an assistant professor of pediatrics in the division of allergy and immunology at the Duke University Medical Center who is not affiliated with the new study.\nIt could be several more years before the patch will be available for consumers.\nThat's a potentially life-saving development.\nAt the end of a year, 50 percent of those wearing the high-dose 250 microgram patch were able to tolerate consuming at least one gram of peanut protein.\nConsuming even trace amounts of a food allergen can cause a reaction.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story lede uses cautionary wording\u2013\u201cprotection may eventually come\u201d\u2013and then, at the bottom of the text, gets reasonably specific about the \u201cseveral more years\u201d needed before a product could become available.", "answer": 1}, {"article": "Deaths from adenomatous lung cancer were cut 30 percent, those from colorectal cancer 40 percent, and those from prostate cancer 10 percent.\nTo be sure, the U.S. Preventive Services Task Force's currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work.\nYes, scientists have already published strong evidence suggesting aspirin can cut bowel cancer and deaths.\nThe benefits of daily low-dose aspirin can exceed the risks for many middle-aged and older people when it comes to preventing heart attacks and strokes, the task force says.\nA British study offers compelling -- though not clinching -- evidence that the humble aspirin tablet can prevent death from a variety of cancers, if you take the medicine long enough in middle age.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of aspirin is widely known. What is unique here is how common is it to be used as a cancer prevention method. This story, like others, makes clear that it is commonly used for other reasons but not for cancer prevention. \u201cTo be sure, the U.S. Preventive Services Task Force\u2019s currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work. The benefits of daily low-dose aspirin can exceed the risks for many middle-aged and older people when it comes to preventing heart attacks and strokes, the task force says.\u00a0So for those already taking prophylactic aspirin for this reason, the possible anticancer effects are just icing on the cake.\u201d\u00a0", "answer": 1}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The supplements are already on the market and the story makes that clear.", "answer": 1}, {"article": "Some recreational swimming pools and homeowners with backyard pools have manual treadmills that are water-safe and can be plunked right in the water.\nWhether you call it water running, aqua jogging or hydrotherapy, you can\u2019t beat a workout in water for an array of health benefits, many experts say.\n\u201cI personally prescribe it for knee issues and low back issues.\u201d\n\nHydrotherapy uses a water-friendly treadmill that can be placed in a pool.\nSo, even older patients with limited mobility and balance don\u2019t have to negotiate getting down into a pool.\nBudd Coates, training director at Runner\u2019s World magazine, said runners don\u2019t just plunge into water\u200b therapy when they\u2019re injured; it\u2019s a great conditioning method for healthy athletes, too.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear from the story how widely available underwater treadmills are for the general public.", "answer": 0}, {"article": "Older mothers are more likely to give birth to Down syndrome babies.\nIf larger clinical trials confirm the results, the test could become standard practice, Patsalis said.\nIt also can identify Down syndrome in the 11th week of pregnancy, early enough for a woman to end her pregnancy if she chooses, Patsalis said.\nDr. Brian Skotko, clinical fellow in genetics at Children's Hospital Boston and a spokesman for the National Down Syndrome Society, said this study has widespread implications for the incidence of Down syndrome.\n\"This is due to an extra chromosome 21, and that leads to physical and mental impairment.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "More reserved than its Reuters competitor, this story emphasizes the test \u201cmay one day\u201d be available\u2026 \u201cif larger clinical trials confirm the results.\u201d\n\u201cSmall study\u201d and \u201cexperimental\u201d stressed in second sentence.", "answer": 1}, {"article": "The Lancet.\nThe clinical efficacy results reported today are from the JET8 Phase-III clinical study (3107) (the JET8 study).\nWASHINGTON, March 5, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that HETLIOZ\u00ae, a circadian regulator, demonstrated significant and clinically meaningful benefits in nighttime and daytime symptoms of jet lag disorder.\nVanda believes that if HETLIOZ\u00ae is approved by regulatory authorities for the treatment of jet lag disorder it will potentially offer a therapeutic solution to many travelers and will likely represent an important commercial opportunity for the company.\nVanda intends to seek marketing approval for the use of HETLIOZ\u00ae in the treatment of jet lag disorder.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that the drug has not been approved anywhere in the world for treatment of jet lag. However, there is a statement at the end of the news release that the company has been granted \u201cmarket authorization\u201d by the U.S. Food and Drug Administration and the European Medicines Agency. Does this mean that they have approval to start selling the drug? The Hetlioz website only lists \u201cNon-24-Hour Sleep-Wake Disorder\u201d as an indication for the use of the drug. \u00a0This is very confusing for readers.", "answer": 1}, {"article": "Colorectal cancer is the third most common cancer diagnosed in both men and women (excluding skin cancers) and a leading cause of cancer death, the American Cancer Society reports.\nThose who would benefit from the regimen, according to the U.S. Preventive Services Task Force, must meet a strict list of criteria -- including a high risk of heart disease and a low risk of bleeding side effects.\nA government panel of experts released updated guidelines today spelling out who should be taking a daily low-dose aspirin for heart health, which also offers the added benefit of protection against colorectal cancer.\nWhen it comes to dosing, experts say sticking to a low-dose baby aspirin is best.\nAt this time, the task force reports that more research is needed to assess whether taking aspirin is beneficial for people who are younger than 50 or those who are 70 and older.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear that aspirin is ubiquitous and sold almost everywhere as an over-the-counter drug, so we\u2019ll rate this one N/A. This story, and the other we reviewed, might have benefited from mentioning that the drug has a generic name (known as ASA or acetylsalicylic acid). Generic versions of the drug do exist, are likely cheaper than the brand name, and equally effective.", "answer": 2}, {"article": "Some see Qnexa as a test of the FDA trying to recalibrate how it weighs risks and benefits for weight-loss drugs.\nThe setbacks put a spotlight on how the FDA handles these drugs.\nAs the FDA works through this, many are watching how the agency handles Qnexa.\nBut some say the agency's aversion to accepting any risks is outdated.\nPart of what's going on is that the FDA has gotten a lot more cautious about approving new drugs in general after some serious drug-safety problems, such as heart problems linked to the painkiller Vioxx.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The whole story was about the FDA review of the drug and its meeting next week.\nAs noted above, the New York Times reported, \u201cThrough a regulatory loophole of sorts, many obesity doctors prescribe two separate drugs that, when taken together, are essentially the same medicine.\u201d This was an interesting perspective that the NPR post didn\u2019t include.", "answer": 1}, {"article": "A capsule of Probiotic Immunity from New Chapter Inc., based in Brattleboro, Vt., contains 1 billion each of 10 different organisms, including Streptococcus salivarius subsp. thermophilus and Lactobacillus acidophilus, two species of bacteria often found in yogurt. Other ingredients include herbs such as cumin, ginger and spinach. Users are instructed to take two capsules each day, preferably one in the morning and one in the evening, on an empty stomach. You can buy a bottle of 90 capsules for about $20 at many health food stores.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of these products is clear from the story.", "answer": 1}, {"article": "Dr Douglas Morrison, author of the paper from the Scottish Universities Environmental Research Centre at the University of Glasgow, commented: \"We developed inulin-propionate ester to investigate the role of propionate produced by the gut microbiota in human health.\nThis study illustrates very nicely that signals produced by the gut microbiota are important for appetite regulation and food choice.\nThis study is filling in a missing bit of the jigsaw -- and shows that this supplement can decrease activity in brain areas associated with food reward at the same time as reducing the amount of food they eat.\"\nThe team found that when volunteers drank the milkshake containing inulin-propionate ester, they had less activity in areas of their brain linked to reward -- but only when looking at the high calorie foods.\nIn a second part of the study, which is published in July edition of the American Journal of Clinical Nutrition, the volunteers were given a bowl of pasta with tomato sauce, and asked to eat as much as they like.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release implicitly makes the point that the powder used in the experiment is not available to the public, but the release would have been better if this had been explicit.", "answer": 1}, {"article": "\u201cSometimes serious addiction needs to be coaxed down the stairs one at a time, not thrown off the top floor,\u201d said Dr. Abrams, who was not involved in the study.\nStill, some researchers not involved in the study said the topic required more work.\nThe study was funded by Pfizer, the drug company that makes Chantix, a treatment that costs about $250 a month.\nAbout 1,500 patients at 61 clinics in the United States and abroad participated in the study.\nIf such studies were funded by the government, which sustains a lot of academic research, taxpayers would bear the burden for what the company would eventually profit from, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that Chantix is already on the market.", "answer": 1}, {"article": "\"Our results suggest that nonsteroidal anti-inflammatory drug use is associated with lower colorectal cancer mortality among postmenopausal women who use these medications more consistently and for longer periods of time,\" Anna Coghill, a doctoral student in epidemiology at the University of Washington and Fred Hutchinson Cancer Research Center, said in the news release.\nIn the study, researchers examined the use of aspirin and non-aspirin NSAIDs among more than 160,000 postmenopausal women in relation to deaths from colorectal cancer.\nStudy participants were enrolled in the Women's Health Initiative, which \"represents a large and well-characterized cohort [group] of postmenopausal women, and the medication data collected in this cohort made it possible for us to investigate multiple types, durations and strengths of NSAID use,\" Coghill explained.\nWhile the study found an association between NSAID use and a reduced risk of colorectal cancer, it did not prove a cause-and-effect.\n\"The results of our study help to further clarify the importance of different durations of NSAID use over time for the risk for dying from colorectal cancer,\" Coghill noted in the news release.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Aspirin and ibuprofen are widely available in US pharmacies.", "answer": 2}, {"article": "People taking resveratrol also showed suppression of the inflammatory protein tumor necrosis factor, or TNF, and other compounds that increase blood vessel inflammation and interfere with insulin action, causing insulin resistance and the risk of developing diabetes.\nThe volunteers took pills once a day for six weeks.\nThe researchers signed up 20 people and put them at random into two groups, one receiving a placebo and the other a supplement containing 40 milligrams of resveratrol.\nNow, Ghanim and colleagues say they have found that resveratrol reduces inflammation in humans that could lead to heart disease, stroke, and type 2 diabetes.\nResults showed that resveratrol suppressed the generation of \u201cfree radicals\u201d -- unstable molecules known to cause oxidative stress and release pro-inflammatory substances into the blood, resulting in damage to the blood vessel lining.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that resveratrol can be found in common food sources.\u00a0 But the study was about resveratrol supplements in pill form and the story never explained to readers whether these were available.\u00a0 Are they at the corner drug store or health food store?\u00a0 Are they experimental?\u00a0 The story should have explained. ", "answer": 0}, {"article": "When researchers compared patients who had gastric bypass surgery to those who lost the same amount of weight by dieting, they found that the surgery patients had lower levels of amino acids that have been linked to insulin resistance.\nNow a new study from Duke University Medical Center and Columbia University may help explain why.\nAnd the patients in both groups had lost just a fraction of the weight they needed to lose at the time of the analysis.\nBut researchers say the preliminary findings could one day lead to diabetes treatments.\n\u201cSurgery puts the diabetes into remission.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that gastric bypass is a readily available surgical procedure.", "answer": 1}, {"article": "Medical-device makers, venture capitalists and surgeons are racing to turn a once-controversial weight-loss procedure into the next big thing in elective surgery.\n\nOnce dismissed by some surgeons as a gimmick, gastric banding -- in which a silicone band is wrapped around the upper stomach to restrict food intake -- is now the focus of a fierce competition pitting consumer-products giant Johnson & Johnson against Botox maker Allergan Inc. Venture-capital-backed outpatient centers are popping up to implant the bands. Growing...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provided a very complete discussion about the various venues at which gastric banding was available.", "answer": 1}, {"article": "Most people turning to surgery for weight loss are probably concerned with how many pounds they can expect to shed.\nAlso, at two years after surgery, data were available for less than half the patients.\nThe cost of the surgery was about $30,000, which exceeds the savings observed directly.\nBy year three, the data were only available for 288 patients, about 13 percent of those who got the surgery.\nThe costs were compared with the median annual health costs before surgery -- $6,367.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story says the researchers argue that the results support coverage of the surgery by insurers. That at least implied that not every plan covers the surgery now for this type of patient \u2013 which is at least indirectly a comment on availability.\u00a0 It could have been more explicit. ", "answer": 1}, {"article": "The Pear Bureau Northwest was established in 1931 as a nonprofit marketing organization to promote the fresh pears grown in Oregon and Washington.\nIf that isn't reason enough to fill your shopping basket, there's another reason to add this fruit to your grocery list.\nThe USA Pear Bureau continues to collaborate with researchers to commission additional studies that show the relationship between pears and positive health outcomes.\nThe epidemiologic study, led by Carol O'Neil of the Louisiana State University Agricultural Center, used a nationally representative analytic sample to examine the association of fresh pear consumption with nutrient intake, nutrient adequacy, diet quality, and cardiovascular risk factors in adults.\n, and follow @USApears on Twitter.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release goes into some detail about the wide availability of pears in the United States.", "answer": 1}, {"article": ".\nThe article is available free on the Journal of Child and Adolescent Psychopharmacology website.\nThe article entitled \"Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder\" is coauthored by Steven Pliszka, MD, from The University of Texas Health Science Center at San Antonio and colleagues from Massachusetts General Hospital (Boston, MA), Westside Medical Family Practice (Clinton, UT), University of Tennessee Health Science Center (Memphis, TN), Meridien Research (Maitland and Bradenton, FL), Children's Development Center (Winter Park, FL), Ironshore Pharmaceuticals & Development (Grand Cayman, Cayman Islands), and Mount Sinai Medical Center (New York, NY), on behalf of the HLD200-108 Study Group.\nThe Journal is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology.\nA complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website: http://www.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release offers no information about the possible availability of the new formulation of methylphenidate. It only mentions that the research was a \u201cphase 3 trial,\u201d which some readers will recognize must occur before a drug gets FDA approval for its use. In this case, it\u2019s unclear whether the new formulation is in the drug approval process.", "answer": 0}, {"article": "Immunotherapy moves to the front lines in fight against lung cancer\n\nThe cancer death rate has dropped again.\nExperts said it was especially significant that the study showed that patients benefited from the Keytruda-chemo combination regardless of the levels of a protein, called PD-L1, found on their cancer cells.\nDrew Pardoll, director of Hopkins\u2019 Bloomberg-Kimmel Institute for Cancer Immunotherapy, said that it is too early to know whether the findings will translate into longer survival.\nAnd he said the trial showed that \u201ctumor mutational burden\u201d is a reliable way to predict who will benefit from the medications.\nThe trial that grabbed much of the spotlight Monday is a randomized effectiveness study that involved more than 600 untreated patients with advanced nonsquamous non-small cell lung cancer \u2014 a common type of the disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the FDA approved the Keytruda-chemo combination last May based on an early-stage trial, but many doctors did not adopt it because the trial was small and didn\u2019t initially show a survival benefit.", "answer": 1}, {"article": "It also triggers the release of the stress hormone norepinephrine, as well as the mood regulator serotonin.\nDr. Courtney Vito, a breast oncologic surgeon at the City of Hope Comprehensive Cancer Center in Duarte, Calif., was pleased that a serious issue in breast cancer treatment is getting a closer look.\nAnd because hormone treatment for breast cancer typically makes the hot flash experience even worse, Razzini added, acupuncture could be a useful tool for helping such patients \"stay on their therapy and improve their quality of life.\"\nThere's more on cancer and hot flashes at the U.S. National Cancer Institute.\nThose in the acupuncture group also seemed to have a generally higher overall quality of life in terms of both physical and mental health, with no serious side effects, the study authors said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "One can infer from the story that acupuncture treatment is available for breast cancer patients, particularly given that the independent source says her patients have used acupuncture in the past. And because most people are generally aware that acupuncture is available, we\u2019re giving this a Satisfactory rating.\nBut, the story would have been stronger if it had told readers whether any certified acupuncturist can provide the relevant therapy, or if a specialist in hot flashes is necessary.", "answer": 1}, {"article": "Kymriah is a leukemia treatment made by pharmaceutical giant Novartis.\nOne-time-only treatments for rare genetic disorders are still unique, he noted.\nThe drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.\nThis is the first to correct an inherited genetic mutation.\nIn the phase 3 clinical trial, 27 out of 29 participants -- 93% -- who received the gene therapy demonstrated a gain in functional vision as assessed by a mobility test performed in a maze, according to the company.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t discuss where one can have access to this treatment. It likely will be very limited. And will it be available to anyone with this condition, or will some people be ruled out?", "answer": 0}, {"article": "Inflammation strips the myelin coating from nerve cell extensions, called axons, and connections at the ends of nerves, called synapses, are lost, together disrupting signaling and eventually causing permanent disability depending on where this occurs.\nThey treated MS mice with a drug that increased expression in cholesterol synthesis genes - and this resulted in improved walking ability.\nWorking with a mouse model of MS, the research team assessed astrocytes in various regions of the brain and spinal cord known to be involved in walking, vision or cognition.\nGene expression in specific cells and in specific regions can provide a more precise, neuroprotective approach than traditional treatments for neurological diseases.\nThe team focused on astrocytes, a type of brain cell that becomes activated in MS and plays several important roles in disease, examining gene expression in astrocytes in different regions.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This experimental treatment on mice is clearly not available to humans yet.", "answer": 2}, {"article": "About CVS Health \n\nCVS Health (NYSE: CVS) is a pharmacy innovation company helping people on their path to better health.\nDespite this, clinical outcomes and quality of care have not previously been systematically evaluated.\nHome infusion services are a rapidly growing delivery model in the health care system with rising rates of chronic and acute conditions that require intravenous therapy.\nResearchers compared measures of quality, safety, clinical outcomes, quality of life and costs of home infusion services to those provided in medical settings.\nCare is administered by experienced infusion nurses and pharmacists, and in addition, patients receive additional disease management education and support throughout their treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Home infusion services are widely available. Their reimbursement is not widely available.", "answer": 1}, {"article": "With Cognivue, patients sit before a video screen that shows a series of images, such as a group of dots, that move around and fluctuate in clarity.\nThe device would be available only for use by medical professionals as part of a more comprehensive assessment of cognitive function.\nThe Pittsford, N.Y.-based company\u2019s FDA application included data from a comparative study involving 401 people recruited from 13 communities for older adults.\nIt is not intended to be a standalone diagnostic tool, and its effectiveness for people with less than 12 years of education is not proven.\nCerebral Assessment Systems\u2019 device received de novo approval from the FDA, a streamlined process for reviewing medical devices that appear to be new enough to have no equivalent and pose little risk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the device/test was approved by the FDA and that it is available for use.", "answer": 1}, {"article": "In a twist in the debate about the safety of menopause hormones, new research suggests the real problem may not be the hormone itself, but the fact that it's typically swallowed as a pill.\n\nThis week, the medical journal Circulation offers some of the strongest evidence yet that the risks of hormones are dramatically reduced when the drugs are absorbed through the skin in patches and gels rather than taken as pills. The study by French researchers showed that one of the most serious risks associated with hormone use -- blood...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the patches are popular in Europe but not used as widely in the U.S.", "answer": 1}, {"article": "- People born without the CCR5 gene are generally healthy, but will deleting it have unforeseen consequences?\nThe results announced Monday at a conference in Boston left experts cautiously excited.\nThe sixth man also had modified cells, but fewer than expected.\nThe research was only meant to show that, so far, it seems feasible and safe.\nThere are a lot of people out there with hopes and dreams around the C-word,\" so caution is needed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0 made it clear that this was a very preliminary report.", "answer": 1}, {"article": "\"I've been through it, it was the past, time to move on,\" he said.\nThis new treatment is still experimental, but it's a step forward in the strategy of manipulating a person's own immune system to fight cancer.\nBut then his doctor offered an additional step: an experimental treatment called immunotherapy, in which antibodies that target the cancer are injected into the bloodstream and attach to the tumor cell.\n\"It was a very aggressive cancer and we needed to start treatment right away,\" said Chris Mullin, Brian's father.\n\"They tested it on me and it was a success, so I hope it works on all other kids,\" Brian said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story ended by informing viewers that the treatment was experimental.\u00a0 There could have been more emphasis on the early nature of the findings \u2013 i.e. so far \u2013 the results have only been presented at a meeting, meaning that they have not yet undergone peer review.", "answer": 1}, {"article": "Autism is characterized by difficulties in social interaction, communication, and understanding other people\u2019s emotions and behavior.\nHe said the findings, published in the journal Autism Research, were very preliminary, but if confirmed in several more and larger studies, they might replace current subjective tests now used to diagnose the disorder.\n\u201cThe basis of autism in the brain is very deep.\nThere may be very little that one can actually change about the disorder for an individual with a severe case,\u201d Lange said.\n\u201cHowever, it has been shown that in the early stages of development, individuals have been aided by intense one-on-one caring to help them with language, social function with their peers and also with emotional problems,\u201d he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story includes this odd claim:\u00a0\u201cYou don\u2019t need any fancy equipment. This is performed around the world,\u201d Lange said in a telephone interview.\u00a0Interestingly, neither the actual published study nor the McLean press release provides any explicit information about the MRI scanner used or the way in which its programming may have been altered. And neither does the story. ", "answer": 0}, {"article": "March 30, 2011 -- Two highly anticipated hepatitis C drugs are poised to usher in a new era in the treatment of the viral disease as early as this summer, experts say.\nThe drugs will be used in patients with HCV genotype 1 -- the hardest to treat form of the viral infection.\nResults from two phase III boceprevir trials are published in the New England Journal of Medicine.\nThe Merck drug boceprevir and Vertex Pharmaceutical\u2019s similar drug telaprevir are expected to win FDA approval within months, following phase III trials showing that both drugs boosted cure rates to around 70% when used with standard therapy.\nAdding one of the drugs to the current two-drug regimen of peginterferon and ribavirin will make the treatment of hepatitis C more complex, but it will also cure a lot more people, hepatitis C specialist Donald M. Jensen, MD, of the University of Chicago Medical Center, tells WebMD.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story makes it clear that boceprevir and telaprevir are not yet available, but they may be reviewed by the FDA at the end of April.\n ", "answer": 1}, {"article": "Researchers compared 136 women with rheumatoid arthritis with 544 healthy women of similar age.\nThe community-based approach and the fact that data on breast-feeding was collected before the onset of disease give the study strength.\nBut they found that the number of children born to a mother did not affect the results.\n\u201cBut even if you breast-feed for a month or two, it makes a difference.\u201d\n\nAlthough the mechanism is not clear, the scientists write that the protective effect may come from long-term changes in the mother\u2019s immune system induced by breast-feeding.\nThe authors acknowledge that it is difficult to separate the effect of breast-feeding from childbirth itself.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nMost readers will be familiar with the \"availability\" of breast-feeding. \n", "answer": 1}, {"article": "In addition, people can obtain folic acid from breads, cereals and other grain products enriched with folic acid, as well as folic acid supplements.\nHowever, there is no scientific evidence that taking folate supplements will be beneficial, Armstrong noted.\nNone of the other factors they examined accounted for their finding, Nilsson's team noted.\n\"Folate intake had a positive association with academic achievement\" in the students studied, the authors wrote in the report published in the July 11 online edition and the August print issue of Pediatrics.\nIn fact, folate deficiencies may be involved in the development of autism, he added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reported on the results of the study without helping readers understand that it was conducted on a population of youngsters without access to a folic acid supplemented food supply.\u00a0 The competing Reuters story made this point clearly.", "answer": 0}, {"article": "Some critics say Medicare would not be doing a review of a drug already approved by the F.D.A.\nBut some analysts said that should be enough for reimbursement.\nA late-stage trial could begin as early as next year, he said.\nSo it cannot be completely ruled out that XL184 somehow stopped bone growth without killing the cancer.\nDr. Jacques said he ordered the review after being contacted by federal lawmakers questioning why their constituents could not get the drug.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provided clear information about the availability of Provenge and XL184.", "answer": 1}, {"article": "More than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\nAn editorial in the same journal by an expert who was not part of the study praised the research, saying it was well designed and carefully performed.\nThe author of that editorial, Dr. Christopher E. Ramsden, from the National Institutes of Health, said the findings would help doctors develop a \u201cprecision medicine\u201d approach in which fish-oil treatment could be tailored to women who are most likely to benefit.\nDr. Bisgaard said it was not possible to tell from the study whether pregnant women could benefit from simply eating more fish.\nThe research was paid for by the Danish government and private foundations.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the\u00a0\u201ccapsules were an over-the-counter product called Incromega TG33/22, a fish extract made by the British chemical company Croda Health Care.\u201d\nAnd in regard to whether women should start taking the supplement to lower asthma risk in their babies, the story lets us know researchers \u201care not ready to recommend that pregnant women routinely take fish oil\u201d due to the very high dose used in this study. Further research is needed first\u00a0to establish safety and confirm benefit.", "answer": 1}, {"article": "LONDON -- Sanofi-Aventis SA's obesity drug Acomplia can improve blood-sugar levels and weight loss in diabetic patients, according to a study presented at the World Diabetes Congress in South Africa.\n\nThe findings from the clinical trial have shown newly diagnosed patients with type-two diabetes who weren't taking antidiabetic drugs had significantly improved blood-sugar levels and lost more weight with Acomplia, compared with a dummy pill over a period of six months. In addition, Acomplia -- also known as rimonabant -- helped...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The fact that the drug discussed in this story is not currently available in the US is not completely clear in this story.\u00a0 The article does mention that this drug is available in Europe, but doesn't clearly state it isn't available in the US.\u00a0 It ends with the prediction that the new data should result in eventual approval of rimonabant by the FDA, though the time frame for such approval is not predictable.", "answer": 0}, {"article": "\"It's basically a piece of plumbing to bypass blockages,\" he said.\nIn 2007, the scientists published preliminary findings for another 4 patients in the New England Journal of Medicine.\nIn the study, doctors took a small snippet of skin from patients.\nAll of the vessels were implanted into patients' upper arms, to connect them to dialysis machines.\nIn the five remaining patients, the vessels worked for at least 6 to 20 months after they were implanted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the tissue-engineered blood vessel grafts are still experimental. It says only that this sort of lab-grown blood might help patients \"one day,\" without predicting success within a specific time period.", "answer": 1}, {"article": "\u201cThe baby will grow and the biodegradable material will disappear,\u201d he said.\nIt was cleared by European regulators even though large so-called pivotal trials have not yet been conducted on the product.\nIt hopes to seek U.S. approval for the product in 2015, several years before any competitor.\nHe said bioresorbable materials have great potential for other uses, particularly for stents to repair the pulmonary arteries and aortas of babies.\n\u201cThat would be one compassionate use of it, a very serious application.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the device is available in Europe but not in the US.", "answer": 1}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The treatment highlighted in this piece is about expanding the use of \u00a0a material already approved for other medical problems as a means for dealing with a variety of problems with heart muscle. \u00a0So although the piece mentioned that the material was currently being tested in animals for this new purpose, the story blurs this distinction because it goes on to include a quote from a patient in whom the material was used to repair a leak due to valve repair.\nSo\u00a0the CorMatrix Extracellular Matrix may be able to solve more problems than it is currently applied to, but we don\u2019t yet know. \u00a0This means the treatment is available for some medical problems, though not the one highlighted in the story. \u00a0The story was a little confusing on this one.\u00a0", "answer": 0}, {"article": "Though randomized controlled clinical trials of bright light are difficult to do properly \u2014 one expert is fond of saying that it is difficult to \u201cblind\u201d studies of bright light \u2014 the American Psychiatric Association considers bright-light therapy an effective low-risk treatment for both S.A.D.\nPatients generally sit in front of the light box, which can be as small as 9 by 11 inches and 5 inches deep, with the bright light emanating from the square surface, in the morning.\nCOSTS Light boxes can be purchased for about $200 online; they are also available for rent.\nSome say their patients don\u2019t have the patience to sit in front of a light for 30 to 45 minutes every morning.\n\u201cIf you can fix the drift, you can fix the depression.\u201d\n\nLight therapy may even help with major nonseasonal depression, experts say, and with sleep disorders.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear how widely used are the light boxes and that they are sold online and available for rent.", "answer": 1}, {"article": "MayoClinic: Find out more about melanoma\n\nOne study presented at the American Society of Clinical Oncology's (ASCO) conference on Sunday focused on the experimental drug vemurafenib.\nNearly 90% benefited from this new targeted drug, Schuchter said.\nResearchers compared this new drug, which comes in pill form, to the only FDA-approved chemotherapy drug for melanoma, dacarbazine: It has been used to treat melanoma patients since 1975, but is only effective in about 10% of patients.\n\"This is an unprecedented time of clinical options -- it is truly practice-changing,\" said Dr. Lynn Schuchter, who heads the Melanoma Center at the University of Pennsylvania and is not involved with the research.\nDoctors and researchers will now explore how to best use these drugs -- give one before the other, or simultaneously.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that vemurafenib is experimental and Yervoy is commercially available. Unfortunately, the story includes a prediction from the ASCO President and others that , \u201c\u2026vemurafenib will almost certainly get FDA approval this year.\u201d While this may occur, it is not certain. And a little shoe leather journalism would easily find someone who would remind readers that FDA approval is not a fait accompli.\u00a0 Because of this, we judge this unsatisfactory.", "answer": 0}, {"article": "This type of drug development program, which enrolled patients with different tumors but a common gene mutation, wouldn\u2019t have been possible a decade ago because we knew a lot less about such cancer mutations,\" said Dr. Gottlieb.\nVitrakvi will run further tests of the drug's safety and effectiveness.\nThe FDA announced Monday that it had approved Vitrakvi (larotrectinib), a treatment for both adult and pediatric cancer patients.\nIts approval reflects advances in the use of biomarkers to guide drug development and the more targeted delivery of medicine.\"\n\"Using our breakthrough therapy designation and accelerated approval processes, we support innovation in precision oncology drug development and the evolution of more targeted and effective treatments for cancer patients,\" the FDA stated.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that the drug has received FDA approval.", "answer": 1}, {"article": "That was longer than we expected, and it's great news for this group of women.\"\n\"Our study found it would take about 16 years for 10 percent of women in the highest bone density ranges to develop osteoporosis.\nTheir findings are based on the women's T-score, which is a measure of bone density.\nResearchers analyzed bone mineral density data from 5,035 women aged 67 or older who had their BMD tested at least twice during the 15-year study period.\n\"If a woman's bone density at age 67 is very good, then she doesn't need to be re-screened in two years or three years, because we're not likely to see much change,\" says study author Margaret L. Gourlay, MD, MPH, of the University of North Carolina at Chapel Hill, in a news release.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story talks about \"women\u2019s T-score, which is a measure of bone density\", but it never explains how a bone density test is conducted or who might conduct it. Does a woman have to go to a specialist? What kind of equipment is involved? It doesn\u2019t take much to address these questions. ", "answer": 0}, {"article": "Kisco, N.Y.\nMore of those undergoing lap-banding, however, needed repeat surgeries (13 percent vs. 2 percent).\nMore people in the bypass group had complications right after the surgery.\nAn editorial accompanying the studies noted the results should be interpreted with caution since longer-term data is not yet available.\nBut obese patients should be careful to choose surgeons who have performed a high volume of these procedures before committing, said Dr. Guilherme M. Campos, lead author of one of two papers appearing in the February issue of the Archives of Surgery.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story did not fully explain who might be a candidate for these procedures \u2013 which is a matter of availability. A brief explanation of the criteria for weight loss surgery would have dispelled any confusion.", "answer": 0}, {"article": "A study believed to be the largest of its kind suggests that the physical aspects of yoga are effective at relieving low back pain, but it didn't find any evidence that yoga provided broader mental benefits.\n\nThe study, funded by the National Institutes of Health's National Center for Complementary and Alternative Medicine, was published online Monday in the Archives of Internal Medicine. It was lead by researchers at Seattle's Group Health Research Institute.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The journalist probably assumed that yoga and stretching programs are widely available in the U.S.\u2014which is a reasonable assumption. So the article wins a \u201csatisfatory\u201d on this point.\nBut in fact, it is not all that clear that similarly standardized \u201cviniyoga\u201d classes designed to accommodate back pain patients are widely available\u2014or whether most health insurance plans will cover them.\u00a0 Intensive stretching classes would appear to be uncommon. So physical therapists or exercise physiologists might have to create them based on the study model.\n\n\n\n ", "answer": 1}, {"article": "A 6-month supply of vitamin D supplements can be bought for less than $10, and many multivitamins contain the recommended daily dose of vitamin D.\n\nAs for calcium, the NIH advises 1,000 mg per day for men ages19-70, and then 1,200 mg per day for men older than 70.\nDespite the findings, people still need to get enough calcium and vitamin D to reduce the risk of osteoporosis, or bone thinning, said Dr. Mone Zaidi, an osteoporosis researcher at the Mount Sinai School of Medicine in New York, who was not involved in the study.\nHowever, there isn\u2019t enough data to say if vitamin D can help treat or prevent these diseases, Zaidi said.\nAdding the supplements to the exercise program provided no extra benefit, hinting that the men already had enough vitamin D and calcium in their diets to be able to boost their bone strength through exercise alone.\nTo build bone density, weight-bearing exercise is needed, such as running or weight-lifting, according to the NIH.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of calciium and vitamin D are not in question.", "answer": 2}, {"article": "Labovitz also points out that the group of men who had fewer strokes were younger, had lower blood pressure and smoked less than the group more prone to stroke.\nTomatoes could contribute to reducing stroke in other ways, Willett says, because they are a good source of potassium, which is known to reduce blood pressure.\nHowever, daily intake of tomatoes may give better protection.\"\nIn other words, perhaps better health habits - not necessarily just the lycopene - lead to fewer strokes.\nIt seems the jury is still out, but researchers suggest we eat healthy as they continue to search for answers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of tomatoes is not in question.", "answer": 2}, {"article": "The U.S. Food and Drug Administration has not yet approved its use.\nIf it is applicable, it could mean patients need not take blood-pressure drugs, Esler suggested.\nThe procedure is safe as well as effective, the study authors said.\nFonarow added: \"While this study demonstrates that renal denervation provides sustained reduction of blood pressure up to one year and appears safe, additional studies with longer-term follow-up are needed.\"\nMONDAY, Dec. 17, 2012 (HealthDay News) -- For patients whose high blood pressure cannot be controlled despite taking several medications, a short burst of radio waves at the nerves around the kidneys may do the trick, a small new study says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that the procedure is used in other countries but not yet approved in the US.\nHowever suggesting it is used in other countries doesn\u2019t really provide the reader with enough information.\u00a0 Here is what the UK\u2019s National Institute for Health and Clinical Excellence (IPG418 Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension: guidance ) had to say about the approach:\n\u201cCurrent evidence on percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension is from limited numbers of patients, but there is evidence of efficacy in the short and medium term. There is inadequate evidence on efficacy in the long term; this is particularly important for a procedure aimed at treating resistant hypertension. The limited evidence suggests a low incidence of serious periprocedural complications, but there is inadequate evidence on long-term safety. Therefore this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.\u201d\nThese evidence-based questions will have some impact on availability \u2013 whether in other countries or in the US.\u00a0 And the story should have dug a bit deeper.", "answer": 0}, {"article": "The National Fibromyalgia Association estimates that about 10 million Americans, mostly women, have fibromyalgia, an unexplained condition characterized by chronic pain and fatigue.\nAlso, small, preliminary studies suggested the drug can reduce pain and fatigue in people with fibromyalgia.\nXyrem, which is approved by the FDA for the treatment of narcolepsy, corrects the same disturbed sleep patterns that studies have shown are common in fibromyalgia patients, Jones says.\nMay 12, 2010 (Baltimore) -- The powerful sleeping medication Xyrem can help relieve the hallmark symptom of pain in people with fibromyalgia, suggests a study that pitted the drug against a placebo.\nThe new study was presented at the annual meeting of the American Pain Society.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is not approved for use in fibromyalgia but is indicated for use in narcolepsy.", "answer": 1}, {"article": "Feb. 22, 2012 -- When women in their 40s get breast cancer , their tumors need less intense treatment and recur less often if they were first detected during routine mammogram screening.\nThese women will suffer the harms of early screening.\nEven the USPSTF accepts the fact that beginning breast cancer screening at age 40 saves lives.\nBut the picture isn't so clear for women in their 40s.\nBut the vast majority of women will never develop breast cancer during their 40s.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 Mammograms are widely available (if you have access to the proper facility and a way to pay for it). So we don\u2019t expect that the story directly address availability.", "answer": 2}, {"article": "Other texts might include something like, \"Hi, Elizabeth.\nNot only does this research provide evidence that a text-based program can improve heart disease risk factors, but it also shows that a bunch of bells and whistles aren't required for successful health outcomes.\nYet patients in Chow's study resoundingly said that the text messaging helped them make the necessary changes \u2013 more than 90 percent of the participants found the program useful.\nAnd although Chow and her colleagues told study participants that they did not need to reply to the text messages, many of them still did.\nIt can be hard to view those everyday decisions in light of more distant consequences, like having another heart attack or not living as long a life as desired.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It was fairly clear from the story that this was a clinical trial, and that this particular service doesn\u2019t seem to be available to offer customized, encouraging text messages for heart disease patients.", "answer": 1}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that Sonata is undergoing clinical trials and is otherwise unavailable in the United States \u2014 though it is approved in Europe.", "answer": 1}, {"article": "Androgens, including testosterone, are thought to contribute to the growth and development of prostate cancer.\nThe specific ADT drug used in the study, bicalutamide, has since been largely replaced by another kind of drug that decreases the amount of testosterone the body produces.\nA commonly used drug could dramatically increase survival rates for men who have to fight prostate cancer twice.\nBut the new finding indicates it could also be a valuable add-on treatment to surgery if the cancer returns.\nThe drug, a type of androgen-depleting therapy, is a frontline treatment for men who opt not to have surgery for the cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies hormone blockers have been around as a technique for decades, but have not been widely used due to their side effects and uncertainty surrounding their actual efficacy.", "answer": 1}, {"article": "Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors.\nHowever, most studies evaluating migraine surgery have relied on migraine-specific questionnaires.\n\"Our study demonstrates the high functional disability experienced by migraine patients, compared to those with other pain conditions, \" comments ASPS Member Surgeon William Gerald Austen, Jr, of Massachusetts General Hospital.\nDr. Austen and colleagues conclude, \"Chronic pain questionnaires such as the PSEQ add to our understanding of functional outcome after surgery and put pain in migraine surgery patients in perspective to better-known pain conditions.\"\nPreoperative pain coping scores in migraine patients were substantially lower than reported for patients with other types of chronic pain--for example, neuropathic (related to nerve damage) pain, arthritis, or lower back pain.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release made no mention of how or where patients could obtain migraine surgery. Online it seems that these surgeries are offered at many boutique plastic surgery centers around the country\u2013though interestingly it is only plastic surgeons who seem to offer this treatment, not neurologists (the doctors that most often treat migraine sufferers). The news release and the study also did not mention that not all migraine patients will be eligible for the procedure. Although we know little about migraines, it is known that they are triggered in different people through different mechanisms. A woman who has hormonal migraines, for example, might not benefit from nerve decompression.", "answer": 0}, {"article": "Medicare typically follows USPSTF guidelines in determining coverage and the Affordable Care Act specifies that USPSTF recommendations rated at the strongest levels must be used as a floor for coverage for private insurers.\nThe report greatly expands the universe of people who should be screened to see if they need the medication to everyone over age 40 regardless of whether they have a history of cardiovascular disease.\n\u201cIn deciding on any therapy, it is important to understand the risks and benefits, particularly for healthy people,\u201d they wrote.\nThe task force and AHA groups carry tremendous influence in medical practice and in what insurance companies will cover.\nThe 2013 ACC and AHA guidelines recommend an estimated 24 million more people should be on them.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear and obvious that statins are available via\u00a0a doctor\u2019s prescription.", "answer": 2}, {"article": "Impaired insulin sensitivity is one risk factor for type 2 diabetes, which is associated with age and obesity and happens when the body can\u2019t properly convert blood sugar into energy.\nAnd it doesn\u2019t prove that catching up on sleep will prevent diabetes.\n\u201cIt gives us some hope that if there is no way to extend sleep during the week, people should try very hard to protect their sleep when they do get an opportunity to sleep in and sleep as much as possible to pay back the sleep debt,\u201d said lead study author Josaine Broussard of the University of Colorado Boulder.\nThe researchers did two brief sleep experiments.\nBut then, when they let the men get extra sleep for the next two nights, their blood tests returned to normal, countering the effect of the short-term sleep deprivation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of sleep is not in question.", "answer": 2}, {"article": "But for relapsed ovarian cancer, surgery is usually not an option.\nMoreover, the extra chemotherapy seemed to worsen the quality of life.\nThe finding is another in a series suggesting that early detection of cancer might not always lead to better outcomes for patients.\nThis new study does not refer to initial diagnosis of ovarian cancer, only to a relapse.\nDoctors are convinced that if the initial diagnosis can be made early, which is very difficult, the cancer can be treated by surgery.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly CA-125 is available.", "answer": 1}, {"article": ".\nA free abstract of this article will be available via the Cancer News Room upon online publication.\nPublished early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help resolve controversies over soy's potential link to breast cancer outcomes.\n\"We now have evidence that soy foods not only prevent breast cancer but also benefit women who have breast cancer.\nTo provide some clarity, Dr. Zhang and her colleagues looked at the relationship between dietary intake of isoflavones and death from any cause in 6235 American and Canadian women diagnosed with breast cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It would have been interesting and helpful for the release to note what kinds of soy foods the participants said they ate, and which ones were most popular.", "answer": 2}, {"article": "Schafer Cardiovascular Research Fund, the Johns Hopkins Magic That Matters Research Fund for Cardiovascular Research, grants from the National Center for Advancing Translational Sciences (UL1-TR-000040 and UL1-TR-001079), and contracts from the National Heart, Lung, and Blood Institute (HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169).\nIn the study, published on Jan. 10 in Circulation, the researchers say these calcium scores allow physicians to go beyond the traditionally calculated risk factors to determine which blood pressure treatment strategy may be most appropriate for a particular patient.\nPreviously, the appropriate blood pressure treatment for these patients used risk calculations and some guesswork, potentially leaving many vulnerable to heart disease or taking drugs they don't need.\nThus, even though their calculated heart disease risk is relatively low and their blood pressure is below traditional cutoffs for treatment, the researchers say people in this category with calcium over 100 are high risk and may benefit from more aggressive blood pressure treatment.\n\"It may be that if patients are in that blood pressure treatment gray zone with a high risk score but their coronary artery calcium score is zero, then they don't need to be treated aggressively to 120 millimeters of mercury and can be treated to 140 instead,\" says McEvoy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Though CT scans are widely available, the news release mentions that coronary artery calcium scans aren\u2019t usually covered by insurance. This seems to be an important stumbling block to widespread adoption. Could insurers be persuaded to pay for scans if the cost is outweighed by better targeting of treatments? Addressing this point would have added value to the news release.", "answer": 1}, {"article": "Anderson Cancer Center.\nIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer.\nThe new finding could lead to a blood test that would allow doctors to screen for pancreatic cancer much more effectively.\nThat is due in part to the lack of any easy way to detect the cancer in its earliest stages.\nThe researchers found that the presence of the protein could distinguish with 100 percent accuracy whether patients had early stage pancreatic cancer or chronic pancreatitis, a major risk factor for the cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article is clear that the test is not yet available. In reporting on the finding, the story states that \u201cIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer\u201d and adds that it still needs to be shown that the screening would improve outcomes for patients with pancreatic cancer. The story contains a lot of conjecture for a test not yet developed.", "answer": 1}, {"article": "\"Perhaps most importantly reducing pain medication use.\"\nOne person who might agree is 74-year-old Judith Zaborowski, who took up yoga more than 10 years ago to help with her aching back.\n\"Yoga was as effective as physical therapy for reducing pain intensity,\" Saper said.\nDr. Robert Saper at Boston Medical Center is one of the authors.\nSaper says yoga likely works by strengthening core and lower back muscles and helping with mind-body relaxation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Yoga is widely available, although it may be harder to find for rural and low-income neighborhoods. Ironically, the story does not tell us that the 320 patients in this research study were primarily low-income. The study publication itself does say that.", "answer": 1}, {"article": "Foxman B, Barlow R, D'Arcy H, Gillespie B and Sobel JD.\nThe review explains that the medicinal properties of cranberries may be attributed to their unique polyphenol, proanthocyanidins - or PACs, for short.\nIt is estimated that one third of women in the United States will get a UTI by the age of 24.2\n\n\"Findings like this,\" adds Dr. Luis, \"give practitioners a viable, inexpensive, non-antibiotic option to help patients reduce the recurrence of an uncomfortable and potentially debilitating infection.\"\na total of 28 studies showing results from nearly 5,000 patients were considered.\n\"While recommendations for dosage and duration of treatment require further study, the efficacy of the medicinal properties of cranberry products has been well-established.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t address this, but it can be assumed that most (if not all) readers will be familiar with the availability of products containing cranberries. Ergo, we\u2019ll rate this as not applicable. It\u2019s worth noting that the release gives readers little idea of what sort of cranberry products a patient could \u2014 or should \u2014 use to lower their risk of a UTI.", "answer": 2}, {"article": "\"We need a lot more options in terms of medicines to help curb drinking,\" he said.\nMore research is needed, he noted, but \"this medication may be helpful for people with a drinking problem who are also smokers.\"\nWEDNESDAY, Feb. 15, 2012 (HealthDay News) -- The quit-smoking drug Chantix may also help problem drinkers cut their alcohol consumption, a small new study suggests.\nExactly how this drug curbs drinking is not fully understood, but its use may increase blood pressure, heart rate and feelings of sadness and nausea, thereby blunting the pleasurable effects of alcohol, the researchers said.\nChantix costs roughly $3 per pill.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that Chantix is currently available to help smokers quit.", "answer": 1}, {"article": "Kids with August birthdays are more likely to get an ADHD diagnosis.\nIn an editorial, Madhav Goyal and Jennifer A. Haythornthwaite of the Johns Hopkins University School of Medicine said that the mechanisms for why meditation might work on back pain is still a mystery but that this question is merely \"academic\" for many clinicians and their patients who need immediate relief.\nThe results for both techniques were very positive.\nThe two wrote that despite this and other unknowns, the study provides \"a compelling argument for ensuring that an evidence-based health care system should provide access to affordable mind-body therapies.\"\nThe study looks at adults with chronic low back pain, one of the leading cause of disabilities in the United States and one reason why more and more people are addicted to painkillers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear from the story whether MBSR is widely available, is available in mainly metropolitan areas, or is a relatively new field that is still uncommon. The story does quote from a separate editorial in JAMA that says health care systems \u201cshould provide access to affordable mind-body therapies,\u201d\u00a0implying that it\u2019s not widely available. Is this the case, or can it be easily accessed?", "answer": 0}, {"article": "score of 0.9 or higher at the age of 50.\nStill, the absolute risks for men with elevated scores were lower than might be expected.\nFinally, some new research offers simple, practical advice \u2014 at least for men 60 and older.\nBut the advice continues to be murky for younger men.\nThey still have a very low individual risk of dying from prostate cancer, judging from the new data.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0While not being explicit, the story strongly implied (correctly) that the PSA test is readily available.", "answer": 1}, {"article": "\"What was unique about this study is the very large number of children studied,\" Dawson noted.\nThe study, conducted by researchers at Harvard University Medical School, looked at the synchronization of brain activity across different brain regions, as measured by EEG.\n\"Consistent with many previous studies using EEG and functional MRI with both children and adults with autism, these investigators found that, overall, children with autism show reduced coordination (coherence) across brain regions.\"\n\"This reduced functional connectivity in the brain helps us understand impairments associated with autism,\" she added.\n\"Although autism is still principally a clinical diagnosis, this study ... may allow for a new approach to classifying children with autism and may even assist in the early identification of affected children at a younger age,\" said Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at the Steven & Alexandra Cohen Children's Medical Center of New York in New Hyde Park, NY.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear from this story that EEGs are widely used in research or whether they currently have other clinical applications. We can\u2019t assume that consumers know this. If my chlid is not speaking by a certain age, can I go to my doctor and ask for an EEG? And, if I do, what would be the next steps?\n\u00a0\n\u00a0", "answer": 0}, {"article": "Then the researchers, led by Dr. Frank Hu of the Harvard T.H.\nThat is, each year, coffee would be keeping 1 person in 1,000 from dying.\nBut given the 2013 research suggesting \u201ctoxicity of high coffee doses\u201d in some people, he said, \u201cto me the most reasonable approach would be to keep coffee intake to two to three cups most days.\u201d\n\nSecond Take: STAT knows better than to get between coffee lovers and their cup o\u2019 joe, so if you want to take this study as permission to keep beating a path to your Keurig, we\u2019re not going to slow you down.\nThat eliminated the stereotypical coffee-swilling, cigarette-sucking types.\nThe Claim: If you drink coffee you\u2019ll live forever!\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Coffee is widely available, and that\u2019s obvious from the story.", "answer": 1}, {"article": "Thousands of heart-failure patients die each year because they aren't able to get a transplanted organ. Now, many medical experts are touting the benefits of a new mechanical pump that gives a patient's own heart a new lease on life.\n\nPatients surgically implanted with the new pump, known as a left-ventricular assist device, or LVAD, had a survival rate of 58% after two years, according to a recent study. That's not as good as a heart transplant, which offers a survival rate of about 70% after 10 years. But it surpasses the...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the Heartmate II device is currently in limited use, to keep patients alive until a heart is available for transplant. The Heartmate II clearly is available only at advanced cardiac care centers. \nYet the story fails under this criterion because it stumbles across one of the most durable trip-wires on the field of health journalism: Predicting the device is \"widely expected\" to be approved for broader use, \"possibly\" early next year. This invites the reader to assume imminent wide availability.\u00a0 ", "answer": 0}, {"article": "The Kennedy Institute's Professor Kim Midwood said: 'What is particularly exciting is that when we looked at samples taken from people before their arthritis began, we could see these antibodies to cTNC up to 16 years before the disease occurred - on average the antibodies could be found seven years before the disease appeared.\nThis latest research provides the basis of tests that could improve diagnosis and, importantly, detect disease at a very early stage, with the promise even that people at risk of developing rheumatoid arthritis can be followed before the disease begins.\nThat might also indicate whether it could be used in tests to indicate the disease.\nWe decided to see if it could be citrullinated and, if so, whether it was a target for the autoantibodies that attack the body in RA.\nA team from the Kennedy Institute of Rheumatology at Oxford University found that a blood test that looks for antibodies that recognize the protein tenascin-C could reliably show those who will contract the condition.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "As noted above under \u201cCost,\u201d if the test is promising enough to issue a news release about it, readers should be given some idea of when and where it might be available.\nWe aren\u2019t told until the very last paragraph that the research \u201cprovides the basis of tests that could improve diagnosis and, importantly, detect disease at a very early stage, with the promise even that people at risk of developing rheumatoid arthritis can be followed before the disease begins.\u201d In other words, it could be a very long way off. We think there should have been a caveat that more studies are needed or that this test may be years off before it will be ready for routine practice.", "answer": 0}, {"article": "Necator americanus, the New World hookworm, is as long and thin as a vermicelli noodle.\nAnd because of the risks associated with parasites, going around infecting people isn't a viable treatment option.\nThis study would also suggest that humans lost something when we rid ourselves of the microbes and parasites that had evolved alongside us for tens of thousands of years.\nOnly so many people are willing to have a parasite put inside them for science.\nIt was important that the participants be adults, because even relatively benign parasites can cause serious problems for children, pregnant women and others.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does\u2019t address availability. As we explain in the quantified benefits criterion above, the most readers get is an\u00a0erroneous statement about the next steps: \u201cNavarro said their next step is a phase one clinical trial, which would test the effectiveness of an AIP-2 pill.\u201d A phase one trial is actually to test safety\u2013not effectiveness\u2013and this error may have the effect of making this pill seem closer to reality than it is.", "answer": 0}, {"article": "The risk of lung cancer death was 30 percent lower, the risk of colorectal cancer death was 40 percent lower and the risk of esophageal cancer death was 60 percent lower, the study reported.\n\u201cThis is important as a proof of principle that a single simple compound like aspirin can reduce the risk of cancer substantially,\u201d said the study\u2019s lead author, Dr. Peter M. Rothwell, professor of neurology at the University of Oxford.\nThe specific dose of aspirin taken did not seem to matter \u2014 most trials gave out low doses of 75 to 100 milligrams \u2014 but the participants in the longest lasting trials had the most drastic reductions in cancer death years later.\nAs part of the new study, published online Monday in the journal Lancet, researchers examined the cancer death rates of 25,570 patients who had participated in eight different randomized controlled trials of aspirin that ended up to 20 years earlier.\n\u201cThere\u2019s been a lot of work over the years showing that certain compounds can increase the risk of cancer, but it\u2019s not been shown before that we can reduce the risk with something as simple as aspirin.\u201d\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that \u201cMany Americans take aspirin to lower their risk of heart disease\u201d but not necessarily for a cancer benefit.", "answer": 1}, {"article": "Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow.\nVYXEOS was also granted Fast Track designation for the treatment of elderly patients with secondary AML.\n\"The successful outcome of this Phase 3 trial represents an important advance for AML patients, their families and clinicians,\" said Scott Jackson, Chief Executive Officer of Celator Pharmaceuticals.\nThe Company is advancing its CombiPlex platform and broadening its application to include molecularly targeted therapies.\nThe trial met its primary endpoint demonstrating a statistically significant improvement in overall survival.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We learn that the company hasn\u2019t yet sought regulatory and marketing approval for the new drug but will be doing so soon.", "answer": 1}, {"article": "Having a large waistline, high blood pressure, high blood sugar, low levels of HDL (good) cholesterol and high levels of triglycerides, are among the factors that make up metabolic syndrome.\n\u201cCurcumin is the active ingredient of the famous spice turmeric and has a long history of culinary and medicinal use in the Asian countries,\u201d said the study\u2019s senior author Amirhossein Sahebkar.\nThe study team also analyzed data from eight previous studies and confirmed that curcumin had shown a significant reduction of CRP concentrations in a total of 281 patients.\nAt the beginning of the study and again at the end, the researchers measured levels of three blood markers of inflammation, including C-reactive protein (CRP), which even on its own has been linked with heart disease risk.\nThe researchers didn\u2019t examine the effect of curcumin on any diseases, and it was a fairly brief study, so it\u2019s not clear what the long-term implications may be they caution in their report.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that one of the study co-authors is affiliated with companies that make curcumin supplements, so it is easily inferred that such supplements are available.", "answer": 1}, {"article": "Eat as you dare.\nScientists believe this style of eating offers some protection against mental aging, and, above all else, it is heart healthy.\nA new study of over 15,000 people in 39 countries explored the benefits of this diet for one special group: those already diagnosed with heart disease.\nNow here\u2019s the interesting part: eating more foods thought to be less healthy \u2014 those typical of Western diets \u2014did not link to an increase in heart attacks, strokes, or deaths.\nThis classic diet does not exclude a dinnertime glass of wine, however, sugary drinks, fried food, and sweets are not on the menu.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both Western and Mediterranean foods are widely available. However, Western foods are known to be\u00a0cheaper and more widely available in low-income areas, and that could have been mentioned.\u00a0", "answer": 2}, {"article": "The study\u2019s median follow-up was 18.5 months.\nThe Merck drug is awaiting U.S. Food and Drug Administration approval, but Tecentriq was approved by the agency last year, contingent on verification of its clinical benefit.\nMerck announced in October that the second-line bladder cancer study met its main goal and was stopped early.\nAccording to the FDA approval letter, the company has until December to submit the full trial data to the agency.\nThe company is currently enrolling patients in a phase three trial of Keytruda, combined with chemotherapy, as an initial treatment for bladder cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is not currently approved for this type of cancer, but is approved for other types.", "answer": 1}, {"article": "Flavonoids have been found to relax blood vessels and thereby improve blood flow, inhibit platelets from sticking together in the blood, and have a beneficial antioxidant effect. What still is not known is whether regularly eating dark chocolate, especially with its high sugar and fat content, eventually will lead to an unhealthy weight gain that would erase the beneficial effects of the flavonoids found in the cocoa.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Though it would seem reasonable to think that the Hershey\u2019s cocoa mixes used in this study are available on grocery store shelves, it\u2019s impossible to know. (It\u2019s not readily clear from Hershey\u2019s web site either.) Nonethless, we'll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "The use in spine surgery of bone-growth proteins like Medtronic Inc.\u2019s product Infuse has led to widespread nationwide increases in hospital charges ranging from 11% to 41% above conventional surgical costs, researchers found.\n\nThe researchers studied the results of a broad U.S. sample of 328,000 spine surgeries from 2002 through 2006. They report their findings this week in JAMA, the Journal of the American Medical Association.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states correctly that about 25 percent of spinal fusion surgeries use bone-growth proteins [BMPs].", "answer": 1}, {"article": "More than 20 percent of Americans have significant symptoms of depression or anxiety each year, but only around 20 percent of people with a mental health problem get adequate treatment.\nIndividuals can download the apps free with no financial obligation.\nSome also will have access to an IntelliCare coach via text messaging and phone calls, who are available to support them in using the apps.\nAlthough the apps are not validated, each one was designed by Northwestern clinicians and based on validated techniques used by therapists.\nThe apps offer exercises to de-stress, reduce self-criticism and worrying, methods to help your life feel more meaningful, mantras to highlight your strengths, strategies for a good night's sleep and more.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release invites people to download the apps for free.", "answer": 1}, {"article": "CDE causes inflammation that can prevent tear production, according to Allergan.\nOn Restasis.com, you can take the brand\u2019s \u201cdry eye quiz\u201d\u2014 for every quiz taken, Allergan has agreed to donate $1 to the organization.\n\u201cIt was as simple as going to the doctor, getting a prescription and trying RESTASIS\u00ae,\u201d Tomei, 51, who stars in the upcoming \u201cSpider-Man: Homecoming\u201d movie, told FoxNews.com.\nThe quiz on Restasis.com can help individuals learn whether they\u2019re a candidate for the drug.\nTo raise awareness about CDE and help other people find relief, the \u201cMy Cousin Vinny\u201d and \u201cThe Wrestler\u201d star has teamed up with pharmaceutical company Allergan and Guide Dogs for the Blind, an organization that trains dogs and pairs them with visually impaired individuals.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s available and as \u201csimple as going to your doctor,\u201d according to the celebrity spokesperson. (But as we discuss in the Costs criterion, it\u2019s not free nor necessarily covered by insurance.)", "answer": 1}, {"article": "Friedman, who is now 70 and lives in Los Angeles, lost 175 pounds.\nIt's one of several procedures designed to help people maintain the benefits of bariatric surgery.\nAbout one in three patients regain significant amounts of weight a few years after surgery to reduce the size of the stomach pouch.\nAnd research conducted over the past decade suggests it works.\nThere are no significant side effects to the surgery, and patients can return to work the day after they have the procedure.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although not explicitly stated, it is apparent that the TORe procedure is available since cost and insurance coverage are noted. It would have been useful to include additional details on how widely the procedure is used, whether it\u2019s used by both gastroenterologists and bariatric surgeons, and whether patients should look for doctors who have special training or credentials for performing this procedure.", "answer": 1}, {"article": "Dr. Henderson stated, \"Misconceptions about ketamine abound among psychiatrists, particularly related to possible chemical dependence problems.\nIts findings stand in direct contrast to warnings from the American Psychiatric Association (APA).\nCiting over 60 published scientific research studies, the new research article also reviews the molecular mechanisms by which ketamine invokes a robust activation of the brain's own repair mechanisms.\nThe study, \"Practical application of the neuroregenerative properties of ketamine: real world treatment experience,\" addresses key points in the controversy surrounding the use of intravenous ketamine for the treatment of depression.\nThe study also challenges concerns about neurotoxicity and a recent hypothesis that patients must experience hallucinations during ketamine infusion in order to have an anti-depressant benefit.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Other than to note that the author of the study is co-founder of an unspecified number of ketamine infusion centers, the news release does not address where to access the treatment.", "answer": 0}, {"article": "\u201cThat\u2019s something that we almost never see in someone who\u2019s manifested the degree of disease one needed to have in order to get into the study,\u201d Smith said.\nHowever, while only 10 percent of patients who received the drug had double vision before the study, that rose to 50 percent by 24 weeks.\nSmith said FDA approval could come sometime in 2018.\nMore people who received the drug had sizeable reductions in disease activity and reductions of 3 mm or more in eye bulge compared to the placebo group, the researchers note.\nThe study \u201cincluded some of the worst cases imaginable and we\u2019re now wondering whether the drug might find expanded utility in much-less-severe disease,\u201d Smith told Reuters Health in a telephone interview.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does state that FDA approval for this use of the drug could come sometime in 2018 so readers can easily assume the drug is not available now and won\u2019t be for the immediate future.\u00a0 It said that the next phase of the clinical trial is expected to begin within a month or two.", "answer": 1}, {"article": "Chronic diseases of aging, like diabetes, hypertension, heart problems, cancer, joint disorders and Alzheimer\u2019s, are all believed to have inflammation in common.\nWe are able to point, with a much higher resolution picture, at aging and the things that should be markers for inflammation.\u201d\n\nThe key will be to figure out when the inflammatory response starts to spiral out of control.\nIn the meantime, following the example of caffeine-drinking adults with lower levels of inflammation \u2014 by having a cup of joe or two \u2014 might be a good idea.\nTo the age-old question \u201cIs coffee bad for you?\u201d, researchers are in more agreement than ever that the answer is a resounding \u201cno.\u201d A new study published in the journal found that older people with low levels of inflammation \u2014 which drives many, if not most, major diseases \u2014 had something surprising in common: they were all caffeine drinkers.\nThe goal isn\u2019t to make every trace of inflammation disappear, the scientists stress.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As with cost, it can be assumed that most readers are familiar with how to make or purchase coffee. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "Frustrated by the high relapse rate of traditional addiction treatments, scientists are working on a strategy that recruits the body's own defenses to help addicts kick drug habits.\n\nThe new approach uses injected vaccines to block some addictive substances from reaching the brain. If a vaccinated addict on the path to recovery slips and indulges in a drug, such as tobacco or cocaine, no pleasure will result.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article helpfully states that \u201cIt could be years, if ever, before any vaccines to treat addiction reach the market.\u201d The article does a good job of describing how far along the various experimental vaccines mentioned in the article are in their development.", "answer": 1}, {"article": "The U.S. National Institute of Allergy and Infectious Diseases has more on sinusitis.\nThis second finding is probably explained by the fact that people going for second or further surgeries were probably sicker to begin with, Josephson said.\nNone of which is to say that patients shouldn't try medical therapies first, he added.\n\"These were patients who have chronic sinusitis so, by definition, they have at least three months of symptoms and they have evidence of an ongoing inflammation or infection of their nose and sinuses on either a CT scan or an examination of the nose and sinuses,\" Smith said.\nPatients with worse disease at the outset seemed to fare the best after the procedure, as did those undergoing surgery for the first time.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that endoscopic sinus surgery has been used for a long time and the reader can infer that it\u2019s been in widespread use. ", "answer": 1}, {"article": "Women who carry a defective gene on one X chromosome can compensate with the good copy on their other X chromosome, but they bequeath the defective copy to half their children.\nDr. High is listed as a co-author of the report because her laboratory helped monitor the patients and provided proof for regulators that the virus would not insert its human gene into the patients\u2019 sperm and make the change hereditary.\nThe virus used by Dr. Nathwani\u2019s team, known as adeno-associated virus-8, generally stays outside the chromosomes, so it should not present this problem.\nHigh of Children\u2019s Hospital of Philadelphia, said the new therapy had worked because the delivery virus had been made more efficient and because the research team had treated the patients with steroids to suppress immune system attacks on the virus.\nOne patient, a geologist, had a good response at first, but his level of Factor IX has declined to 1 percent of normal, the level at which the disease kicks in.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this is an experimental approach, but the story didn\u2019t challenge a researcher\u2019s claim that a genetic treatment for hemophilia B \u201ccould be available for widespread use in a couple of years.\u201d\u00a0 That kind of statement requires some kind of explanation of what the road to widespread use may look like\u2026and how unpredictable such a prediction can be.", "answer": 0}, {"article": "The F.D.A.\nhas also tentatively approved a stent system from the Cordis division of Johnson & Johnson.\nEveryone agrees that clinical evidence about the relative risks in different types of patients is only beginning to emerge.\nNot only does she believe her risk of stroke has been reduced, Ms. Packer is also convinced the procedure has other benefits that device companies have not yet even asked regulators to consider.\nBut with less than a third of the enrollment goal of 2,500 patients completed, doctors will have a long wait for esults.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Very clear presentation of FDA \napproval of devices made by two manufacturers and that others are awaiting full approval.", "answer": 1}, {"article": "Both groups went to their V.A.\nBased on the study results, it could be that patients need to renew their regimen with the cream every year.\nThe dose is the same as dermatologists currently employ to treat actinic keratosis.\nHe and colleagues are planning further studies, including one to determine the cost-effectiveness of 5-FU treatment.\nThe cream does have common side effects including reddened, more sensitive and often crusty skin, effects that resolve when the application of the cream stops, Weinstock acknowledged.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the cream, available as a generic, has been used to treat other conditions. That suggests the cream is widely available.", "answer": 1}, {"article": "The Food and Drug Administration does not endorse DHA or fish oil capsules, but recognizes doses of up to 3 grams a day of fish oil as generally safe.\nEating fish is not a guarantee of having high levels of DHA.\nThe study was financed in part by Martek, a concern that manufactures DHA, and one author received a grant from Pfizer, France.\nDr. Ernst J. Schaefer, the lead author of the study, was cautious in interpreting the results.\nFatty fish, he said, is best, and frying will cause DHA to deteriorate.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story mentioned that omega-3 fatty acid docosaheaenoic acid (DHA) was found in fatty fish, as well as supplements in the form of fish oil or DHA.\u00a0 It was good to point out that neither DHA or fish oild supplements have FDA approval for prevention of dementia.\nThe story curiously mentioned that it was also found in some meats.\u00a0However, the only tissues in which DHA is found in significant quantities are the brain, retina, and testes \u2013 which are not frequently consumed by people.\u00a0 Thus the story ought not to have included 'some meats' as a source of DHA. ", "answer": 1}, {"article": "Women who undergo Caesarean sectionsmore than seven days before their due dates put their babies at higher risk of respiratory problems, longer hospital stays and other complications.\nAll of the women had previously had C-sections.\nOf those, more than 13,000 had elective C-sections.\n\"I think it points to a role for the baby in the initiation of labor and the baby's readiness to make the transition.\"\nThe findings from the study sponsored by the National Institute of Child Health and Human Development's Maternal Fetal Medicine Units Network also underscore the importance of a woman seeking medical care as early into her pregnancy as possible, so that doctors can accurately gauge the gestational age with an ultrasound, Mercer said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The \"growing number of planned C-sections\" is clear from the story. ", "answer": 1}, {"article": "\"It's odd and it's tough and people say, 'I'm sorry.'\nAnd for one patient, it is promising.\nMason believes the stem cells accelerated his recovery.\nResearchers have followed Mason and five other patients -- all with the most severe spinal cord injuries.\nGambuti said the most devastating part of the whole process was the first day that they lifted Mason out of a bed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the treatment is experimental, and correspondent LaPook acknowledges at the end, \u201cMore research will be needed to try to establish whether (stem cells) actually repair damage to the spinal cord.\u201d But that strikes us as too little, too late. The story does not explain that it takes years to gain FDA approval for a new treatment, and many therapies particularly in the stem cell field never reach the finish line due to cost, safety, and efficacy hurdles.", "answer": 0}, {"article": "What happens with age-related macular degeneration is that the center of the retina deteriorates, and people gradually lose sight.\nThe treatment doesn't work for those who have had cataract surgery.\nFor one, the treatment doesn't work for those who have had cataract surgery.\nThis is why the telescope is implanted in only one eye.\nDespite its terrific potential, the new eye telescope isn't for everyone.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this is an experimental study and says that the FDA\u00a0plans to monitor the side effects for five years. We\u2019re not quite sure why this story was coming out now given that the FDA approved this device at\u00a0the beginning of the month.\u00a0(Read about it.)\u00a0How widely available is it? Never made crystal clear. ", "answer": 1}, {"article": "For ella, \u201cwhile you\u2019re going to have to go and get a prescription for it, it gives you a little bit more leeway in terms of putting your ability to put your life on hold and get this healthcare need taken care of,\u201d said Amy Allina, program and policy director for the National Women\u2019s Health Network.\nIf it is approved, it should be clearly labeled as an abortifacient, which would limit its distribution, the American Association of Pro Life Obstetricians & Gynecologists said in a letter to the FDA earlier this month.\nIf approved, Watson Pharmaceuticals Inc would sell the drug in the United States.\nHRA is not seeking to sell ella without a doctor\u2019s prescription.\nData shows the one-pill treatment, called ella and made by French drugmaker HRA Pharma, is effective when taken as many as five days after unprotected sex, Food and Drug Administration staff reviewers said in documents released ahead of a public meeting on the drug scheduled for Thursday.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that the FDA is now reviewing the drug and that it is not yet available in the US but is available in Europe.", "answer": 1}, {"article": "To address this gap, researchers conducted a randomized controlled trial including 352 healthy infants from 3 pediatric outpatient clinics, including 7 physician practices, who received scheduled vaccinations in their first year of life.\nFor babies under age 1 year, lidocaine cream, combined with a small amount of sugar given by mouth and infant soothing, can help relieve pain from routine vaccinations, according to a study in CMAJ (Canadian Medical Association Journal).\nThe study was conducted by researchers at SickKids, the University of Toronto, York University and several Toronto-based pediatricians.\n\"The effects of consistent pain management on the development of preprocedural anxiety (fear), hypersensitivity to pain and compliance with future vaccination warrant future investigation,\" they recommend.\n\"We found that, when used consistently during vaccine injections in the first year of life, only liposomal lidocaine combined with parental video instruction and orally administered sucrose showed a benefit on acute pain when compared with placebo, video alone, and video and sucrose together,\" wrote the authors.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Lidocaine creams come in many different over-the-counter products but it\u2019s unclear whether the lidocaine formulation used in the study is the same as one might find over-the-counter, or if it\u2019s EMLA (a cream using equal parts lidocaine and prilocaine) or another prescription product.", "answer": 2}, {"article": ".\nAn advantage of small-molecule PPF -- which has been previously used in clinical trials in an attempt to treat Alzheimer's disease and dementia -- is that it can penetrate the blood-brain barrier and reach the tumor.\n\"PPF could be easily translated to the clinic as an adjuvant therapy in combination with standard of care treatment for GBM patients.\"\nHowever, this security system is so effective at protecting the brain that it prevents many life-saving drugs -- all but some small molecules -- from being able to treat cancer and other diseases of the brain.\nThis study -- Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway -- also was funded by the National Institutes of Health under grants NS86853 and P50 CA108961.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although the release is clear that this approach is experimental, by failing to clearly point out the fact that the drug has yet to be tested in a single glioblastoma multiforme patient, it obscures just how preliminary and tentative these results are.The release gives the reader the false impression that PPF has already been approved for this purpose with this statement:\n\u201cAn advantage of small-molecule PPF \u2014 which has been previously used in clinical trials in an attempt to treat Alzheimer\u2019s disease and dementia \u2014 is that it can penetrate the blood-brain barrier and reach the tumor. And, the FDA has already approved it.\u201d", "answer": 0}, {"article": "Their systolic blood pressure, which was in the normal range when the study began, dropped by 4.5 mmHG, while their diastolic blood pressure dropped by 3.1 mmHg.\nThe researchers said further investigation will determine whether the benefits of the diet can continue for several months.\nThe phase II trial, conducted by researchers at the USC Leonard Davis School of Gerontology, demonstrated a host of benefits from the regimen.\nThe researchers had invited participants in the study for one last set of tests three months later, at the end of the diet.\nPeople in the second group were placed on a three-month test of the fasting-mimicking diet.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not explain whether materials used in the clinical study are widely available. The product website, however, is actively promoting the kits.", "answer": 0}, {"article": "For those with early stage breast cancer, \"lumpectomy is just as effective if not more effective than mastectomy,\" said researcher Dr. Shelley Hwang, chief of breast surgery at Duke Cancer Institute in Durham, N.C.\n\n\"There are lots of women who think the more [treatment] they do, the better they will do,\" she said.\nThe study is scientifically sound in many ways, Kruper said.\nThe study was observational, Hwang stressed.\nHwang believes the study does arm women with valuable information.\nThe findings may reverse the mastectomy trend, said Dr. Laura Kruper, co-director of the breast oncology program at the City of Hope Comprehensive Cancer Center in Duarte, Calif., who was not involved in the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No discussion of availability of either approach, but we don\u2019t think that was necessary in this case.", "answer": 2}, {"article": "\"This work is very exciting and promising,\" said Nichols, who added, \"The FVII-deficient dogs tolerated the initial gene therapy infusions very well and have had no adverse side effects over several years of follow up.\nThe current study sets the stage for clinical trials in humans.\nThis success in large animals holds considerable potential for a safe, effective and long-lasting new treatment in humans with the same bleeding disorder.\nBased on kidney function, liver function, and blood measurements in the dogs, the treatment was safe, and did not elicit unwanted immune responses.\nThe Margaritis team collaborated with University of North Carolina (UNC) scientists, led by Tim Nichols, M.D., professor of Medicine and Pathology at the UNC School of Medicine.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that this treatment will not be available until human clinical trials are conducted.", "answer": 1}, {"article": "The researchers noted that thousands of people in this final group were participants in the Women\u2019s Health Initiative, a long-term study sponsored by the National Heart, Lung and Blood Institute in the U.S. Earlier reports based on data gathered by the Women\u2019s Health Initiative found that calcium and vitamin D supplements were associated with a lower risk of fractures, but only for women who took hormone therapy after menopause. To get a clearer picture of the direct link (if any) between supplements and fracture risk, Zhao and his colleagues opted not to include data from women on hormone therapy.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We think it\u2019s safe to presume that readers know that vitamin and mineral supplements are widely available.", "answer": 2}, {"article": "\u2022 Try to stay indoors, and avoid mowing lawns or raking leaves.\nBut you can also tell by the ads: TV spots selling remedies for drippy, congested noses, itchy eyes and other symptoms are in heavy rotation.\nYou can tell by the sniffles and sneezes of the afflicted.\nPeople with mild to moderate symptoms have the best chance of full relief, he says.\nHere's what some top allergists say you need to know about these non-prescription options.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All these drugs are available over the counter, which the article mentions early in the story.", "answer": 1}, {"article": ", follow us on Twitter @H_SeniorLife, like us on Facebook or read our blog.\nResearchers analyzed the bone density scans of over 1000 older women from Australia for the presence of calcium deposits in the large artery in the abdomen called the aorta.\nBOSTON -- Researchers from Hebrew SeniorLife's Institute for Aging Research, University of Western Australia, University of Sydney, and Edith Cowan University have discovered that bone density scans, typically used to determine fracture risk, could also be an aid in identifying cardiovascular disease.\nThey graded the severity of these calcium deposits using scans done for osteoporosis screening.\n\"We found that that the presence of calcifications increased the likelihood of having cardiovascular disease such as heart attacks, and even the likelihood of cardiovascular deaths and mortality in general.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that bone density scanning is routinely used to diagnose osteoporosis and presumably it is widely available. What is not clear is whether bone density scanning to determine the degree of aortic calcification is generally available.", "answer": 0}, {"article": "\"That's where the money is,\" Malmgren said.\nHowever, she said, the study does not provide support for all women aged 40 to 49 to have routine mammograms.\nMalmgren, a breast cancer survivor, says more focus should be placed on the benefit of early diagnosis, because it often means less treatment is needed.\nIn 2009, the U.S. Preventive Services Task Force issued mammogram recommendations.\nThey also took these into account: the cancer's stage at diagnosis; type of treatment; annual follow-up; recurrence; and survival.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 Availability of mammograms is not in question although access to care is dependent upon many factors including distance to facility with instrument, insurance coverage, etc.", "answer": 2}, {"article": "\"And I thought, 'If we could do that in people, this is going to be amazing.'\nWhat Belvin didn't know at the time was that a revolutionary treatment for melanoma had begun testing in clinical trials.\nA clinical trial to study the drug \u2014 now called ipilimumab, or Ippy for short \u2014 was set up at Memorial Sloan Kettering Cancer Center in New York City.\nAllison's treatment was still experimental, but if it worked, it had the potential to save Belvin's life.\nBelvin was the first recipient of the immunotherapy that Allison had ever met.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that ipilimumab is currently available for clinical use, marketed under the name Yervoy.", "answer": 1}, {"article": "That heat can then be used to interrupt the troublesome brain connections responsible for the tremor.\nThe site includes a list of frequently asked questions and will be updated as UVA prepares to make the treatment available.\nThe procedure is not for everyone with essential tremor.\nThe FDA approval means UVA can make the procedure available to eligible patients.\nThe essential tremor research has been supported by InSightec, the Focused Ultrasound Foundation and the BIRD (US-Israel Binational Industry Research and Development) Foundation.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is clear in that the medical center is preparing to make the procedure available to qualified patients but it certainly is not available to the public at this time. It also mentions the uncertainty of insurance coverage.", "answer": 1}, {"article": "One group of researchers, for example, recently worked backward to take on the problematic overlap between depression and bipolar disorder\u2014many bipolar patients are initially and incorrectly diagnosed with depression.\nDespite these exciting preliminary findings, there aren\u2019t yet any biological tests for mental illness widely used in medical practice.\nIt took a few years to find the right \u2018formula\u2019 of meds.\u201d While the doctors recommended some medication that helped, it was a matter of trial and error, since Orlando still doesn\u2019t have a concrete diagnosis today.\nIf there was a blood test for depression, it could just become part of a standard panel\u2014and thus help achieve earlier diagnoses, and in turn earlier treatment, across the board.\nThe test, says Bahn, can accurately predict whether someone will \u201cdevelop schizophrenia over the next two years.\u201d\n\nBahn\u2019s finding is one of several recent advancements toward a comprehensive system of biological mental health diagnostic tools.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story goes into some detail about how experimental these diagnostic tests are and even some of the difficulties entailed in bringing them to market.", "answer": 1}, {"article": "Past studies have found that compared with people without fibromyalgia, those with the disorder have higher rates of stressful life events, such as childhood abuse, marital problems and high levels of job stress.\nThe therapy involves an educational component where patients learn about the emotion-pain connection.\nAnother difference is that, right now, only a small number of healthcare providers practice affective self-awareness, according to Schubiner.\nThe study, of 45 women with fibromyalgia, found that those who learned a technique called \u201caffective self-awareness\u201d were more likely to show a significant reduction in their pain over six months.\nHe said that he and his colleagues have applied for funding to conduct a larger clinical trial comparing affective self-awareness with standard cognitive-behavioral therapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that only a small number of healthcare providers practice affective self-awareness, suggesting that the treatment is not widely available. ", "answer": 1}, {"article": "As examples, smoking rates were highest among those without a graduate education degree certificate and lowest among those with a graduate degree; higher among those living below the poverty level versus above it; and higher among some minorities such as American Indians and Alaska Natives, multiple- race individuals and blacks.\nSix of the eight cases found in the screening were considered potentially curable with surgery.\nAlso, about half of patients screened continue to smoke so screening might also be a logical point for smoking intervention, Schroeder said.\nFollowing the trial, the National Comprehensive Cancer Network, a nonprofit organization of cancer centers that develop guidelines for cancer diagnosis and treatment, along with the United States Preventive Services Task Force, which makes recommendations for preventive medicine, recommended screening high-risk individuals on a slightly broader scale, which the Lahey and Augusta area screening used.\nLike the previous experiences, the Augusta area screening that started in 2014, also reiterated the ability of LDCT to find lung cancer early, said Schroeder, corresponding author of the study in Southern Medical Journal.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that the relevant diagnostic techniques are in widespread use; that there is limited access to the screening initiative (based on availability); and that there is an effort underway to expand the screening initiative.", "answer": 1}, {"article": "Kite Pharma is racing to get the first FDA approval of an experimental gene therapy to fight cancer.\n\nAn experimental gene therapy that turns a patient\u2019s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.\n\nIn all, 82 percent of patients had their cancer shrink at least by half at some point in the study.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0mentions this is an \u201cexperimental gene therapy\u201d and that, if approved, it could become the first such treatment to be available\u00a0in the United States. The story notes that the company is seeking approval for the drug by the end of March. While this is sufficient for a satisfactory grade, we think the story could have elaborated on this a bit, and noted that the approval would be based on preliminary phase 2 data \u2014 not the typical phase 3 study data that the FDA normally requires for approval. The drug appears to be eligible for expedited approval based on the FDA\u2019s \u201cbreakthrough\u201d therapies program.", "answer": 1}, {"article": "High blood pressure increases the risk for heart attack, stroke and kidney problems.\nThe rate of side effects was no greater among those who took the three-in-one pill than among the usual care group.\nAll had high blood pressure.\nThe finding stems from a study of 700 people, who averaged 56 years old.\nShe's a researcher with the George Institute for Global Health at the University of New South Wales in Sydney, Australia.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t explain where or even whether the \u201ctriple pill\u201d is available.\u00a0", "answer": 0}, {"article": "BOSTON -- In 2006, the FDA warned the public that the use of common antidepressants, like Prozac and Paxil, late in pregnancy could put a baby at risk for respiratory failure.\nBut now a new, large-scale study finds that the risk is negligible -- much lower than previously believed, reports CBS Boston's Dr. Mallika Marshall.\n\"So for women with severe debilitating depression that is not responsive to other non-pharmacological treatments, this should be reassuring information.\"\nIt's certainly reassuring news for Dr. Katherine Economy, a maternal fetal medicine specialist at the Brigham who cares for many pregnant women on antidepressants.\n\"And for many women, they cannot get through their daily activities, getting out of bed, taking a shower, and preparing food for themselves.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told\u00a0this study applies to \u201ccommon\u201d antidepressants, and a few widely known prescription name brands are mentioned. The availability (through diagnosis and a medical professional\u2019s prescription) isn\u2019t overtly established, but it\u2019s implied.", "answer": 1}, {"article": "In the study entitled \"Long-term physiological T3 supplementation in hypertensive heart disease in rats,\" aging female rats with hypertension progressing to heart failure were treated for one year (half their lifetime) with a low oral dose of the active form of thyroid hormone, T3.\nBut, they were proven to be wrong and these life-saving drugs are now standard therapy for heart failure treatment.\n\"Thus, T3 treatment inhibited the major cause of stiffening of the heart in hypertension.\n\"The studies demonstrate that we should be able to implement a similar, safe treatment and monitoring program for use in human clinical trials.\nI predict the same will eventually be true for thyroid hormones in a large subpopulation of cardiac patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does an excellent job of making clear that this was an animal model study and that clinical trials have not yet been approved for this treatment technique \u2014 meaning that this work is at least years away from widespread clinical use.", "answer": 1}, {"article": "They are packed full of growth factors, of healing factors, and when given into a specific area, you get a hyper-healing response,\" Gearhart says.\nHe is one of the few patients to get it so far \u2014 clinical trials are now testing PRP's safety and effectiveness.\nThe hope is that if PRP can get an elite athlete like Bornstein up and running, it can help the baby boom generation and their creaky joints get back in the game.\nThe hope is that the same technology that allowed Bornstein to get back on the field so quickly can now be used to treat injuries in weekend warriors as well.\nA leading sports medicine expert, he believes we can speed up the body's ability to heal itself with a remarkably simple technique.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story only hinted at the limited availability of the Platelet Rich Plasma Therapy procedure.\u00a0 While it said that \"doctors have now taken first steps tomove this treatment beyond the world for elite athlete,\" and mentioned that clinical trials had begun, it did not answer viewers\u2019 probable questions of \"Where can I get it?\" or \"Is it being tried at my local hospital?\"\u00a0 And when the story lead-in frames the problem as one pertinent to 15-million American medical visits per year, this is an oversight.\u00a0 The very limited availability and preliminary nature of the research should have been emphasized STRONGLY. ", "answer": 0}, {"article": "Jay Konduros used to rush home several times a year after accidentally cutting or bumping himself.\nThe researchers presented earlier findings on the gene therapy a year ago at the American Society of Hematology's annual meeting, but the latest data covers a larger patient group and a longer time period.\nThe treatment also \u201cnearly universally eliminated\u201d the need for preventive infusions of clotting factor a few times a week, the scientists said.\nThe results, published Wednesday online in the New England Journal of Medicine, represent \u201canother example of the gene-therapy renaissance,\u201d Matthew Porteus, a pediatrician at Stanford University, wrote in an accompanying editorial.\nStill, the therapies can produce at least some offsetting savings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Since the story notes that the research is at an early stage with only 10 participants, a reader can easily infer that the treatment is not yet available. However, additional information about remaining evaluation stages for this treatment would have been a useful reinforcing addition. Hemophilia B sufferers who see this story will likely be contacting their doctors.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It's clear that hormone therapy is readily available and has been for many years.", "answer": 1}, {"article": "Although the company selling Xiaflex will be Auxilium Pharmaceuticals of Malvern, Pa., the F.D.A.\nIt now has only five employees and a business of collecting a roughly 11 to 12 percent royalty on sales of Xiaflex.\nWith its belated success, BioSpecifics has sold off its ointment business.\napproval was a belated triumph for the drug\u2019s original developer, BioSpecifics Technologies of Lynbrook, N.Y., on Long Island.\nWith Dr. Korn\u2019s help, BioSpecifics licensed the drug to Auxilium in a matter of weeks, receiving $5 million initially.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that Xiaflex was approved last month and will go on sale later this month.", "answer": 1}, {"article": "The F.D.A.\nNovartis said that about 2.2 million Americans would be eligible for the drug, which was approved for patients with so-called Class II to Class IV chronic heart failure with so-called reduced ejection fraction.\nNovartis is sponsoring another study to see if the drug is effective for those with preserved ejection fraction, which accounts for half of heart failure cases.\nBut such talks, while encouraging, are still in the early stages, a Novartis spokesman said.\nNovartis is considering trying so-called risk-sharing with some health plans, meaning it might charge more if the drug really does keep people out of the hospital and less if it doesn\u2019t.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is about the FDA approval of the drug, which suggests that it will shortly be available for purchase. Novartis says as much in its news release which indicates the drug will begin shipping this week. The story doesn\u2019t explicitly address this, but we\u2019ll give the benefit of the doubt. Again, we\u2019d add that half of this drug combination is already widely available.", "answer": 1}, {"article": "Symptoms of heart failure include fatigue, breathlessness and swelling in the limbs.\nBut the study was small, and the stem cells had only a minor impact on patients' heart function.\nThe message for patients, he added, is that heart failure can be treated, and researchers are looking for \"innovative\" ways to improve that treatment.\nThe tactic appeared safe, the researchers said, and there were signs of symptom improvements over the next six months to a year.\nBut it's not clear whether the stem-cell tactic was actually effective, said Gorodeski, who was not involved in the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is another strong point, with the story making it very clear that this is not a viable treatment option for the foreseeable future. \u201cAll stem-cell therapies remain experimental,\u201d the story says at one point. Shortly thereafter, the story quotes a heart failure specialist as saying: \u201cThere\u2019s no cell therapy we can offer patients right now.\u201d", "answer": 1}, {"article": "Follow us: twitter.com/CocoaHealthSci\n\nIn 1911, Frank C. Mars made the first Mars candies in his Tacoma, Washington kitchen and established Mars' first roots as a confectionery company.\nThis test product is currently not commercially available.\nThis study, conducted by researchers from Italy's University of L'Aquila and Mars, Incorporated, reinforces the results of several recent cognitive studies--throwing more light on the important role diet plays in maintaining cognitive health.\nExcitingly, there was also evidence of improvements in these cardiometabolic outcomes.\nThis second study just published in the AJCN looked to address this question.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states in an editor\u2019s note that this test product is not commercially available.", "answer": 1}, {"article": "I weigh 160 pounds, and when I do this I put about half my weight into it,\" he said.\nHe said the latest research on CPR supports the notion that in the critical minutes before an ambulance or defibrillation device arrives, it is very important to provide uninterrupted, deep chest compressions.\nThe bystander who needs to provide those chest compressions is often a loved one of the victim.\nTwo years ago, after considering multiple studies, the Heart Association recommended hands-only CPR only in cases where people were unwilling or unable to provide the rescue breaths as well.\nThe Heart Association also stressed that three-quarters of sudden cardiac arrest cases outside the hospital occur in the home.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The news article makes it clear that virtually anyone can perform hands-only cardiopulmonary resuscitation (CPR). It requires no devices or drugs. The major barrier to treatment appears to be fear\u2013of harm to the victim or rescuer, and/or and fear of failing to perform CPR correctly.", "answer": 1}, {"article": "In its statement, the panel said that \"for some adults ages 76 to 85, the benefits of screening are smaller, and the potential for harm greater.\nHowever, the U.S. Preventive Services Task Force stopped short of saying any one screening method was better than another.\n\"There are multiple screening options for colorectal cancer that reduce the risk of dying from the disease.\nPeople with disorders or medical histories that raise their odds for colon cancer may need more rigorous screening, the USPSTF said.\nThe USPSTF notes that only one-third of eligible adults in the United States are screened for colon cancer, and more need to take advantage of this effective method of prevention.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that all of the screening tests mentioned in the story are generally available.", "answer": 1}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story identifies several therapeutic apps and, in a video, shows one individual using a \u201cmobile therapy platform\u201d to text and videochat with a therapist.\u00a0 Several comments in the story about the continuing evolution of these applications suggest that these strategies remain works in progress.", "answer": 1}, {"article": "\"Started looking in the cupboard and I saw pie pans and I said, 'These are perfect.\nThe last thing John Kanzius thought he'd ever do was try to cure cancer.\nHere's the important part: if clinical trials pan out - and there's still a long way to go - the Kanzius machine will zap cancer cells all through your body without the need for drugs or surgery and without side effects.\nWell it's true, and if you think it sounds improbable, consider this: he did it with his wife's pie pans and hot dogs.\nKanzius put his hand in the field to demonstrate that radio waves are harmless to humans.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The segment makes clear that the technique is not available for human use. It says it is at least four years away from human trials, assuming all goes well.", "answer": 1}, {"article": "The U.S. Centers for Disease Control and Prevention has more on hepatitis C.\nHowever, Meanwell said, it could become part of a combination treatment of several drugs.\nThe side effects, particularly of the treatment component known as interferon, can be \"pretty hard to deal with,\" said Nicholas A. Meanwell, a co-author of the study and a researcher with the Bristol-Myers Squibb pharmaceutical company.\nCombination treatments using these drugs will become the standard treatment for many people, he said, and boost cure rates into the range of 70 to 80 percent.\nThe greater possibility of a cure and fewer side effects, in turn, will lead more people who think they have hepatitis C to \"come out of the woodwork,\" said Schiff, who's familiar with the study findings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story\u00a0points out that BMS-790052 is in an early phase testing and nowhere near being available to patients, it improperly relayed\u00a0the prediction of a researcher who said that\u00a0two other investigational drugs were expected to become available by 2011. The prediction is especially troubling given the undisclosed financial ties between the researcher and the manufacturers of the investigational agents (see source/conflict of interest criterion below). ", "answer": 0}, {"article": "Tobias Hartmann, the project's coordinator, said, \"We have known for a while that diet can reduce the risk of developing dementia.\nThe clinical trial, headed by Professor Hilkka Soininen is part of a large EC project (LipiDiDiet) to explore the therapeutic and preventative impact of nutrition on neuronal and cognitive performance in ageing, AD and vascular dementia.\nIn addition, earlier randomised controlled trials (RCTs) with the product have shown an improved memory performance in drug-na\u00efve mild AD patients, along with a good safety profile.\nAs part of the LipiDiDiet project, the first randomised clinical trial to investigate the effects of a medical food Fortasyn Connect (Souvenaid), in patients with very early AD (pre-dementia), has just been completed.\nThe project's predecessor, LipiDiet, was incorporated within the 5th EU research programme in 2002.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t state whether the product is available in the United States. It is not. However, the product is marketed widely in Europe under the brand name Souvenaid.", "answer": 0}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article offers no information on availability of the supplement, nor does it reflect on the type of intervention that might make sense to people (i.e., eat lots of cruciferous veggies, take sulforaphane supplements). The basic nature of the research likely makes all of that premature, but that then raises the question of why a media outlet would publicize research at such an early stage.\nAnd this is an important question to ask, because it\u2019s not hard to envision that based on this story alone, companies that make supplements (which are held to a much lower standard of efficacy compared to medication classified as drugs) could start marketing this supplement, and use this single study and news story to back up its usefulness.", "answer": 0}, {"article": ".\nThe current results demonstrate the importance of prompt imaging and treatment of patients with clot-caused stroke, even in those who wake up having experienced a stroke or who for other reasons are not identified in the first few hours after the onset of symptoms.\nThe association has strict policies to prevent these relationships from influencing the science content.\nThe Dallas-based association officially launched in 1998 as a division of the American Heart Association.\n\u2022 Available downloadable B-roll, animation and images to this news tip are on the right column of the tip link https:/\n\u2022 For more news at AHA International Stroke Conference 2018, follow us on Twitter @HeartNews #ISC18.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Unfortunately, this news release did not mention that the results from the DAWN trial contributed to updated guidelines for treatment issued by the AHA and the ASA. While thrombectomy after a stroke is already practiced in many larger centers across the country, it is unclear whether this treatment \u2014 actually an expanded indication for an existing treatment \u2014 will now be offered in more hospitals as a result. The release should have addressed that issue as well as described where the procedure is currently offered.", "answer": 0}, {"article": "Compared to women who received inactive placebo pills, those who took flibanserin at bedtime were more likely to get relief from self-reported sexual distress, to experience more sexual desire, and to have more sexually satisfying experiences.\nThe findings come from phase III clinical trials that drugmaker Boehringer Ingelheim hopes will convince the FDA to approve flibanserin for the treatment of hypoactive sexual desire disorder (HSDD).\nIn the 24-week \"Bouquet\" studies (each of the Boehringer Ingelheim-funded studies is named after a flower), there were few drug-related side effects.\nData suggest that the drug begins to affect sexual satisfaction after four weeks of continuous treatment.\nHowever, it's not an on-demand treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indirectly informs that reader that flibanserin is not available by noting that it is in phase III clinical trials and that the manufacturer\u00a0is seeking FDA approval (despite early direct to consumer marketing campaigns).\u00a0 ", "answer": 1}, {"article": "A little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\nA glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do.\nYou must then summon the speech centers in your frontal lobes, which recruit your breath and muscles and at last allow you to utter the words Hi, Mom.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicates that the highlighted treatment, deep-brain stimulation (DBS) , is a technology used to treat the tremors of Parkinson\u2019s disease, and provides a list of other conditions for which it\u2019s use is being investigated.\u00a0 \nIt would have been best to\u00a0be absolutely clear\u00a0that its use for patients with minimally conscious state is investigational.\u00a0 In the publication describing this case study, the authors state \"\u2026the generalizability of the results is unknown, and expectations raised by this report should be tempered.\" (Nature (2007)448:600-604.\nThe article mentions many conditions for which there does not appear to be FDA approval for the use of this technology.\u00a0 ", "answer": 0}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nCo-authors with Dr. Falk are Liana C. Del Gobbo, PhD, Robin Feldman, MBA, Kara Lewis, PhD, and Dariush Mozaffarian, MD, PhD.\nThis study was supported in part by funds from The International Tree Nut Council Nutrition Research and Education Foundation.\nCWC is an equal opportunity employer and provider.\nFor more industry information, health research and recipe ideas, visit http://www.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Walnuts are widely available so we won\u2019t ding the story for not saying so.", "answer": 2}, {"article": "New vertebral fractures occurred less frequently in the active treatment groups vs placebo: in 0.58 percent (n = 4) of participants in the abaloparatide group; in 0.84 percent (n = 6) of participants in the teriparatide group; and in 4.22 percent (n = 30) of those in the placebo group.\n\u201cFurther research is needed to understand the clinical importance of risk difference, the risks and benefits of abaloparatide treatment, and the efficacy of abaloparatide vs other osteoporosis treatments,\u201d the authors write.\n: This study was funded by Radius Health.\nOverall, there were no differences in serious adverse events between the treatment groups.\nThe trial was conducted at 28 sites in 10 countries.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not make it clear whether the drugs being studied are on the market.", "answer": 0}, {"article": "Hot flashes, which mostly affect women transitioning to menopause and already in that phase of life, involve a sudden sensation of heat, sometimes accompanied by sweating or visible reddening of the skin.\nFreedman said that the overall research on antidepressants and hot flashes is still inconsistent.\nSo far, Freedman noted, the only hot-flash treatment that has consistently worked in studies is hormone replacement therapy (HRT).\nThose findings appear in a separate report in the journal Menopause.\nIn fact, Freedman said, there\u2019s some evidence that lowering serotonin levels does not worsen hot flashes \u2014 which would be expected if the \u201cserotonin theory\u201d is correct.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article made it clear that the use of antidepressants to treat hot flashes was off-label use of the drug. \u00a0Even though the article presented results from studies, it is not clear how widespread is the off-label use of antidepressants to treat hot flashes.", "answer": 1}, {"article": "Dec. 14, 2009 -- Every cup of coffee a person drinks per day may lower the risk of diabetes by 7%.\nThey say several studies have suggested that drinking coffee may lower the risk of developing type 2 diabetes and others have shown that decaffeinated coffee and tea may offer similar benefits, but there has not been a recent review of the research on the issue.\n\u201cDespite considerable research attention, the role of specific dietary and lifestyle factors remains uncertain, although obesity and physical inactivity have consistently been reported to raise the risk of diabetes mellitus,\u201d write researcher Rachel Huxley, DPhil, of the George Institute for International Health, University of Sydney, Australia, and colleagues in the Archives of Internal Medicine.\nOverall, the studies involved nearly a million participants.\nTea drinkers who drank more than three to four cups of tea per day had about a one-fifth lower risk of diabetes than those who didn\u2019t drink tea.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The availability of coffee and tea is not in question.\u00a0 ", "answer": 2}, {"article": "Foods with fiber, such as fruits, vegetables and whole grains, can reduce cholesterol levels, while carbohydrates that are low in fiber tend to raise triglyceride levels and lower \"good\" HDL cholesterol levels.\nWhat effects, if any, the prunes had on cholesterol levels were not mentioned in the study abstract.\nShapiro also advised against making any changes to your medications, including cholesterol-lowering drugs, without talking to your doctor first.\nDespite the addition of several hundred calories a day to their diet, the apple-eating women didn't gain weight over the course of the study.\nThe daily serving of dried apples contained about 240 calories, according to the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The availability of apples is not in question.", "answer": 2}, {"article": "Doppler ultrasound, done in the third trimester, is an established way to monitor high-risk pregnancies \u2014 those complicated by problems like poor fetal growth or health conditions in the mother, such as high blood pressure and heart and kidney diseases.\nAnother question, Alfirevic said, is whether ultrasounds of blood vessels other than the umbilical artery might improve pregnancy outcomes.\nThe review assessed a technology called Doppler ultrasound, which measures blood flow through the umbilical cord.\n\u201cThere is no evidence to suggest that it should be done in low-risk women,\u201d Alfirevic said.\nResearch, according to Alfirevic, has moved on to other questions, including how to best manage abnormal findings from a Doppler scan.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story notes that Doppler is an established technique used to monitor high-risk pregnancies.", "answer": 1}, {"article": "Dr. Eric A. Klein, chairman of the Cleveland Clinic Glickman Urological and Kidney Institute, said that the study \"is confirmatory of a lot of other, smaller studies.\nAnti-hormone therapy was developed to treat the pain and other problems of advanced prostate cancer, Albertsen said, and so it was generally used for only three to five years.\nPrevious studies have shown potential dangers related to androgen deprivation therapy in older men, Keating said.\nDr. Peter Albertsen, a professor and chief of urology at the University of Connecticut Health Center, said that \"the point of this paper is to help physicians understand that long-term use of this therapy carries consequences.\"\nHormone deprivation therapy is started, Keating said, when levels of cancer-associated prostate-specific antigen (PSA) increase after surgery or radiation therapy, but there are no other indicators of danger.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story accurately indicates that androgen deprivation therapy is commonly used in men with prostate cancer.", "answer": 1}, {"article": "\u201cOurs is probably a bottom estimate,\u201d Dr. Cahill said.\nWhile use of the products in such operations has since fallen, one expert said the new report should convince doctors to stop using them in anterior cervical fusions, as the procedure is known.\nHe added that the study also confirmed how quickly physicians had adopted the proteins both for approved and unapproved uses.\nBy 2006, just four years after such products were first sold, the proteins were used in about 25 percent of all spinal fusions, the review found.\nMarybeth Thorsgaard, a Medtronic spokeswoman, said the company was close to completing a clinical trial involving the use of Infuse in anterior cervical fusion.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n \nThe story notes that bone-growth protein infusion received FDA approval in 2002 for use in spinal fusions to treat lower back pain. It reports that by 2006 the proteins were used in about one-quarter of all spinal fusion procedures in the hospitals included in the study, including procedures in other regions of the spine\u00a0\nThe story also states that the use of these proteins in upper spine fusion procedures has dropped following reports of complications.", "answer": 1}, {"article": "If green coffee extract were a medication seeking approval from the Food and Drug Administration, these results would make it a viable candidate \u2014 more than 35% of subjects lost more than 5% of their body weight, and weight loss appeared to be greater while subjects were taking the pills than when they were on the placebo.\nThere were no signs of ill effects on any subjects, Vinson reported Tuesday.\nThe pilot study drew strong cautions from several scientists who weren't involved in the research.\nIn the meantime, he said, consuming an extract that contains both good and bad chemicals in dense concentration seems an unwise thing to do.\nOf the 16 volunteers, six wound up with a body mass index in the healthful range.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "One can infer the availability of the extract from the story.", "answer": 1}, {"article": "For more information, see www.scripps.edu.\nThe antibiotic has been prescribed by doctors for 60 years, and bacteria are only now developing resistance to it.\nThe next step in this research is to design a way to synthesize the modified vancomycin using fewer steps in the lab, as the current method takes 30 steps.\n\u201cMaking this molecule is important, even by the current approach, if the failure of antibiotics continues.\u201d\n\nIn addition to Boger, authors of the study, \u201cPeripheral modifications of [\u03a8[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics,\u201d included first author Akinori Okano and Nicholas A. Isley, both of TSRI.\nBut Boger calls this the \u201ceasy part\u201d of the project, compared with the challenge of designing the molecule in the first place.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release says that \u201cThe next step in this research is to design a way to synthesize the modified vancomycin using fewer steps in the lab, as the current method takes 30 steps. But [lead researcher Dale] Boger calls this the \u2018easy part\u2019 of the project, compared with the challenge of designing the molecule in the first place.\u201d Readers could be forgiven for thinking that this modified antibiotic could be in pharmacies by Christmas. But a lot of work remains to be done, in terms of both additional studies on safety and efficacy and (presumably) finding pharmaceutical industry partners who want to help this discovery move beyond the lab bench. We say presumably, because the release doesn\u2019t address either of these hurdles.", "answer": 0}, {"article": "\"What we found was a very coherent pattern of less cervical cancer among people who\u2019ve used the IUD based on thousands of women \u2014 and the pattern wasn't subtle at all, it was stunning,\" Dr. Victoria Cortessis, the study's lead author and associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California, told BuzzFeed Health.\n\nIUDs are small, T-shaped devices that are placed in the uterus to prevent sperm from reaching an egg. They are a highly effective form of birth control and they can offer protection against pregnancy for up to three, five, or ten years.\n\nThe study is the first of its kind to combine and analyze data from multiple studies to look at the issue. \"We went through all of the relevant human epidemiological data on this topic and narrowed it down to 16 high-quality observational studies of over 12,000 women from all over the world,\" Cortessis says.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "IUDs have been available to women for decades. The only issue the story might have considered further is how available they are in low-income nations where vaccines and regular screening are not accessible to many women.", "answer": 1}, {"article": "Smokers who count on nicotine patches or gum to help them quit may want to reconsider: A new study finds that these and other nicotine replacement products aren't effective at preventing former smokers from relapsing in real-world conditions.\nBut the latest results are in line with other studies that have found little \u2014 if any \u2014 benefit from the products when used by smokers in real life.\nThe findings run counter to the results of several randomized clinical trials conducted before the Food and Drug Administration gave the thumbs-up to these nicotine replacement products in the 1990s.\nThose who had used nicotine patches, gum, inhalers or nasal sprays were just as likely to relapse as those who had quit without them, researchers from Harvard University and the University of Massachusetts found.\nIn those trials, volunteers using such products were up to three times more likely to kick the smoking habit.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story basically used sales information to indicate availability. We did appreciate that this story mentioned a wide variety of nicotine products, including nasal sprays.", "answer": 1}, {"article": "Patients getting canakinumab also suffered significantly more deaths from infections than those on placebo - but, on the positive side, they appeared to be at lower risk of cancer.\nCanakinumab had stirred considerable scientific interest because it appears to finally deliver proof that fighting inflammation offers a promising new way to counter heart disease in patients who already get cholesterol-lowering treatment.\nOne leading expert described the benefit as \u201cmodest\u201d.\n\u201cIn view of the additional oncology findings, we don\u2019t think you should just think about this as a cardiovascular drug,\u201d Narasimhan said.\n\u201cIf the company cuts the price of the product in its current orphan indications, then it instantly sacrifices sales which currently total about $400 million per year with the hope that future sales in a new CV setting will more than offset this,\u201d Anderson said in a note.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The lede graph says \u201cNovartis will seek regulatory approval\u201d for the drug\u2019s use against heart disease, \u201cthough some experts fear fatal infection risks and a high price may overshadow the medicine\u2019s limited scientific benefits.\u201d At least for now.", "answer": 1}, {"article": "The meeting is jointly sponsored by the Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research.\nPatients in this clinical trial were left with the bacterial infection for one week, and then everyone was given antibiotics to kill off the Clostridium novyi-NT, Janku said.\nA potentially dangerous bacteria appears to target malignant cells and could provide a new means of fighting cancer, a small, preliminary study reports.\nResearchers have moved on to the next phase, in which patients taking the immunotherapy drug pembrolizumab (Keytruda) will also be treated with a single injection of Clostridium novyi-NT, Janku said.\nFirst, the bacterial infection itself could cause direct destruction of the tumor cells, Janku said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that researchers are still studying this approach, implying it\u2019s not available widely.", "answer": 1}, {"article": "\"In most cases, a recall doesn't mean you have cancer,\" says Hubbard, a biostatistician at the Group Health Research Institute in Seattle.\nAfter 10 years of annual screening, more than half of women will be called back at least once for another mammogram.\nThe task force says the decision to start regular, biennial mammograms before age 50 should be an individual choice based on each patient's situation.\nThose false-positives may cause inconvenience and anxiety, and biopsies can cause pain and scarring, the researchers note.\nMeanwhile, the American Cancer Society continues to recommend that women get mammograms every year beginning at age 40.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Screening mammography is widely available throughout the United States.", "answer": 2}, {"article": "\"My impression is, even with the newer band, the results are not significantly better,\" he says.\nBut a spokesman for the company that manufactures Lap-Band says the study is flawed.\nThe critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\nBut some, including the manufacturer of the Lap-Band -- used in a technique called laparoscopic adjustable gastric banding -- take exception to the study, criticizing the small sample size and the number of patients lost to follow-up.\nEven so, a majority of the patients in their small study said they were satisfied with the procedure.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the gastric banding procedure is available and provides a link to information from the National Institutes of Health.", "answer": 1}, {"article": "He walks about 50,000 steps a week, golfs, works out and tap dances and consumes about 1,800 daily calories.\nThat means lifestyle changes were twice as effective as medicine in delaying or preventing diabetes.\nThat was 10 years ago, when he joined the Diabetes Prevention Program Outcomes Study with the University of Pittsburgh Graduate School of Public Health, one of 27 institutions participating in the research.\nThe prevalence of diagnosed diabetes has more than doubled in three decades due in large part to an upsurge in obesity, the study states.\nThat's to say, he's delayed the onset of type 2 diabetes and potentially can prevent the onset for the rest of his life.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The reporter fails to mention how and where diabetes prevention programs are available.\nLifestyle-modification diabetes prevention programs are a staple offering of hospitals, community centers, insurance companies and corporate wellness programs. The article could at least have mentioned this\u2013and provides a local resource\u2013to allow readers to follow up if they wanted to.\nMany people with high blood sugar but not diabetes take metformin as prevention. It would be useful to know how widely used the treatment is. ", "answer": 0}, {"article": ".\nDr. Wally Ghurabi, emergency department director at Santa Monica-UCLA Medical Center, said a group of ongoing studies there include a similar focus on MRIs and stroke.\nThe study, reported online Nov. 2 and in the December issue of the journal Radiology, reinforces results from similar research, Oppenheim said.\nWith the MRI data, radiologists could predict with more than 90 percent accuracy which patients had experienced stroke symptoms for longer than three hours.\nOppenheim said the next step would be clinical trials to validate whether MRIs serve as a \"surrogate clock\" for stroke onset.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have done a better job raising the question of availability of MRI around the US for urgent use at times like those described in the story or in the study \u2013 when there is a question about the 3 hour window. \u00a0The story alluded to this but was not fully discussed in the context of availability of treatment. Do 80% of hospitals or hospital regions have MRIs ready for this use?\u00a0 50%?\u00a0 10%? Availability of the technology in question is a key concern \u2013 with huge cost implications.", "answer": 0}, {"article": "Andrew Keaveney, now 73, shattered his ankle in a fall from a truck while hanging flags as an American Legion volunteer.\nThe procedure is among the most difficult that foot and ankle surgeons perform, and one of the biggest challenges is getting proper alignment of the replacement joint.\nEven with a successful implantation, patients should not necessarily expect to have the same ankles they did at 18.\nDr. Deland cited data showing that for some recent models, 90 percent of ankle replacements were still in place after an average of eight and a half years.\nDr. Brian Donley, an orthopedic surgeon who is director of the foot and ankle center at the Cleveland Clinic, says patients should always ask their doctor to disclose any financial interest in a device.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story correctly notes that ankle replacement has been available for\u00a0several\u00a0decades but is not\u00a0widely performed.\u00a0 However, there was an omission in not indicating that\u00a0that knee and hip replacement are\u00a0most often associated with osteoarthritis, the most common form of arthritis, while ankle replacement is largely\u00a0performed in patients with post-traumatic osteoarthritis and the much less common rheumatoid arthritis.\u00a0\u00a0 In addition, the article inaccurately states that 4 models are FDA\u00a0approved.\u00a0 A fifth model, the STAR,\u00a0which has\u00a0a unique design, was FDA approved in May 2009.", "answer": 1}, {"article": "Michael T. Lotze, a professor of surgery and bioengineering at the University of Pittsburgh, said that \"the work is heroic.\nThe new report, however, is believed to be the first time that genetically engineered immune system cells -- specifically, T lymphocytes -- have produced the same effect.\nWhile the good results in two patients are encouraging, \"in terms of response rates, the overwhelming data is that T cells, even in high numbers, are inadequate to mediate sufficient anti-tumor effects,\" Lotze said.\nThe report, published online by the journal Science, is the latest result of a three-decade effort by surgeon Steven A. Rosenberg to find ways to manipulate the human immune system to fight cancer.\nResponse by others in the field was positive but not effusive.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that for now only 17 patients have undergone the experimental approach as part of an ongoing and novel study and mentions that the researchers have recently applied to the FDA for approval to conduct a clinical trial in several hundred patients. If approval is obtained, then it is possible that patients without other treatment options might be able to participate in the trial. The article did not specifically state that the approach is not widely available yet, but this can be inferred. However it is important for patients to understand that participation in a trial is not the same as receiving treatment. ", "answer": 1}, {"article": "The F.D.A.\ninstead said it wanted more proof that the drug worked and would await results from a trial that was then under way.\nAnd the drug failed to do that by a statistically significant measure.\nDr. Gold said there were about 100,000 men who get such a diagnosis each year.\nJudy Leon, a spokeswoman for the F.D.A., said the agency sympathized with patients but that it was necessary for drugs to meet agency standards for safety and efficacy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story describes the findings of the clinical trial as \"decisive,\" and speculates the \"widely anticipated results could pave the way\" for the drug\u2019s approval. \nThe result is to imply imminent availability, an outcome that is by no means certain.\u00a0 ", "answer": 0}, {"article": "But when the Toronto-based artist and mother puts on a new kind of camera-equipped headgear, she looks at me like no one has before.\nThe visor that allows legally blind people to see is no longer Star Trek fiction.\nGeoffrey A. Fowler discusses the headset with Yvonne Felix, a blind artist and supporter of the technology.\nA next-generation visor from eSight can improve vision for many legally blind people.\nPhoto/Video: Emily Prapuolenis/The Wall Street Journal\n\nYvonne Felix\u2019s eyes don\u2019t work well enough on their own for her to read, recognize faces or cross the street without help.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the eSight is cleared by the FDA as a Class I\u00a0device \u2014 something that\u2019s presumably about as safe as dental floss (which is also a Class I device, according to the FDA). The story mentions that most insurance carriers reject compensation, which itself implies the eSight 3 is freely available to anyone as long as they have $10,000.", "answer": 1}, {"article": "Jan. 18, 2011 -- Low doses of the antidepressant Lexapro (escitalopram) cooled off hot flashes better than placebo in about 200 menopausal women, according to a new study.\nPrevious studies of other antidepressants have yielded mixed results, according to Freeman.\nIn the study, Freeman found the antidepressant reduced both the number and severity of hot flashes compared to placebo.\nThe findings are published in TheJournal of the American Medical Association.\n''We believe escitalopram provides an option for treating moderate to severe hot flashes that are disrupting people's lives and quality of life,\" says study researcher Ellen Freeman, PhD, a research professor in the department of obstetrics-gynecology and psychiatry at the University of Pennsylvania School of Medicine, Philadelphia.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Barley reduced both low-density lipoprotein, or LDL, and non-high-density lipoprotein, or non-HDL, by seven per cent.\nDespite its benefits Dr. Vuksan said barley is not as well-established as some other health-recommended foods -- such as oats.\nThe research review, published today in The European Journal of Clinical Nutrition, included 14 studies on clinical trials conducted in seven countries, including Canada.\nDr. Vuksan said barley can be enjoyed in a variety of ways.\nIt is the first study to look at the effects of barley and barley products on both LDL and non-HDL cholesterol in addition to apolipoprotein B, or apoB, a lipoprotein that carries bad cholesterol through the blood.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We learn that barley is everywhere, readily available and ready to add to your food.", "answer": 1}, {"article": "So patients are caught in the middle.\"\nIn an editorial accompanying the new paper, another addiction and pain specialist, William C. Becker, Ph.D. of Yale University and the Connecticut VA, notes that the new results are even more impressive because ImPAT was compared with another psychosocial approach.\nAnd the study's authors note that the ImPAT approach has the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\nThe larger ongoing study, based in an abstinence-based treatment facility in Michigan and funded by the National Institute on Drug Abuse, has largely avoided that issue by decreasing the delay between study recruitment and the start of the treatment groups, Ilgen says.\nANN ARBOR, Mich. -- It's a Catch-22 with potentially deadly consequences: People trying to overcome addiction can't get treatment for their pain, because the most powerful pain medicines also carry an addiction risk.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that researchers have launched a larger, follow-up study of ImPAT, and that ImPAT could potentially be widely adopted. That seems to infer that ImPAT is not currently available outside of the treatment facility where the researchers work. However, it\u2019s not clear whether that\u2019s the case. Are other facilities offering this treatment technique, or something like it? Readers really have no way of knowing.", "answer": 0}, {"article": "While smoking is a public health scourge, the nicotine in cigarettes may have some promise in treating another growing problem, mild cognitive impairment (MCI), which can be a precursor to Alzheimer\u2019s disease or other forms of dementia.\nHowever, when clinical experts rated overall general change in the patients, they did not see a significant difference between the two groups.\nMORE: Is Nicotine a \u2018Gateway\u2019 to Cocaine Addiction (and Cancer)?\nWas the nicotine actually having an effect on memory?\nPatches were provided by the manufacturer, Pfizer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re going to rule this one Not Applicable because \u2013 while availability was not explicitly addressed \u2013 this is a product that\u2019s probably well known to most readers.\u00a0 However, both stories we reviewed could have been more specific about the exact types of patches that were studied and in what doses.", "answer": 2}, {"article": "(\u201cEnjoyed\u201d?\nThe mice with running wheels voluntarily ran an average of more than six miles a night, decreasing to about two miles late in pregnancy.\nThe research in question involved mice, not women.\nSo maybe women who won\u2019t exercise for their own sake will do it for the baby.\nThe Baylor scientists were able to correct for those variables.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Running as an activity is presumably accessible to\u00a0women.", "answer": 2}, {"article": "Dr Carol Routledge, from Alzheimer's Research UK, said: \"The diseases that cause dementia begin in the brain up to 20 years before any symptoms start to show, presenting a vital window of opportunity for us to intervene before widespread damage occurs.\nThe Alzheimer's algorithm was able to teach itself to recognize patterns in brain scans that indicated disease.\nDoctors used the self-learning computer to detect changes in brain scans too subtle for humans to see.\nIt proved to be 100 percent accurate at detecting Alzheimer's disease many years before the patient was later diagnosed.\n\"It was able to predict every single case that advanced to Alzheimer's disease.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this machine-learning technology is not yet available and needs further study.", "answer": 1}, {"article": "\u201cIt may provide more of a one-stop shop.\u201d\nThe developer, Ironwood Pharmaceuticals, said the drug, linaclotide, met all the goals in the first late-stage trial testing it as a treatment for the type of irritable bowel syndrome accompanied by constipation.\nLaxatives can relieve the constipation but often do not help with the pain, said Dr. Chey, who is a consultant to Ironwood.\nAn experimental drug can reduce abdominal pain and increase bowel movements in people with irritable bowel syndrome, a condition that affects millions of Americans, the drug\u2019s developer said Monday.\nIf the drug succeeds in a second Phase 3 trial, with results expected by the end of the year, Ironwood plans to file for regulatory approval next year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this is an experimental drug that is not yet approved by the FDA. It notes that the drug will have to succeed in another phase 3 trial before the manufacturer plans to submit an application for approval to the FDA. It doesn\u2019t speculate inappropriately about when the drug is expected to be approved.", "answer": 1}, {"article": "\u201cBut it is definitely a breakthrough.\nThe study\u2019s authors noted that patients would need to stay on the drug in order to receive protection against the allergy.\n\u201cReactions from the oral challenges at the end of the study were much milder than prior to treatment,\u201d Tilles said, according to EurekAlert.\nWhile the drug is not being hailed as a cure for peanut allergy, it has proven successful in building up patients\u2019 tolerance to peanuts over time, lessening the potential for life-threatening complications.\nIn addition, the symptoms caused by the 100-fold higher dose at the end of the study were milder than the symptoms on the lower dose at the beginning of the study.\u201d\n\nEXPERTS: CHILDREN AT RISK OF LEAD POISONING IN CHATTANOOGA\n\nWith FDA approval this drug would mark the first treatment available by prescription for peanut allergies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the treatment is not yet FDA-approved, and is not currently commercially available.", "answer": 1}, {"article": "March 7, 2011 -- Traditional Chinese acupuncture may be useful in reducing the severity of hot flashes and other symptoms of menopause, a new study suggests.\nTwenty-seven women received traditional Chinese acupuncture twice a week for 10 sessions from an experienced and licensed acupuncturist.\nA five-point scale was used to measure the severity of hot flashes, vaginal dryness, urinary symptoms, mood swings, and other symptoms in the postmenopausal women.\nThose in the comparison group were treated with shams needles at the same acupuncture points.\nHalf of them received traditional acupuncture treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No discussion of the availability of acupuncture.\u00a0 Picture a woman who\u2019s just begun experiencing menopause and has never had any reason to think about acupuncture.\u00a0 She reads this story about Turkish research on Chinese acupuncture.\u00a0 Even if she\u2019s interested, she is not given any clue about the availability of the approach in the U.S.", "answer": 0}, {"article": "Hot flashes and night sweats are the most common symptoms of menopause, affecting some 80% of women.\nThe progression is familiar to most women of a certain age.\nThe alternative therapy reduced hot flashes by as much as 74% in the study conducted by researchers at Baylor University\u2019s Mind-Body Medicine Research Laboratory and funded by the National Institutes of Health.\nA total of 187 postmenopausal women who reported having at least seven hot flashes a day, or 50 a week, were recruited for the trial.\n\u201cIf you compare this treatment with off-label use of antidepressants or other non-hormonal therapies, it works as well or better,\u201d he says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It wasn\u2019t clear whether a clinician could conduct the self-hypnosis trainings, or whether the patient needed to find another certified professional. And how were the hypnotic recordings obtained?\u00a0 Towards the end, the story does include the comment about finding a qualified hypotherapist. But readers aren\u2019t given any sense of how easy/difficult that might be.", "answer": 0}, {"article": ".\nIn the end, fennel was concluded to be a safe and effective treatment to reduce menopause symptoms without serious side effects.\nIn this small trial of 79 Iranian women aged 45 to 60 years, soft capsules containing 100 mg of fennel were administered twice daily for eight weeks.\nImprovements were compared between the intervention and placebo groups at four, eight, and 10 weeks, with a significant statistical difference documented.\n\"A larger, longer, randomized study is still needed to help determine its long-term benefits and side effect profile.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll rate this Not Applicable since most readers will likely be aware that fennel can be purchased and that supplements are available. However, as noted above, it\u2019s not clear at all how 100 mg doses are formulated.", "answer": 2}, {"article": "However, contrary to the popularly held belief that a greater number of concussions are linked to CTE , no connection was found between levels of CCL11 and reported number of concussions.\nAn early step in the right direction\n\nMcKee also cautioned that this is still early research.\n\"This may be one of the abnormalities [of the disease], but it may take 2-3 to be useful to diagnose CTE,\" said McKee.\n\"The findings of this study are the early steps toward identifying CTE during life.\nWhile it is hoped that this will be one avenue to help detect the disease in the living, McKee believes that it will just be one part of a larger process.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Once readers get past the first couple paragraphs, the story makes clear that this research is far removed from clinical applications.", "answer": 1}, {"article": "Inflammation can make urination difficult.\nCase Western Reserve dental researchers Nishant Joshi, Catherine Demko and Robert Skillicorn; and University Hospitals Case Medical Center researchers Donald Bodner, Lee Ponsky, Sanjay Gupta and Gregory T. MacLennan contributed to the study.\n\"This study shows that if we treat the gum disease, it can improve the symptoms of prostatitis and the quality of life for those who have the disease,\" said Nabil Bissada, chair of Case Western Reserve's Department of Periodontics and the new study's corresponding author.\nResearchers found 21 of the 27 participants had no or mild inflammation, but 15 had biopsy-confirmed malignancies.\nThose with the highest levels of inflammation benefited the most from the periodontal treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release suggests that dental care should probably be a routine part of efforts to control prostate disease, but doesn\u2019t address the issue of financial barriers\u00a0to such care, particularly for the uninsured. But we\u2019re inclined to overlook this because of the nature of the study: it\u2019s a pilot; it was designed to add to evidence for a relationship between gum and prostate disease via an inflammatory process; and the dental care involved is widely available and commonly provided to those who have regular dental care.", "answer": 1}, {"article": "In the study, four groups of mice received different diets -- two of which were supplemented with green tea or black tea extracts:\n\nAfter four weeks, the weights of the mice that were given green or black tea extracts dropped to the same levels as those of the mice that received the low-fat diet throughout the study.\nBenefits of green tea were already known; new UCLA study shows that polyphenols in both varieties alter gut bacteria\n\nUCLA researchers have demonstrated for the first time that black tea may promote weight loss and other health benefits by changing bacteria in the gut.\nThe new study also concluded that both green tea and black tea have different effects on liver metabolism.\nThe new findings show that black tea polyphenols, which are too large to be absorbed in the small intestine, stimulate the growth of gut bacterium and the formation of short-chain fatty acids, a type of bacterial metabolites that has been shown to alter the energy metabolism in the liver.\nPrevious studies indicated that chemicals in green tea called polyphenols are absorbed and alter the energy metabolism in the liver.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Black and green tea are widely available so mentioning that fact is unnecessary.", "answer": 2}, {"article": "\u201cIt\u2019s easier to pop a pill,\u201d Dr. Altman said.\nBut a number of new controlled trials and meta-analyses like Dr. Moore\u2019s suggest that topical Nsaids are as effective as their oral counterparts for treating osteoarthritis in the knee and hand as well as musculoskeletal injuries like soreness and tendinitis.\n\u201cNow that you can just write a prescription, I use them in my practice a lot more.\u201d\n\nSince the Food and Drug Administration approved the first topical Nsaid in 2007, sales in the United States have soared \u2014 to more than $264 million in 2009, according to IMS Health, a health care research company.\n\u201cSuddenly there were tons of folks who thought topical Nsaids were a good idea.\u201d\n\nDr. Roy D. Altman, a rheumatology professor at the David Geffen School of Medicine at the University of California, Los Angeles, said the drugs might be especially helpful for \u201cthe elderly or those taking multiple medications, who were not getting treated but who can now use topical Nsaids and get some benefit.\u201d\n\nAnother leading pain researcher, Dr. Roger Chou, an associate professor of medicine at Oregon Health and Science University, noted that the skin creams delivered \u201cvery high joint concentrations of the topical Nsaid, higher than with standard oral doses, with very low blood levels\u201d \u2014 less than 5 percent of those found with oral Nsaids.\nIn clinical trials, the skin creams are linked to a higher rate of redness, irritation and rash.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n\nThe story reports that only three topical NSAIDs (nonsteroidal anti-inflammatory drugs) are approved for sale with a prescription in the United States, while several brands are sold over the counter in Europe. ", "answer": 1}, {"article": "that its retinal cells contained virtually no residual embryonic stem cells.\nDr. Peter J. Francis, an associate professor at the Oregon Health and Science University, which will be a site for the trial, says the eye is a good place to test stem cell therapy because it is accessible.\nThe hope is that the implanted cells will replace those injured by the disease.\nIt is likely to be several years before such a treatment can reach the market, if it works.\nRegeneron and its partner, Bayer, said they planned to apply for approval of the drug in the first half of 2011.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story calls VEGF Trap-Eye \u201cexperimental\u201d and says the drug\u2019s developers\u00a0plan to\u00a0apply for approval of the drug in the first half of 2011.", "answer": 1}, {"article": "\"These cells proliferated rapidly, and were susceptible to damage to their DNA - both factors that help them transition towards cancer,\" she said.\nAustralian researchers have discovered that an existing medication could have promise in preventing breast cancer in women carrying a faulty BRCA1 gene.\nIf confirmed in clinical studies, this would provide a non-surgical option to prevent breast cancer in women with elevated genetic risk.\nBy pinpointing the cells that give rise to breast cancers in women who have inherited a faulty version of the BRCA1 gene, Walter and Eliza Hall Institute researchers have identified that the drug denosumab may have potential to prevent breast cancer from developing.\nProfessor Lindeman, who is also a medical oncologist at The Royal Melbourne Hospital, said the discovery of RANK as a marker of cancer precursors was an important breakthrough, because inhibitors of the RANK signalling pathway were already in clinical use.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that denosumab is already used to treat other conditions, but that clinical trials are needed to determine whether denosumab should be used to reduce breast cancer risk for women with the BRCA1 mutation.", "answer": 1}, {"article": "\"They are so good for you,\" Greene said.\nOne serving of blueberries or strawberries equals about one cup.\nThis held true even among women who ate a diet rich in other fruits and vegetables.\nWhat does a heart attack look like in women?\nDuring the study period, 405 participants had heart attacks.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of strawberries and blueberries is not in question.", "answer": 2}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that these drinks are widely available. ", "answer": 1}, {"article": "Tobacco kills one-third to one-half of those who smoke.\n\u201cThis important laboratory study, together with prior laboratory and epidemiology research, suggests that metformin may be useful in cancer prevention and treatment,\u201d said Dr. Michael Pollak of McGill University in Montreal, who wrote a review on metformin research in the same journal.\nThe findings were so strong the team now wants to test it in smokers to see if it can keep then from developing tumors.\nThey said metformin prevented lung tumor growth in mice exposed to a cancer-causing agent found in tobacco smoke, and because it is already widely used in people, it may be worth further study.\n\u201cAlthough smoking cessation is the most important step for current smokers, over half of lung cancer cases are diagnosed in former smokers, raising the importance of identifying those at highest risk and identifying effective preventive treatments,\u201d Dennis, whose findings were published in the journal Cancer Prevention Research, said in a statement.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says metformin \"is already widely used in people.\" ", "answer": 1}, {"article": "Modern water dispensers may be more effective than old-fashioned water fountains since water quality and cleanliness may deter kids from using older fountains, and they're not as efficient at serving large numbers of children, experts noted in an accompanying editorial.\nThe editorial, entitled \"Power of a Simple Intervention to Improve Student Health: Just Add Water,\" said the study's findings are significant.\n\"The study by Schwartz and colleagues in this issue of JAMA Pediatrics adds to a growing body of evidence supporting the importance of providing drinking water access in schools.\nIn this study, the findings demonstrate that water access in schools can promote healthy weight outcomes among students,\" Turner and Hager said.\nThe study, published in JAMA Pediatrics, analyzed data collected from 1,227 elementary and middle schools across New York City - some with and some without \"water jets.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of water dispensers is not in question, which is why we rate this Not Applicable.", "answer": 2}, {"article": "(Reporting by Susan Kelly, editing by Dave Zimmerman)\n\u201cWhat we\u2019ve been able to show is that by combining this technology, you can lower the A1C, which reduces your risk of complications, and you can do it safely without increasing your rate of hypoglycemia,\u201d said study author Dr. Richard Bergenstal, executive director of the International Diabetes Center at Park Nicollet Health Services in Minneapolis.\nBergenstal said patients who are not achieving their goals with multiple daily injections should consider using a pump and sensor.\nPatients in the study, which was presented at a meeting of the American Diabetes Association in Orlando, Florida, and sponsored by Medtronic, achieved better glucose control over a one-year period without an increase in hypoglycemia, or dangerously low blood sugar.\nAdult and pediatric patients using the pump and continuous glucose monitoring device saw reductions in levels of A1C, a commonly used measure of blood sugar, that were four times greater than those who received regular insulin injections in the study of 485 patients ranging from age 7 to 70.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nThe story points out that these results are from a post-market study, thus indicating the device is already available. However, an editorial in the New England Journal of Medicine accompanying the research article made an important point that was not included in the study: devices are not enough, effective glucose management requires effective management\u2026 and the \u201cexpert training and guidance received by patients in clinical trials cannot be readily duplicated in a busy clinical practice.\u201d In other words, the results of this trial may not necessarily be achieved in general clinical practice because while the devices tested are widely available, expert support services are not.\n", "answer": 1}, {"article": "Feb. 10, 2011 (Los Angeles) -- Giving clot-busting drugs to people with mild strokes could prevent more than 2,000 of them from becoming disabled each year, researchers say.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nThose parts of the brain soon start to die.\nBut people with mild strokes are typically denied tPA because the studies that established its effectiveness excluded mild cases, says Pooja Khatri, MD, of the University of Cincinnati.\nIt's been assumed that people with mild strokes \"generally [do] well and the risk of tPA treatment, which includes a slight but significant risk of life-threatening bleeding in the brain, would not be worth the benefit,\" she says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story isn\u2019t crystal clear on the widespread availability of the drug tPA but it can be inferred from the story.", "answer": 1}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that cupping treatment is available through acupuncturists, chiropractors and massage therapists.", "answer": 1}, {"article": "Anton P. Porsteinsson, MD, Professor of Psychiatry at the University of Rochester School of Medicine and Dentistry and Director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester in Rochester, NY, and an investigator in the North American Phase 3 clinical trial, commented: \"The genetically-defined population of APOE4 carriers has an 8-12 fold increased risk of developing AD and has more rapidly progressive disease, usually becoming symptomatic a decade earlier than non-carriers of the APOE4 genotype.\nBased on the analyses in the publication, Alzheon is developing ALZ-801, an optimized oral prodrug of tramiprosate, and has refined the design of the pivotal clinical trial to evaluate ALZ-801 as a potential disease-modifying agent in symptomatic AD patients who are APOE4/4 homozygotes.\n\"Replication of these findings in Alzheon's planned Phase 3 study would provide a meaningful therapeutic advance for AD patients with the APOE4/4 genotype, and we are now preparing to carry forward these results into the development of ALZ-801.\"\nThe results published in JPAD are the first evidence from a large clinical trial to associate efficacy of an amyloid-targeted agent with APOE4 status in AD patients.\nThe efficacy and safety analyses with tramiprosate published in JPAD reveal a therapeutic effect in patients who are carriers of APOE4 after segmenting them from the larger, non-genetically-defined study population in the Phase 3 clinical program, involving more than 2,000 AD patients in North America and Europe.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states the drug is in on-going trials and one can infer the drug is not and will not be available in the foreseeable future. It describes next steps: \u201cWe are preparing to advance ALZ-801, a promising new treatment for Alzheimer\u2019s disease, into confirmatory clinical studies in 2017.\u201d", "answer": 1}, {"article": "Flu season has already begun, and last year\u2019s was one of the most lethal in decades; about 80,000 Americans died of flu or its consequences, the Centers for Disease Control and Prevention said earlier this month .\nThe pill will cost $150, according to a spokeswoman for Genentech, which will sell Xofluza in this country.\nThe first new flu drug in 20 years won approval Wednesday from the Food and Drug Administration.\nGenentech will offer coupons that lower the price to $30 for patients with health insurance and to about $90 for the uninsured.\nstill strongly recommends that every American over the age of six months get a flu shot as soon as possible.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Xofluza has received FDA approval.", "answer": 1}, {"article": "A health claim, in the language of the FDA, characterizes the relationship between a substance and a reduction in the risk of contracting a particular disease.\nNonetheless, the belief that drinking green tea confers health benefits has driven its popularity over the past decade, the Tea Association of the United States has said.\n\"There is no credible evidence to support qualified health claims for green tea or green tea extract and a reduction of a number of risk factors associated with (cardiovascular disease),\" the FDA said on its Web site last week.\nThe Food and Drug Administration said it reviewed 105 articles and other publications submitted as part of the petition but could find no evidence to support claims of the beverage's health benefits.\nIto En Ltd., a Japanese company that bills itself as the world's largest green tea company, and its U.S. subsidiary, Ito En (North America) Inc., petitioned the FDA in June, seeking to make the claim that drinking at least five ounces of green tea a day may reduce the risk of heart disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article explained that green tea is made from unfermented tea leaves and mentioned that its popularity had grown over the last decade. ", "answer": 1}, {"article": "Prostate cancer is very common, showing up in 240,000 U.S. men every year.\nIt\u2019s yet another piece of evidence showing that the so-called Western diet can worsen the risks for cancer, as well as all sorts of other diseases from heart disease to Alzheimer\u2019s.\n\u201cOur findings with Western diet and prostate cancer-specific mortality, however, were surprising, in part because there are very little data regarding how diet after diagnosis may impact disease prognosis.\u201d\n\nThe findings could be important for many men.\nSo-called Mediterranean-style diets, with plenty of fresh vegetables and fruit, olive oil instead of saturated fat, whole grains and more fish than meat, ward off these same diseases.\nMany studies have shown it doesn\u2019t take a whole lot of adjustment to greatly lower the risks.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "With some notable exceptions, such as \u201cfood deserts\u201d in areas of high poverty, prudent diets are widely accessible and the article spells this out pretty well.", "answer": 1}, {"article": "Oct. 18, 2010 -- Vitamin B12 may help protect the brain against Alzheimer's disease, according to new evidence that suggests the vitamin and an amino acid called homocysteine may both be involved in the development of Alzheimer\u2019s.\nBlood levels of folate, another nutrient believed to lower homocysteine levels, were not linked to Alzheimer's disease risk.\nDuring the study, published in Neurology, 17 people developed Alzheimer\u2019s disease.\nIn addition, each micromolar increase in blood homocysteine level raised the risk of Alzheimer's disease by 16%.\nHigh levels of vitamin B12 in the blood are already known to help reduce levels of homocysteine, which has been linked to an increased risk of Alzheimer's disease, memory loss, and stroke.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "If an AAA is found, doctors sometimes use a stent to repair the aorta, but it doesn't always work since the aneurysms are often in places where a stent can\u2019t fit.\nWe can anticipate challenges by practicing the procedure beforehand.\u201d\n\nSo far doctors at Mayo Clinic have done this personalized procedure on more than 450 patients.\nBy using 3-D printing technology, Oderich's team can create an individualized model of the patient's aorta.\nAnd even if the stent does fit, patients often undergo a long, painful recovery.\n\u201cEvery patient differs in their aortic anatomical geometry so it can be hard to precisely ascertain the perfect sized graft, despite advances in CT imaging techniques, but newer patient-specific 3-D printed models may circumvent these challenges.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states: \u201cSo far doctors at Mayo Clinic have done this personalized procedure on more than 450 patients. They are now training doctors nationally.\u201d It\u2019s not clear how many doctors are being trained.\nAlso, we\u2019re assuming they\u2019re referring to the 3-D printing aspect of this procedure. But regarding the endoscopic procedure, it\u2019s not clear how widely available it is. It\u2019s also not clear if this custom-printed device is\u00a0still being tested in clinical trials.", "answer": 0}, {"article": "In this study, these induced pluripotent stem cells were then directed toward a neural progenitor cell fate, known as induced neural progenitor stem cells, or iNPCs.\nThis work was supported by the Simon and Beathrice Apple Stem Cell Fund for Eye Research, the David and Janet Polak Foundation Stem Cell Core Laboratory; National Institutes of Health (R01 EY020488), Department of Defense (W81XWH-12-1-0617), Foundation Fighting Blindness and the Knights Templar Eye Foundation Inc.\n\u201cThough additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.\u201d\n\nNext steps include testing the efficacy and safety of the stem cell injection in preclinical animal studies to provide information for applying for an investigational new drug.\nCurrently, there is no treatment that slows the progression of the disease, which is the leading cause of vision loss in people over 65.\nThe stem cell injection resulted in 130 days of preserved vision in laboratory rats, which roughly equates to 16 years in humans.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release suggests, through researcher quotes and other descriptions that this treatment may be just around the corner.\u00a0 That is clearly an exaggeration.\u00a0 The researchers still need more work in animal models.\u00a0\u00a0 Then they will require FDA approval for an investigational drug.\u00a0 If that comes about, then substantial clinical trials in humans will be needed.\u00a0 All told, that could mean\u00a0years of additional wor, before the procedure might be available for people.\nIs that how you would define \u201csoon\u201d or \u201cclose to a time\u201d?", "answer": 0}, {"article": "(That\u2019s a high dose; a 3 oz.\nIt\u2019s the first encouraging strategy for protecting the heart a heart attack; the more remaining healthy tissue that can be saved, the stronger the heart will be.\nThe effects remained strong even after the researchers accounted for the fact that all of the people were taking standard heart disease treatment drugs, including cholesterol-lowering statins and blood pressure medications.\n\u201cBut I do think it\u2019s logical that our results hold promise, and may reduce bad outcomes in patients after a heart attack.\u201d\nThese are questions Kwong and others hope to answer with more studies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Most people understand that fish oil is available over the counter, so we\u2019ll rate this Satisfactory\u2013though just marginally, because the fish oil prescribed to people in the treatment arm of the study was not standard over-the-counter fish oil pills; see our discussion on\u00a0this in the \u201cDiscuss costs\u201d section\u00a0above.", "answer": 1}, {"article": "Over the last decade, the makers of medical devices have developed techniques that have widened diabetes management options beyond pricking the finger several times a day to test blood glucose levels.\nThe study not only indicated that the algorithm system prevented very low glucose overnight, Dr. Hovorka said, but it also indicated that the experimental system was better able to keep blood glucose in an acceptable range.\nAlthough the Lancet study was small \u2014 only 17 children completed the entire protocol \u2014 it is significant because it demonstrated that a computer algorithm could safely interpret glucose data and calculate appropriate insulin doses for a pump, he said.\nBut there were nine instances of very low blood sugar among children who had the standard treatment, according to the study, conducted by researchers in Britain at the University of Cambridge.\nBased on algorithms like the ones used in the Lancet study, the devices would continually monitor glucose levels, calibrate insulin dosages and then dispense insulin in real time \u2014 automating a delivery task performed by a nurse in the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The Times did a good job of describing the system used in this study and how close it is to being commercially available.\u00a0\u00a0It called the system \"experimental\"\u00a0and said that it was \"not\u00a0fully automated.\" It said that a fully\u00a0automated glucose monitor/insulin\u00a0delivery system was still \"hypothetical\" and would face regulatory hurdles before it could be marketed to the public.", "answer": 1}, {"article": "When Ali Andrew Li was born on Jan. 7, he was gently placed on his mother's chest, where doctors cleaned and examined him and covered him with a warm blanket.\nAnd if mothers or babies are very sick and have to be isolated, Gray suggests mothers take any opportunity to hold their infant skin to skin.\nAt Ronald Reagan UCLA Medical Center where Ali was born, the technique is routinely practiced for healthy mothers and newborns.\nThere, hospitals with no access to incubators and other equipment often sent home preemies with no expectation that they would live.\n\"The baby gets landed in a trusting environment,\" he says, reassuring them that life outside the womb can also be \"soft, comfortable and warm.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We would have liked to see more information, such as how widely this approach is used to treat premature infants, and what some of the barriers might be in high-income countries where incubator care has been the norm. For example, how many U.S. neonatal intensive care units incorporate skin-to-skin contact in their care? Which babies don\u2019t or can\u2019t get this kind of care?\u00a0Given how many births are delivered via c-section these days, is kangaroo care an option for these moms?", "answer": 0}, {"article": "Infection with H. pylori is associated with increased risks of stomach and throat cancers.\nImmunochemical FOBT is now largely replacing the older test.\nA newer version called immunochemical FOBT (iFOBT) is supposed to zero in on colon growths better than an older version known as guaiac FOBT \u2014 which often picked up bleeding originating in the upper digestive tract, such as from a stomach ulcer.\nThe findings, reported in the Canadian Medical Association Journal, give some extra weight to fecal occult blood testing (FOBT) as a valid option for early detection of colon cancer.\nBut there\u2019s been surprisingly little evidence that it really is highly \u201cspecific\u201d to colon cancer, according to Dr. Yi-Chia Lee of National Taiwan University Hospital, one of the researchers on the new study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that immunochemical FOBT is now largely replacing the older blood stool test.", "answer": 1}, {"article": "\"Our thinking is similar to how you might approach a battle against two enemies,\" said Dr. Soran.\nThe study was selected for the society's \"Best of ASCO,\" an effort to condense the research \"most relevant and significant to oncology\" into a two-day program to increase global access to cutting-edge science.\nDr. Soran began the trial in 2007, ultimately recruiting a total of 274 women newly diagnosed with stage IV breast cancer from 25 institutions.\nThe results of the phase III randomized, controlled trial will be presented Saturday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.\nThe study received scientific advisement from UPMC and assistance with statistical analysis from epidemiologists at the University of Pittsburgh Graduate School of Public Health.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It should be clear to any audience that these types of basic surgeries are available, and so we are giving this criteria a pass.", "answer": 2}, {"article": "Of the men who had a raised platelet count of the same value or higher six months after being diagnosed with thrombocytosis, 18.1% developed cancer, while for women the figure was 10.1%.\n\u201cThis work should begin to change practice, so that GPs should be testing patients with raised platelet counts for cancer, especially those without other potential cancer symptoms,\u201d he added.\n\u201cThis is an excellent study that demonstrates the potential for a commonly used blood test to identify some patients with cancer earlier,\u201d he said.\n\u201cThis is a clue which can be used in practice by GPs to help them select patients for further investigation \u2026 most excitingly in some patients who may not already have other symptoms of cancer to achieve earlier diagnosis,\u201d said Sarah Bailey, co-author of the research from the University of Exeter.\nThat, say the researchers, makes testing for raised platelet count a valuable tool, and could speed up cancer diagnosis by at least three months for thousands of patients a year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "They did mention blood tests being ordered by GP\u2019s making assumptions that it is widely available.", "answer": 2}, {"article": "Consumers can wake up with Red Bull and then wind down with Slow Cow.\nThe back of the Snooz'n bottle says the beverage will \"combat stress, energy drinks and sleeplessness\" and takes about 30 minutes to take effect.\nThe relaxation drink market is tiny compared with the energy drink market, says Garima Goel Lal, a senior analyst at the consumer research firm Mintel.\nWhen it launches nationally in March, Snooz'n will be available in grocery and convenience stores and pharmacies, like most of these drinks.\nMelatonin is used for the latter, while ingredients such as valerian root and chamomile take care of the former, Healy says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provided some good information on the regulatory differences between beverages and dietary supplements and how manufacturers who don\u2019t follow the rules can run afoul of the FDA.\u00a0As to the more basic question \u2014 where do I buy this stuff?\u00a0\u2014 the story says the drinks are available\u00a0in grocery and convenience stores and pharmacies.", "answer": 1}, {"article": "Most American women begin to experience menopause around age 50, with some changes in their menstrual cycles earlier.\nDr. Noushin A. Firouzbakht, an obstetrician-gynecologist at Texas Health Harris Methodist Hospital Fort Worth, says that despite the alarm provoked by the Women\u2019s Health Initiative study, much was learned, especially about the ideal candidate for hormone replacement.\nJohnson, who runs the Institute of Endocrinology and Preventive Medicine in Dallas, says she only trusts the quality-controlled, safety-tested pharmaceutical bio-identical hormones that are made by drug companies and approved by the Food and Drug Administration.\nIt\u2019s a process, but hormone replacement therapy is helping women have a better life in an era when they live longer.\u201d\n\nJohnson, Firouzbakht and other experts will tell you that hormone therapy protects against heart disease, a much more common killer of women than breast cancer, as well as against dementia, colon cancer, osteoporosis and other health issues.\nIt\u2019s an unfortunate thing that that\u2019s out there,\u201d Firouzbakht says, \u201cbecause women also need to know: You don\u2019t have to suffer, you don\u2019t have to have incontinence or vaginal prolapse or hot flashes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "HRT is available from your doctor, but at the end of the article, there is a statement that Dr Firouzbakht \u201cprescribes pharmaceutical hormones and also works with a pharmacy she trusts to develop bio-identical hormone combinations for some patients. Such custom compounds are not FDA-approved.\u201d The article goes on to state:\n\u201cIt doesn\u2019t matter what formulation of the hormones you are using, it\u2019s the surveillance of it all that is very important,\u201d Firouzbakht says.\nThese statements are confusing about the actual availability of HRT and hormones and dismisses the importance of FDA approval.", "answer": 0}, {"article": "\u201cI used to be so irritable because I was so uncomfortable,\u201d Joyce said.\nShe consulted an allergist at Weill Cornell Medicine/New York-Presbyterian Hospital, where a clinical trial involving immunotherapy toothpaste was taking place.\nVolunteers using the toothpaste were also required to log their usage in a journal.\nAllerdent is not covered by insurance, meaning Joyce spends about $400 every three months but said the cost is worth it.\nJoyce, who lives in the Bronx, New York, signed on for the year-long study that required six of the 12 volunteers to brush their teeth for two minutes using two pumps of the toothpaste in either the morning or night, and the other six to use drops under their tongue.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions the product price tag, the fact that it\u2019s not covered by insurance, and includes a link to the company website that can link readers to a prescribing doctor.\nWhile the promotional aspect of this information in a news story is somewhat troubling, it does satisfy the criterion.", "answer": 1}, {"article": "Researchers at Italy's Institute of Neuroscience injected rats and mice with botulinum neurotoxin A in doses comparable to those used in people.\nYes, there was some evidence the toxin slipped into the bloodstream or the lymph system, but Botox in the bloodstream cannot enter the brain, says its manufacturer.\nA big reason Botox and its cousins, such as Myobloc, were OK'd was that preclinical testing showed that after being injected, they did not travel along the body's highways\u2014nerve cells\u2014to the brain and spinal cord.\nIn a reversal of the usual sequence in science, researchers have discovered, after millions of people have received the drug, something fundamental about how Botox can act.\nOne of the deadliest poisons in nature and a possible bioterrorism agent, this neurotoxin reached the market, in very dilute doses, starting in 1989 as Botox.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that Botox reached the market in 1989. ", "answer": 1}, {"article": "Researchers from the University of Pittsburgh Medical Center and Rutgers University studied 408 males from adolescence to their mid-30s.\nYesterday\u2019s coffee science: It\u2019s good for the brain.\n\"Therefore, continued data collection and longer follow-ups are needed.\"\nBut there were none.\nHere's the scientific proof.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story leads with the \u201cwidespread availability of marijuana in recent years\u201d \u2013 especially \u201cthanks to its legalization in a growing number of states.\u201d", "answer": 1}, {"article": "Hot flashes typically begin in the year or so before menopause and tend to abate in the years afterward.\nTo prove it is effective in reducing hot flashes, the Mayo team needed to demonstrate that it was superior to sham, or placebo, treatment.\nThe 2,000-year-old treatment is widely used around the world, according to the National Center for Complementary and Alternative Medicine (NCCAM), part of the National Institutes of Health (NIH).\nThat doesn't surprise Adriane Fugh-Berman, associate professor in the complementary medicine program at Georgetown University School of Medicine.\nThat requirement has hobbled other alternative treatments, including the herb red clover and vitamin E supplements.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that acupuncture is used worldwide.", "answer": 1}, {"article": "October 26, 2017 - For younger patients with severe damage to the rotator cuff muscles, a \"reverse\" shoulder replacement provides lasting improvement in shoulder function, according to a study in The Journal of Bone & Joint Surgery.\nWith refinements in technique and components in more recent years, the procedure has been used in younger, more active patients.\nBut there are concerns about how well the results of RTSA will hold up over time in this group of patients.\nThis group of patients typically gets limited benefit from shoulder replacement with conventional implants, which rely on the rotator cuff muscles to provide shoulder movement.\nThe improvement was similar for patients with and without prior shoulder surgery.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since the study is reporting the long-term results of this form of surgery in patients, readers can assume that it is available.\nThe implant is widely available to be used at the surgeon\u2019s discretion.", "answer": 1}, {"article": "Chinese herbal medicine increased IELT by about two minutes, Ayurvedic herbal medicine increased IELT by nearly a minute and topical cream increased IELT by more than eight minutes.\nWhen they were reported, the adverse effects were generally mild, the study team writes.\nIn some instances, a combination of traditional and alternative options was the most effective.\nIn addition, the authors write, the studies are so different, it\u2019s tough to draw conclusions about the different options.\nThe main limitation of the study is the underlying weakness of the studies evaluated.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear how available these products are.\u00a0Considering how many products are sold online for this problem, some information on what these products are, and how available they are, would be useful.", "answer": 0}, {"article": "In a similar study published in the journal Pediatrics in 2004, researchers recruited 100 children with upper respiratory tract infections who had been coughing for an average of over three days.\nUltimately, the honey produced the greatest improvements when it came to better sleep and reduced cough frequency and severity.\nIn this occasional series, the New York Times \u201cReally?\u201d columnist, Anahad O\u2019Connor, explores the claims and the science behind alternative remedies that you may want to consider for your family medicine cabinet.\nAlthough children in all three groups experienced a reduction in coughing, those who received the flavored water fared the best.\nThe thinking is that sweet substances of any kind help soothe the back of the throat and break up mucus in the airways.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the standard treatment for colds in kids was the subject of a 2007 ban by the FDA, and that the other standard remedy \u2013 honey \u2013 is a grocery store staple.", "answer": 1}, {"article": "And if you wake up in the middle of night and don\u2019t fall back asleep easily, get out of bed.\u201d\n\n\u201cYou don\u2019t want to have any linkage between the experience of lying in bed and being awake,\u201d he said.\nWhen the researchers looked at information from a different, more in-depth sleep monitoring system, however, they failed to find significantly better outcomes with the behavioral therapy.\nThese improvements were sustained for at least 6 months, and were backed up by data from a sleep monitor worn on the wrist or ankle.\nAnd the risks may be even more pronounced among older patients, added senior author Timothy Monk, also of the University of Pittsburgh.\n\u201cThis (therapy) has the effect of compressing your sleep into a more solid block,\u201d Buysse told Reuters Health in an e-mail.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story says this form of \u201cbrief behavioral treatment for insomnia is not yet generally available\u201d. It also described this study as being a first step in the process of making such an intervention available without making predictions about a timetable.", "answer": 1}, {"article": "Though these children are larger, they do not have increased rates of obesity,\" Wu added.\nAccording to Dr. Jill Rabin, co-chief of the division of ambulatory care, Women's Health Programs-PCAP Services at Northwell Health, in New Hyde Park, N.Y., \"In pregnancy and beyond, adequate intake of fish is important for normal human development, and this paper certainly adds to the literature.\"\nThose whose mothers took the fish oil supplements during pregnancy sustained a higher body mass index (BMI) from the age of 1 to 6 years.\nThe children were assessed 11 times between birth and the age of 6 years.\nBut Rabin, who was not involved in the study, did add a few caveats about the findings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Fish oil supplements are readily available.", "answer": 1}, {"article": "\u2022 The percentage of days with full asthma control were virtually the same for acetaminophen and ibuprofen: 85.8 and 86.8 percent, respectively.\n(The asthma therapies were given in varying order as part of a concurrent randomized trial, making this, in effect, a \"trial within a trial.\")\nWhile the study was modest in size, it was powered to detect any clinically significant differences, more so than past retrospective studies, Phipatanakul notes.\nFurther studies will be necessary to answer those questions.\n\u2022 Use of \"rescue\" medication (albuterol) was essentially the same: 2.8 vs. 3.0 puffs per week.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of acetaminophen and ibuprofen is not in question, since these are well-known, over-the-counter drugs. We rate this one Not Applicable.", "answer": 2}, {"article": "They found that compared with the placebo, there was a 27% reduced risk of coronary heart disease, a 28% reduced risk of dying from coronary heart disease, and a 25% reduced risk of coronary \u201cevents\u201d such as a heart attack.\nResearchers from Imperial College London and the University of Glasgow found impressive results among those on statins, who were given the widely-prescribed type pravastatin.\n\u201cThis legitimises current guidelines which recommend treating this population with statins.\u201d\n\nRay said people with lower levels of cholesterol, around 4mmol/L, who otherwise appear healthy, should also be treated with statins.\n\u201cThe role of cholesterol in causing heart disease has been disputed by some, but this paper provides yet more evidence of the link, and the benefits of statins to prevent heart disease.\u201d\n\u201cIt shows the enduring and long-term benefit of taking statins, including the extent to which they reduce the risk of dying from heart disease, which can only be seen in a study of this length.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Statins are widely available drugs, and the story tacitly implies they\u2019ve been available for about 20 years.", "answer": 1}, {"article": "\"Can't say,\" replies Dendreon COO Hans Bishop.\nThe way the study was done, he says, \"does not allow one to conclude\" that Provenge is working because it mobilizes the immune system specifically against prostate cancer.\nThe company estimates 100,000 American men have the kind of hormone-resistant, metastatic cancer the drug is approved to treat.\nThat's better than the only other approved treatment for such advanced cancers.\nThe theory is that the custom-made vaccine incites patients' immune cells to attack the cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear the drug was just approved by the FDA and that \"Dendreon, the Seattle-based company that makes Provenge, says there\u2019s a waiting list for the drug. The company estimates 100,000 American men have the kind of hormone-resistant, metastatic cancer the drug is approved to treat. But the company can only make enough at this point for 2,000 patients in the first year.\"", "answer": 1}, {"article": "And, yes, they do get into the brain,\" Fleming explains.\nAnother surprise was a decrease in serotonin in brains of pigs fed the prebiotic.\nThe researchers hypothesize that the prebiotics may alter levels of tryptophan, serotonin's amino acid precursor, but it's too early to say.\nAlthough more work is needed to tackle remaining questions, the study adds to the growing body of research suggesting a strong and potentially modifiable link between the gut and the brain: a link that makers of infant formula should strongly consider.\nThe article, \"Dietary polydextrose and galactooligosaccharide increase exploratory behavior, improve recognition memory, and alter neurochemistry in the young pig,\" is published in Nutritional Neuroscience.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This published study (but not the release) mentions that infant formula supplemented with prebiotics are currently available.", "answer": 0}, {"article": "Without strong evidence for its efficacy, the American Congress of Obstetricians and Gynecologists does not include the treatment in its Practice Bulletin for Urinary Incontinence in Women. L. Elaine Waetjen, professor of obstetrics and gynecology at the University of California, Davis Medical Center, who has spent more than 15 years treating women for this problem, said that there is \"no scientific evidence that the O-Shot works for incontinence and there is also no clear biological mechanism for why it should treat this condition.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provides a website link and features one practitioner in the Philadelphia Inquirers\u2019s readership area. Readers will get the hint that there aren\u2019t a lot of front-line gynecologists and urologists offering this therapy, especially since the story explains that\u00a0insurance will not pay for it.", "answer": 1}, {"article": "Using the Clinformatics Data Mart, a database of one of the largest commercially insured populations in the U.S., Baillargeon and colleagues examined data of 450 men aged 40 to 63 with COPD who began testosterone replacement therapy between 2005 and 2014.\n\"The findings suggest that testosterone replacement therapy may slow the progression of disease in men with COPD.\"\nThe paper is currently available in Chronic Respiratory Disease.\nThe goal of the study was to find out whether testosterone replacement therapy reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD.\n\"However, we are the first to conduct a large scale nationally representative study on this association.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is pretty obvious that TRT is available to men, so the fact it wasn\u2019t mentioned as available is a moot point.", "answer": 1}, {"article": "Bernard M.Y.\nTwo died within a few weeks of developing the disorder, with one cause of death mentioning the muscle disorder as a contributing factor.\nThe study was supported by a grant from Merck (manufacturer of the simvastatin).\nTheir doctors should consider prescribing a statin, either at a high dose or using a more powerful statin, he said.\n\"But if you are at risk from those diseases, you would need intensive treatment to lower LDL cholesterol, even if your LDL cholesterol level is not very high,\" he added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The class of medications, statins, discussed in the story are commercially available as indicated.", "answer": 1}, {"article": "Chemotherapy deals heavy damage to tumors \u2014 but often, the cancer cells are able to regroup and repair themselves.\nBut the data it presented at the European conference showed that the drug may not actually be more effective than Lynparza, the PARP inhibitor that\u2019s been marketed by AstraZeneca since 2014.\n\u201cAt this time, there\u2019s nothing available that has been approved by regulatory agencies for these women who have recurrence to their ovarian cancer.\u201d\n\nThe company aims to use its PARP inhibitor, rucaparib, to treat only patients with BRCA mutations who have had two or more chemotherapies.\nIts results built upon exciting data it released in June \u2014 showing that its drug can increase the window of time in which a woman\u2019s cancer doesn\u2019t get worse.\nThe company is now planning trials in lung cancer, and is considering other cancers to pursue.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As said above, Lynparza is approved and already being used. And the information provided on the other three newer drugs makes clear they are in various stages of clinical trials and not yet on the market.", "answer": 1}, {"article": "\u201cIt\u2019s just not a good operation,\u201d he asserted.\nTwo years after surgery, duodenal switch patients had lost more weight: about 50 pounds more, on average.\nIn this study, one-quarter of gastric bypass patients still had a BMI that high two years after surgery \u2014 versus none of the duodenal switch patients.\nIn a 2008 study, it accounted for just 1 percent of weight-loss, or bariatric, surgeries done in the U.S., and 5 percent in Europe.\nIn the U.S., he said, about one in three weight-loss surgery candidates have a BMI of 50 or higher.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that duodenal switch is \u201cless common\u201d and that \u201cDuodenal switch is not a popular procedure.\u201d In a 2008 study, it accounted for just 1 percent of weight-loss, or bariatric, surgeries done in the U.S., and 5 percent in Europe.\u201d", "answer": 1}, {"article": "Journal of Child and Adolescent Psychopharmacology.\nBoth findings reaffirm the potential that mindfulness therapy could bring to the table.\n\"Mindfulness-based therapeutic interventions promote the use of meditative practices to increase present-moment awareness of conscious thoughts, feelings, and body sensations in an effort to manage negative experiences more effectively.\u201d\n\nChildren who are at a high risk for bipolar disorder or other anxiety disorders, such as the participants, often have poor coping skills when confronted by stress, and only a lucky few get help.\nSome mental health professionals have suggested that mindfulness exercises can help bridge the treatment gap, and there is some encouraging, if early, evidence showing that these techniques can be used to prevent relapses of depression or anxiety.\n\"Increasingly, patients and families are asking for additional therapeutic options, in addition to traditional medication-based treatments, that have proven effectiveness for improved symptom reduction.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear to readers whether mindfulness-based cognitive therapy for children with anxiety disorders is still in experimental development by a select group of researchers or is widely available. Can local therapists learn this technique?", "answer": 0}, {"article": "Amid a dry spell for breakthrough cancer drugs, recent U.S. approval of Eisai Co.'s Halaven represents some vindication for a small group of researchers who believe, contrary to recent pharmaceutical fashion, that molecules from nature hold promise against hard-to-treat diseases.\n\nThe Food and Drug Administration's approval of Halaven in November for treating late-stage breast cancer was a triumph of chemistry and tenacious research. Its path, extending nearly three decades from the first studies, demonstrates not only potential...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Alcohol is known to activate some of the same receptors in the brain that opioids do, and studies find that by tempering the pleasure from alcohol, naltrexone can help people drink less.\nAs as long ago as 1997, a published study showed that treatment of alcohol dependence with naltrexone by primary care doctors can be effective; follow-up research has confirmed that the primary care approach not only works, but makes treatment much more accessible.\nBut there's good evidence that the combination of counseling and drugs such as naltrexone can help people cut back on drinking, or move toward abstinence.\nPart of the challenge, researchers say, is that many drinkers don't realize that a medicine long used to help people addicted to opioids quit their drug habit can help alcoholics and other heavy drinkers cut back, too.\nNaltrexone is certainly not a cure-all, researchers say.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is a strong point of the story:\nAny health care provider who is licensed to prescribe medicine can prescribe naltrexone \u2014 not just mental health professionals or addiction specialists. As as long ago as 1997, a published study showed that treatment of alcohol dependence with naltrexone by primary care doctors can be effective; follow-up research has confirmed that the primary care approach not only works, but makes treatment much more accessible.", "answer": 1}, {"article": ".\nAfter five weeks of treatment, subjects receiving dTMS lost more than 3 percent of their body weight and more than 4 percent of their fat--significantly more than controls did, Luzi reported.\nCurrently approved in the U.S. for treating major depression, dTMS is being studied in some countries for the treatment of other neuropsychiatric disorders, especially addiction.\nResults of the fecal analysis demonstrated that, after five weeks, dTMS-treated subjects had greatly increased quantities of several beneficial bacterial species with anti-inflammatory properties, such as are found in healthy people.\nThis study expands on the researchers' previous finding that dTMS reduced food cravings and induced weight loss in obese individuals.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not discuss the availability of this treatment and the treatment does not appear to be available for obesity at this time. Since dTMS is only approved in the U.S. for treatment of depression, it\u2019s unlikely that it would be available to people without a formal diagnosis of depression.", "answer": 0}, {"article": "\"You start doing research on that type of tumor, and you're saying, 'Oh my God, you're history.'\nKnowing more about the genetic mutations of a tumor enables doctors to find a potentially effective drug much more quickly and accurately.\nShe's been in the clinical trial for a year now, and continues to take Zelboraf (or vemurafenib generically) daily.\nBut in the meantime, patients like Anselmo are grateful to have time they wouldn't have had otherwise.\nMore doctors are taking advantage of the information to treat patients with a targeted approach.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The skin cancer drug this patient received is stated to be available through a clinical trial, at least for GBM. The article also links to NIH-curated information about the drug. But this story is mainly about cancer treatment that is guided by genetic testing of the tumor, and the availability of that testing and related treatment is not satisfactorily established. The story states that the patient\u2019s\u00a0family sent samples of her tumor to several leading cancer hospitals, suggesting that this is not something that would\u2019ve been done as a routine part of her care. But what about patients whose families may not be savvy enough to coordinate this kind of testing? And how much does it cost and would the testing be covered by insurance? This story is going to create interest and demand for such testing, so a few more details about the logistics of having it carried out would have been very useful.", "answer": 0}, {"article": "Article reference: Thomas L. Jang, Neal Patel, Izak Faiena, Kushan Radadia, Dirk F. Moore, Sammy E. Elsamra, Eric A.\n\"This important study demonstrates that many men with high-risk prostate cancer derive a survival advantage through a multi-modality approach to their disease.\nAnother interesting finding from the research was that slightly more than half of men diagnosed with the disease did not receive combination therapies for their prostate cancer.\nThey found that 10 years after treatment, 89 percent of the prostate removal plus radiation group was still alive.\nThe research was published September 25th in the journal Cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s evident these treatment options are widely available. However, the news release said researchers found many men aren\u2019t getting treatment that\u2019s recommended in medical guidelines.", "answer": 1}, {"article": "Of these, 85 percent were mild or moderate.\nBecause this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nThe studies were funded by Pfizer Inc. and Janssen Alzheimer Immunotherapy.\nThe researchers, who said monitoring of bapineuzumab will continue, are now awaiting the results of a larger Phase III trial on the drug.\nBut no problems were seen with lower doses.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The subject of the story is the drug bapineuzumab, which was reported as not yet available to consumers.\nIt would have been useful to include a link to Clinicaltrials.gov so that readers who might be interested could learn about the other trials being conducted.\nhttp://clinicaltrials.gov/ct2/results?term=Bapineuzumab", "answer": 1}, {"article": "Then they took tests involving memorizing words.\nA third group made no dietary changes.\nThe other groups showed no significant change.\nParticipants were advised by dietitians but monitored their own eating over three months, Dr. Fl\u00f6el said.\nThe calorie-restricted group averaged 20 percent improvement in memory performance.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of caloric restriction is not in question.", "answer": 2}, {"article": "Two studies published Tuesday lend support to controversial new cholesterol guidelines that could vastly increase the number of Americans advised to take cholesterol-lowering drugs called statins.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d said an editorial that accompanied the publication of the studies in JAMA, a journal of the American Medical Association.\nThe new studies are not large clinical trials that will definitively settle the matter of whether to expand drug treatment to millions more people in hopes of preventing cardiovascular disease, the leading killer of Americans.\nBut they could help dispel some of the criticism of the new guidelines and strengthen the position of those who contend treatment should be extended to more people.\nThe other suggests that treating people based on the new guidelines would be cost-effective, even with the tremendously increased use of statins.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that statins are widely prescribed. One in four Americans take them by some estimates.", "answer": 1}, {"article": "Side effects of dopamine agonists can include euphoria, hallucinations, weight loss, nausea, insomnia, tiredness or weakness, dizziness and drowsiness.\nNonetheless, for people with moderate to severe restless legs syndrome symptoms, these medications provided important benefits, at least in the short term, Wilt said.\nThe harms of medications may outweigh benefits for these individuals, Wilt said.\n\"These are the only treatments approved by the [U.S. Food and Drug Administration],\" he added.\nThe report was published in the March 4 online issue of JAMA Internal Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the drugs discussed are all approved by the FDA.", "answer": 1}, {"article": "Still, little is known about its cause.\nA separate analysis of 15 studies found that ever being breastfed compared with never being breastfed was associated with an 11 percent lower risk of childhood leukemia.\nBreast milk is meant to exclusively supply all the nutritional needs of infants and current recommendations include exclusively breastfeeding for the first six months of life to optimize growth, development and health.\nThe many potential preventive health benefits of breastfeeding should also be communicated openly to the general public, not only to mothers, so breastfeeding can be more socially accepted and facilitated.\n\u201cBecause the primary goal of public health is prevention of morbidity, health care professionals should be taught the potential health benefits of breastfeeding and given tools to assist mothers with breastfeeding, whether themselves or with referrals to others who can help.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While it may be assumed that breastfeeding is available to all, this is an oversimplification. Many women have trouble initiating breastfeeding and may have jobs or other limitations that make it difficult to breastfeed. The public can be hostile to breastfeeding women. Some women do not produce enough milk to exclusively breastfeed their babies. Studies have found that while about 75% of women attempt to breastfeed in the first week, only about 30% are still exclusively breastfeeding by three months. Some acknowledgment of the difficulties involved would have provided an opportunity to mention programs and interventions, including postpartum skin-to-skin contact, partner education, lactation consultants, etc, that may improve breastfeeding success.", "answer": 0}, {"article": "Vegetable and canola oils, soybeans, flaxseed, walnuts and vegetables including spinach, kale and salad greens are also a source of omega-3 fatty acids.\nDHA has the added benefit of improving mood and reducing symptoms of depression, he said.\nThe only people who should avoid DHA are patients on a blood thinner like Cumadin, he added.\nThe study was published Tuesday in the print edition of the journal Neurology.\nFotuhi recommends his patients get 1,000 mg per day of DHA, a nutrient that increases blood flow in the brain, reduces inflammation in the brain, heart and elsewhere, and reduces the toxic aggregation of amyloid in the brain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish and fish oil supplements is not in question.", "answer": 2}, {"article": "A birth-control pill that eliminates women's monthly periods could hit pharmacy shelves later this year, marking the latest effort by a drug company to expand a contraceptive's features beyond preventing pregnancy.\n\nSince \"The Pill\" was introduced nearly a half-century ago, most regimens have mimicked a woman's cycle by having a pill-free week each month when women can have bleeding and other symptoms.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that the drug maker has applied to FDA for approval, and expects a response by the end of June. The story also claims that the new birth control pill could be on the market by year\u2019s end. However, there is no independent source cited in support of these claims. The trail of past baseless predictions of FDA approval and market availability is long. ", "answer": 0}, {"article": "European Journal of Gastroenterology & Hepatology, 22, 1402\u20131411.\nAn international scientific and medical review team reported that there are a range of agents available to treat IBS and physicians should be knowledgeable about the efficacy and risk profile of any option they are about to prescribe.\nThe company is dedicated to developing products to address gastrointestinal issues where there is a high unmet need.\nIt is a privately held company based in Boca Raton, Florida, that is also the innovator of FDgard\u00ae for the dietary management of functional dyspepsia.\nAdditionally, the support from the medical community builds on a previously important review article about the use of peppermint oil in IBS.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that IBgard is for sale without a prescription at many pharmacies and other stores.", "answer": 1}, {"article": "\"But it's a slippery slope to saying 'OK, maybe two is better.'\nThere's no evidence drinking in your 20s or 30s has any health benefits.\nStudies will continue, and not everyone has given up the idea that moderate drinking \u2014 up to two drinks a day for men and one day for women \u2014 might have some cardiovascular benefits.\nFor some people, even moderate drinking is clearly risky.\nStudies have failed to prove any difference.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of alcohol is not in question.", "answer": 2}, {"article": "AMHERST, Mass.\nDiet was assessed five times over the 20-year study, allowing the researchers to capture within-person variation in changes in food and nutrient intake over times, Boutot explains.\nBoutot and Bertone-Johnson add, \"Though relatively few women in our study consumed very high levels of vegetable protein and our power for analyses of more extreme intake levels was limited, women consuming 9 or more percent of their calories from vegetable protein had a hazard ratio of 0.41 (95 percent confidence interval = 0.19-0.88)\" compared to those eating less than 4 percent.\nParticipants in the study contributed more than 1 million person-years of follow-up, during which 2,041 women experienced early menopause.\nBoutot and Bertone-Johnson suggest that more prospective studies of their findings are warranted, including studies that compare soy-based and non-soy vegetable proteins.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability isn\u2019t an issue. Adding vegetable protein to your diet in the modest amounts involved in this study is a fairly easy thing to do. A completely vegetarian diet is more challenging, but that\u2019s not what the study suggests.", "answer": 2}, {"article": "It has also been linked to vulvar, anal and throat cancers.\nAccording to a study presented last year by researchers at the University of Maryland, just one-third of teen girls and young women who start the three-dose series actually finish, and almost three-quarters don't start it at all.\nWEDNESDAY, Feb. 2, 2011 (HealthDay News) -- A large international trial finds that the Gardasil vaccine shields young men from human papillomavirus (HPV) as well as it protects young women.\n\"This well-designed study reinforces the idea that there is value in vaccinating young men against a virus that is nearly ubiquitous among sexually active individuals.\"\nThis study involved more than 4,000 boys and men aged 16-to-26 from 18 different countries who were randomly assigned to get the vaccine or not.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story met this standard by telling us the vaccination is \"approved\" by the FDA, but not \"recommended\" by the CDC advisory board. Some readers will be a bit confused processing that seeming contradiction. \nEven better would be telling us why these two \"expert\" bodies appear to disagree about the widespread benefits to most young men. How about saying: \"While the FDA labeled the vaccine as safe, the CDC\u2019s advisers do not recommend it for routine use.\" Why not? Even better would be a quote from one of those advisors about the why not, and whether this new evidence has the potential to change CDC recommendations.", "answer": 1}, {"article": "WASHINGTON\u2014The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's Avodart to cut the risk of prostate cancer.\n\nAvodart is currently approved to treat benign enlargement of the prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s Proscar, a drug similar to Avodart.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that\u00a0Avodart\u00a0is approved by the FDA for treatment of non-cancerous enlargement of the prostate.\u00a0It also explains that\u00a0Glaxo Smithkline\u00a0is seeking\u00a0new approval to\u00a0market Avodart for the prevention of prostate cancer. The story could have been more clear about the fact that Avodart can\u00a0already be\u00a0prescribed off-label for cancer prevention (even though it is not officially approved for this), and that the FDA approval would\u00a0sanction this\u00a0existing use as well as\u00a0expand it to other clinicians and patients.", "answer": 1}, {"article": "\"We only need to increase concentration beyond levels found in a healthy diet for an effect on prostate cancer cells.\"\nThis is a neat solution: blocking the uptake of a nutrient needed by prostate cancer cells with nutrients that are commonly in the human diet.\nNew research from The University of Texas at Austin identifies several natural compounds found in food, including turmeric, apple peels and red grapes, as key ingredients that could thwart the growth of prostate cancer, the most common cancer afflicting U.S. men.\nPublished online this week in Precision Oncology, the new paper uses a novel analytical approach to screen numerous plant-based chemicals instead of testing a single agent as many studies do, discovering specific combinations that shrink prostate cancer tumors.\nThe researchers first tested 142 natural compounds on mouse and human cell lines to see which inhibited prostate cancer cell growth when administered alone or in combination with another nutrient.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "These foods can be obtained at most grocery stores; availability is not a question. The release could have lent more clarity by telling readers whether supplements are available. For example, resveratrol supplements are available and have been extensively studied for diabetes, obesity, and cardiovascular disease.", "answer": 2}, {"article": "\"It's my job to see that she gets what she needs to protect herself,'\" he says.\nMillions of Americans have seen the ad blitz for Merck's new drug Gardasil.\nBut some worry that may sends a mixed signal by protecting girls against a sexually transmitted disease while at the same time telling them they shouldn't have sex.\nThe vaccine promises to reduce the number of HPV related cervical cancers by more than 70 percent, CBS News correspondent Cynthia Bowers reports.\nBut is it something that we are in position to sort of ramrod down people's throats?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the FDA only recently approved the vaccine.", "answer": 1}, {"article": "\"They say, 'Oh my God, this has changed my life.\nThe drug, Addyi, or flibanserin , has been on the market since October.\nIn their editorial, Woloshine and Schwartz said Sprout and others put pressure on FDA to approve the drug.\n(CNN) A new review of the \"little pink pill\" for women with low sexual desire says the drug doesn't work very well -- but some doctors and patients who've been using the treatment disagree.\nStreicher, an associate professor of clinical obstetrics and gynecology at the Northwestern University Feinberg School of Medicine, said the study drew \"erroneous conclusions.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the drug has been on the market since October, 2015.", "answer": 1}, {"article": "Enlarged prostate is characterized by a host of unpleasant symptoms, including weak or slow urine flow, an urgent need to urinate frequently, incomplete bladder emptying and having to get up repeatedly at night to urinate.\nAnd while this study showed some symptomatic improvement, it didn't have enough objective data to show that the new technique would surpass surgery, she said.\n\"PAE is potentially fraught with complications,\" Lowe said, adding that the study follow-up of less than one year was short for a disease that lasts decades.\nSince the study is being presented at a medical meeting and has not yet been published in a peer-reviewed journal, the findings should be considered preliminary.\nCurrent surgical procedures typically require no more than one night in the hospital and complications such as incontinence and impotence are uncommon, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story allowed the lead researcher to boast that prostatic artery emoblization was \u2018ready to be used in certain patients\u2019.\u00a0 But then it quickly countered that with \u201cbut other experts aren\u2019t so sure.\u201d\nThe story could have stated much more emphatically that it is a stretch to think that PAE would be utilized in this new population on the basis of a single, small scale study, presented as an oral presentation at a meeting. \u00a0Given that the procedure is still experimental at this point, it is unlikely to be widely available.\nAnd although the story noted that few physicians are \u2018trained to perform the procedure\u2019 it should have been explicit that this is currently not an option for most men.\nNonetheless, we\u2019ll give the story a BARELY satisfactory on this criterion.", "answer": 1}, {"article": "SpermCheck, which is approved by the U.S. Food and Drug Administration, assesses sperm count with 98% accuracy in 10 minutes and does away with the unpleasantness of conjuring up a sperm sample in a doctor\u2019s office.\nAs SpermCheck\u2019s website puts it, a \u201ctrip to a fertility clinic for a semen analysis is not for everyone.\nWhy should women bear the brunt of infertility testing?\n\u201cMen don\u2019t say, \u2018Let me go to the urologist and give a semen sample.\u2019\u201d That reluctance has created a $440 million-a-year market for male fertility tests in the U.S., Lopez says.\nFor women who are having trouble getting pregnant, the test may very well be one they \u2014 and not their squeamish partners \u2014 snap up along with over-the-counter ovulation kits.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The entire story is based on the pending \u201cdebut\u201d of the test.\n\u00a0", "answer": 1}, {"article": "Moderate-fat diet with one avocado a day lowered 'bad' cholesterol by 13.5 mg/dL\n\nThe researchers found that participants' levels of low-density lipoprotein (LDL) - referred to as the \"bad\" cholesterol - were an average of 8.3 milligrams per deciliter (mg/dL) lower after following the lower-fat diet without an avocado and 7.4 mg/dL lower after following the moderate-fat diet without an avocado, compared with their baseline average.\nOur Knowledge Center article on the health benefits of avocado reveals some of the other ways the food may be good for us, as well as the potential risks of avocado consumption.\nIt should be noted that this research was supported by the Hass Avocado Board, but the researchers say the organization played no other role in the study.\nStill, the team believes their findings indicate that people should consider replacing saturated fatty acids in their diet with healthier fats from avocados and other sources.\nAlthough these findings demonstrate that an avocado a day alongside a moderate-fat diet has the potential to reduce bad cholesterol, the team notes that their research was a controlled feeding study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does note that avocados are available but somewhat expensive at certain times of the year. We\u2019ll call this satisfactory, although the story could have noted that some areas may lack access to more exotic fresh produce such as avocados.\n\u00a0", "answer": 1}, {"article": "\"In some cancers, a part of the TRK gene has become attached to another gene, which is called a fusion.\nLarotrectinib is the first cancer drug to receive FDA breakthrough therapy designation for patients with a specific fusion of two genes in the cancer cell, no matter what cancer type.\nThe larotrectinib research was supported by Loxo Oncology Inc., the National Institutes of Health, the Cancer Prevention and Research Institute of Texas, the National Center for Advancing Translational Sciences, and Alex's Lemonade Stand Foundation.\nDr. Laetsch will be the national leader for that clinical trial in children.\nBriana enrolled in the phase 1 clinical trial of larotrectinib and began taking the drug twice a day.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not make it clear that the drug is not yet available in the US beyond clinical trials.\nThe company recently completed its application for fast track approval from the FDA but it is not yet approved.", "answer": 0}, {"article": "With advanced heart failure, a leading cause of hospitalizations, blood-pumping ability is diminished as the heart\u2019s left ventricle becomes enlarged and weakened.\n\u201cFor patients, this is a really hopeful thing.\u201d\n\nHenry, who presented the data at the ACC meeting, stressed the need for larger trials to prove the benefit of ixmyelocel-T\n\nFor the treatment, bone marrow is taken from the patient and enhanced over two weeks to increase two types of cells associated with healing.\nHowever, the treatment failed to improve secondary goals of the trial, such as heart-pumping efficiency and six-minute walking distance, and Vericel shares fell more than 31 percent by afternoon trading on Monday.\n\u201cThis is strong evidence in a well-designed trial that we can decrease events,\u201d said Dr. Timothy Henry, the study\u2019s lead investigator and chief of cardiology at Cedars Sinai Heart Institute in Los Angeles.\nAfter one year, the Vericel treatment led to a 37 percent reduction versus placebo in a composite of adverse events, including death, heart-related hospitalizations and unplanned clinic visits related to heart failure.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The doctor and lead investigator who was interviewed in the story noted the need for larger trials, meaning this therapy is nowhere close to being available to the general public. Although the audience is aware this is early testing, it would have been helpful to know how the study will address the limitations of failing to meet the secondary goals, such as the walk test and heart pumping efficiency.", "answer": 1}, {"article": "\u2022 Fat mass in the abdominal region, liver and heart was measured with accurate analyses (computed tomography, CT), along with a number of key risk factors for cardiovascular disease.\nThe researchers found strikingly similar health effects of diets based on either lowly processed carbohydrates or fats.\nRather, the \"good\" cholesterol increased only on the very-high-fat diet.\nEven the participants who increased their energy intake during the study showed substantial reductions in fat stores and disease risk.\n\"Participants on the very-high-fat diet also had substantial improvements in several important cardiometabolic risk factors, such as ectopic fat storage, blood pressure, blood lipids (triglycerides), insulin and blood sugar.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Both high-carbohydrate and high-fat foods are widely available.", "answer": 2}, {"article": "So, for example, a person who is actively using opioids and can't manage the withdrawals may be better suited for buprenorphine, while someone coming from a facility where he or she has detoxed and who doesn't want to use opioids may be better suited for naltrexone.\nWhat was important, Lee said, was for opioid addicts as well as treatment providers to understand that addiction isn't one-size-fits-all.\nOnce on either of the medications, people fared equally well.\nWithout the opioids, people can go into withdrawal, all contributing to a cycle of dependency.\nPublic health experts consider medicated-assisted treatment the gold standard of opioid addiction treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All three drugs mentioned in the story are available, though more could have been said about how accessible they are to people who are trying to overcome addiction.", "answer": 1}, {"article": "African-American women are more likely than white women to report hot flashes.\nAlthough the benefit was modest, it appeared to be significant enough that women might consider trying it, the researchers said.\nThe hot flashes increased after the women stopped taking the drug but not among those taking a placebo.\nLexapro seemed to work even among women who were not anxious or depressed.\nThe study is the first to examine whether there are any racial differences in how well an antidepressant works in alleviating hot flashes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story did not comment on the availability of Lexapro to treat hot flashes. Although many readers may be aware that\u00a0this drug is approved to treat depression and may therefore be\u00a0used to treat other conditions off-label, the story\u00a0should have spelled this out as the competing WebMD coverage did. \u00a0", "answer": 0}, {"article": "\u201cI\u2019ve been doing clinical trials for 30 years in C.F.\nThe drug also reduced the frequency of disease exacerbations that required treatment with antibiotics.\nShe said other results of the trial were encouraging.\nDr. Ramsey, a professor of pediatrics at the University of Washington, was briefed on the results by Vertex.\nMany do not live past age 40.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "A study of more than 20,000 patients with traumatic injuries and at risk of bleeding to death found those who were treated with tranexamic acid were significantly less likely to die than those who got a placebo.\nAlso, there was no difference in deaths from clots blocking blood vessels in either group, a potential safety concern for the medicine.\nThat means 66 people would have to get tranexamic acid to prevent one death.\nThe drug is used to reduce bleeding during surgery and is also approved in the U.S. to prevent bleeding in hemophiliacs who have teeth pulled.\nThat improvement may not seem so dramatic, but drug is pretty easy to give -- an initial 10-minute infusion within 8 hours of injury, followed by a second infusion over 8 hours.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that TXA is a 25-year-old medicine that is approved in the U.S. to prevent bleeding in hemophiliacs who have teeth pulled.", "answer": 1}, {"article": "CHICAGO (Reuters) - Pathway Genomics, a company known for pushing the boundaries of direct-to-consumer genetic testing, on Thursday will launch a cancer screening test designed to detect bits of cancer DNA in the blood of otherwise healthy people.\nSeveral oncology experts said liquid biopsy tests like Pathway\u2019s, while exciting, still require large clinical studies proving they help people beat cancer through early detection.\nThe cost to consumers begins at $299 to periodically check for DNA in their blood that could act as an early warning sign of cancer.\nRoche-backed Foundation Medicine Inc, Genomic Health Inc, Illumina Inc and Sequenom Inc say they have similar tests in the works.\nThe company is focusing on mutations that are relatively well-understood, and for which there are specific treatments, said Chief Executive Jim Plante.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that \u201cThe tests must be ordered by a doctor, based on a patient\u2019s risk profile.\u201d However, it\u2019s not clear that this fully describes the process. While the tests can be ordered through the patient\u2019s physician, the Pathway website also suggests that patients can order them autonomously online through Pathway\u2019s \u201conline physician network.\u201d Here\u2019s the text:\nPatients can also order CancerIntercept\u2122 Detect online through Pathway Genomics\u2019 online physician network.\u00a0After speaking with a client services representative, the patient must create a personal account with Pathway\u00a0Genomics Member Site (members.pathway.com) and enter all personal health information into the website for\u00a0physician review. It will take up to 1-2 business days for physician review, at which time a sample collection kit\u00a0will be sent to the patient\u2019s provided shipping address if the test is approved.\nThis process seems essentially to be a direct consumer purchase with the involvement of an online physician middleman \u2014 something which is not fully conveyed by the text. We\u2019ll give the benefit of the doubt since it\u2019s debatable whether the story is technically wrong on this point or not. But we wish more detail had been provided.", "answer": 1}, {"article": "Dupuytren's disease is a common condition of the hand that affects 4% of the UK population and causes the fingers to curl irreversibly into the palm.\nThe researchers are continuing to investigate the use of this drug to treat Dupuytren's disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.\nThe team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells.\nIn conjunction with Professor Sir Ravinder Maini, Sir Marc identified TNF as a therapeutic target in patients with rheumatoid arthritis.\nFunding for the drug was provided by 180 Therapeutics.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s noted that this treatment approach is in phase IIa trial; that is, preliminary evaluation of short-term safety and efficacy.\nHowever, the language used in the release: \u201cThe team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection\u201d\u00a0suggests this drug (which is commercially available for other conditions) could be used to stop the growth of disease causing myofibroblast cells. A simple statement in the release noting the preliminary nature of the research would have gone a long way into placing the the drug\u2019s availability into proper perspective.", "answer": 1}, {"article": "\"It's premature to make any conclusions,\" he said.\nThe findings also need to be replicated in a much larger number of patients, D'Amico said.\nHowever, the study was small, and results from a larger trial aren't expected for several years, he added.\nD'Amico stressed that men should not start taking vitamin D supplements in hopes of slowing or curing prostate cancer.\nThe study results were scheduled for presentation Monday at the annual meeting of the American Chemical Society in Denver.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Vitamin D is ubiquitous in stores, food and sun exposure, and that fact was made clear.", "answer": 1}, {"article": "The P-Cure team is committed to enabling all oncology centers and hospitals globally to establish cost-effective proton therapy services for the best possible care and cure,\u201d said Dr. Marash.\nThe P-Cure system is based on a diagnostic-quality computed tomography (CT) enabling treatment planning, positioning and treatment delivery for cancer patients in a seated position.\nP-Cure\u2019s first product was cleared by the FDA in 2010.\nP-Cure is the innovative provider of image-guided solutions for better clinical effectiveness of proton therapy at a fraction of the current capital and operating costs.\nP-Cure (P-Cure, Ltd.), a leading provider of Patient-Centric solutions for proton therapy, has received U.S. Food and Drug Administration (FDA) approval for its patented upright imaging solution.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that this therapy has just been cleared and that proton therapy is currently not widely available.", "answer": 1}, {"article": "First published on June 22, 2006 at 12:00 am\nBut Dr. George Merriam, a professor of medicine at the University of Washington, cautioned that much more study is needed to determine whether the medication should become widely available to help counteract the effects of aging.\nDr. Julia Zehr, a Michigan State University researcher who led the study, said the findings suggest that biological factors may influence those behaviors, not just the psychological effect of changes in body composition during puberty.\nA tablet that stimulates the production of growth hormone may help older adults improve their physical functioning and lower their body fat percentage, a researcher said yesterday.\nThe study did not examine whether the medication improved cognitive functioning.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that growth hormone to counteract the effects of aging is controversial and it is not FDA approved for this use. However, the story also subtly suggests it is available for non-approved use. \u201cAnti-aging\u201d clinics may administer growth hormone, but federal law states that distributing or administering human growth hormone for age-related health problems or for cosmetic use is illegal. Growth hormone is currently only approved for adults with Growth Hormone Deficiency (GHD) and for children with pituitary disorders. The American Association of Clinical Endocrinologists does not recommend growth hormone to prevent age-related muscle loss in otherwise healthy adults, due to a lack of information on long-term safety: http://www.aace.com/pub/pdf/guidelines/hgh.pdf ", "answer": 0}, {"article": "\"This is the first study looking at women who have failed so many other treatments,\" Krop tells WebMD.\nThe new drug, called T-DM1, combines Herceptin with a potent chemotherapy drug.\nDec. 15, 2009 (San Antonio) -- A new targeted cancer drug has been shown to shrink tumors in women with metastatic breast cancer after an average of seven other drugs, including Herceptin, failed.\nThe findings were presented at the San Antonio Breast Cancer Symposium.\nIn another 12%, tumors stopped growing for at least six months.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "By not mentioning that this was a Phase II trial \u2014 an early stage, uncontrolled, non-randomized study \u2014 and that the compound is still investigational, the\u00a0article is unclear about T-DM1\u2019s development status and prospects for becoming available in the future.\u00a0In addition, some of the results are preliminary, or \"immature\" according to\u00a0Genentech press release, with final results to be presented at a future meeting. The fact that these are early data is also not mentioned.\nThe article does mention that other studies of T-DM1 are ongoing and are comparing T-DM1 to other treatments. However, the key explanation is missing that the other ongoing trial is Phase III, and comparisons of T-DM1 to other treatments is the key to its FDA approval for use in patients.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/09/national/a005536S75.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability is clear from the statement that nevirapine \u201chas become a mainstay in the effort to prevent mother-to-child HIV transmission in poor countries\u201d. ", "answer": 1}, {"article": "Disease-free survival and overall survival three years after treatment were 48.3% and 55.8%, respectively.\nThis type of radiation therapy has not yet been approved by the FDA as a lung cancer treatment, but this study brings it one step closer.\nIn the study, researchers evaluated the safety and effectiveness of SBRT in treating 55 people with early-stage but medically inoperable lung cancer.\nResearchers say that rate of tumor control is more than double that found with conventional radiation treatment for inoperable lung cancer.\nA new study shows stereotactic body radiation therapy (SBRT) effectively controlled more than 87% of early-stage inoperable non-small-cell lung cancer tumors for up to three years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that SBRT is not FDA approved and is still \"experimental\" and in clinical trials. The story could have provided some information on how someone with inoperable lung tumors\u00a0could get access to the clinical trial. ", "answer": 1}, {"article": "Traditionally, highly sensitized patients in need of a kidney have languished on waiting lists because it's so hard to find a compatible donor.\nThose patients were all successfully treated with standard anti-rejection drugs, according to the researchers.\nIdeS is still experimental, and the only way patients could receive it is through a clinical trial.\nBut the findings mark another step forward for patients like these, according to Jordan, who is medical director of the kidney transplant program at Cedars-Sinai, in Los Angeles.\nLead researcher Dr. Stanley Jordan agreed that more work is necessary.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that the only way for patients to receive the experimental therapy at present is through a clinical trial, although it does not say where such trials are taking place or recruiting patients.", "answer": 1}, {"article": "Quitting can reduce the risk of heart attacks, strokes, and cancers of the mouth, throat, esophagus and bladder.\nThe U.S. Food and Drug Administration placed a black box warning - its most severe and restrictive warning - on the product in 2009, highlighting the drug\u2019s adverse neuropsychological effects.\nThis held true even after treatment stopped.\n\u201cThis is very strong support for changing clinical practice to include gradual reduction aided by medication.\u201d\n\nSmoking is the leading cause of preventable death in the U.S., according to the Centers for Disease Control and Prevention.\n\u201cIt offers compelling evidence that gradual reduction should be considered to facilitate quitting,\u201d she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that Chantix is already available in the U.S. and elsewhere.", "answer": 1}, {"article": "\"Blueberries are one of the more potent foods in terms of protecting the brain,\" Morris said.\nNow here are the five food groups it says you should avoid to reduce your risk of developing dementia...\n\nYou already know they're not so good for your waistline, and it turns out pastries and other sweets could have a negative effect on brain health as well.\nBut even if you slip up on the diet from time to time, the researchers say it can still have benefits.\nThe MIND diet recommends limiting yourself to no more than five of these treats per week.\nNow there's growing evidence that the same is true for your brain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Certainly all of the components of the MIND diet are available in most supermarkets.\u00a0 While there might be a problem in areas where supermarkets are scarce, overall the diet\u2019s foods are available. This would have been easy to mention in the story. Since the story did not touch on availability, however, we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "\u201cIt started out so innocent,\u201d his mother, Betty Vertin, told Newsweek.\nMany of the clinical trials failed to satisfy the statistical requirement to prove a drug works\u2014at least not for the main outcome the company was looking at.\nIf they do say no, the Vertins could lose access to the drug that has stabilized their condition.\nUntil then, Betty and her sons are living with a lot of uncertainty.\nTo Betty, the benefits are clear, even if they aren\u2019t easily quantified.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "A main point of narrative tension in the story is the family\u2019s wait to see if the FDA will approve the drug. So it is clear that the drug is not yet available.", "answer": 1}, {"article": "Dr Iain Foulkes, Cancer Research UK's executive director of research and innovation, said: \"It's exciting to see how Cancer Research UK's partnerships with both academia and industry are bringing urgently needed new tests and treatments to patients.\nThe trial is still ongoing, so results are not available yet.\nResearchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.\nProfessor Tony Barrett, from the Department of Chemistry, said: \"This work is the result of extensive collaboration between chemists, biologists and clinicians, which has helped to bring a new treatment from discovery to clinical testing in record time, streamlining the process.\"\nFrom early attempts, a large collaborative team was eventually founded for drug discovery from 'bench to bedside', directed by Dr Matthew Fuchter in the Department of Chemistry.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We applaud the news release for stating in the second paragraph that the \u201cdrug may not become available to patients for a number of years yet.\u201d Of course, the \u201cyet\u201d is optimistic; it remains to be seen whether this will ever become available.", "answer": 1}, {"article": "LONDON -- GlaxoSmithKline PLC said it has produced an effective bird-flu vaccine for humans and could begin producing the shots at year's end, leaving it to governments to decide whether to begin ordering the shots.\n\nGlaxo, the world's second-biggest drug maker by sales behind Pfizer Inc., called the findings a breakthrough but said it needs to gather additional data before it can answer several important questions, including how much of the vaccine it will be able to manufacture.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that Glaxo expects to submit the vaccine for FDA approval in the future. ", "answer": 1}, {"article": "Further,Dr.\nCrucially, this woman was in good health, suggesting that therapies aimed at blocking PCSK9 would not only be effective, but also safe.\nDr. Cohen, Professor of Internal Medicine and with the McDermott Center, holds the C. Vincent Prothro Distinguished Chair in Human Nutrition Research.\nTheir research led to the development by drug companies of evolocumab and alirocumab, the two approved PCSK9 inhibitors, which are delivered by monthly or semimonthly injections.\nTwo of these drugs, in a category known as PCSK9 inhibitors, were approved by the Food and Drug Administration last summer for use by some individuals with extremely high cholesterol levels.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the drugs have been approved by the FDA, and that at least one of them was available to the patient described in the release. The reader can infer that the drugs are available to the public.", "answer": 1}, {"article": "\"By actually (measuring) the brain network activity directly, you can look at really what is the functional health of the brain,\" he said.\n'Way too early to know'\n\nHowever, the editorial authors, Dr. William P. Meehan III of Micheli Center for Sports Injury Prevention at Boston Children's Hospital in Massachusetts and Dr. Rebekah Mannix of Brain Injury Center at Boston Children's Hospital, noted that \"the relatively small sample size in this study requires larger-scale studies to determine the reliability\" of the results.\n(CNN) A saliva test may someday be able to diagnose a concussion and predict how long symptoms last, according to a study published Monday in the JAMA Pediatrics.\nThe study was funded in part by Quadrant Biosciences, a biotech company that hopes to bring a saliva test for concussion to market in the next 12 to 24 months, Hicks said.\nDr. Jeffrey Kutcher, a neurologist and National Director of The Sports Neurology Clinic at The CORE Institute, said that \"work like this is important because it does provide potential for tests that can be helpful in the clinical setting.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story quotes the lead author of the saliva test study as saying that many hospitals and clinics already use the technology that would be needed to assess microRNAs in saliva. This implies that the saliva test could be readily available to patients if further research confirmed the association between specific microRNAs and prolonged concussion symptoms. The story does not provide any specific discussion of how long it could take or how much further study would be needed before the saliva test would be available for use. However, the story does communicate that the saliva test is not yet available.", "answer": 1}, {"article": "The hormone progesterone also feeds uterine fibroids, so blocking its effects may help treat painful fibroids.\nAlthough EllaOne is not available in the U.S., an FDA advisory panel recently voted that it should be.\nAs of now, EllaOne is used in Europe as a morning-after pill because it blocks the effects of key hormones -- namely progesterone -- involved in ovulation.\nThe new drug is manufactured by HRA Pharma, a European pharmaceutical company, which provided funding for the new study.\nIt is effective for up to five days after unprotected sex.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that EllaOne is available for emergency contraception only in Europe but is being considered for approval in the US.", "answer": 1}, {"article": "...\nThe U.S. Food and Drug Administration has not approved pharmacologic treatments for BED, according to background information in the study.\nSimilarly, BE episodes decreased in the 50- and 70-mg/d treatment groups.\nThe one-week BE episode response status was improved in the 50- and 70-mg/d treatment groups, and a greater proportion of participants achieved four-week cessation of BE episodes and global improvement of symptom severity with all lisdexamfetamine dosages.\nThe medication was administered in dosages of 30, 50 or 70 mg/day or placebo.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release\u00a0clearly indicates that the drug is already approved to treat other medical problems. It also indicates that the next step in making the drug available for the need at hand rests on \u201cconfirmation of these findings\u201d in additional clinical trials. This release was issued in January 2015, and the drug has subsequently been approved for the treatment of binge-eating disorder.", "answer": 1}, {"article": "Uridine, which is produced by the liver and kidneys, is also found in some foods as a part of RNA, which helps make protein in the body.\nWhether Souvenaid will slow the progression of Alzheimer's isn't known.\nTo be effective, all three compounds must be given together, the researchers said.\nBut more research is needed before the drink could be made available to the public.\nThere is, however, a longer trial going on that might answer that question, Wurtman said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The fact that there were no plans yet to market the product was explained.", "answer": 1}, {"article": "But from other research \"we know it's safe to place an electrode in the nucleus accumbens, it's safe to stimulate it electrically, and we expect to be able to tune [the electrode] as we already do with DBS.\nThe current study used a brain stimulation device already approved for hard-to-treat epilepsy.\nWhether this strategy could block harmful impulses in people remains unclear.\nTrouble is, the moderation wore off in a few days, and the DBS also interfered with the animals' social behavior.\nFiguring out if this biomarker would also work in people is challenging.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that this is very early research and that the treatment is not clinically available for behavioral problems.", "answer": 1}, {"article": "Nov. 24, 2016.\n\u201cWith standard aggressive chemotherapy, we only see about 20 to 30 percent of these patients achieving remission, which is the critical first step to have a chance to cure patients with additional therapies.\nBut new research indicates that such patients, paradoxically, may live longer if they receive a milder chemotherapy drug.\nThen, the researchers correlated these molecular markers with treatment response to identify subgroups of patients likely to benefit from decitabine.\n\u201cIt\u2019s exciting to think we may have a therapy that has the potential to improve response rates in this group of high-risk patients.\u201d\n\nThe research is supported by an AML-SPORE grant and the Genomics of AML Program Project grant, both from the National Cancer Institute at the National Institutes of Health (NIH), grant numbers P50 CA171963 and P01 CA101937.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that decitabine is an existing FDA-approved drug. However, its off-label use in this trial does not mean that it is now available for other AML patients. The researchers note repeatedly that larger trials are required.", "answer": 1}, {"article": "Studies have found that runners have significantly higher injury rates than walkers (one study found that young men who run or jog had a 25 percent higher risk of injuries than walkers), and that ultramarathoners are at an even greater risk.\nAll this research, while illuminating, didn\u2019t offer up any clear conclusions on whether running or walking was better for you overall.\nSo the answer to the running versus walking question will probably vary from person to person.\nBut even a small amount of running carries more injury risk than walking.\nToo little isn't helpful for health, but too much might be harmful.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While it\u2019s certainly true that some people in the United States\u00a0might have a harder time finding space places to run or walk, it\u2019s reasonable to argue that both activities are available to most everyone.", "answer": 2}, {"article": "Age-related macular degeneration (AMD) is a condition that affects older people.\nIt provides an image that has been magnified more than two times, the FDA says in a news release.\nIt is intended for use in only one eye because the other eye is used for peripheral vision, the FDA says.\nThe device is intended for patients 75 and older with severe to profound vision impairment that has been stable over time due to blind spots from end-stage AMD.\nTraining would also be needed to verify that there is sufficient peripheral vision in the untreated eye.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The focus of the story was on FDA approval of the device. ", "answer": 1}, {"article": "He says he plays basketball with his granddaughter, works on his farm, and gets on the treadmill for 30 minutes three times a week.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\nIt is stories like that that makes these results really encouraging.\"\nIt's early -- results are in for only the first 16 patients -- but the results already are drawing praise from experts not easily impressed by first reports.\n\"The reported benefits are of an unexpected magnitude,\" writes Gerd Heusch, MD, PhD, chair of the Institute of Pathophysiology at the University of Essen, Germany, in an editorial in the Nov. 14 online issue of The Lancet.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that these findings are from a small study early in the development of a stem cell therapy and that the treatment is not going to be available in the near term. It says that a \u201clarger, phase II study is planned.\u201d More important, it clearly states \u201cthe experimental treatment simply will not be available to other patients in the near future.\u201d ", "answer": 1}, {"article": "Ellis also is a McNair Scholar at Baylor.\nBased on the estimate that the new mutation is present in 2 to 3 percent of cases, the researchers calculated that approximately 4,000 to 6,000 patients with metastatic breast cancer carry a HER2 mutation and are therefore potential candidates for neratinib treatment.\nThe results of the clinical trial were encouraging in that about 30 percent of the 16 patients treated with neratinib had a meaningful clinical response showing significant disease stabilization or regression.\nIn addition to bringing to the table a novel treatment for metastatic breast cancer carrying a HER2 mutation, the researchers have tested the value of the circulating tumor DNA as a disease-monitoring marker.\n\"A circulating tumor DNA-based blood test also could therefore be potentially used to monitor tumor progression and to determine whether patients are responding or not to treatment after just one month of therapy,\" Ellis said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release didn\u2019t make it clear that more research is needed following the phase 2 trial. The release could have mentioned that neratinib has already been approved by the FDA for women with early-stage HER2+ breast cancers as a follow-on therapy.", "answer": 0}, {"article": "\"It didn't stop the drinking,\" says researcher David M. Penetar, PhD, assistant professor of psychology at McLean Hospital and Harvard Medical School.\nThe study is published in Drug and Alcohol Dependence.\n\"They still drank, but they drank less.\"\nHe studied the extract puerarin.\nIt is one of the substances known as isoflavones found in kudzu.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We wish the story had been clearer about the difference between the standardized kudzu extract that was tested in the study, which apparently is not yet approved for sale, and the other kudzu supplements that are widely available. Why is it ok to sell some kudzu root preparations as dietary supplements, while other extracts need approval from the FDA as though they were drugs? The story never tells us.\nThis confusion notwithstanding, the info needed to fulfill the criterion was presented in the article for those willing to puzzle it out, so we\u2019ll award a grudging satisfactory.", "answer": 1}, {"article": "In a related editor's note, Mitchell H. Katz, M.D., a deputy editor of JAMA Internal Medicine, writes: \"Of course, no study is perfect.\n\"The results of the PREDIMED trial suggest a beneficial effect of a MeDiet [Mediterranean diet] supplemented with EVOO in the primary prevention of breast cancer.\nMiguel A. Mart\u00ednez-Gonz\u00e1lez, M.D., of the University of Navarra in Pamplona and CIBEROBN in Madrid, Spain, and coauthors analyzed the effects of two interventions with the Mediterranean diet (supplemented with extra virgin olive oil [EVOO] or nuts) compared with advice to women to follow a low-fat diet.\nThe study was conducted within the framework of the large PREDIMED (Prevenci\u00f3n con Dieta Mediterr\u00e1nea) trial, which was designed to test the effects of the Mediterranean diet on the primary prevention of cardiovascular disease.\nThe intervention paradigm implemented in the PREDIMED trial provides a useful scenario for breast cancer prevention because it is conducted in primary health care centers and also offers beneficial effects on a wide variety of health outcomes.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the release that the foods in the Mediterranean diet are widely available. However, it might be harder to find certain component foods like fish, fresh fruits and vegetables, and extra virgin olive oil in some places in the U.S. (i.e. \u201cfood deserts\u201d). The release could have acknowledged this.", "answer": 1}, {"article": "Colic occurs during the first three months of an infant's life in which an otherwise healthy child cries and cannot be comforted for three hours or more every day.\nResearchers from the University of Turin, Italy, found that a few daily drops of Lactobacillus reuteri, a bacterium that can help improve digestion, significantly reduced crying among infants with colic.\nAll the infants were diagnosed with colic, born full-term at a healthy gestational weight, had no history of gastrointestinal disorders, were breastfed, not formula fed, and did not receive any other probiotic supplements during the week prior to the study.\nThe infants' mothers were also advised to avoid cow's milk in their own diets during the study period.\nAug. 16, 2010 -- A probiotic supplement may be an option for parents trying to soothe a colicky baby, according to a new study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not enough information here. The probiotic tested in this study is actually a commercially available product distributed by the study\u2019s sponsor, BioGaia\u2013information which was never provided to readers.\u00a0(More on this later under the \"Sources\" criterion below.) Moreover, the story\u00a0attributed the benefits\u00a0observed in the study to\u00a0the Lactobacillus reuteri\u00a0species of probiotic; it should have pointed\u00a0out\u00a0that the researchers\u00a0tested a specific commercial strain of\u00a0L. reuteri\u00a0known as\u00a0Lactobacillus\u00a0reuteri DSM 17 938. Different strains of the same probiotic are known to produce widely varying effects, so the\u00a0reduction in crying\u00a0observed in the study might not be seen with other strains of L. reuteri. \u00a0\u00a0\u00a0\u00a0", "answer": 0}, {"article": "The vegetarian diet consisted of vegetables, grains, legumes, fruits and nuts, with animal products limited to a maximum of one portion of low-fat yoghurt per day; the conventional diabetic diet followed the official recommendations of the European Association for the Study of Diabetes (EASD).\nHowever, we also showed that a vegetarian diet is much more effective at reducing muscle fat, thus improving metabolism.\nLosing muscle fat improves glucose and lipid metabolism so this finding is particularly important for people with metabolic syndrome and type 2 diabetes, says lead author, Dr. Hana Kahleov\u00e1, Director of Clinical Research at the Physicians Committee for Responsible Medicine in Washington DC.\nThey found that both diets caused a similar reduction in subcutaneous fat.\nUsing magnetic resonance imaging, Dr. Kahleov\u00e1 and colleagues then studied adipose (fat-storage) tissue in the subjects' thighs to see how the two different diets had affected subcutaneous, subfascial and intramuscular fat (that is, fat under the skin, on the surface of muscles and inside muscles).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes no statement about availability, but it seems at first blush that the\u00a0diet would be readily available. Then again, perhaps that\u2019s not the case since people who eat a conventional diet containing a lot of processed foods are very likely to turn to processed foods for their vegan or vegetarian meals, as well. Prepared vegetarian foods might be hard to find and expensive, not to mention not very tasty to everyone. To help clarify, the release could have pointed to resources that would help readers eat like participants in the study.", "answer": 2}, {"article": "Knee replacements were first offered in the 1960s, and hip replacements began in the 1940s, so many boomers are facing the same surgeries their fathers and mothers underwent.\nWhile physical activity obviously plays a role in joint deterioration, genetics may be the biggest factor in determining who needs a replacement and when, he said.\nBut he has already resumed golfing \u2014 on a March trip to visit his son and his family in Atlanta.\nBut having had the procedures, many say they wish they\u2019d done it sooner.\nAnd, he promised, \u201cI will get on the skates again.\u201d\n\nLike Smith, many boomers endured months or years of pain before surgery, pain caused by \u201cbone-on-bone\u201d friction when cartilage deterioration eroded their bone cushioning.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that knee replacements are widely available and covered by insurers.", "answer": 1}, {"article": "Among 46 chronic pain sufferers, those who spent time each day in a sauna for four weeks enjoyed a 54% improvement in sleep quality and were 27% more likely to return to work compared to a no-sauna group.\nBut if you\u2019re wondering whether an infrared sauna is worth a try, the evidence suggests you have little to lose and possibly something to gain by checking one out.\nWhile there\u2019s not a ton of published research looking specifically at infrared saunas, Beever has published a review of all the existing studies he could turn up on the subject.\nThe heart health benefits were even greater for men who sweated it out in a sauna more frequently.\nAnd, for now, there don\u2019t seem to be any significant health risks.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Saunas\u00a0can be found in many health gyms\u2013but what about infrared saunas, which is the focus of the piece? We\u2019re not told.", "answer": 0}, {"article": "A viral vector is a virus that has been modified to deliver foreign genetic material into a cell.\nIn fact, the experiment was largely successful, with cells now able to produce WAS protein, resulting in increased platelet counts and improvement of some immune-system cells.\nThe boy is currently on chemotherapy, the study authors noted.\nPreviously there had been some concern that drugs needed to get the stem cells out of the bone marrow and into the bloodstream where they could be accessed might pose a risk of leukemia.\nThe National Marrow Donor Program has more on Wiskott-Aldrich syndrome.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never explicitly addresses the availability of this new technique or how close it may be to approval. However, it does\u00a0note that the research represents just\u00a0a \u201cfirst step\u201d and \u201cproof of concept\u201d for the new approach. Although we would like to have seen\u00a0a more direct comment about the many years of testing that lie ahead for any therapy based on this technique, we think most readers\u00a0will understand that this is preliminary research and not something they\u2019re likely to have access to anytime soon.", "answer": 1}, {"article": "Bone-marrow transplants, which infuse healthy blood cells taken from a donor, are used when chemotherapy and radiation fail to stop cancerous blood cells from taking over and ultimately destroying a person\u2019s immune system.\nQuinn, who has a science background, knew that finding a donor would be difficult.\nIt\u2019s an indescribable feeling.\u201d\n\nIn haploidential transplants, rather than wiping out the patient\u2019s immune system, doctors use just enough drugs to suppress it.\nEverybody now has a donor, and that is a major advance.\u201d\n\nYet doctors and patients may not be aware there are choices other than conventional bone-marrow transplants, Jones said.\nUmbilical-cord stem cells, however, are sort of a blank slate because they haven\u2019t been exposed to much life \u2014 such as bacteria and viruses \u2014 and thus are more easily accepted even if they aren\u2019t a perfect match.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not make it clear how frequently these treatments are performed or how widespread they are. Does one have to travel to Seattle to have this treatment? It\u2019s unclear.", "answer": 0}, {"article": "Prostate cancer begins when cells in a man\u2019s prostate gland mutate and start to grow uncontrollably.\nThis procedure is the first in the world that is precise enough to potentially avoid negative ramifications like urinary incontinence or sexual impotency.\nCanfield worked closely with Halas and Nanospectra Biosciences, the company where the shells are licensed, to incorporate the state-of-the-art technology into the trial that is also underway at the Icahn School of Medicine at Mount Sinai and the University of Michigan to test the efficacy of the therapy.\n\u201cThe side effects of current prostate cancer treatments can be extremely traumatic.\nNewswise \u2014 HOUSTON \u2013 (Nov. 8, 2018) A small clinical trial using gold nanoparticles that act as tumor-seeking missiles on a mission to remove prostate cancer has begun at The University of Texas Health Science Center at Houston (UTHealth).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release gives the sense that this new technique is very experimental, and being done inside the bounds of a trial, but that is never made very clear. The trial will enroll only 45 patients and the follow up (a repeat biopsy) is only for 3 months.", "answer": 0}, {"article": "His doctor prescribed a C.P.A.P.\nBut not everyone finds that Provent alleviates their apnea.\nIn those people, Provent typically doesn\u2019t work.\nIt is also more expensive, and it doesn\u2019t work for every patient.\n\u201cMy symptoms subsided dramatically.\u201d\n\nProvent works like a traditional C.P.A.P.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this device is becoming more widely prescribed but is not necessarily found everywhere.", "answer": 1}, {"article": "They found that Chinese women who ate the most soy were also less likely to die of lung cancer, the No.\nIt wouldn\u2019t be difficult to eat enough soy to be protected, Patel noted.\n\u201cPeople should consider eating a diet that is healthy.\nStudies have shown that supplements containing soy protein don\u2019t have much health benefit.\nHow can people add soy to their diets?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of soy foods is not in question.", "answer": 2}, {"article": "Commenting, Professor Andreas Meyer-Lindenberg, Central Institute of Mental Health, Mannheim and member of the ECNP executive board, said: \"This work builds on previous studies that have shown a critical role of excessive activity of subregions of the temporal lobe in the generation of voice hallucinations in schizophrenia.\nThis is the first controlled trial to show an improvement in these patients by targeting a specific area of the brain and using high frequency TMS.\nTo move this into treatment, controlled trial such as the one by Dollfus and coworkers are important.\nFor the first time, scientists have precisely identified and targeted an area of the brain which is involved in \"hearing voices\", experienced by many patients with schizophrenia.\nNOTE: The full title of this release is \"Scientists discover brain area which can be targeted for treatment in patients with schizophrenia who 'hear voices'\" It has been shortened in some versions to comply with Eurekalert title limits.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not address availability of TMS for treatment of AVHs specifically. The release does note that TMS \u201chas been shown to be effective in several psychiatric conditions.\u201d However, it\u2019s not clear from the release how widely available TMS is, or even whether it is clinically available at all. This may be because the release is aimed more at practitioners (who are aware of TMS\u2019s availability) than at a more general audience. However, since many reporters and news consumers don\u2019t have that professional background and insight, it would be much better to simply address the issue of availability head on.", "answer": 0}, {"article": "Hair changes about as fast as grass grows, which is to say it\u2019s extraordinarily slow and not visible to anyone checking impatiently in the mirror every day.\nFor now, Maryanne Senna, a dermatologist and the director of the Hair Academic Innovative Research Unit at Massachusetts General Hospital in Boston, said the best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\nClients must also use the company\u2019s shampoo, conditioner and styling products, forsaking all others \u2014 a psychological as well as a financial buy-in, Dr. Senna said.\nOne is how much emphasis the company places on compliance, the major stumbling block in the efficacy of any treatment, said Dr. Senna, an author of studies on the subject.\n(Mr. Skjoth, who has a master\u2019s degree in nutrition and chemistry but is not a doctor, said this is because other products may clog the scalp, causing hair loss.)\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the company \u201cis beginning an aggressive expansion into the $3.6 billion hair-loss market in the United States, meaning you\u2019re likely to hear a lot more about it.\u201d It also mentions clinics has a physical presence in New York City, Florida and Beverly Hills, Calif., and plans to \u201chave a presence in every state in the next two years.\u201d The product also appears to be available online.\nThe story also says that the company is \u201coffering a customized hair extract that\u2019s given only to those who pass a fairly rigorous selection process,\u201d and its products \u201care not available to anyone with autoimmune illnesses like alopecia or baldness from scarring, or anyone who is unlikely to see at least a 30 percent increase in growth.\u201d\nThe story also mentions that the treatment requires nightly six-hour applications, which could be prohibitive for some people.", "answer": 1}, {"article": "Other ways women can protect their bones as they age include weight-bearing exercise, and osteoporosis drugs for women at high risk for fractures.\nIt's important to note that calcium intakes on food labels are based on adult requirements of 1,000 milligrams per day.\nThe message here, Senay says, is that calcium supplements are useful for bone health \u2014 but you should only take them if you do so regularly, as directed by a doctor.\nNow, says Senay, a study in the Archives of Internal Medicine shows calcium supplements do reduce the risk of fractures in elderly women, but only among those who take them regularly.\nSupplements are an additional tool to be used when needed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if the supplements are available, if they are available over the counter and if you can buy them in the formulation used in the study (600mg 2x/day).", "answer": 0}, {"article": "Their average age was 69.\nAn editorial accompanying the study said which drug is selected may be less important than identifying and starting an approved treatment.\nThere needs to be a large head-to-head trial between Forteo and abaloparatide, she said, to really see which drug is better.\nAbaloparatide works differently from Forteo and improves bone density more than Forteo, Miller said.\nAbaloparatide and Forteo are synthetic peptides that help grow and strengthen bone, Miller said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that abaloparatide is currently in a Phase 3 trial stage.", "answer": 1}, {"article": "\"Your eyes look like they're responding beautifully!\"\nThe medical procedure was developed by a husband-and-wife team \u2014 eye surgeon Dr. Al Maguire and gene therapy expert Dr. Jean Bennett.\nBut the most dramatic result brought Manuela one step closer to her dream of reading.\nShe told ABC's \"Good Morning America\" today she always hoped for a medical miracle.\n\"She said 'no problem,' which was probably oversimplified.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not explain that the procedure is not ready for general application.\u00a0 It does not make clear\u00a0 that this is part of an on-going clinical trial currently recruiting study subjects.\u00a0 Instead, it referred to the experiment as \"a medical milestone\" and as \"a cutting-edge therapy.\"\u00a0 It\u2019s not yet a therapy.\u00a0 It\u2019s an experiment. \n\u00a0", "answer": 0}, {"article": "It will still grow shorter and slower than scalp hair,\u201d he said.\n\u201cHe had resorted to cropping his hair short to obscure the problem.\u201d\n\nWith the patients under local anesthesia, Dr. Umar used a device that creates microscopic wounds around hair follicles in the back of the leg; the follicles were then removed and transplanted to the hairline.\nIn each case, Dr. Umar and his team extracted about 1,000 leg hair follicles and grafted them, one by one, to the patients\u2019 hairlines.\nAbout 75 to 80 percent of the transplanted leg hair grew successfully on the patients\u2019 heads after the operations, and both men were happy with the results, Dr. Umar said.\n\u201cThe hairline was fully grown and soft-looking by nine months\u201d in the 35-year-old, he wrote, \u201cat which time the patient started combing his hair backward and sporting a ponytail, exposing his hairline comfortably.\u201d\n\nSince then, Dr. Umar has done eight more of the procedures, including one in a woman.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "From the claims made at the top of the story, one would think that there is only one place in the world to undergo this technique: a clinic in Redondo Beach, California. That does not appear to be the case. In a brief online search, we were able to identify multiple dermatologists who suggest transplanting of hair from legs, chest and pubic region.", "answer": 0}, {"article": "Dozens of biotechnology and pharmaceutical companies including Alnylam, Merck, Pfizer, Novartis and Roche are looking for ways to manipulate RNA to block genes that make disease-causing proteins involved in cancer, blindness or AIDS.\nBut getting the treatment to the right target in the body has presented a challenge.\nThe finding, reported in the journal Nature on Sunday, offers early proof that a new treatment approach called RNA interference or RNAi might work in people.\nDavis could not say whether the therapy helped shrink tumors in the patients, but one patient did get a second cycle of treatment, suggesting it might be.\nDavis said that part of the study will be presented at the American Society of Clinical Oncology meeting in June.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "An astute reader can probably figure out that this experimental approach isn\u2019t available yet.\u00a0 But the story never really says that.\u00a0 Instead, rather than calling it an \"experimental approach,\" the story calls it a treatment approach.\u00a0 We think the semantics are important.\u00a0 It\u2019s not a treatment yet.\u00a0 It\u2019s an experiment. ", "answer": 0}, {"article": "In the United States, the National Heart, Lung and Blood Institute, a unit of the National Institutes of Health, is supporting efforts by two separate groups, one led by Dr. O. H. Frazier of the Texas Heart Institute in Houston, the other by Dr. Leonard A. R. Golding of the Cleveland Clinic.\nAnother device is being developed by scientists at the Helmholtz-Institute for Biomedical Engineering at the University of Aachen in Germany.\nThe device was developed over 15 years by a team that included Alain F. Carpentier, the French surgeon-scientist who, along with Albert Starr, received the 2007 Albert Lasker Award for Clinical Medical Research.\nCiting World Health Organization data that shows heart disease is the world\u2019s leading cause of death, Mr. Conviti, the Carmat chief executive, estimated the potential market at \u201ca minimum\u201d of 100,000 patients a year in the United States and Europe.\nCarmat estimates its device will cost $176,000 to $226,000.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that human testing is far off:\u00a0 \"The company hopes to start human testing in France by the end of next year.\"", "answer": 1}, {"article": "Larry Holzman \u2014 avid mountain-biker, skier and guitarist in a band \u2014 plays hard.\nNot all physical therapists are sold on the FlexBar.\nBut he understands the appeal: The FlexBar is easy to use and you can do it at home.\nAnd the FlexBar makes it simple to do this kind of stretch.\nIt usually happens when people grip things too hard or too long.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that the FlexBar is commercially available.", "answer": 1}, {"article": "One 2016 study compared Coolief to popular cortisone injections, with patients reporting greater, longer-lasting pain relief with the new treatment than injections.\nBecause it was just approved by the FDA in April, the treatment is not widely available yet, but pain centers across the country are beginning to offer it.\nCoolief can be repeated if necessary, but it's not a permanent solution.\nSome of the reported risks from the procedure include bleeding and infection.\nMarketed as \"Coolief\", the procedure uses radio frequency to target and mute the nerves responsible for sending pain signals from the arthritic knee to the brain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Recent approval by the Federal Drug Administration means that the technique is not yet widely available, the story notes.", "answer": 1}, {"article": "Angioplasty, which uses a balloon to open blocked arteries, has been a popular alternative to bypass surgery in part because it brings less trauma to the patient.\nUsing robotics to bypass major blocked arteries and putting stents in other blocked arteries is gaining some currency, Rabbitt said, although few surgeons have come close to Srivastava's familiarity with the robot.\nSrivastava said it is true that the normal sense of touch is missing from robotic work, and that is a shortcoming, but it can be overcome with practice.\nFor Mary Lou Coulter, 77, of Westville, Ind., the main aftereffect of her robotic procedure was some soreness and numbness.\nThe maker of the robotic systems, Intuitive Surgical Inc. of Sunnyvale, Calif., is an enthusiastic backer of the University of Chicago's initiative.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does not clearly\u00a0state how widely robotic treatments are available, either for bypass surgery or other operations. The article reports 504 units are in use in the U.S., but it\u2019s not clear how they are distributed or what they are used for, even in the Chicago area. Nonetheless, we\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "Co-authors are Evgeny Pokushalov, M.D.\nIf confirmed in heart bypass patients, Botox injections could also help prevent AF in people undergoing valve repair or replacement.\nThe results must be replicated in larger studies before Botox injections are routinely used to prevent AF after bypass surgery, researchers said.\nAbout half of those patients will develop AF after surgery.\nTo avoid bias, neither patients nor doctors knew whether the injections contained Botox or saline.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since the release makes no claim that this therapy is ready to be used outside of clinical trials we\u2019ll give this a satisfactory. The story makes it clear that botulinum toxin is available and is routinely used in cosmetic dermatology. For that use it\u2019s sold under the trade name Botox Cosmetic. However, there are four different FDA approved strains of the toxin. Various formulations of the toxin have received\u00a0 FDA approval for use in treating excessive sweating, migraines, dystonia, bladder control issues, and several other non-cosmetic conditions. Those formulations have been available for many years as well. Since this is the first time botulinum toxin has been tested in human hearts, it\u2019s safe to say that it could be several years before it receives approval as a preventative for heart complications. The release is clear that larger studies are needed.", "answer": 1}, {"article": "When that occurs, the next step is to examine the suspicious area, with the physician ordering a biopsy or inserting a scope into the lungs to evaluate further.\nIf perfected, the test could help spare patients the need to undergo invasive procedures such as biopsies when lung cancer is suspected, they predict.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\nHe is the senior author on the study, presented at the American Association for Cancer Research-International Association for the Study of Lung Cancer's joint conference in Coronado, Calif.\n\nAbout 219,000 new cases of lung cancer were expected to be diagnosed in the U.S. in 2009, according to the American Cancer Society, and about 159,000 deaths were expected.\n''Currently, 20% to 25% of surgeries done for suspected lung cancer turn out to be benign diagnoses,\" says Steven Dubinett, MD, professor of medicine and pathology and director of the Lung Cancer Research Program at the Jonsson Comprehensive Cancer Center at the David Geffen School of Medicine, University of California, Los Angeles.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story acknowledges that the results are preliminary and the test is [in the best-case scenario] a few years away from being clinically available. The investigator\u2019s quote that \"It might take three or four more years before these tests are clinically available\" assumes the test will be proven valuable in trials, which is a premature claim. Availability is not inevitable.", "answer": 1}, {"article": "\"Migraine is one of the most disabling conditions known to man, but patients need to know that there is hope,\" says Stephen Silberstein, a neurologist at Thomas Jefferson University in Philadelphia and lead author of the guidelines from the American Academy of Neurology and the American Headache Society.\nNot everyone with migraines needs prevention medicine.\nStill others try the treatments and decide they don't work or have unacceptable side effects.\nBut about 80% will get relief, he says \u2014 defined as a headache reduction of at least 50% \u2014 after trying three or four drugs, alternative remedies and lifestyle changes.\nFinding the right medication for the right patient can take a lot of trial and error and careful dosing, Silberstein says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s apparent from the story that these drugs are widely available.", "answer": 1}, {"article": "\"During immersion in water, particularly cold water, susceptible people have an exaggerated degree of the normal redistribution of blood from the extremities to the chest area, causing increased pressure in the blood vessels of the lungs and leakage of fluid into the lungs,\" said Richard Moon, M.D., an anesthesiologist and medical director of the Duke Center for Hyperbaric Medicine & Environmental Physiology.\nHe also said research is ongoing to further illuminate the causes of SIPE and potential ways of diagnosing it early.\nShe coughed up blood and was once hospitalized.\nIn addition to Moon, study authors include Stefanie D. Martina, Dionne F. Peacher, Jennifer F. Potter, Tracy E. Wester, Anne D. Cherry, Michael J. Natoli, Claire E. Otteni, Dawn N. Kernagis, William D. White, and John J. Freiberger.\nMoon and colleagues studied these responses in 10 athletes who had experienced the condition while exercising or competing in triathlons.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The very first sentence of the release characterizes sildenafil as \u201creadily available.\u201d Indeed it is. It is Viagra \u2122.", "answer": 1}, {"article": "Ulcerative colitis, which affects about 38,000 people in the United States annually, is a chronic condition causing abdominal pain, intestinal ulcers, bloody diarrhea and weight loss.\nBoth 6 mg/kg and 130 mg doses of the intravenous treatment showed clinical remission in significantly more patients, compared with those on placebo, after eight weeks, the company said.\n\u201cMore than half of UC patients have not experienced remission with currently available treatment options,\u201d the study\u2019s lead investigator Bruce Sands said.\nThe treatment and the placebo arms reported similar proportion of side effects, with one patient on the 6 mg/kg dose dying following excessive bleeding, J&J said.\nCurrent treatments include Pfizer Inc\u2019s Xelijanz, an oral treatment for adults patients with moderate-to-severe UC, and Merck & Co\u2019s Renflexis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Stelara is already on the market. However, it\u2019s not clear whether Stelara could currently be prescribed \u201coff label\u201d to patients suffering from UC. Nor is it clear whether the \u201clate-stage\u201d trial is still ongoing or has been completed. Is there a pathway to FDA approval? If so, what might the timeframe be?\nThe complexity of the drug approval process is such that news reports should help the public understand that this use of the drug is still experimental. that although the drug may be used \u201coff-label,\u201d it is not clear whether the company is seeking to broaden the FDA-approved indications or drum up interest among clinician researchers to design their own clinical trials.", "answer": 0}, {"article": "Merck & Co. and Schering-Plough Corp. said a long-awaited trial showed their cholesterol drug Vytorin failed to slow progression of heart disease better than a cheaper drug, threatening the companies' $5 billion-a-year cholesterol-fighting franchise.\n\nSchering-Plough's shares fell 8% to $25.52 and Merck declined 1.3% to $59.78 at 4 p.m. in New York Stock Exchange composite trading.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The drug detailed in the story was described as heavily marketed direct to consumers and several clinicians\u2019 quotes included in the story questioned the wisdom of prescribing this medication. \u00a0", "answer": 1}, {"article": "July 14, 2010 -- An experimental weight loss drug that targets the brain\u2019s hunger center was shown to be safe and effective for helping dieters shed pounds in a two-year study, researchers say.\nThe company hopes to win FDA approval to market the new drug later this year.\nBy the end of year one, 55% of the patients in the placebo group and 45% of those taking the diet drug had dropped out of the study.\nThe study appears in the July 15 issue of the New England Journal of Medicine.\nHe says that all the patients in the study were monitored closely for heart valve irregularities, and no difference was seen in the two treatment groups.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is still in trials although it could have done a better job explaining how far it has come and what steps it still has to take to win approval. ", "answer": 1}, {"article": "Oxytocin,which is produced in abundance when a mother is breast-feeding her baby, is known as the \"bonding\" hormone.\nAlso, scientists would need to come up with a different method of delivery, Young said.\nThere were, however, wide variations in individual responses, the team noted.\nWhile there are drugs for the secondary symptoms of autism, such as irritability and aggression, doctors have nothing yet for the core symptoms in the areas of language, social interaction and intellectual deficits.\nAlthough there are many kinks to be worked out, experts feel the strategy holds promise to treat one of the core symptoms of autism spectrum disorder.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that the strategy used in this laboratory study is uNPRoven in the real world, particularly in children and young adults. They even note the issues in translating the delivery method to clinical practice.", "answer": 1}, {"article": "June 28, 2010 -- Cholesterol-lowering statin drugs appear to reduce the risk for prostate cancer recurrence in patients who have had a surgical procedure called radical prostatectomy.\nBut the fact that the fewest recurrences were seen in men who took the highest statin doses is compelling, says senior investigator Stephen J. Freedland, MD, of the Duke Prostate Center.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nThe research does not prove that taking cholesterol-lowering drugs directly slows the growth and progression of prostate cancer.\nThose who took the highest doses saw their recurrence risk drop by half.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Statins are widely available under several brands, many of which are mentioned in the story. At the same time, the reporter does explain that additional study would be needed before doctors would know whether to prescribe statins to prostate cancer patients and at what point in their treatment regimen.", "answer": 1}, {"article": "American veterans coping with PTSD are traveling to lodges in the Amazon that offer ayahuasca, a hallucinogenic brew. Some say it has helped them manage emotional trauma from war, but others say it\u2019s not worth the journey. Photo: Ryan Dube/WSJ\n\nAfter surviving firefights and a roadside bomb in Afghanistan, U.S. Army veteran Asa Barrett tried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\n\nBut then, like many other foreigners, he journeyed to Peru\u2019s remote Amazonian jungle to drink ayahuasca, a centuries-old, sacred indigenous brew that some Western scientists think can help to heal psychological traumas.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story describes numerous \u201cayahuasca centers\u201d that have cropped up around the city of Iquitos in Peru\u2019s northeastern Amazon.", "answer": 1}, {"article": "Before the introduction of whooping cough vaccine in the 1940s, more than 200,000 cases a year were reported in the U.S. By 1965, that number plummeted to fewer than 10,000 a year. But the disease made a comeback in the 1990s, as the newer \"acellular\" vaccine \u2014 containing only cellular material but not whole cells \u2014 was phased in. While it is safer and has fewer side effects than the old version, studies have found that its protective effects wane more quickly than originally expected.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is widely understood that these vaccines are available to almost everyone. The story notes only half of pregnant mothers receive the vaccine, which is important and why the CDC is researching the topic.", "answer": 1}, {"article": "Greek researchers offered fresh evidence of the health benefits of the Mediterranean diet, reporting in a large study that it helps improve several risk factors linked to diabetes, obesity and heart disease.\n\nThe Mediterranean diet is high in monounsaturated fats such as olive oil and also relies heavily on whole-grain cereals, fruits and vegetables, fish and low consumption of animal fats. It has been shown in numerous studies and clinical trials to reduce mortality from such causes as cardiovascular disease and cancer.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story included an outline of the foods that are included in a \u2018Mediterranean diet\u2019 , enabling readers to appreciate that these foods are available in grocery stores.", "answer": 1}, {"article": "\"Regorafenib has shown it can improve survival in patients with advanced hepatocellular carcinoma progressing on sorafenib.\nThis trial provides evidence that regorafenib is the first systemic treatment for patients whose HCC progressed during treatment with sorafenib, the only other drug with proven clinical benefit.\nThe success of this trial opens the field for testing drugs in third-line treatment of HCC and provides a rationale to test regorafenib as a first-line treatment or in combination with therapies administered directly into the tumor or diseased liver in patients in an earlier stage of HCC, according to Dr. Llovet.\n(New York, NY - January 18, 2017) An international phase 3 trial has found that the drug regorafenib improved survival in patients with advanced hepatocellular carcinoma (HCC), a form of liver cancer, giving people who previously had no other options a better chance at survival.\nThis study tested regorafenib's effectiveness as a second-line therapy on 573 patients previously treated with sorafenib, 194 of whom were given a placebo.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does tell readers that \u201cIn January, Bayer announced that the U.S. Food and Drug Administration had granted priority review status for Stivarga (regorafenib) as a second-line systemic treatment for patients with hepatocellular carcinoma.\u201d However, the release doesn\u2019t tell readers that regorafenib has already passed FDA review for treatment of other cancers, nor does it explain to readers what \u201cpriority review status\u201d means in terms of when the drug might be used for HCC treatment on a widespread basis.", "answer": 0}, {"article": "The fibers within the tendons fray.\nBut that cautionary experiment and others didn\u2019t slow the ascent of cortisone (also known as corticosteroids).\n\u201cIt\u2019s not insignificant, but it\u2019s not kidney stones.\u201d\n\nSo the question of whether cortisone shots still make sense as a treatment for tendinopathies, especially tennis elbow, depends, Dr. Khan said, on how you choose \u201cto balance short-term pain relief versus the likelihood\u201d of longer-term negative outcomes.\nWhy then does a cortisone shot, an anti-inflammatory, work in the short term in noninflammatory injuries, providing undeniable if ephemeral pain relief?\n\u201cThey change the pain biology in the short term.\u201d But, he said, cortisone shots do \u201cnot heal the structural damage\u201d underlying the pain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe story explained the history of steroid injections, hinting at trends in availability. Steroid injections are widely available in both primary care and specialty settings. .\n", "answer": 1}, {"article": "The Web site naturalaugmentation.com lists several doctors, mostly ob-gyns and family medicine physicians, not plastic surgeons, who offer coupons for \u201cnatural augmentation\u201d and even something called \u201cstem-cell breast augmentation.\u201d\n\nA company called makes a machine used in that concentrates the cells within fat tissue that aren\u2019t strictly fat cells, including .\n\u201cAnyone can take fat and inject it into the breast, and the patient will look good immediately afterwards,\u201d Dr. Khouri said, but a few months later, the fat injected by a doctor with sub-par skills may result in \u201coil cysts, masses, and scarring.\u201d\n\nTo some, this kind of fat recycling seems simple.\nNor has \u201cconcentrating\u201d cells in fat been proved to make a difference in controlled studies, said Dr. Karol A. Gutowski, chairman of the plastic-surgery society\u2019s task force.\n\u201cI didn\u2019t have to put anything foreign in my body.\u201d\n\nAt the October meeting of the American Society of Plastic Surgeons, Dr. Khouri presented a long-term study that suggested liposuctioned fat was now a \u201cviable alternative to breast implants.\u201d It tracked 50 women, ages 17 to 63, for an average follow-up of 3.5 years.\nThe pleased mother of three in the news clip said her breasts grew \u201covernight,\u201d which is misleading.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThis story points out that only a handful of surgeons across the country offer breast augmentation using fat grafts and that the results are highly dependent on the skill and experience of the surgeon. The story also warns about doctors who promise unrealistic results.\n However, the story offers readers no information about how to locate a surgeon who has a good track record.", "answer": 1}, {"article": "Normally it's the very old or very young that die from flu, but every year there are deaths from influenza A,\" said Gilbert.\nThe initial results are positive, says Peter Palese, professor and chair of microbiology at Mount Sinai School of Medicine, New York, but more research is needed before the new treatment is approved.\nThe vaccine would be an important step in treating seasonal flu, not just pandemics.\n\"Whether it's this vaccine or another one someone else develops, I don't think we'll be continuing with the type of flu vaccines that we have at the moment.\"\n\"It took a further six months before it was possible to vaccinate a large number of people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the vaccine is in the early stage of development and will not be available for at least several more years. ", "answer": 1}, {"article": "Highlighting the significance of the findings, the study\u2019s senior author, George A. Macones, MD, the Mitchell and Elaine Yanow Professor and head of the Department of Obstetrics and Gynecology, said, \u201cThis study is a tremendous addition to the literature on preventing surgical-site infections after cesarean.\nBut according to Tuuli, the unique circumstances of a C-section \u2014 that bacteria come from both skin and vagina and that a woman\u2019s immune system is altered during pregnancy \u2014 mean the results of these studies may not apply.\nThere are few circumstances when a single study should change our practice.\nThe researchers argue that the evidence is strong enough to change standard skin-prep practices for C-sections.\nA new study from Washington University School of Medicine in St. Louis offers strong guidance on the best way to reduce the infection risk.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We believe both skin-cleaning agents are widely available. So while the release never explicitly addresses availability, we don\u2019t dock points for this.", "answer": 2}, {"article": "Eating more fiber during adolescence was linked to a 16 percent lower risk of breast cancer overall, and a 24 percent lower risk of breast cancer before menopause.\n\"The results of this study emphasize the role of an early life high-fiber diet on prevention of breast cancer in later life.\nEating more fruits and vegetables was especially beneficial, the researchers said.\n\u2022 Lesser-known signs of breast cancer women should watch out for\n\nDr. Deanna Attai, assistant clinical professor of surgery at the David Geffen School of Medicine at the University of California Los Angeles, said that while it's an observational study, not a clinical intervention, its larger point about diet and health is important.\n\"Having the recommended 25 to 30 grams of fiber daily would decrease the risk by 30 percent and potentially even greater with higher fiber intake,\" Farvid said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There are no new products or services at issue in this story, and we addressed access to healthy foods under \u201cCost,\u201d so we\u2019ll rate this not applicable.", "answer": 2}, {"article": "Suits against tobacco companies have sought to force cigarette makers to pay for annual CT screens of former smokers.\nAnd they pointed out that the study offers no reassurance about the safety of smoking or the advisability of CT scans for younger smokers or nonsmokers.\nBut health officials involved in the study refused to endorse widespread screening of current or former smokers, saying more analysis of the study\u2019s results is needed to further identify who benefited most.\n\u201cWhat we also have found is that low-dose CT scan gives information on cardiovascular disease, emphysema\u201d and other pulmonary diseases, Dr. Henschke said.\nDr. Claudia Henschke, a clinical professor of radiology at Mount Sinai Medical Center and a longtime advocate for use of CT to screen for lung cancer, said the study was likely to have underestimated the benefits of CT scans because participants were screened only three times.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nWhile it may seem obvious that CT scanning is widely available, this trial used a specific and rigorous protocol for selecting the type of low-dose CT scanners used, how they were maintained and operated, as well as certifying the training and practices of the radiologists who interpreted the scans. The sort of CT machines, operators and radiologists generally available to smokers may not meet the demanding standards of this trial and thus may not be able to match the results.", "answer": 0}, {"article": "The home self-collection test indicated that 12.4 percent of women were infected with high-risk HPV, the self-collection tests used in the clinic found 15.5 of the women had high-risk HPV infection, and the clinician-collected test identified 11.4 percent of the women had high-risk HPV infection.\nThe brush samples were then tested in a lab for HPV and other sexually transmitted infections.\nOffering HPV testing using self-collection by mail has a lot of potential to reach women who are the highest risk of being screened: those who don't access regular medical care.\"\n\"This is a proof-in-principle study that we used to determine whether home self-collection is highly effective for detecting high-grade disease,\" Smith said.\n\"We are already working on the next step, which is a clinical trial in which women who aren't up-to-date on screening get either a referral to a free clinic appointment to receive a screening, or receive a self-collection kit in the mail, followed by referral to a free clinic appointment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the release that at-home, self-collected screening samples are not even close to being adopted for widespread use.", "answer": 1}, {"article": "He explained: \"When teixobactin was discovered it was ground breaking in itself as a new antibiotic which kills bacteria without detectable resistance including superbugs such as MRSA.\nThe Lincoln team has successfully synthesized new simplified versions of teixobactin which harness the same powerful antibiotic effects in a way that could be produced on a commercial scale.\nWe have been investigating a way to simplify the design while retaining the high potency against resistant bacteria such as MRSA.\nThe work builds on the success of the team's pioneering research to tackle antimicrobial resistance over the past 18 months.\nThe breakthrough by researchers at the University of Lincoln, UK, marks another important step to realising the potential of teixobactin in aiding the global fight against antibiotic-resistant pathogens.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that this work is a step closer toward creating drug treatments. There are no claims about how long subsequent testing and development may take. However, the failure to point out that this work is confined to laboratory tests and that human clinical trials have yet to begin implies a shorter path to potential clinical use than seems likely.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28healthwatch.lede.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The story didn\u2019t discuss availability of multivitamins but this is common knowledge.\u00a0 ", "answer": 2}, {"article": "A new study confirms that long-acting forms of contraception such as intrauterine devices and implants are better than birth control pills and patches at preventing pregnancies, giving doctors new ammunition to recommend these methods.\n\nThe study, to be published Thursday in the New England Journal of Medicine, involved about 7,500 women in a project promoting long-acting birth control to reduce unintended pregnancies. There are an estimated three million unplanned pregnancies a year in the U.S., often because of incorrect or...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The higher cost of IUDs and implants can be a significant barrier to availability, as can access to health care providers trained to insert these devices. The story briefly mentions cost issues and lack of insurance coverage for these two options, but it is not clear how often lack of access to care affects availability.\u00a0 We\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "Staying sexually active\u2014and considering sexuality an important part of life\u2014may be linked to higher cognitive functioning as people age, according to a study in the March issue of the American Journal of Geriatric Psychiatry.\n\nOlder men and women who were satisfied with their sexual relationships and considered sexuality an essential component of aging performed better on tests of cognitive function than those who felt sexuality and intimacy were unimportant, the research showed.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t address any of the health problems or other issues that can make sex less available or fulfilling for older adults. For example, the death of a spouse, erectile dysfunction, arthritis, chronic pain, etc. Then again, these factors may not affect availability of sex for the elderly as much as we think \u2014 what goes on in assisting living facilities may surprise us all.\u00a0Regardless, we\u2019d like to see the story explore this. We\u2019d reiterate that people in worse overall health are also likely to have worse brain function and have less ability to perform sexually. This is an example of where our EVIDENCE and AVAILABILITY criteria comments overlap, but build on each other.", "answer": 0}, {"article": "\"Cancer patients tend to develop clots in their legs and lungs more frequently and also patients who develop clots in their legs and lungs tend to develop cancer more frequently,\" Choe noted.\nOf the almost 2,000 patients on anticoagulants in the study, 1,649 were taking aspirin, 428 warfarin, 287 clopidogrel (Plavix), 26 enoxaparin, and 408 a combination of blood thinners.\n\"This benefit was seen whether these patients were treated with surgery or radiotherapy,\" Choe added.\nAn initial review at six years suggested that those taking the combination therapy had a 43 percent reduced risk of dying from prostate cancer, while side effects were not \"major,\" Mason said.\nAt 10 years, 4 percent of those taking one of these medications had died versus 10 percent in no-blood thinner group.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe study looked at the use of available anticoagulant medications.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070805/13knee.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the Gender Knee is generally available to women who are candidates for total knee replacement.", "answer": 1}, {"article": "It\u2019s of phenomenal significance in that regard,\u201d he told Reuters.\nExperts described the study results as phenomenal and said the device, developed by German researchers, could eventually change the lives of up to 200,000 people worldwide who suffer from blindness due to a degenerative eye disease called retinitis pigmentosa.\nZrenner said further trials of the implant should be completed in two to three years and if those proved successful the device could be on the market and available for thousands of patients in about five years\u2019 time.\nEberhart Zrenner, chairman of the University of Tuebingen Eye Hospital in Germany and director of a small company called Retinal Implant AG which is developing the device, said the trial results were a \u201cproof of concept\u201d and would now be taken into further trials in around 25 to 50 patients in Europe.\nThe implant device, which sits completely within the eye, is a tiny plate, measuring just 3 mm squared and a 10th of a millimeter thick, which has around 1,500 tiny light sensors connected to amplifiers and electrodes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a credible job noting that the device is under study and not commercially available. Unfortunately it also suggests, based on the manufacturer\u2019s statement, that the device in a very early stage of development will be available in 5 years. The hyperbole used is indefensible \u2013 \u201cthe device could become routine for some kinds of blindness in five years\u201d\u00a0and \u201ccould eventually change the lives of up to 200,000 people worldwide.\u201d\u00a0 This comes after a test in 3 people.", "answer": 0}, {"article": "\u201cA 5 percent loss of weight is associated with a 50 percent lower risk of diabetes and a 10 percent loss is associated with an 80 percent lower risk.\u201d\n\nPatients in Bohula\u2019s study did see improvements in hypertension and blood sugar levels with weight loss.\nNo one medication for hypertension works for every single person.\nThe latest generation of drugs seems to do just that.\nI think a lot of physicians are uncomfortable prescribing weight loss medications.\n\u201cThat\u2019s why treatment of hypertension is so effective.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that, in general, the \u201clatest generation\u201d of weight loss drugs are FDA approved. But it never explains which ones fall under that category. There are at least nine weight loss drugs on the market.", "answer": 1}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is a tricky one. Because the study was funded by Jenny Craig, it seems some mention of how widespread Jenny Criag programs are would have been warranted. Absent that, the story could have said how easy it might be for the typical person to find a diet program of any sourt that would provide people once-weekly face-to-face counseling, which was the regimen that had the best results \u2013 and for free! It might seem obvious that these programs are popping up all over the place, but they are not uniformly available, especially in rural and poor areas in counties that have high concentrations of obesity. If the story had even mentioned how many Jenny Craig centers (according to the company\u2019s website it is 565) we would have given this one a passing grade.", "answer": 0}, {"article": "...\nOf course, the idea that high-fiber diets can help keep us healthy is not new.\nThis new study provides some evidence of yet another potential benefit.\nThis is a question Kristi King, a dietitian at Texas Children's Hospital, has thought about a lot.\nA Diet High In Fiber May Help Protect Against Breast Cancer\n\nIf the advice to eat more fiber seems easy to ignore, you're not alone.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There are no new products or services at issue in this story, and we addressed access to healthy foods under \u201cCost,\u201d so we\u2019ll rate this not applicable.", "answer": 2}, {"article": "Collaborating with Dr. De Giglio were Francesca Tona, M.D., Francesca De Luca, Psy.D., Nikolaos Petsas, M.D., Ph.D., Luca Prosperini, M.D., Ph.D., Valentina Bianchi, Psy.D., Carlo Pozzilli, M.D., Ph.D., and Patrizia Pantano, M.D.\nThe results suggest that video-game-based brain training is an effective option to improve cognitive abilities of patients with MS.\nThey also plan to look at how the video game can be integrated into a rehabilitation program together with other rehabilitative techniques.\nThe results provide an example of the brain's plasticity, or ability to form new connections throughout life.\nAt follow-up, the 12 patients in the video-game group had significant increases in thalamic functional connectivity in brain areas corresponding to the posterior component of the default mode network, which is one of the most important brain networks involved in cognition.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does identify the specific video game used in the study and its manufacturer, Nintendo, allowing readers to do a quick web search showing both it and accompanying equipment are readily available on the market.", "answer": 1}, {"article": "But another finding from that study sheds an interesting light on one of 5-Hour Energy\u2019s central claims \u2014 that the energy shot, unlike competitors\u2019, produces \u201cNo Crash Later.\u201d\n\nAccording to the study, 24 percent of test participants who received 5-Hour Energy had reactions similar to a \u201cmoderately severe crash that left them extremely tired and in need of rest, another drink or some other action,\u201d lawsuit filings show.\nShe added that another study showing the benefits of 5-Hour Energy was undergoing \u201cpeer review\u201d for possible publication in a scientific journal.\nAmong them: bringing out Lipovitan Junior, a caffeine-free version for children.\nThat study found a benefit when 5-Hour Energy was compared to a placebo like flavored water, she said.\nWhatever the case, the energy drink boom has come full circle in Asia, the region where it started.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of energy drinks is not in question.", "answer": 2}, {"article": "Ultraviolet light can alter chromophores so they no longer absorb color, but UV light can damage the retina.\nTo make cataract treatment available to more people around the world, a less-invasive, less-expensive technique is needed.\nMuch more research and development work remains, Dr. Kessel said, but the goal is a relatively simple procedure that would last half an hour at most and use largely automated equipment in mobile clinics.\nThe laser treatment reduces the light absorption and also helps restore the lens proteins to their proper structure.\nIn their approach, described in the open-access journal PLoS ONE, they \u201cbleach\u201d the lens with a laser.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The final line \"much more research and development work remains\" may help readers understand that this is not a readily available approach. ", "answer": 1}, {"article": "\"Not every cancer cell becomes a metastatic cancer cell.\nThe problem is that just having circulating tumor cells may not be enough information to foretell the future, she noted.\nIn the new study, if even one cell was detected in the bloodstream, a woman had a greater chance of her cancer recurring and of dying.\nThe more tumor cells a woman had in her bloodstream, the higher the likelihood of relapsing or dying, according to the report.\nAlthough the test may not be far off in terms of clinical practice, \"we need additional studies,\" Lucci said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No information about the availability of the blood test is given.\u00a0 There\u2019s only the line about \u201cmay not be far off in terms of clinical practice.\u201d\u00a0 But readers might not pick up on that subtle note.", "answer": 0}, {"article": "The researchers thank the Biotechnology and Biological Sciences Research Council (Grant 324594, Systems Biology studentship for J.M.H.\nThe researchers argue that the drug could be cheaper to produce, less harmful to healthy cells than existing treatments and has been shown to be active against cancer cells which have become resistant to platinum-based drugs.\nSimilar results were obtained by the National Cancer Institute USA in tests conducted on 60 cell lines.\n\u201cIt is clear that a new generation of drugs is necessary to save more lives and our research points to a highly effective way of defeating cancerous cells\u201d.\nOur new compounds work by attacking the energy balance in cancer cells\u201d.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the compounds are not available to human patients yet.", "answer": 1}, {"article": "\"The truth is that quit smoking programs, like other programs that treat addictions, often have fairly low success rates. But that doesn't mean they're not worthwhile or that you should be discouraged. Your own success in quitting and staying that way is what really counts, and you have some control over that. Even if you don't succeed the first few times, keep trying. You can learn from your mistakes so that you'll be ready for those pitfalls next time.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of cigarettes or smoking cessation products is not in question, which is why we rate this one Not Applicable.", "answer": 2}, {"article": "In MS, it\u2019s the fatty protective sheath around the nerves; in type-1 or juvenile diabetes it\u2019s cells in the pancreas that make insulin; in rheumatoid arthritis it\u2019s tissue in the joint.\nBut polystyrene is no good to use in people.\nBut Miller says the experiment also seemed to show they were beginning to repair the patients\u2019 immune systems.\nSo far the team has only shown the process is safe \u2013 a phase 1 clinical trial.\nIf the treatment was done as soon as the mice had their first MS-like attack, the attacks stopped.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the treatment is not currently available.", "answer": 1}, {"article": "Kidney stones are small, hard mineral deposits that form inside the kidneys, affecting up to 12 percent of men and seven percent of women.\nHCA is chemically similar to CA and is also available as a dietary supplement.\nThe head-to-head studies of CA and HCA determined that while both compounds inhibit the growth of calcium oxalate crystals, HCA was more potent and displayed unique qualities that are advantageous for the development of new therapies.\n\"HCA may be preferred as a therapy over CA (potassium citrate).\"\nHCA was also tested in human subjects, as seven people took the supplement for three days, allowing researchers to determine that HCA is excreted through urine, a requirement for the supplement to work as a treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that, like citrate, hydroxycitrate is available as a dietary supplement.", "answer": 1}, {"article": "Fish-oil supplements don't appear to help pregnant women prevent post-partum depression or boost the baby's brain development as previously believed, according to a large trial published Tuesday in the Journal of the American Medical Association.\n\nThe 2,400-woman, randomized study complicates the advice for pregnant women. It adds to a body of mixed research on some potential benefits of the popular omega-3 fatty acid known as DHA, or docosahexaenoic acid. DHA, which can move from the mother to the baby during pregnancy, accumulates...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that fish oil is widely available and has been widely used for the described uses.\u00a0 However, it would have been helpful for readers/consumers if the story had discussed the challenge of assessing product purity, quality control, etc. \u2013 that it\u2019s not just a simple matter of \"just take fish oil.\"\u00a0", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5disease.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentions that Lucentis was approved last June for wet AMD, but doesn't tell the reader how available it is \u2013 that is, is it in widespread use?", "answer": 1}, {"article": "Omega-3 fatty acids are unsaturated fats found in most fish, but especially in fatty fish that live in cold seawater, such as salmon and herring.\nCAVEATS Most participants were white.\nWHO MAY BE AFFECTED?\nAnyone considering changing or beginning treatment of any kind should consult with a physician.\nTesting and measurements were done once, providing no data for comparison over time or to determine any link to dementia.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish and fish oil is not in question.", "answer": 2}, {"article": "Proton therapy is a precise form of radiation therapy that deposits all of its energy within the tumor and allows for less irradiation of noncancerous tissue.\n\u201cBy continuing to develop a comprehensive thermal oncology program, we are giving patients more effective treatment options and therefore another reason to hope for better outcomes.\u201d\n\n\u201cThe Maryland Proton Treatment Center has achieved another milestone by becoming the first center to offer both deep-thermal therapy and proton therapy,\u201d says E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs at UM Baltimore and the John Z. and Akiko K. Bowers Distinguished Professor and dean at UMSOM.\nMPTC \u2013 which is affiliated with the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) at the University of Maryland Medical Center \u2013 is the only proton treatment center in Maryland.\nThe acquisition of the deep-tissue thermal therapy system was made possible by donations from Jack and Emily Howell and the Middendorf Foundation, Inc.\n\n\u201cWithin the Department of Radiation Oncology and throughout our cancer center, we strive to make every available tool in the cancer-fighting toolbox available to our patients,\u201d says William F. Regine, MD, FACR, FACRO, the Isadore & Fannie Schneider Foxman Endowed Chair and Professor of radiation oncology at UMSOM and chair of radiation oncology at UMGCCC.\nMPTC offers a robust clinical trial program to all its patients to further evidence-based medicine.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release says that the Maryland Proton Treatment Center, \u201cis the only proton treatment center in Maryland.\u201d While this is technically true, they neglect to mention that there is another proton treatment center in the region, an hour\u2019s drive away in Washington, D.C. Nor do they mention any of the other 28 proton centers currently open around the country, or the 10 more under development.\u00a0", "answer": 0}, {"article": "Some of the stem cells did become heart muscle, Hare said; they also triggered the heart to produce more of its own stem cells which became new heart muscle as well, he said.\n\u201cAlmost certainly, I would be deceased or in much worse shape had I not had the opportunity to be in this program.\u201d\n\nHare stressed that the current trial is only a small, run-up phase of extensive testing that will take up to five years and involve dozens of hospitals and hundreds of patients before winning U.S. Food and Drug Administration approval for routine use.\nThe trial was primarily about the safety of the procedure, and all eight patients came through without significant side effects, he said.\nThe study shed new light on a question of prime interest to cardiologists: whether the injected stem cells actually transformed themselves into heart muscle, or improved heart function in some other way.\nThe first, which started in 2009, is a double-blind, placebo-controlled study of 60 patients designed further to test the safety of the procedure, but primarily its efficacy, or how well it works.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story stands out for taking readers through the application and approval process instead of just leading readers to believe that a therapy is around the corner. It says: \u201cThe next step is two more near-term studies. The first, which started in 2009, is a double-blind, placebo-controlled study of 60 patients designed further to test the safety of the procedure, but primarily its efficacy, or how well it works. Another study about to get underway will see whether bone marrow from a donor can work as well as the patient\u2019s own bone marrow. Later, researchers will conduct a study involving 50 to 100 hospitals and many hundreds of patients aimed at winning final FDA approval.\u201d\n", "answer": 1}, {"article": "Carl Alexander, a spokesman from the charity Cancer Research UK, said: \u201cThis study is an exciting example of how research can find clues in our genes to help us uncover those more likely to develop the disease.\nIf it is found to be effective, it could be an important tool for physicians.\nRosalind Eeles, an author of the study at the U.K.-based Institute of Cancer Research (ICR) who specializes in finding genetic variants that increase the risk of prostate cancer, told The Guardian the team is \u201cexcited by the test\u201d because it can be used by doctors to offer patients targeted screenings.\nThe new method is being trialed on 300 men in doctors' offices across London, and is due to be expanded to 5,000 next year, according to BBC News.\nBy testing a man\u2019s DNA, researchers can look for genes linked to the disease, which one in seven men in the Western world will be diagnosed with in their lifetime.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear this test isn\u2019t available but would have served readers better by explaining that higher. It stated the test \u201cis being trialed on 300 men in doctor\u00a0surgeries across London, and is due to be expanded to 5,000 next year.\u201d\nIt also provided this quote: \u201cIf it is found to be effective, it could be an important tool for physicians.\u201d [emphasis ours]", "answer": 1}, {"article": "Commenting on the study, Oliver Sartor, MD, Cancer Research, Department of Medicine and Urology, Tulane University School of Medicine, New Orleans, LA, stated, \"The end point deserves special mention, as the end point of undetectable PSA after testosterone recovery has been previously discussed but rarely studied.\nLonger follow-up is needed to determine whether these patients were in fact cured.\nSuch results could not have been achieved with any single therapy alone.\nIt is expected that an upcoming Phase 2 trial will further test this endpoint and combined modality approach.\nThe combined treatment regimen including surgery was well tolerated.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that all of the treatment options are currently available.", "answer": 1}, {"article": "During such a surge, healthy vessels dilate, or relax, but unhealthy ones stiffen and narrow, impairing blood flow and indicating possible incipient heart disease.\nSuch fatty, low-carbohydrate Atkins-type diets are well established as a means of successful weight reduction, Dr. Stewart said.\n(In the current study, participants followed a diet based on the New Atkins for Life approach, which includes more vegetables than the original Atkins diet, Dr. Stewart said, adding that he and his colleagues have no ties to and receive no financing from the Atkins diet organization.)\n\u201cThere was no evidence of any harmful vascular effects from the low-carb diet,\u201d Dr. Stewart said.\nThe study did not include a control group of men and women who performed no exercise, making it impossible to tease out the exact physiological role that exercise played, Dr. Stewart said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story referred to the diets studied in broad terms including avoidance of trans fats and indicated that study participants reduced their daily caloric intake by about 750 calories. The Atkins diet is broadly available and widely recognized.", "answer": 1}, {"article": "CT scans became popular because they offer a quick, relatively cheap and painless way to get 3D pictures so detailed they give an almost surgical view into the body.\nThat puts them at risk of developing radiation-induced cancer, Brenner and Hall said.\nThe radiation and risk from one CT scan is low, but it carries a dose 50 to 100 times greater than a traditional X-ray, reports LaPook.\n\"There are some serious concerns about the methodology used,\" but the authors \"have brought to attention some real serious potential public health issues,\" said Dr. Arl Van Moore, head of the American College of Radiology's board of chancellors.\nIt's also a good idea to keep a diary of X-ray exposure, especially for children.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story did not include information about availability of CT scans (i.e. in hospital setting, in free standing imaging centers).\u00a0 However, the point of the story was that the technology is over used.\u00a0 While not meeting our usual standard of describing availability, the context of the news spot makes this less important.\nAlthough the story mentioned that patients ought to make sure that the doctor gives you \u2018the least possible dose\u2019, it did not inform the viewer that this option is not available on all CT equipment.", "answer": 1}, {"article": "Achillion\u2019s ongoing mid-stage study tests its NS5A inhibitor, ACH-3102, with Sovaldi in previously untreated genotype 1 hepatitis C patients over six and eight weeks of therapy.\nThe all-Achillion regimen could hit the U.S. market by 2020 in a conservative scenario, Deutsche Bank\u2019s Alethia Young estimated.\nShe expects the treatment to cost about $35,000 per patient per year, assuming a 55 percent discount.\nMonday\u2019s data shows Achillion\u2019s NS5A inhibitor, ACH-3102, looks best-in-class, which could make up for its nuke, ACH-3422, being perhaps less effective than Sovaldi, analysts said.\nThe new-generation hepatitis C regimens use a two- to three-drug combination \u2013 a nucleotide analog inhibitor or \u201cnuke\u201d and a NS5A inhibitor in Gilead\u2019s case \u2013 to achieves a cure in about eight to 12 weeks, making them faster and more effective than older treatment options.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story calls the new drug \u201cexperimental,\u201d suggesting it\u2019s not yet available. But the story doesn\u2019t really address what will be the major obstacle to availability should the drug make it to approval: the cost and who will pay for it. What will be the limitations put on coverage by insurance companies looking at a huge potential total cost?", "answer": 0}, {"article": "For their analysis, Gibbons and his colleagues looked at outcomes for each individual patient in published and unpublished trials testing the effects of six weeks of treatment with antidepressants versus placebo pills.\nStill, not everyone in the studies improved \u2014 on average, about five people had to be treated with one of the drugs for one person to feel better, and the benefits seemed to be diminished among some of the oldest patients.\nThe benefits were seen regardless of how severe patients\u2019 symptoms were before starting treatment.\n\u201cThere are alternative treatments for depression that also produce about the same symptom reduction as the drugs do, but without the risk of side effects,\u201d Kirsch added, including psychotherapy and exercise.\nIrving Kirsch, who studies antidepressants and placebos at Harvard Medical School in Boston, said the new report didn\u2019t make him more optimistic about the drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of antidepressants was not in question.", "answer": 2}, {"article": "Both show that antibiotics are more effective than placebos in relieving ear-infection symptoms such as fever, poor appetite, decreased activity and irritability and suggested that their benefits warrant their being administered early on, regardless of the seeming severity of a child's symptoms.\nInterestingly, antibiotics were no more effective at reducing pain, as reported by parents or children, than placebos.\nNow two new studies (bolstered by an accompanying editorial) in the New England Journal of Medicine demonstrate what we parents have suspected for years: When it comes to ear infections, antibiotics are in order.\nStill, some of the placebo-group kids required \"rescue treatment\" when their symptoms grew markedly worse.\nEar infections hurt, and waiting for them to run their course can be excruciating.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of antibiotics isn\u2019t in question, so this is not applicable.", "answer": 2}, {"article": "\"Dark chocolate may be a pleasant and effective way of delivering important dietary components that can provide health benefits to the ever increasing numbers of people at increased risk of cardiovascular disease,\" says researcher Christopher M. Reid, PhD, professor of cardiovascular epidemiology and preventive medicine at Monash University in Australia.\nThey did not study actual people eating actual chocolate.\nThe study is published in the journal BMJ.\nMaybe, according to a new study from Australia.\nReid and his team constructed a mathematical model to predict the long-term health effects of eating dark chocolate daily in high-risk people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of dark chocolate is not in question.", "answer": 2}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is general knowledge that estrogen and progesterone hormone therapies are common and widely available. The story cited some data on the decline in estrogen and progesterone use in the US.\n\u00a0", "answer": 1}, {"article": "Partial replacements, also known as unicompartmental replacements, are suitable for people who have arthritis in just one side of the knee, usually the inner.\nThose surgeons who carried out more partial replacements had better outcomes from them than surgeons who did fewer.\nThe NHS, however, needs to get the support of surgeons, many of whom rarely carry out the less invasive procedure.\nIn addition, more partial knee replacements will be done and more patients will benefit from this procedure.\u201d\n\nEd Burn, first author of the paper, said they needed to get surgeons on board.\nThe main reason for the surgery is osteoarthritis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that partial knee replacement surgery is available.", "answer": 1}, {"article": "CHICAGO\u2014Using whole-brain radiation to treat cancer that has spread to the brain is a treatment that for many patients is worse than the disease, a new study suggests.\n\nResearchers said the technique, when used after a more precise radiotherapy to kill the cancer, resulted in more memory loss and other cognitive deficits than treating with radiotherapy alone. While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn\u2019t extend survival.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that whole-brain radiation treatment was prevalent for many years and is now declining in popularity.", "answer": 1}, {"article": "In a study recently published in the European Journal of Applied Physiology, Seeley and a group of BYU colleagues, as well as Dr. Eric Robinson from Intermountain Healthcare, measured inflammation markers in the knee joint fluid of several healthy men and women aged 18-35, both before and after running.\nSpecifically, they're looking to do similar tests on people who have suffered ACL injuries.\nHyldahl said the study results indicate running is chondroprotective, which means exercise may help delay the onset of joint degenerative diseases such as osteoarthritis.\n\"Instead, this study suggests exercise can be a type of medicine.\"\nBYU professors Sarah Ridge and Ty Hopkins were also coauthors on the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Obviously, running is available to anyone who\u2019s able to do it for no cost. The release could have pointed out that areas with sidewalks and dedicated trails make this activity more accessible.", "answer": 2}, {"article": "Patients taking briakinumab had more serious infections and more cancers than those taking methotrexate.\nGordon was not involved in the current study, but he has been involved in research of the drug and has been a paid consultant and investigator for Abbott.\n\"Many of us were disappointed it was withdrawn because there would be a subset of patients who wouldn't respond to anything else and it would have been nice to have for them.\"\nThe study is published in the New England Journal of Medicine.\nBut as successful as the drug appears to be for some patients, it may come with a significant risk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The experimental nature of briakinumab was made clear in the story.", "answer": 1}, {"article": "A lot changed in between the births of my second and third daughters. For one thing, this time around I really am getting no sleep; for another, the pediatrician recommended something for our 1-month-old that is different from what had been suggested for our other children. She said we needed to pick up a liquid multivitamin that contains 400 international units (IUs) of vitamin D. It was a little confusing, because with our first daughter, now almost 4, the doctor told us to simply get her out in the sun from time to time to let her body produce vitamin D,...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story described a recommendation to \u2018pick up a multivitamin\u2019 with a given level of vitamin D, suggesting that this is a simple over the counter purchase. \u00a0That said \u2013 the article failed to distinguish among the types of vitamin D available and whether this made any difference.", "answer": 1}, {"article": "In one study, researchers found that people who have long telomeres, the small strips of DNA that cover the ends of chromosomes, have a 30 percent increased risk of developing colon cancer.\nAhlquist noted that the test still needs to be refined.\nAccording to Ahlquist, Cologuard is the first noninvasive test to detect pre-cancerous polyps, he added.\nSavings over time on a more accurate test done fewer times could justify the higher cost of the Cologuard test, Ahlquist said.\nAhlquist noted that the cost of the test has not yet been established.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that \u201cCologuard is not yet available for sale. Clinical trials comparing the test with colonoscopy are slated to start next year.\u201d\u00a0But then it allows the lead researcher to get away with saying he \u201chopes that the test will be approved and available within two years.\u201d\u00a0 Sure he does.\u00a0 That doesn\u2019t make it a prediction you can bank on.", "answer": 1}, {"article": "CRISPR stands for \"clustered regularly interspaced short palindromic repeats.\"\nBut he said there continues to be significant safety concerns around this type of CRISPR application.\nDr. Kmiec said there are chemotherapies that have helped patients achieve remission or at least live longer and enjoy a better quality of life by significantly slowing the progress of the disease.\nThis multidisciplinary clinical/scientific team has been working together to develop a compassionate bench-to-bedside approach.\nDr. Kmiec said the lung cancer work reflects an approach adopted by the Gene Editing Institute to move cautiously in developing medical applications of gene editing.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes it clear that this is not yet a treatment option.", "answer": 1}, {"article": "BioZorb has received 510(k) clearance from the U.S. Food and Drug Administration.\nThe study also noted that the device provides a helpful guide for post-treatment mammograms and other long-term follow-up to check for any cancer recurrence in these patients.\nThe article reports that the device provides clear visualization of the surgical site where the tumor was removed, thereby improving communication between the surgeon and radiation oncologist.\nBy providing better targeting, they said, the marker could also play a role in facilitating the use of external beam partial breast irradiation.\n\"The marker tells us where the tumor was and helps us determine appropriate forms of treatment, whether with partial breast irradiation or standard whole breast irradiation and a boost dose at the end of the treatment process.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We aren\u2019t told where the device is available or whether it\u2019s covered under most insurance plans. It was noted that the implant has received clearance by the FDA.", "answer": 0}, {"article": "After 78 weeks, they found that patients given bapineuzumab had about a 25 percent reduction in plaque compared with those on placebo.\nCommenting on the results, Sam Gandy from New York\u2019s Mount Sinai School of Medicine said it was too early to say effective disease-modifying drugs were at hand, but the ability to measure plaque in living subjects was \u201csomething of a breakthrough\u201d.\nBapineuzumab \u2014 being developed by Pfizer Inc (PFE.N), Irish drugmaker Elan Corp ELN.I and Johnson & Johnson (JNJ.N) \u2014 is a potential game-changer because it could be the first drug to treat the underlying cause of the degenerative brain disease.\nRinne\u2019s imaging study was funded by Elan and Wyeth, which is now part of Pfizer.\nThe drug\u2019s developers have since dropped the top dose from large ongoing Phase III trials.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0Bapineuzumab, the drug reported on, is experimental and not available for use outside of clinical trials. \u00a0The story mentioned the experimental status once, but the fact that it is not available was probably lost on many readers who may have been swept away by the enthusiastic reporting: \"potential game-changer because it could be the first drug to treat the underlying cause of the degenerative brain disease.\"", "answer": 0}, {"article": "And we know there are certain basic mechanisms which seem to be common to both inflammation and cancer,\" he said.\nPrevious research in animals has suggested that ginger can reduce inflammation but isn't potentially toxic to the stomach like aspirin, Zick noted.\nHowever, more study needs to be done, and the researchers aren't yet recommending that people head to the supplements' aisle or start gobbling up more ginger at meal times.\nThe amount of ginger in the pills is equivalent to 20 grams of raw ginger root, the authors said.\nAs for cost, she said that a month's supply of similar ginger supplements typically runs about $10 to $30.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says ginger is found in supplements and in many foods. The availability of ginger supplements is implied elsewhere in the story.", "answer": 1}, {"article": "\u201cDid you somehow get a biased sample of people, and is that why you\u2019re seeing this difference?\u201d\n\nHer 2008 study analyzed data from nearly 64,000 people who were melanoma-free at the beginning of the investigation, then followed them for a few years to see who developed the disease.\nAs a result, \u201cI wouldn\u2019t recommend (taking NSAIDs to reduce melanoma) just based on this\u201d new study, Asgari noted.\nNow, a smaller study that asked people with melanoma and those without the disease to recall their use of NSAIDs has found that taking these drugs - particularly aspirin - at least once a week for more than 5 years may have offered some protection against the deadly disease.\nPeople with a family history of melanoma are better off wearing sunscreen and getting regular skin checks from a dermatologist, Asgari recommended.\n\u201cI think the jury is still out.\u201d\n\nThere\u2019s reason to hope NSAIDs might offer some protection against this type of cancer, however - earlier this year, a review found that people who use painkillers such as ibuprofen on a regular basis may be less likely to get bladder cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 There isn\u2019t any question about the availability of aspirin, ibuprofen or related painkillers.", "answer": 2}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\nAll patients received a single, 19 Gy fraction of HDR brachytherapy.\nAt an average of nearly three years following treatment, cancer control rates were favorable and the toxicity profile was highly favorable.\nNewswise \u2014 ARLINGTON, Va., March 1, 2017 \u2013 Results from a new prospective clinical trial indicate that high-dose-rate (HDR) brachytherapy administered in a single, 19 Gray (Gy) treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer.\nReducing this exposure is of particular concern for treating tumors in the prostate, which is surrounded by multiple critical structures.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability but high dose brachytherapy has been available for years\u2013and a Google search reveals many sites offering this treatment.", "answer": 2}, {"article": "Brain waste includes amyloid \u03b2 (amyloid) and tau proteins, chemicals that negatively affect brain processes if they build up.\n\u201cThe study therefore adds further support to the concept that sleep subserves a distinct biological function of sleep and that is to \u2018clean up\u2019 the mess that accumulates while we are awake.\nDr. Benveniste cautioned that while the research team speculates that the human glymphatic pathway will clear brain waste most efficiency when sleeping in the lateral position as compared to other positions, testing with MRI or other imaging methods in humans are a necessary first step.\nTheir finding is published in the Journal of Neuroscience.\nThe method enables researchers to identify and define the glymphatic pathway, where cerebrospinal fluid (CSF) filters through the brain and exchanges with interstitial fluid (ISF) to clear waste, similar to the way the body\u2019s lymphatic system clears waste from organs.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Because everyone sleeps this criteria doesn\u2019t apply for this particular release.", "answer": 2}, {"article": "Serotonin imbalances have also been linked to depression.\nStudy results were also endorsed in 11 accompanying editorials from leading experts in psychiatry, addiction, and palliative care.\nAll patients in the study \u2014 mostly women age 22 to 75 who are or were patients at the Perlmutter Cancer Center of NYU Langone \u2014 had either advanced breast, gastrointestinal, or blood cancers and had been diagnosed as suffering from serious psychological distress related to their disease.\nStudy participants, he says, experienced no serious negative effects, such as hospitalization or more serious mental health conditions.\nApproximately half way through the study\u2019s monitoring period (after seven weeks), all participants switched treatments.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not specifically address drug availability. However, the release does note that psilocybin is a banned substance, and makes clear that larger clinical trials would have to be successful before psilocybin could be used as a \u201csafe, effective and inexpensive medication \u2014 dispensed under strict control.\u201d That\u2019s sufficient to merit a satisfactory rating.", "answer": 1}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that the company that produces the drug is planning on seeking FDA approval for a new indication.\u00a0 It also reported that the drug is currently available and used for the treatment of Paget\u2019s disease and for treating osteoporosis in wpmen after menopause.\nIt is noteworthy that this story accurately reported on both of these aspects about availability.", "answer": 1}, {"article": "Vitamin D is found in certain foods and beverages such as fortified milk and cereals, and fatty fish such as salmon.\nThe study involved more than 35,000 female nurses whose mothers answered questions about their diet habits during pregnancy.\nThe disease most often strikes adults after age 20, but it can develop in children.\nGrowing evidence has suggested that vitamin D, found in fortified milk, may lower one\u2019s risk of MS. Now, researchers with the Harvard School of Public Health in Boston have shown that it\u2019s possible this protective benefit could begin while a baby is developing in the womb.\nIt revealed that women born to mothers who had the highest intake of vitamin D had a much lower risk of developing MS as an adult.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story lists common sources of vitamin D, all of which are widely available.", "answer": 1}, {"article": "Elevated sweat chloride confirms that an infant actually has CF.\nThe findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers.\nThe biomarkers also point to other underlying mechanisms that contribute to the progression of CF and could lead to better therapeutic interventions earlier in life.\nFurther benefits are expected with the advent of newborn screening programs that have resulted in early detection.\nBut there are some obstacles that complicate clinical decision-making, explains Britz-McKibbin, because sweat chloride can result in ambiguous diagnoses in some borderline cases and does not reveal how the disease might progress for individual patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear how far these research findings are from making their way into clinical use.", "answer": 0}, {"article": "By measuring the sternal notch-nipple distance and the nipple-inframammary fold distance ( proxies for upper and lower sensory ligament strength, respectively), the study found a differential rate of stretch - for every 1 cm in upper sensory ligament stretch, the lower sensory ligament length increases by 0.45 cm.\nThe paper, The Sternum-Nipple Distance is Double the Nipple-Inframammary Fold Distance in Macromastia, is published Ahead-of-Print online in the Annals of Plastic Surgery.\nOn that basis, the authors recommend that techniques such as the Boston modification of Robertson technique should be preferred by surgeons seeking to avoid pseudoptosis.\nOther advantages of the Boston modification of Robertson technique include decreased operative time and elimination of the \"triple point,\" the most common site of postoperative incision rupture.\nIn all patients, only one reduction technique was performed per patient.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release mentions standard therapy and a modified technique but doesn\u2019t tell us how widely available the modified technique is, whether it is new or how many plastic surgeons are skilled in the procedure.", "answer": 0}, {"article": "Immunotherapy usually starts with clinicians harvesting immune system cells called T cells that have attached themselves to a tumor in an effort to attack.\nBut Yee bet that the extra effort would pay off with better results and fewer side effects.\nThe last step was to infuse the resulting army of cancer-fighting clones back into the patient.\nYee's team tried to do this more precisely.\nSeveral independent researchers said the study results were promising.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We think it\u2019s clear from the story that this is only an experimental approach right now.", "answer": 1}, {"article": "Guidelines also suggest that pregnant women not drink more than two cups a day.\nI can\u2019t think of any other product that has this much positive epidemiologic evidence going for it.\nI\u2019m also not suggesting that people start drinking coffee by the gallon.\nI\u2019m not suggesting that we start serving coffee to little kids.\nMost of us aren\u2019t drinking coffee because we think it will protect us, though.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Coffee is everywhere, in every culture, and in every corner of the planet \u2014 and the story mentions places you can get it.\nThere is an intersection in Vancouver with a Starbucks on EVERY corner.\nHave you heard about the new Starbucks that opened in the bathroom of an existing Starbucks?", "answer": 1}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\nFewer than two percent of all patients experienced serious side effects in the five years following SBRT.\nThe study is the first large, multi-institutional study of SBRT in prostate cancer with long-term follow-up.\n\u201cSingle-institution studies on the use of SBRT as the primary treatment for prostate cancer have illuminated the treatment as a cost-effective and faster alternative to IMRT,\u201d said Robert Meier, MD, lead author of the study and a radiation oncologist at Swedish Medical Center in Seattle.\nBiochemical failure was assessed using the ASTRO-consensus and the nadir+2 definitions.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states that patients in the trial were treated at 21 academic, regional, and community medical centers, which suggests that SRBT is widely available.", "answer": 1}, {"article": "The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease.\n\nThe research, by doctors from the U.S. and Liberian governments and elsewhere, was published Wednesday in the New England Journal of Medicine. The study looked at 1,500 patients in Liberia, and took place amid and after the outbreak of Ebola in Liberia from 2014 into 2015.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of an Ebola vaccine would be reasonable to address. For example, it a new epidemic developed today, would one of these vaccines be used? This is an important clinical point that researchers might have been able to provide information about.", "answer": 0}, {"article": "\u201cWe can\u2019t tell from the existing study if that is going to hold up or not,\u201d he said.\nThe task force advises that men age 45 to 79 take aspirin to stave off heart attacks, as long as the benefit outweighs the risk of bleeding.\n\u201cI don\u2019t think this paper is inconsistent with previous work.\u201d\n\nNichols, who was not involved in the study, said aspirin is clearly beneficial for people who\u2019ve already had heart disease, and that it also seems to help those at high risk.\nOne recent study has suggested that despite the increase in bleeding ulcers from aspirin, the reduction in heart attacks might make the cheap drug cost-effective for men over 45.\nThe new work, by Alfred Bartolucci of the University of Alabama at Birmingham and colleagues, was supported by aspirin-maker Bayer AG.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of aspirin is not in question.", "answer": 2}, {"article": "\"Here, fertility is very important to many young women,\" he said.\nAnd no cancer developed in the transplanted tissue, Jensen said.\nThis new study shows that ovarian tissue transplants are safe and effective and pose little risk of the cancer coming back, the Danish researchers said.\nAnd for 15 of the women, transplantation had taken place more than five years earlier, the researchers said.\nDr. Avner Hershlag, chief of the Center for Human Reproduction at North Shore University Hospital in Manhasset, N.Y., called the new research \"innovative and exciting.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not say whether this approach, which requires a lot of planning ahead for a cancer patient, is widely available outside of research centers. The research was done in Denmark and it\u2019s not clear if it\u2019s offered here in the United States or how widely.", "answer": 0}, {"article": "Milo A. Puhan, MD, is director of the Epidemiology, Biostatistics and Prevention Institute and professor of epidemiology and public health at the University of Zurich.\nHere\u2019s the problem: The lower an individual\u2019s risk of a future heart attack or ischemic stroke, the less he or she will benefit from taking daily low-dose aspirin.\nThat\u2019s ironic because aspirin is ubiquitous and most patients perceive it to be safe and harmless.\nAs I showed in a commentary in the Journal of the American College of Cardiology, when combined with a statin, aspirin\u2019s net benefit in primary prevention is almost completely lost.\nThat means for some low-risk individuals, taking daily aspirin could do more harm than good.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear that aspirin is ubiquitous and sold almost everywhere as an over-the-counter drug, so we\u2019ll rate this one N/A. This story, and the other we reviewed, might have benefited from mentioning that the drug has a generic name (known as ASA or acetylsalicylic acid). Generic versions of the drug do exist, are likely cheaper than the brand name, and equally effective.", "answer": 2}, {"article": "\u2022 Gaziano TA, Fonarow GC, et al.\nPlease see full Prescribing Information, including Boxed WARNING available at http://www.pharma.us.novartis.com/product/pi/pdf/entresto.pdf.\nPatients are encouraged to report negative side effects of prescription drugs to the FDA.\nHCUP facts and figures: statistics on hospital-based care in , 2009. : Agency for Healthcare Research and Quality, 2011.\nPatients should either take Entresto or breastfeed.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s noted that the drug is FDA approved.", "answer": 1}, {"article": "NEW YORK (Reuters) - The U.S. Food and Drug Administration approved on Tuesday the sale of Amgen Inc\u2019s osteoporosis drug Prolia to help prevent fractures in post-menopausal women just days after the medicine received European approval.\nThe approval comes with a risk evaluation and mitigation strategy (REMS) that includes a medication guide for patients and information for healthcare providers that explains the risks and benefits of the drug, the FDA said.\nAmgen said the drug will be available within the next two weeks and cost $825 per 60 milligram injection based on wholesale acquisition cost.\n\u201cI believe it will have gradual uptake in the commercial setting given that this is a silent disease and existing therapies are pretty good,\u201d Schmidt said.\nAmgen last month applied for U.S. approval to market the drug for reduction of fractures and other skeletal-related problems in patients with advanced cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Too much LDL cholesterol circulating in the blood can lead to the thickening of artery walls, making them less flexible and therefore impairing their function and increasing the risk of heart disease.\nEarlier studies had shown this effect in primates, but this new study, published Wednesday in the New England Journal of Medicine, provides the first clinical trial data for testing the drug on humans.\nThis new drug is being developed by Regeneron Pharmaceuticals and Sanofi, who funded the research.\nAll of those subjects were also receiving treatment with the statin Lipitor.\nIf the results are confirmed, \u201cThis is game changing science,\u201d said Dr. Richard A. Stein, a spokesman for the American Heart Association who's not related to the study author or involved in the research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this is an experimental approach.", "answer": 1}, {"article": "Urothelial carcinoma is the most common type of bladder cancer and occurs in the urinary tract system, involving the bladder and related organs.\nTherefore, today the FDA also approved the Ventana PD-L1 (SP142) assay to detect PD-L1 protein expression levels on patients' tumor-infiltrating immune cells and help physicians determine which patients may benefit most from treatment with Tecentriq.\nThe FDA granted the Tecentriq application breakthrough therapy designation, priority review status and accelerated approval for this indication.\nTecentriq is the first FDA-approved PD-L1 inhibitor and the latest in the broader class of PD-1/PD-L1 targeted biologics approved by the FDA in the last two years.\nThe Ventana PD-L1 (SP142) assay companion diagnostic for Tecentriq is marketed by Ventana Medical Systems, based in Tucson, Arizona.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The FDA\u2019s approval of a drug clears the way for the drug sponsor to scale up production and begin marketing and selling the product. (The FDA doesn\u2019t state this explicitly but it can be inferred.)\u00a0 A NYT article said the drug would be available in about two months.", "answer": 1}, {"article": "Many back patients are afraid certain movements will cause them pain, so they avoid them.\nThe program led to a significant and clinically important reduction of pain, she said.\nBut this study suggests these methods also can help reduce spinal pain, she said.\nWhereas back pain studies involving exercise and drugs have shown changes to the brain's gray matter, the program in this study found no brain changes, Malfliet said.\n\"They should also avoid the use of scary, unreassuring labels or diagnoses,\" and not limit movement in therapy, she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that this is an experimental therapy.", "answer": 1}, {"article": "Aggression scores declined to 3.8 from 7.1 in the dextromethorphan-quinidine group and to 5.3 from 7.0 in those who took a placebo.\nNow researchers report that a combination drug already in use for treating certain neurological problems may be a better remedy.\nThere are no currently approved treatments for agitation, and we\u2019re very enthusiastic about this finding.\u201d\n\nCorrection: October 8, 2015 \n\nA report in the In Brief column on Sept. 29 about a combination drug that could ease the agitation of Alzheimer\u2019s disease described incorrectly a disorder treated with the combination drug, dextromethorphan and quinidine.\n\u201cFifty-five percent of the people who were on drugs had a 50 percent reduction in their agitation,\u201d said the lead author, Dr. Jeffrey L. Cummings, director of the Cleveland Clinic Lou Ruvo Center for Brain Health.\n\u201cThat\u2019s a lot when a patient is striking and hitting and cussing.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the drug tested is \u201calready in use for treating certain neurological problems,\u201d and we think most readers can work out from that that the drug is available.", "answer": 1}, {"article": "\u201cI couldn\u2019t wear a brassiere for three months,\u201d she recalled.\nBut it is worth remembering that however effective it is, screening can\u2019t ward off disease.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\nIn fact, if screening finds cancer, some seniors won\u2019t withstand the surgery, usually a lobectomy, that may cure it.\nThe post-surgical death rate in the national trial was just 1 percent, but that involved major medical centers with specialized radiologists and surgeons \u2014 the ideal setting.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The issue of interest here is whether low-dose CT scans are available for older, heavy smokers to screen for lung cancer. While this is satisfactorily addressed (it\u2019s the main topic of the story), it isn\u2019t entirely clear from the story if screening has actually begun or when it will. Programs to do the shared decision-making for Medicare patients haven\u2019t been established and Medicare hasn\u2019t yet released codes for billing for the initial visit where the issue is reviewed. It\u2019s also unclear if commercial insurers are covering and for whom.", "answer": 1}, {"article": "Developed in the laboratory of UHN transplant surgeon Dr. Markus Selzner, with the help of UHN transplant surgeons Drs.\n\u201cThis technique will change the landscape of organ donation by improving organ preservation, allowing us to better assess and regenerate the donor organ on the device before we transplant it into a patient.\n\u201cThis new technology can help us answer the critical question, \u2018What\u2019s the best way to improve function and recover and repair the kidney before transplantation to get the best results for our patients?\u2019\u201d\n\nDr. Grant, who is also Professor of Surgery at the University of Toronto, emphasized that high-impact research projects such as this require strong collaborative teams \u2013 including researchers, surgical residents, nurses, Canadian Blood Services, perfusionists, colleagues at SickKids - working together on experimental and clinical trials.\nThe new warm preservation technique avoids the damage of cold storage and instead allows the donor organ to improve and repair itself, potentially leading to better outcomes for patients.\nDr. Grant also praised the strong support and efforts of Trillium Gift of Life, which co-ordinates organ and tissue donation across Ontario, in helping to ensure that the transplant team could begin their clinical trials with this new technique.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "As noted above, the release does tell readers that this work was done as part of a phase 1 clinical trial, so we\u2019ll rate this Satisfactory. However, many \u2014 if not most \u2014 readers are not familiar with clinical trials, and we think the release would have been stronger had it translated that.", "answer": 1}, {"article": "\u201cThe studies are small and the longest of them lasted only three years.\nBefore the most recent study, at doses considered normal, the testosterone gel showed little or no effect on cardiovascular risk, the two doctors reported.\nAlthough low hormone levels are widely thought to increase a man\u2019s risk of depression, the researchers found that \u201cpsychological symptoms had little or no association with the testosterone level.\u201d\n\nThere are four main approaches to testosterone therapy available in this country: intramuscular injections every one to three weeks; skin applications through a patch or gel; and pellets implanted under the skin that last for months.\nA $45 million study financed by the National Institute on Aging is under way at 12 medical centers to see if a year of treatment with testosterone will help 800 men aged 65 and older with low levels of the hormone and problems with physical functioning, fatigue and sexual or cognitive performance.\nDr. Abraham Morgentaler, a urologist at Harvard Medical School and author of \u201cTestosterone for Life\u201d (McGraw-Hill, 2009), said in an interview that other noted benefits include a decrease in body fat and total cholesterol and improved blood sugar metabolism.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study notes that testosterone therapy is available in the U.S. as an\u00a0intramuscular injection, a skin patch\u00a0or gel,\u00a0pellets inserted under the skin, and in oral preparations. \u00a0", "answer": 1}, {"article": "According to the findings, people older than 65 who had higher blood levels of caffeine developed Alzheimer's disease two to four years later than their counterparts with lower caffeine levels.\nCoffee was the main, or only source, of caffeine among people in the study.\nThe findings will appear in the Journal of Alzheimer's Disease.\nThis is equivalent to drinking several cups of coffee a few hours before giving blood.\n\"There is no reason to stop if you are experiencing memory problems.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of coffee is not in question.", "answer": 2}, {"article": "Screening patients for heart disease with a heart-imaging test prompted greater follow-up care but had little to no effect on the number of heart attacks and other cardiovascular events in those patients, a new study found.\n\nResearchers at Johns Hopkins Hospital in Baltimore led the study, which was published online Monday in the Archives of Internal Medicine.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that the test is available in the U.S. and is being used with increasing frequency.\u00a0 It is actually not clear how often it is being used \u2013 the article said \u201cSome anecdotal evidence suggests such screening is happening and becoming more common.\u201d", "answer": 1}, {"article": "Boston, MA - Women who eat more high-fiber foods during adolescence and young adulthood--especially lots of fruits and vegetables--may have significantly lower breast cancer risk than those who eat less dietary fiber when young, according to a new large-scale study led by researchers at Harvard T.H.\nThe study will be published online February 1, 2016 in Pediatrics.\n\"From many other studies we know that breast tissue is particularly influenced by carcinogens and anticarcinogens during childhood and adolescence,\" said Walter Willett, Fredrick John Stare Professor of Epidemiology and Nutrition at Harvard Chan School and senior author of the study.\nThe researchers looked at a group of 90,534 women who participated in the Nurses' Health Study II, a large long-running investigation of factors that influence women's health.\n\"This work on the role of nutrition in early life and breast cancer incidence suggests one of the very few potentially modifiable risk factors for premenopausal breast cancer.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll give this a Not Applicable since it\u2019s commonly assumed that fresh dietary fiber is widely available in various products at many grocery stores.\u00a0 We discussed problems with this assumption under the \u201ccosts\u201d criteria.", "answer": 2}, {"article": "\u2022 Kim TI, Lee YK, Park SG, et al.\nHowever, more research is needed to clarify the nature of the beneficial association between the EGCG and cognitive training intervention (ie, synergistic or additive).\"\n\"It's an important trial,\" says Dr. Steven Hirsh, director of clinical research for Life Extension in Fort Lauderdale, Fla. \"The findings are very noteworthy and support further study in randomized controlled trials with larger sample sizes and durations.\n\"This new research adds to the growing body of evidence that suggests compounds in green tea, such as EGCG, may support cognitive health.\"\n2012; http://www.ndss.org/Down-Syndrome/What-Is-Down-Syndrome/.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release could have been more explicit in pointing out that green tea extract supplements are easily available online or at the local health foods store. However, we give it here the benefit of the doubt, since it disclosed Life Extension\u2019s support in this study. Furthermore, the availability of green tea is not in question.\nWe rate this one Not Applicable.", "answer": 2}, {"article": "Cocoa contains flavanols, plant-based compounds that also are credited with giving red wine its heart-healthy benefits.\nVolunteers for the study ate just over six grams of dark chocolate daily for almost five months \u2014 one square from a German chocolate bar called Ritter Sport, equal to about 1\u00bd Hershey's Kisses.\nUniversity of Cologne researcher Dr. Dirk Taubert, the study's lead author, said the blood pressure reductions with dark chocolate were small but still substantial enough to potentially reduce cardiovascular disease risks, although study volunteers weren't followed long enough to measure that effect.\nTests suggested that steady exposure to dark chocolate prompted chemical changes that helped dilate blood vessels and regulate blood pressure, the researchers said.\nShe stressed that the study results should not be viewed as license to gorge on chocolate.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study that this story reported on found\u00a0one particular type of dark chocolate (Ritter Sport Halbbitter) had an effect on blood pressure.\u00a0 While the story was helpful in that it included information about portion size in terms a typical consumer could understand (i.e. about one and a half Hershey\u2019s dark chocolate kisses), it failed to provide information about the availability of the chocolate used in this study. Is it common?\u00a0 Is it found in many other products?\u00a0 ", "answer": 0}, {"article": "The F.D.A.\nThe result was a requirement that a hospital should be doing at least 50 surgical aortic valve replacements a year to have access to the technology.\nAnd new data from another large study by Edwards found that patients at intermediate risk did better with the newest version of its valve than would be expected with surgery in the first 30 days, when most deaths occur.\nMore recent 2015 data from Medtronic indicates that its valve is better than surgery for high-risk patients, resulting in fewer deaths, at least in the first two years.\n\u201cThere are very few treatments in all of cardiovascular medicine that could claim that \u2014 I can think of heart transplant, and that\u2019s it.\u201d\n\nThe results were even more notable, he said, because the early versions of the devices were clunky, stiff and difficult to use.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story summarizes the approval status of several devices. However, it doesn\u2019t explore important caveats about which patients are eligible for TAVR and implies that all comers who are too sick for surgery are eligible.", "answer": 1}, {"article": "And if I can be saved, so can other people.\u201d\n\nThe study results were unveiled Thursday in advance of a major cancer conference next month.\nThere is no such screening tool currently in use.\nBut she added that an ongoing study in the United Kingdom involving 200,000 women should more definitively determine the test's value.\nBut none proved as accurate as CA-125 after a Harvard scientist developed a mathematical model combining trends in test results and a patient's age.\nAmong the study participants was Liz Stegall, who enrolled at the request of the family of Linda Nelson Taylor, a friend who died of ovarian cancer that wasn't diagnosed until it was advanced.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The CA-125 test is clearly available. What is not clear is whether the clinical algorithm used in this study to identify high risk women is available widely or only in a research setting.", "answer": 1}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that about 30% of mammography centers use computer-aided detection (CAD) technology. ", "answer": 1}, {"article": "About the American College of Surgeons\n\nThe American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for surgical patients.\nAlong with discovering that the use of laparoscopy for the surgical treatment of GERD has increased significantly in the last decade, the researchers also found that, on average, the minimally invasive approach reduced length of hospital stay by approximately two days, and open operations were more than $9,000 more expensive than minimally invasive procedures.\nThe study showed that the rate of laparoscopic procedures increased from 24.8 percent in 2000 to 84.3 percent in 2013.\n\"Our study highlights the fact that laparoscopic anti-reflux surgery is as effective as the open approach, and in 2017, with all its advantages, should be the standard of care,\" said senior study author Marco G. Patti, MD, FACS, a surgeon and Director of the Center for Esophageal Diseases and Swallowing, University of North Carolina, Chapel Hill.\n\"Anti-reflux surgery should be considered in patients who do not achieve complete control of their symptoms [regurgitation or cough] with medications; who do not want to take medications for the rest of their lives; or who experience complications of medical therapy.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the release that both methods of surgery have been widely available nationally and the outcomes of 75,000 surgeries were tracked by the National Inpatient Sample (NIS) database.\nThe release also notes that \u201curban academic or teaching hospitals\u201d perform laparoscopic anti-reflux surgery more often than \u201copen\u201d procedures, 54.4 percent versus 45.6 percent. And it recommends that anti-reflux surgery should be performed laparoscopically in specialized centers.", "answer": 1}, {"article": "\"In many of those cases we decide, 'OK, this lesion is too small to be treated with a filling.'\nThe treatment, called Icon, is one of several new cavity treatments that avoid drilling.\nWolff says that while the no-drill approach to treating this type of tooth decay has promise, fluoride treatments and other patient-applied methods are still more inexpensive, less invasive and have a much longer track record of success.\nTo Drill Or Not To Drill\n\nPhark says that when decay is caught very early or very late, dentists have a clear course of action: Early problems can often be reversed with better brushing, fluoride or calcium-containing toothpastes -- and late-stage cavities need to be filled.\nA new procedure used by Phark and other doctors claims to stop the progress of cavities without drills or Novocain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story reports that this product has been available in the United States for just over a year. However, it does not say whether dentists need to be trained to use the product.", "answer": 1}, {"article": "The etonogestrel implant is a small plastic rod resembling a matchstick that is inserted under the skin in the upper arm.\nWith both implants and IUDs, fertility returns quickly as soon as the devices are removed.\nOf the many embarrassing health statistics in this country, the huge number of unwanted pregnancies is perhaps the easiest to rectify.\nThe risk of an unwanted pregnancy with these other methods was especially high among women under 21, whose rate of unintended pregnancy was nearly double that among older women.\nIn real-world use, these methods are associated with a one-year pregnancy rate of less than one per 100 women.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "You could say this story was about availability itself, and especially about why things that are widely available are not prescribed by doctors more often. All of these long-term contraceptives are available.", "answer": 1}, {"article": "It's a success story you might dream of when you start, but it actually seeing to happen is a great feeling.\"\nLead author Claudia Buntrock, a PhD candidate in clinical psychology at Leuphana, says that because the study only tracked participants' mental health over the course of 12 months, the long-term effectiveness of the intervention is unknown.\nSimilar programs have been used to treat depression, but this may be the first one tested to prevent it, the researchers say.\nIt's also not clear if this kind of program could be scaled up.\nOther experiments with online therapy have found that people didn't continue it if it wasn't guided by an actual human.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story not only makes clear that this preventive approach to online interventions is fairly novel, but that there are significant questions about whether it could be scaled up.", "answer": 1}, {"article": "The women were then followed for an average of three years.\nActivities like these account for more than 55% of older adults\u2019 daily activity, says LaCroix, so the fact that they were protective in this study is very good news.\nQuestionnaires used in self-reported studies don\u2019t do a good job of encompassing all the ways people get physical activity throughout the day, she says, which may have skewed previous study results.\nThe authors say that improving doing more light and moderate physical activity could be almost as effective as rigorous exercise at preventing disease and prolonging life.\nThe researchers hope their work sparks more discussion about how people\u2014especially older ones\u2014think about exercise and their goals for being active.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job of defining what light activity means, which is important for understanding how accessible it is. Bike riding is a moderate activity, for example, whereas \u201cstrolling around the neighborhood\u201d is a light activity.", "answer": 1}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nIn addition to King, the study's other authors are Sarah J Zyba, Swapna V Shenvi, David W Killilea, Tai C Holland, Elijah Kim, Adrian Moy, Barbara Sutherland, Virginia Gildengorin, and Mark K Shigenaga, conducting the research at CHORI's Nutrition and Metabolism Center.\n\"These results present a new strategy for measuring the impact of zinc on health and reinforce the evidence that food-based interventions can improve micronutrient deficiencies worldwide.\"\nThis amount of zinc is equivalent to what biofortified crops like zinc rice and zinc wheat can add to the diet of vulnerable, nutrient deficient populations.\nIn the absence of sufficient zinc, our ability to repair everyday wear and tear on our DNA is compromised.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We wish the news release could have talked more about existing zinc fortification efforts around the world, since it\u2019s not clear in the release whether zinc fortification practices are already in place.\nIn the original journal article, researchers mention the zinc fortification programs initiated in more than 30 countries and point out how Bangladesh increased its rice zinc concentration by 50 percent through its biofortification methods.\nFor this reason, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "SAN FRANCISCO \u2014 Tech company developer conferences always feature a wacky demo or three.\nThe goal of further research is to determine whether Emma Watch could help other people with similar Parkinson\u2019s symptoms.\"\nBut at Build 2017 in Seattle Wednesday, Microsoft went for the waterworks at the conclusion of CEO Satya Nadella's keynote address: it showcased a prototype watch that temporarily eliminated the arm shaking that often plagues those suffering from the neurological disease Parkinson's.\nWatson erupts in tears as she calls her mother to say this is the first time she's been able to write her name in ages.\nThe video showed Lawton trying to draw a square with her shaky right hand, and then again, wearing Emma.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states the device is just a prototype. More could have been said about what this means, but it\u2019s enough to rate satisfactory.", "answer": 1}, {"article": "\"This is a strengthening of the argument that people with less [omega-3 fatty acids] have higher risk of dementia,\" said Dr. Nikolaos Scarmeas, associate professor of clinical neurology at Columbia University Medical Center in New York City.\nA clinical trial comparing high and low intake of omega-3s in relation to brain imaging would help answer those questions, he said.\nThis might include reducing blood pressure and inflammation, he added.\nBut questions remain over whether fatty-acid levels really influence changes in brain size, Scarmeas added.\nThe decrease in brain volume was enough to make their brains appear two years older than those of people in the top three-quarters for fatty-acid levels.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish isn\u2019t in question.", "answer": 2}, {"article": "However, prostate cancer is one of the few cancers that\u2019s not strongly linked to smoking (and falling cigarette consumption over the past 40 years is a major reason for falling cancer rates).\nIt\u2019s saying that, for most men, the (albeit small) risk of sexual dysfunction and urinary leakage from eventual treatment is not worth it, given the even smaller chance that PSA testing could save your life.\nMany health experts think that\u2019s too much risky treatment to justify the results.\nBut that decision does remain a judgment call.\nThat test can have side effects.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that PSA screening is widely available.", "answer": 1}, {"article": "\"Done haphazardly and irregularly, it is probably worse than no breast self-exam at all,\" Steiner said.\nIt defies common sense, she says, for scientists to conclude that breast self-exams do women more harm than good.\nA small study in Canada in 1997 found that self-exams seemed to improve survival among a subset of women using proper technique.\nShe encourages women to schedule an appointment devoted to learning the technique, which should take at least a half-hour.\nLitt, the breast cancer survivor, has another piece of advice: \"Do not ignore your own judgment; and be assertive,\" she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of breast self-exams (BSE) is implicit; however, the story appropriately notes that not all physicians or health educators know current BSE technique, and there is a suggestion that inappropriate technique may influence the sensitivity of the self-exam. The story mentions a more sensitive technique\u2013the vertical-strip, three pressure test\u2013 used in Canada, which has been validated in a small subset of women. ", "answer": 1}, {"article": "\"That time frame is not anything to write home about,\" Gulley says.\nOverall, however, the limited success in some patients and the complete success in one is good news, he says.\nAs exciting as that is, he says, \"a lot of work needs to be done to prove whether this can be effective [for more patients].\"\nThe study, funded by the National Cancer Institute, is published in Clinical Cancer Research.\nOne woman who got the investigational vaccine now has no X-ray evidence of cancer, says study researcher James Gulley, MD, PhD.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We give high marks to the story for saying right in the lead that the findings are from \u201ca preliminary study in 26 patients.\u201d That tells readers both that the findings need to be interpreted with caution and that the treatment is not available to most people.", "answer": 1}, {"article": "Researchers have two main theories on why light therapy works.\nThe researchers said enough clinical evidence now supports mental health professionals recommending light therapy as a treatment for depression.\nAlthough the light therapy helped many patients, it provided the most benefit to those who were also taking the antidepressant.\nBut now a study has found that light therapy also works in treating non-seasonal depression.\nThe research, published Wednesday in JAMA Psychiatry, is significant because major depression is one of the most common mental health disorders in the United States and one of the leading causes of disability worldwide.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Since these lights probably aren\u2019t very difficult to find, we\u2019ll rate the story Not Applicable here.\u00a0The story doesn\u2019t specifically address availability and it could have noted what kind of light is needed and whether these lights are widely available. But we won\u2019t ding the story for not mentioning this.", "answer": 2}, {"article": "Essential fatty acids are substances that are not produced by the human body and are only available from diet.\nThe study, published Monday in the journal Reproductive Health, found that taking capsules containing about 1 gram of a blend of three essential fatty acids produced a significant reduction in PMS symptoms.\nAccording to the study, women who took the supplements for six months saw a bigger benefit than those who took them for three months.\nThe study, authored by researchers from the Federal University of Pernambuco, is not the first to address the possible link between PMS and essential fatty acids, substances that play a complicated role in a woman's reproductive system.\nAccording to the study, the 120 women who participated reported few side effects, and most of those were mild and may have been due to sensitivity to mineral oil, the placebo taken by some of the participants.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story described the availability of essential fatty acids in diet and in supplement form.", "answer": 1}, {"article": "Dr Golam Khandaker, who led the study, says: \"It's becoming increasingly clear to us that inflammation plays a role in depression, at least for some individuals, and now our review suggests that it may be possible to treat these individuals using some anti-inflammatory drugs.\n\"It's too early to say whether these anti-cytokine drugs can be used in clinical practice for depression, however,\" adds Professor Peter Jones, co-author of the study.\nMeta-analyses of the other types of clinical trials showed similar results.\nThe team of researchers carried out a meta-analysis of these clinical trials and found that the drugs led to an improvement in the severity of depressive symptoms independently of improvements in physical illness.\nBy looking at additional beneficial side-effects of the treatments, the researchers were able to show that there was a significant antidepressant effect from the drugs compared to a placebo based on a meta-analysis of seven randomised controlled trials.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While this meta-analysis was done on clinical trials data, all of the drugs involved are currently available for treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis, and the release makes this clear.\n\u00a0", "answer": 1}, {"article": "In 2016, he was ranked the No.\nFAU is ranked as a High Research Activity institution by the Carnegie Foundation for the Advancement of Teaching.\nIn a commentary published in the current issue of the American Journal of Medicine, researchers from the Charles E. Schmidt College of Medicine at Florida Atlantic University reassure clinicians and their patients that varenicline, whose brand name is Chantix, is a safe and effective way to achieve smoking cessation and that failure to use this drug has caused preventable heart attacks and deaths from cardiovascular disease.\nSuch a large randomized trial was recently completed that included both apparently healthy individuals as well as those with severe mental illness.\nJust a few months ago, the FDA removed the black box warning from varenicline.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that Chantix is commercially available.", "answer": 2}, {"article": "But, that's an entirely different problem, compared with atrial fibrillation,\" he said.\nThe study was funded by Bristol-Myers Squibb and Pfizer, the makers of apixaban.\nWith apixaban, patients can use a standard dose that doesn't need monitoring and adjusting, Ansell said.\n\"Sometimes it impairs the patient's quality of life and the outcomes are very dependent on how well the drug dosing is managed,\" he added.\nWhile generic warfarin is just pennies a dose, any new brand-name drug is likely to be much more expensive.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that apixabane, the medication reported on, was experimental.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5laser.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions LASIK is a common surgery, accounting for 87% of all laser eye surgeries last year. The story notes that more surgeons are tailoring techniques and procedures as laser eye surgery grows in popularity,\u00a0but the story also notes that\u00a0corrective eye surgery is not a \"one size fits all\".\u00a0 The story\u00a0 mentions newer tools to improve the LASIK and PRK procedures, but it does not mention if these are widely available. ", "answer": 1}, {"article": "Currently, people who do not have HIV but are at substantial risk of getting it--because they have multiple sexual partners, for example, or an HIV-infected partner--can receive antiviral medications to prevent disease, a strategy called pre-exposure prophylaxis (PrEP).\nThis is why researchers continue to look for other ways to control the virus--and broadly neutralizing antibodies could prove to be part of an alternate treatment strategy.\nIn an effort to accomplish this, the investigators are looking into modified variants of the antibodies with prolonged activity, so that they would need to be given less often in the PrEP setting.\nThe purpose was to determine whether the antibody was safe and whether it had antiviral activity in humans.\nAlthough these patients were found to have some resistant virus in their blood, further research in the lab showed that those viruses were still sensitive to other broadly neutralizing antibodies, including 3BNC117, that target different parts of the pathogen.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We can assume that this is preliminary data collection but it would have been useful if the release included information about how long the research process may be before eligible patients might have access to this new therapy. Next steps regarding future clinical trials are mentioned in the last paragraph.", "answer": 1}, {"article": "Commenting on the next stage of the research, she said: \u201cIn the larger phase II trial we\u2019ve recruited 140 women with relapsed ovarian cancer across the U.K. to standard chemotherapy (paclitaxel) or paclitaxel in combination with vistusertib.\nDr. Dean A. Fennell, professor and consultant in thoracic medical oncology at the University of Leicester, who was not involved in the study, told Newsweek the study presents an \u201cexciting result.\u201d\n\nHe was particularly surprised by the magnitude of the response triggered by vistusertib combined with paclitaxel, which is closely related to standard chemotherapy.\nThe cocktail also stopped the cancer growing for almost six months, which is unexpected for patients with advanced-stage cancers who were unresponsive to currently available treatments, including chemotherapy, the authors said.\nThat is why the patients\u2019 tumors shrunk, the study suggests.\nThe U.K.-based researchers used a new drug along with chemotherapy medication known as paclitaxel on 25 women with high-grade, serous ovarian cancer, and 40 participants with squamous non-small cell lung cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned a larger trial with 140 ovarian cancer patients that will test the drug\u2019s effectiveness versus chemotherapy alone, with results \u201cexpected later this year.\u201d This is enough information that a reader can infer that it\u2019s not available yet.\nHowever, the story didn\u2019t explain what scientific and regulatory hurdles would have to be overcome for this drug to become available.", "answer": 1}, {"article": "Magnetic resonance imaging measured cortical thickness and resting-state functional connectivity (rsFC) before training, after training and three months post-training.\nThe findings, published in Brain and Behavior, further suggest that changes in cortical thickness and neural network connectivity may prove an effective way to quantitatively measure treatment efficacy, an ability that has not existed until now.\nBuilding upon previous research, the study challenges the widely held belief that recovery from a TBI is limited to two years after an injury.\nThe knowledge-based training group learned information about the structure and function of the brain as well as the effects of sleep and exercise on brain performance.\nOver an eight-week period, the strategy-based training group learned strategies to improve attention and reasoning.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "From the news release alone, it is not entirely clear if the brain training program already existed and was simply now applied to those with chronic TBI for the first time.", "answer": 0}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nThe results, published by the Journal of the American Medical Association, demonstrate the first major therapy advance for the condition in nearly 40 years.\nOverall, the drug\u2019s benefits are particularly clear for people with both PDR and DME.\nSlightly more than half (53 percent) of eyes in the laser group received Lucentis injections to treat DME.\n\u201cLucentis should be considered a viable treatment option for people with PDR, especially for individuals needing anti-VEGF for DME,\u201d said Jeffrey G. Gross, M.D., of the Carolina Retina Center in Columbia, South Carolina, who chaired the clinical study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that Lucentis is already used to treat other diabetes-related eye problems, and \u201cshould be considered a viable treatment option for people with PDR.\u201d", "answer": 1}, {"article": ".\nShah and Mazhari say that their patients, many of whom have undergone both kinds of catheterizations, much prefer the wrist approach.\nBut in Europe, Canada and Japan, about 50 percent of catheterizations are performed using the technique devised in the early 1990s.\nSome senior interventional cardiologists say they worry that the method may be hyped.\n\"There's no data out there to suggest it is worse and growing evidence that it may be better,\" said Shah, an assistant professor of medicine at Harvard Medical School, who performs 60 to 70 percent of procedures through the wrist.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that radial catheterization is most likely not routinely available and that a low percentage (1%) of catheterizations are performed this way.", "answer": 1}, {"article": "For more on obesity, visit the U.S. National Institutes of Health.\nCaution is vital when using any drug that has been approved for one condition for another, Sandon said.\nAll study participants followed their treatment plan for one year.\nThe authors said such side effects were typically \"mild.\"\nPsychological factors or lifestyle factors may play a role, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that zonisamide is already used as an anti-seizure drug.\u00a0 It did not discuss whether it\u2019s used off-label for weight loss.\nFrom an availability perspective, it also didn\u2019t provide enough detail about this statement:\n\u201cAll study participants followed their treatment plan for one year. During this time, they all also received monthly individualized nutritional counseling, which Gadde described as \u201cnot intensive,\u201d to help them reduce their overall caloric intake.\u201d\nWhat does \u201cnot intensive\u201d actually mean?\u00a0 Since this was part of the treatment \u201cpackage,\u201d how generalizable is this approach?\u00a0 What kind of setting would be capable of delivering it?\u00a0 The vague \u201cnot intensive\u201d comment just isn\u2019t helpful at all.", "answer": 0}, {"article": "There were 812 deaths (32.2 percent) among heart failure patients not treated with Plavix and 709 deaths (28.1 percent) among heart failure patients treated with Plavix.\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\nMONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\nThe study appears online March 23 and in the March 30 print issue of the Journal of the American College of Cardiology.\nHe said the benefit of the drug found in this study is \"of unquestionable practical importance,\" and added that the positive outcomes seen in a relatively short follow-up suggests potentially even better long-term survival.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0Plavix (clopidogrel) is a medication already on the market. \u00a0While the story did not state this explicitly, it was implied.", "answer": 1}, {"article": "Dr Arthur Roach, Director of Research at Parkinson's UK, which funded the study said:\n\n\"People affected by Parkinson's, their carers, and health and social care professionals have said that preventing falls and improving balance is the biggest unmet need for people living with the condition, other than finding a cure.\nScientists have discovered that a commonly prescribed dementia drug could hold the key to helping prevent debilitating falls for people with Parkinson's.\nParkinson's UK is the UK's leading charity supporting those with the condition.\nDr Henderson and her team at the University of Bristol studied 130 people with Parkinson's who had fallen in the past year.\n\"This trial shows that there may be drugs already available, being used for other purposes, that can be tested to help treat Parkinson's.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the drug is already available as a treatment for Alzheimer\u2019s disease patients.", "answer": 1}, {"article": "Worldwide, more than 10 million people have impaired vision or blindness as a result of corneal damage, but only a small fraction ever receive transplants from cadaver donors.\n\u201cWe are still in the prototype stage, but this shows that regenerating a human cornea is possible.\u201d\n\nTwo years after having the corneas implanted, six of the 10 patients had improved vision .\nAfter several years of testing in her lab, Griffith began collaborating with Swedish eye surgeon Per Fagerholm of Linkoping University, who implanted the engineered collagen corneas into the 10 patients in Sweden.\nNine of the 10 experienced cell and nerve regeneration, meaning that corneal cells and nerves grew into the implant.\nTo make the material, the researchers placed a human gene that regulates the natural production of collagen into specially programmed yeast cells.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Of the three stories, this one does the best job making it clear how preliminary this study is. The second sentence says that the results are from \"the first 10 people in the world treated with the biosynthetic corneas,\" signaling that much more work needs to be done. To underscore that point, two paragraphs later the first quote in the story, from one of the lead researchers in the study, says \"We are still in the prototype stage, but this shows that regenerating a human cornea is possible.\" This is the best quote in any of the stories.", "answer": 1}, {"article": ".\nA number of companies now market nootropic \u201cstacks,\u201d or formulas, some of which include piracetam, herbal remedies, amino acids and citicoline, a naturally occurring brain chemical that can be taken orally as a supplement, intravenously or as a shot.\n\u201cIt\u2019s the few who are getting ahead who are using supplements to do that.\u201d\n\nThe word \u201cnootropic\u201d was coined in 1972 by a Romanian scientist, Corneliu Giurgea, who combined the Greek words for \u201cmind\u201d and \u201cbending.\u201d Caffeine and nicotine can be considered mild nootropics, while prescription Ritalin, Adderall and Provigil (modafinil, a drug for treating narcolepsy) lie at the far end of the spectrum when prescribed off-label as cognitive enhancers.\nMost often they mean piracetam, which Giurgea first synthesized in 1964 and which is approved for therapeutic use in dozens of countries for use in adults and the elderly.\nBut it\u2019s only one of many formulations in the racetam drug family.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job here, although it injects confusion when it states that in the U.S. piracetam \u201ccan be sold only for research purposes,\u201d but later says that piracetam and similar drugs are available online. In fact, the FDA at least twice warned suppliers, in 2010 and 2012, that piracetam was classified as a drug and could not be sold as a supplement. According to online accounts, that FDA action prompted major retailers to stop carrying it, which could explain why it\u2019s not present in some products marketed as nootropics.\nThe story also states: \u201cA number of companies now market nootropic \u2018stacks,\u2019 or formulas, some of which include piracetam, herbal remedies, amino acids and citicoline, a naturally occurring brain chemical that can be taken orally as a supplement, intravenously or as a shot.\u201d", "answer": 1}, {"article": "A surgically implanted electrical device that stimulates the sacral nerve can calm an overactive bladder, according to a company that sells it. Physicians say sacral neural stimulation works well for many patients, but a test period with an external device is recommended first.\n\nMillions of Americans suffer from \"urge incontinence,\" accidents caused by a strong, sudden need to get to the bathroom, or overly frequent urination, defined as eight or more times a day. Quality of life is affected, as sufferers must...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly the device is available, but it is not clear how widely and how many practitioners are trained in implanting the device.", "answer": 0}, {"article": "The group that received standard education lowered their scores by an average of 1 point.\nThe problem, Spira said, is that behavioral therapy for sleep problems is not always easily found -- and even when it's available, the process takes some effort.\nBlack said the benefits of mindfulness training were on par with what's been found in studies of sleep medications and cognitive behavioral therapy -- a form of \"talk therapy\" that is often helpful for insomnia, for example.\nBy learning \"non-judgmental mindful awareness,\" Black said, people can begin to see their thoughts and feelings without reacting to them.\nThere are still plenty of questions about the effects of mindfulness meditation on sleep quality.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the type of meditation therapy is available in various forms and even includes a link to the specific therapy from UCLA that was included in the study. In addition, there was a very nice general description of the technique to help readers imagine how it works: \u201cIn general, \u2018mindfulness\u2019 practices encourage people to focus their attention on the present moment, instead of the past or future, and to take an objective look at their thoughts and emotions.", "answer": 1}, {"article": ".\nThat is why patients need a CT scan to confirm the type of stroke before receiving tPA.\n\"Time is brain in acute stroke after vascular collaterals fail, and faster treatment yields better outcomes,\" said May Nour, M.D., Ph.D., lead researcher, interventional neurologist and director of UCLA's Mobile Stroke Rescue Program.\n\"Our study shows pre-hospital clot-busting is a promising, evolving approach to providing tPA stroke therapy.\nThe association has strict policies to prevent these relationships from influencing the science content.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability is not addressed beyond UCLA\u2019s Mobile Stroke Rescue Program, which collected the data for the study.\nIt would have been good to mention that specialist-staffed mobile stroke units have been popping up in different parts of the country over the last 3-4 years. They are mainly affiliated with larger medical centers and funded by private donations. ", "answer": 0}, {"article": "\"Doctors are already doing these [glucose and HbA1c] tests together -- if a patient is obese, for example, and has other risk factors for diabetes, the physician is likely to order tests for both glucose and HbA1c from a single blood sample.\nAccording to Bernstein, if only one diagnostic test were needed, \"this would mean that a follow-up visit would be a look at the treatment benefits -- rather than a confirmation of an abnormal glucose.\"\n\"Given these numbers, any abnormality of glucose should be regarded as sufficient reason to start preventative treatment with an education program, lifestyle change and first-line medication such as metformin.\"\nBut taking the test twice takes up time and money and could still result in missed diagnoses, said a team from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nThe new study \"helps us move quicker to treat diabetes,\" he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that both blood tests are routinely performed for diabetes.", "answer": 1}, {"article": "Previous recommendations from the Centers for Disease Control's Advisory Committee on Immunization Practices (ACIP) had previously called for nasal sprays, or live attenuated influenza vaccine (LAIV), not be used during the 2016-2017 flu season.\nPublished today in the scientific journal Annals of Internal Medicine, the study shows that the nose spray had a similar effect to the standard flu shot.\nThis study was funded by the Canadian Institutes for Health Research.\nThen, subsequently, it was no longer preferred and now not recommended at all.\nOur study challenges previous studies because our results show conclusively that the vaccines show similar protection when both direct and indirect effects are taken into account.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Both forms of immunization \u2014 shots and nasal spray \u2014 have been around for some time, their availability is widely known, earning the release a Satisfactory in this category.", "answer": 1}, {"article": "Whether you've been relatively inactive or fairly athletic, age is the enemy of one of the most important sets of muscles in the body: the group of four known as the rotator cuff that surround the ball of the shoulder joint.\n\nAbout 54% of adults older than 60 have a completely or partially torn rotator cuff, compared with just 4% of those between 40 and 60. But tears are most frequently caused by degeneration of the tendon due to age, rather than injury from sports or trauma. Studies show that tears can be managed without...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story does not tell us whether what it calls the \u201cmini-open\u201d and other less invasive surgical techniques are widely available. \u00a0It implies that they are, but by calling them \u201cnew\u201d it likewise makes one wonder whether it may take time for them to penetrate to all surgical practices.", "answer": 0}, {"article": "Designated as one of only 47 comprehensive cancer centers, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the world.\nThe team of researchers chose to focus on low-dose \"baby\" aspirin, because not only is it inexpensive and readily available as potential means of prevention, but because there are already a lot of people already taking it for prevention of other diseases such as heart disease and even colon cancer.\nThis study differed from other studies that have looked at aspirin and cancer risk because it focused on the dose levels of the aspirin women had taken and tracked the frequency of the use of low-dose aspirin as opposed to regular aspirin.\n\"The study found an interesting protective association between low-dose aspirin and breast cancer,\" said lead author Christina A. Clarke, Ph.D., M.P.H., from the Cancer Prevention Institute of California.\n\"We thought that if aspirin can inhibit aromatase, it ought to reduce the likelihood that breast cancer would develop and it could also be an effective way to improve breast cancer patients' prognosis once they no longer take the more potent aromatase inhibitors.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release explicitly states that low-dose aspirin is \u201creadily available\u201d and that\u2019s widely known to be the case.", "answer": 1}, {"article": "Guidelines from the American Cancer Society and other organizations recommend that women age 30 and older are screened using Pap smears and tests for the human papillomavirus, or HPV.\nIn that case, women would need more invasive tests to rule out disease, Roland said, and risk \u201cundue harm\u201d from those procedures.\n\u201cOften a provider just does the HPV test\u201d without telling the patient.\nThat\u2019s because HPV \u2014 which causes changes in the cervix that can lead to cancer \u2014 may take a decade to progress to that point.\nWomen should talk to their doctors about screening, especially if they think they are being screened too often, researchers added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The entire story was about cervical cancer screening being made TOO available too often.", "answer": 1}, {"article": "A new study raised questions about the benefits of a relatively common procedure for heart patients\u2014implanting tiny devices that prop open clogged arteries to relieve chest pain.\n\nThe 200-patient study conducted by U.K. researchers found that patients with stable chest pain, or angina, who received stent devices experienced no significant improvement in exercise time on a treadmill, compared with similar patients who received no stents during sham procedures.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that stent insertion is widely available and frequently done.", "answer": 1}, {"article": "Accumulations of neurotoxic beta-amyloid protein can be detected with positron emission tomography, or PET scans, and analysis of cerebrospinal fluid, but these are invasive, inconvenient and costly, making them impractical for routine screening and follow-up evaluation.\n\"In 2010, our research group published an article providing the first evidence for the existence of Alzheimer's-specific plaques in the human retina, and we demonstrated the ability to detect individual plaques in live mouse models using a modified ophthalmic device.\"\nThe study's first author, Yosef Koronyo, a research associate at Cedars-Sinai and a scientist and inventor at NeuroVision, said the latest findings cap a decade of study that has produced several landmark discoveries.\nWith the imaging technology's ability to detect autofluorescence signal related to retinal beta-amyloid, these findings may lead to a practical approach for large-scale identification of the at-risk population and monitoring of Alzheimer's, the researchers say.\nFindings from this study strongly suggest that retinal imaging can serve as a surrogate biomarker to investigate and monitor Alzheimer's disease,\" said Maya Koronyo-Hamaoui, Ph.D., an associate professor of Neurosurgery and Biomedical Sciences and a research scientist at the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai, and a co-founder, inventor and scientist at NeuroVision.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although not as clearly stated as it could be, it does come across in one of the quotes that this is a technology that is not yet available for use.\n\u201cIt\u2019s exciting to see these studies demonstrating the power of the technology applied to the Alzheimer\u2019s field. Our goal is to develop a product that is easy to use, affordable and widely accessible. We look forward to the potential of retinal imaging playing a vital role in solving the problem of Alzheimer\u2019s, both in identifying and monitoring those who may be affected by the disease. Our next step is to continue with clinical trials, building upon the existing pharmaceutical company collaborations, to ensure our technology is ready for the medical community to help manage this disease.\u201d", "answer": 1}, {"article": "Former NASA astronaut Mark Kelly announced that he is running for John McCain's Senate seat in Arizona in the 2020 election.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "In the lead-in to her interview with the reporter, the CNN anchor states in passing that \"as always with things that are seeking approval, and there are benefits and there are of course risks.\"\u00a0She is alluding to the fact that this\u00a0asthma treatment involves an investigational device that has not yet been approved by the FDA. However,\u00a0this is never directly stated. We\u00a0think there\u2019s a good chance the average\u00a0viewer will think that this\u00a0treatment\u00a0is already available, but it isn\u2019t.\u00a0\u00a0", "answer": 0}, {"article": "Traditionally, patients with leukemia, lymphoma and myeloma have first tried to find an adult bone marrow donor either from a close relative or from a national bone marrow registry.\nAt that point, Mumford said, his choices were to continue chemotherapy and live for, maybe, another year and a half.\nBut Tirpak's physician, Dr. Mary Laughlin, turned to something deemed medical waste until recently: umbilical cord blood.\nUntil recently, Tirpak would have faced a death sentence without a bone marrow transplant.\nEven siblings are not a sure thing, with the chance of matching a brother or sister only 25 percent.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This topic was unclear. The story implies that the chain of events from cord blood donation, national registration, and transplantation is currently available. We would like to have seen a clearer, more direct discussion on its current availability, and the statistics were vague. \"Cord blood transplants among unrelated donors have risen from 1 percent in 2001 to 24 percent last year.\" 24 percent of what? Of all stem cell transplants? How many of those recipients were children?\nThe important distinction between use of this procedure in children and in adults should have been discussed.", "answer": 0}, {"article": "The researchers conclude that the added sensitivity of cotesting versus HPV alone for detection of treatable cancer affected extremely few women.?\nHowever, reports of rare HPV-negative, Pap-test-positive cancers are motivating continued use of both tests (cotesting) despite increased testing costs.\nThis remains the most extensive experience of HPV testing incorporated into routine screening in the world.\nGiven the rarity of cancers among screened women, the contribution of the Pap test to screening translated to earlier detection of at most five cases per million women per year.\nResearchers were searching for realistic performance data to quantify the additional benefit of the Pap test component of cotesting, as the costs of intensive screening of all women using two screening tests are substantial.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is implied that these tests are widely available in the US.", "answer": 1}, {"article": "\"This is a multi-channel implantable device,\" Peckham explains.\nThat's what happened to Annette in 2002 when a car accident left her paralyzed.\nWith the touch of a button, Annette turns on a device much like a pacemaker that's implanted in her chest.\nIt was the lowest point of Annette's life; the woman who once trained dogs to assist the disabled would now be relying on one herself.\n\"Electrodes are implanted in the body.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if the device is available anywhere other than this clinic in Cleveland. In addition, it isn\u2019t clear whether it is investigational or FDA-approved. Is the woman in the story a study subject or is this part of routine care?", "answer": 0}, {"article": "The amygdala and hypothalamus are regions of the brain that control several memory and emotional functions.\nThe research, published online Jan. 19 in the American Journal of Geriatric Psychiatry, examined the effects of an easily absorbed curcumin supplement on memory performance in people without dementia, as well as curcumin\u2019s potential impact on the microscopic plaques and tangles in the brains of people with Alzheimer\u2019s disease.\nThe people who took curcumin experienced significant improvements in their memory and attention abilities, while the subjects who received placebo did not, Small said.\n\u201cThese results suggest that taking this relatively safe form of curcumin could provide meaningful cognitive benefits over the years,\u201d said Small, UCLA\u2019s Parlow\u2013Solomon Professor on Aging.\nNewswise \u2014 Lovers of Indian food, give yourselves a second helping: Daily consumption of a certain form of curcumin \u2014 the substance that gives Indian curry its bright color \u2014 improved memory and mood in people with mild, age-related memory loss, according to the results of a study conducted by UCLA researchers.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Theracurmin is available from several sources not mentioned in the news release. The initial comments in the release give the reader the erroneous impression that eating Indian food is equal to the form used in the study. (We also discuss this under Unjustified Language.)\nThe lead sentence of the news release \u2014 \u201cLovers of Indian food, give yourselves a second helping \u2026\u201d \u2014 implies that the alleged benefits of curcumin might be achieved through diet alone, thus making availability a no-brainer. But the dosages used in the study (which we\u2019re not told are about three times the commonly recommended dose) require oral supplements, which certainly are widely available in health stores and online, but at a much greater cost than the kitchen spice.", "answer": 0}, {"article": "\u2022 Swelling or thickening in part of the breast.\nAnd there are some lifestyle-related risk factors that can be controlled, such as hormone therapy after menopause, obesity, alcohol intake and physical inactivity, Evers said.\nIn some cases, women never develop any of these symptoms, Evers noted.\nThese tests can help find breast cancer in its early stages, even before symptoms appear.\"\nThere are three tests often used to look for breast cancer, Evers said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that all of these screening methods are available.", "answer": 1}, {"article": "They included sharing news about friends or relatives or plans for the day as a way to involve their spouse in day-to-day events; waiting patiently and keeping eye contact while spouses searched for words; and finding alternate ways to communicate \u2014 for example, singing songs together when attempts to engage the spouse in certain topics failed.\nThe caregiving spouses seemed to value their partners\u2019 efforts to communicate as much as or more than the actual content of their conversations.\nThe couples, who were recruited from a day program for people with memory disorders and their spouses, were receiving coaching in communication, with caregivers learning to listen, to avoid arguing, to not treat their spouse like a child.\n\u201cAt the same time, people with Alzheimer\u2019s do have moments of clarity or show affection when it\u2019s unexpected.\nSome of the caregivers did voice frustration or tried to teach their partners information they had forgotten.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The behavioral approaches derived from this study seem to be easily adoptable by caregivers. However, the story mention that the couples were receiving specific training on these communication techniques. Is such training widely available? The story doesn\u2019t say, and the average reader probably doesn\u2019t know.", "answer": 0}, {"article": "If doctors know someone is at risk for premature labor earlier in pregnancy, they might start efforts to help delay labor, such as recommending bed rest.\nThe test, if it does turn out to work in clinical trials, would be cheaper than ultrasound, said Quake.\nBut the findings are promising, particularly because premature delivery is such a serious problem.\nThere's a lot more work to be done before these tests becomes available, including clinical trials.\nThe study was funded by the March of Dimes and other nonprofit sources, although Quake and his colleagues have filed for a patent on the test.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear about the test\u2019s availability in above-the-fold copy, stating it \u201cis still experimental and not yet available outside of a research lab.\u201d There\u2019s even a reference to it being experimental in the story summary. (But why not include \u201cexperimental\u201d in the headline, too?)", "answer": 1}, {"article": "To see if healthy tissue surrounding the cavity could be coaxed into healing the stroke injury, Segura engineered a gel to inject into the stroke cavity that thickens to mimic the properties of brain tissue, creating a scaffolding for new growth.\nThe mice with new neurons showed improved motor behavior, though the exact mechanism wasn't clear.\nThe study was supported by funds from the National Institutes of Health.\nIn addition to Carmichael and Segura, other authors of the paper are Lina Nih and Shiva Gojgini, both of UCLA.\n\"This study indicated that new brain tissue can be regenerated in what was previously just an inactive brain scar after stroke.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s made fairly clear that the gel used in this study was developed by the authors, is experimental, and most likely not available for widespread use.", "answer": 1}, {"article": "Lactoferrin supplementation also enhances the expression of salivary immune proteins, which may help reduce oxidative stress and resulting side effects.\nAlthough TSA is widespread and a frequent complaint of cancer patients, until now, there have been no established therapies that reliably prevent or treat this problem.\n\"The prevailing symptom described by patients undergoing chemotherapy is a persistent metallic flavor or aftertaste, with or without food intake.\nTheir most recent study builds on the previous body of work through the application of lactoferrin supplements in treating taste and smell abnormalities.\nTheir findings could bring relief to millions of patients undergoing cancer treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It wasn\u2019t made clear enough in the release that lactoferrin supplements are available online. Many readers might erroneously think the only source is drinking milk.", "answer": 0}, {"article": "It will also help remove the uncertainty surrounding which sub type of the disease an individual has and therefore be a catalyst for better outcomes for all people with MS.\"\n\nMultiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS).\nPublished today in Scientific Reports, the discovery identifies tiny 'dysregulated' micro-RNA molecules that correctly diagnose MS and discriminate between patients at different disease stages - all in a simple blood test.\nThe team also validated eight out of nine micro-RNA molecules in an independent group of progressive MS cases, confirming the reproducibility of the findings.\nThe research was made possible through the generosity of patients at the Brain & Mind Centre's multidisciplinary Multiple Sclerosis Clinic, a collaborative service offered by Royal Prince Alfred Hospital, and the University of Sydney.\nA breakthrough study led by the University of Sydney's Brain and Mind Centre and Royal Prince Alfred Hospital has revealed unique molecules in the blood of people with Multiple Sclerosis (MS) that could become definitive diagnostic biomarkers of the world's most common neurologic disability in young adults.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This research is basic, so one might expect a reader to infer that the blood test is not yet available.\u00a0 But the text could have reinforced that by indicating what next steps need to be taken in order to validate this discovery and move it into clinical use.", "answer": 2}, {"article": "Strawberries have the potential to prevent esophageal cancer, according to a preliminary study released Wednesday.\n\nResearchers, led by Ohio State University, were able to show that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of strawberries is not in question. The story notes that a strawberry-industry-funded agency supplied the fruit for the study.\u00a0 One online commenter on the WSJ site wrote, \u201cIf you need someone to \u2018contribute\u2019 strawberries for research .. you already know the outcome.\u201d", "answer": 2}, {"article": "Please see paper for the complete list.\nWithout effective prevention and treatment, the prospects for the future are bleak.\n\u201cThe magnitude of improvement in these ten patients is unprecedented, providing additional objective evidence that this programmatic approach to cognitive decline is highly effective,\u201d Bredesen said.\nTHE BREDESEN PROTOCOL, Dr. Bredesen\u2019s book describing for a lay audience the interventions described in this paper, will be released by Penguin Random House in May 2017.\nOther collaborators on the study include Edwin C. Amos, Jonathan Canick, Mary Ackerley, Cyrus Raji, Milan Fiala, and Jamila Ahdidan.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Some of the MEND interventions, such as dietary changes and exercise, may be readily available. But the intensiveness that this approach requires would make it hard for most people to access financially and logistically. Perhaps the book about the program, when it publishes, will make this clear, but the news release does not.", "answer": 0}, {"article": "Ancient Greek and Chinese medical practitioners used a patient\u2019s scent to make diagnoses.\nBut not every physician\u2019s nose is a precision instrument, and dogs, while adept at sniffing out cancer, get distracted.\nThese molecules offer a whiff of who we are, revealing age, genetics, lifestyle, hometown \u2014 even metabolic processes that underlie our health.\nSo researchers have been trying for decades to figure out how to build an inexpensive odor sensor for quick, reliable and noninvasive diagnoses.\nModern medical research, too, confirms that the smell of someone\u2019s skin, breath and bodily fluids can be suggestive of illness.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told we\u2019re 3-5 years away from seeing this technology on the street, so that establishes\u00a0its current (lack of) availability.\nBut the certainty with which this estimate is passed along by a researcher who\u2019s developing such products should have received more scrutiny. This assumes that current testing will work out as planned. Moreover, three to five\u00a0years is likely\u00a0only enough time to show that the detection of cancer may be earlier by using the odor technology, and not the needed outcomes that we discussed above.\n5-year predictions in medicine generally have a poor track record.", "answer": 0}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the stent in question is not yet approved by the FDA. ", "answer": 1}, {"article": "Subsequently, a clinician will help a patient learn to slow down or speed up those brain waves, through a process known as operant conditioning.\nDr. Norman Doidge, a psychiatrist at the Center for Psychoanalytic Training and Research at Columbia and the author of \u201cThe Brain That Changes Itself\u201d (Viking, 2007), said he considered neurofeedback \u201ca powerful stabilizer of the brain.\u201d Practitioners make even more enthusiastic claims.\nRobert Coben, a neuropsychologist in Massapequa Park, N.Y., said he had treated more than 1,000 autistic children over the past seven years and had conducted a clinical study, finding striking reductions in symptoms, as reported by parents.\nThe treatment is also gaining attention from mainstream researchers, including some former skeptics.\nWhen it comes to to the actual devices, Dr. Kerson, at the International Society for Neurofeedback and Research, cautioned that they should never be used without experienced supervision.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story mentioned that there are 7,500 mental health professionals that offer neurofeedback services.", "answer": 1}, {"article": "Prostate cancer is the most common cancer among men.\nThe study was published Tuesday in the journal The Lancet Oncology.\nFewer side effects would also lower other health care costs, he said.\nThe procedure was carried out under general anesthesia and most of the patients had hospital stays of less than 24 hours after the treatment.\nThe new study, designed as a proof-of-concept study, involved just 41 men.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was about a British study.\u00a0 There was no mention of the availability of HIFU in the US.", "answer": 0}, {"article": "\u201cMore often than not, it\u2019s not clear-cut which way to go,\u201d explained Barry Rosenstein, professor of radiation oncology at Mt.\nThe next step, he said, is for group members to validate the predictive power of the markers his team found.\nThis early-stage study represents a big step toward doctors and their patients making that decision.\n\u201cAnd if we can do that, then there\u2019ll be enough confidence to put it into use in the clinic.\u201d\n\nEven better, he suggested, it may one day be possible to use drugs to target the SNiPs, or the biological processes they influence, as a way to prevent damage from therapy.\nThat hope is evident to other researchers, such as Dr. Ithaar Derweesh, a urologic oncologist and associate professor of surgery at the University of California San Diego Moores Cancer Center.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article clearly indicates that this work is experimental and would require extensive validation before it could be considered for clinical practice.", "answer": 1}, {"article": "THE AMERICAN SOCIETY OF ANESTHESIOLOGISTSFounded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology.\nAnd, therefore, alleviating this pain might help reduce the risk for postpartum depression.\nResearchers found the higher the PIP scores, the lower the EPDS scores.\nNewswise \u2014 CHICAGO \u2013 Epidural anesthesia may do more than relieve pain during labor; in some women it may decrease the likelihood of postpartum depression, suggests a preliminary study presented at the ANESTHESIOLOGY\u00ae 2016 annual meeting.\nThey calculated the percent improvement in pain (PIP) throughout labor after the implementation of epidural analgesia.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Epidurals are so widely available we don\u2019t think the availability needs to be stated.", "answer": 2}, {"article": "The latest health and science updates, breakthroughs, research, and the best in investigative and informative journalism.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned the availability of the products discussed.", "answer": 1}, {"article": "For more information, visit us at allinahealth.org, Facebook, Twitter, YouTube or Healthy Set Go.\nThe study, funded by Engelsma Family Foundation and Abbott Northwestern Hospital Foundation, was published recently in The Breast Journal, the official journal of the National Consortium of Breast Cancers.\n\"These findings allow surgeons to select which patients with microinvasive tumors may actually benefit from lymph node sampling, while sparing other patients from this procedure,\" said Tamera Lillemoe, M.D, pathologist and a study co-author.\nPhysicians at the Virginia Piper Cancer Institute wanted to know if surgical procedures to test the lymph nodes for cancer were always necessary.\nHow to treat patients who have microinvasive breast cancer - tumors that are 1 mm or less in size (the thickness of a dime) -- is somewhat controversial.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does not address availability specifically but readers can glean from the release that lymph node biopsy is a common surgical procedure. The release summarizes the study\u2019s research question: Should lymph node biopsies in tumors that are 1mm or less in size remain common practice?", "answer": 1}, {"article": "But we don't know we're right yet.\"\nBut there are reasons to think aducanumab may succeed where other drugs have failed.\nThose efforts have failed to produce a single approved drug so far.\nBut it will take much larger studies to show for sure whether aducanumab really does slow down Alzheimer's disease, Reiman says.\nOfficials of Biogen, which is developing the drug, were also cautious about interpreting the results of the study, which included 165 patients in the early stages of Alzheimer's disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story calls the drug experimental and says that it will take several years for larger studies to report results. It\u2019s apparent that the drug won\u2019t be available outside of a research study any time soon.", "answer": 1}, {"article": "It\u2019s easy to get into the habit of popping a pill to have a good night\u2019s sleep. Insomnia, which affects a third of adults, becomes more common as we age.\n\nBut as evidence has mounted about the risks of drugging the brain to induce or maintain slumber, more doctors are steering patients away from sleep aids, including over-the-counter medications, and are offering innovative behavioral-change solutions.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that CBT can be provided by any trained therapist or nurse. The story could have been more\u00a0helpful if it had specified how common this training is and how a patient seeking CBT could go about finding a health care professional trained in the technique. The article also might have mentioned that systematic analysis of studies has shown that even web-based versions of cognitive behavioral therapy can effectively treat insomnia, making it even more widely available.", "answer": 1}, {"article": "To study what effect THC has on the aging brain, scientists gave low doses of THC to mice at three different life stages\u2014two months, 12 months and 18 months.\nMoving this research forward, however, will be problematic: \u201cTesting in humans is going to be difficult.\nResearchers are increasingly examining THC (tetrahydrocannabinol) for its potential medical benefits.\nWith a cannabinoid like THC, which does have adverse effects in certain individuals, there would be worries about the chronic dosing of this kind of medicine.\nHuman lifespan is very extensive.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty widely known that cannabis products are becoming increasingly available in many states, and medicinally in some.", "answer": 2}, {"article": "If a robot is to be enlisted, he recommends asking how the procedure would be performed if the robot is not available or if it doesn\u2019t work.\nThe robotic equipment provides better three-dimensional vision, increased range of motion and intuitive, downscaled movements, while adding a few thousand more dollars to the procedure\u2019s price tag, the authors note.\nHowever, about half as much blood was lost when robots were enlisted than with standard laparoscopy.\n\u201cRobotics increases the chance that a hysterectomy can be done by laparoscopy,\u201d he added.\n\u201cRobotic-assisted surgery is in its infancy, and it definitely has a future,\u201d said Nezhat.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t include \u2013 and it wouldn\u2019t have taken much to do so \u2013 any estimate of the number of robotic surgery facilities in the US.\u00a0 And it didn\u2019t give any estimate of how often the open, laparoscopic or robotic procedures are done.", "answer": 0}, {"article": "Deep brain stimulation involves implanting electrodes in the brain, then connecting them to a pulse generator placed under the skin of the chest.\nWhat's needed, said Fargo, is research that compares deep brain stimulation against a placebo device.\nAnd those issues have a huge impact on daily life, for patients and their caregivers, Scharre added.\nBut it's far too early to know whether it has value for people with Alzheimer's, Scharre stressed.\nIf DBS ever becomes an option for Alzheimer's, Scharre said it would not be for everyone.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We like the prominent placement of the caveat that \u201cit\u2019s far too early to know whether it has value for people with Alzheimer\u2019s\u201d and it\u2019s \u201cnot something patients can ask their neurologist for.\u201d It also mentions DBS \u201cwould not be for everyone\u201d including people who are frail or have other serious medical conditions.", "answer": 1}, {"article": "\u2022 Prostate cancer mainly occurs in older men; about 6 in 10 cases are diagnosed in men aged 65 or older.\nWhile the findings need further research, larger clinical trials could give better information on individualized treatment for each prostate cancer type.\nThe researchers said the analysis in their study is better at forecasting how prostate cancer will advance compared to the current diagnostic tests being used for prostate cancer such as the prostate specific antigen test and the Gleason score.\nThis could lead to a better quality of life and more effective treatment based on which prostate cancer a man is diagnosed with.\nFor men with a family history of the disease, contact Dr. Samadi to learn more about your risk factors and to get a baseline PSA blood test.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We can\u2019t be sure if the testing protocol discussed in the release is available or not. One might reasonably assume that genetic cancer screening for the five identified genetic types of prostate cancer is available at the specialist\u2019s hospital. However, the release isn\u2019t clear on this point.", "answer": 0}, {"article": "\"We talk with older folks and many say, 'I can't exercise, but maybe I can become more physically active.'\n\"Walking was the cornerstone of the program,\" says Thomas Gill, a professor of geriatrics at the Yale School of Medicine and an author of the study, which appears in Annals of Internal Medicine.\nPhysicians can also help.\nThe exercise program pretty closely followed the government's recommendations for all adults, including older ones: 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity exercise per week, plus two strength sessions that hit all the major muscle groups.\nCardinal says older adults need to realize that exercise can greatly improve their quality of life by maximizing function as long as possible.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Since walking and physical activity are available to all capable of such exercise, there is no question about availability here.", "answer": 1}, {"article": "When nicotine enters the body, it binds to the same receptors in the brain that acetylcholine binds to, resulting in smoking's rewarding and reinforcement effects.\nBefore the trial began, researchers assessed the smokers' cognitive function to get a baseline.\nFor both drugs, \"we were able to show a reduction in total nicotine self-administered,\" Schmidt said; however, there was a caveat.\nThe findings sparked the CIRNA clinical trial, which has to date studied 33 smokers ages 18 to 60.\nFinally, the researchers asked the study subjects to do their best to not smoke for seven straight days, a time during which the participants still took either galantamine or a placebo.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that galantamine is FDA approved which speaks to its availability. The release responsibly points out that \u201cThere\u2019s no data to suggest that a clinician treating a smoker should prescribe one of these AChEIs now,\u201d according to the lead investigator.", "answer": 1}, {"article": "Aromatase inhibitors block an enzyme that the body needs to produce estrogen.\nThe women had taken another breast cancer drug, tamoxifen, for several years and then were started on an aromatase inhibitor, which doctors usually prescribe for five years.\nExperts said the study was significant because some women and their doctors choose to continue aromatase inhibitors past the standard five years.\nDr. Debra Patt, a breast cancer specialist at Texas Oncology who was not involved in the study, called the difference of a few percentage points in the risk of recurrence (95 percent vs. 91 percent) \u201csubstantial.\nThere was no difference in survival, however: 100 women in each group died during the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The drug letrozole is already available, and the story makes this clear.", "answer": 1}, {"article": "\"What would you want for your wife, or your mom, or your sister, or your best friend?\"\nAbout 90 percent of all gall bladder surgeries are done laparoscopically, so why not hysterectomy?\nLike all laparoscopic procedures, a camera is inserted through a tiny incision to see into the abdomen; two other small incisions are made so that tools can be inserted to perform the surgery.\nWhat's happening now is that the vast majority, about 70 percent, are done the old-fashioned way, with a large surgical incision, lots of pain, and a six-to-eight-week recovery.\nMost are recommended because of pain and bleeding from fibroids.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does comment on the fact that the availability of laparoscopic hysterectomy is somewhat limited. However, the story does not address the reasons why laparoscopic hysterectomy is limited, including the fact that it doesn\u2019t provide many advantages compared to vaginal hysterectomy. In fact, according to a Cochrane review, laparoscopic hysterectomy is associated with increased operating time and blood loss relative to vaginal hysterectomy.", "answer": 0}, {"article": "It's OK to ask the question,\" Hoberman said.\nStudy authors and other experts say doctors should be sure the child really is suffering from an ear infection before writing that prescription.\nBut here's the rub \u2013 diagnosing ear infections in very young children, who tend to squirm, is not easy.\nIf many children in prior studies didn't really have ear infections, then it's not surprising the antibiotics didn't work for them, says Dr. Jerome Klein of Boston University, who wrote an editorial that accompanies the new studies.\nTwo new studies add substantial weight to one side of a long-running controversy over whether to give antibiotics to young children suffering from ear infections.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that the \u201cwait and see\u201d approach to ear infections is widely recommended. The accompanying radio piece reported that there are \u201c13 million prescriptions every year for ear infections,\u201d in part because only about 20% of doctors actually follow that approach.\n", "answer": 1}, {"article": ".\nPrevious, mostly experimental research has suggested that spices and their bioactive ingredient, capsaicin, have anti-obesity, antioxidant, anti-inflammation and anti-cancer properties.\nThe authors suggest further research should investigate the benefits of other spices and the effects of certain chili pepper subtypes.\nBut experts caution that this doesn\u2019t mean everyone should pile on the spices at dinner time to improve their health and increase their longevity.\nStill, the authors say the study strengthens the growing body of evidence that spicy food may have protective health properties that can lead to a longer life.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Red hot chili pepper are widely available in American supermarkets.", "answer": 2}, {"article": "Sept. 28, 2010 -- Intrauterine devices (IUDs) -- used to prevent pregnancy -- may also be an effective treatment for some patients with early-stage uterine cancer who want to preserve their fertility.\n\nIn a small, early study, carefully selected patients with cancer that had not spread beyond the inner lining of the uterus were treated with IUDs that released the hormone progesterone.\n\nThe treatment was found to be as effective as oral hormone therapy, which is the most widely used nonsurgical, fertility-sparing treatment for the cancer.\n\n\u201cOur results show promise for the treatment of younger endometrial cancer patients with early disease who desire pregnancy in the future,\u201d gynecologic oncologist Lucas Minig tells WebMD. \u201cBut patients must be screened very carefully to make sure their disease has not spread.\u201d", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Progestin IUD is clearly available.", "answer": 1}, {"article": "Of those 40 women, 26 had mutations carrying low to moderate risk of breast or ovarian cancer, eight had mutations associated with Lynch syndrome, which increases colon and ovarian cancer risk, and three had high-risk breast cancer genes.\nAnd for many, family testing would be recommended for first-degree relatives, according to the report in JAMA Oncology.\nEarlier this year, 17 genetic experts argued against testing for a wider panel of breast cancer-related gene mutations until they are proven to be valid and useful in clinical practice (see Reuters story of May 27, 2015 here: reut.rs/1TvOoDf).\nEven among all appropriate candidates who are sent for genetic testing, only nine percent will test positive for the BRCA mutations, so an additional four percent who have non-BRCA mutations is a significant number, Ellisen said.\nBut new tests for breast cancer risk mutations beyond the well-known BRCA genes would offer actionable information for many women and their doctors, a new study finds.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although availability isn\u2019t explicitly addressed, the story does note that women and their physicians are \u201cordering a wide selection of multiplex tests daily,\u201d from which one can infer that they are available. The story could have been more specific as to which panels were tested here and what others are available from physicians and even online. A good review is included in a table in this recent article from the NEJM.", "answer": 1}, {"article": "They identified a total of 24 breasts reconstructed by DTI in 19 patients, all with at least 30 days' follow-up and most with one year of follow-up\n\nPatient characteristics and outcomes were compared to those of 109 breasts with TEI reconstruction in 98 patients.\nThe authors note some important limitations of their study--particularly the fact that it was a review study of one hospital's experience with a relatively new procedure.\nDr. Moreira and colleagues write, \"These reported cases include our learning curve patients as we familiarized ourselves with appropriate patient selection and surgical technique.\"\n\"The DTI approach is a powerful tool for breast reconstruction in elderly patients,\" comments ASPS Member Surgeon Andrea Moreira, MD, of the Cleveland Clinic.\nDr. Moreira adds, \"In appropriately selected cases, DTI reconstruction is a viable alternative to staged techniques requiring multiple surgeries.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although the release does mention that the tissue expander approach is more established and widely used, it could have been more explicit \u2014 as the authors of the study were \u2014 in letting us know \u201cthis is relatively new technique.\u201d\nWe\u2019re told\u00a0 that DTI \u201chas emerged as a single-stage approach to immediate breast reconstruction after mastectomy\u201d and we get this quote from one of the lead authors:\nThe DTI approach is a powerful tool for breast reconstruction in elderly patients.\nTaken together these two quotes could give readers an erroneous sense that this is an established and proven option. It\u2019s not.", "answer": 0}, {"article": "Unlike a heart attack, which happens when blood flow to a portion of the heart is blocked, cardiac arrest occurs when the heart\u2019s electrical system malfunctions, often due to irregular heart rhythms.\nThe study is observational and doesn\u2019t prove bystander CPR increases survival odds, the authors note in Circulation.\nAfter 13 minutes, patients who got CPR at the scene continued to have better survival odds but the difference was no longer statistically meaningful.\n\u201cEarly CPR saves lives, and the lack of CPR efforts from bystanders could result in significantly decreased chances of survival,\u201d said lead study author Dr. Shahzleen Rajan of Copenhagen University Hospital in Denmark.\nThe biggest obstacle to bystander CPR remains that too few people know how to do it, said Dr. Peter Pons, an emergency physician in Denver and professor emeritus at the University of Colorado School of Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t outright state that pretty much anybody is capable of performing CPR. However, it does imply that CPR is widely available\u00a0by explaining that the biggest barrier to bystander CPR is that too few people know how to do it. More explanation about how easy it is to learn the procedure (training can be done in just a few minutes) would have improved that aspect of the article.", "answer": 1}, {"article": "\u201cWe are not quite there yet, but it may become a real possibility for finding out real information without having to risk a pregnancy.\u201d\n\nFor example, \u201cIf this comes back negative, you don\u2019t need an amniocentesis, but if it comes back positive, we would probably still do an amniocentesis to confirm the results,\u201d she says.\nIt is not a diagnostic test for Down syndrome, she says.\nThe new test looks \u201cvery promising,\u201d says Cathy Sullivan, a genetic counselor at the University of Texas Health Sciences Center in Houston.\n\u201cIt\u2019s not ready for prime time, but researchers are actively working on methods to increase its efficiency,\u201d he says.\n\u201cThis test looks very promising, but it is also very expensive,\u201d\n\nWhile there are risks attached to amniocentesis and CVS screens, these are minimized when the test is performed by a skilled obstetrician, she says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story leans on an independent expert to say that the test is \u201cnot ready for prime time\u2026.in a year or two, this test may be available.\u201d", "answer": 1}, {"article": "The U.S. Food and Drug Administration approved the first therapy to treat an underlying cause of cystic fibrosis, a pill that targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.\n\nThe drug, Kalydeco, from Vertex Pharmaceuticals Inc., will be among the most expensive therapies on the market, costing $294,000 a year.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story focused on FDA approval.\u00a0 It also mentioned the drug company\u2019s financial assistance plan.", "answer": 1}, {"article": "JACC is ranked No.\nThe mission of the College is to transform cardiovascular care and to improve heart health.\nThe latest research and clinical practice updates in cardiology are at your fingertips with the JACC Journals app for iPhone/iPad and Android.\nThey also looked a several early indicators of heart disease.\n\"There are many patients with heart disease who also experience depression - we need to study whether encouraging them to exercise will reduce their risk of adverse outcomes.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "With the \u201ctreatment\u201d being physical exercise, availability is a given. There are countless ways to exercise and there need not be any cost involved.", "answer": 1}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s made clear that testosterone is available. It would have been\u00a0helpful to clearly state that this requires a prescription, but this is a minor quibble.", "answer": 1}, {"article": "As a nicotine-gum addict, Mike Metzger used to worry about the warning on its label: \"Stop using the nicotine gum at the end of 12 weeks.\"\n\nBut that was before a prominent smoking-cessation scientist, K. Michael Cummings, told him to keep chewing the gum as long as it helped him stay off cigarettes. So 15 years after quitting smoking, Mr. Metzger, a 63-year old retired New York telephone worker, still chews 16 pieces of nicotine gum a day.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that these over-the-counter drugs are widely available and that Nicorette is the market leader. \u2018Glaxo products\u2014which include Nicorette gum and lozenges and NicoDerm patches\u2014account for more than half of the $835 million market in annual U.S. retail sales of over-the-counter smoking-cessation aids, according to market-research firm Euromonitor International. Pfizer Inc. and Novartis AG also market NRT.\u201d", "answer": 1}, {"article": "In 2008, Medicare paid for 480,000 injections of Avastin to treat macular degeneration and 337,000 injections of Lucentis, according to a study led by Dr. Philip Rosenfeld of the University of Miami.\nSales of the drug for each company were about $1.5 billion last year.\nYet Medicare paid only $20 million for the Avastin compared to $537 million for the smaller number of Lucentis injections.\nSafety of the two drugs will also be closely watched.\nA far less expensive alternative proved roughly as effective as Genentech\u2019s costly drug Lucentis in preserving or improving vision in elderly people with a common eye disease, according to two people familiar with the results of a closely watched clinical trial.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provides information on\u00a0the FDA\u00a0approval status, off-label usage, and utilization of both drugs.\n", "answer": 1}, {"article": "Niki Munk, an assistant professor of health sciences in the School of Health and Rehabilitation Sciences at Indiana University-Purdue University Indianapolis and one of the co-first authors of the study, said that the study's findings are important, given the large number of people who suffer low back pain in the U.S.\n\nLow back pain leads all disorders in years lost to disability in the U.S.\nAdditional investigation is needed to replicate the results of the initial study and to conduct a cost-benefit analysis of massage therapy, Munk said.\nPrevious studies of the effectiveness of massage were conducted in controlled research situations.\nWhile the study results are promising, much more work needs to be done, Munk said: \"The fact of the matter is that chronic lower back pain is very complex and often requires a maintenance-type approach versus a short-term intervention option.\"\nIn this study, patients were referred by a physician to a massage therapist.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that massage is widely available. We give the release credit for noting that it\u2019s not covered by insurance and therefore not accessible to everyone.", "answer": 1}, {"article": "Postmenopausal patients tend to take aromatase inhibitors like anastrozole or letrozole, which are more effective than tamoxifen at preventing breast cancer recurrence, though they do not work for premenopausal women.\nThe results, while answering one question, raise many new ones, including whether even more than 10 years of treatment would be better still.\nWhether these differences are big enough to cause women to take the drug for twice as long remains to be seen.\nHalf were chosen at random to take the drug another five years, while the others were told to stop.\nThere was virtually no difference in death and recurrence between the two groups during the five years of extra tamoxifen.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicates the drug has been available, studied, and inexpensive.", "answer": 1}, {"article": "Dr. William Nelson, co-vice chair of the SU2C Scientific Advisory Committee and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland, said:\n\n\"Understanding the link between prostate cancer and DNA repair mutations is incredibly important for patients and their families.\nIts efforts have helped produce a 20-fold increase in government funding for prostate cancer.\nThe trial is a milestone in cancer treatment as the first to show the benefits of 'precision medicine' in prostate cancer - with treatment matched to the particular genetic characteristics of a man's tumour.\nThe trial, called TOPARP-A, received support from a wide range of funders including Cancer Research UK, the Prostate Cancer Foundation, Stand Up To Cancer, Prostate Cancer UK and the Movember Foundation.\nIt is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The story nods to the availability of the drug used in the study in the UK when it says it \u201cwas licensed last year for women with ovarian cancer and inherited BRCA mutations, but so far has not been approved for use on the NHS by NICE or the Cancer Drugs Fund.\u201d However, we aren\u2019t left with any idea if the gene testing carried out here is widely available. That\u2019s a critical point that should have been addressed.", "answer": 0}, {"article": "On the other hand, longer treatment was tied to a 24-percent decrease in hip fractures, which along with wrist and spine fractures affect about half of all people with osteoporosis.\nBut that\u2019s a very rare problem, experts say, which only affects about one in 100,000 people on bisphosphonates.\nThe findings add to earlier concern over the medicines, called bisphosphonates, whose U.S. labels have been required since October to include a warning about the thighbone fracture risk.\nAnd the actual risk of having one of the unusual fractures was low, said Laura Y. Park-Wyllie, of St. Michael\u2019s Hospital in Toronto, who worked on the new study.\nThat works out to nearly three times the risk of those who\u2019d taken the drugs for roughly three months or less, after accounting for other risk factors.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that these drugs are widely available.", "answer": 1}, {"article": "Flare-ups , which involve excruciating joint pain, redness, swelling and warmth, can last days or weeks.\n\"(And) this trial provides well-controlled evidence that this IL-1 blocker is effective in preventing acute gout flares in this setting,\" he added.\nDr. Michael A. Becker, a professor emeritus of medicine at the University of Chicago, described the findings as \"very promising.\"\nHowever, he cautioned that the high cost of rilonacept will most likely curtail its use.\nGout, a debilitating and painful form of inflammatory arthritis, now affects upwards of 8.3 million Americans, according to the release.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We are not told that the drug was approved by the FDA for use in gout in November 2011.", "answer": 0}, {"article": "Caught early, lung cancer can be cured surgically, but it causes vague symptoms and usually is not diagnosed until it has spread.\nThe researchers waited until an independent panel could document a 20 percent reduction in cancer deaths, or could determine that there was no significant benefit.\nThe study sponsored by the U.S. National Cancer Institute is the first to show that people can be screened for lung cancer, akin to mammograms for breast cancer and tests for colon and prostate cancer.\nDr. Bruce Johnson of the Dana Farber Cancer Institute in Boston, who is on the board of the American Society of Clinical Oncology, said he doubted most people would see the findings as a green light to smoke.\nThe trial of more than 53,000 current and former heavy smokers, aged 55 to 74, found the \u201cspiral\u201d CT scans apparently catch tumors before they have spread.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story did a better job than others in actually spelling out how commonly used these spiral CT scans are, noting that \u201cAlmost all advanced CT scanners can perform a spiral CT, and about 60 percent of U.S. hospitals have such a machine. Makers include General Electric Co\u2019s GE Healthcare Siemens AG, Toshiba Corp, Hitachi and Philips.\u201d", "answer": 1}, {"article": "Women who took hormones had an average of 24 fewer hot flashes per month, while those who took soy had 12 per month fewer.\nSoy supplements also have side effects: Nausea, bloating, and constipation, according to the NIH.\nWomen with severe or frequent hot flashes or whose hot flashes keep them up at night, should consider treatment, she said.\nAnd not every woman needs treatment, notes Bachmann, who was not involved in the study.\nThat means that if women do take hormones, Bachmann told Reuters Health, it should be the lowest dose and for the shortest possible period of time.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of soy supplements or of hormone replacement therapy is not in question.", "answer": 2}, {"article": "Macular edema can arise during any stage of diabetic retinopathy and is the most common cause of diabetes-related vision loss.\nThe three drugs yielded similar gains in vision for patients with 20/32 or 20/40 vision at the start of treatment.\nDRCR.net investigators enrolled 660 people with DME at 89 clinical trial sites across the United States.\nOf these, about 750,000 have DME.\nAmong participants with 20/40 or better vision at the trial\u2019s start, all three drugs improved vision similarly on an eye chart.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that all three drugs compared are available and in use. It could have noted that payers may not cover them all.", "answer": 1}, {"article": "Lower blinds and turn off lights so your room is as dark as possible.\nThat means turning off all electronics, including the TV, and creating as quiet a sleep space as you can.\nInstead, choose whole-wheat crackers, which can control insulin.\nIf your teen has to get up at, say, 6:30 to be at school by 7:30, that means bedtime's at 9:15 or 9:30 p.m.)\n\nVorona says he'd like to delve deeper into the sleep-obesity question.\nIf sleep extension could have a salutary effect on helping people lose weight,\" he says, we'd have another tool in the fight against obesity.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The criterion is not applicable. The story\u2019s focus is on the connection between sleep and weight, and the lifestyle interventions mentioned are available to everyone.", "answer": 2}, {"article": "For an early version of the study abstract, click on \u201cContents,\u201d then \u201cVolume 44, No.\nAlso, among those in the 40-milligram group, people carrying what is sometimes called the Alzheimer\u2019s gene (APOE-e4) showed more improvement than non-carriers.\nNonetheless, conclusive evidence about a treatment's effectiveness is rarely found in a single study.\nCAVEATS The study involved a relatively small number of participants and lasted a short time; a larger and longer study would be needed to adequately test effectiveness and safety.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Neither this story nor the competing story by Fox News explained that\u00a0this nasally administered form of insulin is currently only available as part of research studies. The story also offers no informed opinion regarding how long additional testing might take.", "answer": 0}, {"article": "The Society works closely with many other sports medicine specialists, including athletic trainers, physical therapists, family physicians, and others to improve the identification, prevention, treatment, and rehabilitation of sports injuries.\n\u201cWhile young athletes and parents may be wary of surgery, our study shows the advantages of this treatment approach,\u201d commented Marshall.\nSurveys given to patients during follow-ups asked for information such as test for shoulder functionality, whether patients returned to sport, postoperative instability events, and if further surgery was required on the shoulder.\n\u201cHowever, this study shows a substantial benefit for athletes undergoing surgery to prevent recurrent instability down the road.\u201d\n\nThe research data was collected between 2003 and 2013 from eight fellowship trained surgical practices, with patient ages ranging from 16 to 30 years old.\nThe study examined 121 patients at an average of 51 months post-surgery.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does not say how available either procedure is. The release would have been stronger if it had clarified whether all orthopedic surgeons perform this procedure or if it is a specialized procedure only available at certain clinics. ", "answer": 0}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "In Finland, saunas are common. Since this story was published for a US audience, it should have included some mention of the relative abundance or scarcity of saunas here and where to find them. The story warned that the same benefits shouldn\u2019t be expected from hot tubs and steam rooms \u2014 a nice addition. As we mentioned above, the cost of access to sauna would have been a great addition to the story.", "answer": 0}, {"article": "Parkinson's is not considered an inflammatory disease, he said, adding: \"We might be missing something.\nTagliati called the study \"eye-opening.\"\n\"So it narrows the focus to a subgroup of [anti-inflammatory drugs].\"\nIn a six-year span, 293 were diagnosed with the disease.\nStudy author Dr. Xiang Gao, an instructor and epidemiologist at Harvard Medical School and Brigham and Women's Hospital in Boston, said the findings are important for anyone at increased risk for Parkinson's because most people with the disease eventually become severely disabled.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that ibuprofen is a common anti-inflammatory drug. ", "answer": 1}, {"article": "\u201cWhen people engage in risky behaviors like driving or smoking, they\u2019re encouraged to take measures that minimize their risk, like wearing a seatbelt or choosing cigarettes with filters.\n\u201cAlthough no substitute for systematic lifestyle improvements, including healthy diet, regular exercise, weight loss, and smoking cessation, complimentary statin packets would add, at little cost, one positive choice to a panoply of negative ones,\u201d the scientists write in their paper.\n\u201cThey are not a magic bullet.\u201d\n\nA study in June in the Archives of Internal Medicine suggested, in fact, that statins do not save lives in patients without heart disease, although they may prevent some non-fatal heart attacks.\n\u201cStatins are a vital medicine for people with \u2014 or at high risk of developing \u2014 heart disease,\u201d he said.\nWhile statins might combat some of the toll that fatty foods take on cholesterol, there\u2019s a lot they can\u2019t negate: \u201csodium content is high, fibres are absent, and caloric load gargantuan,\u201d Messerli said of the fast food the authors looked at.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that statins are widely available and only by prescription in the U.S.", "answer": 1}, {"article": "Dr Joanna Bowtell, head of Sport and Health Sciences at the University of Exeter, said: \"Our cognitive function tends to decline as we get older, but previous research has shown that cognitive function is better preserved in healthy older adults with a diet rich in plant-based foods.\nIn the study, healthy people aged 65-77 who drank concentrated blueberry juice every day showed improvements in cognitive function, blood flow to the brain and activation of the brain while carrying out cognitive tests.\n\"In this study we have shown that with just 12 weeks of consuming 30ml of concentrated blueberry juice every day, brain blood flow, brain activation and some aspects of working memory were improved in this group of healthy older adults.\"\nThere was also evidence suggesting improvement in working memory.\nThe new paper, \"Enhanced task-related brain activation and resting perfusion in healthy older adults after chronic blueberry supplementation\", is published in the journal Applied Physiology, Nutrition and Metabolism.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We know blueberry juice is widely available but what about the concentrated blueberry juice used in the study?", "answer": 0}, {"article": "Yet the women with those tumors also experienced a reduction in cancer recurrence from Herceptin, in some cases as great as that in the Her2-positive women.\nBut he said the studies called attention to the inconsistent quality of Her2 testing in many small laboratories.\nSome experts were skeptical, saying the number of patients in the two studies was too small to draw firm conclusions.\nDr. Soonmyung Paik, who presented the second study at the cancer conference, said the problem might lie not in sloppy testing but rather in the cutoff used to determine which women get Herceptin.\nShe said the findings raised questions of whether women who were Her2-negative should be tested again.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story correctly points out that Herceptin treatment has been approved and available for about ten years, and discusses testing for the presence of the HER2 receptor.\u00a0 ", "answer": 1}, {"article": "A new study shows that computer technology known as machine learning is up to 93 percent accurate in correctly classifying a suicidal person and 85 percent accurate in identifying a person who is suicidal, has a mental illness but is not suicidal, or neither.\nThe results showed that machine learning algorithms can tell the differences between the groups with up to 93 percent accuracy.\nThey then used machine learning algorithms to classify the patients into one of the three groups.\nDr. Pestian and his colleagues enrolled 379 patients in the study between Oct. 2013 and March 2015 from emergency departments and inpatient and outpatient centers at three sites.\nThe researchers extracted and analyzed verbal and non-verbal language from the data.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of the algorithm isn\u2019t made clear in the release, though the study notes that an \u201cunexpected\u201d lack of predictive power means \u201cadditional research\u201d is required.", "answer": 0}, {"article": "For men, the difference came out to 103 fewer cancer deaths a year per 100,000 people; for women, the number was 42.\nIt discourages the use of aspirin to stave off colorectal cancer in people at average risk for the disease.\n\u201cThings are moving forward, but it is still a work in progress.\u201d\n\nMedical guidelines in the U.S. already urge people to take low doses of aspirin to prevent heart disease if the predicted benefits outweigh the risk of side effects, or if they have already suffered a heart attack.\nDr. Kausik Ray of St. George\u2019s University of London, who has studied aspirin, said the new study did not look at overall death rates or side effects such as serious stomach bleeds.\nOne of the problems with the new study as well as with previous aspirin trials, he said, is something called detection bias.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of aspirin is not in question.", "answer": 2}, {"article": "In a study suggesting that red wine might be the next big thing in breast cancer prevention, a study has found that women who drank just under two servings of red wine daily experienced hormonal changes that mimic the effects of a drug used to prevent malignant breast tumors from coming back.\n\nThe study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.\n\nWomen intent on warding off breast cancer have been warned about alcohol consumption: as recently as November, a study found that women who consumed as few as three servings of alcohol a week increased their risk of developing the disease, which strikes one in eight American women at some point in life.\n\nWhite wine and other alcoholic beverages are believed to promote the conversion of androgens--\"male hormones\" such as testosterone, which circulate in all women's blood--into estrogen. And the greater a woman's lifetime exposure to estrogen--whether her own or estrogen that comes from medication or environmental sources--the higher her risk of developing breast cancer.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of red wine is not in question.", "answer": 2}, {"article": "We are actively seeking the best-suited licensees having resources and marketing expertise to maximize sales for each of our products in the U.S. and globally.\"\nThe clinical studies support powerful marketing claims.\nAt 72 hours, OsteoRx\u2122 results were nearly five and a half times better.\nAfter 14 days of treatment, the average improvement was still nearly twice as large as the competition.\nThe proprietary formulations support long product patent lives.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The point of the release appears to be an advertisement for a product that is already available. The supplement was readily found online.", "answer": 1}, {"article": "Up to 30% of men suffer some degree of premature ejaculation, defined as ejaculation that occurs within one minute of vaginal penetration.\nAll used the product for three months, for a total of 23,000 doses.\nNonetheless, doctors like Irwin Goldstein, MD, director of San Diego Sexual Medicine at Alvarado Hospital in San Diego, tell WebMD they're excited because this is the first time a drug is being rigorously tested for men with really serious premature ejaculation problems.\nPSD502, which contains two common topical painkillers, lidocaine and prilocaine, is \"slightly oily, but not objectionably so,\" Sharlip says.\nHe consults for Shionogi Pharma Inc., which makes the spray and funded the work.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that \"The drug is so new that the company has yet to give it a name under which it will be marketed\u2026. the company is preparing to apply for FDA approval based on the results of the new research.\"", "answer": 1}, {"article": "Current methods for determining if a prostate has become cancerous include a physical examination of the prostate (known as a digital rectal examination or DRE), MRI scans, a biopsy or tests to determine levels of the chemical prostate-specific antigen (PSA) in the blood.\nOne in eight men will develop the condition at some point in their lives with more than 47,000 new cases being diagnosed every year.\nThe Dundee University-based team say they have used an ultrasound process called shear wave elastography (SWE) to detect prostate tumours.\n\u201cThe technique now needs to be tested in a much larger number of men to confirm just how well it can detect the aggressive cancers, while also ruling out those who do not have prostate cancer,\u201d said Simon Grieveson, head of research funding at Prostate Cancer UK, which funded the Dundee project (with support from the Movember Foundation).\nSWE technology is already used in diagnosing breast cancer and liver diseases.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story doesn\u2019t explicitly deal with the availability of shear wave elastography (SWE), it\u2019s fairly clear that the new approach is experimental, has only been used on no more than 200 patients, and would require larger clinical trials to prove its efficacy \u2014 all points that suggest that it may not be available to most patients now.\u00a0 It also states that, \u201cSWE technology is already used in diagnosing breast cancer and liver diseases.\u201d", "answer": 1}, {"article": "While the function of sweating is to prevent overheating, those affected sweat even when the body does not need cooling.\nThe first line of defense are anti-perspirants.\n(Reuters) - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the often embarrassing condition.\nThe Menlo Park, California-based company\u2019s shares were up 3 percent at $33.00 in extended trading on Wednesday.\nDermira said it had expected to apply for marketing approval for the drug in the second half of 2017, subject to completion of the drug\u2019s long-term safety trial.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We learn it is still in its experimental stages.", "answer": 1}, {"article": "Eventually, the overwhelmed system leaves these sugars, in the form of glucose, to build up in the blood, which can lead to obesity, damage the heart, and cause other metabolic problems.\nThat\u2019s because experts believed that once the pancreatic islet cells, the body\u2019s insulin-making factories, were compromised, they couldn\u2019t be made to work again.\nMore work will be needed to confirm what benefit betatrophin might have on diabetic patients before that might be possible, however.\n\u201cThat\u2019s a huge difference.\u201d\n\nWhat\u2019s more, it appears the cells are relatively long-lasting, which could indicate they are robust enough to bring glucose levels in diabetics under control.\nBut despite decades of research, scientists haven\u2019t found a better way to address the problem.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that any possible treatment resulting from this research is still a long way away.", "answer": 1}, {"article": "\"There were times when I would yell at myself: 'I can't do this.\nIf made widely available, this kind of brain scan could be an important complement to the assessments -- based on reading and behavior -- already available for diagnosing dyslexia, Hoeft said.\nA larger trial that controlled for remediations would offer more conclusive results.\nA study led by Fumiko Hoeft, psychiatry researcher at Stanford University School of Medicine, used brain imaging to answer this question.\nOf course, the results of the study are only preliminary.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story notes that the type of scan used in this study is not widely available.", "answer": 1}, {"article": "Data from nearly 9,500 people on five continents shows that amyloid can appear 20 to 30 years before symptoms of dementia, that the vast majority of Alzheimer\u2019s patients have amyloid and that the ApoE4 gene, known to increase Alzheimer\u2019s risk, greatly accelerates amyloid accumulation.\nThe findings also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify people for clinical trials of drugs to prevent Alzheimer\u2019s.\nThe largest analysis to date of amyloid plaques in people\u2019s brains confirms that the presence of the substance can help predict who will develop Alzheimer\u2019s and determine who has the disease.\n\u201cThe papers indicate that amyloid imaging is important to be sure that the drugs are being tested on people who have amyloid,\u201d said Dr. Roger Rosenberg, the director of the Alzheimer\u2019s Disease Center at the University of Texas Southwestern Medical Center at Dallas, who wrote an editorial about the studies.\nExperts say previous trials of anti-amyloid drugs on people with dementia failed because their brains were already too damaged or because some patients, not screened for amyloid, may not have had Alzheimer\u2019s.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Dr. Gandy\u2019s quote implied scans were available, although expensive and not covered by many insurance plans. We consider this a satisfactory recognition that the scanning technology is available now.", "answer": 1}, {"article": "While heart disease is the leading cause of death in the United States, according to the Centers for Disease Control and Prevention, blacks have higher rates of cardiovascular disease and death than whites and the disease tends to occur earlier in life.\nThe researchers say a vitamin D supplement is an inexpensive and safe option for most of us.\nParticipants taking 4,000 international units - more than six times the daily 600 IUs the Institute of Medicine currently recommends for most adults and children - received the most benefit, says Dr. Anas Raed, research resident in the MCG Department of Medicine and the study's first author.\nWhile just how vitamin D is good for our arteries isn't completely understood, it appears to impact blood vessel health in many ways.\nThe test essentially measures the speed at which the blood is moving, and in this case, fast is not good, Raed says.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that it would be simple for almost anyone seeking to increase their vitamin D intake to do so. They can drink more milk, eat more yogurt, eat more greens like kale, take a supplement and so forth.", "answer": 1}, {"article": "A new method for performing a \u201cvirtual\u201d colonoscopy that requires less unpleasant preparation was shown in a new study to accurately detect larger precancerous polyps\u2014and was a better experience for patients.\n\nThe second-leading cause of cancer deaths in the U.S., colon cancer can be prevented if precancerous polyps\u2014known as adenomas\u2014are found and removed during a colonoscopy\u2026.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is relatively clear from the story that while virtual colonoscopy is available as a treatment option, this method of preparing for a scan is not (\u201cmay become a useful alternative\u201d).", "answer": 1}, {"article": "Letters being mailed to study participants advise them to discuss with their doctors whether they should have additional scans or not.\nNor is it clear if the study results are applicable to all smokers.\nThe massive National Lung Screening Trial enrolled 53,000 current or former smokers to try to settle the debate.\nMany smokers already had sought out spiral CTs, even though the American Cancer Society hasn't recommended the test - citing a lack of clear evidence that they work - and most insurance doesn't cover the $300 to $400 cost.\nThe NCI said it is not clear that all smokers should get the scans, which are not risk-free.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nWhile this story does call the CT scans used in this trial \u201cspecial\u201d and different from conventional CT scans, it does not make clear that the trial applied rigorous standards to the equipment, operators and radiologists that may not be followed by other providers who offer CT scans to smokers.", "answer": 0}, {"article": "The American Academy of Family Physicians outlines medicines used to treat patients with acute coronary syndrome.\nThe panel's recommendation was based in part on prior findings from this study, called the Platelet Inhibition and Patient Outcomes (PLATO) trial.\nMONDAY, June 27, 2011 (HealthDay News) -- Brilinta, an experimental anti-clotting medication currently awaiting U.S. Food and Drug Administration approval, performed better than the industry standard, Plavix, when used in tandem with low-dose aspirin, a new study finds.\n\"A higher aspirin dose (325 mg versus 81 mg) increases the risk of bleeding without increasing the efficacy of the drug.\"\nA study author agreed that for most patients, using the drug with a lower dose of aspirin is usually warranted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We would have preferred a different tone that didn\u2019t suggest the drug is \u201cawaiting\u201d what then appears as almost inevitable FDA \u201capproval.\u201d The FDA panel that produced the 7-1 vote is not the panel that decides whether to approve drugs. It\u2019s an advisory panel. The FDA usually follows its recommendations, but it has not decided whether to approve the drug. That colors the caveat that the \u201capproval process is still ongoing\u201d as sounding somewhat perfunctory, like it\u2019s only a matter of time. It would be more balanced to suggest it\u2019s still under review.", "answer": 0}, {"article": "Men who only father daughters appear to be at greater risk of developing prostate cancer, according to a study published last week in the Journal of the National Cancer Institute.\nIt was funded by an \"educational grant\" from Glaxo SmithKline, which makes Paxil.\nThe study was published this month in the American Journal of Psychiatry by researchers at Leiden University in the Netherlands and other Dutch centers.\nIn the first controlled study that compared a group of hypochondriacs given the drug with a group that got psychological talk therapy and another group that received sugar pills, the medication significantly reduced people's fears about imaginary illnesses.\nResearchers suggested that a combination of this talk therapy and medication might be especially effective.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is about the\u00a0medication Paxil, which is a\u00a0readily available prescription medication\u00a0though the piece failed to mention this and the fact that\u00a0the use of Paxil in the treatment of hypochondriasis has not been approved by the FDA.", "answer": 0}, {"article": "Probabilities may not grab all patients by the collar. But telling someone he or she has a better than 1-in-3 chance of dying before the next decade's out (or even a better than 1-in-10 chance) would probably be a sobering reminder to hit the gym. The authors said the metric \"can be used to communicate fitness-related risk and motivate behavioral change after exercise stress testing.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We have mixed feelings about this one. On the one hand, the story says, \u201cDo-it-yourself stress testing is probably not very reliable, since a physician or sports physiologist needs to be around to decide when to call a halt to the test (and therefore what maximum a test-taker has achieved).\u201d But then it encourages people to try to develop their own score at the gym or at home and gives them the formula that the researchers used. It\u2019s great to give readers all the information, but we would have preferred that the story emphasize that the validity of the results stems from how these tests were conducted in a clinical setting.", "answer": 1}, {"article": "U.S.-listed shares of Novartis closed up 1.2 percent .\nOn a media briefing following the release of J&J\u2019s trial results, Novartis said it expected the data to have \u201climited clinical relevance\u201d and no impact on plans to expand the Cosentyx label.\n\u201cThese results imply that Cosentyx remains a good option for moderate-to-severe psoriasis patients that want to achieve more rapid skin clearance,\u201d brokerage Jefferies wrote in a note following the results.\nTremfya, first approved in July 2017 as a plaque psoriasis treatment in the United States, is also being tested as a for psoriatic arthritis and Crohn\u2019s disease.\nAbout 7.5 million Americans live with plaque psoriasis, of which 20 percent have moderate-to-severe form of the disease, J&J said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability is implied but it should have been made more clear when these drugs received FDA approval, and what they\u2019re approved for.", "answer": 1}, {"article": "Researchers used CAR-T to treat a man with brain cancer to some success\n\nGlioblastoma is one of the deadliest cancers \u2014 an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.\n\nThe therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma \u2014 but has proven challenging in treating other forms of the disease, including solid tumors.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The STAT story\u00a0notes the availability of CAR-T commercially (by naming the companies) for blood cancers, and it quotes an outside source as essentially saying \u201cdon\u2019t hold your breath\u201d awaiting the viability of this treatment for glioblastoma.", "answer": 1}, {"article": "The requested URL /2011-08-30/business/29945941_1_mark-kris-cancer-cases-lung was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that crizotinib recently received FDA approval for use \u201calong with a companion diagnostic test for just a small subset of lung cancer patients.\u201d However, while the story refers to ongoing research, the actual status of the drug is not explained. The FDA approval letter warns that, \u201cIf postmarketing trials fail to verify that clinical benefit is conferred by XALKORI (crizotinib) Capsules, 200 mg and 250 mg, or are not conducted with due diligence, we may, following a hearing in accordance with 21 CFR 314.530(b), withdraw or modify approval.\u201d \nReaders should have been clearly told that this drug is still very much on trial.", "answer": 0}, {"article": "Many Type 2 diabetics become resistant to insulin and have to inject additional amounts.\nExperts rightfully caution against relying on miracle diet drugs, but a new study offers a novel approach that bears watching.\nThat makes it much safer than, say, systemic stimulants that also rev up the heart and other parts of the body and cause strong side effects, according to the research.\nThe study also found other benefits.\nOther researchers are working on similar approaches, he said, but this drug, so far, passes harmlessly out of the intestine after doing its work.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does caution readers not to expect this drug to be available any time soon.", "answer": 1}, {"article": "Co-authors are: Leslie Donato, Ph.D.; Sandra Bryant; Grant Spears; Peter Berger, M.D.\nThe present study is also the first to test its clinical utility in a U.S. population.\nThe new test is available to health care providers worldwide through Mayo Medical Laboratories, which offers laboratory testing and pathology services to more than 4,000 health care organizations in more than 70 countries.\nThe trial was funded by Mayo Clinic.\nPatients were grouped into four risk categories according to their ceramide levels: low (0\u20132), intermediate (3\u20136), moderate (7\u20139) and high (10\u201312).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states that the \u201cnew test is available to health care providers worldwide through Mayo Medical Laboratories.\u201d It is not entirely clear whether this is the only commercially available test of its kind.", "answer": 1}, {"article": "May 14, 2012 -- Acupuncture may allow people with the lung disease COPD (chronic obstructive pulmonary disease) to breathe a bit easier.\nIn a new study of 68 people with COPD, some got acupuncture, along with their daily medication, for three months.\nMany people with COPD have problems getting optimal nutrition because of their condition.\nThe study showed that acupuncture may improve stomach function, making it easier for people with COPD to eat a healthy diet and maintain a normal weight.\nOthers got a sham acupuncture treatment, in which the needles did not enter their skin.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story does mention that patients \u201cmust choose a licensed and experienced acupuncturist,\u201d it does not detail how many of those professionals practice in the US.", "answer": 0}, {"article": ".\nA private company has purchased the technology and is making it available to hospitals across the country.\nBut now, according to a study published Sunday in the New England Journal of Medicine, there appears to be a new, much less invasive way of determining whether a growth is malignant.\nHe called the technology \"a canary in the coal mine\" for lung cancer, which kills about 160,000 people in the United States each year.\nThe current advance was a long time in coming and shows the difficulty of bringing research from the lab to the consumer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that\u00a0a company bought the test\u00a0and is \u201cmaking\u00a0it available\u201d to hospitals nationwide.", "answer": 1}, {"article": "A study published in 2015 by the Center for Cancer Research found that fusion biopsy is 30 percent more accurate in diagnosing high-risk, aggressive cancers than a TRUS biopsy.\nThat\u2019s one of our strengths.\u201d\n\nYu has seen how MRI technology has changed prostate patients\u2019 care.\nMuch like someone would have an MRI to investigate the cause of back pain, the technology gives doctors eyes on what is happening in prostate tissue.\nOver the course of two years, Harder, 60, an MRI technologist, would have three TRUS biopsies.\n\u201cRight now, I think probably 50 or 60 percent get imaging.\u201d Sometimes, these are patients pushing their doctors for a referral as one of Yu\u2019s patients did last year.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states that \u201cVCU Medical Center is one of the major teaching hospitals in the country doing advanced multiparametric MRI.\u201d That appears to be accurate.\nIt would have helped readers not in the VCU vicinity if the release had included more information about where tests could be done. Is it generally available at major teaching hospitals? If not, how many have it?", "answer": 0}, {"article": "Oct. 25, 2010 -- Aspirin , already linked in some studies to a lower risk of developing colon cancer , may also cut the risk of dying of prostate cancer by more than half, a large study suggests.\nThe risk that cancer spread was also reduced by anticlotting medications, from 7% to 3%.\nThis study was presented at a medical conference.\nThe study involved 5,275 men with localized cancer whose disease had not spread beyond the prostate gland; 1,982 of the men were taking anticlotting medications: aspirin, Lovenox, Plavix, and/or warfarin.\nAspirin and other anticlotting medications carry risks of their own, chiefly bleeding, Zietman says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe study looked at the use of available anticoagulant medications.", "answer": 1}, {"article": "In macular edema, fluid from those damaged vessels leaks into the macula, the part of the retina that is responsible for the straight-ahead vision important for driving, recognizing faces and reading.\nResults of the trial were published online on Tuesday by the journal Ophthalmology.\nHe said treatment with Lucentis in the clinical trial virtually eliminated those incidents.\nDr. Philip J. Rosenfeld, a professor of ophthalmology at the University of Miami, said the decision was \u201cclearly a case of pay to play\u201d since Genentech\u2019s money dictated the choice of drugs.\nThe trial involved 691 patients, some of whom had both eyes treated, resulting in 854 total eyes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story was crystal clear that the drug reported on, Lucentis, is available as it is FDA approved for another condition; the story also mentioned that it is not yet FDA approved for treatment of diabetic macular edema.", "answer": 1}, {"article": "Symptoms range from mild stomach or skin reactions to a constriction of the airways.\nA medically supervised daily dose of peanuts may help children with peanut allergies greatly increase their tolerance to the food, according to two new studies that raise the possibility of a cure for this potentially life-threatening condition.\nWhile drugs can be used to treat an allergic reaction, there are no approved treatments for food allergies.\nNearly half of the 150 deaths attributed to food allergies each year in the United States are caused by peanut allergies, according to Duke University.\nAbout 3.3 million people are allergic to peanuts or tree nuts.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that this experimental treatment for peanut allergy is in the early stages of human research, and not available. \nIdeally it would have made this plain earlier in the story.\u00a0 \n\u00a0", "answer": 1}, {"article": "Mammograms, for example, prevent 25 percent of breast cancer deaths, and the PSA test for men has not been shown to prevent prostate cancer deaths.\n\u201cColonoscopy is a good test, but it isn\u2019t completely effective.\nPerhaps patients did not sufficiently cleanse their bowels of fecal material, a particular problem for the right side of the colon.\nHe is having a stool test, the fecal occult blood test, between colonoscopies.\nDr. Ransohoff and other screening experts say patients should continue to have the test, because it is still highly effective.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly colonoscopy is available.", "answer": 1}, {"article": "Dr. Gaetan Michel, Chief Executive Officer of Volition's wholly-owned subsidiary, Belgian Volition SPRL, commented, \"We would like to thank the Walloon Region for their continued support of the company.\nBased on this data, we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and treatment and substantially reduce the amount of unnecessary procedures in men with low-grade tumors or no tumor.\nIf these results are validated in larger trials, they will present a potentially significant new market opportunity.\nThe correlation of the panel blood test results with Gleason Score shows great promise in this regard.\nThe assay results correlated with the Gleason Score, which is one of the main predictors for aggressive PCA determined on biopsy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that this blood test is experimental and one can safely assume it is not yet available.", "answer": 1}, {"article": "\"So many people say `how can cancer screening be harmful?'\nHalf were screened annually with an ultrasound for four years and a blood test for six years.\nCervical cancer is easy to prevent.\nAdding a Pap after a negative HPV test did little to improve risk prediction.\nHPV tests were twice as good as Paps for predicting risk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Lower disk herniation results when the insulating disks that sit between spinal vertebrae tear open, allowing jelly-like material to protrude and exert pressure on surrounding nerve roots.\nThe therapy is not new, having first received U.S. Food and Drug Administration approval in the 1980s.\nHe noted that because \"the majority of people with back pain improve with time and exercise alone,\" it remains an open question as to whether the pRF procedure really cured the condition.\nAnd the new research suggests the treatment could prove a boon to back pain patients for whom standard therapies have failed to do the trick.\n\"Steroid injections are effective only in portion of the patients, and generally require more sessions,\" he noted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story mentions this treatment has been FDA-approved, but doesn\u2019t explain whether it\u2019s widely available, particularly for treating spinal disk herniation with spinal nerve compression.", "answer": 0}, {"article": "Adolescence is the key period for bone development, and poor development at this stage is linked to reduced peak bone mass (the amount of bone mass at the end of the skeletal maturation, around age 30), increased fracture risk and osteoporosis later in life.\n\"Though we focussed on aspiring professionals who played as much as nine hours a week, playing football for three hours a week might be enough for a substantial effect.\n\"Although we didn't study other sports, it's reasonable to suppose that weight-bearing, high-impact, high-intensity exercise like tennis, badminton, basketball and handball will have similar effects to football.\"\nThe year-long study, of 116 boys aged 12-14, took a variety of measures including bone mineral content (BMC).\nPlaying football can improve bone development in adolescent boys, new research shows.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t mention availability. True, soccer is the world\u2019s most popular sport and there are opportunities to play \u2014 but not all families are able to invest the time and expense required for intense participation in a sport.", "answer": 2}, {"article": "Radiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc.\n\nRSNA is an association of more than 54,000 radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation.\nResearchers said that in some cases MRI findings of additional cancers not seen on mammography may necessitate a change in treatment.\nOf the 2,021 patients, 285, or 14 percent, had additional cancer detected on MRI that was hidden from view on mammography.\nIn addition, the MRI-detected multicentric cancers were greater than 1 centimeter in size in 25 percent of the 73 patients.\n\"The results show that multicentric cancer detected on breast MRI after mammography appears to represent a larger tumor burden in approximately a quarter of patients and can result in potential changes to cancer grade and treatment,\" Dr. Iacconi said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that MRI is widely used for screening high-risk patients and for pre-surgical planning.", "answer": 1}, {"article": "But the F.D.A.\nThe tests, though, were not necessarily specific for Alzheimer\u2019s and none had been studied to see if they accurately predicted plaque on autopsy.\nOther companies, still doing their studies, did not yet have data to examine.\nBut every major drug company has new experimental drugs it hopes will work, particularly if they are started early.\nThat was evident on May 19, when Dr. Skovronsky gave a lunch for patients\u2019 families in City, Ariz., to thank them for participating.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The whole story is about how there is nothing available right now to accurately detect Alzheimer\u2019s and how this procedure may move the ball forward. Although, as the story rightly points out, the new scan won\u2019t necessarily answer all the questions about Alzheimer\u2019s. It should make it clear up high how long it would take for this scan to go through the FDA process.", "answer": 1}, {"article": "Of those, 25 had been admitted with a primary diagnosis of \"acute decompensated heart failure\" while another 16 patients had shown no signs of heart failure but did have other cardiovascular issues.\nDr. Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles, said that if further research were able to establish its effectiveness, a breath-driven tool for identifying heart failure would be a helpful diagnostic innovation -- but more so in a doctor's office or clinic than in the hospital.\nThe study authors pointed out that the most common reason American patients are admitted to a hospital is when there is a suspicion of heart failure -- a tough-to-treat condition in which the heart's pumping action grows gradually weaker over time.\nThe investigators stressed that their evaluation is based on a small group of participating patients, and that more extensive research will have to be done to confirm their initial success.\nThis study is really a proof of concept.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that this test is experimental and quotes a researcher saying, \u201cThere is much more work that needs to be done to get it to the point where it would become widely available.\u201d", "answer": 1}, {"article": "It was Kyle Henn, recovering from his own PTSD after surviving the plane crash, who recommended eye movement desensitization and reprocessing therapy, or EMDR.\nThis distraction had a positive effect on her, she said, allowing her to dive deeply into the therapy without freezing in the face of fear.\nEMDR, Henn said, allowed her to have a do-over \u2014 to be able to grieve properly and then to move beyond grief.\n\u201cEMDR processing is untangling the knot.\u201d\n\nOnce the memories are processed, therapists say, they are less vivid \u2014 less like the film reel Henn would see in her mind.\nTalk therapy helped her manage those attacks, but it didn\u2019t address the root cause.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that one can find clinical psychologists who will administer the therapy.", "answer": 1}, {"article": "They also were published online by the New England Journal of Medicine and will be in the April 12 issue.\nAlso, the clogs treated with angioplasty are not the really dangerous kind.\nThose patients now should try drugs first, experts say.\nAn even bigger surprise: Angioplasty gave only slight and temporary relief from chest pain, the main reason it is done.\nNeither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that stenting is very common in the U.S.", "answer": 1}, {"article": "Professor Francesca Cordeiro at UCL Institute of Ophthalmology, who led the research, said: \"Detecting glaucoma early is vital as symptoms are not always obvious.\nWhile we cannot cure the disease, our test means treatment can start before symptoms begin.\nFurther studies will now be carried out to into DARC and how it can be used not only to diagnose and treat glaucoma patients but also for other neurodegenerative conditions.\nThe initial clinical trials established the safety of the test for patients.\nNow, for the first time, we have been able to show individual cell death and detect the earliest signs of glaucoma.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Despite the enthusiasm about its future uses, it\u2019s pretty clear this test is in early trials and unavailable to the public. ", "answer": 1}, {"article": "Their symptom score dropped by 29 percent and the number of hot flashes by 35 percent, according to Dr. Yan-bin Ye of Sun Yat-sen University in Guangzhou.\nSoy supplements also have side effects such as nausea, bloating, and constipation, according to the National Institutes of Health.\n\u201cThe majority of them are showing no benefit,\u201d said William W. Wong, a nutrition researcher at Baylor College of Medicine in Houston who wasn\u2019t involved in the new work.\nThe standard drug treatment for stubborn menopause symptoms is hormone replacement therapy.\nThe work was supported by Frutarom Netherlands, which also donated the supplements.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 Soy supplements are over-the-counter products sold in most health stores.", "answer": 2}, {"article": "They found testosterone and two hormones needed for the production of sperm were notably suppressed in men who took the highest dose of DMAU.\nPage has high hopes for the results, calling them \u201cunprecedented in the development of a prototype male pill.\u201d Longer-term studies are the next step toward a once-daily male contraceptive pill, she said.\nRead more: Male birth control pill could be made from heart-stopping poison in ancient African arrows\n\nThe once-daily prototype pill suppressed certain hormones to the low levels you'd expect to see with effective longer-term contraceptives, results from an ENDO 2018, the Endocrine Society\u2019s annual meeting in Chicago, abstract show.\n\u201cDespite having low levels of circulating testosterone, very few subjects reported symptoms consistent with testosterone deficiency or excess,\u201d Page said.\nRead more: Side effects are not what's holding back the male contraceptive pill\n\nEighty-three men took various doses of DMAU or a placebo for a month.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does state that \u201cLonger-term studies are the next step toward a once-daily male contraceptive pill.\u201d However, most people are not familiar with how clinical trials work. A little additional information here would have gone a long way. Realistically, these \u201clonger-term studies\u201d will take years \u2014 and that\u2019s if everything goes perfectly. Readers expecting to see a male birth control pill in the relatively near future will certainly be disappointed.", "answer": 1}, {"article": "When Downing expressed concerns about the drug, she said the doctor blew her off: \"He said, 'What are you worried about?\nCandace's treatment, Downing said, involved a one-size-fits-all approach to mental health that sees medications as a magic pill.\nThe idea of a psychiatric evaluation sent chills down the spine of Caroline's mother, Mathy Milling Downing, who believed that her younger daughter, Candace, had committed suicide because of an adverse reaction linked to a psychiatric drug -- the antidepressant Zoloft.\nBy contrast, she said, the multiple screenings that Caroline received carefully evaluated the child as an individual and homed in on the kind of therapy that was best for her.\nThe screening, unsurprisingly, found that Caroline's emotional problems were linked to her sister's death.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story failed to provide information about the availability of recommended treatments for major depressive disorder in adolescents. \u00a0It provided some information about vendors that provided testing for this target population, but it was unclear from the piece where someone ought to turn for help with this. \u00a0It would have been worth mentioning that therapists specializing in adolescents are in short supply.", "answer": 0}, {"article": "\u201cThat\u2019s a simple enough statement, and people are not put off by that,\u201d she said.\nThe new report shows that during the two years, those same people had increasing confidence in their skills, with no increase in embarrassment or discomfort.\n\u201cWe are now trying to see if people can learn, perform and have continuing confidence without the physician reinforcement,\u201d said Robinson.\nAmong people who received the skin exam training, the researchers found a steep increase in their confidence at performing skin exams between the start of the study and four months later.\nThe new study focused on 395 pairs of melanoma survivors who had received training in skin exams in the original study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of having a partner help with mole-spotting would seem to depend on the individual patient. The writer does mention that bringing a partner program into standard practice \u201cpresents some challenges\u201d due to the need for training, and that the\u00a0researchers are looking at ways to help people learn to identify melanomas without reinforcement by physicians. This\u00a0is enough to\u00a0earn a satisfactory rating.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - In a new study of middle-aged New Jersey men, taking cholesterol-lowering drugs was linked to a lower chance of dying from prostate cancer.\nThe researchers also couldn\u2019t tell whether men started using statins before or after they were diagnosed with aggressive cancer.\nResearchers agreed that until there\u2019s clearer evidence for benefit, men with healthy hearts shouldn\u2019t seek out statin prescriptions for the purpose of lowering their prostate cancer risks.\nBut they jibe with previous studies suggesting that getting cholesterol levels under control might help reduce the risk of life-threatening disease, researchers said.\nBut Freedland said that other strategies for lowering cholesterol \u2014 such as eating better and exercising regularly \u2014 are ways almost everyone can lower their disease risks in the meantime.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that about one-quarter of adults age 45 and older in the U.S. take statins to lower cholesterol and protect against heart attacks.", "answer": 1}, {"article": "Separate strands of material become stronger when they link up.\nThere are hundreds of skin products that do this now, but this one sticks better and doesn\u2019t pucker the skin, the team reports.\nIt lasted for 16 hours before it started peeling off, and smoothed out the eye bags that become so common as people age, they wrote.\nThe cream\u2019s effects are detailed in a scientific report in the journal Nature Materials, but as part of the school\u2019s close association with the companies, it\u2019s being patented and produced at almost the same time.\nThe stuff can just be peeled off, or taken off with makeup remover, the researchers said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Since the story mentions that the material has been licensed to two private companies, readers will assume that it\u2019s not on the market yet but may be in the near future.\u00a0 It\u2019s pretty clear that it is not available for public use yet.", "answer": 1}, {"article": "Cancer is the No.\nAnd then it will have to be shown that using the test allows doctors to intervene sooner and help people.\nIt was even more accurate in finding late-stage cancers, but the goal would be to catch cancer in its earliest, easiest-to-treat stage.\nBut there\u2019s nothing yet that can detect cancer in someone who has not yet been diagnosed.\nResearchers say they have taken a big step towards developing a test that can tell people if they have cancer long before the first symptoms show up.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that the potential use of this technology as a cancer-screening tool is some time off in the future, if its usefulness is further proven. Based on the story, readers should understand that this isn\u2019t a tool currently available.", "answer": 1}, {"article": "\"We can't say this research is definitive,\" Dr. Senay said.\n\"The next step would obviously be to do an intervention trial where one group eats the diet, the other eats a traditional American diet and then look at the outcome.\n\"Those who most closely adhered to the Mediterranean diet had a 68 percent reduction in the risk of Alzheimer's disease.\nThey are the first studies to examine the association between the Mediterranean Diet and neurological diseases \u2013 specifically Alzheimer's.\nFor more further information, you can see the studies here and here.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that foods that comprise the Mediterranean diet are available to many people. ", "answer": 1}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although vague, the story reports when the procedure will likely be available based on the best source available \u2014 the manufacturer. The main reference to availability is a quote by the company spokesperson stating that the company hopes to have successful negotiations with insurers and Medicare concluded \u201clater this year.\u201d We\u2019ll rate this sufficient for a satisfactory, but we\u2019d note that the availability will also hinge on patient shared costs and hospital and physician training and location. In addition, low income and minority populations have higher rates of obesity and higher rates of Medicaid use. State Medicaid programs will likely not cover this or will at least establish some pretty restrictive criteria.", "answer": 1}, {"article": "This news-agency article is no longer available on nytimes.com.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that these apps are available in pilot programs and studies. It also refers to Skype, which most readers will know is generally available. One issue that remains to be seen is how accessible these apps will be to lower-income or homeless people, or those who have limited technology experience and/or limited eyesight.", "answer": 1}, {"article": "For example, the U.S. Preventive Services Task Force, a federal expert panel, currently doesn\u2019t recommend routine cholesterol screening in any children.\n\u201cIt is therefore prudent to implement universal screening in the pediatric population independent of family history,\u201d the researchers conclude.\nAnother existing set of guidelines doesn\u2019t call for screening in any children.\nBut a third of those children didn\u2019t have relatives with heart disease or high cholesterol, and so wouldn\u2019t have been screened under the current guidelines, issued by the government\u2019s National Cholesterol Education Program.\nYet among the kids without heart disease in their family, the percentage of children who might benefit from treatment was closer to two percent than to one, meaning that family history didn\u2019t seem to make a difference.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nThe availability of cholesterol screening is not at issue.\n", "answer": 2}, {"article": "The American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels.\n\"This type of osteochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\nAOSSM is also a founding partner of the STOP Sports Injuries campaign to prevent overuse and traumatic injuries in kids.\n\"Our findings note that patients older than 40 may benefit from using a fresh osteochondral allograft transplantation to treat focal cartilage defects, a common cause of knee pain in adults,\" said lead author, Dennis Crawford, MD, PhD from the Oregon Health and Science University in Portland, Oregon.\nGreatest changes were seen in the ability of patients to perform Sports and with improvement in healthful daily activity.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that \u201costeochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\u201d Readers can infer from this that the technique is already available, although it may not be available everywhere and not all insurers will cover these procedures.", "answer": 1}, {"article": "Scientists still haven\u2019t discovered a cure for the common cold, but researchers now say zinc may be the next best thing.\nWhile the findings are certain to send droves of miserable cold sufferers to the drugstore in search of zinc treatments, the study authors offered no guidance on what type of zinc product to buy.\nAlthough a majority of trials have shown some benefit from zinc, many of them have been criticized for failing to \u201cmask\u201d the treatment, meaning the participants most likely knew they were using zinc, which may have skewed the results.\nSince that study, 18 more trials of zinc for colds have been conducted: 11 of them showed it to be a useful treatment, while seven of them showed no benefit, according to the review.\nIn some of the cited studies, the benefits of zinc were significant.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is no question regarding the availability of products containing zinc; however, as the writer points out, the most effective formulation and dosage for reducing cold symptoms is currently unknown. \nOf note, the story specifically mentions that zinc lozenges from Coldcure.com were used in many of the trials evaluated in the Cochrane systematic review, but failed to note that they are no longer manufactured.\u00a0", "answer": 1}, {"article": "At that point, a valve designed to open on its own, allowsthe balloon to empty and be excreted naturally from the body,eliminating the need for endoscopy or another procedure.\nAllurionTechnologies, the manufacturer of the device called Elipse\uf0d4, whichis not yet commercially available, is studyingwhat it says is the \u201cfirst procedureless gastric balloon\u201d inpatients with a body mass index (BMI) of 27 or more.\nimmediate pastpresident of the ASMBS and vice-chair, UC Irvine Department ofSurgery and chief of gastrointestinal surgery, who was not involvedin the study said the device is not a permanent solution to weightloss, but has the potential to help those individuals who areoverweight or have obesity and are not candidates for bariatricsurgery.\nThe Agency for Healthcare Research andQuality (AHRQ) reported significant improvements in the safety ofmetabolic/bariatric surgery due in large part to improvedlaparoscopic techniques.\nThe FDA also approved threeweight-loss drugs since 2012.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that the device is not yet commercially available.", "answer": 1}, {"article": "BOSTON (Reuters) - If you\u2019re checking into the hospital for surgery, doctors may soon be swabbing your nose in an effort to prevent an infection from appearing after your operation.\n\u201cPreventing one infection will pay for thousands of these screenings,\u201d Dr. Henri Verbrugh of Erasmus, a coauthor of the study, said in a telephone interview.\nAlthough his team did not evaluate enough patients to study the problem directly, \u201cWe feel this technology is capable of preventing those types of infections as well,\u201d Verbrugh said.\nThe research team, led by Dr. Lonneke Bode of Erasmus University Medical Center in Rotterdam, estimated that 250 patients would need to be screened to prevent one infection.\nThe new study, published in the New England Journal of Medicine, used a rapid test to identify which patients, most of whom were scheduled to undergo surgery, had the bacteria in at least one nostril.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability is not discussed. The story should have noted that the resources used in the Bode study are currently available in US hospitals, just not routinely applied. We think this should have been noted in the story. ", "answer": 0}, {"article": "\"My reaction was, 'Well, you smoked for 30 years.\nLike many patients his age, he didn't expect there would be any effective treatment.\nHe was senior author of a study published in the Journal of Clinical Oncology in October.\nAnd, after five years, almost 9 out of 10 patients were alive and cancer free.\nThen his luck ran out.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The surgery is clearly already available.", "answer": 1}, {"article": "Dr. David E. Neal, a professor of surgical oncology at the University of Cambridge in the U.K. and author of an accompanying editorial, believes that, \"PSA testing detects prostate cancer early in its natural history when it causes no symptoms.\nThis study adds to previous evidence that PSA testing and screening for prostate cancer saves lives, he said.\nStill, the PSA test remains \"a blunt instrument,\" when it comes to determining the aggressiveness of a particular tumor, Neal said.\nMoreover, the risk of over-diagnosis was less than previously thought, with just 12 men needed to be diagnosed to save one life.\nThe report is published in the June 30 online edition of The Lancet Oncology.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story accurately reported the widespread use of the PSA test to screen for prostate cancer in the U.S.", "answer": 1}, {"article": "During menopause, levels of estrogen decline in vaginal tissues, which may cause a condition known as VVA, leading to symptoms such as pain during sexual intercourse.\nIntrarosa, when compared to placebo, was shown to reduce the severity of pain experienced during sexual intercourse.\nEfficacy of Intrarosa, a once-daily vaginal insert, was established in two 12-week placebo-controlled clinical trials of 406 healthy postmenopausal women, 40 to 80 years of age, who identified moderate to severe pain during sexual intercourse as their most bothersome symptom of VVA.\nThe safety of Intrarosa was established in four 12-week placebo-controlled trials and one 52-week open-label trial.\nThe U.S. Food and Drug Administration approved Intrarosa (prasterone) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t disclose how soon consumers can expect to find Intrarosa at their local drug store. However, it does make clear that DHEA is already out on the market as a dietary supplement, although these have not been FDA approved for safety and efficacy for \u201cdiagnosing, curing, mitigating, treating or preventing any disease.\u201d\nWe feel this mention is good enough for a Satisfactory rating here.", "answer": 1}, {"article": "Chronic insomnia is defined by the Diagnostic and Statistical Manual of Mental Disorders as sleeping poorly at least three nights a week for a month or longer, despite adequate opportunity for a full night's sleep.\nAdditional training in the therapy for behavioral health providers in all branches of the military is needed, he said.\nHe noted that that cognitive behavioral therapy is \"a multifaceted intervention that can be difficult to administer without the benefit of a therapist.\"\n\"About 10 percent of deployed military personnel take sleep medications, which are effective for short-term treatment of insomnia in civilian populations.\nIt is \"a significant problem in the military,\" said Taylor, who noted that military personnel often develop insomnia because of rapidly changing schedules and deployments that keep them constantly on alert.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The extent to which Internet-delivered CBTi is available for military personnel or the general public isn\u2019t mentioned.", "answer": 0}, {"article": "Your cells might be aging faster than you are, and new tests purport to help you find out.\n\nA few companies are offering mail-order testing to measure the length of people\u2019s telomeres, the protective caps of DNA on the ends of chromosomes that have been likened to the plastic tips that prevent shoelaces from fraying. Telomeres gradually shorten as people age and eventually may disappear, leaving cells vulnerable to disease and death.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that these tests are available through the mail from a number of companies.", "answer": 1}, {"article": "Espiritu started work at Henry Ford just as the program was starting, and she remembers the initial staff meetings: \"There was a lot of, 'How can you do this?\nThe story of the health system's success is a story of persistence, confidence, hope and a strict adherence to a very specific approach.\nThat approach saved the life of a woman who prefers to be known only by her first name, Lynn.\nThe list includes her therapists' phone numbers.\nThe behavioral health provider in Nashville implemented the Henry Ford approach for nearly 200 patients who'd already made a suicide attempt.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that \u201cperfect depression care\u201d has been either adapted or adopted by other health systems, and names two of them. It also says that health insurers and other health systems have expressed an interest in the approach. In short, the approach is not yet in widespread use, but may eventually be adopted in additional areas. Given that the story can\u2019t be expected to incorporate a list of every health system currently using the approach, this earns a Satisfactory.", "answer": 1}, {"article": "(Reuters) - Amgen Inc said its potent cholesterol fighter Repatha significantly reduced the risk of heart attacks, strokes and death in patients with heart disease, according to initial results of a large, eagerly-anticipated trial released on Thursday.\nThe company said Repatha would be well on its way to becoming a $1 billion seller if all prescriptions written had been filled.\nNo new safety problems cropped up in the 27,500 patient study called Fourier, Amgen said.\nThe primary goal also included need for a new artery-clearing procedure and hospitalization for angina.\nBut those who control budgets wanted concrete proof that the drug could actually reduce the risk of heart attacks and death before making it easier for patients to get the medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the drug Repatha is already on the market and available for use.", "answer": 1}, {"article": "Others mixed them with applesauce and cinnamon in a blender or chopped them up and added them to meatloaf, hamburger, and spaghetti sauce.\nThe other men were told to continue their regular diet but not to eat any tree nuts.\nHalf the men were randomly assigned to eat 2.5 ounces of walnuts a day, along with their usual diet.\nWalnuts, that is.\nThe new study, funded in part by the California Walnut Commission, enrolled 117 men aged 21 to 35 who ate a typical Western diet.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of walnuts is not in question.", "answer": 2}, {"article": "For more on omega-3 fatty acids, visit the National Institutes of Health.\nIn the study, researchers focused on a group of more than 4,800 Dutch heart attack patients between the ages of 60 and 80, slightly more than three-quarters of whom were men.\nThe amount of supplementation added to the various margarines was deemed to be \"low-dose.\"\nAll had experienced a heart attack at some point in the decade leading up to the study, and all were taking blood pressure medications, anti-clotting drugs and statins.\n\"But it's also possible that the different dosing used in this study relative to previous work made a difference in the outcome.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story was not clear that the margarines used in the study reported on were formulated specifically for use in the study and are not commercially available.\u00a0 Nor did it explain \u2013 as other stories did \u2013 that there are similar products already on the market.", "answer": 0}, {"article": "The women who ate more berries also tended to eat healthier overall, consuming more vegetables and fruits than those who didn\u2019t eat as many berries; but when the scientists broke down the women\u2019s diets, they found that the highest consumers of berries even had a lower risk of heart attack compared with women who still ate plenty of fruits and vegetables but fewer berries.\nThe benefits for the heart of eating strawberries and blueberries can build up over a lifetime, according to the latest research.\nThe researchers focused on blueberries and strawberries because these are the most widely consumed varieties in the U.S.\nThat means that regular consumption of berries might be a relatively easy way to lower a woman\u2019s risk of having a heart attack later in life, possibly even insulating her from heart problems.\nBoth berries contain high levels of anthocyanins, as well as other flavonoids, which fight the effects of stress and free-radical damage to cells as they age.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of strawberries and blueberries is not in question.", "answer": 2}, {"article": "Wisdom teeth, also called the third molars, are four teeth that grow at the very back of each corner of the mouth.\nThe question comes down to which side of the fence medical professionals fall on\n\nIt's worth noting that oral surgeons make a good chunk of their paychecks by removing wisdom teeth, so there is a financial incentive involved.\nA simple surgical extraction for a wisdom tooth that's showing through the gums should run about $230, according to Healthcare Bluebook.\nSo the question comes down to which side of the fence medical professionals fall on, and what works best for their patients.\nBut taking out wisdom teeth when there aren't any symptoms is where the professionals get into it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t acknowledge the gap in dental care access and how that might affect the numbers of people having wisdom teeth removed. Uninsured people are far less likely to pay out-of-pocket for elective surgery.\u00a0These issues could have been addressed with one additional sentence", "answer": 0}, {"article": "Surgical removal of cancerous tissue also can spur the spread of cancer in the body.\n\u201cSo the cancer trap is really complementary to current cancer treatments and especially beneficial at the early stages when it is difficult to see if the cancer is spreading as there are few cancer cells.\nWe have also found it very effective in late stage cancers to stop the spread of the disease and to prolong lifespan,\u201d he added.\n\u201cWe are putting biological agents in a cancer trap to attract and kill cancer cells.\n\u201cThis method is effective for both diagnosing and treating metastasis cancer and can be used in combination with traditional chemotherapy and radiation therapy,\u201d he added.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release appears to be in conflict with itself here. On the one hand, the first paragraph talks about the patenting of an implantable medical device. On the other hand, the release also tells us that the researchers are \u201choping to move toward clinical trials in the next few years.\u201d The first paragraph may make many readers think this is a prototype that may be close to the market. But the lack of a timeline for clinical trials suggests that this could be many years away from clinical use (if it reaches clinical use at all). This lack of clarity is problematic.", "answer": 0}, {"article": "They should leave it alone.\"\nTHURSDAY, April 21, 2011 (HealthDay News) -- For men who believe size matters -- and that their penises don't measure up -- success can be found in certain non-surgical penile lengthening treatments, a new study analysis by Italian researchers contends.\nDr. Elizabeth Kavaler, a urologist at Lenox Hill Hospital in New York City, said functional issues resulting from conditions such as birth defects or prostate cancer surgery may warrant penile surgery, but such cases are unusual.\n\"All procedures aimed to increase the penile girth should be considered unsafe, leading to potentially poor cosmetic and functional results,\" Gontero added.\nLong-term vacuum treatments did not appear effective, producing no significant physical changes after six months, Gontero said, but did provide a degree of psychological satisfaction.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story suggests but does not makes it clear that many \u201ctreatments\u201d are available. It implies that surgical procedures are performed by urologists and plastic surgeons. We would have liked to have seen some additional comments about the availability of and a definition of traction methods. A comment on the frequency of these procedures from one of the plastic surgery societies would have been a good addition.\nBesides the comment, \u201curologists are constantly approached by men concerned about their penis size,\u201d we are not given any idea about how widespread or available are the methods to address these concerns.\nAnd cognitive behavioral therapy isn\u2019t given much attention at all.", "answer": 0}, {"article": "\"Are [aromatase inhibitors] better than tamoxifen?\nAromatase inhibitors are not effective in this age group, the experts note.\nThey might also be associated with a greater risk of hypertension and high cholesterol.\"\nThe new guidelines replace previous guidelines issued in 2002, and subsequent updates in 2003 and 2004.\nAll three aromatase inhibitors on the market - Arimidex (anastrozole), Femara (letrozole) and Aromasin (exemestane) - were essentially equal in their benefit.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Estrogen stimulates the growth of ER+ tumors.\nThe most common form of breast cancer, ER+ accounts for about three-quarters of all breast cancer cases in the United States, the authors noted.\nThe women were classified into three groups as the study began: \"marginal\", meaning that the women were eligible for a lumpectomy to conserve the breast, but that it would be disfiguring or require several operations; \"mastectomy-only\", meaning a lumpectomy was not considered possible; and \"inoperable\", meaning that doctors believed that even a mastectomy would not completely remove the cancer.\nMore than half of those women who had been categorized as mastectomy-only patients were also able to go the lumpectomy route and experience a good outcome.\nAfter the four months of estrogen-lowering therapy, the research team found that 82 percent of those women in the marginal group were, in fact, able to undergo successful breast-conservation surgery.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story should have done a better job of explaining how the drugs discussed in this story, known as aromatase inhibitors,\u00a0are\u00a0currently used in\u00a0cancer treatment and why this study may represent an advance over current approaches.\u00a0All of the drugs\u00a0discussed are currently approved\u00a0by the FDA for breast cancer, but they are typically administered to women\u00a0only after\u00a0surgery or as\u00a0an adjunct to other drugs\u00a0in order to prevent a cancer recurrence. The new study is testing these treatments prior to surgery to see if this improves outcomes. The\u00a0story isn\u2019t explicit about most of this and\u00a0assumes that readers are already\u00a0aware of this background.\u00a0Many probably are, but others are not.\u00a0\u00a0\u00a0", "answer": 0}, {"article": "Independent committees look at the details of the patients and how well they are doing in drug trials like these.\nUsually, cancer drugs are only tested at first in patients who have tried everything else available and their cancer has come back, anyway.\nThe company now can ask the Food and Drug Administration if it will approve Keytruda to use as the first treatment a lung cancer patient tries.\nIt helped patients live longer overall and helped them live longer without their tumors growing or spreading, Merck said.\nRelated: Keytruda Keeps Some Patients Alive For Three Years\n\n\"Immunotherapy is a whole new way of treating cancer, including lung cancer,\" said Janne, who was not involved in the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does establish availability, though it is confusing.\nIt calls the drug \u201cthe Jimmy Carter drug\u201d in the headline, leading readers right away to believe this is an available drug that the former president took. But then it provides a\u00a0tidy\u00a0summary of drug trials and why the halting of this particular trial matters, saying:\n\u201cCancer research goes forward in slow steps. In tests of new drugs, patients always get either the very best therapy already available, or the new drug. Often they get both. Usually, cancer drugs are only tested at first in patients who have tried everything else available and their cancer has come back, anyway. So\u00a0it\u2019s an important break for a company if its drug is the first one a patient gets and it works better than the so-called standard of care.\u00a0The company now can ask the Food and Drug Administration if it will approve Keytruda to use as the first treatment a lung cancer patient tries.\u201d\nThe nuance there might be missed by readers. But we are giving the story a pass here because later, the story says more clearly that Keytruda was \u201capproved October last year for lung cancer and in 2014 for melanoma.\u201d", "answer": 1}, {"article": "The majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London\n\nThe majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London (QMUL).\nDespite the limitations, the researchers say that the study provides a reasonable reassurance that vaping does not promote respiratory infections and may in fact reduce them.\nThis misinformation includes a misreported study on rats that claimed that vaping may increase vulnerability to infections.\nThe on-line survey of 941 respondents assessed subjective changes in respiratory symptoms in smokers who switched to vaping for at least two months.\nHuman trials have reported no significant adverse respiratory effects associated with e-cigarette use for up to 1.5 years and a follow-up study of smokers with asthma who switched to vaping found significant improvements.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "E-cigarettes are widely available at nearly every drug store and gas station convenience store in the United States and are widely available in the\u00a0 UK where the study was conducted. The release could have mentioned that, in the U.S. at least, new rules require buyers to be at least 18 years old to purchase them.", "answer": 2}, {"article": "As measured by an electroencephalogram (EEG), small children's brains show a specific pattern of activity when they look at a picture of a human face.\nJust the reverse happens in children with autism.\nBut that's not all, researchers Geraldine Dawson, PhD, and colleagues report.\nWithout such interactions, language and social skills do not develop.\nNormal child development depends on interactions with parents and other people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear from the story whether this therapy is being used anywhere or whether it is something that only Dawson and her colleagues are testing out in small settings.", "answer": 0}, {"article": "People who were given the 60 mg doses saw a nearly 16 percent reduction in the amount of amyloid, and those given the 200 mg doses saw a 36 percent reduction.\nThe need for a drug to delay the onset or slow progression of Alzheimer's disease can't be underestimated, Aggrawal said.\nThere are approximately one dozen therapies, including vaccines, for Alzheimer's disease that are currently in the pipeline, Lyden noted.\nThat said, these experimental drugs carry the potential for serious side effects, including causing the immune system to go haywire.\nThe new study was conducted and funded by the drug's manufacturer, F. Hoffmann-LaRoche Ltd., in Basel, Switzerland.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The early, experimental stage of the research was clear in the story.", "answer": 1}, {"article": "Older age and African-American race are risk factors for colon cancer, and there is evidence linking obesity and a sedentary lifestyle to the disease as well.\nThe implications of that finding, if any, are not yet clear.\nThe findings are based on 56,864 menopausal women who took part in the California Teachers Study, a health study begun in 1995.\nOver the next decade, 442 women were diagnosed with colon cancer.\nHowever, no one is recommending that women take HRT to ward off colon cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of hormone replacement therapy is not in question. ", "answer": 2}, {"article": "\"I just didn't want to do that for my children.\nThe study findings are extremely reassuring to Rebbeck -- no breast cancer diagnoses among women who had double mastectomies after three years of follow-up.\nWhile surgical decisions are up to patients, the findings of this study should help them decide what to do, she says.\n\"We found mastectomy provided huge risk reduction of subsequent breast cancer diagnosis and death.\nIn an editorial accompanying the study, Virginia Kaklamani, an oncologist at Northwestern University, says lives can be saved if women have genetic testing.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not mention that the type and quality of genetic testing, genetic counseling, surgery and surveillance offered to women in this study may not be available to women in other settings.", "answer": 0}, {"article": "Symptoms can include sadness, insomnia, difficulty concentrating and making decisions, feelings of shame or guilt, as well as difficulty bonding with the baby or thoughts about harming the baby.\nEven though the small study had several women drop out and lacked a control group of moms who received different treatment, the results are consistent with previous research that has proven peer counseling works, said Dr. Ruta Nonacs, a psychiatrist at the Center for Women\u2019s Mental Health at Massachusetts General Hospital in Boston.\nBy midway through the study, 37 new moms had received at least one call from a peer counsellor.\nOver the second half of the study, 34 mothers had at least one phone conversation with a peer counsellor.\nMothers who left the study said they no longer needed support, sought counseling from mental health professionals, or didn\u2019t have time for the phone calls.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is a borderline call where we\u2019ll give the story the benefit of the doubt. The story does not explicitly address availability of peer counselors, although it implies that they are not generally available for PPD. And the story does give enough detail to help the reader understand what would be necessary to create such a system of peer counselors. A comment about availability of peer counseling for other health issues would have been useful.", "answer": 1}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the test, marketed as GeneSight, is available.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story contained estimates of how many people are currently taking statin medication.", "answer": 1}, {"article": "S. Bagla; R. Piechowiak; T. Hartman; J. Orlando; A. Isaacson; Vascular Institute of Virginia, Woodbridge, VA; UNC Chapel Hill, Chapel Hill, NC; University of North Carolina, Chapel Hill.\nThis prospective, multicenter clinical trial evaluated 13 patients with severe osteoarthritis pain.\nAs an outpatient treatment, GAE does not require open surgery or physical therapy, and takes 45-90 minutes to perform.\nWhile preliminary data shows that the treatment does work and is feasible, it has only been used in a clinical trial setting.\n\"A majority of our patients with osteoarthritis of the knee saw significant pain reduction, not only just a few days after the procedure, but a month after as well, making this an accessible treatment for patients looking to improve their quality of life without surgery,\" said Sandeep Bagla, M.D., director of interventional radiology at the Vascular Institute of Virginia and lead author of the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is confusing for readers on this point. The release suggests that GAE is an intervention already in current use when it states:\n\u201cInterventional radiologists perform GAE for knee pain by inserting catheters through a pinhole-sized incision, blocking the very small arteries or capillaries within the lining of the knee, reducing the inflammation caused by osteoarthritis. As an outpatient treatment, GAE does not require open surgery or physical therapy, and takes 45-90 minutes to perform.\u201d\nHowever, further down in the release its noted that the procedure has \u201conly been used in a clinical trial setting.\u201d", "answer": 0}, {"article": "It is less common than Type 2 diabetes, which is associated with obesity.\nBurt, who wrote the study protocol, said the research was done in Brazil because U.S. doctors were not interested in the approach.\nFor now, the new treatment does not apply to the nearly 20 million Americans with Type 2 diabetes, reports CBS News medical correspondent Dr. Jon LaPook.\nIn addition, Ross said that the study should have had a comparison group to make sure the treatment was indeed better than standard diabetes care.\nThough too early to call it a cure, the procedure has enabled the young people, who have Type I diabetes, to live insulin-free so far, some for as long as three years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The\u00a0story tells readers that the new treatment is still experimental and this treatment appears to have been used for the first time in a recent research study.\u00a0 One physician is quoted saying the idea \"is not ready for prime time\" so viewers should know they can not turn to their local doctor to have this treatment.\u00a0 ", "answer": 1}, {"article": "\"Because cancer cells are different to healthy ones, they produce a different mixture of chemicals.\nMarkar added that the test needs to be validated in a bigger group before it could be used on patients.\nThe researchers said they are planning a larger trial of the breath test over the next three years.\n\"A breath test could be used as a noninvasive, first-line test to reduce the number of unnecessary endoscopies.\nIt was 85 percent accurate in detecting these cancers in more than 300 patients, the new study found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job here. It not only notes that \u201cthe test needs to be validated in a bigger group before it could be used on patients,\u201d but makes clear that the study findings were presented at a conference. Further, the story explains that \u201cStudy results presented at meetings are generally considered preliminary until they\u2019ve been published in a peer-reviewed journal.\u201d That\u2019s valuable context for readers.", "answer": 1}, {"article": "\"It's an outpatient procedure, and no physical therapy is required before or after this procedure,\" he said.\nResearchers are already kicking off a second, larger trial to better understand how the procedure works and which patients it might benefit, Bagla said.\n\"This therapy is very well-targeted to that particular mechanism, and certainly it should be investigated further,\" said Vedantham, who wasn't involved with the study.\nMuch of the pain that comes from knee arthritis actually stems from inflammation in the lining of the knee joint, also called the synovium, Bagla said.\n\"Patients overall were able to improve their physical function in the knee after the procedure, and there were no adverse events related to this treatment,\" said lead researcher Dr. Sandeep Bagla.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does acknowledge the need for further research. But this is a bit of an extreme case, in terms of how preliminary the research is, and so we feel the story should have made it very, very clear that we have no idea how this will pan out. Another more skeptical source would have helped on this one.", "answer": 0}, {"article": "\"Strikingly, these fasting-stimulated changes in the growth of vascular cells and subsequent immune alterations occur even after a single cycle of 24-hour fasting, and are completely reversed when mice start eating again,\" adds Yun Hye Kim.\nSuch fasting already shows benefits after only six weeks.\nThe recurring regimen saw the animals being fed for two days, followed by one day without anything to eat.\nThe fasting regime helped lower fat build-up in the white fat by increasing the brown-like fat (involved in burning energy and producing body heat) of mice on the high fat diet.\nTheir glucose and insulin systems also remained more stable.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Fasting is widely available.", "answer": 2}, {"article": "Pancreatic cancers, also uncommon, were numerically fewer with Januvia, 9 versus 14.\nMerck in April said the study, called Tecos, of 14,724 patients with type 2 diabetes and a history of heart disease demonstrated that adding Januvia to usual care did not increase major heart problems any more than adding a placebo, removing a cloud that has been holding back sales of the medicine and the company\u2019s share price.\nThe detailed results also showed no increase in hospitalization for heart failure, which had been a particular concern with DPP-4 inhibitors, the class to which Januvia belongs.\n\u201cWe can be reassured we can use this drug for glucose lowering without affecting the already high cardiovascular risk in people with type 2 diabetes,\u201d said Professor Rury Holman, the study\u2019s lead investigator, who presented the data at the American Diabetes Association meeting in Boston.\nIt was undertaken after heart safety concerns were raised over other diabetes medicines.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug has been available but has been hampered in terms of sales because of safety concerns. The drug\u00a0is widely available, widely used, expensive, and of unproven value in terms of important outcomes.", "answer": 1}, {"article": "In one patient who had Alzheimer\u2019s, the pathologist and the radiologist analyzing the scan did not see much plaque, but the computerized analysis of the scan and the two autopsy reports did.\nAnd the data showed that the scans were completely accurate in ruling out Alzheimer\u2019s pathology: unlike doctors, they never said people had Alzheimer\u2019s pathology when they did not.\nAlthough the scans looked promising, the companies needed to show that what they revealed was the same as what a pathologist would see on autopsy.\nNeither the radiologists nor the pathologists knew whether the patients had dementia.\nThat was what Avid demonstrated with its study, presented Sunday by its medical director, Dr. Christopher M. Clark.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story was clear that it was reporting on a screening test for Alzheimer\u2019s disease that is undergoing study. That said \u2013 it would have been better to state explicitly that this test is currently unavailable to patients.", "answer": 1}, {"article": "University of Eastern Finland, Institute of Public Health and Clinical Nutrition, tel.\nThe new study provides further evidence on the health benefits that fermented dairy products may have over non-fermented ones.\nLower consumption levels were not associated with the risk.\nThe findings were published in the British Journal of Nutrition.\nSour milk was the most commonly used low-fat fermented dairy product.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Fermented dairy products are widely available and the news release does clearly outline several types.", "answer": 1}, {"article": "Their average dose of mealtime insulin decreased by seven units (30%) and their need for all-day insulin dropped by eight units (32%).\nAnd during Victoza treatment, patients needed less and less insulin.\nAdding Victoza to insulin therapy quickly eliminated these peaks and dips in blood sugar.\nThose who continued treatment for a full year continued these improvements and felt much better overall, says study leader Paresh Dandona, MD, of the State University of New York, Buffalo.\nThis appeared to be due to reduced appetite and food intake.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the drug is not approved for use in type 1 diabetes, but that it could be used off-label in this population by a diabetologist since it is approved for use in type 2 diabetes.", "answer": 1}, {"article": "\u201cI don\u2019t think at this point this one test is going to prevent further testing.\nThe researchers, who published their findings in the Annals of Internal Medicine on Monday, compared patients\u2019 CT scans to their dual-energy X-ray absorptiometry (DXA), which is traditionally used to diagnose osteoporosis.\n\u201cWhat we found is that there is pretty good correlation,\u201d said the study\u2019s lead author Dr. Perry Pickhardt, professor of radiology at the University of Wisconsin School of Medicine and Public Health in Madison.\nDr. Sumit Majumdar, who wrote an editorial accompanying the new study, said a lower threshold for bone density would catch most cases of osteoporosis and limit \u201cincidentaloporosis\u201d - incorrect osteoporosis diagnoses \u201cdiscovered\u201d while doctors were looking for something else.\nIn an editorial accompanying the study, however, experts wrote that using CT scans to gauge bone density could lead to some people being incorrectly diagnosed, particularly if people at low risk are tested.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story touched on availability and use patterns in this succinct statement:\n\u201cDespite DXA scans being safe and cost effective, Pickhardt and his colleagues say the test is underused. CT scans, however, are considered overused \u2013 with more than 80 million performed in the U.S. during 2011.\u201d", "answer": 1}, {"article": "It's very exciting.\"\nThe experiments, detailed online yesterday in the journal Nature, raise the prospect that patients suffering from not only diabetes but also heart disease, strokes and many other ailments could eventually have some of their cells reprogrammed to cure their afflictions without the need for drugs, transplants or other therapies.\nThe work was hailed as a welcome development even by critics of research involving embryonic stem cells, which can be coaxed to become any tissue in the body but are highly controversial because they are obtained by destroying embryos.\nMelton and other researchers cautioned that many years of research lay ahead to prove whether the development would translate into cures.\nAlthough the experiment involved mice, Melton and other researchers were optimistic that the approach would work in people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story was clear that this highly experimental approach in mice is currently not available for humans, it provided a wholly unrealistic estimate for its application to human disease. \u00a0\nAlthough interesting from a number of perspectives, the story is about a novel but relatively untested approach to managing diabetes in mice. \u00a0The story is somewhat excessive in its language related to the potential for this approach suggesting the line of research will indeed be transferable to humans in a relatively brief period of time. While some caveats are included, we don\u2019t think balance was achieved.\u00a0 ", "answer": 0}, {"article": "The page you are looking for has either moved or is not available (error 404).\n\nPlease return to the homepage or use the search box above to see if the page is available in a new location.\n\nIf you think this message is in error or need assistance, please email the webmaster.", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s understood that the drug is already being used in sickle cell treatment and is FDA approved.", "answer": 1}, {"article": "Newly postmenopausal women who received estrogen via a skin patch had reduced beta-amyloid deposits, the sticky plaques found in the brains of people with Alzheimer\u2019s disease, a Mayo Clinic study published this month in the Journal of Alzheimer\u2019s Disease found.\nThe oral treatment was not associated with lower amyloid deposition.\n\u201cThis study showed, for the first time, that the brain amyloid deposition \u2500 a hallmark of Alzheimer\u2019s disease \u2500 is reduced in newly postmenopausal women who received 17beta-Estradiol patch form of hormone therapy,\u201d says lead author Kejal Kantarci, M.D., a Mayo Clinic radiologist.\nThe researchers used positron emission tomography, also known as a PET scan, to look for the brain amyloid deposits three years after the trial ended.\n\u201cIt also may have a significant impact on women making the decision to use hormone therapy in the early postmenopausal years.\u201d\n\nStudy co-authors are Val Lowe, M.D.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that numerous estrogen supplements \u2014\u00a0 including those delivered via patch \u2014 are readily available.", "answer": 2}, {"article": "Examining more than 500,000 Facebook posts from both groups, researchers determined which words, post lengths, frequency of posting and timing of posts were most associated with a depression diagnosis. They found people with depression used the words \"I, my, and me,\" as well as such words as \"hurt, tired, and hospital,\" more often than others in the months preceding their diagnosis. Using indicators such as these, they built a computer model that could predict which people would receive a depression diagnosis with comparable accuracy to commonly used clinical surveys.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the social media diagnostic model is not close to being viable for clinical use.", "answer": 1}, {"article": "We're sorry, but Newspapers.com doesn't work properly without JavaScript enabled. You will need to enable Javascript by changing your browser settings. Learn how to enable it.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that cethromycin, the new antibiotic under development, is not yet approved for sale.\u00a0 ", "answer": 1}, {"article": "Parkinson\u2019s disease is a progressive neurological disease that causes symptoms including muscle tremors, shaking, and stiffness.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nNor is it clear why the results differed for men and women.\nThe study doesn\u2019t prove that berries (or flavonoids in any other food) prevent Parkinson\u2019s disease.\nThis was an observational study and therefore can\u2019t establish cause and effect.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The availability of the flavonoid-containing foods mentioned in the story is not in question.", "answer": 2}, {"article": "In addition, some people have implanted defibrillators or pacemakers.\nDespite the encouraging results of this first trial, a lot more testing will be needed before cimaglermin can be considered a standard treatment for heart failure, Bishopric said.\n\"These findings need to be replicated in larger trials, and you have to be able to predict whether improved heart function from cimaglermin will help people live longer and feel better,\" she noted.\nBased on these preliminary findings, larger trials are being planned, Lenihan said.\nOne patient who received the highest dose of cimaglermin developed abnormal liver function, which cleared up over a two-week period, Lenihan said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll rate this category satisfactory, given that the story admits that it is reporting on a phase one trial, and includes the following information:\n\u201cBefore cimaglermin could be used to treat patients, it must prove its worth in a series of progressively larger and challenging trials and then be approved by the U.S. Food and Drug Administration. The process can take several years.\u201d", "answer": 1}, {"article": "Rather, surgeons move electronic instruments that are linked to the movement of other instruments inside the body, while they watch a three-dimensional image of what\u2019s going on inside.\nIn this case, the robot could turn what would have to be an open surgery into a simpler one.\nTo test this idea, they looked back at 78 minor surgeries that were done on women with endometriosis - half using the assistance of a robot, half without it.\nUsing a robot for basic surgery, like the kind studied here, would be like using a computer to do addition, he told Reuters Health.\nBecause the robot lets the surgeon get a better picture of the inside of the body, the authors had expected that surgeries using the robot would go more smoothly than those without it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was one of the missing elements. At a minimum, the story should have said how many companies even make these things, how long they have been in production and how many hospitals/surgical centers have them. As far as\u00a0we know, the major manufacturer is da Vinci, and we\u2019re sure they would be glad to provide some numbers. If you just do a search on the da Vinci site of how many surgeons in western\u00a0Washington use these machines for gynecological procedures, you come up with a list of 1,500 names. imagine what that would be like in an area like Los Angeles or New\u00a0York?", "answer": 0}, {"article": "DOI: 10.1016/j.ophtha.2016.01.036.\nThe research is also the first to show that diet and lifestyle may play a greater role than genetics in cataract development and severity.\nResearchers noted that the findings only pertain to consuming the nutrient through food and not vitamin supplements.\nHow vitamin C inhibits cataract progression may have to do with its strength as an antioxidant.\nThese results make the study the first to suggest that genetic factors may be less important in progression of cataract than previously thought.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that Vitamin C-rich foods are widely available, although in different types and costs, so we rated that Not Applicable.", "answer": 2}, {"article": "\"The work by [first author] Price et al.\nWe should be very careful about claiming the importance of resveratrol for medical purposes.\nTesting the effect of resveratrol on SIRT1 in mice was difficult, Sinclair said.\nThe study is in the May 1 issue of Cell Metabolism.\nstrongly supports the basic rationale being pursued at Sirtris, which focuses on the development of small-molecule compounds that directly activate the enzymatic activity of SIRT1 as a new therapeutic approach to many diseases of aging,\" Vlasuk wrote in an email to the journal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The preliminary nature of these findings was clear in the body of the story (although not in the headline).", "answer": 1}, {"article": "For example, 75% of all smokers reach for their first cigarette within 30 minutes of waking up.\n\"Gums and patches are designed to help manage cravings, but they are only 5 to 9 percent effective.\nThe data were presented today at the Society for Research on Nicotine & Tobacco's 22nd Annual Meeting.\nThe clinical trial was a randomized, double blinded study of 24 adult males who smoked 11 or more cigarettes per day, indicating a high level of nicotine dependence.\n\"Achieving statistical significance in a 24-subject trial is very striking and happens infrequently in biopharma; so these results are very encouraging,\" noted Wende Hutton, general partner at Canaan Partners and a member of Chrono's board of directors.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There is no mention of the availability of this device, such as next steps in testing or application for FDA approval. The news release also does not discuss whether this device would require a prescription.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a131601S24.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is no mention of whether this device is still in testing or whether it has garnered FDA device approval. (In fact, the FDA has determined that the device may be marketed as of August 18, 2005; the company was FDA approved to market it for \u201cfailed diuretic therapy\u201d not as an alternative for heart failure patients \u2013 FDA Feb 2, 2006 .)", "answer": 0}, {"article": "Nuts, seeds, whole grains, legumes and even dark chocolate are high in fiber\u2014as are vegetables.\n\u201cThat means if you\u2019re not eating dietary fiber, your immune system may be existing in kind of a simmering pro-inflammatory state,\u201d he says\u2014the very state that predisposes us to different Western diseases.\nLoading up on fiber-fortified processed foods isn\u2019t likely a good way to increase the kind of fiber that benefits the gut.\nSonnenburg was not involved with this study, but research from his lab also suggests that fiber plays a big role in promoting good bacteria.\nScientists are hard at work trying to determine how and why that\u2019s that case, as well as which bacteria are beneficial\u2014and how to protect them.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions a range of healthy dietary options for increasing fiber intake \u2014 all of which are available to consumers.", "answer": 1}, {"article": "\u25a0 A woman who freezes eggs rather than embryos avoids potential custody problems if she and her partner split up.\nFreezing eggs now is no guarantee of a baby later.\nCheck out more than one clinic and make sure you know what it defines as a \u201csuccess\u2019\u2019 \u2014 a viable transferring of an egg leading to a baby, or just a safely thawed egg.\n\u25a0 The \u201csuccess\u2019\u2019 rates of egg freezing may vary widely from one fertility center to another.\nShe owns her eggs, no question.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear about the availability:\u00a0 \"half of 282 US fertility centers surveyed offer egg freezing.\" ", "answer": 1}, {"article": "But for others, doctors may prescribe a more invasive treatment that involves injecting hyaluronic acid in to the knee, called viscosupplementation.\nThe authors of the study discourage patients from getting this treatment.\nThe researchers in Switzerland reviewed the existing studies and concluded that viscosupplementation was associated with an increase in these and other adverse events.\nNow, a new report questions the efficacy of this treatment for osteoarthritis in the knee.\nHowever, Richmond says patients considering viscosupplementation should discuss this as a treatment option with their doctor.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never explained the availability of the viscosupplementation approach.", "answer": 0}, {"article": "For people hoping to shed some pounds, changing the type of protein in the diet, rather than the amount of it, is an idea the researchers think deserves more study as a weight loss strategy.\nThe research was funded by the American Egg Board, and will be presented at the19th European Congress on Obesity in Lyon, France.\n\"This study shows that diets with higher protein quality may enhance satiety, leading to better compliance and success of a weight loss diet,\" researcher Nikhil Dhurandhar, PhD, says in a news release.\nOne large egg has about 70 calories, and it contains about 6 grams of protein, 5 grams of fat, and 186 milligrams of cholesterol.\nScientists suspect that egg protein may be better at making people feel full longer compared to the protein found in wheat.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of eggs and cereal is not in question.", "answer": 2}, {"article": "The median age was 75 years (range 41to 94).\nThe study evaluated safety and efficacy outcomes of 1,083 patient reports collected in a multi-institutional database.\n\"In addition to providing important support for using SBRT to treat early-stage lung cancer in elderly patients, these findings highlight the value of multi-institutional collaborations and large data sets that can provide statistically meaningful answers to critical questions about treatment outcome and guide clinical decision making.\"\nTo date, they have accumulated data on close to 1,200 such patients and identified medical and technical factors that affect tumor control and toxicity.\nElekta (EKTA-B.ST) today announced new data demonstrating stereotactic body radiation therapy (SBRT) is a safe treatment option for early-stage lung cancer patients aged 80 or older.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the release that the treatment is available at the five sites that participated in the observational study, but whether it is available outside of major academic cancer treatment centers isn\u2019t spelled out.", "answer": 0}, {"article": "... Then a lot of guys eventually were like, 'I'll go.\nThe study, published Monday in the New England Journal of Medicine , tested whether pharmacist-led programs in barbershops could significantly lower high blood pressure in black men in the United States.\nAdditionally, more research is needed to determine whether similar study results would occur on a national level, since the study was conducted only in the Los Angeles area.\nOn the other hand, the barbershop represents a safe haven in the black community -- a no-judgment zone -- where conversations about health and other personal topics are commonplace.\nAs part of a study, these health services were provided at his barbershop and others across Los Angeles County.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that this research was conducted in the Los Angeles area and cautions that a national study would be needed to show the approach\u2019s applicability in other locales. Readers would not assume that this kind of health care assistance was available in black-owned barber shops elsewhere.", "answer": 1}, {"article": "Advising patient with chronic sinus congestion to use nasal irrigation - a popular nonpharmacologic treatment - improved their symptoms, but steam inhalation did not, according to a randomized controlled trial published in CMAJ (Canadian Medical Association Journal).\nPatients who were instructed to use nasal irrigation showed improvement at 3 and 6 months, as measured by the Rhinosinusitis Disability Index.\nResearchers from the United Kingdom conducted a randomized controlled trial on the effectiveness of advice from primary care physicians to use nasal irrigation and/or steam inhalation for chronic sinusitis.\nSteam inhalation did not appear to alleviate symptoms of sinusitis.\nTo alleviate symptoms, steam inhalation and nasal irrigation are widely suggested as an alternative to common treatment with antibiotics, which are often not effective and contribute to antibiotic resistance.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Nasal irrigation and steam are both widely available.", "answer": 2}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\nIt\u2019s not known if the diet leads to any nutritional deficiencies or keeps working in the long run \u2014 especially for patients who get little support from doctors or dietitians.\nIn 2014, IBS treatment guidelines from the American College of Gastroenterology said the diet showed promise, but that the quality of evidence was \u201cvery low.\"\nShe credits the diet, along with medication, with a big reduction in her symptoms, but says \u201cit has not been a miracle cure.\u201d\n\nThe diet has generated enough interest to prompt some food companies to introduce low-FODMAP products \u2014 hoping for a market surpassing that for gluten-free foods, according to some industry reports.\nHigh- and low-FODMAP food lists are updated frequently at websites and apps run by the University of Michigan and Monash University in Australia.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The text offers links to online explanations of the diet, as well as to lists of foods that would be eliminated initially as part of it. Anyone could give this a try, though the article recommends that IBS sufferers implement the diet under a dietitian\u2019s supervision.", "answer": 1}, {"article": "Army veteran Vivian Cooke has long struggled with debilitating depression.\nFinzi notes previous studies show between 50 to 60 percent of patients may benefit from the treatment.\n\u201cSo Botox basically inhibits the muscle and calms it down, so it becomes more difficult to feel those negative emotions.\u201d\n\nThe makers of Botox recently announced plans for the final phase of testing it as a treatment for depression.\n\u201cI had less problems with depression.\u201d\n\nEven though the study she took part in is now over, she said she will continue to get Botox injections.\nCosts vary widely, but the American Society for Aesthetic Plastic Surgery said the average price for a Botox treatment in 2016 was $376.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No statement is made about the availability of botox, but readers can reasonably\u00a0assume that it will continue to be widely available.", "answer": 2}, {"article": "Aug. 10, 2011 -- Two of three patients dying of chronic lymphocytic leukemia (CLL) appear cured and a third is in partial remission after infusions of genetically engineered T cells.\n\"Our results were absolutely dramatic.\nThey kill cancer in the test tube.\nBut the therapy worked vastly better than University of Pennsylvania researchers David L. Porter, MD, Carl H. June, MD, and colleagues had dared to hope.\nThe treatment success came in a pilot study that was only meant to find out whether the treatment was safe, and to determine the right dose to use in later studies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Neurosurgeons performing EDAS reroute arteries from the scalp and the membranes that cover the brain and place these arteries under the skull near areas of the brain at risk of stroke.\nPreviously, EDAS has been used for moyamoya disease, a rare cerebrovascular disorder that affects younger patients.\nGonzalez said his team is working with the stroke prevention working group of the National Institutes of Health to develop a proposal for a Phase III randomized clinical trial across multiple institutions to further test the effectiveness of EDAS as compared with intensive medical management.\nTwo of the EDAS patients had small wound openings that required additional surgical interventions, but there were no intracranial hemorrhages or other serious adverse events, the researchers reported.\nWhile this Phase IIa trial selected patients from previous studies as the control group, the Phase III study would enroll new ICAD patients for both the control and experimental groups, he explained.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This procedure is currently available, as explained here:\u00a0 \u201cEDAS has been used for moyamoya disease, a rare cerebrovascular disorder that affects younger patients.\u201d However,\u00a0 there are relatively\u00a0few facilities that treat moyamoya disease.\u00a0 Saying how many sites have the ability and expertise to do the EDAS procedure would\u00a0have been more helpful.", "answer": 0}, {"article": "Hialeah bucket list: All the things you need to do in Hialeah before you die\n\nYou can spend your whole life working on this list.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0indirectly states\u00a0that lung cancer screening is not widely available (e.g.\u00a0\"would widespread screening reduce cancer deaths?\").\u00a0\u00a0 ", "answer": 1}, {"article": "Studies conducted by the CDC through its Adult and Youth National Tobacco Surveys found increased experimentation by youth trying out e-cigarettes but not conventional cigarettes.\nBut as it seems e-cigarettes are here to stay, most calls are for informed regulation rather than prohibition.\nThe growing fear is the increasing domination of big tobacco in the e-cigarette market, which was once seen as a competitor.\nThat's backed up by Etter's research as well as a recent study by researchers at Penn State College of Medicine, in which e-cigarettes were found to be less addictive than tobacco cigarettes.\nThe selling point is the clean image e-cigarettes purvey by removing the simultaneous exposure to the tar and thousands of chemicals found in the tobacco smoke of regular cigarettes -- removing the cause of lung diseases as well as other tobacco-related conditions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All of the products discussed are readily available.", "answer": 1}, {"article": "New research analyzing more than 22,000 U.S. cases of aortic aneurysm repair is likely to hasten the trend toward more procedures being done with a device called a stent-graft instead of the typical surgery that requires up to eight weeks of recovery.\n\nThe study by doctors at Harvard Medical School and the federal Centers for Medicare and Medicaid Services found the death rate in surgery, 4.8%, was four times that of the 1.2% death rate in placing stent-grafts to seal off the aneurysm. Surgery tended to provide a more permanent...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was about a study comparing two treatments for abdominal aortic aneurysms.\u00a0 Because the story mentioned that it was about aneurysm repair in 2001 and 2004, a reader could infer that both are current procedure.\u00a0", "answer": 1}, {"article": "Most recently, the F.D.A.\nThomas E. Rathjen, a spokesman for Nabi Biopharmaceuticals, said the results of the study should be available sometime next year.\nIf the vaccine helps smokers quit, Dr. Reus said, a central question will be whether booster shots could help prevent relapse.\nAn effective vaccine could play a major role in reducing smoking around the world, said Dr. Vocci, who estimated that current rates of smoking would lead to one billion deaths in the 21st century.\nThe multishot sequences being tested are designed to extend the antibody response for many months, although eventually the body will stop producing the anti-nicotine antibodies, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly describes the current stage in the drug approval process: The story discusses that NicVax (Nicotine Conjugate Vaccine) has been fast-tracked for approval by the FDA, however, the story also notes that this vaccine is still in Phase 2 clinical trials (tests of safely and efficacy), and additional large-scale, randomized controlled Phase 3 trials are needed before NixVac can apply for final FDA approval. ", "answer": 1}, {"article": "More: The hidden side of dementia: Families fight over care, end-of-life decisions, finances, estates\n\nDementia is a term used to broadly describe symptoms of cognitive decline; Alzheimer's disease is the most common cause of dementia.\nDoris Lambracht-Washington, a professor of neurology and neurotherapeutics at the University of Texas Southwestern Medical Center, said researchers believe the vaccine could extend lives by preventing the disease from developing.\nIf the vaccine proves safe and effective in humans, it could slice the number of dementia diagnoses in half, the study's senior author told USA TODAY.\nTesting in mice showed that the vaccine safely prevents the buildup of substances in the brain associated with the fatal disease, the team reported this week in the journal Alzheimer's Research & Therapy.\nThe vaccine is one of several promising treatments aimed at reducing the buildup of those substances before they become deadly plaques and tangles in the brain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the vaccine is not available and has not even begun clinical research in human patients. However, it would have been appropriate to give a sense of the time frame. Even if trials started in humans and the vaccine was shown to be safe and effective, it would be years before this became widely available.", "answer": 1}, {"article": "Feifel recalls one patient whose depression would disappear like magic after a dose of ketamine.\nAnd ketamine's safety record is so good that it's often the painkiller of choice for children who arrive in the emergency room with a broken bone.\nSince then, thousands of depressed patients have received \"off-label\" treatment with ketamine.\nAnd it didn't have the FDA's OK for treating depression.\nIt's been used for decades as an anesthetic that can rapidly stop pain without affecting vital functions like breathing.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that ketamine is not approved for treatment of depression, but it is widely used as an anesthetic.", "answer": 1}, {"article": "Qi Sun of the Harvard School of Public Health and his colleagues analyzed data collected from 13.984 female nurses participating in the Nurses\u2019 Health Study, an ongoing study examining a variety of health issues.\nNow, the researchers stressed that wasn\u2019t the case for women who consumed more than two drinks a day or four drinks or more at a time.\nFor women who like a nice glass of wine at the end of the day, there\u2019s more good news: Even middle-aged women can have about a drink a day of any kind of alcoholic beverage as part of what they do to try to stay healthy as they age, according to new research.\nThat was after accounting for other factors, such as smoking.\n\u201cThese data suggest that regular, moderate consumption of alcohol at midlife may be related to a modest increase in overall health status among women who survive to older ages,\u201d the researchers wrote.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of alcoholic beverages isn\u2019t in question.", "answer": 2}, {"article": "Bladder cancer is the fourth most common cancer in men, but it is less common in women.\nDr. Gupta added that the study provides evidence demonstrating that the robotic approach performs at least as well as the open approach.\nThe RAZOR trial found that two years after surgery, 72.3 percent of patients in the robotic surgery group were alive, with no disease progression and essentially cured, compared with 71.6 percent in the open surgery group.\nThree Loyola Medicine urologists, Marcus Quek, MD, Gopal Gupta, MD, and Alex Gorbonos, MD, are co-authors of the study.\nResearchers wrote that the findings \"underscore the need for further high-quality trials to assess surgical innovation before this surgical technique is widely adopted in clinical practice.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that both techniques are available\u2026 including at the institution that issued the release. The release could have informed readers that, according to the published paper, that all of\u00a0the operators in this study had\u00a0done at least 10 robot-assisted cystectomies before being allowed to participate in the study. When widespread adoption of the robot-assisted procedure occurs, it would be possible that many surgeons would not have completed that many robotic cystectomies.", "answer": 1}, {"article": "Rosie Dow, Head of Sing with Us at Tenovus Cancer Care and co-author of the research, added: \"This research is so exciting, as it echoes everything all our choir members tell us about how singing has helped them.\nThe research raises the possibility that singing in choir rehearsals could help to put people in the best possible position to receive treatment, maintain remission and support cancer patients.\nWe have been building a body of evidence over the past six years to show that singing in a choir can have a range of social, emotional and psychological benefits, and now we can see it has biological effects too.\nFollowing on from this research, Tenovus Cancer Care is launching a two year study looking in more depth at the longitudinal effect of choir singing over several months.\n\u2022 At Tenovus Cancer Care our aims are simple: to help prevent, treat and find a cure for cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We think choir-singing is widely available. The news release provides a link to 17 Tenovus Cancer Care centers that offer group singing in England and Wales. However, it\u2019s worth noting that most people do not have access to choirs that are meant to support people in cancer treatment and their caregivers.", "answer": 1}, {"article": "Briakinumab works by dampening the immune system response that causes psoriasis, said Bruce Bebo, director of research and medical programs for the National Psoriasis Foundation, based in Portland, Ore.\n\nMore serious infections were seen in people taking briakinumab (2.6 percent) vs. those taking methotrexate (1.8 percent).\nThe study was funded by the drug's manufacturer, Abbott Laboratories.\nAt the time, Abbott withdrew its application for approval from the U.S. Food and Drug Administration pending further research.\nAn ongoing three-year trial involves 248 people from the current study.\nThe current study included 317 people with moderate to severe psoriasis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The experimental nature of briakinumab was made clear in the story.", "answer": 1}, {"article": "Compared to coffee, soft drink and iced tea drinkers, study participants who consumed a cup or more of hot caffeinated tea daily had 74 percent lower odds of having glaucoma, the study authors report in the British Journal of Ophthalmology.\nThat includes more than three million Americans, only half of whom are aware they have the disease, according to the Glaucoma Research Foundation.\n\u201cThis makes sense, but we\u2019ll see if it holds up in future studies.\u201d\n\nFuture studies should look at the habits, activities and nutrition that affect lifestyle and glaucoma risks, said Idan Hecht of Tel-Aviv University in Israel, who wasn\u2019t involved in the research.\n\u201cPatients can and should be involved and take an active role in the management of their ailments,\u201d Hecht said.\n\u201cGlaucoma can lead to blindness, and it would be great if it could be prevented because there is no cure,\u201d said lead author Dr. Anne Coleman of the University of California, Los Angeles.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Other than water, tea is the most widely consumed beverage in the world.", "answer": 2}, {"article": "GLYX-13 targets parts of the brain linked to learning and memory.\nFor his part, Bruno cautioned that the long-term effects of the drug need to be studied before it can be used regularly in clinical practice.\nMoskal, however, said he is confident that this drug will be a breakthrough in treating depression.\nAn advantage is that the drug doesn't have the side effects of other drugs that target these same areas, such as hallucinations and schizophrenia-like symptoms, the researchers noted.\nThe new drug -- called GLYX-13 -- is so far given in an intravenous form and was recently tested in patients who had not responded to other antidepressants.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that the study is in phase II clinical trials and that results are considered preliminary. The lead researcher says that the new drug is not projected to be available before 2016. The independent expert also cautions that the long-term effects of the drug need to be studied before it can be used regularly in clinical practice.", "answer": 1}, {"article": "More women are undergoing genetic testing after a diagnosis of breast cancer, and improvements in both mastectomy and breast-reconstruction techniques have made the option of a double reconstruction less daunting.\nSeveral developments may be driving the trend toward prophylactic mastectomies, experts said.\nThough the researchers had limited information about the patients, Dr. Tuttle suggested that younger women might be choosing the procedure because their cancers tended to be very aggressive, and they had more years ahead of them in which a second cancer might develop.\nHe and other experts emphasized that though the removal of the healthy breast sharply reduced the risk of a new cancer developing in that breast \u2014 the risk is not zero because some tissue can remain \u2014 it was the cancer that had already been diagnosed that posed the greatest threat to a patient\u2019s life.\nDoctors and patients\u2019 advocates urged women considering the procedure to go for counseling and take their time before making a decision, noting that other risk-reducing options were available, like tamoxifen therapy for estrogen receptor-positive breast cancer and the use of more sensitive magnetic resonance imaging screening for earlier detection.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes surgical treatments available for women who are diagnosed with breast cancer. The story also notes via Dr. Gralow\u2019s comments\u00a0 that women should be appropriatley informed about the absolute survival benefits of their treatment choices. ", "answer": 1}, {"article": "Despite a similar number of reported cases of breast cancer among African-American and European-American women, African-Americans experience a more aggressive clinical course and a 40 percent higher death rate than European-Americans among premenopausal and menopausal breast cancer patients.\nThis is the first clinical study to suggest that neoadjuvant chemotherapy (treatment prior to surgery) may improve breast cancer recurrence rates and patterns in African-Americans.\nThe researchers studied rates and patterns of tumor recurrence after hormone, radiation and chemotherapy among African-American and European-American breast cancer patients.\nDifferences in recurrence rates and patterns between the races following various forms of treatment have not been thoroughly investigated.\nCo-authors of the study include Jun Xia, Sergey Klimov, Pranay Neema, Dr. Dora Il'yasova, Dr. Padmashree C. G. Rida, Dr. Remus Osan and Dr. Aneja of Georgia State; Dr. Guilherme Cantuaria and Dr. Mildred Jones of the Northside Hospital Cancer Institute; Dr. Uma Krishnamurti, Dr. Xiaoxian (Bill) Li and Dr. Michelle D. Reid of Emory University; and Dr. Meenakshi Gupta of West Georgia Hospitals.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "None of the treatments given are new or experimental and it\u2019s clear they\u2019re readily available within cancer treatment facilities.", "answer": 1}, {"article": "No relationship was observed between exercise and later anxiety, but the researchers did find a link between exercise and later depression.\n\u201cGiven that the intensity of exercise does not appear to be important,\u201d the authors wrote in their paper, \u201cit may be that the most effective public health measures are those that encourage and facilitate increased levels of everyday activities, such as walking or cycling.\u201d\n\nOf course, there are other benefits to more frequent and more intense bouts of exercise.\n\u201cThere is good evidence that physical activity can help people recover from depression, though we recommend it be used in addition to the usual treatments we would prescribe for established depression, like medication and counseling,\u201d says Harvey.\nMORE: A New Hope For Depression\n\nThe authors write that the combined physical and social benefits of exercise are likely responsible for its ability to help stave off depression.\nIt\u2019s also possible, they add, that exercise may trigger changes in self-esteem, the release of mood-boosting endorphins and the production of certain proteins.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While it makes no statements about availability, most readers will realize that exercise, such as walking and cycling, are usually readily available.", "answer": 2}, {"article": "Needle-phobia, or trypanophobia, is a recognized medical condition that causes sufferers to avoid medical care.\nThe patch, which is lined with microscopic needles that dissolve into the skin, could provide a painless alternative to hypodermic needles and make visits to the doctor's office or clinic for a traditional flu shot a thing of the past.\nThe muscle into which needles deliver vaccine is not nearly as active immunologically.\nThe microneedle technology may also be used for other vaccinations, such as polio and measles, said Prausnitz.\nIn a mouse study reported Sunday in the online edition of Nature Medicine, Prausnitz's team found the patch improved the immune system's antibody memory and was more efficient at clearing the lungs of the flu virus, compared to a placebo and hypodermic needle-delivered vaccine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this technology is not yet available. But why waste the introduction\u00a0predicting that the patch \"could be available in 5 years\"?\u00a0That\u00a0space\u00a0would have been better used to provide an important detail about the research: This was a mouse study!\u00a0Instead, readers have to wait 5 paragraphs to learn this. And what is that five-year prediction based on besides the hopes and prayers of a researcher and whatever company will market it? ", "answer": 0}, {"article": ".\n\u2022 Smoking cessation, weight loss (if indicated), limiting or avoiding alcohol, maintaining adequate levels of vitamin D and calcium, eating a healthy diet, and regular physical activity are suggested for all women with prior breast cancer\n\u2022 Non-pharmacologic therapies for VMS such as cognitive behavioral therapy, hypnosis, and acupuncture may be helpful as are vaginal lubricants and moisturizers\n\u2022 Several emerging approaches such as selective estrogen receptor modulators (SERMs), Tissue selective estrogen complex (TSECs), estetrol, and neurokinin B inhibitors show promise as useful agents to expand options for symptom relief with less breast cancer risk but have not yet been tested to confirm safety in women with prior breast cancer\n\nOther authors of the study include: Cynthia A. Stuenkel of the University of California, San Diego in La Jolla, Calif.; Susan R. Davis of the School of Public Health and Preventative Medicine, Monash University in Australia; JoAnn V. Pinkerton of the University of Virginia in Charlottesville, Va.; Ann Gompel of Paris Descartes University in France; and Mary Ann Lumsden of the University of Glasgow School of Medicine, Dentistry, and Nursing in Scotland.\nA comprehensive review published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism focuses on current and future approaches to management of menopausal symptoms after breast cancer.\n\"Following breast cancer, women should generally not be treated with menopausal hormone therapy but should instead focus on lifestyle modifications such as smoking cessation, weight loss, and regular physical activity,\" said the study's first author, Richard J. Santen, M.D., of the University of Virginia Health System in Charlottesville, Va. \"Pharmacologic agents are also available to treat women with severe symptoms.\nHormone therapy may help relieve a woman's menopausal symptoms but is not recommended for women who have had breast cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although lifestyle changes are readily available, it\u2019s unclear if the emerging approaches (\u201cselective estrogen receptor modulators (SERMs), Tissue selective estrogen complex (TSECs), estetrol, and neurokinin B inhibitors\u201d) listed in the release are even available. Some of the recommended lifestyle changes aren\u2019t available to women with limited access to healthy foods which are often more costly even if they are available. \u00a0Lack of insurance coverage and lack of availability of alternative treatments like cognitive behavior therapy, acupuncture and hypnosis put these modifications out of reach for many women.", "answer": 0}, {"article": "In people with atrial fibrillation, disorganized electrical activity causes ineffective contraction of the upper chambers of the heart.\nThe drug has not yet been approved by the U.S. Food and Drug Administration.\nCurrent practice guidelines permit the use of either anti-clotting therapy with aspirin or warfarin.\nMONDAY, Oct. 1, 2012 (HealthDay News) -- A new anti-clotting drug called apixaban was better than warfarin at preventing stroke in patients with the heart rhythm disorder atrial fibrillation, a new study found.\nThe study was published online Oct. 1 in The Lancet.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the drug has not yet been approved by the FDA.", "answer": 1}, {"article": ".\nMore than 41,000 screening mammography exams were examined for callbacks and recall rate, biopsies performed, cancers detected, and sensitivity and specificity of screening mammography.\nThere was also a lower positive biopsy rate among women ages 40-49 compared with women over 50.\nBy adding the women ages 40-49 to the screening population of 50 and over, the overall callback rate increased 1.5%, the biopsy rate increased 0.1% and 19.3% more cancers were detected.\nThe study to be presented by Abid Irshad of the Medical University of South Carolina examined the effectiveness of screening mammography between ages 40-49 in comparison to age groups 50-59 and 60-69.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Mammograms are a widely available intervention. However, like all medical care, women in rural areas far away from clinics or hospitals may have trouble accessing mammograms.", "answer": 2}, {"article": "Calcineurin is an enzyme that regulates communication between brain cells and memory formation.\nAn early online version of this paper detailing the findings has been published and is scheduled for publication in the July 7 issue of the Journal of Alzheimer's Disease.\nTo bypass this issue, the UTMB team analyzed data from the medical records of 2,644 patients who received organ transplants and must take calcineurin inhibitor-based medications, such as Tacrolimus or cyclosporine, for the rest of their lives to prevent rejection of the transplanted organ.\nBecause of this, there is a large consensus that preventing this kind of toxicity would be an effective treatment strategy.\nUTMB's Cristiana Rastellini, Professor in the departments of Surgery and Microbiology & Immunology also was an author on this paper.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although not explicitly stated, it is clear that the drugs in question are available. That raises a possible concern, as their availability and the news release\u2019s enthusiasm may result in patient demand for access to this as-yet unproven strategy.", "answer": 1}, {"article": "An infarct, a kind of stroke, happens when the passage of blood is slowed or completely blocked by clotting.\nIt is possible that the diet protects the brain vessels themselves, irrespective of other problems such as high blood pressure, Scarmeas said.\nIn general, dietary patterns are consistent for at least seven or eight years, Scarmeas said.\nThe next step would be to have controlled experiments concerning food and dementia in which participants are randomly assigned to follow a diet, Cole said.\nThe bottom line for dementia is that fish oil may help in the very early stages, but more research must be done to confirm this, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There isn\u2019t any question about the availability of the \u2018mediterranean diet\u2019 so this criterion is not applicable for this story. ", "answer": 2}, {"article": ".\n\"Much of the variation in the published study findings can be explained by the daily dose of zinc administered in the zinc lozenges,\" said Hemila, who funded the research himself.\nWhile surprised to note how strong the correlation was between daily doses of zinc and its effect on colds' duration, he said he and his colleagues still don't know why it seems to work.\nAllowing the lozenge to dissolve instead of swallowing it seemed to provide a therapeutic effect.\nTUESDAY, Aug. 2, 2011 (HealthDay News) -- There's still no cure for the common cold, but there may be a way to shorten its misery: A new study suggests that higher doses of zinc lozenges in certain formulations may cut the length of colds by more than 40 percent.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned the \u201cpopularity of zinc supplements\u201d but never established how popular, widespread are their use and never explained\u00a0\u00a0 if the lozenges on market shelves are at the same dosages as discussed in the story.\nWe can\u2019t give it a satisfactory score; we\u2019ll rule it N/A.", "answer": 2}, {"article": "Doctors diagnose Alzheimer\u2019s by excluding other causes of memory loss, such as stroke, tumors and heavy drinking.\nThe study is the latest to show that measuring disease-related proteins in spinal fluid is useful in diagnosing Alzheimer\u2019s disease.\nAnd they may also help identify early signs of the disease in healthy people, the team reported in the Archives of Neurology.\nWhen they looked to see how accurate these signatures were at spotting the disease, they found 90 percent of those with Alzheimer\u2019s had the disease pattern in their spinal fluid.\nBut biomarkers \u2014 proteins and imaging techniques \u2014 are helping to identify the disease much earlier.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThis story does not point out the hurdles that need to be cleared before this sort of spinal fluid test for Alzheimer\u2019s Disease could be considered for use outside of research trials, so readers may get an unrealistic sense of how soon it might enter routine clinical use.", "answer": 0}, {"article": "\"I hear a lot of moms say, 'I'm disappointed I had to have a C-section.'\nCamann says the gentle C-section is not a replacement for a vaginal birth; it's just a way to improve the surgical experience.\nBut for many women, being told they need a C-section is unpleasant news.\nAnd there were a bunch of little adjustments, such as moving the EKG monitors from their usual location on top of the mother's chest to her side.\nShe says she'd like nothing more than to know that other women having C-sections are able to have the same amazing experience she had.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was a tricky one. The piece said family-centered cesareans are not routine, and it did not firmly establish if every mother who asks for the procedure would be accommodated. We\u2019ll give the benefit of the doubt, but we\u2019d note that the story could have addressed how women can find providers who are known to offer family-centered cesareans. It also could have discussed whether hospitals are generally willing to accommodate these practices if asked to do so.", "answer": 1}, {"article": "Observers measured the symmetry of their smiles, checked for drool and listened to them read sentences.\nDr. Papas, an adviser to Novalar and an investigator in its clinical trials, said she thought the drug would appeal especially to those receiving cosmetic dentistry \u201cwho like to look good when they leave the dentist\u2019s office.\u201d\n\nNovalar said its surveys showed great interest in the product among consumers and among dentists, some of whom said they would mark up the price of the drug as a source of profit.\nNovalar and some dentists who advise the company said it might be useful for children, who can injure themselves by biting their lip or tongue without knowing it.\nWith about 300 million anesthesia injections given by dentists each year, company executives say the drug could easily achieve sales of hundreds of millions of dollars a year.\nIn two trials of 484 patients in total, people were given either OraVerse or a sham injection.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article says the company that makes OraVerse, which has just been approved by the FDA for use in speeding the return of sensation after local dental anesthesia, expects to be selling it by the end of the year. ", "answer": 1}, {"article": "Lucinda Bateman is a doctor at the Fatigue Consultation Clinic in Salt Lake City who specializes in chronic fatigue syndrome.\nWhen patients adopt a more positive attitude, Barsky points out, it often translates into greater confidence and more energy.\nShe's skeptical about the Lancet study, pointing out that patients improved only moderately, and not much more than those who were counseled about pacing themselves.\nIn the study, over 600 patients with chronic fatigue syndrome were assigned to different treatments.\nPeople should start with mild, gentle exercise like clearing the table, doing the dishes, or taking the dog for a short walk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions \u201ca form of talk therapy\u201d but never makes it clear how exactly the therapy works and whether any psychiatrist could provide it. This is one of many places in the story where additional detail would help. Cognitive behavior therapy (CBT) was offered for up to 14 sessions over 23 weeks. A booster session was offered at 36 weeks. CBT is a widely available and standard psychological treatment used for many conditions. Similar to CBT, details on the duration, frequency and availability of the competing interventions would be useful. Helping readers understand what might be involved in the intervention would improve understanding.", "answer": 0}, {"article": "About half were given the probiotic product twice daily for three weeks; children in the comparison group were given a dairy product without the probiotic.\nBut in a new study the kids who consumed the fermented dairy product did no better, based on number of stools produced, than youngsters in a comparison group.\nThe finding is significant, the researchers say, because probiotics have helped some adults with constipation.\nIt seemed logical that probiotics, live microorganisms that are often called \u201cfriendly\u201d or \u201cgood\u201d bacteria, might work for children.\nThe study examined 159 children with constipation for at least two months with a defecation rate of less than three times per week.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story opened by informing readers that it was about \u201ca specific bacterium, known as a probiotic\u201d and although the story did indeed name the particular bacterium used in the study, it neglected to inform readers whether it was currently available to the public. And, since this was a European study, it raises even more questions in readers\u2019 minds about how the findings relate to American products.", "answer": 0}, {"article": "But are they receiving it?\n\u201cThe public is dramatically misinformed about the relative risks of substitutable tobacco and nicotine products.\n\u201cYet, such facts are being kept from adult consumers of legal tobacco/nicotine products, either by not informing or actively misinforming consumers.\nThis fear, however, is not based on actual evidence and cannot be used to suppress or otherwise keep the public uninformed of what is clearly known about the lower risks of these products,\u201d adds Kozlowski, PhD, one of the world\u2019s leading researchers on smoking behavior.\nIn fact, they found that the Mayo Clinic perpetuated a misrepresentation discovered in 2003 \u2014 erroneously informing visitors that smokeless tobacco was as dangerous as cigarettes.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Anyone who has been to a drug or convenience store knows that smokeless tobacco products are readily available.", "answer": 1}, {"article": "The most common side effects of atezolizumab included skin rash, colitis, and low thyroid hormone.\nThis is the first phase III trial of an immunotherapy-based combined modality treatment to show a significant improvement in progression-free survival in advanced squamous NSCLC, according to the authors.\nAlthough the rate of severe side effects was higher with the combined modality treatment than with chemotherapy alone (68% vs. 57%), it had a manageable safety profile, consistent with known safety risks of the individual therapies.\nGiven those findings, along with the results from this trial, a rapid change in clinical practice is expected, noted Dr. Jotte.\nThe researchers will explore tumor PD-L1 expression and other molecular markers, such as tumor mutational burden (TMB), that may predict whether a patient will benefit from this treatment regimen.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release refers to the brand name of the immunotherapy drug, which would be enough to alert most journalists covering the ASCO meeting that that this drug is approved for other uses.\nHowever, given the cost and marginal benefit, many insurers will not pay for it which would make it prohibitive for most.", "answer": 1}, {"article": "Mice, as well as humans who have albinism or lack of pigmentation, have profound vision loss and changes in the eye structure , especially the macula, the oval-shaped area near the center of the retina associated with a person's ability to see clearly.\nThe next step in this research is to perform a clinical trial to determine the ability of this drug to prevent AMD.\nThis work grew out of research using albino mouse models.\nThey then determined the age patients developed AMD.\n\"In the end, L-DOPA may not be the drug that ends the disease but the pathway identified is likely to be a key observation as the search for a cure continues.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "L-DOPA is readily available to patients now and the story makes this clear.", "answer": 1}, {"article": "Prediabetics are at increased risk for developing diabetes, which can damage the eyes, kidneys, nerves and blood vessels and often leads to cardiovascular disease.\nUsing a simple device for eight hours a night to treat sleep apnea can help people with prediabetes improve their blood sugar levels and may reduce the risk of progressing to diabetes, according to a new study published online in the April 21, 2015, issue of the American Journal of Respiratory and Critical Care Medicine.\nMany people with prediabetes also have untreated sleep apnea, although few of them are aware of it.\n\"Assessment of sleep apnea should be considered in patients at high risk for diabetes and cardiovascular disease, since our study shows that treatment of sleep apnea can reduce these risks.\"\n\"Our study showed that CPAP in patients with prediabetes can lower their risk of progressing to diabetes when CPAP is used for eight hours, a full night's sleep,\" said the study's lead author, Sushmita Pamidi, MD, a former fellow at the University of Chicago who is now on the faculty at McGill University in Montreal, Canada.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does not establish how easy or difficult it is to obtain treatment with a CPAP machine. Many people with prediabetes do not know they have sleep apnea. Diagnosis requires either an expensive overnight sleep study (not widely available) or sometimes, with a cheaper home sleep monitor (becoming more available). There are many insurance limitations on testing for sleep apnea. Once the condition is diagnosed, treatment is usually covered by insurance and provided by respiratory care supply companies in the home. Some discussion of this context would have been helpful.", "answer": 0}, {"article": "At Cooper, cardiologist Phillip Koren said he and colleagues have used the Lariat on the left atrial appendage of about 10 patients in the last six months. The closure was unsuccessful in a few of those cases, but in those, there have been no strokes, said Koren, deputy director of the Cooper Heart Institute. None of the 10 patients suffered adverse events from the device.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There was ample explanation of the Lariat being available, even though the JAMA study authors recommend that it no longer be used for the purpose of atrial fibrillation surgery. The story also discusses recent FDA approval of the Watchman device.", "answer": 1}, {"article": "MS can cause many symptoms, including blurred vision, loss of balance, poor coordination, slurred speech, tremors, numbness, extreme fatigue, problems with memory and concentration, paralysis and blindness.\nThose deaths are a major concern, one neurologist said, because MS is not in itself life-threatening.\nThe researchers think these deaths were most likely due to the transplant technology used before 2006, which has since improved.\nBut the treatment can be risky because the patient's immune system has to be wiped out before the stem cells are transplanted, the researchers said.\nA trial that compares stem cell transplants with other therapies to see whether stem cell transplants can become a treatment for patients who have progressive MS is about to start, added Racke, who co-authored an editorial that accompanied the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not explain if stem cell transplants are currently available to MS patients. The National MS Society states they are not FDA approved, and are considered experimental.", "answer": 0}, {"article": "However, Owens said, \u201cit\u2019s hard to do all of that in your head.\nThe problem with the old-fashioned way, he told Reuters Health in an email, is that there are many pieces of information about a patient to consider.\nBut the new study looked at a more sophisticated way of estimating individual patients\u2019 needs.\nThe calculator used in this study is a simplified version of that model.\nAbout one-quarter of surveyed doctors said they had \u201cbasic\u201d electronic medical record systems in their offices.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have been more explicit about the availability \u2013 or lack thereof \u2013 of the computerized risk calculator in question.\nHowever, a reader should be able to deduce from the following hints that the idea is not in widespread use:", "answer": 1}, {"article": "I couldn't get anything done,\" Ham said.\nMany medical professionals say there's not enough evidence for them to confidently prescribe it.\nThen, a friend mentioned marijuana, which Maine had legalized in 1999 for chronic pain and scores of other medical conditions.\nGetting on that list is crucial and has resulted in a tug of war in many states, including several in which veterans have been unsuccessful in getting post-traumatic stress disorder approved for marijuana treatment.\n\"However, I think one place where sometimes cannabis advocates go too far is when they talk about using cannabis to treat opioid addiction.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article adequately\u00a0discusses that availability varies widely from state to state.", "answer": 0}, {"article": "The United States Preventive Service Task Force (USPSTF) currently recommends that physicians screen patients for dysglycemia (prediabetes or type 2 diabetes) when they are 40 to 70 years old and are overweight or obese.\nBut there has been little attention focused on this group's most recent diabetes screening guideline.\nO'Brien will be presenting his findings today at the Society for General Internal Medicine conference in Denver, Colorado.\nThis is the first study to report how these expanded screening criteria would perform in practice among a nationally representative sample of U.S. adults.\nThe study was published today, Friday, April 13, in the Journal of General Internal Medicine.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "More intensive screening is obviously available.", "answer": 2}, {"article": "Jan. 25, 2010 -- A low-carbohydrate diet may have health benefits that go beyond weight loss.\nResearchers say studies have already shown that the two weight loss methods are effective at promoting weight loss, but it's the first time the health effects of each have been compared head to head.\nA new study shows that a low-carbohydrate diet was equally good as the weight loss drug orlistat (the active ingredient in Alli and Xenical) at helping overweight and obese people lose weight, but people who followed the low-carb diet also experienced a healthy drop in their blood pressure levels.\n\"I expected the weight loss to be considerable with both therapies but we were surprised to see blood pressure improve so much more with the low-carbohydrate diet than with orlistat,\" researcher William S. Yancy, Jr., MD, an associate professor of medicine at Duke University Medical Center, says in a news release.\n\"It's important to know you can try a diet instead of medication and get the same weight loss results with fewer costs and potentially fewer side effects,\" Yancy says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The\u00a0story mentioned that\u00a0orlistat, the weight loss medication tested in the study,\u00a0is the active ingredient in Xenical and\u00a0Alli. Unlike the competing piece in HealthDay, however, it did not specify that Xenical is a prescription drug and that Alli is available over the counter. Although this information would have been helpful, providing the trade names for both drugs is probably enough to orient most readers.", "answer": 1}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG\u2019s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.\n\nMS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body and is among the most common causes of neurological disability in young adults.\n\nGilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS, the U.S. health regulator said.\n\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\n\nGilenya was first approved by the FDA to treat adults with relapsing MS.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that Gilenya has already been approved to treat adults with MS. However, it would have been stronger it had mentioned that the expanded indication is for ages 10 and older.", "answer": 1}, {"article": "They had 68 percent fewer spine fractures and 40 percent fewer hip fractures than the study participants who got dummy shots.\nAmgen Inc. will stress that only two shots of its genetically engineered denosumab, which could be approved for sale this fall, are needed each year.\nDenosumab, an injection just under the skin, would have to compete against eight major types of pills and injected medicines, including estrogen and generic and brand-name Fosamax pills, long the market leader.\nDenosumab would be the first osteoporosis treatment that is such a monoclonal antibody \u2014 a type of immune cell cloned from the same parent cell to bind to a specific substance.\nHe expects that would be covered by insurers, who pay for multiple medicines for other conditions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the study drug, denosumab, is not yet approved by the FDA, but indicates that it could be available this fall.", "answer": 1}, {"article": "\"Fast and junk food seem like an easy and affordable option for busy parents, but defaulting to high-fat, high-sugar, high-calorie foods is putting their children's health and future at risk,\" Heller said.\nThey speculate that good nutrition may promote brain growth and cognitive development.\nCommenting on the study, Samantha Heller, a dietitian, nutritionist and exercise physiologist in Fairfield, Conn., said that \"most of us do not realize that the foods we eat have direct consequences on brain growth, function and performance.\"\nA more health-conscious diet was associated with small increases in IQ, she said.\nHowever, to truly understand the effect of diet on children's intelligence, further studies are needed, they said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of healthy foods is not generally in question, although it may\u00a0be\u00a0difficult to find fresh produce\u00a0in\u00a0urban areas\u00a0that aren\u2019t served by grocery stores.", "answer": 1}, {"article": "For nine months, the developing fetus is attached to its mother by the umbilical cord.\nThere was not enough evidence before to extend that recommendation to full-term babies, but Rabe thinks this study should tip the balance in favor of delay.\nNow, research suggests there may be benefits to keeping mom and baby attached a few minutes longer.\nImmediate clamping started about 70 years ago out of concern that leaving the delivered infant attached to the placenta could rob the mother of too much blood.\nAndersson's study marks the first time researchers have followed children to see whether the clamping makes a difference later in life.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Hypothetically, a delay in cord-clamping is something equally available to all those who deliver babies and their patients. But in the real world it\u2019s different:\u00a0A delay is only available to a woman\u00a0if her\u00a0doctor/health system decides to offer it (barring the role of patient advocacy). The story didn\u2019t explore how common delayed cord-clamping is, or how willing doctors are to consider it. But since the story does at least suggest that women can raise the issue with their doctor and make a shared decision about what to do, we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The news story notes that laminectomy is one of the most common operations performed in the U.S., suggesting that it is widely available. Most readers are likely aware of the availability of nonoperative treatments such as pain medications and physical therapy.", "answer": 1}, {"article": "\u201cA.A.\n\u201cAlthough the randomized controlled trial is the gold-standard methodology in comparing between conditions,\u201d said Thomas G. Brown, an assistant professor of psychiatry at McGill University, \u201cit washes out a factor that may be important in potentiating A.A.\u2019s benefits, namely patient choice and preference.\u201d In other words, having a patient choose the form of treatment, rather than being assigned to it as in most studies, could be an important factor.\nBut observational data can.\u201d\n\nIt is unlikely that substance abuse experts will widely reject A.A. on the basis of these findings.\nDespite the largely negative findings, John F. Kelly, a clinical psychologist at Harvard, said he still believed that A.A. and other 12-step programs were effective.\nBut Sarah Zemore, of the Alcohol Research Group of the National Alcohol Research Center, said studies that observed the results of a treatment without setting up randomized control groups could also be informative.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains Alcoholics Anonymous (AA) and similar 12-step self-help programs for reducing alcohol dependence. The story does not mention that A.A. groups are widely available to anyone regardless of finances, and many groups allow people to attend any meeting without prior membership in the group. This would be important to note when discussing comparisons with more time-limited and potentially costly psychological treatments. ", "answer": 0}, {"article": "Air is suctioned through the side channels to emulate breathing.\nMore often than not, these studies produce mixed data that don\u2019t tell researchers much about whether it is safe and effective for humans.\n\u201cBiology is very complex.\u201d\n\nIncorporating the chips into drug testing could save millions of dollars and years of time on research.\nThis proved the chips could provide real world information to scientists studying the effects of new drug compounds.\nThe institute\u2019s goal is to create 10 different organ systems that can be joined together by blood vessel channels to simulate human physiology on a microscale and provide a cheaper, more reliable way to test new drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that this technology is still under development, with a recent grant from the Defense Advanced Research Projects Agency to create chips for all systems in the body. But we were concerned that the story allows a researcher who, according to this story is part of a team seeking to commercialize the technology, to speculate about FDA approval within two years and\u00a0to say that it\u2019s \u201conly a matter of time\u201d before these chips replace rodents. Those statements seem highly optimistic to us \u2014 another reason why the story should have consulted with an independent authority.", "answer": 0}, {"article": "Research on a bacterial toxin first discovered in Adelaide has led to the development a new blood test for the early diagnosis of ovarian cancer - a disease which kills over 1000 Australian women and 150,000 globally each year.\nThe team is currently seeking scientific and commercial partners to further test the technology with larger numbers of patient samples and to adapt it for mass screening.\nThe team has now engineered a harmless portion of the toxin to enhance its specificity for the cancer glycan and used this to detect it in blood samples from women with ovarian cancer.\nThe new blood test has the potential to dramatically improve early detection of the disease, although it will require further testing before it is available for clinicians.\n\"Ovarian cancer is notoriously difficult to detect in its early stages, when there are more options for treatment and survival rates are better.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Here\u2019s the last sentence of this very brief news release:\n\u201cThe [research] team is currently seeking scientific and commercial partners to further test the technology with larger numbers of patient samples and to adapt it for mass screening.\u201d\nIt doesn\u2019t completely clarify for readers whether the test is currently available, but suggests it isn\u2019t.", "answer": 0}, {"article": "Their overall risk of death was 30% lower than the sedentary adults, with the risk of cardiovascular and cancer deaths lower by 40% and 18% respectively.\nThe findings will reassure people who find it hard to make time for a daily exercise routine and opt instead to break a sweat once or twice a week in the hope of keeping fit.\nBut the weekend warriors also saw substantial health benefits if they met the physical activity target too.\n\u201cA middle aged or older person should do as much as 12 weeks of moderate exercise before introducing vigorous exercise,\u201d he said.\n\u201cWeekend warriors are people who meet the recommended volume of physical activity each week through only one or two sessions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The ability to exercise is generally available, so this is N/A.", "answer": 2}, {"article": "Nancy U. Lin and Harold J. Burstein, of the Dana-Farber Cancer Institute and Harvard Medical School in Boston, said: \"EMBRACE provides much needed, high-level evidence for chemotherapy use in patients with heavily pretreated breast cancer.\nThe study included 508 women who were given eribulin and 254 women who received treatment of the physician's choice, which was defined as: any single-agent chemotherapy, hormonal or biological treatment approved for cancer treatment; radiotherapy; or symptomatic treatment alone.\n\"This global phase 3 study establishes a potential new standard treatment for women with heavily pretreated metastatic breast cancer, for whom there was previously no chemotherapy treatment with proven survival benefit,\" the authors wrote.\nThe researchers found that among patients whose cancer had spread, those who took the drug lived a median of 2.5 months longer than those who received a physician-chosen treatment -- 13.1 months versus 10.6 months.\nThe study, known as the EMBRACE trial, was funded by Eisai Inc., which markets eribulin.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does not report that eribulin, the drug studied, received approval in the United States based on the results of the study.\u00a0 Eribulin is approved for patients who have previously\u00a0been treated for metastatic breast cancer with at least two chemotherapies, including an anthracycline and a taxane.\nAs a result, the availability of the drug is unclear to readers.\u00a0 Information about drug approval and availability is valuable for patients with metastatic breast cancer.", "answer": 0}, {"article": "\u201cIf it weren\u2019t for the trial I wouldn\u2019t be here,\u201d she said.\nThe effect was so marked that the trial was stopped early for ethical reasons, so that patients in the control group could be offered the new drug.\nThe drug is expected to be approved by the Food and Drug Administration within a few months.\nThe trial of ipilimumab, paid for by Bristol-Myers, involved 502 patients with late-stage melanoma.\nThe drug significantly shrinks tumors in about half of these patients \u2014 or about a quarter of all melanoma patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Vemurafenib was described as experimental and as \u201cexpected to be approved by the FDA within a few months.\u201d\u00a0 Ipilimumab was explained to be approved in March and already on the market.", "answer": 1}, {"article": "Swaminath noted that one study published in 2012 found that \"colonoscopy reduced the risk of death from colon cancer by 53 percent, by removing polyps.\nFor now, he said, the data from this study is not strong enough to spur any changes in current screening recommendations.\nOne expert said more efforts are needed to get people to undergo colonoscopy, which is currently recommended once every 10 years beginning at age 50.\nTUESDAY, Aug. 11, 2015 (HealthDay News) -- Colonoscopy can save lives, but experts agree that testing rates remain too low.\n\"While high-risk patients may ultimately require a screening colonoscopy, many average- and low-risk patients could undergo less invasive screening procedures.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although availability isn\u2019t explicitly addressed, this risk calculator is now available (implicitly) by virtue of publication of the paper. \u00a0It is a simple scoring system that can be implemented based on the information in the paper, and the story makes this clear. We\u2019ll rate this Satisfactory.", "answer": 1}, {"article": "Two new devices\u2014one that deflates fat cells, one that destroys them\u2014have just been cleared for \"body contouring\" in doctors' offices by the Food and Drug Administration.\n\nZeltiq grabs onto love handles and belly pouches and freezes the fat cells inside, causing them to self-destruct over several months. Zerona...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The two devices mentioned in the story were described as FDA approved, which is true. The story could have made it clear, though,\u00a0that both devices have been in use for a while and that\u00a0off-label use of devices is common. \u00a0", "answer": 1}, {"article": "Patients with Type-1 diabetes typically compensate by monitoring their blood sugar levels every few hours and injecting themselves with insulin as many as five times a day.\nThe experimental therapy eliminated the need for insulin injections for months or even years in 14 of 15 patients who were recently diagnosed with the disease.\nEven if patients continue to require insulin shots, the treatment should be considered a success if it halts the destruction of beta cells, said Dr. Jay Skyler, with the Diabetes Research Institute at the University of Miami Miller School of Medicine, who wrote an editorial accompanying the study.\nThe treatment had no effect on one patient, whose disease had already progressed too far, doctors decided.\nAbout two weeks later, the patients checked into the hospital and received chemotherapy and other drugs to kill off their immune systems over five days.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states the treatment is experimental, letting readers know this procedure is not available at your local doctor's office just yet.\u00a0 ", "answer": 1}, {"article": "In undeveloped countries, 75,000 women die from pre-eclampsia each year.\nThe cost of treating mothers with pre-eclampsia is $45 billion a year in the United States, Europe, Asia, Australia and New Zealand, the researchers said.\n\u201cIt would also ensure that those women are educated about the warning signs of pre-eclampsia.\nSuch a \u201cmetabolic fingerprint\u201d test could save the lives of thousands of women, Philip Baker of the University of Alberta in Canada, who helped lead the study, said in a statement.\nThey ran the test at about 15 weeks gestation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is an experimental diagnostic test and not available beyond research settings. The story makes that clear.", "answer": 1}, {"article": "Not a single cancer was undetected that became palpable,\" she said.\nHowever, with breast cancer remaining a major cause of cancer death in women, there is good reason to pursue the search for improved screening methods, according to the study's lead author, Christiane Kuhl, M.D., chair of the Department of Radiology at RWTH Aachen University in Aachen, Germany.\nAccording to Dr. Kuhl, the results suggest that MRI can serve as a useful supplemental screening tool for women at average risk, especially those with dense mammographic tissue, and that MRI is superior to supplemental ultrasound for this purpose.\nThe new study showed that, consistent with previous research, breast MRI can depict these rapidly growing cancers with high reliability.\nThe results also highlight the ability of MRI in the detection of more aggressive types of cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that MRI screening is already available. The release notes that there\u2019s been a resistance to expand MRI screening to average risk women because of the cost.", "answer": 1}, {"article": "Allergy shots may be used for hay fever when antihistamines and other allergy medications do not control a person\u2019s symptoms adequately, or for people who want to reduce their reliance on medication.\nStill, Nelson said that if sublingual products do win approval in the U.S., they will likely boost the number of hay fever sufferers who want to use under-the-tongue immunotherapy.\nIn addition, the long-term effectiveness of the grass-pollen tablets is not yet fully clear.\nDr. Harold Nelson, an allergist at National Jewish Health in Denver, said that the body of evidence indicates that sublingual immunotherapy beats antihistamines and other medications used to control hay fever symptoms.\nOn the other hand, Nelson said, allergy shots appear to outperform the oral versions, with a symptom reduction about twice that of sublingual immunotherapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>1clip_themedata.thmx\" rel=\"themeData\"/>1clip_colorschememapping.xml\" rel=\"colorSchemeMapping\"/>\n\n\n\n \nThis story makes it clear that sublingual immunotherapy is not available in the U.S.; however, this might have been mentioned sooner in the text.\u00a0\u00a0 \n", "answer": 1}, {"article": "Mayta-Apaza AC, Pottgen E, De Bodt J, et al.\nHowever, the new study does suggest that Montmorency tart cherries can be added to the list of gut-friendly foods.\nWhile the dietary intervention was based on a limited number of human volunteers and more research is needed to support these conclusions, the results help build the foundation for future research and suggest Montmorency tart cherries can play a role in positively shaping the microbiome and maintaining gut health.\nResearchers conducted both human and laboratory experiments to determine the impact of Montmorency tart cherries on the microbiome.\nWhile previous studies on Montmorency tart cherries have ranged from heart health and exercise recovery to sleep, this is the first study to explore the potential gut health benefits.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We can presume that tart cherry juice is widely available, and the news release does mention that Montmorency cherries are a common domestic variety \u201cavailable year-round in dried, frozen, canned, and juice forms.\u201d", "answer": 1}, {"article": "Glaucoma is a leading cause of blindness.\nBut they added that blood pressure and other factors that can contribute to vessel size would need to be considered.\nIn the study, researchers were able to predict who was at increased risk of developing the eye disease with some accuracy by measuring blood vessel thickness in the retinas of study participants using a computer-based imaging tool.\nThe study appears in the latest issue of the journal Ophthalmology.\nThose with the narrowest vessels at the beginning of the study were four times more likely to have developed glaucoma a decade later.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There was no discussion of what the \u201ccomputer-based imaging tool\u201d really was.\u00a0 Is it equipment already readily available and in use?\u00a0 If not, what is it, and what would it take to implement?\nNo details were provided \u2013 a weak spot in the story.\nThe story should have made the connection between retinal photography that is currently done for diabetic eye screening and this new, alternative use of the same images.", "answer": 0}, {"article": "\"If someone really feels they need to take this and they need to try it, well go ahead and do it.\nStill, Schneider won't object if someone wants to try it.\nHowever, ginkgo was safe and no serious side effects were noted, DeKosky added.\nThis age group is not typical of the age of both healthy people and those with mild cognitive impairment who use ginkgo for improving mental performance.\"\nThe report, published in the Dec. 23-30 issue of the Journal of the American Medical Association, supports the findings of earlier, smaller studies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that ginkgo biloba is used widely. ", "answer": 1}, {"article": "I wouldn\u2019t wish it on my worst enemy, but I have to go through with it.\u201d\n\nDr. Lowy explored the entire cavity from the diaphragm to the pelvis.\n\u201cIt\u2019s maximally invasive,\u201d said Dr. Sugarbaker, who often removes the \u201cspare parts\u201d \u2014 organs a patient can live without, like the spleen, the gall bladder, the ovaries and the uterus.\nAnd critics say that since that trial was conducted, new drugs have come to market that allow patients with metastatic colorectal cancer to live two years with intravenous chemotherapy alone.\nOne randomized trial done more than a decade ago involving 105 patients in the did show a striking benefit.\nBut Dr. Alan Venook, a colon cancer specialist at the , said that a couple of patients referred by him had \u201cdied miserable deaths.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that \u201can increasing number of the nation\u2019s leading medical centers has been offering the costly \u2014 and controversial \u2014 therapy to patients with the more common colorectal or ovarian cancers\u201d and names some of them.", "answer": 1}, {"article": "The scans, called coronary computed tomography angiography or CCTA, produce a detailed image of the heart that reveals cholesterol buildups in the coronary arteries.\nMcEvoy said there have been several reports of doctors doing CCTA heart scans in healthy patients, although the practice is currently discouraged by the American Heart Association.\nYet there\u2019s no evidence that treating people based on heart scan results does any good, said Dr. John McEvoy, of Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, who led the new study.\n\u201cTesting might lead to more harm than good,\u201d McEvoy told Reuters Health, adding that heart scans may cost $600 or more.\nIn an editorial, Dr. Michael S. Lauer of National Heart, Lung, and Blood Institute in Bethesda, Maryland, said the new study serves as a reminder of the downsides of screening.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that the scans are not currently recommended by guidelines but that \u201cthere have been several reports of doctors doing CCTA heart scans in healthy patients, although the practice is currently discouraged by the American Heart Association.\u201d", "answer": 1}, {"article": "Obesity is associated with heart disease, stroke, diabetes and some cancers, and researchers estimate that it is the second-leading cause of preventable death, after tobacco use.\nInstead, these results show that endoscopic sleeve gastroplasty is another possibility that patients and health-care providers should consider when discussing options.\nDr. Sharaiha noted that these findings do not suggest that endoscopic sleeve gastroplasty will replace the two surgical treatments as weight-loss interventions.\n\"Our research -- the first to compare these treatments -- demonstrates that endoscopic sleeve gastroplasty is safe and effective in helping patients lead healthier lives.\n\"For years, patients seeking weight-loss interventions had limited options because they could not tolerate or did not want surgery, or it was not even an option for them,\" added Dr. Sharaiha.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "For someone reading the news release who is unfamiliar with weight loss treatment procedures, ESG may sound like an entirely novel treatment that is not yet clinically available. However, while it is relatively new, it is already in use. The release doesn\u2019t give us any idea of how many facilities perform any of these procedures.", "answer": 0}, {"article": "For Patients and the General Public:", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Both neratinib and veliptarib are described as \u201cexperimental\u201d so it is clear that neither are\u00a0currently\u00a0available outside of clinical\u00a0trials.", "answer": 1}, {"article": "Actually, nitrous is making a comeback in U.S. maternity circles. It has remained a staple of childbirth in Canada, Australia, and Britain \u2014 Catherine, Duchess of Cambridge (the former Kate Middleton), who welcomed her third royal baby, Louis Arthur Charles, last month, reportedly has used it. But it basically disappeared in the United States in the 1970s. American women preferred to be numbed below the waist with epidural anesthesia, or at least that became the gold standard for pain relief.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s mentioned that currently \u201can estimated 500 U.S. hospitals and birthing centers offer nitrous \u2014 up from a handful less than a decade ago.\u201d", "answer": 1}, {"article": "Fluctuating levels of levodopa result in erratic periods of muscular control and involuntary movements throughout the day, disrupting activity at least half a dozen times a day.\nThe company said the drug is expected to be available in the fourth quarter, and formally launched in January 2018.\nAn estimated 90 percent of levodopa-treated patients, about 200,000 people in the United States, suffer from LID, the company said.\nThe long-acting therapy is taken once-daily at bedtime.\nAdamas is also testing the drug to treat walking impairment in patients with multiple sclerosis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes this clear: \u201cThe company said the drug is expected to be available in the fourth quarter, and formally launched in January 2018.\u201d", "answer": 1}, {"article": "Minimally invasive procedures increased to 31 percent of all radical prostatectomies in 2005 from 12.2 percent in 2003.\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\nBut the surgery increases the chance for longer term problems that require further therapy, the research says.\n\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n\nIn laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs.\nThe study, published on May 10 in The Journal of Clinical Oncology, examined a sample of 2,702 Medicare patients undergoing radical prostatectomy, the complete removal of the prostate, from 2003 to 2005.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies that laparoscopic prostatectomies are widely available, and in fact are done about a third of the time in the studied population.\nBut it would have been useful to state how difficult it is (or is not) to find a surgeon experienced with laparoscopic procedures. ", "answer": 1}, {"article": "Unfortunately, our previous study indicated that, despite their benefits, many patients on statins discontinue their treatment,\" Chodick said.\nA previous study on the same group indicated that persistent use of statins was associated with substantially lower all-cause mortality, which could not be explained only by the prevention of cardiovascular disease, he said.\nThis work received no outside or corporate finding, the researchers noted.\nFor the study, Chodick's team collected data on 1.8 million patients who got their health care through the Maccabi Healthcare Services, an HMO in Israel.\nThe only way to prove the connection is with a clinical trial, Myerburg said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story notes that statins are already used to prevent heart attacks and stroke.", "answer": 1}, {"article": "\"It's known that EPA and DHA can inhibit breast tumour growth, but no one has looked directly at how effective these omega-3s are compared to ALA.\"\n\nMa found overall exposure to marine-based omega-3s reduced the size of the tumours by 60 to 70 per cent and the number of tumours by 30 per cent.\n\"There is evidence that both omega-3s from plants and marine sources are protective against cancer and we wanted to determine which form is more effective.\"\nProf. David Ma has discovered that marine-based omega-3s are eight times more effective at inhibiting tumour development and growth.\nOmega-3s from fish pack a stronger punch than flaxseed and other oils when it comes to cancer prevention, according to a first-ever University of Guelph study.\nBased on the doses given in the study, Ma said humans should consume two to three servings of fish a week to have the same effect.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Fatty fish is widely available.", "answer": 2}, {"article": "A Harvard researcher hopes an old arthritis drug, which he read about in a 19th century German medical journal, could be a cheap new treatment for diabetes.\n\nIn the late 1990s, Steven Shoelson's research suggested that the drug, called salsalate, might also help diabetics. The idea sent him into the basement stacks of a Harvard library to see whether anyone else had pursued the notion.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story described the drug being investigated as \u2018a cheap, generic\u2019 and as currently being sold as \u2018an inexpensive generic\u2019.\u00a0 It would have been useful to clarify whether it was available as a prescription or an over-the-counter medication.", "answer": 1}, {"article": "However, about half of patients who undergo hormone therapy suffer from hot flashes similar to those that women experience during menopause.\n\"The symptoms don't (normally) get better by that much that quickly.\"\nTheir reported level of hot flashes dropped markedly.\n\"We are now designing a randomized clinical trial to further evaluate acupuncture after prostate cancer treatment,\" Ashamalla added.\n\"Usually it's mild and self-limiting and improves with time.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of acupuncture isn\u2019t in question.", "answer": 2}, {"article": "\"It's like 'Star Trek.'\nAnd while some patients like Campbell do well with the implant, there are some who struggle.\nToday, the artificial retina is primarily for sufferers of retinitis pigmentosa, but it could expand to other diseases, like dry age-related macular degeneration, Mech said.\nAnd just recently, during a vision test, Campbell was able to correctly identify a sequence of letters for the first time in decades.\nThen earlier this year, she went from coping with blindness to hoping she might see again.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story plainly says that only 14 people in the U.S. are involved with a study of the artificial retina device, making it clear it\u2019s not in clinical use. ", "answer": 1}, {"article": "Doctors can slow macular degeneration with vitamins, laser surgery, stem cell treatments, and even implantable miniature telescopes.\nBut Dr. Grazia Pertile, director of ophthalmology at the Sacred Heart Don Calabria in Negrar, Italy and one of the Italian researchers, said in a written statement that her team's device could be \u201ca turning point in the treatment of extremely debilitating retinal diseases.\u201d\n\nShe\u2019s not alone in that assessment.\nThe devices are only experimental prototypes with many years of additional research and development likely before they might be ready for commercial use.\n\u201cWe want to create a new class of devices with drastically improved capabilities to help people with impaired vision,\u201d Silva said.\nRelated: This Revolutionary Gene-Editing Tool Could Change the World\n\nWhen the prosthesis was tested in rats, the animals' pupils constricted in response to exposure to light.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0makes quite clear that the new devices are not yet available and likely won\u2019t be for several years. We especially liked that this was brought up near the beginning of the story, versus at the end.", "answer": 1}, {"article": "For more on the definitive guide to alternative methods of healing the mind, body and soul, pick up a copy today.\nThe biggest drawback to TMS, according to advocates, is the limitations on just who can undergo the treatment.\nIts efficacy varies from patient to patient and, like most prescriptions for depression, TMS has its own set of side-effects.\nDespite these setbacks, researchers are optimistic about TMS\u2014and not just as a form of treatment for depression.\nExperiments treating Parkinson\u2019s and autism, the other two conditions for which TMS is approved, have seen some success among neurologists.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states\u00a0\u201cits use is federally restricted with exemptions only for those with severe depression.\u201d\nThis is incorrect and a misinterpretation/misunderstanding of the FDA approved indication for depression. The FDA (the \u201cfederal\u201d\u00a0we assume here) approved TMS for the treatment of depression after a patient fails to respond to one antidepressant, whatever his or her\u2019s degree of depression severity (moderate, severe\u2026). A physician makes the judgement of whether TMS is indicated and can do so even before trying a drug if there is some reason a person cannot tolerate drugs. The FDA does not regulate the practice of medicine.", "answer": 0}, {"article": "Mitochondria are the organelles within the body\u2019s cells that generate energy.\nWhether much lower doses would benefit athletic performance is not clear, Dr. Evans said.\nDr. Ronald M. Evans, a leading expert on the hormonal control of metabolism at the Salk Institute, said that the report by Dr. Auwerx\u2019s team had \u201cshown very convincingly that resveratrol improves mitochondrial function\u201d and fends off metabolic disease.\nThat is the process that he says is reversed by resveratrol and, he hopes, by the more powerful sirtuin-activator drugs that his company is developing, though many years of clinical trials will still be needed to demonstrate whether they work and are safe to use.\nThe two studies were started and performed independently, Dr. Auwerx said, though he obtained supplies of resveratrol from Sirtris, which was co-founded by Dr. Sinclair, and he has become a scientific advisor to the company.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story did not mention that reservatrol is not a substance approved by the FDA.\u00a0 It mentioned an available capsule product but then mentioned that this product's volume of resveratrol \"would have to be gulped in almost impossible quantities for a human to obtain doses equivalent to those used in mice.\"\u00a0 So the true availability issue was unresolved. \u00a0 ", "answer": 0}, {"article": "For instance, yoga may influence brain chemicals known as neurotransmitters (boosting levels of feel-good agents like serotonin), lower inflammation, reduce oxidative stress and produce a healthier balance of lipids and growth factors \u2014 just as other forms of exercise do.\nBut while the research is promising, yoga likely won\u2019t be a panacea for mental illness.\nThe researchers say there\u2019s enough evidence to warrant a larger study on the effects of yoga on mental health, and it should be considered as part of treatment for more disorders.\nSome of the studies included in the analysis even suggested that yoga might affect the body in ways similar to antidepressants and psychotherapy.\n\u201cMost individuals already know that yoga produces some kind of a calming effect.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Yoga classes are widely available, but there is no standardized curriculum. So it\u2019s not clear if classes at the local community center will provide the same benefits observed in these studies.\u00a0The story should have addressed\u00a0this uncertainty.", "answer": 0}, {"article": "Significantly greater improvements in motor function were recorded after three months in patients taking Prozac, where the average test score improved by 34.0 points, than in the placebo group, where the average improvement was 24.3 points.\nRoger Bonomo, director of stroke care at Lenox Hill Hospital in New York, said another way to look at the implications of this trial would be as justification for treatment of post-stroke depression before it progresses.\nExperts commenting on the findings said they had \u201cenormous potential to change clinical practice\u201d and raised the question of whether most stroke patients with motor skill problems should be treated with this relatively cheap type of antidepressant.\nCommenting on the study, Robert Robinson and Harold Adams from the University of Iowa in the United States, said it could change the way doctors treat stroke victims in future, but more research is needed to see if the effects continue over time.\n\u201cThe positive effect of the drug on motor function... suggests that the neuronal ... action of SSRIs provides a new pathway that should be explored further,\u201d said Francois Chollet of Toulouse University Hospital, who led this research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear\u00a0that the story is about a new use for a medicine that has been available for many years to treat depression and anxiety.", "answer": 1}, {"article": "Repeated treatments also resulted in a higher likelihood of remission or a longer time to relapse, with an overall response and remission rate of 68.8 percent for the patients receiving ketamine treatment.\n\"These results are a promising early piece of the puzzle, but the risks of ketamine use are still not wholly understood.\n\"Not only was ketamine well-tolerated by participants, with none experiencing severe or problematic side effects, but giving the treatment by a simple subcutaneous injection (a small injection under the skin) was also shown to be an acceptable method for administering the drug in a safe and effective way.\"\n\"Elderly patients with severe depression face additional barriers when seeking treatment for the condition.\nPrevious studies into ketamine treatments for older people with depression - which are limited to just five case reports - show mixed success, with findings limited by small sample sizes.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address the availability of ketamine for depression head-on. We\u2019re not sure what regulatory issues may apply in Australia, where the release was issued from, but since the information is being distributed to a worldwide audience via a news wire, some comment on this issue would have been appropriate and helpful. The implication is that ketamine is not yet in general clinical use for treatment geriatric depression. But in the U.S., at least, clinics are starting to pop up around the country that offer this therapy. Are these treatment centers reputable? Readers aren\u2019t given any guidance.", "answer": 0}, {"article": "\u201cIn the Northern hemisphere, the body\u2019s testosterone production naturally declines from November through April, and then rises steadily through the spring and summer with a peak in October.\u201d\n\nLow sexual desire can affect significant numbers of men after the age of 40, with studies finding that up to 25 percent of men report problems.\nBut after treatment, the group exposed to the bright light was scoring sexual satisfaction scores of around 6.3.\nFagiolini\u2019s team recruited 38 men diagnosed with either hypoactive sexual desire disorder or sexual arousal disorder \u2013 both characterized by a lack of interest in sex.\nIn contrast, the control group only showed an average score of around 2.7 after treatment.\u201d\n\u201cBefore treatment, both groups averaged a sexual satisfaction score of around 2 out of 10.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Many people are aware that light boxes are available and relatively commonplace, so we\u2019ll rate this N/A. However, the story would have been stronger had it discussed what kind of light box the researchers used, and if it\u2019s available, etc.", "answer": 2}, {"article": "Other researchers contributing to this study include: Robert L. Coleman, M.D., Alpa M. Nick, M.D., Pedro T. Ramirez, M.D., Lois M. Ramondetta, M.D., Diana Urbauer, Jack L. Watkins, all from MD Anderson; Susan K. Lutgendorf, Ph.D. from University of Iowa; Sanjeev Kumar, M.B., B.S.\n\"The stratification of patients by beta-blocker use and selectivity in this study makes it unique among all other studies examining the impact of these drugs on cancer.\nAccording to Sood, the preliminary data from these feasibility trials will be used to design prospective, randomized clinical trials examining NSBBs on patient outcomes.\nThis study builds on a large body of research by principal investigator Anil Sood, M.D., professor in Gynecologic Medical Oncology and Cancer Biology at MD Anderson.\nFuture trials will seek to identify patients who would benefit most from beta-blocker use and the best beta-blocker for a specific tumor type based on adrenergic receptor expression.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This is a close one. Yes, the release notes that beta blockers are already in widespread use. Yes, the release mentions the two ongoing clinical trials and how they\u2019ll be used to design additional clinical trials. But the information on clinical trials is in the penultimate paragraph and the ramifications aren\u2019t necessarily clear to lay readers \u2014 it will be years before researchers can determine whether beta blockers should be incorporated into clinical treatment of EOC patients.", "answer": 1}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nSome study limitations should be considered.\nThere are numerous possible active properties in walnuts that may be contributing factors in providing health benefits.\nThis research was supported in part by the California Walnut Commission (CWC).\nThe CWC has supported health-related research on walnuts for more than 25 years.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Walnuts are known to be widely available.", "answer": 2}, {"article": "\u201cThe question has been, \u2018What do you do with the rest?\u2019\u201d he says.\nSimilar to treatment with thalidomide, most of the patients had a relapse of their skin problems within weeks of stopping the drug.\nHe says about 75% of patients with affected skin will go into remission with these standard treatments.\nThe lenalidomide study included 15 women with lupus skin conditions; six had lupus in other areas of the body, too.\nThe researchers note that the study dose was \u201cgenerally well-tolerated.\u201d No new nerve symptoms were reported.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that \u201d Lenalidomide is available as Revlimid to treat people with multiple myeloma and myelodysplastic syndromes.\u201d\u00a0 But for the lupus skin conditions in question, it is unclear if some doctors were currently using it off-label.\u00a0 We think the story should have discussed this.\u00a0 Any of the doctors interviewed could have answered this.", "answer": 0}, {"article": "The first figure is systolic pressure, generated when the heart is pumping, and the second figure is diastolic pressure, created when the heart is relaxing and filling with blood.\nAs for the next step in confirming the relationship between beetroot juice and blood pressure, she says this was a small trial.\nThe trial was double-blind, which means neither the administering clinicians nor the patients knew whether the beetroot juice they were given was the placebo or the active supplement.\nMedical researchers have recently returned to this plant product to investigate its effect on blood pressure and explore opportunities to put it to use in modern medicine and the home management of conditions.\n\"The possibility of using a natural product, rather than another pill, to help lower blood pressure, is very appealing,\" adds Dr. Amoils.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have mentioned options for purchasing or preparing beet juice. While it didn\u2019t emphasize this or discuss the availability of beets or other nitrate-containing vegetables, we think most readers will understand that these foods and juices are available.", "answer": 2}, {"article": "In Canada, heart failure patients stay an average of almost 10 days for each hospital admission, accounting for 1.4 million hospital stays a year.\nThe first Canadian patient implanted with the heart monitor will be among 25 patients within the Ted Rogers Centre for Heart Research at the Peter Munk Cardiac Centre to be fitted with the device over the next nine months.\nThis is a big game-changer.\u201d\n\nFunded by the Ted Rogers Centre for Heart Research, the device called CardioMEMS\u2122 HF System was successfully implanted by interventional cardiologists at the Peter Munk Cardiac Centre in March 2017.\nSince it opened in 1997, the Centre has saved and improved the lives of cardiac and vascular patients from around the world.\nThe system features a small butterfly-like sensor that then sits inside the pulmonary artery of a heart failure patient.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes it clear that this device is not widely available in Canada, since it\u2019s a \u201cnovel\u201d sensor and not yet approved by Health Canada.\nIn the last sentence, it states that CardioMEMS was approved by the US FDA, implying that the implantation procedure is more widespread there.\nWe rate this one Satisfactory.", "answer": 1}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that Vascepa is available by prescription to treat high triglyceride levels.", "answer": 1}, {"article": "During the DaTscan test, an imaging drug is injected into a patient's bloodstream and the patient undergoes a single-photon emission computed tomography, or SPECT, scan.\nSince June, 25 men and women of all ages have been tested with DaTscan at Central DuPage, Rezak said.\nIn cases where a diagnosis isn't necessarily clear-cut, the DaTscan offers important advances in patient care and treatment, said Dr. Michael Rezak, director of the Movement Disorders Center at Central DuPage Hospital, where the scan is offered.\n\"DaTscan is used in difficult-to-diagnose cases and must be used in conjunction with a clinical evaluation and a patient's response to medications,\" Rezak said.\nApproval of DaTscan followed two Phase 3 clinical trials in which 284 adult patients with tremors were studied.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe availability of the DaTscan test is the main point of the story. It reports the test was approved by the FDA in January 2011 and is now available at more than 80 hospitals in the United States. It also reports that the test was approved for use in Europe a decade ago. ", "answer": 1}, {"article": "Zeitzer was on the committee that removed jet lag as a \u201cdisease\u201d from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), the guide that psychiatrists use to diagnose mental illnesses.\n\u201cFor moving your system to an earlier time, such as would be necessary when traveling West-to-East, light during the last few hours of the night is ideal.\u201d\n\nThe night flashes require special technology and equipment, beyond just a smartphone, which are still in development, Zeitzer said.\n\u201cHowever, the treatments that are developed for jet lag can be used for less prevalent, though far more significant societal problems including delayed sleep in teens (in whom we have an ongoing clinical trial using the flash technique) and shift workers who try to flip between a night time schedule for work and a day time schedule for leisure,\u201d he told Reuters Health by email.\nIn a previous study, the short flashes of light at night did not interrupt sleep or reduce its quality, he added.\nAs for frequent flyers trying this themselves, it is \u201cfar too early \u2013 neither the methodology is available outside research, nor any guidance about safety, nor tests of simulated jet lag in an appropriate \u2018realistic\u2019 protocol,\u201d Wirz-Justice told Reuters Health by email.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This article made it fairly clear that this technology wasn\u2019t ready for consumers by mentioning that further research needed to happen and that frequent flyers shouldn\u2019t try this on their own.", "answer": 1}, {"article": "We've had a lot of migrants from European nations, so they're fair-skinned ... and we do have a very intense sun here,\" Ziman said.\nThe Australian team believe theirs would be the first to detect melanoma.\nThe test could speed up the diagnosis process, saving thousands of lives.\nFor potential sufferers in remote areas, away from skin specialists, diagnosis can be especially tricky, he said, making a simple blood test an easy alternative to identify those at risk.\nHowever, she stressed the fact this new test has not undergone clinical trials.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that the tests are in the experimental stages and not available commercially.", "answer": 1}, {"article": "Depression presents an enormous disease burden, with a reported 350 million people worldwide suffering from the disease, but traditional SSRI treatments carry a burden of their own - in dollars and side effects.\nTheir results showed that magnesium is safe and effective and comparable to prescription SSRI treatments in effectiveness.\nThe study team found that in 112 participants with analyzable data, consumption of magnesium chloride for six weeks resulted in a clinically significant improvement in measures of depression and anxiety symptoms.\nIn addition, these positive effects were shown quickly, at two weeks, and the supplements were well tolerated and similarly effective regardless of age, sex, or use of antidepressants, among other factors.\nNew clinical research published today in PLoS One shows that over-the-counter magnesium appears safe and effective to treat mild to moderate depression.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release mentioned that magnesium can be found over-the-counter.", "answer": 1}, {"article": "U.S.\nThe paper outlines the case study of a 56-year-old male with a chronic meniscus injury.\nTo management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.\nThe healed tear could not be penetrated by the probe.\nExcept as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release never emphasizes the early stage nature of this work.\u00a0 Knowledgeable readers might know that news of a single case study\u00a0may be\u00a0just the beginning of a long-term research effort, but nothing in the release expresses that to readers who may be less knowledgeable.", "answer": 0}, {"article": "\"Doing that could be a lot easier than nudging children about going to bed,\" Raine said.\nIf it also improves cognitive performance -- like we've seen here -- even better.\n\"We have found that omega-3 supplements reduce antisocial behavior, so it's not too surprising that fish is behind this.\"\nBut they've never all been connected before.\n\"If the fish improves sleep, great.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear that fish is a common food source, available everywhere.\n\u00a0", "answer": 2}, {"article": "Post-traumatic stress disorder (PTSD) is a term for a broad range of psychological symptoms that can develop after someone experiences or witnesses a traumatic event.\nThis is called 'reconsolidation', and we now plan to test the effect of doxycycline on reconsolidation of fear memories.\nThe study, published in Molecular Psychiatry, was a pre-registered, placebo-controlled, double-blind randomised controlled trial in 76 healthy volunteers.\nA week later, under no medication, participants returned to repeat the experiment.\nPTSD is caused by an overactive fear memory, and the new research shows that doxycycline can reduce the fear memory response in healthy volunteers.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that \u201cmore realistic models\u201d of clinical PTSD are needed and any testing of doxycycline in those models is years away.", "answer": 1}, {"article": "Among parents of children with autism, Mr. Frank said, \"some will say, 'Come on, who are you kidding?'\nWith so many doubts -- and so few answers -- about effective autism treatments among the growing community of families affected by the condition, the institute said openness is vital to the experimental method's success.\nThe Children's Institute plan would be taking what is arguably a fringe movement into the mainstream: It would be the first autism treatment of this kind staged in an American hospital setting.\nDr. Faber noted that Ms. Slimak's clean room work -- like much of the research on toxicity in autism -- \"hasn't been written for the main [scientific] literature\" but instead has been written mostly for the Internet.\nWith roots in autism treatment theories that until now have lived mostly on the Internet, the pediatric clean room plan would be the first of its kind in a mainstream American hospital environment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The pollutant-free \"clean room\" experiment, designed to attempt to detoxify the bodies of young patients with autism, is in the conceptual\u00a0and fund-raising stages, which have\u00a0yet to be completed.\u00a0 This article does not indicate that the\u00a0experimental protocol will not likely be implemented in the near future and that it will not be available to autistic children who are not enrolled in the research study. ", "answer": 0}, {"article": "Sharon Samuels was a teenager when she was first diagnosed with essential tremor.\nHe added that since these patients were only followed for a year, there isn\u2019t enough data available yet to determine the long-term efficacy of the treatment.\nFor now, the treatment has had an immense impact on patients\u2019 lives.\nBut the procedure brings lasting side effects in some patients, and its long-term usefulness is still being studied.\nThe doctors at Brigham will follow up with Samuels \u2014 and others who undergo the treatment \u2014 for up to five years and run more MRI scans and neurological exams to find out for how long the lesion lasts and keeps the tremor suppressed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the device was approved by the FDA in July. The story could have done readers a service by giving a sense of how many medical centers around the country are geared up to perform the procedure, or will be soon.", "answer": 1}, {"article": "For example, Kramer says, what if a man got a PSA test when his prostate cancer was in the very earliest stages of metastatic disease?\nThe new study seems to make a powerful argument in favor of PSA testing.\nMessing says this misses the point of his study, which appears in the online July 30 issue of the journal Cancer.\nBut it's not that simple, says Barnett Kramer, MD, MPH, associate director for disease prevention at the National Institutes of Health.\nBut he would not yet have symptoms or detectable metastatic disease, so he'd be diagnosed with earlier-stage disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that PSA screening is \u201cwidespread.\u201d", "answer": 1}, {"article": "Post-operative cognitive dysfunction (POCD), a condition mostly observed in older patients following surgery under general anesthesia, is characterized by impaired memory and concentration.\n\"Little is said about rehabilitation or ways of helping patients recover pre-operative cognitive function.\"\n\"Our findings confirm recent evidence that the deeper the anesthesia-induced hypnosis, the higher the incidence of POCD.\nBefore that, older patients were rarely subjected to major surgery, and significant research in this field has only been conducted for approximately 15-20 years.\n\"The results reinforce recent evidence of the importance of avoiding deep anesthesia,\" Carmona said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the release that the relevant tools involved in this particular intervention \u2014 the use of dexamethasone and avoidance of \u201cdeep\u201d anesthesia \u2014 are currently available. However, as noted above, this is a relatively small study, and we suspect that more research would be needed before this approach was considered for widespread clinical practice. Since we already dinged it for that point earlier, we\u2019ll give it a satisfactory here.", "answer": 1}, {"article": "Rheumatoid arthritis, which is felt throughout the whole body, is caused when a person's immune system attacks his or her own tissues.\nThe findings are published in the Nov. 28 online edition of Arthritis & Rheumatism.\nThe studies included arthritis patients aged 18 or older who had hip or knee replacements.\n\"While complication rates are low, there are some cases with serious consequences that include infection, joint dislocation, blood clots and even death.\"\nThe study team found no differences between the two groups of arthritis patients in rates of follow-up surgery, or 90-day blood clot or death risk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. No details were given about the availability or widespread use of joint replacements.\u00a0 Even though no specific numbers are reported, readers should understand that joint replacement is a widely available treatment.", "answer": 2}, {"article": "Malignant mesothelioma is an aggressive and almost uniformly fatal tumor caused primarily by exposure to asbestos.\nA 510(k) application is being prepared for submission to the FDA to register the ONCOblot test as a medical device.\nThe ONCOblot\u00ae test is based on more than 20 years of basic research.\nThe ONCOblot Test is CLIA registered and meets all current FDA regulations as an LDT.\nMorNuCo Laboratories is elated to share these results with the public, as early detection is widely considered the corner stone of an effective strategy to reduce cancer-related deaths.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release notes that the ONCOblot test is FDA approved as a \u201cLaboratory Developed Test.\u201d It also includes a link to a company web site with more information on the test and how to get it.", "answer": 1}, {"article": "Digital rectal exams can tell a specialist that the prostate is getting bigger, but that happens with normal aging as well as with cancer.\nThe test was approved for use in Europe in 2006 but is not yet approved in the United States.\nThe Progensa test looks for a genetic material called PCA3.\nThe test had a sensitivity of 49 percent, meaning it correctly identified 49 percent of cancers.\n\u201cIf the PCA3 is abnormal, above about 35, you have got an 80 percent chance of having cancer,\u201d Crawford said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story stated that this test is approved for use in Europe but not the US.", "answer": 1}, {"article": "Paul J.D.\nThe team is in the planning stages of developing a start-up company to commercialize the technique.\nThe techniques developed by the interdisciplinary team can be used by dermatologists and will reduce safety concerns in laser dermatology by improving laser transmission through surface layers of the skin.\nWhiteside, a doctoral candidate in the MU Division of Food Systems and Bioengineering, devised a system that will not only improve the process, but will be safer for both clinicians and patients.\nThe sonoillumination research was funded in part by a 2015 Fast Track grant from the University of Missouri System.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although the release is clear that the device is not yet available, there is no support for the claim that the device, which has yet to be tested on tattoos or other skin markings, \u201cwill be available widely in the near future,\u201d especially since clinical trials have yet to be performed.", "answer": 0}, {"article": "\u201cIf we can do the same for other patients, that would be an amazing accomplishment that many decades of work and research on glioblastoma have never done,\u201d says Badie, whose own father passed away a decade ago from glioblastoma.\nBased on this man\u2019s case, his team is hoping to now inject not just the tumor site but also the ventricular space in the brain, since that may help control spread of the cancer.\nThe patient is one of nine in the trial, and so far, many of the other people are having similar experiences on the therapy.\nThis is the first time that immune cells have been injected into these brain regions, because introducing anything into the ventricles can cause dangerous and possibly deadly inflammation.\nBut after being treated with the immune therapy, his cancer did not grow or recur for nearly eight months.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that the therapy is experimental, that complexities are numerous, that much is still unknown, and the trial is ongoing.", "answer": 1}, {"article": "Trials of that vaccine in people, which is also based on man-made copies of virus proteins, began on August 2, when the first study volunteer was given a vaccination through a needle free injector, said Dr. Anthony Fauci, head of the National Institute for Allergy and Infectious Diseases.\nRight now, just one of those three vaccines will be progressing to clinical trials.\nThe protein/cold virus vaccine was especially effective, sparking a significant immune response after just one dose.\nThis kind of vaccine is much safer than ones that depend on live virus particles to foster immunity.\n\u201cIt\u2019s always good to have multiple different vaccine candidates in both clinical and pre-clinical testing,\u201d Barouch said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story offers information about possible timetables for clinical testing and availability. It could have been more emphatic that there are a lot of unknowns here, though.", "answer": 1}, {"article": "A role for dietary macroalgae in the ameliorating ration of certainement Risk Factors Associated with cardiovascular disease.\nBy adding seaweed to processed foods we can make food healthier.\nIn the article the authors offer suggestions to how both individual consumers and the food industry can use seaweed to make our everyday meals healthier.\nIt can even enhance the flavor of the food, they argue.\nDespite these warnings, you can buy dried hijiki in many stores.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We are going to assume here that most people think seaweed is widely available as a food product.", "answer": 1}, {"article": "Regions of the brain that typically contain accumulated tau protein include the temporal lobe, parietal lobe and occipital lobe, among others; grey matter in the cerebellum is thought to contain low or no tau in patients with Alzheimer's.\nThese three most promising tracers were previously tested in nonhuman primates, and the results looked promising enough to test in people.\nThis study was made available online in May 2018 ahead of peer-review and publication.\nAs part of a longer term project funded by F. Hoffman-La Roche, the team previously tested a collection of approximately 550 potential tracer molecules and identified six promising tracers, eventually narrowing them down to three to be made and tested as candidate Tau PET radiopharmaceuticals.\nTwo studies will be published back-to-back in the December issue of Journal of Nuclear Medicine--one as featured article of the month--describing testing of three candidate molecules in patients with Alzheimer's disease, as well as the use of one molecule to measure the accumulation of tau proteins.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not make clear that this work is still far removed from widespread clinical application.", "answer": 0}, {"article": "\"The Suboxone got me far enough away to look and say 'wow, look at your life.\nBut, as CBS News contributor Dr. Sanjay Gupta reports, he's willing to talk about how prescription painkillers took over his life: Ten OxyContin pills a day, costing up to $12,000 a month.\nThe hope is one day that Suboxone can do for painkiller addiction that drugs like Prozac did for depression: convince the public that addiction is a brain disease, not a character flaw.\nIf left unsatisfied, the receptor sends pain signals to the brain - this is withdrawal.\nHere's how it works: When people are addicted, new receptors are created in the brain, which crave opioids.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The segment states that Suboxone (sublingual buprenorphine) is available from \"any doctor, even a family physician.\" \nIt\u2019s a bit more complicated than that. In order to prescribe Suboxone, a physican without specialized training in addiction needs to be certified by submitting an application to the federal government, completing an 8-hour training course and meeting other criteria.\u00a0 \nThe segment is unclear about availability in a second case. The segment itself implies (correctly) that the drug is currently available. But then the host says the drug is currently in clinical trials. The physician-reporter\u2019s response does not clarify that these trials are for approval of an additional, specific use of the currently available drug. \u00a0", "answer": 0}, {"article": "Our scientists are dedicated to learning more about who might derive a greater benefit from Avastin,\" she explained.\nReflecting splits in the medical community, the European Medicines Agency said Thursday that Avastin would remain an approved therapy for breast cancer in European Union countries, although only in one particular combination: with the drug paclitaxel.\nPhysicians who favor Avastin's use say the FDA is being overly cautious, and that the drug can be used safely if patients are closely monitored.\nThe announcement does not affect Avastin's status as an approved therapy for lung cancer, kidney cancer, colorectal cancer and brain cancer.\nHowever, patients currently taking Avastin as part of their chemotherapy regimen will not immediately be affected, and \"doctors should use their medical judgment on whether to continue\" its use, said Dr. Janet Woodcock of the FDA's Center for Drug Evaluation and Research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear about Avastin\u2019s availability and the impact of the FDA decision.\nFYI: it states that the EU has decided to keep Avastin approved for breast cancer\u00a0only\u00a0in combination with paclitaxel. Just to be clear, in the US, it\u2019s only\u00a0approved\u00a0in combination with paclitaxel , too.", "answer": 1}, {"article": "We keep them at that temperature for the first 24 hours, at which time we re-warm them,\" Likosky explains.\nWhen 57-year-old Dean Cowles suddenly suffered a heart attack, he was lucky that he worked at a company that made defibrillators,reports.\nIt's called induced hypothermia.\nBut what helped save his brain \u2014 and left him remarkably undamaged \u2014 was a simple procedure in the ER: chilling his body.\nIt requires training and a lot of coordination.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that this treatment is not available at most hospitals.", "answer": 1}, {"article": "In Manhattan some raw-milk drinkers hire a mule to bring the white stuff to an agreed-upon location in...\nAnd they consider themselves lucky.\nNow that's trickier.\nGot milk?\nNo?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story did not list the states by name, it did mention that six states allow the sale of raw milk in stores and that 28 states allow the sale of raw milk on the farms where it is produced.", "answer": 1}, {"article": ".\nThe metabolic and microbial findings from this study provide a foundation for a larger clinical trial in the pediatric population.\nImportantly, the researchers show that the prebiotic induced specific gut bacterial shifts compared to placebo.\nFor this study, researchers from the University of Calgary, Alberta, Canada, performed a double-blind, placebo-controlled trial with 42 participants.\nThis work was supported by grants from the BMO Financial Group Endowed Research Fund in Healthy Living, Alberta Children's Hospital Foundation, Alberta Children's Hospital Research Institute and the Canadian Institutes of Health Research (MOP115076-1).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability. The supplement used in the trial is from Germany and was not easy to find online, but as noted, similar products appear to be easily available.", "answer": 0}, {"article": "That view is shared by Deborah Giaschi, a professor of ophthalmology and visual sciences at the University of British Columbia in Vancouver who has conducted MRI studies of the brains of people with dyslexia. \"There's really no scientific basis\" for ChromaGen lenses, she says. In her opinion, the claim that the lenses slow down visual processing doesn't make sense. Even if the lenses had that effect, she doesn't see how that would help anyone read.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The column explained that the lenses are marketed on a company website, which also gives a list of providers.", "answer": 1}, {"article": "Type 2 diabetes, which is often tied to obesity, affects about 8 percent of the U.S. population, according to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.\nIt\u2019s also not possible to say from the current evidence that heavy coffee drinkers (and tea and decaf drinkers) don\u2019t have other characteristics that might protect them against developing diabetes, they add, such as eating a healthier diet.\nIn the years since then, they add, the amount of research on coffee and diabetes risk \u201chas more than doubled,\u201d while other studies have suggested that tea and decaf coffee may also be preventive.\nThe current analysis could have overestimated the effect of these beverages on diabetes risk due to statistical issues with the smaller studies, Huxley and her colleagues note.\nClinical trials are needed to investigate whether these beverages do indeed help prevent diabetes, the researchers say.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availabilty of coffee and tea is not in question. ", "answer": 2}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that IVM (in vitro maturation) treatments are not widely available and this method is not as successful or widely accepted in the medical community as IVF (in vitro fertization) treatments.\u00a0 The story notes that Dr. Batzofin is one of the first doctors in Manhattan to offer the treatments and is conducting a clincal trial on IVM.\u00a0 ", "answer": 1}, {"article": "Previous research has also suggested that fructans stimulate the growth of beneficial bacteria in the large intestine in a way that increases the body's absorption of minerals, including calcium and magnesium, which are needed for bone growth.\nBut drinking tequila won't help, the study authors noted.\nTUESDAY, March 23, 2010 (HealthDay News) -- An ingredient in agave -- the plant used to make tequila -- may help fight bone-weakening osteoporosis and other diseases, Mexican researchers say.\n\"These results suggest that the supplementation of the standard diet with agave fructans prevented bone loss and improved bone formation, indicating the important role of agave fructans on the maintenance of healthy bone,\" Lopez said.\n\"They can be used in many products for children and infants to help prevent various diseases, and can even be used in ice cream as a sugar substitute.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of these plants is not in question. ", "answer": 2}, {"article": "The Claim: Red palm oil, a deep orange fat pressed from the palm tree fruit, is a superfood\u2014packed with healthy antioxidants and good for the heart, say companies who sell it.\n\nThe Verdict: The colorful oil is rich in tocotrienols, nutrients in the vitamin E family, and carotenoids, which the body converts into vitamin A. Several studies suggest possible benefits in stroke and liver disease from vitamin extracts made from the oil, but so far there isn\u2019t proof that consuming the oil can ward off disease, scientists say.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As noted above, the story mentions some specific brands. It also provides some details about the differences between varieties of red palm oil.", "answer": 1}, {"article": "Read more at The Wall Street Journal.\nThe drugmaker plans to apply for approval in the U.S. this summer; however, the drug likely wouldn't be available here until next year.\nThe experimental drug, however, kicks into action earlier, working to block the virus from hijacking cells in the first place, the Journal said.\nThe experimental drug worked three times faster than another antiviral drug, Tamiflu, the company told the Journal.\nExisting drugs, including Tamiflu, work to block these viral copies from escaping the cell, the Journal reported.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article, again as noted above, seems to assume that the FDA will automatically approve this anti-viral drug and do so quickly. Neither assumption is necessarily the case.", "answer": 0}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The results presented are acknowledged to be preliminary, with the next step being a second, larger trial. \nThis suggests that use of HSCT for treatment of lupus is not likely to be widely available for some time.", "answer": 1}, {"article": "Women taking oxybutynin also reported improvement in work, social activities, leisure activities, sleep and overall quality of life.\nDrugs in this class -- called anticholinergics -- have been linked with mental decline, he said.\nBut a new study suggests an existing medication may help.\nHowever, he cautioned that its long-term effects aren't known.\nThe patient said endocrine therapy had caused hot flashes so severe that she could not sleep.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that the drug, which is approved to treat incontinence, is readily available.", "answer": 1}, {"article": "Concussion is a major public health concern, often resulting in significant acute symptoms and in some individuals, long-term neurological dysfunction.\nThis new method, fully funded by the Children's Health Foundation and conducted by the Western Concussion Study Group, is unique in that previous attempts have looked unsuccessfully for a single highly accurate protein biomarker that can distinguish concussed from non-concussed adolescent patients.\n\"There is no one metabolite that we can put a finger on but when we looked at all of them, those profiles are different enough that we could easily distinguish concussed patients from non-concussed.\nIn this latest successful attempt, the researchers took a different approach and investigated a full spectrum of 174 metabolites.\n\"With further research, we anticipate that our blood test will also aid clinicians in predicting concussion outcome, as well as aid rehabilitation after concussion.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We aren\u2019t told if it is available or not or even when it might become available. The release could have been much more transparent about its availability. When we assessed the release it appears that there isn\u2019t a test per se, but a series of chemicals that could be combined into a future commercial test.", "answer": 0}, {"article": "Dr. Jeffrey Tice, an internist at the University of California, San Francisco, who wrote an editorial accompanying the study, said: \"With hormones, we really were thinking we were preventing a lot of diseases and it was good for the long term.\nNone of the drugs or extracts are approved by the Food and Drug Administration to treat hot flashes \u2014 only hormones are approved for that purpose \u2014 but doctors are free to prescribe medicines for any use they see fit, and many recommend the drugs or plant products for hot flashes, based on study findings and their patients' experiences.\nAll the nonhormonal drugs have side effects.\nIn the meantime, both Dr. Tice and Dr. Nelson said that for women who find their symptoms intolerable and want treatment, they would favor antidepressants over hormones.\nNow, other drugs have come into use for hot flashes, but not much is known about their effectiveness or long-term safety.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Medications listed in the story are available with a prescription, but they are not yet FDA approved for the treatment of hot flashes. Supplements such as soy and red clover are available without a prescription, however, these are not regulated and the active ingredient (i.e. plant estrogens) in these supplements may vary by manufacturer.", "answer": 1}, {"article": ".\n\"Most patients with this disease are older and tend to have other health conditions such as high cholesterol.\n\"However, further research is needed to assess the benefits of using statins before surgical repair of other types of aneurysms.\"\nOf those who do get to a health facility alive, only about 50 percent survive.\nThe bottom line is that patients who used statins were more likely to survive during and after an elective endovascular procedure.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s assumed that the public is aware that statins are widely available as a prescription drug.", "answer": 1}, {"article": "Restless leg syndrome (RLS) is a neurologic disorder causing unpleasant sensations and an urge to move the legs when at rest.\nPilot study published in the Journal of the American Osteopathic Association finds targeted pressure device significantly increased sleep for those with moderate to severe symptoms\n\nAuthors from Lake Erie Research Institute in Pennsylvania report an adjustable foot wrap caused to treat restless legs syndrome (RLS) is 1.4 times more effective than the standard pharmaceutical treatment.\nPatients using the RLS device also reported an 82 percent decrease in sleep loss.\nThe eight-week clinical trial involved 30 otherwise healthy adults with moderate to severe restless leg syndrome.\nDisclosures: Dr Kuhn worked without compensation through Lake Erie Research Institute (LERI) during the 5 years of the study of the device and is now receiving compensation for that work.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Oddly, the release does not say that this foot wrap was cleared for sale by the FDA in 2013 and is already on the market (brand name restiffic).", "answer": 0}, {"article": "\"It is not going to be reimbursed by insurance, at least for the first generation and certainly for the foreseeable future,\" he said.\nThe device doesn't change the stomach's natural anatomy, according to the FDA.\nBut the device can only be used for six months at a time, and it is not likely to be an alternative for people who require lap-band surgery, stomach stapling or other forms of bariatric surgery, said Dr. Mitchell Roslin, chief of obesity surgery for Lenox Hill Hospital in New York City.\nPatients who did not receive the device lost about half that amount of weight -- just over 3 percent of their total body weight, the FDA said.\nThe balloons take up space in the stomach, which presumably makes people feel fuller faster, the FDA said in its announcement Tuesday.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear the device has just won FDA approval, and has been available in Europe.\u00a0But the story doesn\u2019t comment on what might be the obstacles to use in the US. \u00a0What training is required? \u00a0How many physicians have been trained? \u00a0How might availability be held back if (as the story appropriately suggests) patients have to pay cash for it? Are there any lessons from Europe that would educate American consumers?\n\u00a0", "answer": 0}, {"article": "If a pill could prevent teenagers from taking dangerous risks, would you consider it for your children?\n\nI\u2019d be tempted. My skateboard- and bicycle-riding son was hit by a car\u2014twice\u2014when he was a teenager. I would have welcomed anything that could have averted those dreadful phone calls from the emergency room.\n\nWhile some bumps and scares...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear in the story that the drugs in question are available for prescription. However, the U.S.\u2019s complex behavioral health system and prescription drug payment policies makes obtaining them difficult for many, and the story would have served readers better if it discussed this barrier to access.", "answer": 1}, {"article": "CAM2038 has the potential to alter the current treatment paradigm for opioid dependence,\" said Sharon Walsh, Ph.D, Professor of Behavioral Science and Director of the Center on Drug and Alcohol Research, University of Kentucky, \"Because of its long acting properties, CAM2038 may decrease patient and physician burden, improve access to treatment, and obviate public health concerns about illicit diversion of buprenorphine.\"\nFour more trials, including two Phase 3 studies, are currently ongoing.\n\"Importantly, the fact that CAM2038 will be given in the clinic by health providers should address concerns about diversion of buprenorphine for illicit use.\nThe CAM2038 products are designed for administration by healthcare personnel to ensure proper delivery that minimizes the risks of diversion, abuse, misuse, and accidental exposure.\nFurthermore, CAM2038 was well tolerated across the course of treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t provide a time frame for when the drug, which is still under development, will be available but suggests it will be \u201ca future treatment alternative.\u201d We don\u2019t fault them for not providing a date following a phase 2 trial. There are many steps to be completed before or if it is approved and marketed.", "answer": 1}, {"article": "In particular, it measures rhythmic patterns known as theta and beta waves.\nBut it will take better research to figure out whether neurofeedback can live up to that promise, Rabiner says.\nShe says it might have been because she and her son spent so much time going to all those sessions together, and had pizza together afterward.\nIn the meantime, he says, the study has shown that it is possible to do neurofeedback research that involves a placebo.\nOn the other hand, Rabiner says, neurofeedback may offer something other treatments can't.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this type of treatment is available to the general public.\u00a0We like that the story cautioned readers to look out for\u00a0unqualified therapists and\u00a0gave tips\u00a0for finding reputable clinicians. The story could have been more specific about how many trained professionals there are and how easy\u00a0it is\u00a0to find them outside of large population centers.", "answer": 1}, {"article": "And in an accompanying journal editorial, medical professors Dr. Bo Abrahamsen and Dr. Opinder Sahota wrote that due to study limitations, \"it is not possible to provide reassurance that calcium supplements given with vitamin D do not cause adverse cardiovascular events or to link them with certainty to increased cardiovascular risk.\nThe case against calcium became stronger when researchers added in data from 13 other, unpublished trials involving almost 30,000 women.\nBut even when added to previous studies with similar findings, the new conclusions don't necessarily mark a death knell for calcium supplements, say the authors of a study released online April 19 in the BMJ.\nIn addition, the mammoth, U.S.-government funded Women's Health Initiative (WHI) earlier found no negative link between calcium and heart health.\n\"Our own recommendation is to critically review the use of calcium supplements, since the data in this paper suggests that they do more harm than good,\" added Reid, who is professor of medicine and endocrinology at the University of Auckland in New Zealand.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated:\u00a0\u201cMany older women take calcium supplements with or without vitamin D to keep their bones strong, especially since that has long been standard medical advice.\u201d So availability and widespread use is clear.\n", "answer": 1}, {"article": "Radiotracers work by injecting a small amount of a compound tagged with a radionuclide into patients.\nTwo prostate cancer experts said the tool, if borne out in patients, could prove very useful.\nHe noted that, as of now, doctors typically rely on results of the PSA blood test and/or standard diagnostic scans to help guide treatment decisions.\nSince these changes could not be detected based on a PSA blood test alone, this new test would be very helpful in determining early on which therapy to choose in a given patient.\"\nThe study also revealed the radiotracer could help identify cases where prostate cancer had spread to the bone.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that the researchers \u201chope to begin a human trial next year.\u201d", "answer": 1}, {"article": "Red and purple fruits owe their colors to...\nAlthough it's a challenge to eat the raw fruit without getting a mouthful of seeds and astringent pith, pomegranates are everywhere now in the form of juice, concentrates and extracts, all heavily promoted for better health.\nIt pays researchers to study the benefits of pomegranate juice, gives doctors information on positive studies and, of course, sells pomegranate products.\nMuch of the popularity is the work of a California-based company, Pom Wonderful.\nThe juice is a beautiful wine-red color and tastes delicious.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentions that pomegranates are now \u2018everywhere\u2019. There has been an increased number of pomegranate-containing products available in grocery stores and other venues. However, the article mentions that there have been few good clinical studies with pomegranates and that the results from those few studies should be followed up with larger, better studies. ", "answer": 1}, {"article": "Stryker says that none of the problems underlying the recall or the warning letter from the F.D.A.\nNow that the squeaking has raised caution flags, researchers are weighing the noted durability of ceramic-on-ceramic hip joints like Stryker\u2019s Trident model against products with other combinations of materials.\nNow, tens of thousands of ceramic hips later \u2014 from Stryker and other makers that entered the field \u2014 many patients say their squeaking hips are interfering with daily life.\nAlready, dozens of patients have elected to endure subsequent surgeries to replace the noisy hips.\nWhatever the actual frequency, some investigators who have looked at the problem say the squeaking seems to be associated with extreme flexing of the ceramic implants, but exactly how is unclear.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not explicitly state that ceramic hip replacements are approved by the FDA, but with \u201ctens of thousands\u201d implanted, it\u2019s clear that surgeons\u2019 adoption of the devices is widespread. The FDA\u2019s warning to implant maker Stryker about squeaking suggests the devices may not be perfect, but are approved.", "answer": 1}, {"article": "People with insomnia may have one or more sleep problems, including difficulty falling asleep, trouble staying asleep and difficulty getting back to sleep after waking in the night.\nOn average, it took patients 21.6 fewer minutes to fall asleep with the 40 mg dose of MK-4305 than a placebo on night one, Merck said.\nThe drug, MK-4305, helped patients sleep for a larger percentage of eight hours spent in bed at one night and at the end of four weeks of treatment, Merck said.\nThe drug also demonstrated superiority to placebo in the time it took to fall asleep and time spent awake after initially falling asleep, Merck said.\nHe said the 80 mg dose was likely more than most people need.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The first sentence presents the information as coming from \"a mid-stage study,\" a vague term. Later, though, it says that Merck is going to apply for approval for the drug in 2012. This is satisfactory in the strictest sense of the word.\u00a0To really understand the origin of these results, you need to go read the press release, which calls the study a \"Phase IIb\" study and alludes to ongoing Phase III studies. The story seems to conflate these two things.", "answer": 1}, {"article": "FRANKFURT (Reuters) - Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer\u2019s Inlyta drug in a late-stage study.\n\nThe drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.\n\nThe trial will continue to show whether Bavencio plus Inlyta also prolongs patients\u2019 lives.\n\nWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not make clear that Bavencio and Inlyta are already on the market, much less that Bavencio\u2019s current use is for treatment of a skin cancer called Merkel cell carcinoma.", "answer": 0}, {"article": "Switching to AstraZeneca PLC's breast-cancer drug Arimidex after treatment with older drug tamoxifen not only helps women live longer, but also increases their chances of staying cancer-free after initial therapy for breast cancer, according to a study in the online edition of the Lancet Oncology medical journal.\n\nThe data, which come from more than 4,000 patients in three clinical trials, have shown that switching treatment from tamoxifen to Arimidex reduces the risk of dying by 29%.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that a hormone therapy, anastrozole (trade name Arimidex), was FDA-approved in 2005 for the treatment of early-stage breast cancer (after surgery). What is important, but is not\u00a0emphazied\u00a0is that this drug is only for post-menopausal women. ", "answer": 1}, {"article": "Dr. Stehling is a German Professor of Radiology, a former Associate Professor at Boston University and served as Research Assistant to Sir Peter Mansfield, Prof of Physics and Nobel Prize winner in Medicine in 2003 (for discoveries concerning magnetic resonance imaging).\nCHICAGO, Dec. 2, 2015 /PRNewswire/ -- An analysis of clinical data from over 200 patients treated by Dr. Michael Stehling found that a new procedure that uses MR and ultrasound to guide treatment to the precise tumor location allows for faster recovery times and lower side effects in all stages of prostate cancer.\nThe study which was conducted at the Prostata Center of Offenbach, Germany (www.prostate-center.org) will be presented today at the annual meeting of the Radiological Society of North America (RSNA).\nDr. Stehling has treated the most prostate cancer patients in the world using this image guided treatment, while generating the best therapeutic results.\n\"The patients we have treated at The Prostata Center have had their cancers destroyed without the need for surgery, with a low incidence of side effects and in most cases have been back on their feet the next day,\" said Dr. Michael K. Stehling, an internationally recognized expert on image guided tumor ablation treatments and primary author of the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "When a release is all about a \u201cnew\u201d therapy, it is important to establish whether this technology and expertise is available only in academic centers or more widely in the community or hardly at all and only in clinical research. This release does not tell us anything about when and where this might be made available.\u00a0If the investigator is just now reporting up to 4 years of data on only 265 subjects then this is not widely available.", "answer": 0}, {"article": "The results were published in Wednesday\u2019s edition of the Journal of the American Medical Assn.\nThe researchers also found that the popularity of folic acid supplements rose as time went on.\nBut not all mothers were equally likely to take folic acid supplements.\nIt\u2019s unclear how these findings apply to mothers and children in the United States.\nMothers who took folic acid supplements around the time they became pregnant were less likely to have children with an autism spectrum disorder, a new study has found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that folic acid supplements are widely available and have long been recommended for women considering pregnancy.", "answer": 1}, {"article": "Autistic children are prone to seizures.\nGeier's promotional materials said he has treated hundreds of children with Lupron and has launched nine ASD Centers in eight states.\nShe said Geier plans to continue the Lupron for several months to see if it helps Marco's other autistic behavior.\nLupron critics said autism parents may not understand the dangers.\nClayman said he would not comment until he treats patients with Lupron therapy for a year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that Lupron is already used to treat endometrial cancer and prostate cancer.\u00a0 The story might have addressed more directly its current off-label use.\u00a0\u00a0 \nIt\u2019s also clear that this is about a Maryland medical group taking its idea on the road to South Florida.\u00a0 Ideally, the story might have addressed whether it\u2019s being tried elsewhere. ", "answer": 1}, {"article": "Furthermore, a study from the University of Rochester, published in March in Environmental Health Perspectives, found that men with shorter anogenital spans had lower sperm counts, poorer quality sperm, lower sperm concentrations and lower motility.\nBut one urologist said the the finding is too preliminary to introduce into clinical practice, however.\nFurther research is needed to compare techniques for measuring anogenital distance and assess their accuracy, he and his colleagues said.\n\"This paper also provides new data on infertile men, who have shorter (less masculine) anogenital distance.\"\nOne expert who's done her own research in this area applauded the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of such a measurement approach is not in question.", "answer": 2}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does state that the availability of the new\u00a0ultrasound may be limited to academic or large city hospitals.", "answer": 1}, {"article": "AsthmaNet is a nationwide clinical research network created by the NHLBI in 2009.\nAsthmaNet studies are currently being conducted in 14 states.\nThe study, funded by the National Heart, Lung, and Blood Institute's (NHLBI) asthma network (AsthmaNet), appears in the August 18, 2016, issue of the New England Journal of Medicine.\nThe Division of Pediatric Pulmonology and Allergy/Immunology at UH Rainbow is currently recruiting for a number of asthma-related clinical trials.\n\"Results from this randomized controlled study showed that in young children with mild asthma, acetaminophen used as needed was not associated with increased asthma flares or more asthma symptoms.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of acetaminophen and ibuprofen is not in question, since these are well-known, over-the-counter drugs. We rate this one Not Applicable.", "answer": 2}, {"article": "It describes circulating tumor cells as cancer cells that have detached from a tumor and are found at very low levels in the bloodstream.\nVeridex launched the first commercial test using circulating tumor cell technology in 2004, the company said.\nDr. Mehmet Toner, director of the BioMicroElectroMechanical Systems Resource Center in Massachusetts General's Center for Engineering in Medicine, says while it will take at least five years before the test is on the market, it's another step toward personalized medicine and the implications for patients are significant.\nResearchers hope the test will be used by oncologists as a diagnostic tool aimed at discovering as early as possible if a cancer has spread, as well as by researchers in coming up with new drug therapies.\nToner said you are likely to find just one circulating tumor cell in 5 to 10 billion blood cells.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story quotes a researcher saying it \u201cit will take at least five years before the test is on the market\u201d but treats that as a fait accompli. But the story doesn\u2019t make clear the staggering amount of testing that remains ahead.", "answer": 1}, {"article": "But researchers controlled for these and many other factors, and found that compared with women who ate no walnuts, those who consumed 8 ounces of walnuts or more a month reduced their risk for Type 2 diabetes by 24 percent.\nEating walnuts may reduce the risk for Type 2 diabetes in women, a large new study concludes.\nWomen who ate walnuts tended to weigh less, consume more fish and exercise more than those who did not.\nThey found 5,930 cases of Type 2 diabetes.\nWalnuts may have some unique benefits.\u201d\n\nThe study was supported with grants from the National Institutes of Health and the California Walnut Commission.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of walnuts is not in question.", "answer": 2}, {"article": "So, indeed, there has been a strong interest in giving the best additional therapy possible,\" Choti added.\nAnd even for those, unfortunately 75 to 80 percent of those will go on to recur even after the surgery appears to be successful.\nDr. Michael Choti, a professor of surgery and oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, described the study as \"important,\" but he does not believe it will alter the current approach to post-surgical chemotherapy.\nThe study authors noted that, currently, the prognosis for pancreatic cancer is very poor, with a five-year survival rate of less than 5 percent.\nAfter nearly three years of treatment, the researchers found almost no difference between survival rates in the two groups.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not clearly establish whether gemcitabine or the other drugs mentioned are currently on the market. (They are.)", "answer": 0}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Mentioned that statins are widely used and considered safe. Mentioned that use as cancer \npreventative would be an off-label use (i.e. drugs not approved for this purpose)", "answer": 1}, {"article": "Fibrosis - where persistent inflammation causes scar tissue to form in the liver, but the liver is still able to function normally \n\n4.\nPublishing in the academic journal GUT, the Newcastle team describe the proof of principle research in which they measure specific epigenetic markers to stratify NAFLD patients into mild or severe liver scarring, known as fibrosis.\nThe test detects chemical changes on tiny amounts of \"cell-free\" DNA that are released into the blood when liver cells are injured.\nIt is the first time an epigenetic signature in blood has been discovered which is diagnostic of the severity of fibrosis for people with Non-alcoholic Fatty Liver Disease (NAFLD).\nIn this first stage of research the team developed the blood analysis in 26 patients with NAFLD.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release includes a quote that says \u201cWe are now working on confirming these findings in a larger group of patients.\u201d Based on that, readers can infer that the technique is not yet available \u2014 so it gets a pass. However, it would have been better to state that more explicitly. As the paper itself says: \u201cWith validation, this blood-based biomarker could become an important contributory clinical tool alongside other epigenetic, genetic and biochemical biomarkers, mitigating the future need for biopsy to evaluate fibrosis.\u201d", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Taking multivitamins may help women without cardiovascular disease to ward off a heart attack, new research shows.\nThe women ranged in age from 49 to 83 at the study\u2019s outset, and about 60 percent in each group used some type of dietary supplement.\nTo investigate the relationship between vitamin use and heart disease in women, Rautiainen and her team followed 31,671 women with no history of heart disease and 2,262 women who did have cardiovascular disease for about 10 years.\nAmong the women with heart disease, 13 percent of the non-supplement-users had heart attacks, compared to 14 percent of women who took multivitamins only, which wasn\u2019t a statistically significant difference (meaning it could have been due to chance).\nFor the women without heart disease at the study\u2019s outset, taking a multivitamin for less than five years reduced heart attack risk by 18 percent compared with non-users of supplements.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of multivitamins is assumed. However, the researchers did not collect deatiled data about which vitamins the women took or in what amounts, so it is unknown whether the results truly reflect on typical multivitamins or possibly other products.", "answer": 1}, {"article": "The U.S. National Institute of Neurological Disorders and Stroke has more about autism.\nTwo experts agreed that early intervention is key.\nHe was cautiously optimistic about the promise of the video feedback approach.\nThe goal of the therapy -- delivered over five months while the infants were ages 7 to 10 months -- was to improve the infant's attention, communication, early language development, and social engagement.\n\"Although it would be wonderful if a relatively simple, video-based intervention could reduce the recurrence risk of autism spectrum disorder in later offspring, further studies are needed to examine this very issue,\" he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although there is no mention of where and when the potential therapy might be available, the story did establish that more research would be needed before it should be used. Since the story didn\u2019t give the impression that anyone should use this approach right now, we\u2019ll rate this satisfactory.", "answer": 1}, {"article": "As myelin damage continues over the course of the disease, neurons progressively lose their ability to reliably transmit electrical signals, resulting in progressive loss of vision, weakness, walking difficulties, and problems with coordination and balance.\nThe new results are particularly notable, Chan said, because patients in the trial had suffered from MS symptoms caused by injury to myelin for years.\nThe researchers said that the Phase II results, published online on 10 October, 2017 in The Lancet, are the first in which a drug has been shown to reliably restore any brain function damaged by a neurological disease in human patients.\nThis \"flip-flop\" technique gave the researchers the ability to compare patients to themselves -- a form of control that increased the statistical power of the study by nearly an order of magnitude, Green said.\nThat myelin increases the speed of neural transmission is one of the most well-established concepts in neurobiology, and combined with the clear evidence from Chan's preclinical research showing that clemastine fumarate promotes myelin formation, myelin regeneration is the only plausible explanation for the VEP results, the authors said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release reports that clemastine was first approved by the US FDA in 1977 for allergies and that its generic form has been available over the counter since 1993.\nWe rate this Satisfactory.", "answer": 1}, {"article": "Spinal fluid can also reveal the disease but that can be a difficult and painful test.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nToday only an autopsy can establish for sure that a patient had Alzheimer's.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\nIn a study of 259 blood samples, the test identified early markers for Alzheimer's with 90 percent accuracy, reports CBS News correspondent John Blackstone.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The report clearly states that \"plenty of lab work\" still remains before it\u2019s proven that a simple blood test can diagnose Alzheimer\u2019s.\u00a0 Even though this is tacked on as a disclaimer as the last sentence of an otherwise exuberant report, we\u2019ll give it the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "For more about multiple sclerosis, visit the National Multiple Sclerosis Society.\nStill, one MS specialist who reviewed the new study said patients need to be cautious about taking the drug.\nThe new trial of more than 600 patients with relapsing-remitting MS was funded by Sanofi Genzyme and Bayer HealthCare Pharmaceuticals, the drug's makers.\nBecause of the potential for side effects, people who received this treatment have to undergo monthly blood and urine tests for four years after the last dose, Giovannoni said.\n\"Although alemtuzumab [Lemtrada] treatment is associated with safety risks, those risks are manageable in most patients,\" Miskin said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states\u00a0that the drug is approved in the U.S. for patients who have failed other treatments.", "answer": 1}, {"article": "Among the 620 adults (average age, 71 years; 74 percent women) who were randomized, 96 percent completed the study.\nThe researchers add that close contact casting may be an appropriate treatment for older adults with unstable ankle fracture.\nFurther studies are needed to help identify which patients will not benefit from casting.\nCasting required less operating room time compared with surgery.\nAlthough close contact casting may be unfamiliar to some orthopedic surgeons, it can avoid surgery for older patients with ankle fractures, yet result in equivalent functional outcomes.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release quotes an accompanying editorial stating that \u201cclose contact casting may be unfamiliar to some orthopedic surgeons.\u201d Although that\u2019s a vague statement, we can assume it\u2019s not in widespread use.\nIn the U.S., most orthopedists are not trained in close contact casting nor do they feel comfortable using it. \u00a0Most patients will not be offered this treatment as an option for their fracture care.", "answer": 1}, {"article": "The data indicate that for every 10,000 women in their 50s, those using estrogen would experience 12 fewer heart attacks, 13 fewer deaths and 18 fewer adverse events like blood clots or stroke in a given year, compared with those taking a placebo.\nThe research, part of the landmark Women\u2019s Health Initiative study, is likely to surprise women and their doctors, who for years have heard frightening news about the risks of hormone therapy.\nThe most surprising new finding relates to breast cancer.\nDr. Chlebowski previously led research that showed cancer risks associated with combination hormone therapy, but he says the new data on estrogen alone show that in certain women, estrogen use to relieve menopausal symptoms is a \u201cgood choice.\u201d\n\n\u201cWhen you look at the debate, people are saying hormones are good or not good \u2014 it\u2019s been all or nothing.\nThe new findings, reported Tuesday in The Journal of the American Medical Association, come from 10,739 women in the Women\u2019s Health Initiative study who had previously had a hysterectomy, the surgical removal of the uterus.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Estrogen is widely available and story does not need to talk about that.", "answer": 2}, {"article": "America\u2019s ongoing battle with weight-loss that has led to fad diets and invasive surgeries like gastric bypass and stomach stapling.\nDr. Prem Chattoo, a New York based gastroenterologist, told FoxNews.com that the balloon is placed it into the stomach through the mouth.\nThe hope is that patients can train their body to eat in a much healthier fashion without feeling overly hungry.\nChattoo said that even if the balloon were to pop, the saline would be absorbed and pose no harm to the patient.\nIn addition to eliminating the scarring and risks involved with more invasive options, Chattoo said that the recovery time is also much faster.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t tell readers that Orbera is available, but it can be inferred from the patient\u2019s testimonial, so we\u2019ll give it a pass.", "answer": 1}, {"article": "Atopic dermatitis is inherited and involves patches of highly itchy skin on any part of the body.\nTrial results were also reported on Tuesday in the New England Journal of Medicine, along with an editorial that said results of the study appeared \u201ccompelling\u201d at first glance and superior to those seen in previous studies of other asthma drugs.\nBut she cautioned that longer trials are needed to fully assess the drug.\nThe medicine, if approved, could hold promise for patients with moderate to severe persistent asthma that is not well controlled by standard drugs.\nBut the editorial said effectiveness of dupilumab has been established in just a \u201climited subpopulation of patients with asthma\u201d because only 21 percent of those screened for enrollment in the study met its criteria.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Right in the lead, the story signals that this drug is not currently available, and, to the knowledgeable reader, shows where it is in the regulatory process, referring to a \u201cmid-stage trial.\u201d\u00a0 Later, it also says that \u201cfar larger trials will be needed to confirm findings from the \u201cproof of concept\u201d study.\u201d\nHowever, calling this \u201ca potential game changer for patients with moderate to severe disease\u201d may imply a more imminent definitive answer than actually exists.", "answer": 1}, {"article": "Dr. Heather Hayes, Director of Food Innovation with Devenish, said:\n\n\"Offering birds a natural and sustainable source of omega-3 PUFA is good for the bird and good for the consumer.\nThe chicken meat and eggs used in the study came from birds offered OmegaPro, a sustainable and algae-based source of omega-3 PUFA, developed by Devenish.\nThey also deliver tailored nutritional products and solutions for their customers' specific requirements.\n\"This science has demonstrated the importance of food nutrients to promote good health and prevent ill health.\n\"We worked closely with Moy Park, Waitrose and the Royal College of Surgeons in Ireland, to deliver an innovative, nutrient-rich food, that increases omega-3 levels in consumers, naturally.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although it isn\u2019t made clear in the release whether the new chicken feed is on the market yet, one might assume that it will be shortly, based on the fact that the release seems aimed more at promoting a commercial product than it does describing actual clinical research.", "answer": 2}, {"article": "And the warriors had a 40 percent lower risk of cardiovascular death and an 18 percent lower risk for cancer-related death.\nThis could be something as simple as a brisk walk or other low-impact options for vigorous exercise about 20 minutes a day.\nHe says middle-aged adults should exercise moderately during the first 12 weeks and then slowly build up to more vigorous activity.\nThis study shows that it doesn\u2019t matter how you decide to split up the recommended weekly amount of exercise.\nHowever, there are also some limitations to this study, the researchers say.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We think that the ability to exercise is generally available, so this is N/A.", "answer": 2}, {"article": "Autism is a group of complex brain developmental disorders characterized by impairments in social interaction, communication, and stereotypical and repetitive behaviours.\nA five week treatment with the synthetic hormone oxytocin significantly improved social, emotional and behavioral issues among young children with autism, according to University of Sydney research published today in Molecular Psychiatry.\nIt is also the first clinical trial investigating the efficacy, tolerability and safety of intranasal-administered oxytocin in young children with autism.\nThe study, led by researchers at the University's Brain and Mind Centre, is thought to be the first evidence of a medical treatment for social impairments in children with autism.\nStudy co-author and co-director of the Brain and Mind Centre, Professor Ian Hickie noted the new results were a critical first advance in the development of medical treatments for the social deficits that characterize autism.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t mention that synthetic oxtocin (in this trial Syntocinon was used) has been widely available for many years. It was first synthesized by American Nobel prize-winning biochemist Vincent du Vigneaud in 1955. It is most frequently used as an injectable to induce labor in pregnant women.", "answer": 0}, {"article": "\n\u2022 Detailed Results of Phase 2 Trial Presented at the American College of Gastroenterology 2016 Annual Scientific Meeting\n\u2022 93.3% of Patients Treated Using the Lead Formulation of Novel Prep Achieved a Colonoscopy Rating of Excellent or Good, Compared to 85.7% of Those Using Standard Prep Products in Colonoscopist-blinded Trial\n\u2022 More 'Patient-friendly,' Palatable Prep Could Help Increase Patient Acceptance of Colonoscopies for Colorectal Cancer Screening\n\nNewton, MA (October 17, 2016) - Detailed results from a Phase 2 study of a novel colonoscopy prep (ECP) under development by ColonaryConcepts, LLC show the investigational treatment to be at least as effective and safe as two currently available colonoscopy prep formulations, while offering a much higher level of patient satisfaction and preference than standard preps.\n\"Results from this study show that this innovative investigational product performed as well as or better at colon cleansing than two currently available colonoscopy prep formulations.\nMoreover, the higher levels of patient satisfaction reported by those who used the lead ECP formulation in the trial suggest this new approach to colonoscopy prep may have a positive impact on patient willingness to undergo this potentially life-saving colorectal cancer screening procedure.\"\nThe company currently has two product candidates in clinical development: ECP, which is expected to enter Phase 3 clinical trials in early 2017, and the \"C-bar\", a novel product candidate for chronic constipation, which is currently being studied in a Phase 1b clinical trial.\nThere were no serious adverse events across any of the treatment groups.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes it clear that the results reported come from a Phase 2 clinical trial and that Phase 3 trials may begin in early 2017. Put another way, the prep is not yet available.", "answer": 1}, {"article": "New Jersey and Ohio were the first to participate statewide in the program.\n\u2018\u2018They do it because they want to be nurturing and they are, but it\u2019s not safe.\u2019\u2019\n\nTo get the boxes, prospective moms can register through babyboxuniversity.com, watch a handful of videos on sleep safety and pass a quiz.\nParents can then take their digital or printed-out certificates to a participating hospital for their boxes.\nMcCans says the complimentary items like diapers and onesies are nice, but the more important objective behind the boxes is bringing down infant deaths and grounding parents on safe sleep practices: Place babies on their backs to sleep; Don\u2019t use bumpers in cribs; Keep stuffed animals and blankets out of infants\u2019 sleep spaces; Avoid sleeping in the same bed as infants.\nThe boxes can also be sent in the mail, if a nearby hospital is not designated as a distribution center.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The boxes are given away, but parents have to \u201cregister\u201d through babyboxuniversity.com.\nThey must \u201cwatch a handful of videos on sleep safety and pass a quiz. Parents can then take their digital or printed-out certificates to a participating hospital for their boxes. The boxes can also be sent in the mail, if a nearby hospital is not designated as a distribution center.\u201d\nWe are left unsure whether any parent can get a box from the company without registering or can a parent watch the educational material without registering and giving away his or her identity?", "answer": 0}, {"article": "The results have not previously been published or presented.\nThese phase III trial results demonstrate that C-Tb is safe, has comparable diagnostic performance to QFT-GIT and addresses the problem of false positive TST results in BCG vaccinated persons.\nThe cost of a C-Tb test is to be determined; however, it is expected to be significantly less than an IGRA.\nThe test, known as C-Tb, combines the \"field friendliness of the PPD-based tuberculin skin test with the high specificity of interferon gamma release assays, or IGRAs,\" said lead researcher Morten Ruhwald, MD, PhD, head of human immunology at Statens Serum Institut in Denmark, which developed the test.\nThe test is easy to administer but produces too many false positives to achieve the WHO's goal of reducing TB deaths by 95 percent and new cases by 90 percent by 2035, Dr. Ruhwald said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release informs readers that the test still faces a regulatory and commercial path, which strongly implies it is not yet available: \u201cRegulatory approval for C-Tb is currently being sought and Statens Serum Institute is actively seeking a commercial partner for marketing of C-Tb. The cost of a C-Tb test is to be determined; however, it is expected to be significantly less than an IGRA.\u201d", "answer": 1}, {"article": "Along with obesity, high levels of blood fats can lead to heart disease and other health problems, including diabetes.\nThat allowed Neal and his team to determine how many children who actually had high cholesterol would have been missed if they had been screened based on federal guidelines.\nThe next update of the recommendations is expected in spring 2011.\nExperts believe using family history is a good way to identify children who may be at greatest risk of high cholesterol \u0097 and therefore of future heart disease.\nFurther, Neal says, the findings apply not only to heart-disease risk but also to the risk of diabetes, since high cholesterol at a young age is a strong predictor of prediabetes and diabetes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe availability of cholesterol screening is not at issue.", "answer": 2}, {"article": "For clinical or PR inquiries, please call (405) 400-0680.\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\nThis therapy has recently been highlighted by several professional football players traveling to Europe for treatment.\nOKLAHOMA CITY, Sept. 7, 2017 /PRNewswire/ -- Arthrokinex announces the release of IRAPjoint\u2122 therapy in the USA.\nFinally, a U.S. based company has a solution for America's professional and weekend athletes as well as those struggling with aching or arthritic joints.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The specific treatment in the news release is only offered at one clinic in the U.S., but the news release didn\u2019t mention if any other clinics or companies offer a similar therapy. The release also makes it sound like this treatment is available for anyone with bad joints, though theoretically there would be people who do not qualify for the treatment based on their symptoms or medical history. ", "answer": 0}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\nRelated: Why Young Women are Having Heart Attacks\n\nThe team studied more than 450 people having heart bypass surgery, removing some of the fat clogging their arteries.\nResearchers say they\u2019ve developed a better way of scanning someone\u2019s heart to predict who is most at risk of a heart attack or stroke \u2014 long before conventional imaging methods can do it.\n\u201cBut until now, there's been no way to detect inflammation in the coronary arteries.\u201d\n\nRelated: Half of People Who Have Heart Attacks Don\u2019t Even Know It\n\nDoctors run many different tests to assess someone\u2019s risk of heart disease.\n\u201cTreatments that are known to reduce the risk of heart attacks, such as statin drugs, reduce inflammation much more than any detectable reduction in coronary artery narrowing,\u201d said Oxford\u2019s Keith Channon, who also worked on the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that more research is needed before the technology might be available to everyone.", "answer": 1}, {"article": "\"So, yes, one of the limitations of this kind of study is always the question of its generalizability to other populations,\" he cautioned.\nThey did so by substituting safflower oil for animal fats, common margarines and shortening oils, salad dressings, baked goods and other products, according to the study.\nRamsden acknowledged that the Sydney study had been narrowly focused on a specific group of people: middle-aged men with a history of heart disease, who were asked to consume linoleic acid in quantities far exceeding both AHA guidelines and the dietary habits of most Americans.\nDespite the fact the American Heart Association (AHA) currently recommends that 5 percent to 10 percent of all calories come from polyunsaturated fat (principally from omega-6), the NIH team found no evidence to support the notion that linoleic acid confers health benefits.\nThe first group was told to consume linoleic acid, in the form of safflower oil and safflower oil polyunsaturated margarine, at levels equal to 15 percent of total calorie intake.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story mostly used terms like \u201comega-6 fat\u201d and \u201clinoleic acid.\u201d But\u00a0food fats and oils\u00a0\u2014 things like corn oil and soybean oil\u00a0that people actually look for in the grocery store \u2014\u00a0contain\u00a0differing\u00a0combinations of omega-6 linoleic acid,\u00a0omega-3 fats, and other fatty acids. Although the story notes that the study involved safflower oil, it would have been helpful to explain how much linoleic acid is found in other types of oils, and\u00a0whether these oils also include omega-3 fats.", "answer": 0}, {"article": "He contended that kratom does not act on the brain's opioid receptors the way prescription painkillers and heroin do. But back in 2016, the Journal of the American Chemical Society reported that kratom indeed works this way. Last month, an FDA study found that 22 of the 25 of the most prevalent compounds in kratom do bind to opioid receptors, and so should be considered an opioid. The study also said most deaths did occur in people who used kratom in addition to other drugs, though in one case, only kratom was detected.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that kratom is widely available in Philadelphia at gas stations and convenience stores, but that a number of states have banned kratom or\u00a0have legislation to ban it pending.", "answer": 1}, {"article": "Lauren Gravitz is a science writer and editor in Hershey, Penn.\nRight now, the longest patients have been on one of these new therapies is one to two years.\nSo, four pharmaceutical companies rejiggered their approach.\nAnd so far, patients on the experimental treatments report limited side effects that consist mostly of pain at the injection site.\nYet, despite decades of research, there isn't a drug on the market today that prevents them by targeting the underlying cause.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear these injections aren\u2019t available yet:\nTwo manufacturers, Amgen (in collaboration with Novartis) and Teva Pharmaceuticals, have completed clinical trials and expect to hear from the FDA by June whether the therapies have been approved. Two more companies, Eli Lilly and Alder Biopharmaceuticals, plan to file for FDA approval later this year.\nIt also cautions that their high cost means insurance companies might \u201crequire patients to have tried just about everything else first.\u201d", "answer": 1}, {"article": "\u201cFor now I think what this study does is to create another shade of gray in the understanding of gray matter,\u201d he said.\nWithout this context, Dr. Fins said, the imaging tests could create some confusion, because like any medical tests they may occasionally go wrong, misidentifying patients as exhibiting consciousness or lacking it.\nAbout 50 percent of people with such injuries recover some awareness in the first year after the injury, studies find; very few do so afterward.\nBy contrast, brains starved of oxygen \u2014 like that of Ms. Schiavo, whose heart stopped temporarily \u2014 often suffer a massive loss of neurons, leaving virtually nothing unharmed.\nThe imaging technique, called functional M.R.I., reveals changes in activity in specific brain regions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if the functional MRI imaging is available and in use for clinical practice or if it is simply a research tool. Functional MRI is an established imaging technique but is not widely available at the present time like standard imaging studies including MRIs and CTs. Functional MRI is mainly used for research purposes, but its potential role in clinical care is likely to increase over time.", "answer": 0}, {"article": "In a study published in the Jan. 19 issue of Neurology, Carlesimo and colleagues found that DTI scanning predicted declines in memory performance with more accuracy than traditional MRI.\n\"This type of brain scan appears to be a better way to measure how healthy the brain is in people who are experiencing memory loss,\" Carlesimo says in a news release.\nBut it is increasingly clear that DTI can also be used to identify very small structural changes in the gray matter of the brain, which is critical for learning and memory, researcher Giovanni A. Carlesimo, MD, PhD, of Italy's Tor Vergata University tells WebMD.\n\"This might help doctors when trying to differentiate between normal aging and diseases like Alzheimer's.\"\nThe technique, known as diffusion tensor imaging (DTI) or diffusion MRI, is used to assess changes in the white matter regions of the brain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story provided no insight about whether hospitals have the facilities needed for this test.", "answer": 0}, {"article": "\"We're extraordinarily encouraged by what we see with this data,\" says Mitchel Berger, chairman of neurosurgery at the University of California, San Francisco and director of its center for brain tumors.\nBut the researchers and other brain-cancer doctors caution the research is at a very early stage.\nMuch more follow-up research is needed to better assess and hopefully improve the treatment's effectiveness, the researchers say.\nSome other researchers praised the results.\nTwo patients have survived more than six years, Bigner says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made clear this is an experimental therapy and thus not yet widely available.", "answer": 1}, {"article": "One-third of the patients took aspirin alone; 54 percent took only an anticoagulant; and 13 percent took an aspirin/anticoagulant combination.\nAlthough warfarin costs a few dollars for a 30-day supply, its cost approaches that of the other anticoagulants when doctor visits for monitoring are factored in, Hallstrom says.\nThose reasons include shorter surgical times, less invasive procedures and use of regional anesthesia that allows early mobilization after surgery, Hallstrom says.\n\"Patients can get it over the counter for pennies, while the other anticoagulants require monitoring, injections, frequent dose adjustments and are extremely expensive.\"\nBased on the experience of 41,537 Michigan patients undergoing knee replacement, the study may further the debate about the routine use of aspirin for clot prevention.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that many knee replacements surgeries are performed every year.", "answer": 1}, {"article": "Researchers around the world are seeking ways to regenerate damaged hearts, spines and skin with stem cells. At an operating table here recently, Kotaro Yoshimura leaned over a 51-year-old woman and put stem cells to use for a different purpose: cosmetic breast surgery.\n\nDr. Yoshimura jabbed the underside of the woman's left...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story focuses on this fat injection with stem cells as a procedure for cosmetic augmentation or reconstruction following breast cancer surgery.\u00a0 The story notes that while some plastic and cosmetic surgeons are experimenting with this procedure, it is a \"biologic product\" (due to mixture of a person\u2019s own fat w. additional stem cells) which is not currently approved by the FDA.\u00a0 ", "answer": 1}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes an effort to establish the availability of night milk by\u00a0providing a hyperlink\u00a0to a company that sells night milk. But the website obviously caters to German customers and seems like it could be a headache for US consumers to navigate. And we couldn\u2019t find any other online sources of night milk besides this company that would be more accessible.", "answer": 1}, {"article": "Editor's note: Tune in as Dr. Sanjay Gupta explores the signs, tests and lifestyle changes that could make cardiac problems a thing of the past on \"The Last Heart Attack,\" Saturday, August 27, 8 and 11 p.m.\nLead author Dr. David Jenkins, Canada research chair in nutrition and metabolism at the University of Toronto and St. Michael's Hospital, had previously shown the effectiveness of a cholesterol-lowering diet when all the meals were provided to participants.\nResearchers in Canada have shown that a special cholesterol-lowering diet works well \u2013 even with only two nutritional counseling sessions over six months.\nJenkins said participants achieved these results even though compliance to the whole grain, vegetarian diet was only about 40%.\nThe 351 participants in the study suffered from high cholesterol but were not on a cholesterol-lowering statin medication.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no\u00a0discussion of the difficulty people in poor urban and rural areas may have finding some of the vegetarian foods called for in this diet, which includes some fairly exotic soy products (e.g. soy deli slices) as sources of protein. Also, considering the lack of physician reimbursement for dietary advice, patients may\u00a0have trouble finding a health professional who can\u00a0counsel them on this approach.", "answer": 0}, {"article": "The Biggest Loser diet and the DASH diet came in second and third, respectively, in the diabetes category.\nThe DASH (Dietary Approaches to Stop Hypertension) diet was designed to lower blood pressure and cholesterol levels by limiting fats, red meat and sugar in favor of healthy grains, poultry, low-fat dairy and nuts, the U.S. National Heart, Lung, and Blood Institute says.\nThe Raw Food diet was also considered the most difficult diet to follow, though it was one of the top ranked weight-loss diets, the panel found.\nThey also considered how easy each diet was to follow, as well as safety and nutritional value.\nThe panel of experts -- including nutritionists and doctors specializing in diabetes, heart health and weight loss -- scored each diet for short-term and long-term weight loss.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s understood that the DASH diet is widely available. It has been available and promoted to the public for many years. There are books, public and private websites, shopping lists and menus devoted to it. It has been named the \u201cTop Overall Diet\u201d by one magazine six years in a row.\nThe concern that a broad swath of the public does not have the financial means or a neighborhood grocery store they can walk into and acquire the menu items is another matter.", "answer": 1}, {"article": "Master said each participant was asked to carry an accelerometer to record movements and an iPod Touch loaded with an app that would ping them prompts at intervals during each day to report any symptoms they were feeling. They also completed activity questionnaires and summaries. In addition, they wore a device called an ActiGraph to monitor sleep.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers may feel mislead about the availability of the app, given the story\u2019s headline (\u201cHow to heal head injuries? Try new app\u201d) which very strongly indicates that not only is this app publicly available, but also that it\u2019s capable of healing head injuries. Neither are true. \u00a0", "answer": 0}, {"article": "The study, conducted at the University of Texas M.D.\nPrevious research into diet and breast cancer has shown mixed results, but the authors of this study said the earlier ones were not rigorous.\nAnderson's department of health disparities and the study's principal investigator here.\nBut he also acknowledged the results so far were a surprise.\nThe findings, published in today's Journal of the American Medical Association, are a setback to the hope that better diets can prevent breast cancer recurrence.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This criterion does not apply in this story. ", "answer": 2}, {"article": "Cao looked at data from over 86,000 women who were part of the Nurses' Health Study between 1980 and 2012 and over 43,000 men who were part of the Health Professionals Follow-Up Study from 1986 to 2012.\nIt may also reduce your chances of dying from cancer, according to a study on long-term regular aspirin use and different kinds of cancer.\nNot everyone can take aspirin, particularly if you are at high risk for ulcers and gastrointestinal bleeding.\nStudies have also found that aspirin can help patients who have had (or are at high risk for) a heart attack or stroke, and of course it is a good drug to relieve pain.\n(CNN) An aspirin a day may keep the doctor away.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Aspirin is\u00a0widely available.", "answer": 2}, {"article": "Yet stroke patients admitted on the weekends were no more likely to die than stroke patients admitted during the week: 1,420 patients admitted on the weekend died versus 3,993 patients admitted on a weekday, which worked out to roughly the same rate of death.\nOverall, Kazley added, this study offers \u201cgood news that indicates that the quality of care is similar regardless of when patients present at the hospital for treatment.\nThe current study, she added, shows that \u201chigh quality (stroke) care is available in hospitals on the weekends and weekdays.\u201d In fact, care might even be more aggressive on weekends.\n\u201cEven in a country with universal health insurance coverage (such as Canada), disparities in resources, expertise, or the number of healthcare providers working during weekends\u201d may affect the stroke mortality rate, the researchers concluded.\nIn fact, that authors note that patients who received tPA were more likely to die in the hospital.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Similar to the story from HealthDay, this report\u00a0emphasizes\u00a0that\u00a0an early diagnosis\u00a0is a critical\u00a0factor in the availability of\u00a0tPA for stroke patients. Although more detail could have been provided, this is the key point.", "answer": 1}, {"article": "\"This is pretty exciting,\" said Alycia Halladay, senior director for environmental and clinical sciences for Autism Speaks, an autism advocacy group.\nThe Norwegian study is the largest to date on the benefits of folic acid for autism prevention, and marks one of the first tangible things a woman can do to reduce her risk of giving birth to a child with the disorder.\nBut some experts aren't quite ready to tout the benefits of folic acid too loudly, particularly for autism prevention.\nThe Norwegian researchers do admit that more studies should be done to confirm the link.\nDespite the fact that a link between taking folic acid and reducing autism risk isn't fully proven, Halladay says there's no harm in taking the supplement, and women should be taking it anyway to prevent birth defects.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of folic acid supplements is not in question.", "answer": 2}, {"article": "Dr. Farah, who serves as the Chief Medical Officer for the Phoenix Health Center in Hagerstown, prior NE Regional Medical Director for United Healthcare Clinical Services and Director ASAM explains, \"Based on ASAM's definition of addiction, about half of substance abuse is due to genetic factors.\nStudy author, Gregory A. Smith, M.D, former Director of Pain Management at Harbor UCLA, explains, \"Having used this technology for 6 years, this data provides further evidence that clinicians can use Proove Opioid Risk\u00ae for ruling out patients unlikely to exhibit aberrant behaviors, and identifying high-risk patients for alternative therapies.\"\nProove\u00ae's medical advisory board is led by those NIH-funded researchers and the company has licensed some of its technology from leading academic centers, such as the University of North Carolina at Chapel Hill, the University of Utah, and other institutions.\nThis study shows that analyzing genetics with lifestyle and behavioral variables in a predictive algorithm can accurately stratify patient risk.\"\nPeer-reviewed clinical studies show that the Proove Opioid Risk\u00ae profile accurately identifies patient risk for opioid abuse.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release quotes one of the study authors as saying he has used the \u201ctechnology\u201d for six years, suggesting that it should be available. However, the news release does not provide information about any use of the POR algorithm by health professionals not affiliated with Proove or this specific study. The release neglects to mention whether the FDA has cleared the device for marketing.", "answer": 0}, {"article": "Please use our search feature and update your bookmarks. Thank you!", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that estriol is widely available now for other uses and that researchers have yet to complete Phase lll trials and apply for FDA approval for application in MS patients. However, it should be noted that estriol is far more commonly used in topical skin creams and not in tablet form as was the case with this study.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070506/14healthwatch.lede.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if the intravenous (IV) zoledronic acid (Reclast) has been FDA approved or whether it is available or not.", "answer": 0}, {"article": "Baselga reports receiving honoraria from Roche; other co-authors report receiving speaking fees or honoraria from GlaxoSmithKline and fees from other drug companies.\nThe researchers are continuing to evaluate that.\nThat's the effect on overall survival in using the two-drug approach.\nThose given Tykerb alone had a 25 percent response.\nThey looked to see which drug was better at eliminating invasive cancer in the breast and metastatic cells in the lymph nodes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers have to connect the dots to figure out the availability of these drugs.\u00a0 We\u2019re told that Tykerb was approved in 2007 and we\u2019re told its retail price \u2013 so you can infer that it\u2019s available. There was no overt description of the availability of Herceptin.\nWe\u2019ll call this satisfactory by a weak nod.", "answer": 1}, {"article": "Both Prozac and Celexa belong to a class of antidepressants known as selective serotonin reuptake inhibitors, or SSRIs.\n\u201cIt takes the edge off,\u201d Hollander explains, noting that the findings were statistically significant and clinically meaningful.\nTaking Prozac (fluoxetine) doubled the chances that a patient would show overall improvement, measured by their clinicians.\nThe study was published in the American Journal of Psychiatry.\nWhen the research was originally funded, Hollander says, autism was considered to be a rare condition.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that Prozac is widely available and that other drugs are approved for use in autistic patients.\n\u00a0\n\u00a0", "answer": 1}, {"article": "When an ultrasound revealed she was carrying a girl, \u201cI was absolutely shocked,\u201c she said.\n\u201cIt\u2019s very important to educate health care providers that pregnant women are buying these tests.\u201d\n\nAnother type of test not studied by the researchers has become popular because it is cheaper and can be done at home.\nOne potential worry is that women might abort fetuses of an undesired sex.\nMost tests that were highly accurate were conducted on a mother\u2019s blood, not urine.\nA typical blood test like Pink or Blue, for example, costs $25 for the kit.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Yes, the story explains there are a variety of tests that have been widely available to consumers. But the story could have done a better job of connecting the dots for readers. Exactly how does one get a blood test done for a home test kit? Raises questions like: do I go to a lab? Finger stick? Are their costs other than the test? Shipping? Do I do this at home myself? Working with my medical care team? How soon do I get the results?, etc. Process of using several common kits could have been better described.", "answer": 1}, {"article": "Median length of stay was 6 days (range, 4-58) with a median follow-up of 25 months.\n\"This new analysis of IRE could help change the standard of care for Stage III pancreatic cancer patients whose only treatment options until now were chemotherapy or a combination of chemo-radiation therapy, which will only stabilize the disease and not destroy the tumor.\n\"The STAR data adds to the growing body of evidence that IRE ablation may represent a new treatment paradigm for patients with locally advanced pancreatic cancer,\" said Robert Martin, M.D., Ph.D., F.A.C.S., director of the Division of Surgical Oncology, and Professor, Department of Surgery, University of Louisville, James Graham Brown Cancer Center.\nThe NanoKnife\u00ae IRE system is approved by the U.S. Food and Drug Administration for the surgical ablation of soft tissue.\nIRE was successfully administered to all patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told the NanoKnife\u00a0system \u201cis approved by the U.S. Food and Drug Administration for the surgical ablation of soft tissue\u201d and that it \u201cis not approved for use in specific cancers.\u201d So does that mean a pancreatic cancer patient could ask for this treatment? It\u2019s unclear. It\u2019s also unclear if insurance will pay for it.", "answer": 0}, {"article": "Hill called the new research \"a call to action\" and added, \"we should be studying these policies.\nAll of these states include chronic pain -- either directly or indirectly -- in the list of approved medical conditions for marijuana use, according to Bradford.\n\"There is a great deal of movement in the Northeast, with New Hampshire and New Jersey being well-positioned to legalize adult use,\" Moore said.\nThe details of the medical cannabis laws were found to have a significant impact on opioid prescription patterns, the researchers found.\n\"I don't think that's the only reason, but certainly, it was too easy at many points to get prescriptions for opioids.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article included information about the number of states that have legalized certain types of marijuana use.", "answer": 1}, {"article": "In those procedures, doctors either extract a small amount of the fluid that surrounds the fetus (amniocentesis) or they take a sample of the placenta (chorionic villus sampling).\nWhile it\u2019s available over the Internet, she said her team had only looked at hospital-based test performance.\n\u201cBut it should only be used by families that are at risk for sex-linked diseases.\u201d\n\nBianchi said she owns stock in Verinata Health, a company that is developing cell-free fetal DNA tests for Down syndrome, although that company had no role in the new study.\n\u201cIf parents are using it to determine gender and then terminate the pregnancy based on that, that could be a problem,\u201d she told Reuters Health.\nThe American College of Medical Genetics did not respond to requests for comment on the DNA tests.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The test to determine fetal gender is available in the United States, as an unregulated procedure outside a doctor\u2019s purview. The Reuters story does not mention this. The competing NY Times story was explicit on this.", "answer": 0}, {"article": "But in this case, if anything, we're taking money out of our own pockets.\"\nThe American Cancer Society, which has led the opposition to the mammography guidelines issued by the U.S. Preventive Services Task Force, was involved in the discussions leading up to the Pap test guidelines and will consider them in reevaluating its own recommendations, an official said.\nThe National Cervical Cancer Coalition, a patient advocacy group, endorsed the recommendations.\nThe change comes amid sharp controversy over new recommendations from a federal task force that women wait until age 50 before they begin having routine mammograms and that women age 50 to 74 scale back to getting the exams routinely every two years.\n\"We are persuaded that the guidelines are really consistent with the evidence,\" said Robert Smith, the society's director of cancer screening.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of Pap testing is assumed. ", "answer": 2}, {"article": "For more on chemotherapy, visit the American Cancer Society.\nSpecifically, nearly 70 percent of those in the fish oil group either kept their pre-chemo muscle mass or gained muscle.\nThe authors concluded that fish oil supplementation appears to be a safe and effective way to prevent malnutrition among cancer patients, and may ultimately prove to be of benefit for other groups of people, such as elderly patients who also face a significant ongoing risk for muscle loss.\nTo explore the therapeutic potential of fish oil supplements, the authors offered 16 cancer patients undergoing an initial 10-week chemotherapy regimen a daily dose of 2.2 grams of a particular omega-3 fatty acid called eicosapentaenoic (EPA).\n\"And other similar studies have looked at omega-3 and muscle preservation and have also suggested that fish oil can act to prevent inflammation caused by both disease and hardcore medications, like chemotherapy agents.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There isn\u2019t any question about the availability of fish oil supplements.\u00a0 More importantly, the independent perspective from dietitian Lona Sandon pointed out that the amount of concentrated fish oil supplement used in the study was much more than any recommended dietary allowane.", "answer": 1}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nCancer Causes Control.\nshould contact the CWC offices at (916) 922-5888.\nCWC is an equal opportunity employer and provider.\n#250, Folsom, CA 95630\n\n1.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We accept that walnuts are widely available.", "answer": 1}, {"article": "Meningitis is a condition \u2014 inflammation of the membranes that surround the brain and the spinal cord \u2014 that can be triggered by some viruses and several types of bacteria.\nBut the same component is one of several in the Bexsero vaccine, which was used in Quebec when the government decided to vaccinate against meningococcal B disease in a part of the province with a high relative rate of cases a few years ago.\nResearchers in Quebec say they saw the same phenomenon after a meningitis outbreak there, and previously published data from Cuba and Norway also hint of the vaccine\u2019s unexpected benefit.\nThat may explain why the B vaccine appears to offer some protection against Neisseria gonorrhea.\n\u201cMathematical modeling has shown that even a vaccine of moderate efficacy and duration could have a substantial effect on the transmission and prevalence of gonorrhea, if coverage in the population is high and protection lasts during the highest risk period,\u201d Kate Seib, of Australia\u2019s Institute for Glycomics, wrote in a commentary that accompanied the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the single-component vaccine used in New Zealand is no longer made but that the component is part of GSK\u2019s Bexsero vaccine, which is on the market. The story also distinguishes the B vaccine from others on the market: \u201cMeningococcal vaccines that protect against the other strains do not seem to have the same effect (on gonorrhea).\u201d", "answer": 1}, {"article": "Only children with moderate cough and severe stuffy nose were eligible, and those were divided into three groups.\nThere were no side effects in the two other groups.\nAlthough Vicks VapoRub is often used to fight colds and congestion, there has never been proof of how well it works.\nVicks VapoRub is not recommend for children under the age of 2.\nThe current study shows that Vaporub is more effective than placebo.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe availability of VapoRub is well known.", "answer": 1}, {"article": "Sunlight's ultraviolet (UV) rays can damage the DNA in skin cells, increasing the risk for skin cancer.\nOne patient who could benefit from the vitamin treatment is Charity Wiese, who has been diagnosed with skin cancer more than two dozen times in the last five years.\nThey found patients who took vitamin B3 twice a day cut their chances of developing new skin cancers by 23 percent.\nResearchers say vitamin B3 gives skin cells an energy boost -- \"turns back on the immune system,\" in Agus's words -- helping them repair the damage.\nResearchers found that a form of vitamin B3 called nicotinamide could help reduce the chance of skin cancer recurring in patients who've had it before.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article\u2019s first paragraph establishes that nictotinamide is an \u201cover-the-counter vitamin supplement\u201d and thus readily available \u2014 at least in theory. The study\u2019s lead author also adds: \u201cIt\u2019s safe, it\u2019s almost obscenely inexpensive, and it\u2019s already widely commercially available.\u201d\nWe\u2019ll award a Satisfactory, but we\u2019d note that the competing AP story dug deeper, cautioning that \u201cA check of one major drugstore chain found only other forms of B3, such as niacin, or combination B vitamins.\u201d", "answer": 1}, {"article": "\"Emergency departments are going to have to think twice about a test like that,\" says Michael Shannon, senior physician in emergency medicine at Children's Hospital Boston.\nThe test is expected to be used mainly in hospitals and emergency rooms, but doctors can send the swab to a local lab.\nA new cold and flu test can precisely diagnose a dozen winter ailments and reduce unneeded use of antibiotics, says the company that sells it.\nPhysicians say the test is accurate and the most comprehensive available, but some say its long processing time limits usefulness in emergency rooms.\nAccording to data submitted to the FDA, the test detects each virus 78% to 100% of the time, depending on the type, and has few false positives.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story provides good information about availability.\u00a0 The Xtag test is mainly used in hospitals and emergency rooms but can also be done in the primary care setting.\u00a0 Other important information on variability of the length of time needed to process the test, from hours to 1-2 days, was also provided. ", "answer": 1}, {"article": "\"Women should recognize that CAD comes with some potential risks,\" Fenton said.\nDr. Daniel Kopans, a professor of radiology at Harvard Medical School and senior radiologist in the breast imaging division at Massachusetts General Hospital, said the study provides additional information to doctors and women, but has some limitations.\nNow, with about 75 percent of mammograms adding it, it is even more common, Fenton said.\nCAD is becoming more widespread, said Dr. Joshua Fenton, an associate professor of family and community medicine at the University of California, Davis, and lead study author.\nAlthough it has rapidly become part of mammogram screening, Fenton said there is limited and conflicting research on its effect.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Early in the article, the study author is quoted observing that \u201cIt\u2019s an add-on and now is used in probably three-quarters of U.S. mammograms.\u201d\nWomen would have to ask if CAD is being used to read their mammograms.", "answer": 1}, {"article": "But she added, \u201cThe community hopes that if telaprevir is approved by the F.D.A.\nBut experts hope that eventually several of the pills now in development could be used together, much as AIDS is treated, doing away with the need for interferon.\nThat shorter time line, plus a higher chance of success, could entice more people to be treated, experts say.\nMost of the other new drugs also work by blocking viral enzymes.\nIf approved, telaprevir would have to be used initially with the existing drugs to prevent the virus from evolving resistance.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The second word in the story is \"experimental.\" It talks about the drug being in three different Phase 3 clinical trials and about the company looking forward to applying for approval from the FDA. What it does not do is make it clear how quickly the drug could be brought to market (or slowly) especially given the problems of side effects also noted in the story.", "answer": 1}, {"article": "With relaxation of the muscles, the distance between the vertebrae returns,\" Dr. Napoli explained.\nNinety percent of the patients were able to avoid surgical treatment.\nOf the 80 patients treated, 81 percent were pain free one year after a single 10-minute treatment session.\nDr. Napoli said no patients experienced side effects after receiving the minimally invasive outpatient treatment.\n\"Evolving technologies like this image-guided treatment may help a substantial number of patients avoid surgery.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does a nice job of explaining the procedure and, we feel, gives readers enough detail to understand how it would work. But it does not make it clear how widely this procedure is available and the type of technical skill necessary to administer it.", "answer": 0}, {"article": "Another approach to assessing the meaning of a PSA reading is to analyze how much antigen is traveling free in the blood and how much is bound to a companion protein, Dr. Scardino suggested.\n\u201cWe don\u2019t want to miss the possibility of a life-threatening disease, but we end up diagnosing and treating disease that would never have caused harm.\u201d\n\nThe new guidelines will lower the PSA level at which a biopsy should be considered, because, as Dr. Carter put it, \u201cthere\u2019s no level below which we can tell a man he doesn\u2019t have prostate cancer or life-threatening prostate cancer.\u201d\n\nAs one important trial showed, among men with a very low PSA \u2014 that is, a reading below the current cutoff of 4 \u2014 biopsies found that 15 percent had prostate cancer.\nFor them, if other factors like prostate infection are not the cause of the high level, a biopsy is in order.\nCurrent guidelines recommend that all men have an annual PSA test starting at age 50 and that biopsies be conducted if the level exceeds 4 or if a \u201csignificant rise\u201d occurs between two tests.\nThis rate, known as PSA velocity, will be part of the new guidelines, which will suggest that in men with low readings, doctors consider the changes in levels over the course of three measurements.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that most men over 40 know that the PSA test is widely used for prostate cancer screening.\u00a0 ", "answer": 1}, {"article": "Dry eye syndrome is a multifactorial disease of the tear film and ocular surface that produces symptoms of ocular discomfort, eyesight disorders, and tear film instability with potential damage to the ocular surface.\nIn this context, the phase III \"Helix\" study is being carried out in more than 30 hospitals in Spain, Germany, Estonia, Portugal, Slovakia and Italy, in 300 patients to evaluate the efficacy of this compound in the treatment of the sign and symptoms of dry eye syndrome.\nSylentis, Pharmaceutical Company belonging to the PharmaMar Group, has presented results from the clinical studies carried out with tivanisiran for the treatment of dry eye syndrome and that has enabled the start-up of the Phase III \"Helix\" clinical trial.\nIt must be empathized that this pathology affects more than 5 million in Spain, between 10% and 20% of the population, mostly women, and almost 100% of these being elderly , .\nWe currently have a robust therapeutic program in ophthalmology with two candidates under development in Phase II and III studies for glaucoma (bamosiran) and ocular pain (SYL1001) , respectively.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "A scientist working for the drugmaker says she hopes \u201cthat tivanisiran will soon become a real alternative.\u201d Savvy readers will note that the drug is still in development and that the drug is not yet ready for patient use outside of a research setting.", "answer": 1}, {"article": "Researchers at Brigham and Women's Hospital and Harvard Medical School set out to test melatonin's effects...\nWhat was lacking was clear evidence that taking melatonin in supplement form had the same sleep-inducing effect.\nThat's why there's so much interest in a study in the current issue of the journal Sleep.\nThere's no question that the hormone helps the brain tell a.m. from p.m.--regulating sleep cycles and circadian timing--when it is produced naturally by the body at night.\nBut the scientific evidence has been slim.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article did not mention that melatonin is sold as a dietary supplement and as such, the FDA neither approves the claims made nor monitors the content of the product.", "answer": 0}, {"article": "Fader no longer holds that role.\nShe notes that using trastuzumab to selectively treat uterine serous carcinoma that express HER2/neu is part of a broader trend at Johns Hopkins and other cancer centers to use the tools of tailored therapy, or precision medicine, based on the molecular and genetic makeup of tumors and patients.\nAdding the monoclonal antibody drug trastuzumab--already used to treat certain breast cancers--to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small phase II trial of the regimen, testing its safety and value.\n\"The fact that these tumors grow rapidly, but also have a propensity to spread to lymph nodes and other organs very early, is a double whammy for women,\" says Amanda Fader, M.D., associate professor of gynecology and obstetrics at the Johns Hopkins University School of Medicine, and first author of the new study.\nThe researchers say this may lead to new national guidelines for treating this cancer subtype, known as uterine serous carcinoma.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that researchers have submitted their findings to the National Comprehensive Cancer Network, \u201cwhich guides the design of standard treatment plans around the country.\u201d However, it\u2019s not clear when or whether USC patients may have access to trastuzumab \u2014 either through FDA approval or via off-label prescriptions by health care providers. More importantly, though, the release could be a bit more clear on the percentage of patients with uterine cancers who may benefit from trastuzumab. There are bits and pieces of information scattered throughout the release, but it would be good to pull them together and add up what it all means. Here\u2019s what we\u2019re talking about (bear with us): according to the American Cancer Society, there are expected to be about 63,230 new cases of uterine cancer diagnosed in the U.S. in 2018; about 92 percent of those uterine cancers are likely to be endometrial, bringing the number to around 58,171; approximately 10 percent of those endometrial cancers will be USC, bringing the number to 5,817; and about 30 percent of those patients with USC test positive for HER2/neu receptor proteins that trastuzumab blocks. In other words, of the 5,817 women who may be diagnosed with USC in 2018, only 1,745 of them may be able to benefit from trastuzumab. That\u2019s an important idea to get across clearly.", "answer": 0}, {"article": "Grocers shelves add new coconut-water products regularly.\nIt\u2019s the whole coconut that needs to be talked about.\u201d\n\nEntrepreneurs are talking about the whole coconut these days.\nIn the past couple of years a couple of brands have figured out the right angle \u2014 electrolytes and hydration.\u201d\n\nCraven estimated the coconut-water market at about $100 million annually right now, but companies are doubling their sales year after year.\nEven so, Little, a coconut enthusiast, doesn\u2019t recommend loading up on coconut fats.\nAnd in contrast to another natural substance that gets transformed into a wide variety of products \u2014 petroleum \u2014 coconuts are viewed as healthy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The sheer volume of people within the retail food industry who seem excited about this trend makes us believe that\u00a0a lot of stores are following this fad, which means coconut products are widely available.", "answer": 1}, {"article": "Ecstasy use can cause depression, severe anxiety, and potential cognitive problems, according to the National Institute on Drug Abuse.\n(All of the participants received additional therapy sessions that did not involve the drug.)\nOn two separate occasions, 12 of the people took a dose of MDMA and then spoke for several hours with a pair of trained therapists.\nThe resulting sense of euphoria and emotional warmth seems to help patients connect with their therapists, says Michael Mithoefer, M.D., the lead author of the study and a Mount Pleasant, South Carolina-based psychiatrist who specializes in PTSD.\nThe use of MDMA in psychotherapy has been studied for decades, but research in the U.S. all but ground to a halt after the drug became illegal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The first sentence states that \"The drug MDMA\u2014better known by its street name, Ecstasy\u2014may be illegal, but a new study suggests that it\u2019s also a promising treatment for post-traumatic stress disorder.\" The story underscores the point several times that the drug is illegal and currently unavailable for therapeutic use.", "answer": 1}, {"article": "The sweating can occur even when the temperature is cool and the person is at rest.\nThe study was small and the findings are preliminary.\nAll had hyperhidrosis, a condition where a person sweats much more than the body needs to cool itself.\nHe presented the findings here at the annual meeting of the American Academy of Dermatology.\nIt works, he says, by heating and destroying the sweat glands under the arm.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never does state the availability of the technology for people with hyperhidrosis.\u00a0 It does state that the FDA has approved it for eyelid lifts.\u00a0 Are many dermatologists (or others) trying it for hyperhidrosis?\nA simple few additional words would have clarified the issue.", "answer": 0}, {"article": "Pulse pressure is the difference between systolic and diastolic (bottom number) in blood pressure readings.\nMango consumption helped relax blood vessels in as little as two hours after intake.\nLonger-term studies involving other population groups are warranted.\nThe research was supported in part by funds from the National Mango Board and USDA.\nThe researchers conclude that mangos may be a heart-healthy fruit that may help play a role in reducing the risk of cardiovascular disease.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t mention this, but presumably people know that mangoes are already available to the public. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "HPV causes cervical cancer, which remains a significant health problem, particularly in less resource-rich areas of the world.\nIt could be done less frequently than the Pap test, which could be used only in women who have tested positive for HPV, they said.\nThe HPV test should become the screening tool of choice for women 35 and older, the researchers said.\nThat decline has been largely attributed to widespread use of the Pap test.\nThe previous recommendation was to start Pap tests three years after becoming sexually active or at age 21, whichever came first.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly the HPV DNA test and pap tests are both available in the US.", "answer": 1}, {"article": "When skin is exposed to sun, it makes vitamin D.\n\nStill, the doctor wanted to run a blood test to see if Rebecca Rosen had adequate vitamin D.\n\n\"So my wife said, 'Well, why do I need to have a vitamin D [test]?'\nBut the group is not expected to embrace the newer claims being made for vitamin D supplementation.\n\"It was believed that megadoses of vitamin E, beta-carotene, selenium, folic acid and the B vitamins would confer a large array of health benefits.\nThe evidence is strongest for colorectal cancer, she says.\nThose who are sick may have low levels because they don't have those healthy habits.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story did mention various means to increase one\u2019s level of vitamin D including supplements, fortified foods, and exposure to sunlight. \u00a0It would have been useful to mention that vitamin D is commonly found in multivitamins, and many calcium supplements contain vitamin D as well. ", "answer": 1}, {"article": "46 babies had a brother or sister with known autism, which means they themselves are at an increased risk for the neurodevelopmental disorder that affects about one in 110 children according to the Centers for Disease Control and Prevention.\nWiznitzer \u2013 a pediatric neurologist at Rainbow Babies & Children's Hospital in Cleveland, Ohio \u2013 notes that what the study can't tell us is what the differences in brain activity between the two groups of babies actually mean.\nDoctors and scientists not connected to the study are intrigued by the results but caution that this is very early research and not something concerned parents can be looking for as a screening tool for their babies any time soon.\nHe, too, is hopeful that further research will provide more concrete information.\nHe said that, judging by the differences in brain activity, he and his colleagues could detect which babies were in the high-risk group.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that this was an experimental diagnostic tool and not ready for the pediatrician\u2019s office.", "answer": 1}, {"article": "Most thyroid cancers can be treated successfully, but advanced cases can be difficult to treat, especially if they do not respond to radioactive iodine (RAI) therapy.\nIn blocking this activity, these new immunotherapy drugs help T cells get back to work in protecting the body.\nQ: What did you find?A: At the time we reported our results, six of the 22 patients remained on treatment.\nAs well, at least when used as single agents, these agents tend to confer side effects that patients find much more tolerable than those associated with chemotherapy.\nThe work is being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting which begins tomorrow in Chicago.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that\u00a0pembrolizumab is under study in an early clinical trial. It does not, however, point out that the drug is in fact commercially available under the trade name Keytruda, a drug we have heard a great deal about in the past few months related to its use in melanoma.", "answer": 0}, {"article": "\"It's an important step along the way,\" Dr. Hadley said.\nPart of the reason for the study, Dr. Ravussin said, was to find out whether people could stand calorie restriction.\nThe participants, who were paid, turned out to be highly motivated, he said.\nThe final group went on an extreme diet of 890 calories a day \u2014 less than half of what most adults need \u2014 for two or three months, until members lost about 15 percent of their body weight.\nAmong the main findings of Dr. Ravussin's study was that calorie restriction led to decreases in insulin levels and body temperature.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions \u2018people experimenting on themselves\u2019, indicating the potential for anyone to self-impose calorie limitations on themselves. However, the article failed to explain that all the food consumed by the research subjects in the study was provided for them thus ensuring nutritional adequacy while restricting calories. That\u2019s beyond the reach of the average American. People were paid $7,000 to be in the study!", "answer": 0}, {"article": "\"As soon as you stop the chemo, you feel stripped, and you think, 'Wow, what do I do now?'\nThen, he discovered in one of his own brain scanner experiments that he -- had brain cancer.\n\"\n\nServan-Schreiber did what he knew best -- he hit the books, and was surprised to find studies on how nutrition and exercise might help the body fight cancer -- information doctors never told him.\nHe says vegetables and fruits such as brussel sprouts, asparagus and raspberries can target specific cancers, at least in test tubes.\nIn addition, LaPook spoke with several other cancer patients who told him they're left in the dark, too, about how exercise and eating the right foods might help them in their battles against the disease:\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly fruits and vegetables, spices and green tea, and physical activity \u2013 mentioned in the story \u2013 are all widely available.", "answer": 1}, {"article": "With the FDA's announcement, drugs like pembrolizumab have also begun to change the way that physicians, patients and government regulators think of cancer. No longer will they see all cancers of the lung, breast, colon, brain, liver, pancreas and prostate as distinct from one another. Instead, they will look for the common genetic mutations that give rise to cancers no matter where they're found. And they'll treat those cancers with a drug that uses that common signature as a homing beacon, either for the immune system or for targeted cancer drugs to attack.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that pembrolizumab is currently being sold under the brand name Keytruda.", "answer": 1}, {"article": "Behavioral counseling is widely recommended, with medication, to help smokers quit.\n\"Long term, our study would not say it would prevent relapse.\"\nThe results of the new study are published online in Tobacco Control.\nThe findings are at odds with clinical trials, Connolly says.\nBetter strategies are needed to prevent relapse, he tells WebMD.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We like that this story was very specific on what types of nicotine products were studied. \u201cThe participants told whether they had used a patch, gum, inhaler, or spray. They told how long they used the product continuously.\u201d", "answer": 1}, {"article": "In Israel, the treatment costs $6,000.\nThe device, which combines electromagnetic stimulation with computer-based cognitive training, is already approved for use in Europe, Israel and several Asian countries such as Singapore.\n\u201cWe see improvement lasting for 9-12 months and the good thing is that patients can return and undergo treatment again,\u201d Baror said.\n\u201cYou stimulate the brain on a biological level as well as on a cognitive level,\u201d Neuronix CEO Eyal Baror told Reuters, saying this double approach created longer-lasting benefits.\nNeuronix received European approval several months ago and has installations in the UK and Germany.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Mixed bag here.\nThe story explained that the the device is approved for use in several other countries.\u00a0 But it also said the company \u201cexpects the system to be approved by the U.S. Food & Drug Administration in late 2014.\u201d\nNo basis for that projection was given.\u00a0 Later the story stated that \u201cUS trials are expected to run till the end of 2013.\u201d\nSo the entire projection of approval and availability is based on a hope and a prayer and a crystal ball of unknown clarity and certainty.", "answer": 0}, {"article": "HONG KONG (Reuters) - Boosting the effect of acupuncture needles with small electric currents may be effective in treating depression, a study in Hong Kong has found.\nThey were later assessed by experts for their depression levels and the group that received genuine electroacupuncture was found to be a lot happier.\n\u201cThe drop (in depression scores) among the group receiving active treatment was more significant than the placebo group,\u201d said Roger Ng, another researcher in the group, which published their findings in the journal PLoS (Public Library of Science) ONE.\nHalf the patients received electroacupuncture nine times over three weeks, while the other half - the placebo group - only had needles inserted superficially into their heads.\n\u201cWhen the acupoints are stimulated, some brain centres responsible for producing serotonin are stimulated,\u201d explained Ng, a consultant at the department of psychiatry at the Kowloon Hospital in Hong Kong.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There was no explanation of the availability of electroacupuncture. This is certainly an important issue in the USA, which is where we \u2013 and presumably many other readers \u2013 found the story online.", "answer": 0}, {"article": "Wasting syndrome is characterized by a loss of weight and muscle atrophy, and largely found in patients who suffer from cancer, kidney disease, chronic obstructive pulmonary disease, and heart failure.\nThe discovery was a \u201cserendipitous finding\u201d in the lab of Rajan Sah, M.D., Ph.D., assistant professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa.\n\u201cWe tested these compounds in sedentary mice and found a dramatic improvement in exercise endurance and a mild increase in muscle size of certain muscle groups,\u201d Sah says.\nThe intellectual property associated with this discovery was recently licensed by the UI Research Foundation to Innovus Pharma, an over-the-counter consumer goods and specialty pharmaceutical company that commercializes non-prescription medicine and consumer care products.\n\u201cThe treatment of cachexia just doesn\u2019t exist.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll give the release a Satisfactory in this category since it states that a company has been licensed to develop a drug based on this research, and therefore readers know that it isn\u2019t available yet.", "answer": 1}, {"article": "The stool was more solid, the diarrhea goes away, and the bloating is much less.\"\nThe study looked only at those IBS patients with the non-constipation form, he tells WebMD.\nWith the drug treatment, Pimentel says, those with the IBS ''can enjoy social outings without the worry of having to run to the bathroom and having diarrhea.\"\n''The major finding was that all IBS symptoms improved,\" says Mark Pimentel, MD, director of the GI Motility Program at Cedars-Sinai Medical Center, Los Angeles, who led the clinical trial of the drug at Cedars.\nThat can translate to big changes in the lives of those with IBS, estimated to affect about 15% of adult Americans.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that\u00a0rifaximin\u00a0\u201cis approved by the FDA only for traveler\u2019s diarrhea and hepatic encephalopathy, a brain disorder caused by chronic liver failure.\u201d And it interviews a physician who\u2019s been using it off-label for the non-constipation form of IBS. But the story does not make clear how widely used it is.", "answer": 1}, {"article": "This measure of metabolic health is called \u201cinsulin sensitivity,\u201d and it is one of many metabolic functions that goes awry in people with obesity. In those who develop type 2 diabetes, sensitivity to insulin becomes so impaired that the body is tricked into believing less insulin is needed, and it pares back its production. The insulin-producing cells in the pancreas will often atrophy and die in response. As a person\u2019s insulin production declines, an external supply of insulin is needed to control blood sugar and deliver fuel to muscles and organs.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that deep brain stimulation is a current therapy, though not yet for diabetes.", "answer": 1}, {"article": "\"Like many things, the evidence changes over time,\" says Hensrud.\nBut he says that newer studies suggest that drinking coffee may actually be good for you.\nHowever, coffee alone may not be the answer according to some experts.\nCoffee did not decrease the risk of a third type of oral cancer \u2013 laryngeal cancer.\nBut he is concerned that the side effects of coffee are not addressed in this study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable \u2013 the availability of coffee is not in question. ", "answer": 2}, {"article": "Between 12% and 20% of women in the 35 countries in the Organisation for Economic Co-operation and Development suffer from perinatal depression, and 20-35% in poorer countries.\nThe study found that women who had least social support such as those who were not living with or near their mother or mother-in-law, benefited most from the therapy intervention, both in the short and long term.\n\u201cThis is an important study for the impact on mothers with depression but there are global implications for the treatment of all human beings suffering from depression.\nCognitive behavioural therapy has significant positive effects on a mother\u2019s mental health, income, employment and parenting skills even seven years after the birth of the child, according to the first study of its kind.\nWhile studies have highlighted the short-term benefits of CBT, until now question marks have been raised about whether it can have long-term effects.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t address availability.\nAs explained in the original clinical trial, the researchers used an existing system of Lady Health Workers who are specially trained to do the intervention, making the treatment available in an area where it normally wouldn\u2019t be.\nBut even in nations with more resources, spotty insurance coverage and lack of providers limit access to this type of care. The story should have at least touched up on the availability issue. This is an area an independent source likely could have given some context on.\n\u00a0", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070805/13folate.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned the folate fortification of the North American food supply; it also noted that folic acid is found in multivitamins.\u00a0 The story is mainly about recent analysis about possible consequences of folate supplementation of the food supply.\n\u00a0", "answer": 1}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that this is an existing drug for osteoporosis that has not been approved by the FDA for use in breast cancer prevention. The story does not make claims about when it may be approved for that purpose.", "answer": 1}, {"article": "In another, ulipristal acetate was found to be as effective as monthly injections of the drug Lupron for reducing heavy bleeding in women with uterine fibroids.\nIf trials now under way in the U.S. prove positive, New Jersey-based Watson Pharmaceuticals Inc. and Swiss-based PregLem hope to market ulipristal acetate as a fibroid treatment under the trade name Esmya, says Watson spokesman Charlie Mayr.\nBoth studies appear in the Feb. 2 issue of The New England Journal of Medicine.\nUlipristal acetate is the active chemical in the emergency contraceptive sold in the U.S. as Ella, but the daily doses taken by the fibroid patients in the studies were much smaller than those in the contraceptive.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is a variation of a drug already on the market but that it is not yet approved for use.", "answer": 1}, {"article": "As the ovaries curb production of the hormones estrogen and progesterone in the years leading up to menopause and afterward, women can experience symptoms ranging from irregular periods and vaginal dryness to mood swings and insomnia.\nFor women who started hormones in their 60s or 70s, however, there wasn\u2019t a meaningful difference in death rates according to whether they got the treatment or a placebo during the initial years of the study.\nWith additional years of follow-up, it also appears that the increased heart attack risk associated with HRT in the initial results from the WHI trials is limited to older women, McNeil added.\nTaking a combination of estrogen and progestin is associated with an increased risk of breast cancer, but advances in screening and treatment since the WHI started now mean these tumors are unlikely to be fatal, McNeil said by email.\n\u201cWomen seeking treatment for distressing hot flashes, night sweats or other menopausal symptoms may find the mortality results reassuring,\u201d said lead study author Dr. JoAnn Manson of Brigham and Women\u2019s Hospital and Harvard Medical School in Boston.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "These therapies are widely available and that\u2019s implied in the story.", "answer": 1}, {"article": "Stay out of the sun, or utilize a proper sunscreen.\nCircumcision, of course, removes this protective environment.\nA few potential caveats to note include the reliance on self-reporting when it comes to a man's history of STIs, as well as his sexual partners.\nIt's important to note, right off the bat, that this study is not purporting to establish a cause and effect relationship.\nThe bottom line from the American Cancer Society: While this is an interesting finding, it's not likely to spur any change in recommendations or medical practice.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of circumcisions is not in question.", "answer": 2}, {"article": "This may predate the onset of other symptoms.\n\u201cThe aim of the study is very simple: can we detect changes in brain function before people are aware that they have them?\u201d\n\nResearchers recently pinpointed the significance of a tiny area of the brain known as the entorhinal cortex, which acts as a hub in a widespread brain network that controls navigation.\nThis now appears to be the first part of the brain that succumbs to Alzheimer\u2019s.\nThose who do worse in the tests will be the ones most likely to succumb to Alzheimer\u2019s later in life, scientists now believe.\nNot all will be destined to be affected by the disease, however.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "On the one hand, the story does tell readers that there will be a forthcoming study to evaluate whether VR technology can be used to test people\u2019s navigation ability in order to determine whether it is an effective technique for diagnosing Alzheimer\u2019s. (In other words, they don\u2019t even know if this is something that will work yet.)\nOn the other hand, earlier in the story, readers run across sentences like: \u201cVirtual reality to help detect early risk of Alzheimer\u2019s\u201d and \u201cThose who do worse in the tests will be the ones most likely to succumb to Alzheimer\u2019s later in life, scientists now believe.\u201d That makes it sound like this is already a useful tool, and availability could be right around the corner. Ultimately, the story never explicitly tells readers that any possible VR tool is years away, at best. That tips the scales for us, and we lean in the direction of \u201cnot satisfactory\u201d on this criterion. One wonders how many people read this story and contacted their general practitioner about taking a VR test to assess their Alzheimer\u2019s risk.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article discusses several consortia or organizations of hospitals that participate in paired matching of organs. Based on the limited number of participating hospitals in selected regions, it seems clear this is not widely available at present. Plus, the article mentions that legislation is needed before a federally funded organ donation organization (UNOS) could get involved, potentially making this much more widely available. ", "answer": 1}, {"article": "Aneurysms are weakening, or bulging, of blood vessels that can rupture and become life-threatening.\n\u201cPrior to gaining approval from the Food and Drug Administration, patients with many types of aneurysms and aortic conditions had limited treatment options,\u201d said Azizzadeh, director of Vascular Surgery at the Smidt Heart Institute at Cedars-Sinai.\n\u201cI feel very lucky to have benefited from this new and improved surgical technique and for the great doctors who cared for me.\nAfter my recovery, I know I will feel stronger and healthier, and will remain forever grateful.\u201d\n\nSince Angelino\u2019s surgery, Azizzadeh who, in conjunction with medical device company Medtronic, served as the national principal investigator in clinical tests of the device \u2013 has performed several additional, successful surgeries.\n\u201cThis was a difficult surgery, but I knew I was in good hands,\u201d said Angelino, 85, of Culver City.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We are given no indication whether the procedure is in use in other hospitals outside the clinicians who were involved in the clinical trial.", "answer": 0}, {"article": "While skeptics may question the idea of using psychedelics as treatment for psychological distress, Hendricks emphasizes that he does not advocate for rampant recreational use of psychedelics, or widespread legalization.\nThe study, published recently in the Journal of Pharmacology, analyzed data from an annual survey conducted by the National Survey on Drug Use and Health that measures substance abuse in relation to mental illness.\nA lack of resources and funding is a hindrance to continuing studies, however, as psychedelics are still classified as schedule 1 narcotics in the U.S. and criminal offenses accompany their possession.\nIn recent years, some scientists, such as this study\u2019s lead researcher, Peter S. Hendricks, have been pioneering innovative treatments to help decrease the suicide rate.\nHe believes the data support the idea of demoting psychedelics to schedule 3 or 4, and that they can be used in controlled therapy situations.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study noted that the drugs are not available legally in the United States.", "answer": 1}, {"article": "\u201cUsing these multiple, possible endpoints was something unique to this study,\u201d Jaffe said.\nJaffe said the study focused on time to treatment failure because delaying or preventing inflammation is the key to successful treatment.\nJaffe said the study\u2019s results are significant not only because they indicate adalimumab delays treatment failure, but also because the investigation considered several signs as causes for treatment failure.\n\u201cPatients may have many unwanted side effects when taking steroids long-term, as many uveitis patients do,\u201d Jaffe said.\n\u201cThe goal of these studies was to determine whether there was an alternative that could replace or minimize the use of steroids.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The level of detail is good here, noting that the FDA recently approved adalimumab for noninfectious uveitis, how it was previously approved for other conditions, and in which types of uveitis it\u2019s generally ok to treat.", "answer": 1}, {"article": "Source: Brightling C, et al.\n\u201cA unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works,\u201d said Brightling in the press release.\nThe pill may be a \u201cgame changer for future treatment of asthma,\u201d said Professor Chris Brightling, a National Institute for Health Research (NIHR) Senior Research Fellow at the University of Leicester, in a press release.\nBy measuring the sputum eosinophil \u2014 the inflammation marker that shows how white blood cells increase during asthma attacks \u2014 the researchers were able to track the effects of the drug.\n\u201cMost treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all the types of tests.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The headline makes it sound as if the pill is readily available, with no mention that further trials and approvals are necessary before the drug could be marketed.", "answer": 0}, {"article": "An estimated 5.4 million Americans have Alzheimer's disease, the most common form of dementia, according to the Alzheimer's Association.\nHis test is one of numerous such tests under study, says Heather Snyder, PhD, a spokesperson for the Alzheimer's Association, who reviewed the research results.\nThe research results on the new test are published online in PLoS ONE.\nHe is also founder of Durin Technologies Inc., the company that is developing the test.\nNone are highly accurate, and some are costly and not practical to use on a widespread basis, experts say.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\nDeep in the story, it explains that \u201cif all goes well\u201d the developer is hopeful the test could be available within a year. That is followed by an Alzheimer\u2019s Association spokesman saying this is \u201cpreliminary.\u201d\u00a0 So the developer\u2019s optimism is tempered somewhat.\n", "answer": 1}, {"article": "Ten years ago, scientists started looking at the hormones made in the pituitary gland to see how they act on certain targets.\nTheir next step is to \u201chumanize\u201d the antibody, so it can be tested without triggering an immune response.\nBut it could also be a unique drug because it lowers body fat and makes bones stronger.\nThey found some of these hormones had an effect on bone mass.\nBut how do mice models translate to human treatments?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly notes all of the steps that need to be taken before the antibody could even begin human trials, in three to four years at the earliest.", "answer": 1}, {"article": "\"Parents often say that their biggest concern is, 'When is my child going to be back to normal again?'\nA reliable lab test would help ensure that children who have a head injury don't go back to school, or to the soccer field, before their brain has healed, Bhomia says.\nHicks and a team of researchers have been looking for an objective test that might help.\nBut saliva may not be the best place to measure microRNAs, Bhomia says.\nMost samples were collected about a week after the injury.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the spit test is still being studied. There were no predictions about when or if it would be available.", "answer": 1}, {"article": "Researchers conducted a randomized, double-blind, placebo-controlled study of 40 postmenopausal women ages 45 to 65 with high blood pressure.\nThe lead author, Sarah A. Johnson, a postdoctoral researcher at Florida State University, said she saw no reason for people to radically change their diet, but that if they are not eating blueberries, they might want to try them.\nBut, they say, eating blueberries in larger amounts or for longer periods could increase the effect.\nThe improvement, the scientists write, was moderate compared with that of blood pressure medicines.\nThere were no significant changes in the placebo group.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not discuss or mention the availability of blueberries or blueberry products. Since the investigators were studying a freeze-dried blueberry powder that may be harder to find than typical grocery store blueberries, we would expect the story to look for and comment on the availability of this product.", "answer": 0}, {"article": "\"For example, we know that certain changes in the retina, like thinning tissue [due to cell loss] or weakening electrical activity, occur alongside loss of brain tissue and reduced brain activity in patients with neurological disorders like multiple sclerosis and Parkinson's disease.\nA tiny skin electrode was placed on the skin under the eye to record the retina's electrical activity.\nWe and other researchers are now investigating whether retinal changes are related to brain structure and function changes in schizophrenia.\"\nThe results show the device accurately indicated reduced electrical activity in the retina in multiple cell layers in the participants who had schizophrenia, including in cell types that had not been studied before in this disorder.\n\"Our study should help generate further research into developing a test that clinicians - like psychologists, psychiatrists or nurses - can use in their offices to diagnose, treat and monitor the condition of people with schizophrenia.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release said the device is \u201ccommon in optometrists\u2019 offices.\u201d", "answer": 1}, {"article": "It matters.\nOne expert cautioned that it's too early to say whether the drug will actually prolong patient's lives, or if it might be helpful to patients in earlier stages of the disease.\nIt turns out that the melanoma really cares if we block the gene BRAF.\nThe current standard treatments for metastatic melanoma -- chemotherapy and interleukin-2 (IL2) -- only have response rates in about 15 percent of these patients, said Dr. Paul Chapman, senior author of a study in which the findings are described.\nThat finding opened the door to potential targeted, molecular therapies for melanoma, which has been sorely lacking in effective treatments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story specifies that the new drug is \"experimental\" and in phase 1 clinical research. Readers can conclude from this that the drug is not widely available.\u00a0", "answer": 1}, {"article": "Learn more about intrauterine devices from the Association of Reproductive Healthcare Professionals.\nInsertion of the device may be mildly uncomfortable for some women, she said.\nResults of the study, which was funded by the United Kingdom's National Institute of Health Research, appear in the Jan. 10 issue of the New England Journal of Medicine.\nGetting an intrauterine system generally just requires one office visit, Espey said.\nAnother expert said the findings show promise for women bothered by heavy bleeding.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We are only told that the IUD is \u201csold under the brand name Mirena.\u201d\nWe\u2019ll give the story the benefit of the doubt, although it didn\u2019t discuss anything about how widespread is the use of this IUD.", "answer": 1}, {"article": "In the Swiss research, animals took a drug that dissolved a barrier around the part of the brain where mammals store their fear memories. Afterward, they stopped being afraid of noises that were linked to electric shocks, which meant their bad memories had been erased, according to the Mail. Human brains, explains NYU neuroscience Prof. Joseph LeDoux, could actually \"overwrite\" memories with happier thoughts if the medication is developed for people, according to the Daily Mail.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this \u201cmind-cleansing\u201d drug is not available. ", "answer": 1}, {"article": "The median age was 70, with a range of 50 to 88.\nThe study is titled \u201cQuality of Life in Patients Undergoing Pleurectomy and Decortication for Malignant Pleural Mesothelioma.\u201d The surgeries were performed by Dr. Vigneswaran at University of Chicago Medicine, where he practiced before recently joining Loyola.\nQuality of life was not adversely affected by surgery at any time in patients who, prior to surgery, had performance status of 1 or 2; a tumor volume greater than 600 ml.\nDr. Vigneswaran and colleagues administered a cancer quality-of-life survey known as the EORTC QLQ-C30 to 114 mesothelioma patients who underwent PD surgery.\nWickii Vigneswaran, MD, presented the study during the 2016 annual meeting of the American Society of Clinical Oncology.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We rated this as satisfactory, but just barely. The release notes that surgery in the opening paragraph:\u201dAlthough surgery can prolong the lives of patients with an aggressive type of cancer called malignant pleural mesothelioma, many patients avoid the operation for fear it will degrade their quality of life.\u201d\u00a0 This makes it clear that surgery is a routine option for treatment although not specifically pleurectomy and decortication. We appreciate that the release is intended for a sophisticated audience but think that the wording could have been a bit clearer. ", "answer": 1}, {"article": "Many more stroke victims than previously thought can be saved from disability or death if doctors remove blood clots that are choking off circulation to the brain, a new study has shown.\nThe study showed that the time window could be expanded to 16 hours.\nHowever, the findings do not apply to every stroke victim.\nThe researchers used a special type of brain imaging to identify the patients who still had live brain tissue that could be saved if the blood supply was restored.\nOnly about half the patients who were screened qualified for treatment, known as thrombectomy, which uses a mechanical device to pull clots out of a blood vessel.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While it\u2019s not clear when the new 16-hour guideline will take effect, the article makes it clear that this procedure is currently available.", "answer": 1}, {"article": "The best moment in Rene\u00e9 Ford's life came the day her son Chase, then 2, tried to kick his doctor. It was July 2005, and that angry gesture marked the first time the boy had moved below the neck in more than a month.\n\nThese days when you look at Chase, you don't at first notice any sign of what happened to him that year--not the fall he took while jumping on the couch nor the paralyzing blow to the neck as he hit the wooden armrest. More and more, Chase can do the kinds of things any other 4-year-old can...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that locomotor training is only available in a handful of centers in the U.S.\u00a0and access is limited. The story should not have implied that the treatment has gone \"mainstream\" because it is only available in 17 hospitals in the US.", "answer": 1}, {"article": "The National Institutes of Health, as well as the Michael J.\nCollier is already looking for funding for the next phase of his research and hopes to lead a human clinical trial using the drug in the future.\nIn a proof-of-concept study, published in the journal Neurobiology of Disease, the drug nortriptyline, which has been used to treat depression and nerve pain, stopped the growth of abnormal proteins that can build up in the brain and lead to the development of the disease.\nFox and St. Mary's Foundations, funded the study.\n\"What we've essentially shown is that an already FDA-approved drug that's been studied over 50 years and is relatively well tolerated could be a much simpler approach to treating the disease itself, not just the symptoms,\" Collier said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is about a \u201cproof of concept\u201d and no therapy is available based on this research. We\u2019ll rate this Not Applicable but note that the release should have been more clear in the headline and lede that this therapy hasn\u2019t been tested in humans.", "answer": 2}, {"article": "In contrast, a 2000 Singapore study of 330 adolescents found no difference in 3-month quitting rates for participants treated with real or fake laser therapy.\nStill, Laser Therapeutics\u2019 Camera said, the treatment won\u2019t work on everybody.\nThat\u2019s what Innovative Laser Therapy, a New Haven, Connecticut-based company, advertises on its website.\nTherefore, quitting leads to a quick drop in endorphin levels, he said.\nUsing acupuncture methods to treat addictions such as smoking is not new, White said, but there is still no clear evidence that treatment with needles has any therapeutic effects either.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains how these laser treatments are part of an emerging trend that grew out of acupuncture.", "answer": 1}, {"article": "Similar drugs are under development at companies including Eli Lilly & Co and Teva Pharmaceutical Industries Ltd, but Amgen emphasizes that Aimovig is the only one that targets the CGRP receptor pathway, rather than CGRP itself.\nHe said previous studies excluded patients who had tried more than two other treatments.\nThe drug, a monoclonal antibody, was given monthly by injection at a dose of 140 mg for the trial.\nReuter said the 17-point gap between the treatment and placebo groups was in line with previous Aimovig studies.\nA decision by the FDA is due by May 17.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the drug is under review by the FDA and that a decision is expected in May.", "answer": 1}, {"article": "(Reuters) - Medtronic Inc, a manufacturer of pacemakers, heart stents and spine products, has developed a device to tackle another common health problem: erectile dysfunction.\nRogers said it could be several years before Medtronic undertakes a much larger late-stage trial.\nAfter three months the results were promising, the company said.\n\u201cThis is still investigational and requires more research.\n\u201cED is largely a vascular disease and that\u2019s why Medtronic was interested in this,\u201d said Dr. Jason Rogers of UC Davis Medical Center, one of the researchers of the company-sponsored trial.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that \u201cit could be several years before Medtronic undertakes a much larger late-stage trial\u201d and that \u201cthis is still investigational.\u201d", "answer": 1}, {"article": "A growing number of doctors who treat the estimated 6.4 million American children diagnosed with A.D.H.D.\nexperts challenge this conclusion.\nThe question is whether these effects can last once the drugs have left the bloodstream.\nYet Dr. Bertin has recently changed the way he talks about medication, offering parents a powerful argument.\nAnd other research has raised new concerns.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the medications being discussed are widely available.", "answer": 1}, {"article": "Differences in mean changes in swallowing at radiotherapy week 4 (\u221215 in the CRT group and \u221225 in the radiotherapy alone group, P = .02), loss of appetite at radiotherapy week 4 (\u221211 in the CRT group and \u221218 in the radiotherapy alone group, P = .03), nausea at week 8 after radiotherapy (\u22127.3 in the CRT group and 0.3 in the radiotherapy alone group, P = .04), coughing at radiotherapy week 4 (7.4 in the CRT group and \u22125.6 in the radiotherapy alone group, P = .02) and at week 8 after radiotherapy (\u22123.2 in the CRT group and 1.1 in the radiotherapy alone group, P = .04), constipation at month 8 (2.6 in the CRT group and \u221219 in the radiotherapy alone group, P < .001), and cognitive functioning at month 12 (\u22127.0 in the CRT group and 4.6 in the radiotherapy alone group, P = .04) were not seen at the other time points.\nThe use of concomitant cisplatin and radiotherapy resulted in a statistically significant improvement in laryngeal preservation compared with radiotherapy alone, with a hazard ratio of 0.46.\nOne of the largest randomized clinical trials was designed to evaluate laryngeal preservation compared with radiotherapy alone, concomitant chemoradiotherapy, and induction chemotherapy followed by radiotherapy.13,14 Each treatment group included at least 180 patients, thus providing much greater statistical power than the current communication.\nThis treatment approach warrants further evaluation in larger populations to fully assess the potential value of cetuximab or other molecular targeting agents to augment laryngeal preservation rates.\nUnfortunately, there has been a lack of improvement in overall survival for patients with laryngeal carcinoma in the last 30 years.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This release notes that more research, on a larger scale, needs to be done to \u201cassess the potential value\u201d of interventions like CRT in treating cancer while preserving the larynx. However, the release would have been much better if it had clearly noted that cetuximab is not currently eligible for insurance coverage for this particular condition and a result will not be available to many patients.", "answer": 0}, {"article": "The Lancet.\nThe research, involving more than 12,000 older women and carried out in collaboration between the universities of Birmingham, East Anglia, Bristol, Leicester, York and Sheffield, found that screening through GP practices allowed patients to be targeted for treatment.\nThe study suggests that one hip fracture could be prevented for every 111 women screened and early analysis suggests the approach is likely to be cost-effective.\n\"While we have demonstrated clinical effectiveness of screening, we are also exploring cost-effectiveness of this approach; initial analyses also look promising in this respect.\"\nThe team used a University of Sheffield developed tool called FRAX, which predicts the probability of a hip fracture or a major osteoporotic fracture (a hip, spine, upper arm or lower arm fracture), to identify older women at high risk.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This was a clinical trial of the proposed adoption of a screening procedure which the researchers hope will contribute to national healthcare policy. The risk calculator used in screening, FRAX, is already widely available.", "answer": 2}, {"article": "Oral and injectable medications are also prescribed.\nHowever, previous research led by Dr. Zhovtis-Ryerson's group found extending the dose up to 8 weeks did not negatively affect the medication's efficacy in a retrospective sample of 2,000 people.\nThe authors are planning prospective efficacy studies of extended dose natalizumab.\n\"Our safety findings are clinically and statistically significant, and we believe that extending the dosing schedule of natalizumab is practice changing and may save lives.\"\nThe new research showed that extending dosing of natalizumab from every 4 weeks to every 5 to 12 weeks significantly reduced the risk of developing progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal brain infection.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does mention that natalizumab is a \u2018commonly-prescribed multiple sclerosis (MS) infusion medication linked to a rare but serious side effect \u2026 \u201d\nIt should have been made more clear, however, that the drug has been pulled from the market before (over PML concerns) and is now FDA-approved only for\u00a0highly active, relapsing remitting MS.", "answer": 1}, {"article": "In a healthy brain, microglia act as chemical rubbish collectors, surveying the local environment, clearing up unwanted compounds, but in Alzheimer\u2019s these cells can lose this function and switch into an inflammatory state in which they secrete toxic compounds instead.\nThe latest intervention, scientists predict, should be quicker and cheaper to confirm in humans than pharmaceuticals, which typically take more than a decade to develop and assess for safety before the clinical efficacy is even examined.\nThe authors caution that a \u201cbig if\u201d remains over whether the findings would be replicated in humans \u2013 and whether cognitive deficits as well as visible symptoms of the disease would be improved.\nThe study, published on Wednesday in the journal Nature, hinges on the observation that Alzheimer\u2019s patients show a loss of synchronised brain activity, known as gamma oscillations, which is linked to attention and memory.\nBoosting this synchronous brain activity appeared to act as a cue for the brain\u2019s immune cells, prompting them to absorb the sticky amyloid proteins that are the most visible hallmarks of the disease in the brain\u2019s of people with Alzheimer\u2019s.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story address availability with this\u00a0statement: \u201cThe latest intervention, scientists predict, should be quicker and cheaper to confirm in humans than pharmaceuticals, which typically take more than a decade to develop and assess for safety before the clinical efficacy is even examined.\u201d OK, quicker and cheaper \u2014 but does that mean a year from now or five years or 10?", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061210/18vitamin.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story included a statement that \"a mere 10 to 15 minutes outdoors at midday gives the average fair-skinned person 10,000 international units\" which\u00a0is hyperbole because\u00a0season and latitude greatly\u00a0affect the amount of vitamin D synthesis that occurs. Even though the story included a statement about latitude a little later, the first statement is misleading for the reader.\nThe story included mention of food sources for \"relatively modest amounts\" of vitamin D, though that does little to help the reader know how much of the foods would need to be consumed.\u00a0 Although the last sentence of the article listed one mini-meal plan, which, along with supplements would supply the suggested level of Vitamin D, this was an incomplete method of telling readers how to achieve adequate vitamin D intake.\u00a0 The story also failed to mention the effect of sunscreen on vitamin D production by the body.", "answer": 0}, {"article": "\"Our idea was to find a way to do a quick examination that would allow, during a boxing or American football match for example, to determine whether the athlete can return to the field or if his condition requires hospitalization.\nThis discovery, described in PLOS ONE, will not only relieve emergency departments, free patients from often long waits, but also save on costly medical examinations.\nYet 90% of these patients will be able to return home safely, as no trauma has been detected.\nHis team has developed a rapid diagnostic test (POCT) called TBIcheck, inspired by the principle of pregnancy testing: by placing a single drop of blood on the well of a small 5cm plastic case, the patient knows within 10 minutes whether there is a risk of mild trauma, namely whether or not his H-FABP level is higher than 2.5 nanograms per millilitre of blood.\nToday, the injured patients have to go to the emergency rooms of hospitals equipped with a CT Scan, an expensive examination that sends X-rays to the brain to detect the presence or absence of brain trauma.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release stated that the device will be marketed starting in 2019 by a company called ABCDx. However, it would have been helpful to readers to point out whether or not the device must receive regulatory approvals or any details about the types of patients for whom it is recommended.", "answer": 1}, {"article": "Professor Roy Taylor said: \"What we have shown is that it is possible to reverse your diabetes, even if you have had the condition for a long time, up to around 10 years.\nA previous study led by Professor Taylor, published in 2011, showed that diabetes could be reversed by a very low calorie diet.\nParticipants in this study had Type 2 diabetes for between six months and 23 years.\nThe research is part of a growing body of evidence showing that people with Type 2 diabetes who successfully lose weight can reverse their condition because fat is removed from their pancreas, returning insulin production to normal.\nIn fact, after 6 months a thirteenth patient had reversed their diabetes.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Given that the approach of this study focuses on specific foods as key to maintaining weight, and that these foods are commonplace, one assumes that they are readily available in the marketplace.", "answer": 2}, {"article": "Drug list (formulary): To see a list of covered drugs for the plan you\u2019re considering, use the drop-down menus below.\n\nIf your employer is offering coverage, contact HR for the pharmacy plan name.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Story about FDA approval for women with early-stage invasive disease.", "answer": 1}, {"article": "Shingles is a viral disease produced by the chicken pox virus, a common childhood disease, and is characterized by pain and a blistering rash along the nerves that have housed the dormant virus.\nEveryone in the study, published in the Journal of the American Medical Association, was at least 60 years old, and the researchers didn\u2019t include anybody for whom the live vaccine is not recommended.\nBut researchers cautioned that because they did not follow patients over the longer term, they didn\u2019t know how effective the vaccine is years later.\n\u201cThe human cost of shingles is enormous,\u201d said Michael Oxman, who studies infectious diseases at the University of California, San Diego, and was involved in a previous study of the vaccine.\nDespite the FDA\u2019s approval, the vaccine has not caught on as much as some had hoped.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story notes that this shingles vaccine was approved in 2006. It also makes reference to stringent requirements for storage and handling, which have been cited (along with cost) as barriers to access.", "answer": 1}, {"article": "The findings impress Columbia University researcher Gregg W. Stone, MD.\nAnd in the new study, patients had less bleeding after stent installation.\nThat approval seems likely, given the results of a new clinical trial that compared Plavix to Brilinta in patients with acute coronary syndromes who had stents placed in their arteries to improve blood flow.\nAnd since the drugs irreversibly bind to blood-clotting platelets, a patient has to stop taking these drugs for five to seven days before the body can make enough new platelets.\nThat's probably why the 6,732 study patients who got Brilinta were 16% less likely to die, or have a heart attack or stroke, than were the 6,676 patients who got Plavix.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that ticagrelor is not yet have FDA approval.\nHowever, the story stated that \u2018approval was likely\u2019 and that the drug will be marketed as Brilinta. \u00a0Both pieces of information are more akin to marketing than reporting. \u00a0It would be more accurate to state that the drug is currently under consideration for FDA approval and that the name Brilinta has been proposed.", "answer": 1}, {"article": "Who and When: 8,385 obese patients in Israel who underwent bariatric surgery (laparoscopic banding, Roux-en-Y gastric bypass, or laparoscopic sleeve gastrectomy) from 2005-2014; 25,155 obese patients who received nonsurgical care for obesity management from primary care physicians that may have included dietary counseling and behavior modification.\nWhy The Research Is Interesting: Much is known about the short-term outcomes of bariatric surgery for weight loss but relatively little is known about its long-term effects.\nStudy Conclusions: The association between bariatric surgery and a lower rate of death from any cause adds to the limited literature describing the beneficial outcomes of these surgical procedures for obese patients.\nSome previous research has been limited by a number of factors, including the lack of a comparison group of obese patients who did not undergo bariatric surgery.\nPlease see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability. However, bariatric surgery for obesity is becoming increasingly common and is now available worldwide. The release would have been stronger had it informed readers about the eligibility criteria for the surgery.", "answer": 2}, {"article": "\u201cBut now, we\u2019re seeing this whole new spectrum of treatments.\nIt\u2019s a risky proposition to give patients the foods they\u2019re deathly allergic to \u2014 inducing anaphylactic reactions simply to test drugs in clinical trials.\n\u201cThat hypothetically decreases the risk for adverse events.\u201d\n\nFor all the research on allergies, none of the drugs in the pipeline is a sure thing.\n\u201cThere\u2019s really no doubt that there have been cold feet in the industry about this issue.\u201d\n\nBut investigators around the world have shown they can carry out these \u201cfood challenge\u201d trials safely \u2014 which could help hasten the development of new drugs.\nThe experimental treatment that may be closest to market is also one of the simplest.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article, admirably, makes clear that movement through the new drug pipeline is likely to be slow for most of the newly envisioned therapies.", "answer": 1}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that bisphosphonates are in widespread use, and the article at least implied that the generic versions were generally available at the low quoted price \u2014 giving readers the tools to select the drug and look at reasonable pricing.", "answer": 1}, {"article": "Can a high-tech scan reveal whether Alzheimer's disease is the cause of your forgetfulness? Advocates of Positron Emission Tomography scans for the diagnosis of Alzheimer's say the scans significantly aid in the early and accurate diagnosis of the memory-robbing disease. Neurologists say PET is useful in distinguishing between Alzheimer's and a similar-acting dementia. However, opinions differ on whether the scans are useful in predicting the likelihood of Alzheimer's in people with only mild memory problems.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not comment on the availability of PET scanners.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061105/13healy.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention that lung cancer screening is already being offered and advertised by many hospitals and imaging centers across the country. We're told the study was done in 38 centers around the world but are given no idea of the availability of spiral CT scanners.\u00a0 ", "answer": 0}, {"article": "Vitamin D is called the \"sunshine vitamin\" because human bodies produce it when the sun's ultraviolet rays strike the skin.\nHowever, colon cancer patients shouldn't try to boost vitamin D levels beyond the normal range, one expert said.\nThe report, scheduled for presentation this week at the Gastrointestinal Cancers Symposium in San Francisco, adds more weight to suspicions that vitamin D might be a valuable cancer-fighting supplement.\nEveryone should maintain healthy vitamin D levels anyway, to protect their bone health, Ng and Krishnamurthi said.\nHowever, \"if someone has a normal vitamin D level, I wouldn't take supplements to increase it because we won't know the true effect on cancer until we see the results of a clinical trial,\" she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Most people know that vitamin D supplements are widely available. A brief statement to that effect would have earned the story a satisfactory, as opposed to not applicable.", "answer": 2}, {"article": "Sumathi Reddy has details on Lunch Break.\nThey are live microorganisms\u2014or \"good\" bacteria\u2014that when consumed in capsules or yogurt are said to confer a health benefit.\nBut some researchers are investigating the beneficial bugs for conditions that have nothing to do with the digestive tract.\nOne of the fastest-growing dietary supplements, probiotics are now prominent on drug and big-box store shelves.\nProbiotics, believed to help with digestion, are increasingly being studied to treat wide-ranging conditions, from colic to cholesterol and the common cold.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that probiotics are available in supplements and a variety of other products.", "answer": 1}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that carotid endarterectomy is widely available.", "answer": 1}, {"article": "PHILADELPHIA - According to a new study, women experiencing difficulty with time management, attention, organization, memory, and problem solving - often referred to as executive functions - related to menopause may find improvement with a drug already being used to treat attention deficit hyperactivity disorder (ADHD).\nThe Penn-led team administered a once-daily dose of LDX for four weeks to 32 healthy, non-ADHD-diagnosed women between the ages of 45 and 60 experiencing difficulties with executive functions as a result of mid-life onset menopause, and as measured using the Brown Attention Deficit Disorder Scale (BADDS).\n\"It is also important for clinicians to confirm that a woman's complaints of worsening memory are in the executive function domains, are temporally related to the transition to menopause, and are not indicative of some other pathological cognitive impairment before prescribing a trial of LDX.\"\n\"Although we observed that short-term use of LDX was well tolerated and effective in several subjective and objective areas, long-term studies of menopausal women receiving LDX are needed, similar to those conducted for ADHD patients,\" said Epperson.\n\"Reports of cognitive decline, particularly in executive functions, are widespread among menopausal women,\" said lead author, C. Neill Epperson, MD, professor of Psychiatry and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, and director of the Penn Center for Women's Behavioral Wellness.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release establishes that the drug used in the study is now frequently prescribed for ADHD patients, suggesting that it is available and also could also be used for menopause-related symptoms..", "answer": 1}, {"article": "; Menno V. Huisman, M.D., Ph.D.; Pieter W. Kamphuisen, M.D., Ph.D.; J\u00f6rg Kreuzer, M.D.\nThe new results are part of a large on-going phase III study testing idarucizumab in a range of patients who take dabigatran and have dangerous bleeding or need urgent surgery or other procedures that carry serious bleeding risks.\nIdarucizumab was approved by the U.S. Food and Drug Administration in October 2015 as the first medicine designed to reverse dabigatran.\nResearchers say before idarucizumab was available, patients on dabigatran who needed emergency surgery were given purified clotting factors, which carry the risk of patients' clotting systems forming dangerous blood clots.\n\"I see the biggest impact of idarucizumab as providing reassurance to patients that if bleeding while taking dabigatran does occur, we can quickly reverse the dabigatran.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that idarucizumab was approved by the FDA in October 2015, so readers can assume that it\u2019s available (and it is).", "answer": 1}, {"article": "Referring to Lozano's second clinical study, Dr. Nader Pouratian, a neurosurgeon and DBS researcher at UCLA, comments, \"The recent deep brain stimulation trial for Alzheimer's disease clearly demonstrates the safety of this approach for trying to treat the progression of disease.\nGiven that so few people have had electrical stimulation applied to memory circuits, perhaps the most significant finding was that both the surgery itself and DBS of the fornix appear safe.\nYet the fact that the therapy can in some people rescue recollections \u2013 albeit random ones \u2013 and possibly induce new neuron growth in memory regions of the brain seems reason enough to pursue it further.\nThe technique is also approved for obsessive-compulsive disorder and is being looked at for a number of other brain disorders, including depression, chronic pain and, as in Lozano's work, dementia.\n\"It's easier to stimulate than the hippocampus itself and crucial to memory function.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story acknowledges the preliminary nature of the research, but we\u2019d have liked to see it near the top rather than in the third-to-last paragraph, which states: \u201cDBS for treatment of Alzheimer\u2019s and other dementias is a field in its infancy. Unlike on TV, in all likelihood it won\u2019t be widely used anytime soon to retrieve specific memories.\u201d", "answer": 1}, {"article": "\"Nobody has the answer at this time,\" Perle said.\nBut which treatment is right for any patient depends not only on their specific pain, but their doctor's recommendations and their own comfort level with various options, said Stephen Perle, a spokesman for the American Chiropractic Association.\nMore than 6,000 patients were included in the compilation of results, which the study authors said were sparse in data indicating participants' overall recovery, quality of life and ability to return to work.\nThe analyses indicated that SMT -- which involves manual manipulation of the spine and surrounding muscles -- has only a short-term impact on pain relief, although it eases pain faster than other treatments.\nAbout two-thirds of the studies were not included in a previous review published in 2004, and all patients had suffered from lower back pain for 12 weeks or longer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article gets a \u201csatisfactory\u201d because it pointed out that manipulation is commonly performed by multiple healthcare professions. \u00a0It would have been useful to mention that manipulation is not routinely available in conventional primary care medical settings.\u00a0 And despite its evidence record, it does not generally enjoy completely consistent insurance coverage.\u00a0 The same points apply to massage.\n \n", "answer": 1}, {"article": "Rhesus monkeys and rats performed just as well on memory and attention tasks shortly after being administered DORA-22 as they did on an inactive placebo.\nMerck already has one such drug, suvorexant, under review by the U.S. Food and Drug Administration (FDA).\nSo much so that the FDA recently cut recommended doses of Ambien and other drugs that contain zolpidem for fear that their use, even the night before, might impair driving or other activities the next day.\nThese new medications -- known as dual orexin receptor antagonists (DORA) -- target a more specific region of the brain than popular sleep drugs such as Ambien and Lunesta, promoting sleep without affecting learning and memory (also called \"cognition\"), according to the new research.\nThat means, theoretically, fewer side effects and perhaps less of a tendency to be habit forming, Thorpy explained.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is under study and therefore not available. The story tells readers that Merck has applied for FDA approval to market a similar drug.", "answer": 1}, {"article": "LONDON (Reuters) - British scientists conducting early-stage research have found that a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia(MLL) \u2014 the most common form of leukemia in babies.\nIn a study published in the journal Nature, scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151, mimics a chemical tag which is key to preventing the process of activating the leukemia genes.\n\u201cWe urgently need better ways to treat children with more aggressive forms of leukemia, such as MLL,\u201d said Lesley Walker, CRUK\u2019s director of information.\n\u201cIt is important to remember we will need to be successful on a number of additional steps before we can move this from the lab to testing this compound in humans.\u201d\n\nMLL leukemia is thought to account for up to 80 percent of cases of acute leukemia in children below two years old, and up to one in 10 cases in adults.\nUsing I-BET151 to treat leukaemias in mice and human cancer cells in a lab, the researchers found that the chemical could halt the disease, paving the way for more research to be done in first-stage, or so-called Phase I, human trials.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story had several reminders for readers of the early stage of this research.\u00a0 The reminder that \u201cit will probably be many years before the drug could potentially reach the market\u201d is almost premature in itself given that this is something that hasn\u2019t even been tested outside the lab yet \u2013 with not one human experiment having been conducted.", "answer": 1}, {"article": ".\nThe experience supports a growing body of research showing good outcomes with surgery for chronic temporal headaches.\nHe hopes his new technique will \"lower the bar to adoption\" of effective surgical treatment for patients with this debilitating headache condition.\nIn recent years, surgery has emerged as an effective treatment option for selected patients with chronic, severe headaches.\nThe technique is a new use of an approach that many surgeons are already familiar with: the Gillies incision, used for surgical repair of cheekbone fractures.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release isn\u2019t clear whether or not the surgery is currently available specifically for chronic headache patients. From an online search, it seems that some centers do offer surgery to treat chronic headaches, although it isn\u2019t always clear\u00a0 what techniques the surgeons use.", "answer": 0}, {"article": "All of the babies born by C-section were slightly more likely to use an asthma inhaler at age 5: 10.3 percent of planned C-section babies and 10.19 percent of unscheduled C-section babies wound up using an inhaler, compared with 9.6 percent of vaginally born babies.\nThe finding suggests that the arduous experience of labor \u2014 that exhausting, sweaty, utterly unpredictable yet often strangely exhilarating process \u2014 may give children a healthy start, even when it\u2019s interrupted by a surgical birth.\nHowever, the data do begin to shed light on why babies born through vaginal birth may have fewer health risks than babies born by C-section.\nThe findings are a reminder that although C-sections are appropriate in some circumstances, they are a poor substitute for labor.\nThe Scottish study took advantage of the small country\u2019s rich trove of linked birth and medical databases to track the long-term health of 321,287 babies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All three of the birth methods described are widely available.", "answer": 1}, {"article": "test found a small cancer, and he does not want to take a chance that it will grow slowly and not cause him problems.\nOften it is easier to just order the test.\nAnd there are financial incentives.\nSome men say the cautions just do not apply to them.\nAnd doctors, he added, have many inducements to screen.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that \u2018routine\u2019 PSA testing is readily available.", "answer": 1}, {"article": "+ Loss of fat was associated with faster walking speed, while loss of muscle was associated with reduced knee strength.\nLoss of lean mass could have important consequences given the high risk of physical disability among the growing population of older adults.\nLosing weight is generally recommended for those with obesity, but preserving muscle - while losing fat - is particularly important for older adults in order to maximize functional benefit, Beavers said.\nCo-authors on this paper included W. Jack Rejeski and Anthony Marsh, co-principal investigators of the CLIP-II study, and Jessica Sheedy, Beverly Nesbit and Jill Gaukstern, all of the Wake Forest University Department of Health and Exercise Science; and Walter Ambrosius, Michael Walkup, Jonathan Burdette and Barbara Nicklas of the Wake Forest School of Medicine.\nThis is the latest study from the Cooperative Lifestyle Intervention Program (CLIP-II), a single-blind, randomized controlled trial.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "As mentioned above, weight lifting classes are offered at most gyms and there are online tutorials as well, making it extremely available. However, it would have been nice to include some organizations that specifically offer weight training for elders.", "answer": 2}, {"article": "\"[The study is] one of the first studies that evaluated the role of Mediterranean diet on metabolic syndrome, and revealed a beneficial association- quite a big influence, taking into account that the Mediterranean diet is a non-pharmacological mean,\" said study author Demosthenes Panagiotakos, from the Department of Science of Dietetics-Nutrition at Harokopio University of Athens in Greece.\nThe Mediterranean diet isn't just a little extra olive oil, noted Dr. Robert Eckel, an endocrinologist and past president of the American Heart Association.\nPanagiotakos concludes that this pattern of eating can be easily adopted by people of various cultures and populations.\nThe study notes physical activity is also an important part in preventing the risk factors for the metabolic syndrome.\nThe syndrome is present when someone has three of those five risk factors.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story opened by indicating that readers had likely heard about or even tried the\u00a0\u2018Mediterranean diet\u2019.", "answer": 1}, {"article": "The distorted valve functions poorly, its flaps swinging apart.\nBut that research included many patients with less severe valve problems, the procedure was not performed as adeptly, and the patients\u2019 medications were not as well optimized as in the new study.\nUntil today, researchers were not sure that fixing the mitral valve would do much to help these patients.\nThe result was to convert a valve that barely functioned into one able to regulate blood flow in and out of the heart.\n(The clip is made by Abbott, which funded the study; outside experts reviewed the trial data.)\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was a strong point.\nThe story stated: \u201cIf the device is approved by the Food and Drug Administration for treatment of severe heart failure, as expected, then insurers, including Medicare, most likely will cover it.\u201d\nIt also stated, \u201cNot every cardiologist is equipped to insert the clip.\u201d", "answer": 1}, {"article": "The study was supported by the Andrew Sabin Family Fellowship Program; the American Association for Cancer Research \u2013 Stand Up to Cancer; the National Institutes of Health (CA219896-01A1, HL124112); the Cancer Prevention & Research Institute of Texas; and the Melanoma Moon Shot\u2122, part of MD Anderson\u2019s Moon Shots Program\u2122, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients\u2019 lives\n\nIn addition to Wang, other MD Anderson authors include: Diana Wiesnoski, Christopher Sanchez, and Chia-Chi Chang, Ph.D., all of Genomic Medicine; Beth Helmink, M.D., Ph.D., and Vancheswaran Gopalakrishnan, Ph.D., both of Surgical Oncology; Hamzah Abu-Sbeih, M.D., Gottumukkala Raju, M.D., and John Stroehlein, M.D., all of Gastroenterology, Hepatology & Nutrition; Edwin Parra, M.D., Ph.D., and Alejandro Francisco-Cruz, Ph.D., both of Translational Molecular Pathology; Matthew Campbell, M.D., Jianjun Gao, M.D., Ph.D., and Sumit Subudhi, M.D., Ph.D., all of Genitourinary Medical Oncology; Dipen Maru, M.D., of Pathology; Jorge Blando, DVM, and James Allison, Ph.D., both of Immunology; Padmanee Sharma, M.D., Ph.D., of Genitourinary Medical Oncology and Immunology; Michael Tetzlaff, M.D., Ph.D., of Translational Molecular Pathology and Pathology; Jennifer Wargo, M.D., of Genomic Medicine and Surgical Oncology; and Robert Jenq, M.D., of Genomic Medicine and Stem Cell Transplantation.\n\u201cBased on these results, this should be evaluated even as a first-line therapy for ICI-associated colitis because it\u2019s safe, quick, and the effect is durable - from one treatment.\u201d\n\nImmune checkpoint inhibitors, which release a block on the immune system to attack cancer, have been successful in providing durable responses for patients with several cancer types.\nThe study from The University of Texas MD Anderson Cancer Center, which includes two patients, suggests fecal microbiota transplantation (FMT) is worth investigating in clinical trials as a therapy for this common side effect of immunotherapy.\nFMT continues to be offered to MD Anderson patients on a compassionate-use basis.\n\u201cWe have a limited amount of time to fix the problem so they can resume ICI treatment, but I feel that we\u2019ve made great progress in this area.\u201d\n\nThe researchers chose to investigate the potential for FMT as an alternative, compassionate-use therapy for patients suffering from refractory, or unresponsive, ICI-associated colitis.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Determining this will be confusing to someone reading this release.\u00a0 Fecal transplant procedures are in use to treat a variety of gastrointestinal issues, so this would suggest that the procedure is available.\u00a0 But its employment to subdue inflammation caused by immunotherapy treatment is just being explored and has not even been subjected to clinical testing yet.\u00a0 So whether the procedure would be available to cancer patients receiving immunotherapy is an open question.", "answer": 0}, {"article": "Those in the lower group ate an average of 0.5 meals per week.\nDuring the course of the study, each person received annual, standardized testing for cognitive ability in five areas -- episodic memory, working memory, semantic memory, visuospatial ability and perceptual speed.\nAt study enrollment, none had signs of dementia.\nThe results were the same after researchers adjusted for other factors that could affect memory and thinking skills, such as education, physical activity, smoking and participating in mentally stimulating activities.\nThe study was supported by the National Institute on Aging and the Judith Zwartz Foundation.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "People have been eating fish for rather a long time, so we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "The I.V.\nSchwartz, though, said the supplements are completely safe.\nThere is a published review on the use of Myers\u2019 cocktail \u2014 but it\u2019s just a collection of anecdotal evidence.\nOne didn\u2019t turn up any significant improvement in patients who received the infusions.\nAnd though the IV lends a medical air to the procedure, the infusions suffer from the same problem as many supplements taken orally \u2014 there isn\u2019t any robust evidence to back up their health claims.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that several different companies are selling nutritional supplements delivered by intravenous drip. But it was not clear how easy these are to obtain and the potential for insurance coverage was not mentioned, so this is a marginal satisfactory rating.", "answer": 1}, {"article": "\u201cCAR-T is not the EpiPen,\u201d he said.\nAnd although checkpoint inhibitors are off the shelf, with every patient getting the same drug, CAR T-cell therapy is customized to an individual.\nSuch results are why the treatment is on track to become the first gene therapy approved by the Food and Drug Administration.\nAnd childhood leukemia is just the start for a field that has attracted intense interest in academia and industry.\nThe article that appeared in the New England Journal of Medicine in August 2011 created a \u201cfirestorm,\u201d June said \u2014 one that brought them new resources.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly lays out where this treatment is in the FDA review process, how that process may unfold, and what this may mean for future availability. In addition, the story explains that CAR T-cell treatment would not be rolled out universally, but \u2014 if approved \u2014 would be available only through designated treatment facilities that have the relevant expertise.", "answer": 1}, {"article": "Dr. David Rosenstreich, director of the division of allergy and immunology at Montefiore Medical Center in New York City, added: \"An objective and fast test for diagnosing asthma would be helpful, and this test seems to be a non-invasive way of sampling for the underlying problem.\nThe electronic nose was able to correctly differentiate healthy people from those with physician-diagnosed asthma in 87.5 percent of the cases.\nTo do this, all of the study volunteers were given all three tests.\nEach test is non-invasive, requiring only the use of exhaled air.\nThose with asthma had a history of allergies, and none had been treated with corticosteroids for at least four weeks prior to the start of the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story never explicitly states that the device being discussed is experimental, comments from the experts make it pretty clear that the technology\u00a0is still in development.", "answer": 1}, {"article": "Some years ago, Italy instituted a countrywide rule requiring competitive athletes to undergo an electrocardiogram, a test that records the electrical activity of the heart.\nIf an ongoing program of testing happens, the hospital would try to tap into third-party funding, donations and grants, Towbin says.\nCurrently, an EKG and echocardiogram would cost parents a minimum of $2,500, Anderson says.\nBut the Children's Hospital study is showing more than twice that rate and a higher rate for more minor abnormalities as well, perhaps because of better technology, Grenier says.\nA key challenge now is making these tests affordable; most medical insurance plans won't cover them.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "From the way the tests are described in the story, they appear to be routinely available. However, there is no discussion of whether the capacity exists to test and properly interpret test results for the millions of teens who would need to undergo screening if it were demonstrated to be beneficial.", "answer": 1}, {"article": "Multiple myeloma is the second most common type of blood cancer in the U.S., impacting more than 25,000 people each year and disproportionatly affecting African-American men.\nWith a goal of enrolling 82 patients, those in the trial will be treated with a combination of anti-myeloma agents and immunotherapy that have a proven record of eliminating minimal residual disease, including the drug carfilzomib and the monoclonal antibody daratumumab, agents that are currently only approved to treat patients whose disease has returned.\nMore than improving the results of the initial treatment, the MASTER study will treat patients for the necessary time to confirm elimination of minimal residual disease and then discontinue therapy.\nThe MASTER trial is supported by Amgen and Janseen, both with drug and finaincial support.\nThe hope is that the therapies will eradicate the disease in a significant proportion of patients and measure disease response more accurately than ever before.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the trial uses drugs that are already available, though some are approved for only patients who have relapsed after initial treatment. It makes clear that the \u201cminimal residual disease\u201d testing regime to be used is not routinely available.", "answer": 1}, {"article": "Elective Caesarean-section deliveries can increase problems for a newborn if done too early -- even when the baby has technically reached full term, according to a large new study.\n\nThe findings could help diminish a widely popular practice -- now about one in every 14 births -- in which mothers choose to schedule c-sections, or surgical removal of the baby. The study, published in the New England Journal of Medicine, found that about a third of elective c-sections are done too early -- before 39 weeks. Although a fetus is considered...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The widespread use of c-sections is clear in the story. ", "answer": 1}, {"article": "\"These are children who could have died from a teaspoon of milk before,\" Wood said.\nThe strategy is being tested in a handful of small studies that are part of a surge of research in a field that for years showed little progress.\nNo one should try the approach on his own, because the treatments themselves can trigger potentially life-threatening reactions.\nAlthough the approach appears to be highly effective for some children with milk and peanut allergies, the researchers conducting the studies and others caution that much more research is needed to prove and perfect the approach and that it is far from ready for widespread use.\nBurks and Jones are part of the federal consortium, which is studying the same approach for eggs at research institutions across the country, including Johns Hopkins, and conducting detailed immunological studies to try to get a better understanding of how the treatment works.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story described positive results from a couple of studies and indicated that desensitization in this manner is the realm of research and not widely available clinically. \u00a0\nThat said \u2013 it could have provided readers with some ideas for where they could go to learn about studies in their area. (www.clinicaltrials.gov)\u00a0", "answer": 1}, {"article": "Also, mice that received the drug had slower blood clot formation than untreated mice, but the treated mice did not bleed longer than untreated mice.\nThe serpent-medicine connection isn't new, one cardiologist noted, since venom typically kills by disrupting the blood's clotting mechanisms.\nThe snake's venom contains a protein called trowaglerix, the researchers explained.\nStill, experiments in animals often don't translate to success in humans, so further research is needed.\nWhen mixed with blood, the new compound prevented blood cells called platelets from clotting.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicates more research is needed before this compound will be available (if ever).", "answer": 1}, {"article": "\u201cShe sent me a picture of Giovanni playing in his front yard,\u201d Kefalis said.\nTeichner asked, \u201cDo you believe that gene therapy is finally coming into its own?\u201d\n\nThe MLD trial, she thinks, demonstrates what\u2019s possible -- offering promise to the 30 million Americans who suffer from some 7,000 rare diseases.\nOne sign: Dr. Biffi is now head of the gene therapy program at Dana-Farber/Boston Children\u2019s Cancer and Blood Disorders Center.\nAnd when Kefalis learned about the Italian trial, and the fact that Amy Price had to keep going back to Milan with Giovanni and Ceci, it was clear she would use the money to help families get to Italy.\nHere\u2019s what\u2019s really amazing: That vehicle is the HIV virus, re-engineered so the children can\u2019t get AIDS.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is made very clear that the treatment is not available in the U.S., and likely won\u2019t be for some time.\nWhile this deserves a Satisfactory rating, there are two ways in which the reporter might have dealt with the availability issue differently. First, it might have been worth saying the treatment may\u00a0never be available in the U.S., since the research is at too early a stage to guarantee success. Second, it would have been informative to find out from the drug company what they think will happen next.\u00a0GlaxoSmithKline are reported to have said they will seek approval in 2017\u2013is that based on this current study or are they planning to do more research?", "answer": 1}, {"article": "Chemotherapy before surgery might provide a false assurance that there's no more residual cancer, whereas microscopic tumour may remain after the surgery, leading to cancer recurrence and possibly, death.\nThe goal is to have no cancer visible to the naked eye of the surgeon after the surgery.\n\"Women need support to endure surgery and the rigours of intraperitoneal chemotherapy, but should be encouraged to do so whenever possible, considering the potential survival benefits,\" said Narod.\nThe possibility of a 50 per cent cure rate would be a significant improvement over the current 20 per cent survival rate resulting from more conventional treatment options offered to patients, which consist of a combination of different methods including: chemotherapy before surgery; post-operative chemotherapy delivered intravenously to the whole body (as opposed to localized into the abdomen); and surgery that leaves minimal residual disease in the abdomen, rather than removing all visible cancer cells.\n\u2022 The surgery should be aggressive in an attempt to remove all visible signs of the tumour, and to avoid leaving any residual disease.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the release that the treatment options being urged as the standard of treatment are already well established.", "answer": 1}, {"article": "WINSTON-SALEM, N.C. - Aug. 17, 2015 - Every year falls affect approximately one in three older adults living at home, with approximately one in 10 falls resulting in serious injury.\nThe study showed that the monthly vitamin D supplement was effective in increasing the concentrations of vitamin D in the blood from insufficient to sufficient levels in all but one of the 34 people who received it, and to optimal levels in all but five people.\nAt the beginning of this pilot study, the research team found that more than half of the participants had insufficient concentrations of vitamin D in the blood (less than 20 ng/ml), while less than a quarter had concentrations in the optimal range (30 ng/ml or more).\nSixty-eight study participants received either a monthly vitamin D supplement of 100,000 international units or placebo delivered with their MOW meal.\n\"Falls in homebound older people often lead to disability and placement in a nursing home,\" said Denise Houston, Ph.D., R.D., associate professor of gerontology and geriatric medicine at Wake Forest Baptist and lead author of the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll rate this Not Applicable. Although no mention was made of the availability of the vitamin supplements, it is fair to assume most readers know that they are readily available in nearly any supermarket or drug store. However, the high dose vitamin D used in this study is typically available by prescription only.", "answer": 2}, {"article": "The FASEB Journal, April 2017, vol.\nFurther research is needed to support the hypothesis that the consumption of raspberry puree may change the composition of the gut microbiota.\nMore research is needed to determine if compounds in red raspberries play a role in human cardiometabolic pathways.\nBecause this study was limited to three meals, further research is needed to determine the factors that influenced outcomes.\nThese findings provide a basis for formulating hypotheses for conducting additional studies, particularly in human trials.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability generally isn\u2019t an issue\u2014raspberries are a common fruit known to most who shop at grocery stores. However, prices (and therefore access) can fluctuate widely depending on where you live. ", "answer": 2}, {"article": "LONDON (Reuters) - Scientists in Britain have developed a type of HIV test using a USB stick that can give a fast and highly accurate reading of how much virus is in a patient\u2019s blood.\nBut in some cases the drugs stop working - sometimes because virus has developed resistance to them - and the first sign of that would be a rise in a patient\u2019s so-called \u201cviral load\u201d.\n\u201cWe have taken the job done by this equipment, which is the size of a large photocopier, and shrunk it down to a USB chip.\u201d\n\nThe test, which uses a mobile phone chip, requires a drop of blood to be placed onto a spot on the USB stick.\nAt the moment, testing often requires costly and complex equipment that can take a couple of days to produce a result,\u201d said Graham Cooke, who co-led the research from the Imperial\u2019s department of medicine.\nThe device, created by scientists at Imperial College London and the privately-held U.S. firm DNA Electronics, uses a drop of blood to detect HIV, then creates an electrical signal that can be read by a computer, laptop or handheld device.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re\u00a0told\u00a0the\u00a0technology\u00a0is\u00a0in\u00a0the\u00a0\u201cearly\u00a0stages\u201d and is thus not yet available.", "answer": 1}, {"article": "An experimental drug has proved effective at treating an aggressive form of breast cancer in patients who aren't responding to the widely used drug Herceptin, giving hope to women with otherwise limited treatment options, said drug maker GlaxoSmithKline PLC, presenting the results Saturday at the American Society of Clinical Oncology meeting in Atlanta.\n\nWhen taken with a standard chemotherapy treatment in a clinical study, the new drug, Tykerb nearly doubled the time to 8.5 months before the average patient's breast cancer...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that lapatinib is still being tested in clinical trails and is not yet available for sale. The story says that \u201cGlaxoSmithKline plans to submit the drug for regulatory approval in the U.S. and Europe by the end of this year,\u201d and later mentions Glaxo\u2019s \u201chigh hopes for Tykerb.\u201d It would have been better to get some other perspectives about these prospects, other than comments from the company or company-sponsored researchers. ", "answer": 1}, {"article": "Autologous CD34?\nOutcomes from the \"ACT-34-CMI\" study, a two-year, phase II, randomized, double-blind, placebo-controlled clinical trial, will be published in an upcoming cardiac issue of Cell Transplantation.\nEncouraging early clinical trials suggest that cell therapy is an attractive treatment option for these patients, especially trials in which subjects were transplanted with autologous (self-donated) CD34+ cells.\"\nAll of the 167 patients participating in the ACT34-CMI study saw significant improvement in both angina frequency and exercise at 12 months and a trend toward decreasing major cardiac events.\nAccording to the researchers, the study demonstrated that CD34+ cells have the ability to restore the microcirculation and improve myocardial tissue perfusion.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that this paper stemmed from a phase II clinical trial. It didn\u2019t tell readers how long ago the trial took place, or what the treatment\u2019s prospects are (even in general terms) for potential clinical use. In 2012, Baxter issued a news release announcing plans to launch a phase III trial for CD34+ treatment to \u201d\u00a0increase exercise capacity in patients with chronic myocardial ischemia.\u201d That trial appears to be related to this research, although that\u2019s not entirely clear. Is it related? And, if so, has that trial moved forward?", "answer": 0}, {"article": "Both are reasonable options.\u201d\nNow a placebo-controlled study has found that the treatments are equally useful in reducing the frequency of episodes of incontinence, but vary in side effects and long-term effectiveness.\nThe medicine has to be taken daily, while Botox is given in a single injection that is effective for about 6 to 12 months.\nThe most common treatment for urinary incontinence is a daily dose of an anticholinergic medicine that alters the action of certain nerves.\nSignificantly, those who took Botox were more likely to have their symptoms completely disappear.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentions that anticholinergic medicine is the \u201cmost common treatment\u201d for urinary incontinence. It is also well-known that botox injections are readily available.", "answer": 1}, {"article": "Feb. 3, 2011 -- Children with attention deficit hyperactivity disorder (ADHD) should be offered a special ADHD diet to see if eliminating certain foods might reduce their symptoms, Dutch researchers say.\nU.S. experts had some caveats, saying that the results of the study, which included 100 children, should be repeated in other populations to see if the findings hold up.\nThe diet studied, known as the restricted elimination diet (RED), can work, the researchers say, because they believe ADHD symptoms in some children might be affected by eating specific foods.\nIn five weeks of trying the diet, Pelsser says, parents will know if their child is responding or not; if not, they can move on to other treatments.\nIn the study, published in The Lancet, 78% of children who stuck with the diet did respond by having fewer symptoms.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both the HealthDay story and the WebMD story described the diet in broad strokes, allowing readers, especially parents, to understand the basic components. There are two problem with both stories, though. First, they did not say anything about food preparation. Is serving a child fried chicken the same as grilled? Are french fries as good as a baked potato?\u00a0The other key point is that a dietician has to \u201ctailor\u201d the diet for each child. If there were no experienced dietician available, that would be problematic.\u00a0Still, we thought enough detail was presented to warrant a satisfactory rating.", "answer": 1}, {"article": "\u201cThat\u2019s what\u2019s good about this program.\nThe feasibility study was designed to see if texting could relieve some of the anxiety that comes with the fatigue, hair loss and other body changes that can accompany anticancer drugs.\nOne of the patients texted the program 1,217 times.\nAt the fourth month mark, \u201cthe gap was huge\u201d between the texting and control groups, she told Reuters Health in a telephone interview.\nSurprisingly, the older the patient, the greater the likelihood that she would text back, seeking more information.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned this was a feasibility study, signalling the system isn\u2019t available. Still, it could have explored whether any text messaging systems are being used for chemo patients.", "answer": 1}, {"article": "When planning a day at the beach, should you add Polypodium leucotomos to your picnic basket? The company that sells the natural fern extract says a daily dose can help protect against sunburn, sun-related aging and even genetic mutations that cause skin cancer. Dermatologists say preliminary evidence suggests the extract does protect against the sun -- but don't throw away your sunscreen yet.\n\nEvery year, 36% of U.S. adults get at least one sunburn, according to the federal Centers for Disease Control and Prevention....", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that this supplement is available over the counter.", "answer": 1}, {"article": "\"With milk that\u2019s not too hard,\" Wood says, because one could \"eat pizza a couple of times a week.\"\nIt's still in the early stages, but Dr. Robert Wood of Johns Hopkins, who has been on the forefront of food allergy research, estimates the treatment could be brought to the public within six to eight years.\nResearchers are separately looking at a drug called omalizumab (Xolair), approved by the U.S. Food and Drug Administration for the treatment of severe asthma, to see if it could help people with food allergies, too.\nSome children are allergic to many foods, and it's impossible to know based on preventive testing whether someone will have a mild or severe reaction.\nBut tree nuts may be harder to treat, Wood said, because tree-nut allergic individuals often have multiple kinds of nuts they can't eat.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As noted, the story made it clear that this is preliminary research and that the approach \u201cmay one day\u201d be available.\nThen the story quoted the researcher estimating that \u201cthe treatment could be brought to the public within six to eight years.\u201d\nThis is not entirely accurate, as oral immunotherapy for food allergies (including milk allergy) is currently being administered clinically by a handful of physicians. The concept behind the treatment (basically, exposing patients to food proteins) is not FDA regulated, and so there is theoretically no barrier to physicians offering this type of therapy to their patients. Citing the potential for adverse reactions and other concerns, however, most experts say that it is much too soon to use oral immunotherapy outside of a research setting. And so the story\u2019s bottom line message about availability is correct for the vast majority of patients. Still, the estimate of availability \u201cwithin 6 to 8 years\u201d may cause confusion to parents who have heard, via allergy blogs or other media sources, that it is already available.", "answer": 0}, {"article": ".\nThe findings, which are published in BJU International, could change the way men are treated for low testosterone.\nFull citation: \"Oral Enclomiphene Citrate Raises Testosterone and Preserves Sperm Counts in Obese Hypogonadal Men, Unlike Topical Testosterone: Restoration Instead of Replacement.\"\n\"This study confirmed that Enclomiphene can maintain spermatogenesis while restoring testosterone levels to normal.\"\nEdward Kim, MD, urologist at the University of Tennessee Medical Center and Professor at the University of Tennessee Graduate School of Medicine in Knoxville, and his colleagues compared such a drug, called Enclomiphene citrate, with testosterone replacement therapy (Androgel) in overweight men with low testosterone, or hypogonadism.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release did not explicitly describe the availability of\u00a0Enclomiphene citrate.\nThe study indicated that clomiphene, closely related to the study drug, is used \u201coff label\u201d for hypogonadal men. It has not been approved by the FDA for use in men.", "answer": 0}, {"article": "EEGs measure brain electrical activity through electrodes attached to the scalp.\nAlso, the study predicted who was at high risk of autism, but it's unknown if those babies actually went on to develop autism, he noted.\nDr. Joshua Ewen, a neurologist and director of the clinical neurophysiology laboratory at the Kennedy Krieger Institute in Baltimore, said the study is well done and looks promising, but needs to be replicated.\n\"If it can eventually be shown that this technique can reliably identify which children will indeed develop autism, then we will have a valuable tool for early detection,\" Ewen said.\nThe algorithms can detect subtle patterns in the lines created by EEGs that the human eye might miss, Bosl explained.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job setting up the study by explaining that researchers already know that having a sibling with autism can be a risk factor for developing autism and goes on to explain that this method of reading an electroencephalogram (EEG) is experimental.\u00a0The story accurately states that EEGs are not new, but have been used for detecting seizures for many years.", "answer": 1}, {"article": "POPGis one of several lipids found in the fluid that lines the air sacs of the lungs.\nResearchers say that until now, the function of POPG has been unclear.\nTherefore, together with the results of this study, researchers say the compound merits further research as a treatment for RSV infection in humans.\nNew research suggests the substance, a lipid known as POPG, may prevent RSV infection as well as limit the spread of the virus once infection has occurred.\nIn the study, published in the Proceedings of the National Academy of Sciences, researchers examined the effects of POPG on RSV infection in human lung cells in the lab and in mice infected with the virus.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not until the sixth paragraph does the story explain that this work was done in the lab \u2013 not in people.\u00a0 But later, the story says that the substance in question \"is already used in other treatments and has been safely given to millions of premature infants to protect their lungs.\" So is that a substance that doctors would use (have used?) off-label?\u00a0 This is not at all clear. ", "answer": 0}, {"article": "\u201cWe do not know for sure, and we do not know which particular aspect of olive oil is the most relevant to stroke,\u201d he says.\n\u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\nShe calls the findings \u201cintriguing\u201d but says they \u201cdo not equate a randomized clinical trial and should be used with appropriate caution in making broad recommendations.\u201d\n\nSuzanne Steinbaum, MD, director of women and heart disease at Lenox Hill Hospital in New York, says moderate use of olive oil in cooking and on bread may help protect against stroke in people older than 65.\n\u201cOlive oil is a healthy fat and it can reduce cholesterol and inflammation, and has been shown to help reduce the incidence of heart disease,\u201d she says.\nShe agrees with the study authors and editorialist that it is too early to make any recommendations about olive oil intake and stroke risk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of olive oil is not in question.", "answer": 2}, {"article": "Whether statins have additional properties to reduce risk, in addition to lowering serum cholesterol remain under study.\nBut that\u2019s a misleading association because a variety of illnesses can also cause drop in cholesterol, which is unrelated to diet.\nEat less saturated fat for better heart health: that\u2019s been the conventional wisdom based on decades of scientific study.\nAll that is known is the participants had a normal cholesterol levels and normal blood pressure.\nDoes swapping out all of your saturated fat with unsaturated fat lead to a longer life?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The different oils are widely available; this is N/A.", "answer": 2}, {"article": "It's a substantial number of women,\" Lyman said.\nThe study, involving nearly 900 women who were treated at 115 sites across the country, found that those who did have their lymph nodes removed were no more likely to survive five years after the surgery than those who did not, the researchers reported in a paper published in the Journal of the American Medical Association.\nIn an accompanying editorial, Grant Walter Carlson and William Wood of Emory University in Atlanta called the study an \"important contribution\" that represents the latest development in breast cancer treatment, which has steadily been moving toward less-aggressive options, sparing women from unnecessary surgery and follow-up therapy.\nThe researchers noted that the study was limited to women with tumors known as T1 or T2, meaning they were relatively small, had no enlarged nodes that could be felt, and the cancer had not spread elsewhere.\nIn the new study, Armando Giuliano of the John Wayne Cancer Institute at Saint John's Health Center in Santa Monica, Calif., and colleagues analyzed data collected from 445 women who had their nodes removed and 446 who did not, along with radiation and chemotherapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll address the following concern under this criterion because we\u2019re not sure where else to address it.\u00a0 Readers would have benefited from early clarity that all participants in the study\u00a0still had a sentinel lymph node biopsy and that the research focused on whether removal of all lymph nodes was necessary\u00a0if the sentinel nodes were cancerous.\nThe article pointed out that if breast cancer has spread to any lymph nodes, doctors usually recommend removing all lymph nodes in the arm.\nThe article reported that\u00a0in a phone interview, Gary Lyman of the American Society of Clinical Oncology said the group may revise its recommendations for full lymph node removal based on the results of this study.\u00a0 Since many surgeons and oncologists base their advise to patients on these recommendations, patients may soon be offered this less extensive surgery option. .", "answer": 1}, {"article": "Dec. 20, 2010 -- Scientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\n\nResearchers say their findings reveal activity in specific brain regions during reading that could eventually lead to new treatments for people with dyslexia.\n\n\u201cAt this time, we cannot say which treatment type will each child benefit from,\u201d study researcher Fumiko Hoeft, MD, PhD, an imaging expert at Stanford University, tells WebMD in an email. \u201cBut with more research, and if researchers combine it with intervention studies, then we should be able to identify brain patterns that are predictive of responding to one type of intervention or another.\u201d\n\nShe says in a news release that the study \u201cgives us hope that we can identify which children might get better over time\u201d and that the findings represent \u201ca huge step forward.\u201d\n\nThe discovery of brain regions involved in the learning disorder \u201cmay provide a mechanism for enduring improvement that promotes relatively successful reading development,\u201d according to the study, published in the Dec. 20 issue of the Proceedings of the National Academy of Sciences.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nFunctional MRI and Diffusion Tensor MRI are research tools not routinely available in community hospitals and not routinely used in clinical practice.\u00a0 The story does not provide any information on their availability.\u00a0 It also doesn\u2019t tell us anything about the two approaches and why/how they are different.\u00a0 It just name-drops fMIR\u00a0and DTI as if readers are supposed to know what that means.\n", "answer": 0}, {"article": "Co-authors include Loki Natarajan, Dorothy Sears and Sheri Hartman of UC San Diego; and Linda Gallo and Elva Arredondo of San Diego State University.\n\u201cNew evidence suggests that when and how often people eat can also play a role in cancer risk.\u201d\n\nWomen in the study reported eating five times per day with a mean nighttime fasting of 12 hours.\n\u201cThis is a simple dietary change that we believe most women can understand and adopt.\n\u201cIncreasing the duration of overnight fasting could be a novel strategy to reduce the risk of developing breast cancer,\u201d said Catherine Marinac, UC San Diego doctoral candidate and first author on the paper.\n\u201cThe dietary advice for cancer prevention usually focuses on limiting consumption of red meat, alcohol and refined grains while increasing plant-based foods,\u201d said co-author Ruth Patterson, PhD, UC San Diego Moores Cancer Center associate director for population sciences and program leader of the cancer prevention program.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Again, we\u2019ll rule this criterion Not Applicable. \u00a0Fasting is something that anyone could do, although some people should consult with a doctor before limiting their calorie intake or increasing the amount of time between meals.", "answer": 2}, {"article": "The most common form of breast cancer uses oestrogen to grow.\nOur study also demonstrates that statins could be a valuable addition to breast cancer treatment, and that this warrants investigation in clinical trials.\u201d\n\nThe research has not yet been tested in humans.\nCholesterol production by the tumour will not be the only reason why ER-positive breast cancers recur, but campaigners are excited by the possibilities for a treatment if further research corroborates these findings.\n\u201cThis study breaks new ground in uncovering how some breast cancers continue to survive without oestrogen and suggests that women could benefit from adding statins to standard anti-hormone treatments.\nFar too many women have to deal with the potentially devastating consequences of their breast cancer coming back and this research presents an important opportunity to improve the effectiveness of today\u2019s most commonly used treatments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says statins are currently used for lowering cholesterol. However, it should have described the clinical trials and government approval processes required for statins to become a treatment for breast cancer.\nIt\u2019s important to add that the headline says\u00a0statins\u00a0\u201ccould be\u201d added to breast cancer treatment. This sort of statement may mislead some patients who feel desperate to try anything and therefore may seek out and take statins not currently prescribed for them.", "answer": 1}, {"article": "Their metabolism slows down, they expend fewer calories when they exercise because their muscles become much more efficient, and their thyroid hormone and adrenaline levels drop.\nThe answer, published in the current issue of The Journal of Clinical Investigation, was that the leptin trick worked.\nAnd the leptin study suggests that the weight loss solution may eventually be a pill that tricks the brain into thinking that no weight has been lost.\nWhat is hard is to keep the weight off.\nEveryone who has dieted knows that losing weight is the easy part.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Doesn\u2019t mention that there is no FDA approval for the use of \nleptin in maintenance of weight loss.", "answer": 0}, {"article": "Now she's sharing their secrets with back pain sufferers across the U.S.\n\nAbout two decades ago, Esther Gokhale started to struggle with her own back after she had her first child.\nIn fact, Mummaneni says, stronger muscles might be the secret to Gokhale's success.\nSo Gokhale worked to get her spine into the J shape.\nThis time around, Gokhale wanted to find a permanent fix for her back.\nThen Gokhale realized she could help others.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the Gokhale Method is available.", "answer": 1}, {"article": "In the case of microablative fractional CO2 laser surgery, a series of microscopic laser beams using fractionated energy penetrate the skin to remove old and damaged skin cells, intended to rebuild the vaginal pathway.\n\"This study adds to the literature on vaginal laser therapy for GSM.\n\"Until more data are available, all treatment options, including lubricants, vaginal moisturizers, and FDA-approved vaginal and systemic hormone therapies, should be discussed with women who suffer from GSM to determine the best treatment option for them.\"\nThe results of this small, retrospective, non-sham-controlled study demonstrated that this type of laser surgery was particularly effective in reducing the intensity of dyspareunia (painful sex) and dryness.\nAlthough there is ongoing debate regarding the safety and effectiveness of vaginal laser surgery, a new study suggests that it may be effective, especially after multiple treatments.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s mentioned that vaginal laser surgery represents \u201cone of the newer and more hotly contested approaches\u201d to menopause symptoms.\nSo we\u2019ll give this a satisfactory mark, but it would have helped readers to give them a ballpark sense of how widely the surgery is being used in North America.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Considering having a surgeon remove your cancerous prostate using a robot?\nIn the current study, Murphy and his team looked at 68 studies of robot-assisted laparoscopic surgery to better understand its downsides.\nAnd while the robot-assisted operation is now the \u201cdominant approach\u201d to this surgery in the US and is gaining popularity in other wealthy nations, there\u2019s still too little information on how patients fare after the surgery, Dr. Declan G. Murphy of the Peter MacCallum Cancer Center in Melbourne, Australia and his colleagues write.\nAnd while some studies showed low complication rates, the researchers add, those rates went up when doctors used a standardized approach to reporting complications.\nFinally, the researchers note, expenses associated with the procedure\u2014the robot costs at least 1.8 million ($2.6 million) to install, 100,000 ($145,000) a year to run, and 1,500 ($2,200) extra for each surgical case-mean the procedure is \u201cprohibitively\u201d expensive \u201cfor many hospitals and indeed many countries.\u201d\n\nThe researchers conclude: \u201cThe significant learning curve should not be understated, and the expense of this technology continues to restrict access to many patients.\u201d\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story mentioned that robotic prostatectomy was the \u2018dominant approach\u2019 to this procedure in the United States.\u00a0 But that is an erroneous statement by the physician who is from Australia. It is certainly booming in popularity, but that doesn\u2019t make it the dominant approach. ", "answer": 0}, {"article": "\u2022 Pregnant women who were hospitalized with severe cases of flu illness were half as likely to have been vaccinated as women with non-severe illness.\nA related editorial commentary by Alan T. N. Tita, MD, PhD, and William W. Andrews, PhD, MD, of the University of Alabama at Birmingham, accompanies the new study in The Journal of Infectious Diseases.\nThe findings also underscore the importance of flu vaccination for this risk group.\nPast studies have suggested that flu antiviral therapy is safe and beneficial for pregnant women.\nFor expectant mothers hospitalized with flu, early treatment with the influenza antiviral drug oseltamivir may shorten their time in the hospital, especially in severe cases, suggests a new study published in The Journal of Infectious Diseases and available online.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Readers can infer that oseltamivir is available, since it was used in hospitals to treat patients.", "answer": 1}, {"article": "\"Our idea was that if you had an inexpensive test that was easy to use and wasn't invasive, you could reach a lot of people and prevent deaths from happening every day of the year,\" Markowitz said.\nUp until June 1, LabCorp of America had a product on the market.\nAnd you've probably heard about how early screening means early detection and removal of polyps before they turn into cancer.\nBut it's a huge step forward, especially for those who are skittish about a trip to the doctor.\nBut all of this hasn't been enough to convince a lot of people make those appointments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that one stool DNA test has been commercially available since 2003. Others will be available later in 2008 and in 2009.", "answer": 1}, {"article": "\u201cThe cause of atopic dermatitis is a combination of genetic, immune and environmental factors.\nIt\u2019ll cost $37,000 a year but the drug\u2019s makers, Regeneron Pharmaceuticals and Sanofi, have stressed that\u2019s the wholesale price and make a point of saying there will be programs to help people pay for it.\nActual costs to patients, payers and health systems are anticipated to be lower as WAC pricing does not reflect discounts, rebates or patient assistance programs,\u201d it said.\nIn a nod to the sensitivity around drug prices, the company stressed that there is no single price for the drug.\nThe agency gave it both priority review and breakthrough therapy status, speeding it through the approval process.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is now FDA approved for sale. It also says the drug \u201cis a twice-a-month injection under the skin. Patients can do it at home.\u201d However, it didn\u2019t broach the topic of how likely insurance companies are to cover this drug. Patient demand is likely to be high, but insurers may push back due to the high cost.", "answer": 1}, {"article": "Fluorouracil has the advantage of being less expensive than imiquimod.\n\"The main advantages of noninvasive treatments are good cosmetic outcome, preservation of surrounding tissue, and potential for home application of either creams,\" explained lead investigator Marieke Roozeboom of the Department of Dermatology, Maastricht University Medical Center in the Netherlands.\nThere are over two million cases a year in the U.S. and the lifetime risk of developing a BCC before the age of 85 years is one in five people.\nA three-year randomized controlled clinical trial has found that two topical creams are effective in most primary, low-risk superficial BCC, comparing favorably with photodynamic therapy (PDT), as reported by investigators in the Journal of Investigative Dermatology.\nHowever, prior to this study there has been a lack of randomized controlled trials with a long-term follow-up that compare the effectiveness of noninvasive treatments.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release implies that each of these are available treatments and the goal is to compare existing treatments.", "answer": 1}, {"article": "During the luteal phase, estrogen and progesterone levels are at their highest, which may help a woman keep addictive cravings at bay and reduce feelings of cigarette withdrawal.\nThey called for more studies to help understand all the factors that contribute to sex and gender differences in smoking.\nWomen who want to quit smoking may find it easier if they time their efforts just right.\nThe brain scans showed that during the follicular stage, cigarette imagery activated five areas of the brain which the researchers say are linked to higher-level cravings.\nResearchers asked each participant to smoke one cigarette 30 to 40 minutes before undergoing an fMRI, or brain scan.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story ends with a call for emphasis on \u201cgender-specific programs to quit smoking.\u201d Are such programs available? \u00a0The headline and the first sentence might suggest to some readers that the proof is in and that women can already get help with this. Accordingly, we\u2019ll rate this as unsatisfactory. \u00a0", "answer": 0}, {"article": "Even today, in much of the developing world, people exercise through activities such as farming and fetching water that are necessary for survival.\nWhat is a bit surprising about this chart is that running faster or farther doesn\u2019t seem to reduce death rates any more than running slowly and, in fact, in both cases is slightly worse.\nWe may tend to attribute the health of this group to their running habits.\nHowever, I\u2019d argue that the comparisons the studies make among runners are still valid.\nNothing in the data suggests that running more \u2014 farther, or faster \u2014 will do more to lower your risk of death.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Most people are aware that walking, jogging and running are exercise options. So while no specific comment was made about availability, we\u2019ll rule it Not Applicable. The story could have touched on availability in the sense that injuries, mobility issues, and health problems might prevent some people from participating in such activities.", "answer": 2}, {"article": "But high blood pressure also appears to increase a person's risk of developing Alzheimer's disease, which is associated with the accumulation of plaques and tangles in the brain.\nAnd he says other people with high blood pressure should follow his lead.\nWhen blood pressure rises, it strains the tiny blood vessels that keep brain cells alive, Koroshetz says.\nAt least two large studies have revealed an alarming trend among stroke patients, Koroshetz says.\nThe pill is his blood pressure medication.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear in the story that blood pressure medications and lifestyle changes are readily available.", "answer": 1}, {"article": "\"It's a very important trial,\" added Dr. Angeles Alvarez Secord, associate professor of gynecologic oncology at Duke Comprehensive Cancer Center in Durham, N.C. \"I've been using [the IUD] clinically for several years now for this purpose in patients who desire future fertility and some patients who cannot undergo surgery or who are at high risk for surgical complications.\nThe IUD was removed at the end of the year if there was no evidence of cancer.\nOral hormone treatment to slow down the cancer's growth is a systemic therapy, however, and can have adverse side effects such as skin rashes, nausea and vomiting, headaches and abnormal uterine bleeding, according to background material accompanying the study.\nNo adverse effects from treatment were noted, according to the researchers, who declared no conflicts of interest.\nAlthough the IUD is not yet approved to treat endometrial cancer, it is approved and widely used to treat endometriosis and abnormal uterine bleeding.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The progestin IUD is clearly available.", "answer": 1}, {"article": "Using the gentler technique, called laparoscopy, a surgeon makes small cuts in the abdomen before inserting a tiny camera inside, then performing the operation by watching a television monitor.\nYet again, the patients who had laparoscopy fared much better than those who had conventional surgery.\nThe new study, in the Annals of Surgery, doesn\u2019t settle that question.\nOn average, it cost $17,594, compared to $12,125 for the laparoscopic surgery.\nWhen the appendix had burst, however, the open surgery racked up a considerably higher bill.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The widespread use of laparascopic appendectomy was clear in the story.", "answer": 1}, {"article": "Details of the cases are documented in the paper \"Artemisia annua dried leaf tablets treated malaria resistant to ACT and i.v.\nIn effect, the dried leaves constitute a robust natural combination therapy, one whose benefits far surpass those of ACT and other combination drugs.\nThis supply chain helped produce the tablets used to treat the 18 patients in the Democratic Republic of Congo.\nThe 18 patients, ranging in age from 14 months to 60 years, did not respond to the standard ACT treatment, and all lapsed into severe malaria, defined by symptoms that can include loss of consciousness, respiratory distress, convulsions, and pulmonary edema.\nThere are more than 40 WPI project centers throughout the Americas, Africa, Asia-Pacific, and Europe.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "These tablets are only available as part of experimental compassionate use. We think the release makes it clear they aren\u2019t widely available.\u00a0  ", "answer": 1}, {"article": "Then in 2002, the results of the largest randomized clinical trial of hormone replacement, the Women\u2019s Health Initiative (W.H.I.\nstudy actually had nothing to do with menopausal symptoms.\nDr. Manson is distressed about the large number of women \u2014 about a third of those now on hormone replacement \u2014 who are relying on \u201ccustom-compounded\u201d products that have not been reviewed for safety and effectiveness by the Food and Drug Administration.\n), created a kind of menopausal panic, prompting millions of middle-age women to stop or not start hormone treatments and doctors to not prescribe them.\nfindings have been seriously misunderstood and misinterpreted,\u201d and millions of women for whom the benefits clearly outweigh the risks are needlessly being denied treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All of the therapies in the story are widely available, and the story establishes this with this sentence:\u00a0\u201cThere are also lots of products now available and different ways to use them that enhance the safety of hormone replacement.\u201d", "answer": 1}, {"article": "Human monoclonal antibodies are naturally occurring human antibodies that are genetically altered in a laboratory, cloned in large numbers and introduced into the patient to target disease sites.\nThe study was published online Nov. 5 in the Journal of the American Medical Association, to coincide with a planned presentation at the American Heart Association's annual meeting in Los Angeles.\nThe 12-week, phase 2 clinical trial was conducted at 33 international sites and included adults who suffered muscle problems when taking statins, a class of cholesterol-lowering drugs that includes Crestor and Lipitor.\nMore trials need to be done of this unique treatment, she added.\nMONDAY, Nov. 5, 2012 (HealthDay News) -- An experimental drug may help patients who can't tolerate statins lower their cholesterol, a new Australian study suggests.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that the drug is experimental.", "answer": 1}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The Wall Street Journal article provides accurate information about the availability and stormy history of two Parkinson\u2019s drugs that may increase the risk heart valve disease.", "answer": 1}, {"article": "Alzheimer's disease is the most common cause of dementia, and two out of three Alzheimer's cases are women.\nThe study also showed that the postmenopausal removal of ovaries, uterus or both was not significantly linked to the risk of Alzheimer's disease, irrespective of the indication of surgery or hormone therapy use.\nThe newest results were published recently in Neurology and Maturitas and the earlier results in the Journal of Alzheimer's disease.\nThe study explored the association between postmenopausal hormone replacement therapy, Alzheimer's disease, dementia and cognition in two nation-wide case-control studies and two longitudinal cohort studies.\n\"In the light of these findings, hormonal replacement therapy may have a beneficial effect on cognition if started early, around the time of menopause.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release presumes that people know that hormone replacement therapies are available. In this particular case, there has been so much negative news around hormone replacement therapies because of their linkage to cancer risks that it would have been worth noting that the therapies are available by prescription.", "answer": 0}, {"article": "In patients with age-related macular degeneration - or AMD - the center of the retina responsible for vision deteriorates over time.\nHe was diagnosed with wet macular degeneration, the most acute form, affecting 1.7 million Americans.\nThere's a catch: it's expensive \u2014 about $2,000 per injection \u2014 although Medicare and most insurance companies cover most of it.\n\"These symptoms were these wavy lines \u2014 and especially on the periphery of your vision,\" says macular generation patient Daniel Davison.\nIt's not a cure, but it's a blessing for Rochelle Faller.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that Lucentis was recently approved by the FDA. The story should have been more clear that the approval was for neovascular, or \u201cwet\u201d, age-related macular degeneration (AMD) and not the more common \u201cdry\u201d form of AMD.", "answer": 1}, {"article": "In rural or underserved areas, doctors sometimes must rely on a patient's symptoms or use their own judgement in looking at test sample color results to determine whether a patient has an infection.\nCollaboration with Ping Wang, associate professor of Pathology and Laboratory Medicine at the University of Pennsylvania's Perelman School of Medicine, enabled the design and implementation of the key clinical validation study.\nThey have filed a patent and hope to move forward with clinical trials that could lead to commercialization.\nThe WSU researchers found that their portable smartphone reader worked nearly as well as standard lab testing in detecting 12 common viral and bacterial infectious diseases, such as mumps, measles, herpes, and Lyme Disease.\nThe work could lead to faster and lower-cost lab results for fast-moving viral and bacterial epidemics, especially in rural or lower-resource regions where laboratory equipment and medical personnel are sometimes not readily available.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that the researchers \u201chope to move forward with clinical trials that could lead to commercialization.\u201d", "answer": 1}, {"article": "A tiny but promising study suggests that a medicine used for immune disorders may offer long-term benefits to Alzheimer's patients\u2014a result likely to spur demand for the treatment even though it is in limited supply and isn't approved for the memory-debilitating disease.\n\nThe treatment, intravenous immunoglobulin therapy, or IVIG, is made from the blood plasma of healthy young adults. Since 2004 it had shown early promise for Alzheimer's, which afflicts some five million Americans.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was very clear about availability issues and about concerns over off-label use:\n\u201cdoctors who work with Alzheimer\u2019s patients say they expect patients and families to clamor for the drug. Many say they have been asked about Gammagard for years, and this latest positive result, however small, is likely to bring an increase.\nIn February, when results in mice were published suggesting that a skin-cancer drug, bexarotene, was beneficial for Alzheimer\u2019s, many patients started calling their doctors to find out more about the drug and whether they or a family member should use it off-label.\nA spokesman for Baxter said the company \u201cdoes not support the use of its therapies for unapproved indications. Further, it remains difficult to monitor the use of our IG products for Alzheimer\u2019s disease.\u201d\nDrugs must be approved by the Food and Drug Administration for specific uses, but doctors can prescribe them to patients for other purposes. With any off-label use, there are concerns about safety and efficacy. With Gammagard, there is an additional concern about supply.\nIVIG is costly and difficult to make. Baxter says it takes 130 plasma donations to make enough to treat one patient with primary immunodeficiency today. The amount varies based on patient weight and the disease.\n\u201cThe findings are highly promising but nevertheless a double-edged sword due to the limited supply,\u201d said P. Murali Doraiswamy, an Alzheimer\u2019s researcher at Duke University who wasn\u2019t involved in the study but previously served as an adviser to Baxter. \u201cThe growing off-label demand for Alzheimer\u2019s could threaten supply for immunodeficient patients.\u201d", "answer": 1}, {"article": "People with painfully damaged knees and hips have increasingly turned to \"minimally invasive\" joint-replacement surgery. But these relatively new procedures, though they promise shorter recuperation times, are raising concerns about potential complications.\n\nMany surgeons in recent years have performed joint replacements with ever smaller incisions. In minimally invasive surgery, the incision is typically about three to four inches long, roughly half that of traditional surgery. By cutting less of the surrounding tissue...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe story says nearly half of all total joint surgeries are now being done with so-called \u201cminimally invasive\u201d approaches.", "answer": 1}, {"article": "According to the National Cancer Institute, about 32,050 men died from prostate cancer in 2010 and 217,000 new cases were diagnosed.\nMen who took acetaminophen for less than five years saw no protective benefit.\nAnother potential source of the associated reduction was reduced inflammation due to a lower circulation of interleukin-6, high levels of which \u201cpredicted a 73% increased risk of dying from prostate cancer among normal-weight men,\u201d the researchers wrote.\nThe findings are in line with previous research suggesting that physical activity may help reduce the risk of disease-related death in certain cases of prostate cancer.\nDuring the follow-up, there were 8,092 cases of prostate cancer \u2014 significantly fewer in the group who took acetaminophen daily for five years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 There\u2019s no question about the availability of the two \u201cinterventions\u201d \u2013 walking and acetaminophen.", "answer": 2}, {"article": "\"Wow!\"\nAnd the drug hasn't been submitted for review by the Food and Drug Administration, though Vertex expects to do that later this year.\nBut these results, even with plenty of caveats, suggest the drug is on the right track.\nThe experimental medicine, taken twice a day, goes by the code name VX-770.\nBut a key takeaway is that the medicine gets at a root cause of cystic fibrosis in some people rather than just relieving their symptoms.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that the drug is experimental, and that it hasn\u2019t even been put before the FDA for review yet.", "answer": 1}, {"article": "HIV infects the body by corrupting T cells that are mobilized by the immune system when the virus enters a person's body.\nThe article recently appeared in the Journal of Controlled Release.\nThe implant is composed of a hollow tube and two pliable arms to hold it in place.\n\"By delivering the medication exactly where it's needed, we hoped to increase the chances of inducing immune quiescence.\"\nWhen the T cells stay resting, it's referred to as being immune quiescent.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not made clear enough that this vaginal implant is experimental, in development, and has never been tested on humans and that it could be years \u2014 if ever \u2014 before the device is available.", "answer": 0}, {"article": "But from the beginning, Mr. Hladik resisted.\nHe wanted to be able to go to the beach.\u201d\n\nA nephrologist at the University of North Carolina School of Medicine, Dr. Hladik understood better than most how kidney dialysis could consume a patient\u2019s days.\nHis father\u2019s eventful medical history included a serious stroke and coronary bypass surgery.\n\u201cDialysis may have prolonged his life, but I suspect only by a couple of months,\u201d Dr. Hladik said.\nHis doctors managed his heart disease and hypertension with drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story presents it as a given that dialysis, renal clinics and so on are common in the health system.", "answer": 1}, {"article": "CT scans expose patients to radiation, for example, which can increase the likelihood of developing cancer.\nThe new findings add to other evidence showing that medical testing is on the rise across the U.S., although in many cases the impact on overall health remains unclear.\nUsing national data, the researchers found the rate of so-called pulmonary embolisms, or PEs, nearly doubled with the introduction of a new powerful diagnostic test more than a decade ago.\n\u201cRather than an epidemic of disease, we think the increased incidence of PE reflects an epidemic of diagnostic testing that has created overdiagnosis,\u201d the researchers write in the Archives of Internal Medicine.\nAccording to the new results, such complications rose from three to five per 100,000 people hospitalized with PE per year after doctors began using chest CT scans.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that chest CT scans are \u201cbeing used in millions of patients every year in the US.\u201d", "answer": 1}, {"article": "When it comes to health, I\u2019m skeptical of willpower. Sure, I talk to my students about personal responsibility, but when it comes to the health of populations, I look for big fixes more than for small acts of will.\n\nThat\u2019s why my ears perked up when I heard that two old physician friends had decided to start taking, as a preventive measure, some of the medications often included in what the field has dubbed the \u201cpolypill.\u201d My friends are both top doctors in their 60s, with good diet and lifestyle, and this is now part of their...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was a confusing point for us\u2013the author mentions having two friends who appear to be self-medicating using several of the mentioned drugs, with the aim of preventing heart disease and diabetes. Then we\u2019re told that a similar\u00a0regimen could feasibly be rolled into a one-size-fits-all\u00a0\u201cpolypill\u201d for the general public, and the story speculates what that pill \u201cmight\u201d contain. \nThe story then adds, as an aside, that there is a less comprehensive \u201cpolypill\u201d available via online ordering, and provides a link to the site. \nIt\u2019s not clear if or when a more comprehensive polypill for the masses might become available.", "answer": 0}, {"article": "He is president and chair of the department of public health sciences at the University of Li\u00e8ge in Belgium.\nNearly one in 100 people have evidence of knee osteoarthritis on an X-ray.\nNov. 12, 2012 -- A drug used outside the U.S. to treat osteoporosis may not only lessen the everyday pain associated with knee osteoarthritis, but may even slow down the progression of osteoarthritis, researchers say.\nStudy head Jean-Yves Reginster, MD, PhD, presented the findings today at the American College of Rheumatology (ACR) Annual Meeting in Washington, D.C.\nAnd nearly 19% of women and 14% of men age 45 and older have joint pain, stiffness, and other symptoms of knee osteoarthritis, according to a large 2007 study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that strontium ranelate\u00a0is available as a prescription drug for osteoporosis in some other countries, but is not approved in the U.S.\u00a0It explains that other strontium formulations\u00a0are available as nutritional supplements in the U.S., but that these might not work the same way that the strontium drug tested in the study works.", "answer": 1}, {"article": "Schizophrenia is a long-term mental health condition that causes a range of psychological symptoms, ranging from changes in behavior through to hallucinations and delusions.\nThe game, \u201cWizard\u201d, is designed to help so-called episodic memory \u2014 the type of memory needed to remember where you left your keys several hours ago, or to remember a few hours later where you parked your car in a multi-storey car park.\n\u201cThis proof-of-concept study...demonstrates that the memory game can help where drugs have so far failed.\nScientists at Cambridge University said tests on a small number of patients who played the game over four weeks found they had improvements in memory and learning.\nImportantly, the patients also said they enjoyed the game and were motivated to play it across the eight hours of cognitive training.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t tell readers whether the game, called \u201cWizard,\u201d is currently available for iPad users. This is particularly problematic, because searching for an iPad game called Wizard returns a number of options. Are any of those options the correct game? What is the current stage of availability?", "answer": 0}, {"article": "AURORA, Colo. (Nov. 16, 2016) - Researchers at the University of Colorado Anschutz Medical Campus have found that high doses of vitamin D reduce the incidence of acute respiratory illness (ARI) in older, long-term care residents.\nThe findings of the clinical trial, published today in the Journal of the American Geriatrics Society, could help reduce one of the leading causes of serious illness, debilitation and death among patients in nursing homes and other long-term care facilities.\nThose with higher doses saw ARIs cut nearly in half.\nThey also had over double the incidence of falls, the study said.\nBut Ginde said the primary finding that vitamin D can reduce ARI is a major step forward in treating these dangerous infections.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no mention of availability, but it\u2019s generally understood that vitamin D is widely available.", "answer": 2}, {"article": "Hospice care is intensive palliative care including home nursing, but insurers and Medicare usually cover it only if the patient abandons medical treatment and two doctors certify that death is less than six months away.\nIn practice, Medicare and private insurers do pay for some palliative care, said Dr. Gail Austin Cooney, a former president of the palliative medicine academy.\nIt includes the options any oncologist addresses: surgery, chemotherapy and radiation and their side effects.\nThis trial was paid for by the American Society of Clinical Oncology and private philanthropy.\n\u201cBut I couldn\u2019t have completed the program without the psychosocial support.\u201d\n\nPalliative care experts now want to study patients with other cancers, heart disease, stroke, dementia and emphysema.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Mixed bag here. The Times noted that Medicare pays for some palliative care services but that billing difficulties may deter physicians from offering\u00a0it.\u00a0However, there was no mention of the difficulty patients may have accessing\u00a0the type of outpatient palliative care services that were offered in this study. Most non-hospice palliative care is currently provided only in the inpatient / acute care hospital setting. A borderline\u00a0satisfactory.", "answer": 1}, {"article": "\u201cIt\u2019s not a decision made on a single visit,\u201d she said.\n\u201cThis is the first study to prove women survive longer with these preventive surgeries and shows the importance of genetic testing when there is a family history of early breast or ovarian cancer,\u201d Dr. Virginia Kaklamani of Northwestern University in Chicago wrote in a commentary about the study published in the Journal of the American Medical Association.\nShe said primary care physicians, gynecologists and women \u201cneed to be more aware that these tests exist.\u201d\n\nDr. Sandhya Pruthi, a breast cancer expert at the Mayo Clinic in Rochester, Minnesota, who counsels women with BRCA mutations, said the study adds more evidence that the surgery can help save lives, but the choice is never easy.\nThe study shows the benefits of genetic tests that give women with a family history of cancer the chance to take steps to increase their chances of survival, they said.\n\u201cOur results confirm that risk-reducing mastectomy is associated with a significant reduction in breast cancer risk,\u201d Domchek and colleagues wrote.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not mention that the type and quality of genetic testing, genetic counseling, surgery and surveillance offered to women in this study may not be available to women in other settings.", "answer": 0}, {"article": "If not effectively treated, depression can become a chronic disease that increases a person's risk of mortality from suicide, heart disease or other factors.\nThe research team focused on patients in the database who received ketamine, narrowing their study population down to approximately 41,000.\nThe study, published May 3 in Scientific Reports, also uncovered antidepressant effects for three other drugs typically used for other purposes -- Botox, the pain reliever diclofenac and the antibiotic minocycline.\nThat control group eliminated the possibility that people who take ketamine have less depression because they have less pain.\n\"This study extends small-scale clinical evidence that ketamine can be used to alleviate depression, and provides needed solid statistical support for wider clinical applications and possibly larger scale clinical trials.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not address availability or how many physicians currently prescribe ketamine for depression.", "answer": 0}, {"article": "Publicity in recent years about emotional, cognitive, and memory problems in aging football and hockey players who suffered multiple concussions during their careers has raised the anxiety level around the topic. A lawsuit by thousands of NFL players who claim the league did not keep them well enough informed about the long-term risks of concussion - dementia is one of them - is based in Philadelphia and has raised even higher the profile of what doctors call mild traumatic brain injury.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story refers to the growing use of cognitive rest.", "answer": 1}, {"article": "The liquid is called silver diamine fluoride, or S.D.F.\nIt\u2019s been used for decades in Japan, but it\u2019s been available in the United States, under the brand name Advantage Arrest, for just about a year.\nNow there\u2019s an alternative: an antimicrobial liquid that can be brushed on cavities to stop tooth decay \u2014 painlessly.\nBut studies show it can halt the progression of cavities and prevent them, and dentists are increasingly using it off-label for those purposes.\nNobody looks forward to having a cavity drilled and filled by a dentist.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the use of SDF is not widespread in the U.S., but that it is becoming increasingly available.", "answer": 1}, {"article": "Vasopressin, an anti-diuretic, reduces urine production.\nIn the United States there's no approved drug to treat the problem, the study authors said.\nThere's more on nocturia at the National Association for Continence.\nBut help could soon be at hand in the form of a nasal spray, new research suggests.\nA spritz of a synthetic hormone, already used by bed-wetting kids, might benefit older people struggling with the problem called nocturia.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that it\u2019s not FDA approved yet.", "answer": 1}, {"article": "The findings \"are pretty much in line with what all the other studies have shown comparing Atkins and low-fat diets,\" said Bonnie Brehm, assistant professor of nutrition at the University of Cincinnati College of Nursing and co-author of two, independent studies of the Atkins diet.\nBoth the authors and other weight-loss experts were quick to note that the new findings did not answer the question of what is the best way for most people to shed weight.\nAll the participants reported eating about 2,000 calories a day when the study began.\nBut as researchers noted, if participants ate as little as they said, all the groups would have lost much more weight.\nAll also reported having cut their intake -- some by as much as 500 calories per day at two to six months -- but then gradually adding back many of those calories.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story reported on a study that compared weight loss of overweight and obese individuals who followed one of four popular weight loss diets.\u00a0 The story mentioned that the people in the study were given a book on the diet that they were assigned to follow and\u00a0the books used are available commerically.\u00a0 It would have been helpful to readers to include explicit details on the specific books used.", "answer": 1}, {"article": "\u201cBut there\u2019s never before been data saying how harmful stopping shortly before surgery can be.\nThe scientists had no data on how long patients had been taking statins, but only on when they stopped.\n\u201cWe already knew that people on statins before surgery had a decreased risk of death,\u201d said a co-author, Dr. Yi Deng, an assistant professor of anesthesiology at Baylor College of Medicine.\nResearchers looked at 3,021 heart surgery patients, most of whom were taking cholesterol-lowering statins.\nAfter controlling for many preoperative health and behavioral characteristics, they found that compared with other patients, those who took statins on the day of surgery had a 48 percent reduced risk of dying in the next 30 days.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is no mention of whether statins are widely available, available by prescription only, etc. We might presume that everyone knows how popular statins are and how widely prescribed, but we always think it\u2019s a good idea to make it clear how someone would gain access to a particular therapy.\nA simple line saying something to the effect of \u201cthese medicines have been around for many years, are widely used and available in inexpensive generic formulations\u201d would have addressed this.", "answer": 0}, {"article": "That number was the same in younger people who had large waistlines, and even lower in those with metabolic syndrome, a combination of risk factors including belly fat, high blood pressure and high blood sugar.\nColonoscopy, used in millions of Americans every year, is just one of many methods to detect abnormalities.\nOne gastroenterologist said the results were \u201cimportant\u201d but should not change practice.\nAs a result, he said, it is hard to know whether removing polyps in younger people would in turn lower their risk of getting cancer.\nLeFevre, a member of the U.S. Preventive Services Task Force, a federally appointed expert panel, said the chances that a polyp turns into cancer is currently a matter of debate.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly colon cancer screening is available.", "answer": 1}, {"article": "Women choosing to have both breasts removed face higher surgery costs and slightly higher risks of post-surgery complications and infections.\nIt\u2019s an emotional decision that women often make quickly, considering that surgeries often take place within days of their cancer diagnosis.\nFor other women, a double mastectomy might eliminate another breast cancer, but it won\u2019t stop cancer from resurfacing in vital organs, Tuttle said.\n\u201cIf I didn\u2019t do as much as possible to eliminate the cancer, I would feel like I was almost waiting for the other shoe to drop.\u201d\n\nWomen removing a single cancerous breast have a 1 percent chance per year of suffering cancer in the other breast.\nThe survey results came a decade ago, however, when the safety of breast implants was a major issue, said Mayo\u2019s Dr. Lynn Hartmann.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article implies, accurately, that double mastectomy is available at any facility that provides breast cancer treatment. ", "answer": 1}, {"article": "\u201cWe\u2019ve seen individuals who have lost significant amounts of weight in the six-month period.\nZafgen has not identified the patients who died or said at which of 14 US trial sites they were taking the drug.\nWhile the FDA\u2019s clinical hold prevented Zafgen from completing its trial, Dennis D. Kim, the company\u2019s chief medical officer, said it was largely finished.\nSome analysts have suggested the FDA might approve the drug, despite the adverse events, if Zafgen can prove its benefits outweigh its risks to some patients.\nThomas E. Hughes, chief executive of Zafgen, said the Boston company will use the data to prepare a \u201crisk-mitigation\u201d plan to help persuade the Food and Drug Administration to lift its so-called clinical hold on the late-stage trial, allowing it to resume.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is made clear that the beloranib drug is still under experimentation and pending FDA approval.", "answer": 1}, {"article": "Seizures can be obvious, causing unconsciousness or convulsions, but often they trigger subtler changes in a person's perceptions or behavior -- like a short staring spell, confusion or an altered sense of taste or smell.\n\"We just wanted to see if this is feasible, and this study shows that it is,\" said lead researcher Dr. Mark Cook, of the University of Melbourne and St. Vincent's Hospital in Australia.\nStill, Mehta agreed that the technology could prove helpful to some people with epilepsy.\nIt may be the people who fall in the middle -- who have disabling seizures at unpredictable intervals -- who would stand to benefit the most, he said.\nBut what's still needed is evidence that this device does improve the quality of patients' lives, Mehta said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have been more explicit about how far away from marketing approval such an approach might be.\u00a0 But we\u2019ll call it satisfactory for at least including this from the independent expert quoted:\n\u201cThis study is an important first step,\u201d said Mehta, who was not involved in the research. \u201cThe next step would be to implant these in a larger sample of patients. And you need to see which groups of patients might be good candidates for this.\u201d", "answer": 1}, {"article": "Cigarette smoke causes 90 percent of all cases of lung cancer, which kills 1.2 million people a year globally.\nFewer than half of all lung cancer patients who do well after a first course of chemotherapy get more treatment, but the Italian group said their study shows this is worth doing.\nSix months later, \u201cformer smokers showed significant improvements on all measures, indicating that treatment with iloprost may reduce the risk of developing lung cancer among former smokers,\u201d the researchers said.\n\u201cOral iloprost showed promise for preventing lung cancer in former, but not current, smokers in a phase II clinical trial,\u201d they wrote in a summary presented to a meeting of the American Thoracic Society in New Orleans.\nSeparately, Italian researchers reported that advanced lung cancer patients given the targeted therapy drug Tarceva as so-called maintenance treatment \u2014 after they finished a course of standard chemotherapy \u2014 lived a little bit longer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story gets a marginal satisfactory. In the first half, we\u2019re told of inhaled iloprost\u2019s availability for certain indications, which don\u2019t include the prevention of lung cancer. It could have been a lot clearer that the oral formulation is not currently available to patients; right now, we can only tell that by inference given the indications and brands mentioned for inhaled and IV formulations are mentioned.\nIn the second half, we\u2019re told that erlotinib is currently sold as Tarceva. It would have been good to note its indications, which were expanded in April to cover the approach used in this study because of the results of the study.", "answer": 1}, {"article": "But Dr. Malgorzata Skaznik-Wikiel, an obstetrician-gynecologist who led the study, is encouraged.\nMore studies need to replicate and confirm the role that omega 3 fatty acids might play in fertility, but for now, Skaznik-Wikiel says that there isn\u2019t much harm in consuming more omega 3 fats.\nBut other studies Skaznik-Wikiel has done with mice suggests that these fats may lower levels of inflammation that can adversely affect ovarian function.\nNow, according to scientists at the University of Colorado, there is even evidence that the healthy fat can boost your chances of getting pregnant.\nThe study, presented at the American Society of Reproductive Medicine annual meeting, was in mice, so more research needs to be completed before omega 3 foods or supplements become part of treatment for infertility.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both omega 3-rich foods and omega 3 supplements are widely available.", "answer": 1}, {"article": "While Drs.\nThe present analysis was not supported by industry funding.\nThe FAME 2 trial was supported by St. Jude Medical.\nThe trial was initially sponsored by St. Jude Medical, a global medical device company, until the three-year follow-up.\n\"Our trial over its entire follow-up shows us that the longer you observe these patients, the more pronounced the benefits of the initial PCI become,\" said Dr. J\u00fcni, who is also a Canada Research Chair and a Professor of Medicine at the University of Toronto.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s apparent that PCI is widely available and that there is debate about when to use it.", "answer": 1}, {"article": "Anderson Cancer Center in Houston.\nThe goal of the vaccine, Hale said, is to educate the body to respond to that HER2-based peptide, so it will recognize the cancer when it recurs and attack it.\nThe study is a phase 2 study, meant to evaluate the vaccine's effectiveness and any side effects.\nThe science is early, Hale stressed, and it will take at least five years before the vaccine could conceivably be available if ongoing studies bear out.\nNumerous vaccines to prevent breast cancer recurrence are currently under study, he noted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated \u201d it will take at least five years before the vaccine could conceivably be available if ongoing studies bear out.\u201d", "answer": 1}, {"article": "Who and When: More than 140,000 U.S. women who had DCIS between 1998 and 2014; this study compared lumpectomy plus radiation vs. lumpectomy alone, lumpectomy vs. mastectomy, and lumpectomy plus radiation vs. mastectomy\n\nWhat (Study Measures and Outcomes): Use of radiation and/or extent of surgery (exposures); breast cancer mortality rates within 15 years (outcomes)\n\nHow (Study Design): This was an observational study.\nRelated Material: The invited commentary, \"Systemic Effects of Radiotherapy in Ductal Carcinoma In Situ,\" by Mira Goldberg, M.D., and Timothy J. Whelan, B.M., B.Ch., of McMaster University, Ontario, Canada, also is available on the For The Media website.\nTo Learn More: The full study is available on the For The Media website.\nEvery article is free online from the day of publication.\nWhy The Research Is Interesting: Patients with DCIS are often treated with radiation after lumpectomy, although it has remained unclear whether this can reduce the risk of dying from breast cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that radiation and surgery are widely available treatments.", "answer": 2}, {"article": "He drank to forget.\n\u201cThe MDMA seems to act as a catalyst that allows the healing to happen.\u201d\n\nWhat do patients say about it?\nThe drug floods the brain with hormones and neurotransmitters that evoke feelings of trust and well-being, users report.\nI realized I had viewed myself as a monster, and I was able to start to have some compassion for myself.\n\u201cThe MDMA alone or the therapy alone don\u2019t appear to be as effective,\u201d Dr. Mithoefer said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s made clear that MDMA \u201cis about to enter larger Phase III trials,\u201d the FDA has granted pharmaceutical grade MDMA breakthrough therapy status, and that illegal sources exist but are potentially dangerous.\nIt\u2019s also mentioned that there have already been several other small-scale studies of the drug, and that if MDMA is eventually approved by the FDA it will only be administered by a licensed therapist.\nWe did have one quibble\u2013the story predicts that, if larger studies go well, the drug could be approved for this use \u201cby 2021.\u201d In reality, there\u2019s really no way of knowing what year a drug will get approved.", "answer": 1}, {"article": "If a woman's doctor tells her she does not need radiation after a mastectomy, the woman should be told why and she should ask if the radiation oncologist weighed in on the decision.\nThe guidelines don't offer a single formula for which patients need radiation therapy, Edge noted.\nThe new guidelines help clarify what used to be a gray area, Andrews explained.\nDoctors need to weigh the risks and benefits, Edge added.\nAndrews said that one take-home message for patients is to expect the surgeon to have consulted with the radiation oncologist and others on her team.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t address availability. However, since it is referring to an existing form of therapy that is widely used, we\u2019ll rate this as not applicable.", "answer": 2}, {"article": "\u201cThis is great news,\u201d says Kay Dickersin, PhD, an epidemiologist with the Johns Hopkins School of Public Health and director of the U.S. Cochrane Center.\nIt updates a 1999 Cochrane review that found no strong evidence to recommend zinc as a help for colds.\n\u201cThe evidence from the recent trials does support the use of zinc lozenges in treatment of common cold,\u201d says study researcher Meenu Singh, MD, a pediatric pulmonologist at the Post Graduate Institute of Medical Research in Chandigarh, India.\nFeb. 15, 2011 -- Taking zinc, either as a syrup or lozenge, through the first few days of a cold may shorten the misery of an upper respiratory infection, a new research review shows.\nThe review also found that zinc cut the number of days that kids missed school because of being sick and reduced the use of antibiotics by cold sufferers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not make it clear where zinc treatments are available. One could assume that most readers would know, but we think the Reuters Health story did a better job here by actually pointing out that zinc lozenges are sold in most drug stores and even adding the important detail that a specific zinc nasal spray, Zicam, was removed from the market.\u00a0To its credit however, the story does emphasize that additional research is needed to identify the right zinc preparation and dose.", "answer": 0}, {"article": "For example, insulin resistance, where the body does not use insulin effectively, occurs long before blood sugars reach the level seen in type 2 diabetes.\n\"These findings could provide insight into metabolic pathways that are altered very early in the process leading to diabetes,\" says researcher Thomas Wang, MD, of Massachusetts General Hospital's Cardiovascular Research Center, in a news release.\n\"They also raise the possibility that, in selected individuals, these measurements could identify those at highest risk of developing diabetes so that early preventive measures could be instituted.\"\nResearchers found that blood tests that screened for these amino acids accurately predicted risk of type 2 diabetes in otherwise healthy adults as well as in those with traditional risk factors such as obesity.\nResearchers say metabolic abnormalities that eventually lead to type 2 diabetes can be present years before diabetes is diagnosed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article says that further studies will be needed. It would have been useful to state that any clinically available screening test would be years off. The article doesn\u2019t give readers a sense of how far away this hypothetical test is from practice. Are the tools even being used in blood labs, or is this all being done purely in a research setting?", "answer": 1}, {"article": "\u201cIt all depends on how you approach risk,\u201d Dr. Zelen said.\nBut, cancer experts said, no one would do such a study today when mammograms are generally agreed to prevent breast cancer deaths.\nMarvin Zelen, a statistician at the Harvard School of Public Health and the Dana-Farber Cancer Institute, who was a member of the research team said even though the mammography benefit is small, if he were a woman he would get screened.\n\u201cThis is the first time researchers used real populations to compare the effects of treatment and mammography in the modern era of treatment,\u201d Dr. Kramer said.\n\u201cWe were surprised,\u201d said Dr. Mette Kalager, the lead author of the paper who is a breast surgeon at University and a visiting scientist at the Harvard School of Public Health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe availability of mammography screening is not at issue. This story does point out that the women who were screened in Norway had access to special treatment teams. And it noted that these treatments are available at \u201cmany major medical centers in the United States.\u201d", "answer": 1}, {"article": "The beneficial effects of traditional acupuncture, according to the researchers, did not appear to be associated with changes in levels of hormones that trigger menopause and its associated symptoms.\nAfter 10 weeks, the women in the traditional acupuncture group had significantly less severe hot flashes and mood swings than those who'd gotten the fake treatment.\nThe research included 53 postmenopausal women, with about half receiving traditional Chinese acupuncture twice a week and the others given sham acupuncture treatments.\nThe findings were published online March 7 in Acupuncture in Medicine.\nThere were no differences between the two groups in terms of vaginal dryness and urinary tract infection.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was a story about a Turkish study (not explained in the story) on Chinese acupuncture.\u00a0 If a woman doesn\u2019t know anything about acupuncture, this story told her nothing about its availability in the U.S.", "answer": 0}, {"article": "In 2014, prostate cancer was the leading cause of newly diagnosed cancers in men and the second leading cause of cancer death in men.\nWhen compared to surrounding healthy tissues, it\u2019s hoped that contrast enhanced MRIs will reveal the shape and nature of any tumors present.\n\u201cThis new approach is a more reliable imaging technique for localizing tumors.\nThe technique is also valuable in surgical planning and image staging, said David S. Karow, MD, PhD, assistant professor of radiology at UC San Diego and the study\u2019s corresponding author.\n\u201cProstate cancer can often be an indolent disease, where a patient may only require surveillance rather than aggressive surgery,\u201d noted co-author Christopher J. Kane, MD, professor of urology at UC San Diego.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear from the release when or whether this technology might become available, if it\u2019s not available already.", "answer": 0}, {"article": "The Department of Nutrition, Exercise and Sports conducts research, education, innovation, and dissemination of information in nutrition, human physiology and sports at the highest international level, and incorporates the humanities as well as health and social sciences.\nThe latest findings, as published in AJCN, concluded that a personalized nutritional approach based on an individual's biomarkers will lead to improved weight loss and maintenance success.\nFor people with type 2 diabetes, the analysis found that a diet rich in healthy fats from plant sources would be effective for achieving weight loss.\nThe research analyzed data from three diet clinical trials which collectively looked at more than 1,200 individuals - Diet, Obesity, and Genes (DiOGenes); the OPUS Supermarket intervention (SHOPUS); and the Nutrient-gene interactions in human obesity (NUGENOB).\nThe different studies (six in total) employed a variety of nutrition strategies, including caloric restriction and ad libitum diets, varying the contributions of carbohydrate and fat, and increasing fiber intake.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The two biomarkers are said to be a simple alternative to other means of customizing dietary plans for persons with pre-diabetes or type 2 diabetes.\nHow do you know what kind of diet you\u2019re supposed to eat based on your biomarker profile? Presumably you\u2019re prescribed a diet and told what to eat. But if you\u2019re a consumer, how do you know what that diet is? In other words, how do you benefit from this? Is someone selling personalized nutrition recommendations based on these biomarkers? ", "answer": 0}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"If we're going to drive further improvements in survival from cancer, it's essential that we find ways of prolonging life in people whose cancers have evolved and become resistant to treatment.\nThe new research, published today (Thursday) in The Lancet Oncology, shows that even women with specific genetic changes conveying resistance to hormone therapy can benefit from the new drug combination.\nWe hope our results lead to the adoption of this drug combination in breast cancer, where it delays the need to start chemotherapy by an average of nine months.\nIn the trial, severe side-effects caused by the combination were rare.\nThe combination allowed many women with metastatic hormone-receptor-positive, HER2-negative cancer to delay the start of chemotherapy, which is the traditional treatment option in these patients once hormone drugs have stopped working.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t say whether fulvestrant and palbociclib are available or FDA approved.", "answer": 0}, {"article": "Laurie Fenton, president of the Lung Cancer Alliance, an advocacy group headquartered in Washington, said: \"We think this is a breakthrough for lung cancer.\nOf that group, 85 percent had small tumors that had not spread.\nOthers, including researchers and policymakers in the government, say it is a question that will not be settled for five or six years, when other studies are complete.\nUltimately, 535 were biopsied to see if they were lung cancer -- and 484 were.\nIn the ensuing years, about 27,000 more scans were done, with some people having them annually.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not discuss if the lung cancer screenings are available, or how widely available the screening scanners may be. The story should have mentioned that the tests are being advertised by private\u00a0screening centers and some hospitals, but are not generally covered by insurance.", "answer": 0}, {"article": "In the current review, researchers found several trials that compared different doses of radiation and different types of radiation therapy, including external beam radiation therapy, in which a radiation is delivered through a beam through the skin, or brachytherapy, in which radioactive isotopes are delivered via injection into the prostate.\nFor those methods, too, there was too little research to say with confidence which method was superior in preventing deaths from prostate cancer, the researchers said.\nFinally, patients and their doctors should weight the potential debilitating side effects of the treatments, such as incontinence and erectile dysfunction, against how comfortable the man is with holding off on treatment, experts say.\nIn part, that's because researchers found no randomized controlled trials -- considered the gold standard of research -- that compared radiation therapy with watching waiting, Ip said.\nProton beam therapy in particular is expensive, but according to this report, there isn't enough evidence to show it's any better than other option.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The story didn\u2019t explicitly address the availability of radiation facilities, but that wasn\u2019t necessary.", "answer": 2}, {"article": "\"It affects your whole life.\"\nFor Linda O'Brien, a grandmother and scratch golfer, chronic knee pain was making life unbearable.\nHelp for O'Brien finally arrived in a new kind of knee surgery, developed and perfected at Chicago's Rush University Medical Center by Dr. Richard Berger.\nThe new surgery simply moves them to the side in order to fit the knee with titanium and plastic caps \u2014 creating a knee joint free of pain and arthritis.\nO'Brien first hurt her knee when she was in her 20s and for the next 30 years her many activities only made it worse.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story did not include discussion about availability of this treatment or whether it was an FDA approved medical device. According to the company website, in 2004 there were more than 500 orthopedic surgeons trained in the use of this device. So it\u2019s availability is limited. There was no mention that this particular type of knee replacement was not an option for all patients who were candidates for standard total knee replacement. Factors that may rule out some patients include variation in knee structure, prior surgery on the same knee, obesity, a recent history of deep vein thrombosis (DVT), and other unstable medical conditions. ", "answer": 0}, {"article": "\"If you have your choice, you want to get poked with a needle or you want to try this?\nGomaa's hope is that vaccine patches will cost less than vaccinations do now.\nAnd the patch can be administered by people who aren't trained health professionals.\nA number of the people in the flu patch study applied it to themselves.\nAnquetil notes that the older devices sometimes made patients feel as if they had been punched.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Overall, this story adequately addresses availability. It\u00a0explains that flu patches aren\u2019t yet available on the market; it may be some time until readers can walk down to the corner pharmacy and buy their own flu patch over the counter. The jet injection and nasal spray are described as already widely available.", "answer": 1}, {"article": "Behind that common piece of advice is a complex series of physiological processes that calm the body, slow the heart and help control pain.\n\nBreathing and controlling your breath is one of the easiest ways to improve mental and physical health, doctors and psychologists say. Slow, deep and consistent breathing...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story includes a link to the Spire web site. It\u2019s clear that the device can be purchased.", "answer": 1}, {"article": "The resource you are looking for might have been removed, had its name changed, or is temporarily unavailable.", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u201ds clear that \u201cThe Baseball Diet\u201d materials are for sale now. A link to the product web site is included.", "answer": 1}, {"article": "Since IVM results in lower fertilization rates, protocols that use IVM are more likely to also use intracytoplasmic sperm injection (ICSI), in which one sperm is injected into one egg.\nFor starters, since there is less time involved with IVM, women who are undergoing chemotherapy, radiation or plan to have surgery may be good candidates.\nIVM has the potential to improve the chances for women to have babies without a long course of hormones.\nThey also note that the technology hasn\u2019t been widely used and that there are no studies looking at the outcomes of birth defects or developmental delays.\nAlthough IVF is still considered the gold standard, there\u2019s an infertility treatment available that is offering hope \u2014 in vitro maturation (IVM).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article really could have used some information about how widely available assisted reproductive medical expertise is in the U.S. and the fact that academic medical center, and major public hospitals and health systems, also offer the treatments along with free standing fertility clinics.", "answer": 0}, {"article": "HIV, which stands for human immunodeficiency virus, infects and can destroy or change the functions of immune cells that defend the body.\n\u201cWhat we learn from this could also have implications to other brain-related diseases like Alzheimer\u2019s and Parkinson\u2019s since the same inflammatory cells have been found to be involved.\u201d\n\nKnowing more about this interaction could ultimately lead to new therapeutic agents that could help HIV patients specifically maintain their mental function.\nHis lab was the first to identify the proteins that can bind marijuana compounds on the surface of immune cells.\n\u201cThe patients who didn\u2019t smoke marijuana had a very high level of inflammatory cells compared to those who did use,\u201d Kaminski said.\nUp until then, it was unclear how these compounds, also known as cannabinoids, affected the immune system.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Given that marijuana is still illegal in most states and considered illegal by the federal government, it would be worth mentioning that patients hoping to receive a marijuana treatment would have to live in a state where it is legal for medicinal purposes.", "answer": 0}, {"article": "The website for LipoFuze says that the supplement \"increases the metabolic mechanism in your body.\" The site also says the green tea and caffeine will \"rev up your metabolism\" and \"increase energy, focus and physical performance.\" The site features testimonials it says are from users who claim they have lost huge amounts of weight with the help of LipoFuze. One man says he dropped more than 100 pounds, although it's unclear how long that took. A woman says she lost 40 pounds in less than a year, including 20 pounds in her first month.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The column says that one of the products mentioned is available at many drugstores.\u00a0 There isn\u2019t any comment on availability of the other product mentioned.\u00a0 We\u2019ll give the story the benefit of the doubt on this one.", "answer": 1}, {"article": "For example, before adjusting for these kinds of differences between the groups, the researchers found that light drinking was connected with 33% lower rates of overall behavior problems in boys \u2014 after the adjustment, that effect fell to 23%.\nEven More Evidence for the Health Benefits of Drinking\n\nPhotos: What Booze Looks like Under a Microscope\nA glass of wine or two a week \u2014 and not more than one large glass on any occasion \u2014 may be safe during pregnancy, according to a large study just published in the Journal of Epidemiology and Community Health.\n(More on Time.com: If I\u2019m Drunk, Then You Stepped On My Toes On Purpose)\n\nInterestingly, the new study parallels the effects of alcohol on health more generally; lighter drinkers tend to do better than teetotalers while the heaviest drinkers do worse.\nWhatever the case, American health authorities remain united in their advice that no amount of alcohol is safe for the fetus during pregnancy \u2014 and anyone who is familiar with fetal alcohol syndrome knows why.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This does not seem to apply here.", "answer": 2}, {"article": "A healthy cholesterol level is less than 200 mg/dL, according to the American Heart Association, while 200 to 239 mg/dL is considered \u201cborderline high.\u201d\n\nIn the groups taking 100 and 200 micrograms of selenium daily, total cholesterol dropped an average of 8.5 mg/dL and 9.7 mg/dL, respectively, compared to the group taking a placebo pill.\nStill, the finding is \u201creassuring\u201d because previous research had linked high selenium with higher cholesterol levels, said study author Dr. Eliseo Guallar, from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nResearchers measured participants\u2019 cholesterol levels at the beginning of the study and after six months on the selenium supplements or placebo.\nWhile Guallar said the results are \u201cgood news\u201d in showing that high selenium intake is probably not a risk for high cholesterol, he wanted to add a note of caution.\nThey recruited about 500 older adults in the UK to take one of three different doses of selenium daily \u2014 100, 200, or 300 micrograms \u2014 or a placebo pill with no selenium.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discusses food sources of selenium and notes that the mineral is sold\u00a0as a supplement, so availability is not an issue.The story could have mentioned that selenium is pretty uniformly a component of multivitamin formulations. Individuals adding a selenium-specific supplement to a multivitamin could easily exceed the levels used in this study.", "answer": 1}, {"article": "DURHAM, N.C. - Most high-risk lung cancer patients might not need annual low-dose computed tomography (LDCT) screenings if they are cleared of disease in their initial test, according to a study led by a Duke Cancer Institute researcher.\nHe added that improving the accuracy of LDCT screening for lung cancer would also significantly reduce the number of annual screens.\nOf the initial 19,066 participants with a negative initial LDCT scan, 444 (2 percent) were diagnosed with lung cancer at the time of the last available follow-up.\nAn additional 75 patients (0.4 percent of the initial negative group) were diagnosed with lung cancer between the first and second annual screening.\nThe researchers determined that eliminating the first annual screening after the initial negative test might have resulted in, at most, an additional 28 lung cancer deaths in the LDCT group (186 vs. 212 deaths per 100,000 per years) over the course of the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t specify where low-dose CT is used and if most readers can access it. We do know that the screen has been approved for use in the United States and is being adopted by some health centers.", "answer": 0}, {"article": "A large, new study may be reassuring to women considering mastectomies because of a history of breast cancer in their families.\n\nStanford University researchers affirmed that women with mothers and sisters who carry one of the BRCA gene mutations but who aren't carriers themselves don't have an especially heightened risk of breast cancer.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that BRCA testing is available to women who want it.", "answer": 1}, {"article": "Another person said of their pet birds: \"If I didn't have my pets I think I would be on my own.\nSo they're doing a lot of the work of managing their conditions.\nThe pets provided more than just emotional support and companionship, participants said.\nSixty percent of the people who considered pets to be a part of their social networks placed them in the central, most important circle \u2014 the same place many people put close family and social workers.\nFor many of these people, says Brooks, animals can break through the isolation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re going to act under the assumption that readers are familiar with the idea of pet ownership.", "answer": 2}, {"article": "The company, which says gammaCore is already available in the European Union, expects to start selling it later this year in the U.S.\n\nVagus nerve stimulation is used to treat a range if disorders, including epilepsy, depression and overeating.\nRelated: New Migraine Drugs Would Treat Pain Before it Starts\n\nSilberstein helped test the device, which users press against the neck.\n\u201cIt is a way for patients to treat their symptoms as often as they need to use the device.\nBoth approaches are limited \u2014 it\u2019s not safe to use the injection more than twice a day \u2014 and inconvenient.\nThe device is a vagus nerve stimulator and it\u2019s not entirely clear how it works.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that the product is available in the EU and that the company will begin selling it in the U.S. later in 2017.", "answer": 1}, {"article": "Recipients were at most seven years older or younger than the donors.\nGenerally, guidelines classify donors older than 50 as \u201cextended criteria donors,\u201d but shortages have led to using these donors more frequently.\nA new study has found a kidney transplanted from a deceased 79-year-old can be as effective as one from a person 30 years younger.\nOld age is not necessarily a barrier to kidney donation.\nIn an average follow-up of five years, they found that the rate of unusable donor kidneys and the long-term outcomes of recipients varied little among the first three age groups \u2014 around 18 percent of the organs had to be discarded, and the five-year survival was about 88 percent\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Given that this study ran in a U.S. publication, we wanted to know what the guiding rules are on age of donors, in case they differ from what is standard in Italy. If older donors can donate in the U.S. already, then this study isn\u2019t very newsworthy, for example.", "answer": 0}, {"article": "About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nThe test is not currently recommended to diagnose gestational diabetes at any point in pregnancy.\nThe authors noted that further studies are needed to confirm whether measuring HbA1c levels in early pregnancy could determine a woman\u2019s later risk for gestational diabetes.\nSimilarly, research is needed to determine whether lowering HbA1c with lifestyle changes, either in early pregnancy or before pregnancy, could reduce the risk for the condition.\nAccording to the authors, comparatively few studies have examined whether the HbA1c test could help identify the risk for gestational diabetes, and these studies have been limited to women already at high risk for the condition.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that this test is far from ready for use in clinical screening. It states:\nThe test is not currently recommended to diagnose gestational diabetes at any point in pregnancy.", "answer": 1}, {"article": "Vegetables particularly high in alpha-carotene include yellow-orange vegetables, such as carrots, sweet potatoes, pumpkin, and winter squash, and dark green vegetables, such as broccoli, green beans, green peas, spinach, turnip greens, collards, and lettuce.\nThe study shows that eating foods rich in antioxidants, like vegetables and fruits, fights disease and may prolong life.\nResearchers wanted to see if other carotenoids may also play a role in reducing the risk of disease.\n\"These findings support increasing fruit and vegetable consumption as a means of preventing premature death,\" write researcher Chaoyang Li, MD, PhD, of the CDC and colleagues in the Archives of Internal Medicine.\nNov. 22, 2010 -- Eat your veggies and you may live longer, a study suggests.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story lists a number of common foods that contain relatively high levels of alpha-carotene.", "answer": 1}, {"article": "He whips up a homemade concoction using frozen elderberries, blueberries and honey.\nThe University of Maryland Medical Center says European elder, also called black elder, is the variety most often used for medicinal purposes.\nBefore you start popping elderberries, beware: eating them raw can make you sick.\nBut Kevin Brennan says, for his family, the natural alternative seems to be working.\nAn ancient herbal remedy is getting fresh attention this cold and flu season.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It seems clear from the story that elderberry extract is readily available.", "answer": 1}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says \u201cMerck is expecting the FDA to approve Januvia by mid-October. The company has also submitted an application for a single tablet combination of Januvia and metformin, known as MK-0431a. The FDA is expected to make a decision on that drug by the end of March 2007.\u201d On the first statement, the story should not simply take the word of Merck on the date of \u2013 or the certainty of \u2013 expected FDA approval. And on the second statement, the story doesn\u2019t say who expects the FDA approval of the second drug. Who said that? Who\u2019s the source? ", "answer": 0}, {"article": "Prof Johann de Bono, Regius professor of cancer research at the ICR, and consultant medical oncologist at the Royal Marsden NHS foundation trust, said: \u201cOur study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.\n\u201cFrom these findings, we were able to develop a powerful, three-in-one test that could in future be used to help doctors select treatment, check whether it is working and monitor the cancer in the longer term.\nWe think it could be used to make clinical decisions about whether a PARP-inhibitor is working within as little as four to eight weeks of starting therapy.\nThirdly, they used the test to monitor a patient\u2019s blood throughout treatment to quickly pick up signs that the cancer was evolving genetically and might be becoming resistant to the drugs.\nThe ICR chief executive, Prof Paul Workman, said the test could \u201cusher in a new era of precision medicine for prostate cancer\u201d.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not help readers understand whether this blood test is available now\u2013or if not, when it might become available for wider, non-research use.\n\u00a0", "answer": 0}, {"article": "As with each of our next generation OTC drug products, we intend to license HSRx 2121 to a leading marketing entity that has the resources and expertise to maximize sales, here and abroad,\" Parise said.\nThe HSRx product demonstrated superior treatment performance throughout the entire clinical study.\nEach product is subjected to independently conducted clinical trials against a current market-leading product to demonstrate its ability to deliver superior treatment outcomes with reduced side effects.\nHSRx Group has developed a portfolio of next generation OTC drug products for many categories of common health conditions.\nAll HSRx OTC drug products utilize natural ingredients in their formulations.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t state if the product is available now or when it might become available.", "answer": 0}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t discuss if women can get this test \u2014 a vital piece of information for those with a high risk of endometrial or ovarian cancers. While individual parts of the PapSeek test are FDA-approved, e.g. Pap smears and Tao brushes, the PapSeek genetic analysis does not yet appear to be approved (though approval criteria for medical devices are not as strict as they are for medications).\nAlso, there\u2019s been a reduction in frequency of Pap testing in recent years. It\u2019d be good to have a discussion of how implementing a new screening test in this environment muddies a message that\u2019s already been disseminating about how frequently women should be getting pelvic exams and Pap smears (i.e., less often, with some stopping altogether after a certain age). How would a test like this have to work upstream to be reincorporated into gynecological screening?", "answer": 0}, {"article": "\"Daniel's obstruction was both at the level of the soft palate and at the back of the tongue,\" Thaler says.\nAnd even then, success rates aren't high; they're effective only 20 to 30 percent of the time.\nSheiner is one of only about a half-dozen patients to have this robotic surgery for apnea.\nThat meant Sheiner stopped breathing for at least 10 seconds about two times every minute.\nA sleep study confirmed Sheiner had one of the worst cases of apnea his doctors had ever seen.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not totally clear on this point.\u00a0 The story states this one doctor has done the robotic surgery on only six patients. But it\u2019s not clear if she\u2019s the only one who\u2019s done this surgery.\u00a0 And if not, where else and how often?", "answer": 0}, {"article": "After five years, 74 percent of the angioplasty group and 72 percent of the medication group were free of chest pain \u2014 \"no significant difference,\" Boden said.\nNeither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.\nThe stunning results found angioplasty did not save lives or prevent heart attacks in non-emergency heart patients.\nAlso, the clogs treated with angioplasty are not the really dangerous kind.\nHe led the study and gave results Monday at a meeting of the American College of Cardiology.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story reported on a comparison of treatments for coronary artery disease that are used widely and described them as such.", "answer": 1}, {"article": "Whole plasma must be matched to blood type.\nThe study is a very long way from showing that.\nAnd, McCracken says, the company is working to figure out just what it is in the plasma that might affect aging and disease.\nResearchers trying to answer the question say they found the treatments are at least safe.\nThe work made headlines and launched a company, Alkahest, that\u2019s working to develop young human plasma into treatments for aging-related diseases.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the small \u201cproof of concept trial\u201d is just the beginning, and that the company \u201cplans to move forward with formal clinical trials in 40 volunteers next year.\u201d That presumably would be just a phase one trial to show safety so readers should know that any working product would be years away, at the least (and if ever).", "answer": 1}, {"article": "Corticosteroids are involved in a wide range of physiological processes in the body, including regulating metabolism, blood pressure and helping the body to cope with physical stress.\nThe new treatment - expected to have fewer side effects than existing therapies - could help people with disorders of the adrenal gland whose bodies are unable to produce a class of steroids called corticosteroids.\nThe researchers tested the therapy in a small group of patients with Addison's disease.\nThe therapy could help people with conditions such as Addison's disease and congenital adrenal hyperplasia, who need steroid treatment to avoid the risk of potentially fatal illness during physical stress.\nDr Mark Nixon, of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"The discovery of this selective corticosterone pump in fat cells could lead to a completely new approach in our search for safer steroid medications.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The research article is clear that corticosterone is available only for research purposes at this time, but the release is not specific about that, instead employing phrases such as \u201cAn improved therapy\u2026is a step closer\u201d) that suggest unavailability but also encourage the reader to conclude that the treatment is just around the corner.", "answer": 0}, {"article": "\"We're basically waiting until their red light goes on.\nAs part of the survey, female participants had blood testing for iron deficiency as well as hemoglobin testing to identify anemia.\nSekhar and colleagues hoped to determine risk factors for iron deficiency without anemia that could pinpoint which women could benefit most from this more costly testing.\nWomen are typically tested some time in their teens for anemia -- the severe form of iron deficiency -- using a quick and affordable hemoglobin test.\nMurray-Kolb and Paul also worked on the study in The Journal of Pediatrics, along with Eric W. Schaefer, a biostatistician in the Department of Public Health Sciences.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that low-cost hemoglobin tests are affordable and given to most young women, but that more sensitive tests that screen for iron deficiency are more costly and thus \u201cdifficult to obtain in the doctor\u2019s office.\u201d", "answer": 1}, {"article": "Gluck et al.\nMore study is needed to confirm the safety and effectiveness of tDCS for weight loss.\nObesity 4 Nov.\n\nNIDDK Research Clinical Psychologist Marci Gluck, Ph.D., is available to comment on this study.\nOn each visit, the participants ate a weight-maintaining diet for five days.\nThen for three days, they unknowingly received either active or sham (fake) transcranial direct current stimulation, or tDCS.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "A brief comment that this is not expected to be available anytime soon would have been helpful to readers. However, the release does say that \u201cMore study is needed to confirm the safety and effectiveness of tDCS for weight loss.\u201d While it\u2019s a close call, we think most readers can gather from this that the technique isn\u2019t likely to be available soon.", "answer": 1}, {"article": "PD-1 acts as a brake, or checkpoint, to shut down activated T cells.\n\"The response rate is better than we've seen for other potential second-line treatments and nivolumab is really well-tolerated, which is important because bladder cancer patients are a fragile group after frontline treatment with platinum chemotherapy,\" said Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology at MD Anderson.\nOverall survival will be analyzed in conjunction with the Phase II portion of this clinical trial, which provides nivolumab or a combination of nivolumab plus the immune checkpoint inhibitor ipilimumab.\nThe U.S. FDA approved atezolizumab, which blocks PD-L1, for these patients.\nThis Phase I/II clinical trial treated 78 patients: five (6.4 percent) had complete responses, 14 (18 percent) had partial responses, in which tumor burden shrinks by at least 30 percent, and 22 (28.2 percent) had stable disease.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The main reason that this is not satisfactory is that it is pretty confusing for non-expert readers. Nivolumab has not been approved by the FDA for use in treating metastatic bladder cancer. However, the release tells readers that nivolumab has been approved by the FDA for use in treating a variety of other cancers \u2014 and goes on to discuss survival rates for patients who take the drug (alone or in combination with ipilimumab). What does the FDA approval for treating other cancers have to do with the likelihood of nivolumab\u2019s future availability for treating bladder cancer? That\u2019s not clear, because the release doesn\u2019t tell us.", "answer": 0}, {"article": "[Seriously, why does anyone under 18 still have access to a tanning bed?]\nThat said, the agency warned Wednesday that the new drug can cause serious side effects, including trouble swallowing or nerve damage to the jaw that can result in an uneven smile or muscle weakness in the face.\nThe FDA warned, however, that the treatment also has the potential to kill other types of cells, such as skin cells, if injected improperly.\nPatients can receive as many as 50 injections of the drug in a single treatment, the agency said, with up to six treatments administered no less than a month apart.\nKeith Leonard, chief executive of Kythera, the California-based firm that developed Kybella, said at a conference last month that he believes the new treatment \"can drive a very large market and leave very satisfied patients.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the drug will probably not be available before June.", "answer": 1}, {"article": "Medtronic Inc. and Eli Lilly & Co. agreed to collaborate on an early stage research project for a potential Parkinson's-disease treatment that involves delivering medication directly to the brain\u2014a goal that has long eluded drug makers.\n\nThe pact, announced Tuesday, adds to Medtronic's roster of projects aimed at using implantable drug pumps and catheters to circumvent the blood-brain barrier. The tightly packed network of cells in brain capillaries only lets certain substances through, such as key nutrients, making brain-based...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the effort \u201cis still many years from yielding a marketable treatment or even starting human testing\u2026The drug may not enter human clinical trials for up to five years.\u201d", "answer": 1}, {"article": "\u201cRemember this day.\nAn editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become \u201ca new standard of care\u201d.\nLead researcher Martin Reck of Germany\u2019s Lung Clinic Grosshansdorf predicted that testing for the PD-L1 biomarker would now become standard \u201cfrom today\u201d.\nRoger Perlmutter, Merck\u2019s head of research, said both trials suggested Keytruda could offer a broad array of patients meaningful improvement over standard platinum-based chemotherapy, which is now more than two decades old.\nRival drugmaker Bristol-Myers Squibb had tried a catch-all approach with its Opdivo drug but it failed to help previously untreated patients when given on its own in a trial that included people with low levels of a protein called PD-L1.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says:\n\u201cU.S. regulators are expected to decide whether to approve Keytruda for first-line non-small cell lung cancer, the most common type, by Dec. 24.\u201d\nBut it doesn\u2019t explain how that\u2019s different from it\u2019s already approved use for advanced non-small cell lung cancer.", "answer": 0}, {"article": "\u201cNo metal may also reduce the potential of future blockages that occur with permanent metallic stents.\u201d\n\nData released in October concluded Absorb was comparable to Abbott\u2019s own Xience drug-coated metal stent in safety and effectiveness but showed a higher risk of heart attacks and blood clots.\n\u201cThere are no longer going to be permanent metal implants in the artery.\u201d\n\nAbsorb releases the drug everolimus to combat the growth of scar tissue that can form within a stent and cause the artery to narrow again, the U.S. Food and Drug Administration, which approved the stent, said.\nAbbott plans to roll out the device to about 100 hospitals in the next several months as it trains surgeons on the implant procedure before ramping up sales, said spokesman Jonathon Hamilton.\nAbsorb\u2019s appeal is that it allows the blood vessel to return to a natural state, free from a permanent metal implant.\nAbbott said it expects the risks to lessen as surgeons gain experience with it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Abbott Labs plans to make the stent available to some 100 hospitals in the near future, in order to train surgeons in its use, before \u201cramping up sales.\u201d This was information that we wished had been in the Associated Press story on the topic, which we also reviewed.", "answer": 1}, {"article": "In skin testing, a practitioner makes rows of pricks on a patient\u2019s back or forearm so allergen-containing extracts can seep into the skin.\nDr. Mitchell, the Manhattan allergist, called that approach promising.\nFor that reason, he and other experts say, most sufferers never even see an allergist.\nThe blood test, which is not without its own ouch factor, measures levels of circulating IgE.\nThe quick turnaround allows doctors to offer a diagnosis and immediate advice.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does say that the test is available and comments that its use is limited in the U.S.", "answer": 1}, {"article": "They found that rats with strokes who received DBS had more proteins in the brain that are associated with brain plasticity\u2014and twice as many synapses or connections between nerve cells compared to rats with strokes who did not undergo DBS.\nAnd experts aren\u2019t even entirely sure why it works for Parkinson\u2019s in the first place.\nThat\u2019s why doctors at the Cleveland Clinic will test deep brain stimulation (DBS)\u2014a procedure in which electrodes are implanted in the brain to provide small electric pulses as a way to help people recover control of their movements.\nThe stimulation will hopefully jump-start the brain\u2019s recovery process and help them gain more control while undergoing standard therapy.\nDBS has been used to treat tremors associated with Parkinson\u2019s disease, but Machado said the new approach, if successful, will achieve something novel.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story is pretty clear that actual clinical application of DBS for stroke patients is a long way off, given that the first patient on which this will be tried hasn\u2019t been identified yet.\u00a0 So we\u2019ll rate this a marginally Satisfactory, with the caveat that stories like this which raise patient hopes prematurely can do real harm to people and their families. We would have liked it better if the story had spelled out how many steps it will take before this becomes an actual treatment (if ever).", "answer": 1}, {"article": "\"It's been a miracle to me,\" Wolfe said.\nAll volunteers were encouraged \u2014 but not required \u2014 to stop drinking.\nIt's unclear whether the findings will make a dent in an addiction that affects millions of Americans.\nThe study, published in today's Journal of the American Medical Association, was funded by the maker of the drug, Johnson & Johnson Inc.'s Ortho-McNeil Neurologics.\nThe drug costs at least $350 a month, plus the price of doctor's visits.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made clear that the drug Topamax is not FDA approved for the treatment of alcoholism but that physicians are free to prescribe it for such use.", "answer": 1}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discusses Medicare and private insurance coverage for the procedure, and that description gives readers some insight as to availability. \u201cAs of now, Medicare covers eBx in 21 Western and Midwestern states. It covers the treatment on a case-by-case basis in Texas and the South and doesn\u2019t cover it in Florida or New England, where it is more difficult to find. Private insurance coverage also varies.\u201d", "answer": 1}, {"article": "Their median age was 63.\nStill there may be reasons to remove the cancer in the breast.\nBut with better therapies to control the cancer systemically and improved imaging that finds ever-smaller deposits of cancer in other parts of the body, it may be time to see whether surgery also can help increase the length of survival times, they said.\nA large, randomized, prospective study currently being conducted by the Eastern Clinical Oncology Group should produce the most reliable data on the subject to date, he said.\nTwo small prospective studies have suggested no survival difference among women with Stage 4 breast cancer who have surgery and those who don't, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of risk-reducing\u00a0 breast surgery is not in question, since it is not a new intervention.", "answer": 2}, {"article": "Studies in mice, dogs, pigs, and monkeys have shown that so-called focused ultrasound waves can be used to heat tiny bubbles that then mechanically push open gaps in blood vessels, allowing drugs to leak out into the brain.\n\u201cIt really opens up a lot to the imagination.\u201d\n\nMost drugs are blocked from entering the brain by the \u201cblood-brain barrier,\u201d which protects against infection, but also makes it tricky to treat brain tumors, diseases like Alzheimer\u2019s, and mental illness.\n\u201cIf we feel like we have a safe method of getting drugs in there,\u201d he said, \u201cit will open up a whole new slew of clinical trials.\u201d\n\nMainprize said the patient, a \u201cremarkable woman,\u201d was chosen to go first, because of the status and large size of her tumor, because it was an area of the brain that the ultrasound machinery could easily reach, and because of her willingness to help the research.\nBecause the trial was designed solely to determine the safety of focused ultrasound to the brain, the patient was not given a therapeutic dose of doxorubicin and the procedure is not expected to help in her recovery, Mainprize said.\nNew, safe doses of drugs will need to be determined, once medication is not being diverted by the blood-brain barrier, noted Dr. Gordon Li, a neurosurgeon at Stanford.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes this is a very new, very experimental technology, and several other patients are lined up for testing. Even after that testing, further testing will be necessary to establish appropriate doses etc, so we think it\u2019s pretty clear that this won\u2019t be available any time soon.", "answer": 1}, {"article": ", or find Mount Sinai on Facebook, Twitter and YouTube.\nFurther research is needed to investigate the impact of lung ultrasound on antibiotic use and stewardship.\nTo watch study author discuss this research, click this link: https:/\n\nPneumonia is the leading cause of death in children worldwide, according to the World Health Organization (WHO).\nThe research team was led by James Tsung, MD, MPH, Associate Professor in the Department of Emergency Medicine and Department of Pediatrics at the Icahn School of Medicine at Mount Sinai, and former clinical fellow Brittany Pardue Jones, MD, who's currently Assistant Professor in the Department of Pediatrics at Vanderbilt University School of Medicine.\nMount Sinai's Kravis Children's Hospital also is ranked in seven out of ten pediatric specialties by U.S. News & World Report.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does make a point that ultrasound technology is widely available in health care facilities around the world.\u00a0 We would have liked for the release to include the fact that in perhaps three-quarters of the world, there is a lack of facilities that can provide even diagnostic X-rays. This fact, attributed to the WHO in the journal article, is absent in the news release. High resolution ultrasound machines would be even further out of reach in these countries.", "answer": 1}, {"article": "\"But at the same time it's something we'll continue to look at, and hopefully confirm absence of risk.\"\nBut it is also drawing new manufacturers into the vaccine market, which many drug companies had abandoned in the 1980s and 1990s, citing too little profit.\nThe vaccine won approval from the Food and Drug Administration on Feb. 3, and some doctors have received supplies of it.\nThe recommendation for universal use of the vaccine was approved at a meeting of the Advisory Committee on Immunization Practices, the federal panel that sets vaccination policy in the United States.\nThe decision means that pediatricians are likely to recommend three doses of the oral vaccine for nearly every child at age 2 months, 4 months and 6 months, beginning almost immediately.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"Nivolumab is one of a new wave of immunotherapies that are beginning to have an impact across cancer treatment.\nNivolumab will still have to go through approval by the European Medicines Agency and NICE before it is available for head and neck cancer patients on the NHS.\nThis phase III clinical trial expands the repertoire of nivolumab even further, showing that it is the first treatment to have significant benefits in relapsed head and neck cancer.\nNivolumab became the first treatment to extend survival in a phase III clinical trial for patients with head and neck cancer in whom chemotherapy had failed - and it did so with fewer side-effects than existing therapeutic options.\nMedian survival for patients on nivolumab was 7.5 months, compared with 5.1 months for chemotherapy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that nivolumab is not yet approved for use in head and neck cancer patients in Europe (including the U.K.).", "answer": 1}, {"article": "The closed loop insulin delivery system, for example, computes insulin doses and administers them according to glucose levels detected by a sensor.\nWithout replacement insulin, people with type 1 diabetes couldn't survive.\nThe current study included 24 people with type 1 diabetes and challenged an artificial pancreas prototype in two different real-life scenarios.\nThe autoimmune attack destroys so many beta cells that someone with type 1 diabetes can no longer produce the insulin the body needs.\nThe hope is that an artificial pancreas will closely mimic the way the human pancreas normally releases insulin in response to food or stress.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Statins are such a widely prescribed class of drug that we feel most readers will understand their availability. The story does hint at this by noting that one-third of the patients who had surgery in this study were taking statins.", "answer": 1}, {"article": "\"What it tells us is that statins might not be effective in slowing the progression of disease, but they might ... prevent disease,\" said Mary Haan of the University of Michigan.\nAnd despite this study, there is not enough evidence to prescribe statins for the brain.\nSince cholesterol is part of the tell-tale plaques on the brains of Alzheimer's patients, it made sense to think that statins might help.\nThose who were taking a cholesterol-lowering statin such as Lipitor, had a surprising result.\n\"But statins as prevention for Alzheimers is not indicated at this time.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of statins is not in question. ", "answer": 2}, {"article": "Media campaigns, increased tobacco and tightening of smoking laws have all had an effect as well.\n\u201cPatient compliance is a very big issue,\u201d said Dr. Richard Hurt, director of the Nicotine Dependence Center at the , who was not involved in the study.\nDr. Hurt said products like nicotine gum and patches \u201care absolutely essential, but we use them in combinations and doses that match treatment to what the individual patient needs,\u201d unlike smokers who are self-treating.\nThe use of replacement products made no difference, whether they were taken for the recommended two-month period (they usually were not), or with the guidance of a cessation counselor.\nThe products have been controversial since at least 2002, when researchers at the , reported from a large survey that they appeared to offer no benefit.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story talks about the sales figures for nicotine products as one indication of widespread availability and use.", "answer": 1}, {"article": "Older adults with mild cognitive impairment have less severe memory loss than those with Alzheimer's but often go on to develop the disease.\nThe team cautioned that while eating baked and broiled fish appears to exert some cognitive benefit, other lifestyle and socioeconomic factors may play a role.\nBut fish and chips lovers, take note: No cranial benefit was evident with respect to consumption of fried fish.\nDr. Richard Lipton, vice chair of neurology at the Albert Einstein College of Medicine in New York City, reiterated the point.\nTo assess the impact of fish on cognitive health, the authors focused on 260 mentally healthy elderly individuals drawn from the Cardiovascular Health Study, sponsored by the U.S. National Heart, Lung, and Blood Institute.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish is not in question.\n ", "answer": 2}, {"article": "Stress tests measure the heart's response to exertion, letting doctors see or hear any disease.\nEven more surprising, the rate of bad outcomes among the heart patients studied were extremely low.\nBut \u2014 partly because his mother had died of coronary artery disease at age 49 \u2014 David remained unconvinced by those results.\nBut they had new symptoms that caused physicians to suspect heart disease \u2014 and nearly all had at least one risk factor like high blood pressure, diabetes or a history of smoking.\nThe 10,000-plus patients, who visited 193 health centers in the U.S. and Canada, had no prior diagnosis of coronary artery disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story does not make information about availability explicit, it is reasonably clear from the story that both types of diagnostic tests are currently available.", "answer": 1}, {"article": "L-Nutra, to sell products that serve this purpose, which may be seen as a conflict of interest.\nThe food items used, however, were specific to the trial and if translated to the public would involve designing meals made up of the right combination of nutrients.\nThis activation, or reduction, of pathways is why the components of the diet, such a proteins, must also be controlled.\n\"Cells have a list of things to do every day,...like getting rid of toxins\" says Toribio-Mateas.\nFasting has been performed by communities and cultures for millennia and Longo's team are curious about the advantages.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that fasting participants were given a specific type of meal that isn\u2019t available to the general public.", "answer": 1}, {"article": "For example, she says, someone might say, \" 'I find that I'm staying in my room, not answering the phone, not answering texts, not answering emails.'\nYet only 50 percent of those people have been diagnosed with a mental illness.\nThat follow-up is key, says Julie Goldstein Grumet, a psychologist at the Zero Suicide Institute at the Education Development Center, a Washington, D.C.-based nonprofit.\nBut few of those suicide survivors get the follow-up care they need at a time when they are especially likely to attempt suicide again.\nThe findings offer a way for hospitals and clinics to help reduce the rising numbers of death by suicide across the country.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told that the SPI approach is becoming increasingly more available in hospitals across the country.", "answer": 1}, {"article": "Inflammation is a sign of damage from cholesterol.\nBy then, results will also be in on a large study of a similar drug, dalcetrapib, made by Merck\u2019s competitor, Roche.\nIf the same benefit were seen in all patients at risk of heart disease \u2013 far from a sure thing \u2013 it would translate to hundreds of thousands of fewer deaths and heart attacks over a five-year period, according to Dr. Christopher Cannon, the lead study author and a cardiologist at Brigham and Women\u2019s Hospital in Boston.\n\u201cIt appears to be safe and to not raise blood pressure,\u201d Shah told CNN, \u201cbut it\u2019s not a slam-dunk.\u201d For one thing, despite improved cholesterol levels, patients did not see less inflammation in their blood vessels.\nLee Davies, a Merck spokesman, said the company is not likely to seek FDA approval until those results are in, most likely in 2015.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nWe\u2019ll let this story pass on this criterion because it mentions that the next phase of clinical trials will take at least four years to complete and because it notes that success is not a sure thing. \nHowever, the lead sentence about people having a new cholesterol treatment option \u201csoon\u201d gives us pause. Also, the prediction in the story attributed to a drug company spokesman that application for approval could come in 2015 seems questionable, since the next study is not scheduled to begin recruiting participants until April 2011, and then there will be four years of observation, followed by data analysis. The trial just presented began in April 2008 and the participants were followed for an average of 14 to 16 months, yet it took more than a year after that for these results to be announced. The next trial may include 20 times as many patients.", "answer": 1}, {"article": "It appears that abiraterone is able to shut down androgen production not only in the testes, but also from the adrenal gland and from within prostate tumors themselves.\nThe treatment gave patients with metastatic, castration-resistant prostate cancer only an extra four months of life.\nThe study was funded by Johnson & Johnson, which is developing the drug.\nBut there's more hope than that from the study of some 1,200 men with late-stage cancer at 147 medical centers in 13 nations.\nThis study was presented at a medical conference.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The reader is given no information about whether this drug is available now, or, if not, what stage of research it is in.\u00a0 There\u2019s a hint \u2013 in the line that Johnson & Johnson is \"developing\"\u00a0the drug but news organizations shouldn\u2019t play guessing games with readers on the topic of the availability of prostate cancer drugs \u2013 or any topic. \nThe competing Wall Street Journal story, by contrast, reported:\u00a0\"Johnson & Johnson plans to file for new-drug approval in the U.S. and Europe by year-end, raising prospects that the drug could be on the market next year.\"\u00a0 There\u2019s no doubt about availability when you read that. (Although one could doubt the prediction of when it could be on the market.)\u00a0", "answer": 0}, {"article": "Learn more at: www.DecipherTest.com and follow Decipher on Twitter @DecipherTest and on Facebook.\nDecipher was developed in partnership with the Mayo Clinic.\nThe test provided a more accurate and precise estimate of a patient's risk of recurrence.\nUse of this test therefore has the potential to assist clinicians to better direct utilization of secondary therapy after surgery.\nAdding truly unique information to the treatment decision-making process, Decipher generates a risk result that is completely independent and distinct from PSA, Gleason score and other clinical risk factors.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told Decipher is commercially available and that Medicare can pay for the test.", "answer": 1}, {"article": "Doctor Challenges Cause Of MS And Treatment\n\nOne day 7 years ago, after a long walk with his dog along the Hudson River in Manhattan, Marc Stecker noticed he was limping.\nIt's so seductive, in fact, that Canadians and Americans with MS have been flocking overseas to get the \"liberation procedure.\"\nRobert Zivadinov of the Buffalo Neuroimaging Analysis Center in New York says that not only is the procedure unsafe and costly to many patients, it is impeding necessary research.\nMany desperate patients have spent their life savings flying overseas to have the procedure, only to have it fail a few months later.\nAlthough the doctor who treated him in New York found a significant blockage, he was unable to correct it, Stecker says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article implies that there aren\u2019t yet a lot of doctors performing this\u00a0procedure, but it isn\u2019t clear.\u00a0Early in the story we learn of\u00a0a patient\u00a0who recently had the procedure performed in New York, but later on\u00a0the story\u00a0says that Canadians and\u00a0Americans\u00a0are going to Europe\u00a0to have\u00a0the surgery.\u00a0Are there not enough doctors\u00a0in North America who are trained to perform this procedure? Or are there regulatory, legal, or financial\u00a0issues that are preventing patients in North\u00a0America from getting\u00a0it done here? \u00a0The story should have told us.", "answer": 0}, {"article": "\"This is outside the box. I've never used it this far out,\" Metz said. \"My radar is up if I see [such an injury] again. As we get more follow-up from David, it will be important to publish this case so people will be aware.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentioned hyperbaric chambers are located in about 1,400 hospitals across the US. Given that Medicare also reimburses for hyperbaric therapy, access is probably relatively easy.", "answer": 1}, {"article": "\"I think there\u2019s no one answer,\u2019\u2019 Goldstein said.\nThe drug, which is being developed by the giant German drug maker Boehringer Ingelheim, could become the first treatment approved by U.S. regulators for women who suffer from hypoactive sexual desire disorder.\nMichael Sand, director of clinical research at Boehringer, said the company intends to pursue regulatory approval based on the late-stage study findings.\nFlibanserin could be the first success after a series of failures from drugmakers including Pfizer and Procter & Gamble.\nIt could take two to three years to come to market in the United States, the company said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article accurately states that flibanserin is an experimental drug and is not FDA approved or commercially available.", "answer": 1}, {"article": "Behavior and quality of life also improved.\nThe researchers said that was to be expected and, without surgery, patients probably would have experienced similar problems as a result of their continuing seizures.\nYet the cases were judged to be a success because the seizures decreased in frequency over time.\nRather than pay $35,000 to $50,000 on surgery that might cure the problem and prevent further damage to the child, insurance companies prefer to demand that more drugs be tried, even if the odds of them working in drug-resistant cases is small, he said.\nNot only \u201cdoes it reassure us that several surgical procedures are effective,\u201d she said, it demonstrates that surgery \u201cshould be done as early as possible\u201d once it becomes clear that a child is not responding to two anti-seizure medications.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Beyond noting that costs are a frequent barrier in India to getting the surgery, the article does not say anything about general availability of the operations, or define categories of candidates.", "answer": 0}, {"article": "\u201cIt\u2019s a combination,\u201d Hagan said.\nOptimistic people are likely to have better diets, they\u2019re exercising more, and they\u2019re getting better sleep.\u201d\n\nHowever, even after the researchers accounted for these factors, the results still suggest that optimism itself is linked to a longer life.\nHowever, they note, \u201cthere is no clear basis for believing that the effects of optimism on health differ by sex or race.\u201d\n\nFinally, the researchers emphasize that while some people may think they\u2019re just not optimistic, it is something that is modifiable.\n\u201cIf you\u2019re more optimistic, you tend to have healthier behaviors.\nThey suggested a number of steps people can take to improve their level of optimism.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Optimism\u00a0may not be FDA-approved, but we\u2019ll optimistically assume all readers know that it\u2019s widely available. There could have been more included on how optimism can be a learned skill, for those who would like to become more optimistic.", "answer": 2}, {"article": "\"You're going through all this suffering and stuff and you want to know, am I going to survive?\nGraham said there are maybe a dozen published human studies so far, most involving too few patients to draw a firm conclusion.\nThe hope is that, over time, FLT PET would prove reliable for giving a faster answer on whether an experimental treatment is working.\nAs a practical matter, the goal of researchers is to convince federal regulators to cover the procedure under Medicare and Medicaid, which would open the door to routine use.\nThe new research tests both standard PET scans and a newer approach that involves injecting a different tracer substance.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The treatment is experimental and not currently available. Yet it is not until late in the story that we learn the research is very preliminary. The caveats appear eventually but should have framed the story from the outset.\u00a0 \nThe story allows advocates to offer unsupported speculation that the government may agree to pay for the procedure in \"two or three years\" and new PET technologies will transform cancer treatment within 10 years.\u00a0 \nThe use of the anecdote in the lede implies availability.\u00a0 ", "answer": 0}, {"article": "Unlike the more common obstructive sleep apnea, in which the airway partially collapses and causes pauses in breathing, central sleep apnea (CSA) occurs when the brain fails to control breathing during sleep.\nAbout a third of patients in the treatment group reported therapy-related discomfort that was resolved with some reprogramming of the device.\nIn the randomized study, 151 patients were implanted with the device.\nThe study was funded by Respicardia.\nBetween six and 12 months of follow-up, all patients received the neurostimulation treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The implant was made available to patient volunteers through a clinical trial, and that\u2019s an implication to savvy readers that the device isn\u2019t available to the general public. But there\u2019s no clear indication of whether the device is on the market or not. The news release should have stated that it is not generally available and it is unknown if major payers will cover it if it ever comes into wider use.", "answer": 0}, {"article": "Lung cancer is the most common cause of cancer death in the U.S. for men and women.\nMuch work lies ahead in determining whether the compound and related ones will prove to be effective therapies, but the researchers say their discovery demonstrates the power of screening specially designed compounds against cancers \"with certain genetic quirks.\"\nThe researchers say the framework of the new compound is different from that of other cancer drugs and acts against a protein that carries a structural defect, according to a news release.\nThe Dana-Farber scientists say current [EGFR] inhibitors Iressa and Tarceva prevent EGFR from sending signals that are essential to keep tumor cells growing, the researchers say.\nThe new compound seems promising in mouse models, the researchers say, adding they hope it proves effective in clinical trials and is better tolerated than drugs now used.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not until the very end of the article do we learn that the dramatic results against NSCLC tumors occurred in mice, not human beings. In fact, it never states the setting for any results \u2014 an important point because the article fails to reveal that some results, such as the compound\u2019s apparent ability to spare normal tissues, were achieved in cell lines, not even in mice, according to the\u00a0press release\u00a0and\u00a0article\u00a0published in Nature.\u00a0Therefore, most of the article is misleading .\nRead the pivotal sentence below. Without any mention of animals preceding it, how could we\u00a0not\u00a0assume that the lungs, cancers, and powerful treatment effects were in humans?\nThis sentence, if not the article\u2019s title, should have been qualified with the word \"animal,\" \"mouse,\" or even \"murine.\" \nThe article provides almost no caveats about the preliminary nature of these results, nor the limitations of extrapolating to humans any data obtained from cell lines and animals.\u00a0While the article does contain two statements, essentially quoting the\u00a0press release, about what lies ahead following these early data, both sentences contain a \"but\" followed by the investigators\u2019 optimism.", "answer": 0}, {"article": "Brain imaging has become a popular subject of research in recent years as the technology to be able to scan, store and analyze the terabytes of information in the pictures has become more affordable.\nFiguring out a child's trajectory once he or she is diagnosed is just as challenging.\nNow scientists believe that they have a way to distinguish between those paths, at least in terms of language ability, in the toddler years using brain imaging.\nThere\u2019s no such thing as a blood test, cheek swab or other accepted biological marker so specialists must depend on parent and teacher reports, observations and play assessments.\nAutism has always been a tricky disorder to diagnose.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t state when or if clinicians will adopt the testing protocol for newly diagnosed autism patients. Because the research was only recently published in a journal, one must assume clinicians will not be implementing the protocol anytime soon. But the story doesn\u2019t make this clear or provide any sort of time frame for readers.", "answer": 0}, {"article": "; Francesca Cesari, MSc., Ph.D.; Anna Maria Gori, MSc.\nThe association has strict policies to prevent these relationships from influencing the science content.\nIn an editorial accompanying the study, Cheryl A. M. Anderson, Ph.D., M.P.H., M.S., an associate professor of preventive medicine at the University of California, San Diego, in California, wrote that there were similarities between the two diets that may explain the results.\nAnderson, who was not involved in the study, added that promoting both diets by healthcare professionals \"offer a possible solution to the ongoing challenges to prevent and manage obesity and cardiovascular diseases.\"\n\"To best evaluate this issue, we decided to compare a lacto-ovo-vegetarian diet with a Mediterranean diet in the same group of people,\" said Francesco Sofi, M.D., Ph.D, lead study author and professor of clinical nutrition at the University of Florence and Careggi University Hospital in Italy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release didn\u2019t specifically address availability.\u00a0 We do acknowledge that while different fruits and vegetables are limited in different parts of the world, it is feasible to adopt a Mediterranean style or vegetarian style diet almost anywhere by substituting some vegetables and protein sources for others.", "answer": 2}, {"article": "This can cause less blood to reach the brain and, in rare cases, may also trigger a stroke if plaque breaks off and becomes lodged in the small vessels in the brain.\nThose who would benefit from the ultrasound test are people with known carotid stenosis who are fit for surgery, Topakian said.\nThe patients who are at high risk are candidates for surgery, he said.\nMarquardt noted that the risks associated with the surgery are a lot higher than leaving the stenosis as it is and starting aggressive medical treatment.\nThe problem is identifying the patients at the highest risk for stroke, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is based on what was found with \u201ctwo ultrasound methods.\u201d\u00a0 But it never clarified whether there was something extraordinary about these methods and, if so, how well known are they?\u00a0 How widespread?\u00a0 How available?", "answer": 0}, {"article": "\u201cHe said, \u2018Doc, give me what I got last time.\nUntil there are answers, Zarate of the mental health institute said ketamine should be a last-resort treatment for depression after other methods have failed.\nFor now, ketamine has not received approval from the U.S. Food and Drug Administration for treating depression, though doctors can use it for that purpose.\nClinics have opened around the United States promising instant relief with their \u201cunique\u201d doses of ketamine in IVs, sprays or pills.\n\u201cIt truly has revolutionized the field,\u201d changing scientists\u2019 views on how depression affects the brain and showing that rapid relief is possible, said Yale University psychiatrist Dr. Gerard Sanacora, who has done research for or consulted with companies seeking to develop ketamine-based drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that ketamine is widely available for treating depression \u2014 at \u201cabout 150 US. ketamine clinics,\u201d although it has not been approved by the FDA for that purpose.", "answer": 1}, {"article": "The FDA is not required to follow the advice of its expert panels, but the agency typically does.\n\"While it is true that these bleeding events typically do not lead to death or irreversible harm, these events may represent the biggest problem for both patients and health care providers if rivaroxaban is approved.\"\nIn the FDA briefing documents, an agency reviewer recommended approving the drug for treatment of acute coronary syndrome, mostly because trial data showed there was a reduction in cardiovascular death, even though there was also an increased risk of potentially fatal bleeding.\nThe review came in briefing documents that were filed Monday in advance of an FDA advisory panel meeting Wednesday, at which the panel is to vote on whether to recommend approval of Xarelto for treating people with acute coronary syndrome (a group of conditions brought on by sudden reduced blood flow to the heart).\nXarelto (rivaroxaban) is one of a new class of blood thinners that have been developed to overcome some of the problems that exist with the standard treatment, warfarin (Coumadin), which requires constant dose monitoring.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the drug is already used for atrial fibrillation and in people having hip or knee replacement surgery.\nAnd with that general availability comes the ability of people to ask for Xarelto and for their physicians to prescribe it without the benefit of seeing the final recommendation from the scientific advisory board or final FDA approval for this new indication.", "answer": 1}, {"article": "\u2022 Paulsen AJ, Cruickshanks KJ, Fischer ME, et al.\n\"As a clinician who specializes in diagnosing and treating dry eye, this novel formulation of cyclosporine A would be a unique and welcome addition to our armamentarium to treat these patients\".\nThese results are highly encouraging for millions of Dry Eye patients[4]-[6] across the globe that have yet to find relief for their condition.\n[1] Additionally, several key secondary endpoints showed statistically significant improvements compared to vehicle with some showing an even earlier onset of action.\n[7] Based on this successful confirmatory Phase 3 trial, Seciera\u2122 has the potential to strengthen our emerging ophthalmics pipeline, which includes the recent launch of BromSite\u2122 and late stage development programs for Xelpros\u2122 and DexaSite\u2122.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This was another close call. We\u2019ll rate this category satisfactory since the release reports on a phase 3 trial, which means the product is not yet available to the public, and a Sun Pharma executive is quoted as saying, \u201cWe look forward to discussing these results with US FDA and agree on next steps for the program.\u201d\u00a0 FDA approval is prerequisite on a product\u2019s availability to the public.", "answer": 1}, {"article": "AMG145, along with other PCSK9 inhibitors being developed by companies like Pfizer, Regeneron Pharmaceuticals Inc in partnership with Sanofi and Roche, is a man-made antibody.\nThe new drug, given by injection every four weeks, is part of a promising new class of biotech medicines known as PCSK9 inhibitors designed to target a protein that prevents the body from removing artery blocking LDL cholesterol from the bloodstream.\nThe most common side effects seen in the trial were injection-site reactions, cold-like symptoms and headache.\nThe disorder is estimated to affect about one in 500 people and causes extremely high cholesterol.\nThe trial, presented here at the annual scientific meeting of the American Heart Association, included 168 patients with heterozygous familial hypercholesterolemia, in which a defective gene inherited from one parent impairs the ability to properly metabolize LDL.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story points out that the drug is still experimental.", "answer": 1}, {"article": "Lack of F.D.A.\nThere was a great need, the authors concluded, to \u201cimprove awareness of this important advice.\u201d\n\nThe fact that fish oil is also sold as a nutritional supplement has made it harder for some doctors to regard it as a powerful drug, experts said.\nThe fact that heart patients receive such different treatments in sophisticated hospitals around the world highlights the central role that drug companies play in disseminating medical information, experts said.\nSo community doctors do not learn how to use the drug.\nThis summer, a critical review of existing research in BMJ, The British Medical Journal, \u201ccast doubt over the size of the effect of these medications\u201d for the general population, said Dr. Roger Harrison, an author of the paper, \u201cbut still suggested that they might benefit some people as a treatment.\u201d\n\nDr. Harrison said he believed that people should generally increase their intake of omega-3 acids, best done by eating more fish.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article explicitly states that prescribed fish oil is not approved by the FDA for use in heart patients as a treatment. This is not an accurate statement. The FDA announced approval of a qualified health claim of reduced risk of coronary heart disease for omega-3 fatty acids in 2004. And while not FDA approved for use for all coronary disease, there is currently an omega-3 fatty acid product on the market that has been approved for the treatment of very high triglycerides. Fish oil is widely available over the counter, which is the most important piece of information for readers. This story focuses too much on the availability of one prescription fish oil brand.", "answer": 0}, {"article": "The U.S. National Institute on Deafness and Other Communication Disorders has more about ear infections in children.\nThese infections are the most common reason why children are given antibiotics, the University of Pittsburgh researchers noted.\nWhat's more, the children in the five-day group didn't have a lower risk of antibiotic resistance or of side effects such as diarrhea or diaper rash.\nThe study included 520 youngsters with ear infections.\nWEDNESDAY, Dec. 21, 2016 (HealthDay News) -- A shorter period of antibiotic treatment for ear infections in young children does more harm than good, a new study finds.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story just generally refers to the drugs used as \u201cantibiotics\u201d making it unclear what specific drug was studied. Without that information, availability is impossible to even infer.", "answer": 0}, {"article": "Breast MRI currently is used to screen women at high risk of breast cancer and as a diagnostic adjunct to mammography.\nThe new approach is not intended to replace current contrast-enhanced breast MRI protocols in general, Dr. Bickelhaupt emphasized, but to expand the spectrum of options available for answering specific clinical questions.\nShould the results hold in larger trials, the model has potential advantages in the clinic beyond its ability to reduce unnecessary biopsies in women with BI-RADS 4 lesions.\nThe software algorithm makes the assessment reader-independent, ensuring that its accuracy is maintained across different imaging facilities.\nThe examination relies on gadolinium-based contrast agents that need to be injected intravenously.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This report is based on a retrospective study early in the process of testing the new imaging procedure. It is too early to comment on availability. Also, it appears this study was conducted in Europe so it\u2019s unclear if the algorithm would become available to use in US clinics.", "answer": 2}, {"article": "It's crazy enough to laugh off.\nBut here's the thing: BYU researchers have discovered certain compounds found in cocoa can actually help your body release more insulin and respond to increased blood glucose better.\nBut rather than stocking up on the sugar-rich chocolate bars at the checkout line, researchers believe the starting point is to look for ways to take the compound out of cocoa, make more of it and then use it as a potential treatment for current diabetes patients.\n\"These results will help us get closer to using these compounds more effectively in foods or supplements to maintain normal blood glucose control and potentially even delay or prevent the onset of type-2 diabetes,\" said study co-author Andrew Neilson, assistant professor of food science at Virginia Tech.\nWhile there has been a lot of research on similar compounds over the past decade, no one has been able to pinpoint which ones are the most beneficial or how exactly they bring about any benefit -- until now.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Readers of the entire release are told that this work is an early step toward developing compounds for testing. However, the headline, lead paragraphs and images (featuring Hershey\u2019s bars) all conspire to imply that the researchers looked at chocolate found on candy shelves.\nCocoa is widely available, the compound being investigated in this study is not, and the\u00a0researchers\u00a0don\u2019t give any idea about how hard it is to extract it.", "answer": 0}, {"article": "Drs.\nBupropion should be considered the first-line drug of choice for people who are overweight or obese, Dr. Simon said.\nSo for up to two years the new study followed more than 5,000 Group Health patients who started taking an antidepressant.\nBut patients should consult their doctor about which medication is right for them, before making any changes, including starting, switching, or stopping medication.\nGrant R01 MH083671 from the National Institute of Mental Health funded this research.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that all of the antidepressants are available and approved.", "answer": 1}, {"article": ".\nBut, she added, if her study goes forward, many will be able to participate in it.\nBut Dr. Martha Daviglus of Northwestern University, who led a panel last year that assessed published papers on preventing and treating Alzheimer\u2019s, urged caution.\nCraft reasoned, perhaps if more insulin could be put into the brains of people with the degenerative brain disease, their memories and ability to function might improve.\nIn addition, she said, beta amyloid, a toxic protein that accumulates in the brain of Alzheimer\u2019s patients, seems to tie up insulin in the brain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that this treatment is experimental and\u00a0that the\u00a0device used to administer insulin deep inside the nose is not on the market. It urges readers not to rush out and take\u00a0insulin for the\u00a0treatment of Alzheimer\u2019s\u00a0disease.\u00a0The story closes with\u00a0the implied promise of a larger study in which \u201cmany\u201d people might have access to the intranasal insulin therapy, which sets an overly optimistic tone. Only a small\u00a0fraction of people who might benefit from this therapy will be eligible to participate in any future studies.\u00a0On the whole, though,\u00a0the story\u2019s message on availability is correct and\u00a0merits a satisfactory.", "answer": 1}, {"article": "Gout occurs when uric acid builds up in the body and forms crystals in the joints or in soft tissue.\nThe drug is administered to patients every two weeks as an intravenous infusion.\nThe drug is associated with some serious side effects.\nTwo six-month clinical trials of 212 total patients showed that the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.\nSavient expects Krystexxa to be available by prescription later this year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is about new FDA approval of the drug.\u00a0 It notes that the manufacturer expects it to be available by prescription later this year. ", "answer": 1}, {"article": "\"We always assume there's luxury,\" Wright said.\nWhen validating a new biomarker for disease, \"one should always analyze at least two different (groups of patients and controls) to make sure that the results are reproducible,\" said Hansson, who added that participants should also include both early- and late-stage patients established at different clinics.\nThough other symptoms will show up eventually and help in diagnosing the patient, in the meantime, the patient will be receiving the wrong medicines.\nHowever, the test cannot distinguish between the different atypical disorders, which doctors must rely on symptoms to diagnose.\nAccording to Dr. Paul Wright, chairman of neurology at North Shore University Hospital in Manhasset, New York, and Long Island Jewish Medical Center in New Hyde Park, New York, the importance of this study is that it brings to light that there are new biomarker tests that can delineate between these neurological diseases.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Via the lead researcher\u2019s discussion of what the test may do in the future, the article implies that the blood test is not yet available.\nIdeally that hint should have been more explicit and perhaps accompanied by some details on what\u2019s left before this test becomes available.", "answer": 1}, {"article": "Among them: engaging in regular physical activity, maintaining a healthy weight, and not smoking cigarettes.\nMany other strategies will also reduce the risk of cancer, he says.\nThe benefit, however, may not be as great as believed, says researcher Eric Jacobs, PhD, of the American Cancer Society.\nThe new analysis is published in the Journal of the National Cancer Institute.\nEven so, he says, \"our results provide additional support for the potential benefit of daily aspirin for [reducing] cancer mortality.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of aspirin is not in question.", "answer": 2}, {"article": "Asked if he's suggesting that it's some kind of a rejuvenation drug that would turn a 70-year-old into a 35-year-old, Westphal tells Safer, \"That might be pretty hard to do.\nEveryone from plastic surgeons to your friendly snake oil salesman have been promising a ticket to eternal youth for some time, so the prospect of a prescription pill based on red wine that could trigger a longevity gene sounds too good to be true.\nAnd yet scientists have actually known for years of one surefire of doing that: stay hungry.\nIt's normally inactive, but when it is active, Sinclair believes it triggers a survival mechanism that extends life.\nIf they're right, we all may soon be taking a pill that could give us an extra decade or two of healthy old age.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Here\u2019s an excerpt of the story taken from the CBS website: \nBut the question that most of us want answered is: when do we get this pill? \n\"I would say five years to be conservative that this\u2019ll happen within our lifetimes. I\u2019m fairly certain about that,\" Sinclair says.\u00a0 \n\u00a0Sinclair is one of the co-founders of the company working on the drug.\u00a0 His 5-year estimate should have been checked with at least one independent source for comment.\u00a0 Also, note how that comment \u2013 as transcribed by CBS \u2013 makes no sense.\u00a0 ", "answer": 0}, {"article": "At the same time, we studied a small sample of patients, so our results should be interpreted with caution,\" Fried added.\nStimulation of the entorhinal cortex -- a region considered crucial to transforming daily experience into lasting memories -- produced the improvement, the researchers said.\nAlthough the results are still preliminary, the method may potentially hold promise for boosting memory in patients with early Alzheimer's disease, the researchers said.\n\"Our preliminary results provide evidence supporting a possible mechanism for enhancing memory, particularly as people age or suffer from early dementia.\nSo it's difficult to generalize this study's results to other diseases that affect memory, she said, and the research didn't show if effects of temporary deep brain stimulation last beyond the study period.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that this research is in its early stages, though devices are available that provide similar deep brain stimulation to patients with other disorders.", "answer": 1}, {"article": "His own previous research indicates that cannabis was used as early as 1800 B.C.\nThe study was a randomized, double-blind, placebo-controlled human trial, which is considered the gold standard test for any new medicine.\nHe noted that generating more evidence of effective use is \"a good thing.\"\nGW Pharmaceuticals, a company that is developing cannabidiol medicines, helped subsidize the study.\nBased on the overall results, Devinsky believes CBD should be evaluated for epilepsy types beyond Dravet syndrome, which is caused by a genetic mutation and affects about one in 20,000 to 40,000 children in the United States.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is a significant section on availability of marijuana and marijuana-derived drugs. A reader can fairly easily infer that this intervention is not yet available.\nBut, as we noted in our news release review, \u201cThe FDA does, however, consider cannabidiol an investigational product for treating children with epilepsy and has \u201cexpanded access provisions\u201d that allow its use.\u201d\nThis would have been useful information to include in the story.", "answer": 1}, {"article": "\"First, I think it's very important that we investigate potential new therapies, and that we shouldn't be dissuaded from doing that just because something can be misused,\" he said.\nThis effect, the Bedi and his team suggested, could help people improve their social skills by shielding them from the negative emotions of others.\nEach session lasted at least 4.5 hours, or until all effects of the drug had worn off.\nIn a study involving a small group of healthy people, investigators found that the drug -- also known as MDMA -- prompted heightened feelings of friendliness, playfulness and love, and induced a lowering of the guard that might have therapeutic uses for improving social interactions.\nAll said they had taken MDMA for recreational purposes at least twice in their lives.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that \u201cMDMA is part of a family of so-called \u201cclub drugs,\u201d which are popular with some teens and young at all night dances or \u201craves.\u201d\nBut it doesn\u2019t tell readers anything about whether this is MDMA\u2019s only use, and how it might be made available/distributed.", "answer": 0}, {"article": "People getting the combination of immunotherapy and chemotherapy were 51% less likely to die after 10.5 months than people receiving chemotherapy alone.\n\u201cTo give you some idea of how significant that is, with chemotherapy we normally see the same degree of response around 20% of the time.\u201d\n\nForde says that the strong response seen in people at the beginning of the disease could suggest that immunotherapies might be useful in re-training the immune system to fight cancer for long periods of time \u2014 possibly even a lifetime.\nDoctors can also determine if a person\u2019s lung cancer is genetically vulnerable to the checkpoint inhibitor drugs tested in the current study.\nAnd when the scientists studied the blood of the people receiving the immunotherapy, they discovered a close match between the types of immune cells in the blood and certain targets on the tumor cells, suggesting that nivolumab had released the immune system to pump out the appropriate cells it needed to tackle the cancer.\n\u201cAnd while our study is only with 21 patients, the early indications from this study are very positive.\u201d\n\nTaken together, the results could fundamentally change the way lung cancer is treated, significantly improving people\u2019s ability to both hold off lung cancer for longer periods of time, as well as live longer with the disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says Keytruda is \u201calready approved for treating about 25% to 30% of people with advanced (non-small cell lung cancer) who have a certain genetic profile that makes their cancer vulnerable to the drug.\u201d\nMore generally it says that \u201ca series of checkpoint inhibitor drugs was first approved in 2011 initially for treating melanoma.\u201d\nThe story could have clarified whether additional FDA approvals are needed to expand uses of these drugs.", "answer": 1}, {"article": "Because about one-half of the deaths in people with type 2 diabetes are caused by cardiovascular disease, reducing cardiovascular risk is considered essential to diabetes care.\nHe has not prescribed Jardiance and similar drugs as frequently as treatments like Januvia, but expects that may change based on the new data.\n\u201cIt is probably going to be a more popular drug because of that.\u201d\n\nSanford Bernstein analyst Tim Anderson more than tripled his annual sales forecast for Jardiance and combination drugs containing it to $2.7 billion by 2020.\nZinman, in an interview, predicted the new study would prompt medical societies to recommend that Jardiance be used by type 2 diabetics who have a history of heart disease or who are at risk of cardiovascular events.\nLilly shares jumped as much as 9 percent after data from the trial was released Thursday at a medical meeting in Stockholm.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Jardiance was approved for use in the United States last fall, so it\u2019s clear that the drug is available.", "answer": 1}, {"article": "Zied is also the author, with Ruth Winter, of a book titled \"So What Can I Eat?\"\nOn The Early Show Friday, Family Circle magazine Editor in Chief Linda Fears discussed everyday lessons that can make a big difference.\nFor more information on this subject, see these two articles on WebMD: Weight Loss: How To Read Food Labels and Cracking the Code.\nFor more information about the businesses featured in the series, click on:\n\nThe Consumer Product Safety Commission wishes to remind you that using camp stoves, portable camping heaters, or lanterns or charcoal grills inside your home produces dangerous levels of carbon monoxide, as does using a portable generator inside your home.\nNow, there's new information showing how important folic acid is.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story discussed folic acid supplements,\u00a0but would have been better if it had explicitly mentioned that these are available over the counter.\u00a0 The story mentioned multivitamins, but would have been better had it included the caveat that consumers need to check the label to determine whether the product contained 400 mcg.\u00a0 The story also discussed food sources (leafy green vegetables, liver, dried beans, citrus fuits, whole grain bread and cereals); however this\u00a0was somewhat incomplete because\u00a0without mention of the amounts of folic acid or the % of the recommended 400 mcg they might get in a single serving a person does not know how to use these foods to insure\u00a0sufficient folic acid\u00a0intake.\nIncluding guidance, such as reading labels, would have made this story more useful for the viewer interested in meeting the recommended intake.", "answer": 1}, {"article": "Toshiaki Higashihara, President & COO of Hitachi, Ltd. stated that, \u201cWe are greatly honored that Johns Hopkins selected Hitachi as their proton partner.\nThe next-generation system \u201cPROBEAT\u201d, which comes with IMPT (Intensity Modulated Proton Therapy) and cone-beam CT, will have improved spot scanning capability in all 3 gantry-type treatment rooms, along with a fixed irradiation room dedicated to cancer research.\nIn fiscal year 2015 (ending March 2016), one of Hitachi's new PBT site is planning to start treatment of patients.\nHitachi will continue to globally expand the healthcare business where proton therapy is its flagship solution, and contribute to cancer treatment around the world.\nHitachi has delivered the first hospital based spot scanning system in May 2008 and has treated over 1,500 patients to date.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Several PBT systems are under construction in Washington, DC, proper and within the region. The release did not establish when the newly announced facility is expected to be ready or when those other facilities will be ready. The availability of proton therapy outside the DC area is not discussed.", "answer": 0}, {"article": "Montreal, October 7, 2015 -- Millions of people suffer from asthma.\nCould a prescription for exercise be the result of this study Bacon is hopeful.\nFortunately, new research shows there is a simple antidote: 30 minutes of exercise a day, year-round.\nForty per cent of people don't exercise at all, he says.\nOnly 100 said they engaged in the optimal 30 minutes a day.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of exercise is not in question.", "answer": 2}, {"article": "Anticipating wide interest in the psilocybin research from scientists, clinicians and the public, the journal solicited 11 commentaries to be co-published with the study results written by luminaries in psychiatry, palliative care and drug regulation, including two past presidents of the American Psychiatric Association, a past president of the European College of Neuropsychopharmacology, the former deputy director of the U.S. Office of National Drug Control Policy, and the former head of the U.K.\nThe researchers cautioned that the drug was given in tightly controlled conditions in the presence of two clinically trained monitors and said they do not recommend use of the compound outside of such a research or patient care setting.\nThe study was funded by grants from the Heffter Research Institute, the RiverStyx Foundation, William Linton, the Betsy Gordon Foundation, the McCormick family, the Fetzer Institute, George Goldsmith, Ekaterina Malievskaia and the National Institute on Drug Abuse (R01DA03889).\nBoth studies are published in the Journal of Psychopharmacology on Dec. 1.\nIn general, the commentaries were supportive of the research and of using these drugs in a clinical setting as tools for psychiatry.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear from the release whether psilocybin treatment is currently available, or what the short- or long-term prospects are for psilocybin treatment availability.\nPsylocybin is categorized as a Schedule 1 drug by the Drug Enforcement Administration and its availability is tightly controlled. There is a precautionary note in the release,\u201d\u2026they do not recommend use of the compound outside of such a research or patient care setting.\u201d \u00a0But given the availability of \u201cmagic mushrooms\u201d and the availability of DIY instructions on identifying and growing same, we think that some additional comments would have been worthwhile.", "answer": 0}, {"article": "After her mother unexpectedly died from a tear in the wall of her heart at age 63, Patricia Walters talked to her doctor, Leslie Cho, about how to better monitor her own heart health.\n\nPregnant at the time with her own daughter, Ms. Walters, now 46, says she was \"a nervous wreck\" worrying that she, too, might face serious cardiac risk.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the test is available and most insurers will pay for it.", "answer": 1}, {"article": "The findings, reported in the journal Diabetes Care, do not suggest that yoga should replace other forms of exercise for people with type 2 diabetes \u2014 a disease commonly associated with obesity.\nMeanwhile, their average blood sugar levels held steady \u2014 in contrast to the non-yoga-practicing \u201ccontrol\u201d group, whose blood sugar levels rose.\nThey found that, on average, the yoga group\u2019s levels of the chemicals dipped by 20 percent.\nThe yoga used in this study was a gentle form, Hegde said, and parts of the practice were adapted for people who had additional health problems; certain poses were avoided in people who had heart disease, for example.\n\u201cBut,\u201d she added, \u201cit should be noted that yoga controlled the blood sugar levels which otherwise rose in the control group.\u201d\n\nIn addition to that, the study found, signs of so-called oxidative stress declined in the yoga group.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that gentle yoga classes might be found in hospitals and local community settings.", "answer": 1}, {"article": "Asthma on the Rise in U.S.\nThe study did not look at possible side effects of kampo herbs.\nNorth American allergy experts tell WebMD that although they find the preliminary findings fascinating, further study is needed before they would recommend the herbs.\nHerbs used in the current study include Scutellaria root, Coptis rhizome, gardenia fruit, hoelen, cinnamon bark, and Glycyrrhiza (aka licorice) root.\nHe says it was accidentally discovered that kampo herbs could wipe out symptoms in many people while testing the ancient remedy against an allergic skin disorder known as atopic dermatitis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t discuss the availability or use of the kampo herbs in the US.", "answer": 0}, {"article": "\u2022 This is the first time tandospirone has be shown to reverse the deficit in brain neurogenesis induced by heavy alcohol consumption\n\u2022 The researchers also showed in mice that the drug was effective in stopping anxiety-like behaviours associated with alcohol withdrawal, and this was accompanied by a significant decrease in binge-like alcohol intake\n\n\"This is a novel discovery that tandospirone can reverse the deficit in neurogenesis caused by alcohol,\" said study leader neuroscientist Professor Selena Bartlett from QUT's Institute of Health and Biomedical Innovation.\nIt is commonly used there and shown to be highly effective in treating general anxiety and well tolerated with limited adverse effects.\"\n\"While it could possibly have that effect, it might be able to help reboot the brain and reverse the deficits the alcohol abuse causes - both the inhibition to the brain's ability to regenerate, and the behavioural consequences that come from what alcohol is doing to the brain, like increases in anxiety and depression.\"\n\"This drug is relatively new and available only in China and Japan.\n\"This opens the way to look at if neurogenesis is associated with other substance-abuse deficits, such as in memory and learning, and whether this compound can reverse these.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release clarifies that \u201cThis drug is relatively new and available only in China and Japan.\u201d", "answer": 1}, {"article": "The amygdala processes incoming emotionally salient stimuli, whereas the prefrontal cortex, as the executive center of the brain, decides whether the incoming stimuli are noteworthy.\nThe initial results demonstrate that the efficacy of this digital therapeutic is comparable to drug therapy, with a highly favorable safety profile.\nThis treatment was developed at the Icahn School of Medicine at Mount Sinai by Brian Iacoviello, PhD, an Assistant Professor of Psychiatry who is Director of Scientific Affairs for Click Therapeutics, and Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean and Professor of Psychiatry, Neuroscience, and Pharmacological Sciences.\n\"The aim is to target the thinking abnormality we see in patients with MDD - that of perseverating, ruminating, obsessing, dwelling on the negative - by activating these two nodes (emotion processing and cognitive control) simultaneously.\nThis aims to balance brain activity in these regions to work in concert with each other.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Because the release is about a new therapy, we assume it is not available outside of a clinical study yet.", "answer": 2}, {"article": "Condoms, the most common non-hormonal method of contraception, have an efficacy rate of 82 percent.\nThe company plans to resubmit the marketing application for Amphora in the second quarter next year and if approved, plans to launch the product in January 2020.\nAmphora was found to have an 86 percent efficacy rate in avoiding pregnancies and no serious side-effects were observed in the study, which evaluated about 1,400 healthy women belonging to the age group 18-35 years, Evofem said.\n\u201cOur research and current understanding of women suggests the time is now for there to be a new non-hormonal category in contraception,\u201d Chief Executive Saundra Pelletier said on a conference call with analysts.\nThe company\u2019s shares were up 22.6 percent at $4.28 in mid-morning trade after touching a high of $4.90.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that this a product under development, not yet approved or marketed.", "answer": 1}, {"article": "Animals such as scorpions have venoms that block potassium and other ion channels.\nOne of the components in the venom of the scorpion called Buthus tamulus specifically blocks the potassium channel of FLS and not the channels in other cells such as those of the nervous system,\" said first author Dr. Mark Tanner, a graduate student in the Beeton lab during the development of this project.\nWhen the researchers treated rat models of the disease with iberiotoxin, they stopped the progression of the disease.\nA group of researchers led by Dr. Christine Beeton at Baylor College of Medicine has found that one of the hundreds of components in scorpion venom can reduce the severity of the disease in animal models, without inducing side effects associated with similar treatments.\n\"We think that this venom component, iberiotoxin, can become the basis for developing a new treatment for rheumatoid arthritis in the future.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes it clear that scorpion venom isn\u2019t available yet as a treatment with this researcher\u2019s quote: \u201cWe think that this venom component, iberiotoxin, can become the basis for developing a new treatment for rheumatoid arthritis in the future.\u201d But since the drug is available through Peptide International it is possible that some people may try to get it from the company and try it.", "answer": 1}, {"article": "In an interview, Sakoda said, \"Metformin use was not associated with lung cancer risk when we looked at all patients with diabetes.\nSome laboratory studies and a number of observational studies suggest that metformin may prevent cancer, but the data from human studies, however, are conflicting, explained Sakoda.\nThis study was funded by the National Institutes of Health.\nAssiamira Ferrara, Charles Quesenberry Jr., and Laurel Habel, coauthors on this study, have received research funding from Takeda to Kaiser Foundation Research Institute for a study of pioglitazone and cancer and from Sanofi through a subcontract from University of North Carolina to Kaiser Foundation Research Institute for a study of insulin glargine and cancer.\nThe researchers conducted this study to further clarify the association between metformin use and lung cancer risk.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not directly address the availability of metformin. However, it\u2019s apparent that the drug is available, since thousands of people in the study have been taking it for years.", "answer": 1}, {"article": "The women were asked to keep diaries for six months.\nOn average, both treatments cut the number of \u201caccidents\u201d \u2013 Botox by almost four times a day and the nerve stimulator by about three times a day.\n\u201cWe are actually not surprised that there isn\u2019t a big difference between the two because both therapies are effective at relaxing the overactive bladder muscles.\u201d\n\nWomen can choose between a surgical procedure, which is more expensive at first, versus regular Botox injections, which are less costly and less invasive but which could add up over time, Amundsen said.\nBoth treatments calm down the nerves responsible for signaling the bladder to empty.\nExercises to strengthen the pelvic floor muscles can help, as can \u201cbladder training\u201d to accustom the body to urinating at regular times.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both of these treatments are widely available. But,\u00a0a description of the procedures themselves would have been helpful (they are both quite invasive and require seeing providers with special training). While \u2018regular\u2019 Botox cosmetic treatments can be easily given by various medical professionals, without specialized training, in the office, this may not be the case for Botox injections into the bladder.", "answer": 1}, {"article": "Obstructive sleep apnea (OSA) is marked by interruptions in breathing while asleep; it is common among children with enlarged tonsils or adenoids.\nThere are many other causes of bedwetting, Lakshmanan said.\nHowever, half of the 417 children in this latest study who had sleep apnea and were bedwetters stopped wetting the bed after they had their tonsils or adenoids removed.\nThose who did not stop wetting the bed after the surgery were more likely to be born prematurely, be male, be obese or have a family history of bedwetting, the investigators noted.\nExactly how sleep apnea results in bedwetting is not fully understood, but hormonal changes may play a role.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The story does not explicitly state how common tonsillectomies are, but the surgery is so routine at this point, we do not feel there is a need for further explanation.", "answer": 2}, {"article": "One of the most frustrating aspects of brain injuries is that they can be difficult to diagnose; emergency rooms can sometimes miss subtle symptoms, leading to improper treatment and potentially catastrophic consequences. Now, researchers are close to identifying so-called biomarkers that may soon make it possible to pinpoint brain injuries with a simple blood test.\n\nPresence of these biomarkers\u2014proteins produced by an injured brain\u2014could end up determining the future treatment of the estimated 1.4 million athletes, car-crash...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article is clear that these tests aren\u2019t available in your local hospital, and that the FDA hasn\u2019t approved a blood test. But the overall tone is so unchecked that it seems like a foregone conclusion that it will be available \"soon.\"\nIf researchers are close, why does the article lead with the evidence from rats? Again, the article is clear that the technique is not available, but we think it needed context about how preliminary this research is. Many readers would be shocked to learn how many techniques with promising\u00a0preliminary results in the lab fail when tested in clinical trials.\nThe story is also unclear about the pivotal DOD\u00a0trial. Will it specifically study UCH-L1, the biomarker investigated by Banyan Labs, or is it about a panel of biomarkers? Are they all Banyan biomarkers? Is UCH-L1 even in there? We don\u2019t know how much of the research discussed in this article will even be investigated in the future study and, thus, potentially available.", "answer": 0}, {"article": "For more about cryoablation, visit the U.S. National Cancer Institute.\nAt least in the short-run -- meaning three months after the procedure -- the intervention known as \"cryoablation\" appeared to kill all targeted tumors that had spread to the lung from elsewhere, preliminary results suggest.\nBut they acknowledged that more research needs to be done to track the treatment's impact over the long haul.\nSUNDAY, April 14, 2013 (HealthDay News) -- A method designed to target, freeze and destroy a tumor's cellular function seems effective in combating lung tumors, a small ongoing study finds.\nFor his part, Dr. David Carbone, a professor and director of the James Thoracic Center at the Ohio State University Wexner Medical Center, said that the findings regarding cryoablation are \"not incredibly novel,\" given that the procedure has been around for years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story at least noted that cryoablation \u201chas been around for years.\u201d\u00a0 But to what degree?\u00a0 Around for years in how many places?\u00a0 What level of proliferation/penetration?\u00a0 How likely is a lung cancer patient in Arkansas or Alabama or Albuquerque to find the approach in use nearby?", "answer": 0}, {"article": "And finally, this is a very real world study.\u201d\n\nThe study was received well by the audience.\nOne of the caveats of the study was that participants were highly motivated people looking for ways to cope with and decrease their blood pressure.\nEngaging patients in such a way could be a very powerful tool in promoting behavioral change, Nolan said.\nParticipants were also largely white and well-educated, with most having a postsecondary education, so the results of the study might not be generalize well to other groups.\n\u201cSecondly, we only look at the trade-off between efficacy and safety, but your study is looking more at efficacy and effectiveness and practicality, issues that are also very important.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t address the availability of the web-based program.\u00a0Because high blood pressure\u00a0is so common, we think it would have been useful for the story to address when or if this technology will become widely available.", "answer": 0}, {"article": "Older people tend to get less slow-wave sleep and are at greater risk for memory impairment.\nMusic, nature sounds and white (or pink) noise apps may still help improve sleep, she says\u2014which, in itself, is good for the body and for the brain.\nZee says that the effectiveness of pink noise is all in the timing.\nThe researchers hope to develop an affordable device that people can use at home.\nNorthwestern has a patent pending on the new technology, and one of the study authors has cofounded a company that plans to market it commercially.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that a pink noise generator timed to slow wave sleep is not yet available. The article does mention (parenthetically) that pink noise apps exist.", "answer": 1}, {"article": "\"Our research and clinical teams are immensely proud of these breakthrough findings, which are so profound they will likely result in a paradigm shift that will not be seen again for many years in the field of stroke therapeutics,\" says Michael Frankel, MD, professor of neurology, Emory University School of Medicine, chief of neurology and director of the Marcus Stroke and Neuroscience Center for the Grady Health System.\n\"However, this does not diminish urgency with which patients must be rushed to the ER in the event of a stroke.\nTo select patients for the trial, the researchers used a new approach which used brain imaging and clinical criteria as opposed to just time alone.\nThe DAWN trial results were presented at the European Stroke Organization Conference in May.\nThere was no difference in mortality or other safety end-points between the two groups.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "In this case, availability has to do with whether hospitals offer this procedure. Since the procedure is already part of standard practice we\u2019ll rate this Satisfactory, even though it\u2019s not explicitly stated.", "answer": 1}, {"article": "The procedure, called a prostatic urethral lift, does not improve flow as much as surgery, in which a physician cuts away some of the inside of the prostate to allow better flow. But the lift procedure and recovery are much quicker, with no hospital stay and fewer complications. And patients who get the sutures can always come back for surgery later.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We learn that \u201cthe first patients were treated in Australia by the end of 2005. Initial clearance from the U.S. Food and Drug Administration did not come until 2013, but now more than half of the 30,000 patients treated to date are in this country,\u201d according to the manufacturer\u2019s chief executive officer Dave Amerson.\nThe story would have been stronger if it had discussed how many\u00a0urologists can do the procedure.", "answer": 1}, {"article": "Finally, in 2000, a group of researchers including Dr. Segal in Toronto, J.\nYet so far, the evidence that mindfulness meditation helps relieve psychiatric symptoms is thin, and in some cases, it may make people worse, some studies suggest.\nThe question, said Linda Barnes, an associate professor of family medicine and pediatrics at the Boston University School of Medicine, is not whether mindfulness meditation will become a sophisticated therapeutic technique or lapse into self-help clich\u00e9.\nOthers, like Dr. Linehan, insist that patients in severe mental distress are the best candidates for mindfulness.\nSince mindfulness meditation may have different effects on different mental struggles, the challenge for its proponents will be to specify where it is most effective \u2014 and soon, given how popular the practice is becoming.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that mindfulness training in psychotherapy and for the management of chronic conditions is not standardized; thus, practicioners may have different interpretations of the practice in the clinical setting.\u00a0 The story notes that practitioners who use elements of mindfulness meditation and related therapies may do so with different types of patients and for different conditions; there is not yet agreement or clear evidence for which patients are most helped by mindfulness mediation.\u00a0 The article does a good job of explaining elements of the practice and listing resources (in the form of books, experts, clinical training centers and accessible home-based practices). Readers could practice or learn more about mindfulness mediation on their own based on information presented in the article. ", "answer": 1}, {"article": "While other studies have found a link between eating chocolate and reduced stroke risk, this research found a slight difference in protection, depending on type of stroke.\nThe new Swedish study echoes previous research in men and women.\n\"The protection started at more than 45 grams [about 1.5 ounces] a week,\" says researcher Susanna C. Larsson, PhD, of the Karolinska Institutet in Stockholm, Sweden.\nThose who ate the most chocolate were protected a bit more from strokes caused by hemorrhage than strokes caused by obstruction such as blood clots.\nLarsson isn't sure why.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of chocolate bars is not in question. But it is important to note that the chocolate sold in Sweden typically has a higher concentration of cocoa solids \u2014 the likely source of any protective effect \u2014 than chocolate sold in the U.S. The story makes this clear.", "answer": 1}, {"article": "For the study, the researchers followed 57,872 women in B.C.\nMcRae said the findings add new evidence in support of midwifery care, and support the development of policies to ensure midwives are available and accessible, especially for low-income women.\nThe study, published today in the British Medical Journal Open, found that low-income pregnant women who receive care from a midwife compared to a physician are less likely to go into early labour, to have a baby with a low birth weight, or to have a small-for-gestational age birth, meaning a fetus or infant that is smaller or less developed than normal for the number of weeks in pregnancy.\nThey used maternity, medical billing and demographic data to investigate the odds of small-for-gestational age birth, pre-term birth and low birth weight for low-income women receiving care from a midwife, GP, or OB.\n\"Our research could help develop policies that make the service more accessible to low-income women,\" added senior author Nazeem Muhajarine, a professor in community health and epidemiology at the University of Saskatchewan and McRae's supervisor while she conducted the research.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This was a strong point. The news release noted that midwifery is \u201cnot available in all parts of the country.\u201d\nIt added:\n\u201cWaitlists for midwives can be quite long, so women who are educated and health-conscious typically access midwives early on in their pregnancies,\u201d said [lead author Daphne] McRae. \u201cBut more vulnerable women might not be as aware of the services available to them, so expanding midwifery to make it available for all women is important.\u201d", "answer": 1}, {"article": "What's more, \"people tended to measure the outcomes very differently,\" Matthews says.\nAnd here's a biggie: There wasn't much information about adverse effects on women and babies, something everyone would certainly want to know.\nAnd there wasn't much hard data on psychological, social or economic outcomes, according to the report.\nThe studies in the review comprised more than 4,000 women who were up to 20 weeks pregnant.\nUnfortunately, medicines to relieve morning sickness have a checkered history.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The whole point of the story was to discuss the most commonly used treatments for morning sickness: acupuncture, acupressure, ginger, vitamin B-6 and conventional anti-vomiting drugs. \u00a0", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2009/11/02/financial/f035110S68.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story makes it clear that boceprevir is an experimental drug currently in development. ", "answer": 1}, {"article": "NEW YORK (Reuters Health) - In a small study, people who had chronic pain as a result of damage to the nervous system reported feeling less pain, as well as less depression and anxiety, when they smoked marijuana compared to when they smoked a drug-free placebo.\nThere was also no difference in the quality of life or mood scores that participants reported when they were on any of the four treatments.\nFor that reason, the finding that marijuana may actually help improve patients\u2019 sleep, she said, is \u201cparticularly noteworthy.\u201d\n\nThe cannabinoid family, which includes marijuana, is \u201cemerging as an interesting new class of drugs for pain management,\u201d Ware said.\nThe study\u2019s five-day treatment sessions also leave questions about patients with chronic conditions who might need treatment for months or years.\n\u201cThe trial did not last long ... so the authors cannot really say whether any response would be sustained,\u201d Dr. Henry McQuay, who studies pain and pain relief at the University of Oxford, wrote in an editorial accompanying the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Strangely, neither story we reviewed pointed out that marijuana is illegal in most states and in Canada, where the study took place. The story could have, at a minimum, mentioned which states have medical marijuana laws or talked about whether any other countries currently allow cannabis to be sold in pill form the way it was used in this study.", "answer": 0}, {"article": "Susan Pisano, a spokeswoman for the Association of Health Insurance Plans, the largest trade group, said insurers would wait for guidance from the FDA, but adds, \"If the FDA pulls back its approval for this particular indication, it would trigger a review of plan policies.\nBut some physicians, including Perez, say the issue is getting harder to ignore.\nBut gratitude is tinged with worry, because the Food and Drug Administration is considering the unusual step of revoking its approval of Avastin as a treatment for metastatic breast cancer.\nBecause Avastin is approved to treat other cancers, losing the breast cancer indication would not, technically, remove it from a doctor's toolkit.\nBut here's the catch: Avastin costs more than $8,000 a month.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that Avastin received preliminary approval for treating metastatic\u00a0breast cancer in 2008 and formal FDA approval is currently pending. ", "answer": 1}, {"article": "Iowa Democrats may have saved the caucuses\n\nIf the proposed Democratic plan is adopted, the Iowa Democratic caucuses will be both familiar and new and may well endure as first in the nation.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that although this is a new technology, it is not available everywhere.", "answer": 1}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that \"the new cream may not be widely available for 10 years,\" but that didn\u2019t stop them from writing about it or touting its \"promise.\" ", "answer": 1}, {"article": "A three-year-old Silicon Valley start-up, Counsyl Inc., won the Bronze Innovation Award for its simple, low-cost genetic test that can alert prospective parents who might be carrying genes that could cause hereditary diseases in their children.\n\nCounsyl's technology promises a \"high quality-of-life impact for families at risk for conceiving children with familial diseases,\" says Larry Bock, an Innovation Awards judge and special limited partner at venture firm Lux Capital. \"This technology bundles previously...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story says that after a period during which the test was available only at certain clinics, it now is available nationally. That sounds like good news, but I was left wondering if \"nationally\" meant the same as \"everywhere.\" Are we just as likely to see this test in Casper, Wyoming, as we are in Manhattan?", "answer": 1}, {"article": "New York Eye and Ear Infirmary of Mount Sinai is ranked No.\nThis is the first study to demonstrate that among advanced cancer patients admitted to an inpatient oncology service, standardized use of triggers for palliative care consultation is associated with substantial improvement on multiple quality measures.\nPublished today in the Journal of Oncology Practice, the study also determined that a systemized process of referrals resulted in significant improvements in 30-day readmission rates, hospice referral, and receipt of chemotherapy after discharge in patients with advanced cancers.\n\u201cPalliative care involvement helps patients understand their prognosis, establish goals of care, and formulate discharge plans in line with those goals, and this study is the first to confirm the impact of using standardized criteria and automatic palliative care consultation on quality of cancer care.\u201d\n\nCo-authors of the study include Kerin Adelson, MD, Division of Hematology/Oncology at Yale University School of Medicine.\nThe integration of palliative care improves symptom control and decreases unwanted health care use, yet many patients are never offered these services.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although this piece makes it plain that palliative care has positive implications for cancer care, it doesn\u2019t tell readers what is currently happening at hospitals around the country. It assumes readers are already aware of palliative care availability but that may not always be the case.", "answer": 0}, {"article": "Researchers measured concentrations of three proteins previously identified as potential biological indicators, or biomarkers, for Alzheimer's and MCI: amyloid-beta, tau, and phospho-tau.\n\"Using this approach, which was totally independent of diagnosis, we were able to identify patients with Alzheimer's disease,\" Vanderstichele says.\nLow levels of the amyloid protein amyloid-beta 1-42, along with high levels of total tau and elevated phospho tau 181 (P-tau 181), identified Alzheimer's disease in three independent study groups, Hugo Vanderstichele, PhD, of the Belgian biotech company Innogenetics, tells WebMD.\nIn one study, this protein signature was also seen in spinal fluid samples from all patients with mild cognitive impairment who progressed to Alzheimer's disease within five years.\nAug. 9, 2010 -- Researchers have identified a protein \"signature\" in the spinal fluid of patients with Alzheimer's disease, which could represent an important advance in its diagnosis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story points out that most clinicians are not able to provide this sort of test and that at least one expert says that specialized testing centers would need to be developed.", "answer": 1}, {"article": "About 23 percent of the women reported taking a low-dose aspirin (81 milligrams), 18 percent took ibuprofen, 11 percent took full-strength aspirin (325 mg) and about 10 percent took a COX-2 inhibitor or another nonsteroidal anti-inflammatory drug (NSAID).\nMillions of people take a low-dose aspirin daily in hopes of reducing their chances of having a heart attack.\nHowever, aspirin can increase the risk for internal bleeding, so women should talk with their doctors before starting a low-dose aspirin regimen, for any reason.\nAbout 1 of every 8 women in the United States will develop breast cancer at some point.\nThose who take a daily low-dose aspirin, also called a baby aspirin, usually do so to prevent cardiovascular disease, the leading cause of death for women older than 25.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Low-dose aspirin is already widely available and is used by many women to reduce their risk of cardiovascular disease.", "answer": 2}, {"article": "The requested document is forbidden. Please try your operation again .", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that the robotic apparatus needed for the procedure reported on is not available in all facilities though it was becoming more common.", "answer": 1}, {"article": "Shift workers with chronic sleep deprivation also face an increased risk of accidents.\nExposure to bright light didn\u2019t appear to improve reaction times or sleepiness.\nBut light was associated with better driving.\nBut there are still things drivers can do now to stay safer on the road.\nMore research is needed on the potential of bright light therapy to make exhausted drivers safer, said Dr. Donald Redelmeier, a researcher at the University of Toronto who wasn\u2019t involved in the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Light sources are readily available.", "answer": 2}, {"article": "\"It's kind of amazing that something so simple could be an answer,\" Paul said.\nOne local pediatrician said she wouldn't discourage parents from trying honey with their children, but more studies are needed to draw solid conclusions.\nHoney also beat out no treatment at all.\nThe study comes at a time when parents are on the lookout for new ways to give sick children relief.\n\"(Honey) is a cheap and effective treatment,\" said Dr. Ian Paul, lead investigator for the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly honey and over-the-counter cough medicine are available.", "answer": 1}, {"article": "Aging is never easy, particularly during menopause. But for 30 years women could at least depend on estrogen and progestin supplements, a comforting hormonal hand to hold that would not only ease the uncomfortable symptoms of getting older but also keep skin supple and hair lustrous. Doctors even encouraged women well into their 70s to take the treatments, on the basis of studies showing that they protected against heart disease and cushioned bones against osteoporosis-related fractures.\n\nIt seemed almost too easy--and it was. In 2002 the quick pharmaceutical fix was all but snatched away when a large government study found that...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that hormone therapy has been around for a long time and is very common.", "answer": 1}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that there are a wide range of counseling activities that are available. The story also covers medications for weight loss and the fact that they are under-prescribed given the obesity\u00a0epidemic.", "answer": 1}, {"article": "Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.\n\nThe test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is made clear that the blood test is not currently available, and the article gives a prospective date for\u00a0when the test will be launched.", "answer": 1}, {"article": "Still, the study suggests that brain stimulation \"not only just helps patients who haven't been able to recover from depression, but it seems to be associated with the absence of relapses.\nDeep brain stimulation has been around for more than 20 years, Mayberg said, and is commonly used to treat Parkinson's disease.\nDr. Samuel James Collier, an assistant professor of psychiatry at the University of Texas Southwestern Medical Center at Austin, predicted that even if deep brain stimulation turns out to be an effective treatment for depression, it'll be far from the first line of defense.\nPrevious research by Mayberg and others suggested that deep brain stimulation had potential as a treatment for depression.\nMost of the patients continued to receive the treatment over two years, although researchers temporarily turned it off in three of them as part of the study before realizing that doing so caused their depression to return.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the treatment is widely available, saying, \u201cDeep brain stimulation has been around for more than 20 years\u2026and is commonly used to treat Parkinson\u2019s disease.\u201d", "answer": 1}, {"article": "Consultant hematologist John Snowden said: \u201cThe immune system is being reset or rebooted back to a time point before it caused MS ...\nI\u2019d rather have done 10 rounds with Mike Tyson.\u201d\n\nRichard Burt of Northwestern University in Chicago, who carried out the first HSCT for MS in 1995 and is coordinating the international trials, told the BBC: \u201cThere has been resistance to this in the pharma[ceutical] and academic world.\nThe treatment has traditionally been used to treat bone and blood cancers.\u201d\n\nBasil Sharrack, a consultant neurologist at Sheffield teaching hospitals NHS foundation trust, said: \u201cThe new treatment is showing some remarkable results in the small number of patients we have treated so far.\nPaul Kirkham, another patient who has undergone the treatment at a cost of about \u00a330,000, said: \u201cIt does knock you out.\n\u201cThe MS Society has recently funded a study looking into the impact of HSCT on the immune system and we\u2019d like to see larger trials in this area.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The reader must infer that, because the information comes from an ongoing clinical trial, the treatment is not yet available. And the story implies that it may be available outside of a research study: \u201cIt needs to be carried out at an accredited centre or as part of a clinical trial\u201d. Does this mean that if I have 30,000 pounds, I can have this done to me in the UK?", "answer": 0}, {"article": "A new study has an intriguing finding: Advanced cancer patients who received early palliative care in conjunction with standard care for their disease not only reported better quality of life, but lived a few months longer than patients who received only standard care.\n\nThe research, published in the New England Journal of Medicine, included 151 patients diagnosed with metastatic non-small-cell lung cancer who were randomly assigned to one of those treatment plans. At 12 weeks, 86% of those who were still alive filled out assessments \u2026", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As other stories covering the study pointed out,\u00a0access to palliative care is limited by complicated reimbursement and\u00a0lack of\u00a0skilled providers in some areas. The\u00a0WSJ didn\u2019t mention\u00a0these\u00a0barriers. \u00a0", "answer": 0}, {"article": "Anthony's asthma diminished over time, and he says he can still play soccer, run fast and breathe \"just fine.\"\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\nThere's no official policy from the American College of Cardiology, but officials say most members support screening student athletes.\nThese surprise attacks are due to inherited problems that children are born with.\nDebauche says the heart screening turned out to be life-saving for this student athlete.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>1clip_themedata.thmx\" rel=\"themeData\"/>1clip_colorschememapping.xml\" rel=\"colorSchemeMapping\"/>\n\n\n\n\nThe story states that electrocardiograms are not provided to all student athletes prior to participation in sports. Although it satisfies the minimum standard for a satisfactory rating on this criterion, the story could have done a better job in explaining that heart screening for student athletes (including EKG) is routinely available and relatively easy to obtain. A brief description of the way in which an EKG is obtained would have provided some context for the reader. \n", "answer": 1}, {"article": "Ultrasound waves applied to the whole brain improve cognitive dysfunction in mice with conditions simulating vascular dementia and Alzheimer's disease.\nThe first clinical trials to evaluate the effectiveness and safety of the LIPUS treatment are already underway.\nThe research, conducted by scientists at Tohoku University in Japan, suggests that this type of therapy may also benefit humans.\nThe mice with a condition simulating Alzheimer's disease in humans received 11 LIPUS treatments over a period of three months.\nThis limits the types of drugs and cell therapies that could be made available to treat dementia.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that clinical trials are underway, which tells us (not quite clearly) that the LIPUS treatment isn\u2019t yet available to the public.", "answer": 1}, {"article": "In a study published last month in Nature, 80 percent of infants diagnosed with autism as toddlers had an increased rate of growth in the surface area of their brains in their first year, compared to toddlers who were not diagnosed with autism.\nExcess brain fluid may be more than an early marker for autism, Di Martino said.\nCompletely different mechanisms may be at work for kids without an older sibling with autism, said Shen and Dimartino.\nAdditional studies are needed to confirm the finding, he said.\nHe and his colleagues are working on improving accuracy by combining their brain fluid findings with other recent research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No explicit discussion is provided about the availability of MRIs for this sort of detection procedure (and if any special, different tools or procedures are needed), but the story does make it clear that this idea is still under research, so it\u2019s experimental for now.", "answer": 1}, {"article": "\u201cBut there were other components to it -- there was oppositional defiant disorder, there were some [autism] spectrum-like behaviors, and difficulty later on socializing with other children.\u201d\n\nOppositional defiant disorder is one of the most common conditions linked to ADHD in children and is characterized by anger, tantrums, opposition to authority and, sometimes, aggressive behavior.\n\u201cWe tried some medication therapies that ended up being really a nightmare for us, and making matters worse.\u201d\n\nMedication is often the first line of defense in conventional medicine for kids with ADD and ADHD, with doctors prescribing everything from stimulants to antipsychotics and even antidepressants to help control the symptoms.\n\u201cI thought we weren't going to get accepted to the program, and they told us they could help us and we never looked back.\u201d\n\nThe specialized learning centers, of which there are now 80 throughout the country, were developed by Dr. Robert Melillo, a neurology researcher and author of the book \u201cDisconnected Kids,\u201d to help balance the brains of kids with learning disorders, like Mallory.\n\u201cIf you get a child who has really strong left brain and delayed right brain, those are kids that may be labeled with attentional problems or behavioral problems or social issues,\u201d Melillo said.\n\u201cThere were times I remember saying to my husband that her behaviors are holding our family hostage because it could be one meltdown a day, it could be five meltdowns a day,\u201d Amy said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There are dozens of\u00a0Brain Balance centers in the United States. The story does not directly address availability and could lead readers to think the New Jersey facility was one of a kind. But maybe the news organization felt it covered the issue when it\u00a0generously offered a free link to the centers at the end of the piece.", "answer": 0}, {"article": "\"Those stem cells are given back to the patient where they can go back to the bone marrow and make the blood cells for the rest of the patient's life,\" Kohn said.\nDr. Kohn said of an experimental treatment for SCID, \"It's gone from a 'one day, maybe' to a real clinical reality.\"\nIt's a genetic disorder that leaves the body with a weakened immune system, making infants extremely vulnerable to illness.\nDr. Kohn is currently working with the FDA to make his treatment available nationwide.\nThat means an actual cure for the disease, said Kohn, who is also director of the Human Gene Medicine Program at UCLA.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes, \u201cDr. Kohn is currently working with the FDA to make his treatment available nationwide. He\u2019s also testing the same method as a cure for sickle cell disease. Clinical trials for that treatment are now underway.\u201d This gives the impression that although the approach is still experimental, its availability nationally is a forgone conclusion.\u00a0In fact, many treatments get to this stage and do not pan out.", "answer": 0}, {"article": "In addition to He and Dibaba, other contributors included Pengcheng Xun, a faculty member in IU's Department of Epidemiology and Biostatistics; Kuninobu Yokota of The Jikei University School of Medicine in Tokyo, Japan; and Emily White of the University of Washington in Seattle.\n\"While more study is needed, the general population should strive to get the daily recommendations of magnesium through diet, such as dark, leafy greens or nuts, to prevent any risk of pancreatic cancer.\"\nIndiana University researchers have found that magnesium intake may be beneficial in preventing pancreatic cancer.\nThe study found that every 100-milligrams-per-day decrease in magnesium intake was associated with a 24 percent increase in the occurrence of pancreatic cancer.\nThe study also found that the effects of magnesium on pancreatic cancer did not appear to be modified by age, gender, body mass index or non-steroidal anti-inflammatory drug use, but was limited to those taking magnesium supplements either from a multivitamin or individual supplement.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release briefly mentions dietary magnesium can be found in \u201cdark, leafy greens or nuts\u201d but a longer list of dietary sources might have been helpful. It\u2019s generally understood that magnesium supplements are widely available on any grocery or drug store shelf.", "answer": 1}, {"article": "Shares in Angle, which has a market cap of about 50 million pounds, rose 2.2 percent to 68 pence.\nThe performance of the test would now be validated in another study designed to meet European CE Mark and US FDA regulatory requirements, he said.\nThe test was nearly twice as successful in eliminating false-positives than current tests, he said.\nHeadline results from a study of 400 patients in Europe and the United States showed the test to detect cancerous cells in the bloodstream correctly identified cancer in up to 95 percent of cases, the company said.\nIt also had the potential to identify targets on the tumor that could be used to inform treatment strategies, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicates that further studies are needed to fulfill European and US regulatory requirements, implying that the test is not yet available. But the comments of the company spokesperson make the likelihood of approval seem like a foregone conclusion.", "answer": 1}, {"article": "Radiologists and urologists have been frustrated for decades by the inability of conventional imaging tests, such as CT and MRI, to distinguish benign from malignant kidney tumors.\nAt Johns Hopkins, use of this test has already spared a number of our patients from unnecessary surgery and unnecessary removal of a kidney that would require them to be on dialysis.\nThe research team reports that the potential improvement in diagnostic accuracy will spare thousands of patients each year in the United States alone from having to undergo unnecessary surgery.\nFOR IMMEDIATE RELEASE\n\n\n\nNewswise \u2014 The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition of a widely available, noninvasive imaging test called 99mTc-sestamibi SPECT/CT to CT or MRI increases the accuracy of kidney tumor classification.\n\u201cIn the absence of diagnostic certainty, surgeons tend to remove kidney tumors in an abundance of caution, leading to an estimated 5,600 surgically removed benign kidney tumors each year in the United States.\u201d\n\nOther authors on this paper include, Sara Sheikhbahaei, Christopher S. Jones, Kristin K. Porter, Alex S. Baras, Phillip M. Pierorazio, Mark W. Ball, Lilja B. Solnes, Jonathan I. Epstein, and Mehrbod S. Javadi, all of the Johns Hopkins University School of Medicine, and Takahiro Higuchi of Wurzburg University in Germany.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes in several places, including in the first sentence, that the technique is \u201cwidely available.\u201d We know that to be true.", "answer": 1}, {"article": "WASHINGTON -- A new study shows patients taking the anticlotting drug Plavix along with a type of drug used to block stomach acid have an increased risk of a subsequent hospitalization for heart trouble.\n\nThe study, which is being published in this week's Journal of the American Medical Association, adds to other recent studies that suggest proton pump inhibitors like Aciphex, Nexium, Prevacid and Protonix reduce the effectiveness of Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis SA.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that these drugs have been and continue to be readily available to patients.\u00a0", "answer": 1}, {"article": "\u2018\u2018I\u2019ve had chemotherapy.\nMary Lou Smith, a breast cancer survivor and advocate who helped design the trial for ECOG, the Eastern Cooperative Oncology Group, which ran it, said she thought women \u2018\u2018would be thrilled\u2019\u2019 to skip chemo.\n\u2018\u2018These patients who had low risk scores by Oncotype did extraordinarily well at five years,\u2019\u2019 said Dr. Hope Rugo, a breast cancer specialist at the University of California, San Francisco, with no role in the study.\nBut independent monitors recommended the results on the low-risk group be released, because it was clear that adding chemo would not improve their fate.\nThe study was sponsored by the National Cancer Institute.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The Associated Press report talks about costs of the Oncotype DX gene test by California company Genomic Health and adds that other tests are also on the market.", "answer": 1}, {"article": "You\u2019re shepherding a fixed amount of resources across a large population and trying to do it according to some sort of evidence-based system.\u201d\n\nKaiser Health News is an editorially independent program of the Henry J. Kaiser Family Foundation, a nonprofit, nonpartisan health policy research and communication organization not affiliated with Kaiser Permanente.\nThat 19-member panel voted 10 to 5 last year that studies of the treatment showed it to be as good as or better than usual care for depression.\n\u201cThe initial treatment with rTMS is $12,000: That\u2019s a lot of generic Prozac or Effexor,\u201d which are cost-effective antidepressants with long track records, said Joel Rubinstein, associate medical director of Harvard Pilgrim HealthCare, an insurer that does not cover rTMS.\nThe fee is generally about $10,000, but officials say they work with patients who can't afford that.\nThe treatment, which has been approved by the Food and Drug Administration, is covered by Medicare in five states, but few private insurers pay for it routinely.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that an rTMS device has been approved by the FDA and that availability of treatment is growing. It also explains that treatment usually is not covered by insurance, so patients are on the hook for the $6,000 to $12,000 cost of treatment.\nStill, availability is very limited in most parts of the country", "answer": 1}, {"article": "As a result, sticky mucus builds up in a patient's lungs, causing infections and making it hard to breathe.\nThe time from gene discovery to successful drug may be shortening, but there are only a handful of successful drugs so far, and for a while at least, the appearance of new ones will be slow.\nBut for people who do have that mutation, the drug works remarkably well.\nThat's the day scientists from the U.S. and Canada announced the discovery of the gene associated with the disease.\nBut the success of Kalydeco has been more than two decades in the making.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers can infer that this drug is available from the final sentence that establishes cost. It would have been easy for the story to specify clearly that the drug is now available by prescription, with some estimate of how widespread is the use.\u00a0 Nonetheless, we\u2019ll give the story the benefit of the doubt.", "answer": 1}, {"article": "RA Nash et al.\n\u201cAlthough further evaluation of the benefits and risks of HDIT/HCT is needed, these five-year results suggest the promise of this treatment for inducing long-term, sustained remissions of poor-prognosis relapsing-remitting MS,\u201d said Richard Nash, M.D., of Colorado Blood Cancer Institute and Presbyterian-St. Luke\u2019s Hospital.\nThe treatment carries some risks, and many participants experienced the expected side effects of HDIT/HCT, such as infections.\nFive years after HDIT/HCT, most trial participants remained in remission, and their MS had stabilized.\nOther studies have indicated that currently available MS drugs have lower success rates.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no mention of whether this therapy is currently available, where it\u2019s performed, or whether regulatory approval is required. Also, there\u2019s no discussion of whether it is likely to be covered by most insurance plans. It appears that this is still purely a research therapy and would not be\u00a0available outside of research settings. \u00a0However, there are many physician\u00a0practices that do research, usually for industry, which don\u2019t\u00a0have the same safety features as this\u00a0research lab had.", "answer": 0}, {"article": "One therapy at M.D.\nNow, because drugs are mostly tested on patients whose cancer has resisted previous treatment, it's usually used on tumors advanced to often fatal stages.\nDespite the endorsements, not everyone is ready to proclaim immunotherapy the future of cancer treatment.\nBecause it doesn't inflict the damage to healthy tissue caused by chemotherapy and radiation, immunotherapy's great appeal is its nontoxicity.\nResearchers acknowledge immunotherapy's promise is furthest from realization for bulky solid tumors, perhaps too advanced for the immune system to beat.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story claims that many immunotherapies are almost ready to go up for FDA approval. This is not sufficient information on availability. The story should have made it clear that these therapies are currently only available through clinical trials. Furthermore, the story should have cautioned the reader that these therapies would only be appropriate after first-line treatments have failed (except in certain rare cases).", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that American surgeons perform about half a million total knee replacements annually, suggesting that the operation is widely available.", "answer": 1}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly notes that solanezumab is the subject of a more definitive trial that won\u2019t end until at least 2016, and that aducanumab is still in early-stage clinical trials. That\u2019s sufficient for a Satisfactory rating. However, we wish that the story had explained that it will be years \u2014 at least \u2014 before either drug is on the market. And it\u2019s entirely possible that neither will come to market. On a health issue like this one, when people are often willing to grasp at straws to help a loved one, it\u2019s important to be as clear as possible when it comes to availability.", "answer": 1}, {"article": "The study, published in the December 26 issue of the Journal of Clinical Oncology, showed that patients treated with reduced radiation had less difficulty swallowing solids (40 percent versus 89 percent of patients treated with standard doses of radiation) or impaired nutrition (10 percent versus 44 percent of patients treated with regular doses of radiation).\n\u201cAnd while traditional chemoradiation has demonstrated good tumor control and survival rates for patients, too often they encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration and feeding tube dependence,\u201d said Dr. Burtness.\nOther authors on the paper include: Shanthi Marur (Johns Hopkins Medicine) and Anthony Cmelak (Vanderbilt University).\n\u201cToday, many younger patients are presenting with HPV-associated squamous cell carcinoma of the oropharynx,\u201d said Dr. Burtness.\n\u201cRadiation dose reduction resulted in significantly improved swallowing and nutritional status,\u201d she said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The issue of availability of\u00a0reduced dosages doesn\u2019t apply here.", "answer": 2}, {"article": "For more details and to read the full study, please visit the For The Media website.\nChirag P. Shah, M.D., M.P.H., and Jeffrey S. Heier, M.D., of the Ophthalmic Consultants of Boston, randomly assigned 52 patients (52 eyes) to receive YAG laser vitreolysis (n = 36) in one session or a sham (placebo) laser treatment (control; n = 16).\nSix months after treatment, the YAG group reported significantly greater improvement in self-reported floater-related visual disturbance (54 percent) compared with sham controls (9 percent).\nA total of 19 patients (53 percent) in the YAG laser group reported significantly or completely improved symptoms vs 0 individuals in the sham group.\nTo place an electronic embedded link to this article in your story Link will be live at the embargo time: http://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2017.2388\n\nPatients reported improvement in symptoms of eye floaters after treatment with a laser, according to a study published by JAMA Ophthalmology.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although wording of the release makes it clear that laser treatments are an option for eye floaters, the release does not provide information about availability.\nHowever, there is\u00a0enough information in the published study for any\u00a0ophthalmologist who is skilled\u00a0in the use of the YAG laser to be able to use the\u00a0treatment.", "answer": 0}, {"article": "LDL was 8.3 points lower on the moderate-fat diet without the avocado and 7.4 points less on the lower-fat diet.\nAnd it\u2019s one more piece of evidence in favor of adding good fats to the diet.\n\u201c\n\nAmericans may not be used to eating avocado but Kris-Etherton says it\u2019s easy to add.\n\u201cAnd certainly there's an emerging research base showing that some of these bioactive components may affect another lipoprotein particle favorably, like high-density lipoprotein.\nSo that was the only difference between the two diets, which then tells us that it's the avocado that has additional benefits which are beyond the unsaturated fat.\u201d\n\nThe findings are similar to a batch of studies that showed people who were given olive oil and nuts and told to add them to their diets ended up healthier.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story gives the impression (largely correct) that avocados are widely available. As with the competing stories, we would have liked to have seen some acknowledgment that there are areas where avocados may be more difficult to find.", "answer": 1}, {"article": "CT scanning uses X-rays and computers to produce a clearer image than traditional X-ray techniques, but CT also uses higher radiation doses to generate those images.\nThat\u2019s consistent with the findings of the National Lung Screening Trial in the U.S., which in November released data \u2014 published online in the New England Journal of Medicine last week \u2014 showing that 20 percent fewer middle-aged heavy smokers died of lung cancer when they were screened annually with a CT scan compared to a standard, less detailed chest X-ray.\nResearchers led by Dr. Ryoichi Kondo of Shinshu University Hospital in Matsumoto looked back at outcomes for close to 500 non-smoking lung cancer patients whose cancer was caught by CT scan screening, or by standard X-ray screening \u2014 another strategy for catching cancer early \u2014 or when patients came into the doctor with lung symptoms.\nBut experts say the findings likely don\u2019t apply in non-Asian countries, where the majority of all lung cancers are found in people who smoke \u2014 and where using computed tomography (CT) scans to screen for lung cancer in smokers has recently been a controversial topic.\nDr. Christine Berg, one of the leaders of the U.S. screening studies, said that generally about a quarter of chest CT scans show some kind of abnormality \u2014 but 96 percent of those abnormal scans turn out not to be lung cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story differentiates between this study\u2019s screening in people who\u2019ve never smoked and the practice in non-Asian countries where most lung cancers are found in people who\u2019ve smoked. It stated:\n\u201cEast Asian countries are more likely to regularly screen non-smokers for lung cancer because biological differences seem to put Asians at a higher risk than other non-smokers, researchers explained.\nNon-smokers without symptoms generally are not screened for lung cancer in the U.S.\u201d", "answer": 1}, {"article": ".\nThis suggests that the blood test could be used by clinicians for up to a week after injury to detect brain injury.\nThe results showed that the blood test was able to detect brain injuries with 94 percent accuracy, nearly as effective as state-of-the art CT scans.\nWhen cross-checked with scans, the blood test was able to detect mild to moderate traumatic brain lesions with up to 97 percent accuracy in patients 18 years and older.\nThe blood test also indicated which patients were in need of life-saving neurosurgery.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that the test is only part of a clinical trial and not available.", "answer": 1}, {"article": "[3] Yokell et al.\nRICHMOND, Va., March 29, 2016 /PRNewswire/ -- kal\u00e9o, a privately-held pharmaceutical company, today announced that EVZIO\u00ae (naloxone HCl injection) Auto-injectors have been reported to help save more than 1000 lives.\nEVZIO was the first naloxone product specifically designed, FDA approved and labeled for the emergency treatment of opioid overdose by individuals without medical training.\nOur mission is to provide innovative solutions that empower patients to confidently take control of their medical conditions.\nEach kal\u00e9o product combines an established drug with an innovative delivery platform with the goal of achieving superiority and cost effectiveness.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that the product is FDA approved and quotes numerous public officials discussing its use in their communities, so one can infer that it is on the market. However, since the release suggests that everyone should have the product in their medicine cabinets, it\u2019s really important to know whether and how members of the general public could purchase this product. It\u2019s not made clear that naloxone is something that must be prescribed. So we\u2019re rating this Not Satisfactory on that basis.", "answer": 0}, {"article": "Being around for my daughter, my son, my wife.\nSandoval is alive today because of an experimental form of immunotherapy called CAR-T.\nDespite chemotherapy and a stem cell transplant, the cancer returned before his daughter\u2019s first birthday.\nAbout eight months after a single treatment, 39 percent of patients had no evidence of cancer.\n\u201cThat\u2019s actually quite remarkable knowing that at best only one out of 10 of these patients could have complete disappearance of their lymphoma with standard chemotherapy,\u201d Locke said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that this treatment is being reviewed by the FDA. It says that a decision \u201ccould\u201d come by the end of the year, which provides wiggle room.", "answer": 1}, {"article": "Added Dr. John C. LaRosa, president of the State University of New York (SUNY) Downstate Medical Center in New York City: \"It's very preliminary but it's important because the last drug out of the barrel of this type was not a success.\nA big study to confirm the results would take four to five years to complete so the drug is still years away from market, said Cannon, who is a cardiologist with Brigham and Women's Hospital in Boston.\n\"We saw very encouraging reductions in clinical events,\" said Dr. Christopher Cannon, lead author of the study, which also appears in the Nov. 18 issue of the New England Journal of Medicine.\nA large trial on torcetrapib was killed after investigators found an increased risk of death and other cardiovascular outcomes.\nIt also didn't result in the blood pressure increases that helped doom torcetrapib.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story points out that anacetrapib still must be tested in a large clinical trial and is years away from being considered for approval.", "answer": 1}, {"article": "A serious mood disorder that affects as many as 1 in 7 women after childbirth, postpartum depression can lead to panic attacks, inconsolable sadness, and deep feelings of inadequacy.\nThe company has not submitted study data to federal regulators and isn\u2019t at this point seeking approval of the drug, known as SAGE-547, for postpartum depression.\nOne of the drug\u2019s most promising features: It appears to work quickly \u2014 some women in the study started experiencing relief after 24 hours.\nIt\u2019s also working on an oral form of the drug.\nThe company is also testing SAGE-547 as a treatment for a rare form of epilepsy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that this drug is still being tested and that the company has not applied for FDA approval.", "answer": 1}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that testing of the \"paint\" described in the research would be expected to begin next year.\u00a0 Presumably these would be tests to determine effectiveness; before that there would need to be tests conducted to determine whether it is safe for use in humans.\nIt is not clear that the equipment (Xenogen IVIS-100 system) needed to visualize the \"paint\" in patients is available.\nIn general, the leap that is required from animal research to possible human application is not well explained. \u00a0", "answer": 0}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nAlso, future studies are needed to include a more comprehensive assessment of potential predictors of treatment outcome to identify those patients most likely to benefit from sleep deprivation.\nThe authors note that further research is needed to identify precisely how sleep deprivation causes rapid and significant reductions in depression severity.\nPrevious studies have shown rapid antidepressant effects from sleep deprivation for roughly 40-60 percent of individuals, yet this response rate has not been analyzed to obtain a more precise percentage since 1990 despite more than 75 studies since then on the subject.\nReviewing more than 2,000 studies, the team pulled data from a final group of 66 studies executed over a 36 year period to determine how response may be affected by the type and timing of sleep deprivation performed (total vs early or late partial sleep deprivation), the clinical sample (having depressive or manic episodes, or a combination of both), medication status, and age and gender of the sample.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not say whether sleep-deprivation therapy is available as an alternative for most patients. In fact, sleep deprivation is not used as a treatment \u2014 only in research studies \u2014 and has been for decades.", "answer": 0}, {"article": "\"People are different.\nHowever, the study authors and an outside expert stressed that these are early findings and much longer, larger clinical trials are needed.\nThese drugs carry a note on their labels warning of the possibility of severe adverse events, including death, he noted.\nHowever, at this stage there is no definitive answer whether Spiriva should or shouldn't be used in asthma, she said.\nThe results need to be confirmed in a much larger pool of patients, Peters said, and he noted that the patients were not followed long enough to see if Spiriva was able to reduce the severity of asthma attacks and hospitalizations.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The headline and early sentences establish that Spiriva is available for COPD. It\u2018s not clear about the availability of Severent, one of the comparator regimens used in the study.", "answer": 1}, {"article": "\"We do not want to give anyone false hopes that this is ready for the clinic yet.\nThis method, this test, needs to be tried [and confirmed] with many more subjects outside our laboratory,\" he says.\nLange is quick to caution that this type of test is not yet ready for prime time.\nStill he believes this is new study can help pinpoint the earliest markers of concern in developing brains.\nCarissa Cascio, an assistant professor of psychiatry from Vanderbilt University School of Medicine, who specializes in autism and neuro-imaging, believes these study results are important.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a better job than the Reuters story of showing that these scans will not be rolling into your local mall anytime soon. \u201cLange is quick to caution that this type of test is not yet ready for prime time. \u201cWe do not want to give anyone false hopes that this is ready for the clinic yet. This method, this test, needs to be tried [and confirmed] with many more subjects outside our laboratory,\u201d he says.\u201d", "answer": 1}, {"article": "In postpartum depression, the GABA pathway may play a key role in regulating hormones that researchers believe can lead to PPD.\nSage Therapeutics is the developer of brexanolone injection and sponsor of the trials.\nNewswise \u2014 CHAPEL HILL, NC \u2013 UNC researchers say the results from the multi-site phase 2 and 3 trials of brexanolone injection are not only promising, but could change the way postpartum depression (PPD) is treated.\nThe FDA has assigned a Prescription Drug User Fee Act target date of December 19, 2018.\nA New Drug Application is currently under review by the FDA and brexanolone injection has been granted Breakthrough Therapy Designation.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the drug is currently under FDA review, with a decision on its approval expected by the end of the year.", "answer": 1}, {"article": "The new research provides more evidence of the need for new regional centers of care, in order to minimize the time it takes to transport a patient to hospital capable of providing stent therapy, according to Dr. William J.\n\u201cThey are destined to be in a nursing home or to be dead and when we re-establish blood flow \u2014 often times right there on the table \u2014 they get better.\u201d\n\nStent retriever therapy is a new procedure experts call the most major advance in stroke treatment in two decades.\nRelated: New Recommendations Say More Americans Should Take Aspirin\n\nFor Reisch, the impact was almost immediate: he began to regain feeling while undergoing the procedure.\nCurrently, stent retriever therapy is offered in just a few hundred hospitals across the country, including more than 100 Comprehensive Stroke Centers accredited by the American Heart Association and The Joint Commission.\nWhen it comes to a stroke, time is of the essence and according to the National Stroke Association using the FAST approach can help one determine the warning signs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this procedure is not going to be widely available in the U.S. It says, \u201cCenters accredited by the American Heart Association.currently, stent retriever therapy is offered in just a few hundred hospitals across the country, including all 96 Comprehensive Stroke Centers.\u201d It also provides a map showing how few centers there are in the West.", "answer": 1}, {"article": "of fat lost over 30 days.\n\"Capsimax is supported by multiple studies with findings showing safety, increased lipolysis and satiety and improved healthy body composition.\nThe company develops IP-protected, science-backed branded ingredients from natural sources using cutting edge technologies.\nThe company's centers of excellence are located in North America and India, whereas its cGMP and HACCP system-compliant manufacturing operations are located at multiple FDA inspected sites in India.\n\"Since Capsimax is made using a proprietary beadleting technology, OmniBead, which coats the capsicum extract, releasing it only when it reaches the intestines where it is absorbed without discomfort, we were able to deliver beneficial levels of capsaicinoids to our subjects, which made the MR Study possible.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t offer any advice to readers about where to acquire Capsimax \u2014 just that it\u2019s available in \u201chundreds\u201d of products. An online search for \u201cCapsimax\u201d turns up numerous products containing the extract but\u00a0 can people shopping for supplements online be assured of purity of ingredients and accuracy of dosing? The release could have done a lot better job by directly people to reputable sources of the supplement.", "answer": 0}, {"article": "\"These are very basic facts, concerning simply who lived and died,\" he noted.\nRemote monitoring via telephone lines and online physician access is available for all ICD and CRT-D devices, the authors noted, and enrollment in such programs is typically free with a cardiologist's recommendation.\nThe same is true for 88 percent of CRT-D patients, they noted.\nThe finding is based on an analysis of nearly 186,000 patients outfitted with either an implantable cardioverter defibrillator (ICD), a cardiac resynchronization therapy device (CRT), or a defibrillator combined with a CRT device (a CRT-D).\nThe study team also found that patients whose implants were monitored remotely, on a continual basis, by a health facility network were about half as likely to die as patients who only had intermittent in-person assessments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says, \u201cThe finding is based on an analysis of nearly 186,000 patients outfitted with either an implantable cardioverter defibrillator (ICD), a cardiac resynchronization therapy device (CRT), or a defibrillator combined with a CRT device (a CRT-D).\u201d The size of the study might make one think that these devices are widely available, but because we are talking about three different devices, some nod should have been made to how widespread they are.\u00a0The story does make it clear that the remote monitoring system used is available to patients.\u00a0We give this a barely satisfactory as a result.\n", "answer": 1}, {"article": "Back in April the WSJ wrote about the race to develop ways of detecting Alzheimer\u2019s disease using a brain scan. Currently only a post-mortem sampling of brain tissue can provide a definitive diagnosis. But the hope is that a technology that could be used in living patients could help rule out Alzheimer\u2019s in some patients and for those that have the disease, allow its \u2026", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0This story mentioned that the company producing the labeling compound would be applying for FDA approval this year.\u00a0 ", "answer": 1}, {"article": "Visit the U.S. National Cancer Institute for more on aspirin and cancer risk.\nThe benefit was no longer seen within four years of stopping it, the researchers found.\nMoreover, the benefit of aspirin in reducing overall cancer risk appeared to depend on how much one took.\nAmounts ranged from less than one aspirin a week to 15 or more, the researchers said.\nSo the more aspirin taken, the more the risk was reduced.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No explicit mention is made of aspirin\u2019s availability, but the drug is widely known to be commonly available, and the story certainly conveys that impression.", "answer": 1}, {"article": "Sabourin Lussier, born with spina bifida, faced the possibility of kidney failure when she was just 19 years old. Her bladder, damaged by the devastating birth disorder, leaked uncontrollably and often backed urine up into her kidneys.\n\nA conventional surgery to reconstruct her bladder with intestinal tissue threatened further health complications. So in May 2000, Ms. Lussier and her mother, Gail Johnston, agreed to an experiment under which she and eight other patients with spina bifida would receive partial, laboratory-built...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that this transplantation has only been done in a very small number of people and it is still very experimental. FDA approval has not given because tissue-based products need to be manufactured to standards similar to those for drugs or medical devices. ", "answer": 1}, {"article": "Regular aspirin use may lower the risk of Alzheimer\u2019s.\nThe claim that aspirin can prevent the disease stems from the notion that Alzheimer\u2019s is caused by inflammation that disrupts proteins in the brain.\nDoctors have long said that an aspirin a day can help ward off heart attacks.\nOne recent analysis of previous studies found that people who took a low dose of aspirin every day for several years reduced their risk of developing Alzheimer\u2019s by 13 percent.\nIt\u2019s believed that aspirin, and possibly other nonsteroidal anti-inflammatory drugs, may reduce or head off that process.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story did not explicitly state that low-dose aspirin is a readily available, over-the-counter product, this information is common knowledge.", "answer": 2}, {"article": "Researchers have long known that people who are very thin tend to have a shorter life expectancy, often because they're dealing with cancer or other serious illnesses.\nThey looked at age, sex, smoking, cancer and heart disease.\nThe most relevant was the decline in smoking since the 1970s.\nSo being fatter, at least a bit, may be healthier.\nAnd all of the people in this study are white, so that's a limitation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 2}, {"article": "Psilocybin acts on the serotonin system, suggesting it could be developed for treating depression.\nA small-scale pilot study of psilocybin\u2019s use in cases of treatment-resistant depression showed it was safe and effective, the British researchers said.\nRobin Carhart-Harris, who led the study at Imperial College London\u2019s department of medicine, said the results, published in the Lancet Psychiatry journal, were striking.\nOf 12 patients given the drug, all showed some decrease in symptoms of depression for at least three weeks.\nThat kind of approach could be risky.\u201d\n\nNutt said the results showed that psilocybin \u201cis safe and fast acting, so may - if administered carefully - have value for these patients.\u201d\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There are some small hints (it was called a \u201cpilot study\u201d), and one of the researchers warns readers\u00a0to avoid \u201cpicking their own magic mushrooms,\u201d but the story offers no other availability information. This sort of treatment under the supervision of a physician would not occur until after FDA approval for this specific indication, which would take many years.", "answer": 0}, {"article": "Pulses become more intense when arteries near the heart are worn down -- usually by lifestyle factors such as poor diet and drug use -- and can no longer \"cushion\" the blood flow coming from the heart.\nIf the findings are confirmed by larger studies, they could vastly improve the ability to detect dementia in middle age.\nThe test, which analyzes the pulse of blood vessels in the neck, could become part of routine testing for cognitive decline, according to the study by scientists at University College London (UCL), who presented their work Sunday at the American Heart Association's annual scientific conference.\nThere is currently no cure for dementia, though medication can be used to temporarily treat its symptoms.\n\"Often, a diagnosis is made and then people are sent home with no information, no follow-up appointments and no clue about what is going to happen next.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that more work needs to be done before this becomes anything approaching a standard of care.", "answer": 1}, {"article": "Paul Delios of Saugus, Mass.\nHutcher says it's now about one in 1,000, which makes it less deadly than most major surgeries.\nA big reason the operation works is because it seems to suppress appetite.\nIt's safer because of new surgical techniques which have also made it more effective.\nYet most people who have this operation do not get skinny.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The segment makes clear that the gastric bypass operation is widely available and done as many as 200,000 times per year. ", "answer": 1}, {"article": "Obesity puts children at greater risk of developing preventable conditions like heart disease and diabetes at a younger age, and suffering poor health later in life.\nTaking vitamin D could help overweight and obese children lose weight, scientists believe.\n\"Future studies should explore what the underlying mechanisms are that explain this specific relationship between vitamin D and visceral adipose tissue.\"\nChildren who took vitamin D had a significantly lower BMI, the researchers found.\nIt's encouraging that a simple intervention could have these effects and this certainly merits further investigation to consider its potential impacts on vitamin D supplementation for children with obesity.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Vitamin D is easy to find and used pervasively, so we\u2019ll mark this N/A.", "answer": 2}, {"article": "\"It appears that women who reported taking prenatal vitamins starting three months prior to conception and through the first month after conception seem to have a reduced chance their child will develop autism ,\" says study researcher Irva Hertz-Picciotto, PhD, professor of epidemiology and environmental health at the MIND Institute and Department of Public Health, University of California, Davis.\nExactly why the prenatal vitamins may protect against autism is not clear, she says.\nChildren who had the high-risk COMT gene form were seven times as likely to have autism as children without it whose mothers did take the vitamins.\nThe mothers with the high-risk form of MTHFR had a 4.5 times higher chance of a child developing autism, she says, than mothers without this high-risk form who did take the prenatal vitamins.\nTaking prenatal vitamins was found even more protective for mothers and children who had a high-risk genetic makeup .\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers will know that the vitamins discussed in the story are widely available either by prescription or as over the counter (OTC)\u00a0supplements, so we\u2019ll\u00a0award a satisfactory here.\u00a0However, the story could have been more precise about what exactly these women were taking. Were they using formulations specifically designed for women of childbearing age or\u00a0simply taking a standard multivitamin supplement\u00a0during the prenatal period?\u00a0Did the benefits extend to women who only took folic acid, which\u00a0is widely regarded as the most important vitamin\u00a0to supplement during the prenatal period? In addition, the story\u00a0might have\u00a0noted that there\u00a0are different formulations of prenatal vitamins with varying doses of\u00a0key nutrients. It would have been helpful to include some discussion of\u00a0the nutrients women\u00a0should look for and why.", "answer": 1}, {"article": "The United States recommends that men and women over age 31 eat 420 and 320 milligrams of magnesium daily, respectively.\n\u201cDietary magnesium intake is inversely associated with risk of stroke, specifically ischemic stroke,\u201d wrote lead author Susanna Larsson, a professor at the Karolinska Institute in Stockholm, Sweden.\nAbout 6,500 of them, or three percent, had a stroke in the time they were followed.\nMore in-depth studies are needed before researchers can say that the magnesium was what actually reduced the stroke risk, she added.\nOther experts said the results were consistent with dietary recommendations.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of this kind of diet is not in question.", "answer": 2}, {"article": "\u201cDr.\n\u201cOver the past decade there have been dramatic improvements in breast reconstruction that utilize various types of surgical innovations, implants, and biologic tissue,\u201d notes Dr. Small.\n\u201cThis variation of a standard technique used during breast reconstruction will revolutionize the post-operative recovery in patients who meet certain criteria for the procedure,\u201d notes Dr. Small.\nI want to also commend the pathologists at Valley, who were exceptional in their diagnostic results.\u201d Dr. Wilson and Laura Klein, M.D., Medical Director of the Breast Center, have extensive experience in performing nipple-sparing mastectomy, a technically demanding surgery that is performed within aesthetically appealing minimally invasive incisions.\n\u201cHere at Valley, we are proud to offer this option for our patients and are excited about its potential for vastly improving patient care for women with breast cancer.\u201d The technique involves placing tissue expanders (interim implants) under the skin on top of a woman\u2019s pectoralis muscles after her breast tissue has been removed.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told\u00a0The Valley Hospital performed this surgery, and \u2014 by implication of going through the effort of issuing a news release \u2014 we have to assume the hospital plans to perform\u00a0this surgery again for patients who qualify. However, that isn\u2019t made clear.", "answer": 0}, {"article": ".\nMore than 70 percent of the patients taking the higher dose of the drug showed a significant benefit, according to the researchers.\nStill, pridopidine does not get at the underlying cause of Huntington's disease, Di Rocco said.\nAccording to the study authors, this is the first drug shown to improve patients' loss of ability to move their muscles voluntarily.\nThe results of the phase 3 clinical trial, conducted by Spanish researchers led by Dr. Justo Garcia de Yebenes, of the department of neurology, Hospital Ramon y Cajal in Madrid, appear in the Nov. 7 online edition of The Lancet Neurology.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that study results are from a phase III clinical trial, but it does not clearly comment on the availability of pridopidine, or the class of dopidine drugs in general. The story could have simply said that this drug is investigational and is not available yet.", "answer": 0}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is about a trial of a drug called candesartan, which is currently approved for treating hypertension. Researchers studied it for managing a condition that is now called pre-hypertension. But the story didn\u2019t make clear where the drug stood with the FDA for approval for the use described in the article.", "answer": 0}, {"article": "For instance, it only became apparent after about five years for esophageal, pancreatic, brain, and lung cancer; about 10 years for stomach and colorectal cancer; and about 15 years for prostate cancer.\nThe investigation also showed that the benefits of taking aspirin increased over time.\nThe study looked at eight trials examining the effects of a daily dose of aspirin on preventing heart attacks involving 25,570 patients, 674 of whom died from cancer.\nA previous study by the same authors showed that low doses of aspirin (75-300 milligrams) reduced the number of cases of colorectal cancer by a quarter and deaths caused by the disease by more than a third.\nThe latest study confirms the earlier results and concludes that similar effects can be shown for other types of cancers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that aspirin has been widely recommended for cardiovascular benefits.", "answer": 1}, {"article": "Only 1.8 percent of men with PSA scores below 1.0 were diagnosed with prostate cancer, with only 0.04 percent dying of the disease.\nA final study of almost 4,000 patients found that surgeons needed to perform 1,600 procedures known as robotic-assisted laparoscopic radical prostatectomies (RALP) to become adept at the procedure.\n\"We recommend that this operation should not be done by all urologists in small community hospitals but should be focused and concentrated on high volume centers of excellence... in order to achieve best possible results for patients,\" said study author Dr. Prasanna Sooriakumaran, a visiting fellow in urology at the Weill Cornell Medical College in New York.\nA second study also being presented at the symposium found that a drug already used to treat enlarged prostate gland may delay the progression of low-risk, early prostate cancer among men who choose a wait-and-see approach to treatment.\nOne caution, though, is that the study only looked at three surgeons performing RALP.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reported on three different aspects of prostate cancer testing and treatment \u2013 PSA testing, medical therapy as an adjunct to active surveillance, and data about the learning curve in the use of robots in the surgical treatment of prostate cancer.\nIf one reads between the lines, one can infer the widespread availability of all three approaches from the story.", "answer": 1}, {"article": "Reductions were seen of 35 percent at 10 weeks, and just over 22 percent at one year, for those given real acupuncture, compared with 24.5 percent and 5 percent, respectively, for those given sham acupuncture, the researchers said.\nFibromyalgia treatment usually starts with medications such as the nerve pain medication Lyrica (pregabalin), and if that fails or is only partly effective, doctors might add acupuncture to the mix, Rances said.\nAccording to the study authors, nine out of 10 patients try some form of alternative therapy, such as massage or acupuncture, in addition to their regular pain medication.\nHowever, although taking less pain medication, acupuncture patients were using higher levels of antidepressants after one year, which may have artificially boosted the positive results, he said.\nStill, Shrikhande said, \"the findings in this study help demonstrate that acupuncture is a safe and effective treatment for chronic pain patients.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Acupuncture is now considered a fairly common alternative therapy for a number of conditions and is usually available in most locales. The story hints as much when it says that 9 out of 10 patients with fibromyalgia report using some form of alternative therapy, including acupuncture.", "answer": 1}, {"article": "But the results do merit further research.\nDue to the small size of the study and short follow-up time, researchers say it's too soon to recommend use of salsalate for the treatment of type 2 diabetes.\nHowever, it also has been shown to increase protein in the urine and its long-term safety will need further investigation.\nLike aspirin, salsalate is an anti-inflammatory drug derived from salicylate and is often used to treat arthritis.\nThat prompted researchers to take another look at salsalate in reducing blood sugar levels.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that salsalate is commonly used in arthritis but it\u2019s not recommended yet for the treatment of diabetes.", "answer": 1}, {"article": "UCLA's Bhat noted another limitation in the study: \"These are all genetic cataracts.\nHe's said it's unclear if the results will be mirrored in older cataract patients, the same concern expressed by others in the field.\nShe said, even without answers to the question of whether it will work in aging eyes, it creates hope for children with congenital issues.\nHe hopes the surgery will be available to the general population within four to five years.\nBhat was not involved in the new research, but said it's \"extremely exciting\" because it offers an alternative to \"an extraordinarily invasive\" procedure.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story includes several statements by the researchers saying that larger studies are needed as well as a longer follow-up period in patients before the success with this research is confirmed, which should give the average reader and understanding that this approach is not available at this time. A quote from one of the researchers also lets us know they hope to bring this surgery to the public within four to five years.", "answer": 1}, {"article": "Berzofsky declares no conflicts of interest.\nAccording to Berzofsky, the main scientific limitation of the study is that it is a relatively small, phase I clinical trial with no placebo control.\nAmong the six patients who received the lowest dose of the vaccine, 5 million dendritic cells per injection, no clinical benefit was seen.\nIn the dose escalation portion of the phase I clinical trial, patients were injected with the vaccine on weeks 0, 4, 8, 16, and 24 after enrollment in the study.\nPreclinical studies, which were previously published in the AACR journal Cancer Research, showed that this type of vaccine could eradicate large, established tumors as well as lung metastases in mice.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There was no discussion of the availability, although with it being a phase 1 clinical trial, you can assume that it is not available yet. There was no mention about scaling this work since the vaccine was produced using each individual\u2019s immune cells to create the vaccine. It\u2019s unclear if the trial moves forward and enrolls more subjects, how difficult (or costly) it would be to bring this method of treatment to a wider audience.", "answer": 0}, {"article": "Previous studies have connected high levels of inflammatory markers in the blood to bone loss and to fractures in older women and men, which prompted Orchard and her colleagues to wonder what they'd find if they took one more step back - to the dietary choices that contribute to inflammation in the body.\n\"I think this gives us yet another reason to support the recommendations for a healthy diet in the Dietary Guidelines for Americans.\"\nBecause the study was observational, it's not possible to definitively link dietary patterns and bone health and fracture outcomes.\nThe study, led by Tonya Orchard, an assistant professor of human nutrition at The Ohio State University, appears in the Journal of Bone and Mineral Research.\nThe findings suggest that women's bone health could benefit when they choose a diet higher in beneficial fats, plants and whole grains, said Orchard, who is part of Ohio State's Food Innovation Center.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We are giving this a pass here because the release makes mention of \u201ca diet higher in beneficial fats, plants and whole grains,\u201d which includes foods that are widely available.", "answer": 1}, {"article": "Chemotherapy kills off cells, healthy ones as well as cancercous ones.\n\u201cAt the 1.67 percent high-risk threshold,\u201d Georgetown\u2019s Lin says, \u201cevery woman age 62 and older would be [considered] high-risk.\u201d That might lead to a situation in which millions of women would be encouraged, unnecessarily,to consider this therapy, along with its potential harmful effects.\nWhat if there was a medication that could at least reduce a woman\u2019s risk of developing breast cancer?\n\u201cA discussion on the use of preventive agents needs to become part of routine care in women at high risk,\u201d she says.\nBut there are conflicting views on who meets that \u201chigh risk\u201d definition\n\nChemoprevention should not be confused with chemotherapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discusses the availability of these drug therapies.", "answer": 1}, {"article": "But in leg arteries, the active flexing can cause a stent to break.\nThomas Gunderson, a senior analyst for Piper Jaffray & Co., said the Covidien study could lead to greater use of atherectomy and a bigger market.\nAtherectomy is only used in about 15 to 20 percent of PAD cases, but Dr. Lawrence Garcia, a principal investigator in the study, said he expects that to change with these results.\nThe company says this is a major step forward in treating PAD because, unlike stents, atherectomy \"leaves no metal behind.\"\nThe study is the largest to look at the effectiveness of atherectomy, Covidien said, and enrolled 800 patients at 47 centers in the U.S. and Europe.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never established if the device is approved by the FDA, and, if so, how widely it is used and available. There\u2019s a quote from the principal investigator that atherectomy is \u201conly used in about 15-20% of PAD cases\u201d but that he expects that to change with these results.\u00a0 But not all atherectomy is done with these tools.\u00a0 We actually aren\u2019t told how many are done with these tools.", "answer": 0}, {"article": "One found improvement in infants given fennel extract compared to infants given a placebo; another found that infants given a tea containing chamomile, vervain, licorice, fennel and balm-mint seemed to work; while a third found infants given a tea containing fennel, lemon balm and chamomile cried less than infants given a placebo.\nBut because fennel extract, certain herbal teas and sugar water are generally safe, and because the research does suggest babies may benefit, pediatricians said they would feel comfortable recommending them to parents.\nBecause pediatricians can't offer parents much help with it -- for the most part, babies grow out of colic in time -- desperate parents often turn to alternative or complementary treatments, according to the study.\nAll of the trials reviewed had \"major limitations,\" such as having too few patients, relying on parental reports of symptoms, or the study design (such as not being double-blinded).\nThis may help if the underlying cause of colic is cramping or discomfort due to an immature digestive tract, although that is just a theory, Brown added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All of the alternative therapies discussed are widely available, but we think the story could have made this more explicit. For example, if you are a mom in rural Montana, are you expected to know how widespread is the availability (and where) of fennel extract, probiotics, etc.?\u00a0 Even the line about \u201csimethicone is considered the best available\u201d doesn\u2019t tell you what that means. She may have no idea whether you can find these things in the drug store, in the grocery store, in a health food store or all of the above.", "answer": 0}, {"article": "But in the U.S., most prostate cancers are identified by PSA screening, and less than half have palpable tumors.\nAlmost 90 percent had tumors their doctors could feel on digital rectal exams.\nSecond, the Swedish study compared radical prostatectomy to watchful waiting.\nSo there's reason to think men followed with active surveillance and treated when necessary would fare better than the \"watchful waiting\" group in the newly published study.\nIn an editorial accompanying the study, Dr. Dr. Matthew Smith of Massachusetts General Hospital makes some important points.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discussed the treatments in the study, radical prostatectomy and watchful waiting, and explained how watchful waiting differed from the active surveillance approach used in this country.", "answer": 1}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes it clear that the device is being developed and that human trials are needed to test its accuracy.", "answer": 1}, {"article": "Ann Thorac Surg 2015;100:785-93. doi:10.1016/j.athoracsur.2015.05.021\n\nFull text of the article is available to credentialed journalists upon request; contact Cassie McNulty cmcnulty@sts.org at +1 312 202 5865\n\nAbout The Annals of Thoracic Surgery\n\nThe Annals of Thoracic Surgery is the official journal of STS and the Southern Thoracic Surgical Association.\nWhile the current study did not evaluate other alternative options for TAVR, these techniques may include transaortic, transcaval, transcarotid, or trans-subclavian.\nOur study shows that age alone should not preclude referral for TAVR in patients age 90 years and older.\"\nAs part of the PARTNER-I trial, Vinod H. Thourani, MD, from Emory University in Atlanta, and colleagues from 12 other institutions in the United States found that transcatheter aortic valve replacement (TAVR) is a safe and effective way to treat aortic stenosis in nonagenarians who qualify for the surgical technique.\nHowever, with the advent of TAVR technology, we can now offer these extreme elderly patients a treatment option that otherwise would have been high-risk or prohibitive.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Based on the language in the release, it is not possible to tell whether TF-TAVR and/or TA-TAVR are widely available, if they are available only at specialized medical centers, or if these treatment options are still undergoing review for use outside of clinical trials. It is implied that this is an available procedure, but it could have been stated more clearly.", "answer": 0}, {"article": "One week after surgery I was off the crutches, walking on my own,\" Wallace said.\nThe best candidates for the procedure are patients who still have some cartilage protecting their joint, but have somehow \"overloaded\" and injured the bone, causing swelling and pain, Hepinstall said.\nIt is much less invasive than a knee or hip replacement, and typically is performed on an outpatient basis, Vasileff said.\nThose with full-blown bone-on-bone arthritis or joint pain caused by damage to the cartilage and ligaments will get little to no relief from the procedure, Vasileff said.\nThe procedure, called subchondroplasty, has been available to people with knee problems for years, Vasileff said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Bone cement procedures seem to be widely available for vertebral compression fractures, but it is not clear from this story or an internet search whether access to a bone cement procedure for knee and/or hip pain is still very limited or relatively accessible.", "answer": 0}, {"article": ".\nThey then followed nearly 90,000 people who had filled prescriptions for the anticoagulants warfarin, which has been used as a medication since 1954, and dabigatran, which was approved by the U.S. Food and Drug Administration in 2010.\nFurthermore, restarting therapy with the new oral anticoagulant dabigatran was associated with a lower risk of recurrent hemorrhage in these cases than the old standby drug warfarin.\nMore than 1,500 of those people suffered a major bleeding event while using one of the drugs.\n\"If a patient who is on an anticoagulant to avoid a stroke has a major bleeding event, doctors are faced with a catch-22: Discontinue the anticoagulant to avoid future bleeding, but again place their patient at increased risk of stroke; or resume the anticoagulant to continue avoiding a stroke, but then have to worry about another bleeding event,\" said lead author Inmaculada Hernandez, Pharm.D., Ph.D., an assistant professor in Pitt's School of Pharmacy, who completed this work as a doctoral student at Pitt's Graduate School of Public Health.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states that warfarin has been used as a medication since 1954 and dabigatran was approved by the U.S. Food and Drug Administration in 2010. It could have added that both are usually covered in drug plans, although the co-pay for dabigatran may make it less feasible for some patients.", "answer": 1}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "From the story\u2019s discussion, it is clear that all of the options being discussed in the story are available.", "answer": 1}, {"article": ".\nPatients included in the trials were still having flare-ups despite a year of a standard treatment known as \"triple inhaled therapy\" that includes bronchodilators and glucocorticoids.\nThe safety profile of mepolizumab did not differ from placebo in either trial.\n\"These findings are the first example of a precision therapy that is uniquely effective in a subgroup of patients with treatment-resistant COPD.\"\nThe METREO results narrowly missed statistical significance.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release gets a satisfactory in this category since it mentions that the drug maker intends to seek FDA approval for its use in this type of patient, a fact that suggests to readers that it isn\u2019t currently available to patients.", "answer": 1}, {"article": "The results of the Women's Health Initiative (WHI)--the largest, most scientifically rigorous study of older women's medical issues ever conducted--continue to startle researchers, confuse the public and frustrate headline writers. Case in point: last week's report that taking estrogen for seven years does not increase the risk of breast cancer for many women. There is a lot of good news in that finding, as well as some important caveats.\n\nIn many ways, the story began four years ago when researchers halted a different part of the WHI--one that looked at the long-term health effects of taking the hormone combination estrogen and progestin...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the article that estrogen is readily available.", "answer": 1}, {"article": "Common symptoms are abdominal pain and diarrhea, and it can lead to bowel perforations.\nThe intravenous biotech drug met the primary goal of the study as almost 40 percent of patients who received the 6 milligrams per kilogram of weight dose of Stelara achieved a clinical response \u2014 defined as a 100-point reduction in the Crohn\u2019s Disease Activity Index (CDAI) \u2014 after six weeks of treatment.\nAn approval for Crohn\u2019s would give the drug entry into an estimated $1.3 billion U.S. market and $2.7 billion market worldwide.\nHe said a 100-point drop in the CDAI was clinically meaningful to patients.\n\u201cIt\u2019s effective in the patient population that has the greatest unmet need at this point in time,\u201d Sandborn said of patients who do not respond to anti-TNF drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It was borderline on this criterion. On the plus, the current indication is mentioned, as well as trials into other conditions. But on the minus,\u00a0our standard requires that articles provide readers with information about what phase of research the drug is in. It\u2019s not clear what phase the study is at and how close the drug is to the market in even the best-case scenario.\nThe article calls the trial \u201cmid-stage.\u201d According to the press release, that means phase 2b. Many readers won\u2019t know the significance of mid-stage, or that it\u2019s only at the \u201clate-stage\u201d (phase 3) that trials are designed to meet FDA requirements.\u00a0If it\u2019s phase 2b, mid-stage, generally we\u2019d expect another 2-4 years before piggy gets to market.\u00a0That\u2019s why we like to see a statement about exactly when patients could expect to see this medicine available to them. (Off-label use could occur before FDA approval, but given the expected price, it\u2019s unlikely to be covered off-label.) It tempers the hope of a breakthrough with the reality that, even if it aces its upcoming exams, the drug probably won\u2019t be readily available to patients until 2013-2015.", "answer": 0}, {"article": "Insulin helps glucose (sugar) enter cells to provide fuel for those cells.\nWhen treatment was stopped, the benefits gradually tapered off, Baker said.\nBenefits from the treatment lasted as long as people stayed on the treatment.\nThe study medications were supplied by the manufacturer of the growth hormone-releasing hormone.\nDr. Joel Zonszein, an endocrinologist from Montefiore Medical Center, in New York City, praised the study but said some questions still remain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There could have been a line or two about how GHRH is used now in medicine and whether there is much off-label use of the injections.", "answer": 0}, {"article": "D.C.I.S.\nShe compared the drugs to statins and blood pressure drugs, which people take even though they feel well, to lower their risks of heart attacks and strokes.\nBut Dr. Ford of the cancer institute said raloxifene's ability to prevent invasive cancers was more important.\nHe said the next step should be to test another class of drugs called aromatase inhibitors, already in use to treat breast cancer, to see if they can do better at risk reduction than tamoxifen or raloxifene.\nThe institute emphasized that raloxifene lowered the risk of \"invasive\" breast cancer, tumors that have penetrated surrounding tissue and that have the potential to spread and turn deadly.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that Raloxifene is already marketed as Evista, a drug used to prevent osteoporosis after menopause, but that Eli Lilly has petitioned the FDA to approve it to prevent breast cancer.", "answer": 1}, {"article": "In a hip replacement, an artificial joint comprising a ball and socket is implanted to replace the natural ball and socket in the pelvis, enabling movement that is typical of the hip joint.\nThis exhibit in greater details demonstrates the treatment algorithm, patient cases, and the success with use of the standardized stepwise risk assessment and treatment algorithm to address dislocation risk in patients with spinal deformity.\nAll patients who undergo hip replacement at NYU Langone Orthopedic Hospital now go through the risk assessment screening and treatment algorithm prior to surgery.\nUsing the risk assessment tool, the researchers identified 192 of 1,009 patients as high risk for a dislocation after surgery.\nFuture studies aim to examine how the algorithm affects long-term outcomes and clinical benefits in patients at high risk for dislocation.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that patients who undergo hip replacement at NYU Langone Orthopedic Hospital have access to the risk assessment screening and treatment algorithm prior to surgery. But what about patients who can\u2019t travel to New York? Is anything similar in use at other institutions? The release is silent on this point.", "answer": 0}, {"article": "\u201cThere is a larger program we are putting into place.\u201d\nBYL719 plus fulvestrant cut risk of death or progression in those patients by an estimated 35 percent, Novartis said.\nOther drugmakers including Roche have seen similar investigational medicines stumble, making Novartis\u2019s progress here hopeful news, doctors involved in the trial said.\nBut this specific benefit data is being released on Saturday at the European Society for Medical Oncology\u2019s annual conference in Munich.\nNovartis plans to file with regulators for approval of the drug this year, Hirawat said, adding he also has strategies to broaden the indication, including tough-to-treat triple-negative breast cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that Novartis plans to file for approval for the drug this year.", "answer": 1}, {"article": "During transcranial magnetic stimulation (TMS), a doctor places a large magnetic coil against the patient\u2019s scalp, which creates electric currents to stimulate nerve cells.\nThere were no improvements seen in test scores of those who got the other treatment.\nThis is often not enough to make a meaningful improvement.\nTen out of 20 people who faced this problem following a stroke received the magnet therapy daily for two weeks.\nThe overactive brain circuits also improved among people who got the TMS treatment, the study showed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study is described as \u201cpreliminary\u201d and the treatment is called \u201cnot ready for prime time.\u201d We think readers get the idea that this treatment is not available for stroke rehabilitation outside of a research setting.", "answer": 1}, {"article": "No doubt you have heard that yogurt is teeming with bacteria--and no doubt you try not to think about that as you dig into a cup of the stuff. Yes, they're supposed to be good bacteria, ones that not only don't make you sick but actually improve your health. Still, a spoonful of critters with unlovely names like Lactobacillus reuteri, Lactobacillus rhamnosus and Bifidus regularis will never sound like a palate pleaser to even the most dedicated health nut.\n\nWhether or not you've ever developed a taste--or even a tolerance--for living things in your lunch, more are on the way. Food...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that there are current products for sale in grocery stores that contain probiotic bacteria and that in addition, there are new products being developed. \u00a0However \u2013 the story should have mentioned that there is no evaluation process to ascertain that the products sold as probiotics actually contain the organisms in the doses advertised. So true \"availability\" is difficult to ascertain.\u00a0 Consumers should know this. \nIt should be noted that the table that is a part of this story provides an inadequate listing of sources of probiotic containing foods.\u00a0", "answer": 0}, {"article": "U.S. alone, seventy-five percent of teens and adults are vitamin D deficient.\nThe research shows that RayVio's UV LEDs could be used for treating patients that are vitamin D deficient.\n\"This study will lead to a new generation of technology that can be labeled as photopharmacology in which the use of LEDs with targeted wavelengths can cause specific biologic effects in human skin to help treat and prevent chronic illnesses.\"\nThis device for making vitamin D is ideally suited for patients with fat malabsorption syndromes including inflammatory bowel disease and gastric bypass surgery.\nThanks to the work of the research team and the pioneering work of the Boston University Photonics Center on UV LEDs, we may soon see innovative treatment options like simple integration with a wearable device could aid millions of people.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "RayVio already has other UV LEDs out on the market for health and hygiene purposes, but these don\u2019t include the 293nm UV LED \u2014 the prototype tested in this study. The news release makes clear that this technology is still being developed, hinting that a \u201cwearable device\u201d could be available to consumers in the future.\nWe wish the news release had given more information on the types of UV light therapies accessible now for patients, as well as what a treatment session currently looks like.\nSince the news release makes clear that the 293nm UV LED technology isn\u2019t widely available, we rate this one Satisfactory.", "answer": 1}, {"article": "\u201cIt was a little humiliating, to be honest,\u201d she said of the testing.\nAll the while, the scientists monitored a handful of \u201chot spots\u201d in the brain which, previous work had shown, were strongly related to memory encoding.\n\u201cThe average enhancement effect was about 12 to 13 percent,\u201d Dr. Kahana said.\nThis study used data from 150 patients, and had 20 collaborators from institutions around the country, including Emory University, the University of Washington, the Mayo Clinic and the University of California, San Francisco.\nEach participant carried out the word-memorization tests repeatedly, with different words every time; some lists were memorized with brain stimulation, and other lists with no stimulation, which served as a control.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s made clear that this study focused on epilepsy patients whose doctors deemed they needed brain-stimulating implants, and that the research may not apply to broader populations.", "answer": 1}, {"article": "The rates are highest among Hispanics: Latina women are roughly 20 percent more likely to have a baby with a neural tube defect compared to non-Latina white women.\nSo a coalition of groups including the March of Dimes Foundation and the National Council of La Raza has petitioned the FDA to change its stance and allow corn masa flour to be fortified with folic acid.\n\"The story of folic acid is one of the great public health stories of \u2014 ever,\" says Dr. R.J. Berry, who works with the Division of Birth Defects and Developmental Disabilities of the Centers for Disease Control and Prevention in Atlanta.\n\"The FDA is concerned that the breakdown of folic acid in corn masa flour could yield a substance that raises concerns about safety.\"\nIt all has to do with nixtamalization, the process by which tough corn kernels are softened by soaking in an alkaline solution, usually of slaked lime.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that extra folic acid is already widely available in other flours. It notes that there is debate about adding it to corn flour.\u00a0Concerns about the technical difficulty of\u00a0adding folic acid that remains in usable effective form is a central point.", "answer": 1}, {"article": "A new generation of treatments for severe eczema is on the horizon, which doctors say could help millions more patients gain relief from chronic outbreaks of the oozing, itchy and sometimes debilitating rashes that come with the disease.\n\nAt least two new eczema medicines could be approved by the U.S. Food and Drug Administration in 2017, and a half-dozen more drugs are being tested in clinical trials.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states\u00a0that the drug companies involved plan to ask FDA for approval later this year. This is a clear enough signal that the drugs aren\u2019t available yet.\nHowever, by speculating on how these drugs will be used by doctors, some of the statements imply that the drugs will definitely be approved, e.g.: \u201cMany doctors say they expect the drug to benefit patients whose diseases go undertreated because their fears about steroids cause them to use the drugs less frequently than prescribed.\u201d\nMany FDA applications for approval can be derailed by unforeseen safety concerns or other issues, and so the passage above could have been toned down to indicate this still all hinges on events that haven\u2019t happened yet.", "answer": 1}, {"article": "But the F.D.A.\nSo injecting it is an off-label use.\nShe said veins as large as a Sharpie marker can be tackled with foam sclerotherapy.\n\u201cOtherwise they\u2019ll just come back.\u201d\n\nToday, sluggish underlying veins are best addressed with radio-frequency or laser treatment, said Dr. Min, who developed such a laser.\nThat said, polidocanol was the \u201csecond most commonly used sclerosing agent\u201d because, he said, \u201cmost physicians want to give their patients the best available treatment.\u201d\n\nF.D.A.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provides very specific information as to the availability of\u00a0different treatments for varicose veins in the U.S.", "answer": 1}, {"article": "We have to really ask the question: 'How low do you go?'\nAlthough the reason for the increased risk remains a mystery, Nabel and other experts stressed that the benefits of blood sugar control have been well established for diabetics and said patients should not make any changes in their care without consulting their doctors.\nBecause some of the patients were taking the drug Avandia, which has been the focus of concern that it might increase the risk of heart attacks, the researchers specifically examined whether that was a factor.\nOfficials defended the study, saying previous research had suggested that intensive blood sugar lowering would be beneficial.\nBut the findings cast doubt on a major hope about diabetes treatment -- that pushing levels below current targets would be beneficial -- and would force experts to rethink how to treat one of the nation's leading health problems.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that the medications used in this study where those that are commonly used for lowering blood sugar.\u00a0 ", "answer": 1}, {"article": "A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.\n\nAbout 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This article clearly\u00a0indicates\u00a0that the two studies studies are preliminary and\u00a0that this treatment is in the experimental stages.\u00a0 It is implicit that the treatment is not clinically available but\u00a0available only to patients participating in clinical trials.\u00a0 ", "answer": 1}, {"article": "Last year, 2.3 million young Europeans (aged 15 to 34) used cocaine, and the US National Institute on Drug Abuse estimates that 1.4 million Americans suffer from cocaine addiction1.\nAs far as we know, this work represents the first clinical report indicating that rTMS treatment results in significant reduction in cocaine use.\nIt is also important to emphasize that, in this study patients were seeking treatment for their cocaine addiction in a hospital setting: the group studied, albeit small, was a \"real world\" sample.\nAs author, Dr Antonello Bonci (Scientific Director, National Institute on Drug Abuse, and Adjunct Professor, John Hopkins University, Baltimore) said:\n\n\"Despite the fact that more than 20 million people worldwide suffer from cocaine use disorders2, there are no effective neurobiological treatments for patients with this devastating condition\".\nIt is important that this is taken forward to a larger trial.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While the release does state that this particular form of brain stimulation is being used to treat some other conditions, there is no suggestion that the treatment is readily available in most hospital or out-patient facilities, information which would help readers gauge the practicality of seeking such treatments.", "answer": 0}, {"article": "\"I say, 'Go for it!'\nShe'd consider a second operation, but Metson says usually that's advised only for patients with nasal polyps that regrow -- not a problem she has.\nTo avoid poking through to the brain or into the orbit of an eye, there's a device around the patient's head with a guidance system that tells Metson, in three dimensions, exactly where his sharp instruments are on a CT scan of Butler's head.\nThat's because surgery doesn't touch the root cause of chronic sinusitis.\n\"But probably in over 90 percent of the cases, it does significantly improve a patient's quality of life.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that about\u00a0300,000 people a year\u00a0undergo sinus surgery, making it one of the most commonly performed\u00a0procedures in the U.S.\u00a0 However, it does not provide statistics on the number or percentage of those procedures that are performed endoscopically and the type of hospital setting in which they are done. Enodoscopic surgery with CT guidance as described in the story may be out of the reach of smaller community based practitioners.\u00a0We\u2019ll call this satisfactory, but some additional detail\u00a0would have been appropriate.\u00a0", "answer": 1}, {"article": "Professor Marianne Thoresen said: \"Even if we account for a lesser severity of perinatal asphyxia, our research has shown that therapeutic hypothermia reduces the number of children who develop epilepsy later in childhood.\nEven if a lesser severity of perinatal asphyxia is accounted for, cooling therapy has increased the number of healthy survivors and there are very few children with epilepsy needing drug treatment.\nUntil recently, 20 to 30 per cent of these patients would develop epilepsy and many need regular antiepileptic treatment.\nThe study showed that more children had epilepsy when they reached the age of four to eight years with seven per cent on regular medication.\nCooling treatment also reduces the number and severity of cerebral palsy and increases the number of patients who survive normally.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Someone reading the release could easily think that therapeutic hypothermia is a treatment currently available only from the researchers who worked on this study. That\u2019s not the case. It\u2019s not something available at every hospital, but it is available at many hospitals. A 2014 report from the American Academy of Pediatrics addressed related limitations and challenges regarding the use of hypothermia to treat neonatal encephalopathy. This quote from that report would seem to apply here as well: \u201cInfants selected for cooling must meet the criteria outlined in published clinical trials. The implementation of cooling needs to be performed at centers that have the capability to manage medically complex infants. Because the majority of infants who have neonatal encephalopathy are born at community hospitals, centers that perform cooling should work with their referring hospitals to implement education programs focused on increasing the awareness and identification of infants at risk for encephalopathy, and the initial clinical management of affected infants.\u201d", "answer": 0}, {"article": "Prostate cancer remains the second leading cause of cancer death among men in the U.S., with nearly 30,000 deaths annually.\nThe study showed that 12 months after the draft guidelines were published diagnoses of new low risk cancers had fallen by 37.9%, and continued to fall more rapidly than other disease risk strata, suggesting that, in this regard, the USPSTF recommendation had its intended effect,.\nThe uncertain benefit of PSA based screening, combined with the complications associated with treatment, led the USPSTF to conclude in October 2011 that the harms of PSA based screening outweighed the benefits, leading it to recommend against regular screening.\n\"While some of the effects of this guideline may be beneficial in terms of reducing harms of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern for delayed diagnoses of important cancers associated with inferior cancer outcomes,\" noted Dr. Barocas.\nBy contrast, the number of monthly colon cancer diagnoses remained stable.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is pretty clear from the release that PSA testing and related treatment are widely available.", "answer": 1}, {"article": "The other is that, for tens of thousands of years, parasites and other infections unusual in modern society were a major problem in humans. The body developed a defense mechanism - inflammation - to fight them. Now, there aren't as many of these infectious diseases for our bodies to deal with, but we still have this defense mechanism. It has begun to target other things, such as allergens in the environment. Immunotherapy helps teach the body to better tolerate these harmless parts of our environment.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The report makes clear what\u2019s FDA approved and what\u2019s not; and where to get the latest immunotherapies, and where people cannot get them. Good job on this.", "answer": 1}, {"article": "Performed through the urethra, an urologist uses the UroLift System to push aside the obstructive prostate lobes and positions small, tailored permanent UroLift implants to hold the prostate lobes in the retracted position.\nPatients recover from the procedure quickly, and return to their normal routines with minimal downtime.\n\"The UroLift System has an excellent safety profile and provides men suffering from an enlarged prostate a beneficial first-line treatment alternative to drug therapy or more invasive surgery.\nAdverse reactions associated with UroLift System treatment were comparable to other minimally invasive surgical therapies as well as standard cystoscopy.\nImportantly, the UroLift System provides fast and meaningful relief from BPH symptoms, improving overall quality of life for our patients.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The FDA \u201ccleared\u201d this surgical implant system in 2013 and it is available at Northwestern University, but there are no details about its general availability in other regions or health systems. We are left wondering.", "answer": 0}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Again, the story could\u00a0have benefited from some cost information about the tests and whether they are covered by most insurance plans. It also would have benefited from a sentence about how women can best arrange for such testing, and how widely available they are at prenatal clinics and private practices. But it does give information about the total number of tests done in the U.S. and about their growing popularity.", "answer": 1}, {"article": "Actinic keratoses are typically red, scaly skin lesions that can over time develop into a type of skin cancer.\nThe new study was funded by Picato manufacturer LEO Pharma.\n\u201cThe shorter application period is what makes ingenol mebutate a breakthrough in the treatment of actinic keratosis,\u201d researcher Mark Lebwohl, MD, says in a news release.\nBecause the new gel is only used for a few days, any irritation is usually short-lived.\nThe gel is derived from the sap of the Euphorbia peplus plant.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story repeatedly refers to the drug as a \u201cnew gel\u201d but never explains if it is available.\u00a0 It was recently approved by the FDA.", "answer": 0}, {"article": "Dennis Halmi, a member of the Bluepoint Surgical Group in Woodbridge, says that in 2002 \"we did a handful\" of second operations on obesity patients, \"maybe five, six.\nOf course, a second obesity surgery comes with increased risk.\nThe second time around, many, like Thayer, are opting for the adjustable band, which works differently from the bypass.\nNo obesity operation is \"a magic bullet.\"\nThe band is shaped like a little life preserver that can fill and go slack.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story did not give any indication as to whether all bariatric surgeons perform gastric banding after gastric bypass surgery or if it was a select subset.", "answer": 0}, {"article": "For dementia, which people with Type 2 diabetes have double the risk of developing compared with non-diabetics, metformin has been found in a number of studies to cut that risk substantially.\nMoreover, the drug was being studied in clinical trials as a way to lower the risk of cancer, heart disease and dementia \u2014 not just for diabetics, but for everyone.\nThe one goal the study did not achieve was better blood-sugar control.\n\u201cThere are legitimate reasons to put patients on one drug rather than another.\nFor Price, there was yet another possible benefit \u2014 as a treatment for polycystic ovary syndrome, an endocrine disorder that doctors thought might explain the difficulty she and her husband had had conceiving.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly notes that metformin is an existing prescription drug marketed under a number of unpronounceable names.", "answer": 1}, {"article": "Obese children and those with diabetes often suffer from fatty liver, a condition normally associated with alcohol abuse but increasingly common among non-drinkers who gain excessive amounts of weight.\nMORE: 7 Amazing Things That Happen to Your Body When You Give Up Soda\n\nBecause some of the children lost weight, to convince themselves that the effects weren\u2019t due to the small amount of weight that some of the children lost, Lustig and his team compared those who lost weight to those who didn\u2019t during the study, and found similar improvements in both groups.\n\u201cSo there was no change in [the children\u2019s] weight and no change in calories.\u201d\n\nAfter nine days of having their total dietary sugar reduced to 10% of their daily calories, however, they showed improvements in all of these measures.\nThe only difference in the nine-day diet was that most of the sugar the children ate was replaced by starch \u2014 the overall number of calories remained the same.\nShe also points out that the children self-reported their initial diet, which can often be inaccurate.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the dietary changes they made in the study could be made by anyone. The story says:\n\u201cWe took chicken teriyaki out, and put turkey hot dogs in. We took sweetened yogurt out, and put baked potato chips in. We took pastries out and put bagels in,\u201d says Lustig. \u201cSo there was no change in [the children\u2019s] weight and no change in calories.\u201d", "answer": 1}, {"article": ".\nForward looking statements with respect to predicted improved survival described in the poster presentation and video, are based on current expectations from the presented retroactive study and involve inherent risks and uncertainties about the potential health and medical benefits of MR-guided Radiation Therapy for the treatment of patients with locally advanced pancreatic cancer.\nFurther studies, including the planned prospective multi-institutional study referenced in this press release, as well as patient data covering longer periods of time post-treatment, could lead to different or contrary results from those expressed during ASTRO or in the poster presentation.\nThe early results highlighted above, along with other data obtained using MRIdian will be tested in a multi-center, prospective, single-arm clinical trial for inoperable, locally advanced or borderline resectable pancreatic cancer.\n\"The data presented at the 2017 ASTRO Annual Meeting suggests that higher radiation doses with adaptive MR guided radiation therapy may improve survival in pancreatic cancer while maintaining a very favorable toxicity profile.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release notes that the next step is a prospective clinical trial and that tells savvy readers that this treatment strategy has a long road of testing ahead. Still, we think the release could have done a better job clarifying that this therapy is not yet ready for patients, outside of the clinical trial.\nA study that suggests a doubling of median survival is sure to capture the attention of patients newly diagnosed with pancreatic cancer. These patients and their families are closely aware of the glum statistics for the disease. This is a practical concern that the release should have touched on.", "answer": 1}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the two blood tests have been available since 2009.", "answer": 1}, {"article": "The ATS publishes three journals, the American Journal of Respiratory and Critical Care Medicine, the American Journal of Respiratory Cell and Molecular Biology and the Annals of the American Thoracic Society.\nSumming up the findings of the current study, Dr. McEvoy said that a relatively low dosage of vitamin C may present \u201ca safe and inexpensive intervention that has the potential to help lung health of millions of infants worldwide.\u201d\n\nHowever, she added, helping mothers quit smoking should remain the primary goal for health professionals and public health officials.\nInfants in this study will continue to be followed to track their lung function and respiratory outcomes.\nThis study was funded by the National Heart, Lung, and Blood Institute and the Office of Dietary Supplements.\nThe researchers wrote that study results support the hypothesis that oxidative stress caused by cigarette smoking reduces the amount of ascorbic acid, a component of vitamin C, available to the body.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability but it can be safely presumed that readers know vitamin C supplements are widely available.", "answer": 2}, {"article": "To learn more, visit stjude.org or follow St. Jude at @stjuderesearch\n'However, our work is the first to identify AIM2's role in controlling proliferation of intestinal stem cells.\nHowever, AIM2's established function in the cell was not in the machinery of cancer, said one of the paper's first authors Si Ming Man, Ph.D., a postdoctoral fellow in Kanneganti's laboratory.\nRather, he said, AIM2 was known to work in the immune system to detect invading bacteria and viruses and help 'alert' the immune system to battle them.\n'Since reduced AIM2 activity in colorectal cancer patients is associated with poor survival, it might be useful to detect the level of AIM2 expression in polyps taken from colonoscopy and use this as one of the biomarkers for prognosis,' Kanneganti said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release quotes one story author on this point: \u201c\u2018We have only scratched the surface of the role of AIM2 in controlling stem cell proliferation and the maintenance of a healthy gut microbiota,\u2019 Kanneganti said. \u2018How exactly AIM2 does both of these functions is an exciting research area to pursue.'\u201d Unfortunately, that\u2019s the last paragraph of the release. And the first seven paragraphs talk about research as if it were done in a human model. It\u2019s not until the eighth paragraph that we learn the study was done using mice. In short, this work is far, far removed from any potential clinical intervention for cancer patients. That should be said explicitly somewhere in the text, and the fact that the work was done in an animal model should have been made clear at the very top.", "answer": 0}, {"article": "Microcapsules loaded with stem cell-derived insulin-producing cells retrieved after they had been transplanted into a mouse.\n\u201cThe main issue with type 1 diabetes is a loss of beta cells,\u201d said ViaCyte CEO Paul Laikind, \u201cbut there\u2019s also good data out there to suggest dysfunction in other regulatory cell types.\u201d\n\nThe team behind the studies published Monday, meanwhile, is working on tests now in monkey models.\nScientists on Monday showed they had overcome some of the major hurdles standing in the way of a long-sought therapeutic fix for patients with type 1 diabetes, outlining an approach that the body\u2019s immune system could tolerate and providing a possible pathway toward clinical trials in the next few years.\nBut experts say the findings provide hope for future treatments for people.\nMost of these other companies are taking a different approach from the work done in the studies published Monday.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story at the top makes it clear that the treatment is not available, saying, \u201cScientists on Monday showed they had overcome some of the major hurdles standing in the way of a long-sought\u00a0therapeutic fix for patients with type 1 diabetes, outlining an approach that the body\u2019s immune system could tolerate and providing a possible pathway toward clinical trials in the next few years.\u201d Not the qualifier of \u201cpossible\u201d in that sentence.", "answer": 1}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The \u201cgrowing number of doctors\u201d offering this procedure, the lack of insurance coverage, the FDA OK for one device and off-label use of others all address general availability issues.", "answer": 1}, {"article": "Check it out if you're interested in finding a trial for yourself or someone you care about.\nThe current thinking is that interventions will be most effective when given to a patient as early as possible, Brickman said.\nThat suggests that a five-year follow-up period is not long enough to determine how well biomarkers can predict which patients will develop Alzheimer's disease, researchers say.\n\"The way we diagnose Alzheimer\u2019s disease is by evaluating the behavior and the risk factor medical profile, not by looking at biological markers at this point.\"\nBut it's too early to use this as a diagnostic tool in clinical settings, says Brickman.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Again, the independent expert\u2019s perspective was important:\n\u201cWhen these sorts of studies get published, Brickman and other doctors get phone calls from aging adults wondering whether they should be getting spinal taps to assess their risk.\u00a0 But it\u2019s too early to use this as a diagnostic tool in clinical settings, says Brickman. Down the road, the \u201cfantasy\u201d is that asymptomatic people will be able to get a biomarker test to determine whether they\u2019ll one day get Alzheimer\u2019s, but that\u2019s not possible right now, he adds.\u201d", "answer": 1}, {"article": "\u201cPatients readmitted after surgery almost always have a postoperative complication, either medical or surgical,\u201d Drs.\nDoctors who did not perform the surgery won\u2019t have that context, which may explain part of the survival benefit of returning to the original hospital, he said.\nIt might be harder for patients to get appropriate care at the other hospitals, where they don\u2019t have a pre-existing relationship with a surgeon, and so treatment might be delayed, Dimick and Miller wrote.\nAmbulance drivers and emergency department doctors should make every effort to get a patient who has had major surgery back to their original hospital, he said.\nPatients should try to stay in the immediate vicinity of their surgical hospital for at least a week, Brooke said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As noted above, seeking to ensure that patients who have undergone major surgery would be readmitted to the hospital where the initial surgery was performed would appear to be logistically difficult, at best. The story did not address that concern.", "answer": 0}, {"article": "Melanoma is the most serious, and often deadly, form of skin cancer.\n\"We investigated this (drug) combination because of research we and others have conducted into the molecular underpinnings of resistance to BRAF inhibitor therapy,\" study lead author Dr. Keith Flaherty, of the Massachusetts General Hospital Cancer Center, said in a hospital news release.\nBy targeting different points in the same growth-factor pathway, the kinase inhibitor drugs dabrafenib and trametinib postponed the development of drug resistance in patients with BRAF-positive metastatic melanoma, the study authors said.\nThe drug combination is now being tested in a larger phase 3 study, which is required for U.S. Food and Drug Administration approval.\nThe phase 1 and 2 study was sponsored by GlaxoSmithKline, which developed both drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that the drug combination is\u00a0being tested in a larger phase 3 study, which is required for FDA\u00a0approval. While this is true, it could also have noted that the drugs individually have already been submitted for approval as monotherapies. If they are approved, oncologists could presumably use the drugs in an off-label\u00a0combination treatment similar to the one studied here.", "answer": 1}, {"article": "It is known as BMS-790052.\nA unique thing about the NS5A-targeting drug, according to Meanwell, is that laboratory studies show it to be effective against all HCV genotypes.\nBut the study provides the first clinical evidence that targeting the HCV protein NS5A may be an effective strategy for curing patients who are chronically infected with the HCV virus, says Nicholas A. Meanwell, PhD, who is executive director of chemistry with Bristol-Myers Squibb.\nIn preliminary research published this week in Nature, researchers from Bristol-Myers Squibb -- the maker of the drug -- report that patients who took the drug showed dramatic reductions in viral load while exhibiting few side effects.\nIn fact, no fewer than 90 studies are currently underway examining different HCV-targeting drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story called the research on BMS-790052 \"preliminary\" and made it clear that\u00a0the drug\u00a0was not close to approval. It also was more cautious than the competing HealthDay piece in its description of two other antiviral drugs that are nearing FDA approval.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/060723/31robot.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states the robotic tool is available at selected hospitals throughout the country and that availability is expected to increase. ", "answer": 1}, {"article": "\u201cMuch higher than red wine, for instance.\u201d\n\nThe researchers figured an antioxidant-rich diet might help patients with kidney failure, because the level of free radicals in their blood increases as the blood circulates through the dialysis device.\nBrosius was skeptical of the benefits, although he said the juice was unlikely to cause harm.\n\u201cWho the heck knows what the active ingredients are?\u201d\n\nMarion Nestle, a nutrition expert at New York University, said the effects might not be unique to pomegranate juice.\nThey also made fewer trips to the hospital.\nBy comparison, that number would be nearly 11 in patients not drinking the juice.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The availability of pomegranate juice is not in question.", "answer": 2}, {"article": "\"I could ride a bike!\nThere were other things the 12-year-old boy said he would do if he had two hands.\n\"It's really just a step-by-step process of solving problems.\nHe was wrapped in the joy of leading and advising students on how to help children like himself,\" she wrote in her iReport.\n\"The adoration of college students was an affirmation that money can't buy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story includes links to the groups developing these prosthetics, there is really no exploration of how easy it is to get one. Apparently the process involves finding a group of local volunteers, such as middle school students and Boy Scouts, who can assist with printing and assembling the limbs. Are these volunteers widely distributed throughout the country? Do they have the capacity to meet demand? We\u2019ll give the benefit of the doubt, but relying on such volunteer groups sounds like it could lead to disappointment, especially if the publicity from stories like this one leads to a surge in demand.", "answer": 1}, {"article": "Platelets, the blood cells that promote clotting, contain hundreds of proteins, called growth factors, that are important in repairing injuries.\nThose who seek this treatment must look for a clinician with considerable PRP experience \u2014 someone who does the procedure several times a day, not once or twice a month \u2014 and who has a good success rate, Ferrell says.\nFerrell told me not to use nonsteroidal anti-inflammatories, such as ibuprofen, for a week after the injection because the goal is to encourage, not stifle, inflammation.\nStill, \u201cit has significant cost savings\u201d compared with surgery, Ferrell says.\nIts practitioners believe it will transform orthopedics.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that platelets are removed from a patient\u2019s blood using a centrifuge, equipment readily available in most practices.\u00a0 It makes the point of advising readers to seek out practitioners who do the procedure frequently.\u00a0 The story suggests that the PRP procedure is becoming more available.", "answer": 1}, {"article": "\"Therefore,\" he said, \"we need to be extremely aggressive in treating atrial fibrillation patients with anticoagulants [blood thinners] when indicated.\nThe researchers said that the key is to start blood thinners, such as warfarin, soon after atrial fibrillation is diagnosed.\nBut a new study suggests these drugs may also help keep dementia at bay.\nThat's true even for people at low risk of a stroke who wouldn't normally be given blood thinners.\nThe longer the delay in giving blood thinners, the more the risk for dementia, the researchers said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Warfarin is a common drug, as are a number of other blood thinners.", "answer": 1}, {"article": "The researchers compared breast cancer deaths in women who had a breast cancer diagnosis in counties that had screening with deaths in counties that did not.\nThe study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\nThe study\u2019s authors include Dr. Stephen Duffy, an epidemiologist at the University of London, and Dr. Laszlo Tabar, professor of radiology at the University of Uppsala School of Medicine in Sweden, who have long been advocates of mammography screening.\nThe new study took advantage of circumstances in Sweden, where since 1986 some counties have offered mammograms to women in their 40s and others have not, according to the lead author, Hakan Jonsson, professor of cancer epidemiology at Umea University in Sweden.\nBut their results were greeted with skepticism by some experts who say they may have overestimated the benefit.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe availability of mammography was not explicitly addressed, but we can\u2019t criticize the story for that.\u00a0 Instead, we give a Not Applicable score for this criterion. ", "answer": 2}, {"article": "\u201cIt\u2019s an important part of this challenge,\u201d Frank said.\nBut as Stanford pain specialist Sean Mackey emphasized to me, opioids should not be a first-line treatment due to the risks, and alternatives should be tried first.\nSeveral of the studies were done in pain centers where they have expert programs, and those just are not widespread.\u201d\n\nIn fact, the lack of access to non-opioid strategies may be one big reason that doctors resorted to opioids in the first place.\n\u201cOne day in June, in my inbox were 42 deaths.\u201d\n\nThe findings show the balancing act of opioid policy: Even if doctors need to pull back opioids, they must be careful to ensure patients suffering from debilitating pain and other problems can still meet their other care needs.\nBased on his reading of the data, \u201cit\u2019s John with PTSD on the 10 milligrams.\u201d\n\nBut as is true for addiction and pain treatments, adequate mental health care is also out of reach for many patients \u2014 showing just another way that the US health care system isn\u2019t built to adequately address the full needs of patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story delivers: It states that tapering is available, yet that it\u2019s to be attempted with caution. Non-opioid pain-relief treatments, which are also noted by the story, are also said to be available, though out of reach for many.", "answer": 1}, {"article": "Up to 89 percent of the men who received the combination formulas saw their sperm concentrations plunge to less than 1 million sperm per milliliter, versus just 23 percent of those receiving only testosterone.\nPrevious research involved administering the combination by injection or via a patch, said study senior author Dr. Christina Wang, a professor of medicine at Los Angeles Biomedical Research Institute.\nBecause the new study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\n\"I think [men] would use it more than is realized,\" said Alukal, who was not involved in the new research.\nThe combination contraceptive needs to undergo further testing before it is commercially available.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states: \u201cThe combination contraceptive needs to undergo further testing before it is commercially available.\u201d", "answer": 1}, {"article": "Dr Sheraz Markar, an NIHR Clinical Trials Fellow from Imperial College London, under the supervision of Professor George Hanna, told the Congress: \"At present the only way to diagnose oesophageal cancer or stomach cancer is with endoscopy.\nThe results showed that the test was 85% accurate overall, with a sensitivity of 80% and a specificity of 81%.\nThe new research, involving more than 300 patients, showed that the test could diagnose cancer with an overall accuracy of 85%.\nThis study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the oesophagus and stomach, and which do not.\nOver the next three years, the researchers will continue with a larger trial, using the test with patients who are being given an endoscopy for gastrointestinal symptoms but not yet diagnosed with cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the breath test is not available. The release did not make any predictions about when such a test might make its way through the full course of experimental trials.", "answer": 1}, {"article": "\"The band has a spotty history,\" Deveney said.\n\"[I] therefore think patients will continue to ask for the procedure.\"\nBut he cautioned that patients undergoing band surgery should do so knowing that they need to commit themselves to rigorous long-term follow-up.\nAlmost 50 percent had to have the bands entirely removed, while 60 percent needed to undergo subsequent surgery.\nWith gastric bypass that's not as much of an issue.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The gastric banding procedure was appropriately described as an available treatment.", "answer": 1}, {"article": "In fiscal year 2017, Penn Medicine provided more than $500 million to benefit our community.\nIn addition to the benefits for antibiotic stewardship, Barbieri pointed to several studies showing long-term oral antibiotic use may be associated with antibiotic resistance, lupus, inflammatory bowel disease, and even colon and breast cancer.\nSpironolactone is not approved for the treatment of acne by the U.S. Food and Drug Administration despite expert opinion supporting its use, and Barbieri says the findings of this study should be confirmed by a randomized controlled trial that directly compares the two treatment options.\nHowever, those same anti-hormonal effects can help prevent acne outbreaks in women.\n\"This indicates spironolactone may have a better safety profile than oral antibiotics, which is another factor that makes it such an appealing option,\" Barbieri said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release explains that both methods are currently available and in use. It states that while some dermatologists already prescribe\u00a0spironolactone for acne, the FDA has not approved it for that use. Without FDA approval, most insurers will not cover the cost of treatment.", "answer": 1}, {"article": "\u2022 4.9 million babies are born with a serious birth defect worldwide every year\n\u2022 3.3 million children under five die from serious birth defects annually\n\u2022 Congenital heart disease is the most common form of birth defect, affecting 1 in 100 babies\n\u2022 42 babies are born with a heart defect in Australia every week\n\u2022 30 babies will undergo heart surgery in Australia every week\n\u2022 Heart defects account for 30% of deaths in children under five\n\n[1] Baker H, DeAngelis B, Holland B, Gittens-Williams L, Barrett T Jr. Vitamin Profile of 563 Gravidas during Trimesters of Pregnancy.\nAt the heart of the paramount discovery is the dietary supplement vitamin B3, also known as niacin.\nThis discovery is akin to the revolutionary breakthrough made last century that confirmed folic acid supplementation can prevent spina bifida and other neural tube defects in babies.\nThe landmark study found that a deficiency in a vital molecule, known as NAD, can prevent a baby\u2019s organs from developing correctly in the womb.\nWorld first research at the Victor Chang Institute has found that this deficiency can be particularly harmful during a pregnancy as it can cripple an embryo when it is forming.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release noted that niacin is available as a dietary supplement. ", "answer": 1}, {"article": "In the United States study, 80% of the children on antibiotics felt better on the seventh day of treatment; 74% of the children taking a placebo also felt better on the seventh day.\nAccording to one of the studies, ear infection, or acute otitis media, is the most frequently diagnosed illness in children in the United States, and most children with these ear infections are routinely given antibiotics.\nRosenfeld says it's never wrong to prescribe an antibiotic for a well-diagnosed ear infection.\nThe Finnish noted that limiting use of antibiotics may reduce the development of drug-resistant bacteria and increase the chance the future use of antibiotic will be effective.\nOnly children who really had ear infections were included in the trials.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of antibiotics to treat ear infections is not in question.", "answer": 2}, {"article": "Dr. Kenneth Liao used the da Vinci surgical robot Thursday to restore lost blood flow to the heart of 58-year-old John Carter Holmes.\nUnlike other surgeries, there are no minimally invasive alternatives for valve repairs, he said.\nThose limitations haven\u2019t deterred hospital executives, though, who see the robotic systems as crucial for attracting and retaining surgeons and patients.\nThe robotic systems come with million-dollar price tags and are used for a limited number of surgeries \u2014 mostly the removal of cancerous prostates in men or uteruses in women.\nThe da Vinci is criticized by health policy experts as the poster child for the medical arms race \u2014 the competitive fever among hospitals to buy new technology whether or not it improves care.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does a good job of specifying how many daVinci surgery robots are available in Minnesota\u2013and which facilities have them. ", "answer": 1}, {"article": "At the end of the day I don't know that this will be the best technology out there, but it is a step forward to allow continued innovation in this area,\" Foreman said.\n\"The diagnosis of melanoma is the most serious one a dermatologist makes, and we have sleepless nights worrying about it,\" said Pariser, who consulted for the device's maker, Mela Sciences Inc. of Irvington, N.Y., on its presentation to FDA.\nThe company plans to bring them next year to just 200 dermatologists on the East coast, all of whom must undergo company training before they can begin using the device.\nMela Sciences does not plan to ask insurers to cover the device until several years from now, after it is more widely used.\nThe company's study was not intended to show that screening with the device saves lives, only that it can help improve a doctor's ability to spot melanoma.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says clearly that the devices are not currently available in most areas. \u201cBut don\u2019t expect to see a MelaFind machine at your next doctor\u2019s appointment. The company plans a limited rollout next year of just 200 dermatologists on the East coast, all of whom must undergo company training before they can begin using the device.\u201d", "answer": 1}, {"article": "\u201cBut this is a small study, a proof of concept.\n\u201cWe can\u2019t yet say that this study means that DHEA is a viable alternative to HRT, but ... we should be looking to do larger studies to confirm these initial results.\u201d\n\nDHEA, or dehydroepiandrosterone, is a natural steroid hormone mostly made in the adrenal glands and has a variety of therapeutic uses.\nGenazzani said the results showed DHEA has potential, especially for those women who may have problems in taking more conventional HRT.\nItalian researchers writing in the journal of the International Menopause Society, Climacteric, said they had found the first robust evidence that low doses of DHEA can help sexual function and menopausal symptoms, suggesting it may one day become an alternative to hormone replacement therapy (HRT).\nHRT, which is a combination of the hormones oestrogen and progesterone, is an approved treatment for women going through the menopause, who often experience unpleasant symptoms such as hot flushes, night sweats, loss of sex drive and mood swings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability is implied, but the story could have been more explicit about how readers might purchase the specific drugs that were studied or whether they were in specific trial stages for this type of treatment. In fact, tibolone is not available in the U.S. though it is available in Europe.\u00a0 DHEA is sold as a supplement over the counter.\n\u00a0", "answer": 0}, {"article": "Watch Sanjay Gupta MD Saturday at 4:30pm and Sunday at 7:30am ET.\n(Agatston does not make any money from the coronary calcium scan.)\nA calcium score would answer that question, she says.\nThere's a third test Agatston likes: a $65 blood test that looks at a patient's LDL, or bad cholesterol.\nAgatston says relatively new imaging tests give real-time pictures showing whether plaque is building up in key blood vessels, alerting doctor and patient to an increased risk of a potentially deadly heart attack.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story makes it clear that the three tests discussed are available at most hospitals.", "answer": 1}, {"article": "Vemurafenib, approved in 2011, can cause non-lethal skin cancers.\nFor the first time, however, patients such as Herry have options.\nAnd none are risk-free.\nPatients with a limited time to live may not be so positive, Turnham says.\nAll improve survival by a few months.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The varying stages of availability of the various drugs was made clear in the story.", "answer": 1}, {"article": "\"That's about what you see with standard drug therapy,\" says researcher J. David Prologo, MD, assistant professor of interventional radiology at Case Western Reserve University\u2019s School of Medicine in Cleveland.\nBut other experts tell WebMD that questions about the long-term consequences remain.\nA time to ejaculation of more than two minutes is normal, he tells WebMD.\nIts supporters say the technique, or a similar one involving heat therapy, could someday become a standard treatment for the condition.\nResearchers tested the technique on 24 men who hadn't been helped by standard treatments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that this procedure is not currently available to the typical patient.", "answer": 1}, {"article": "Due to diffuse symptoms, pancreatic cancer is usually diagnosed very late in the disease progression.\n\"Our test can detect pancreatic cancer with 96% accuracy at stage I and II, while there is still the possibility of successful surgical intervention.\nThe next step has already been initiated, which is a large US prospective study for high risk individuals.\nSince the immune system is the first to respond to threats like complex diseases, such as cancer, autoimmune diseases and infections, the microarray was designed to mirror this early response.\nA new blood test developed by researchers at Lund University in Sweden, Herlev Hospital, Knight Cancer Center and Immunovia AB, can detect pancreatic cancer in the very earliest stages of the disease.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "At the very end of the news release we read:\n\u201cIn the future, the screening method could be used to screen people who are at high risk of developing pancreatic cancer, such as those with a hereditary risk, newly onset diabetes patients, and patients with chronic inflammation of the pancreas. The next step has already been initiated, which is a large US prospective study for high risk individuals.\u201d\nThis is an important inclusion but it would have helped to put this higher up in the news release because it provides an opportunity to emphasize that the blood test is unproven as a screening tool.\nMore importantly, it\u2019s currently not commercially available and the news release should have made this clear.", "answer": 0}, {"article": "Compared with the 35 stroke patients who got clot-dissolving medicine alone, the 35 who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days. Imaging results revealed that for those who got both treatments, 100% of the brain tissue initially affected by a clot had blood flowing to it after 24 hours. Among the subjects who only got alteplase, the median level of restored blood flow was 37%.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a wonderful job highlighting concerns about the availability of the treatment offered in these studies. \u00a0We are told that only specialized centers have the expertise and technology available to perform the procedures, \u00a0and that insurance coverage has been spotty. The story also mentions the three clot retrieval devices that are approved for use in the United States.", "answer": 1}, {"article": "Those whose tumors expressed PD-L1, but not at high levels, did not show such a statistically significant benefit in progression-free survival.\nSafety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients, Merck said in a release that included only summary \u201ctopline\u201d information from the results.\nThe approval was contingent on the company providing more detailed data in the future on Keytruda\u2019s safety and effectiveness.\nKeytruda and a similar treatment from Bristol-Myers Squibb Co called Opdivo are antibodies designed to block the interaction between PD-L1 and another protein, PD-1, whose natural function is to put checks on the immune system.\nMore detailed data from the study will be provided soon, Merck said, adding that it will ask the U.S. Food and Drug Administration later this year to add the new data to the drug\u2019s package insert label.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Keytruda has been approved for use in treating lung cancer.", "answer": 1}, {"article": "Arthritis pain is caused by bones rubbing together after protective cartilage is damaged or worn away.\nAfter years of cortisone treatments and therapy, wrist replacement became a last resort.\nShe still can't lift more than 11 pounds, but the pain has greatly subsided.\nAfter replacement surgery and months of physical therapy, patients can lift no more than 15 or 20 pounds, he said.\nMore than a dozen bones lie beneath the skin and muscles of the hand and wrist, compared with two or three for those larger joints.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article explains that wrist replacement has been available for decades. But why is the procedure \u201cseldom used\u201d? Is the device FDA-approved? Is the operation widely available in the U.S., offered in the local community hospital, or mostly consigned to large or academic medical centers? The article does not say.", "answer": 0}, {"article": "But another found that the stroke rate was 22 percent lower in people who ate chocolate once a week, and a third reported that death from stroke was 46 percent lower in those who ate 50 grams of chocolate once a week.\nAnd dietitians say too much chocolate can be harmful.\nFor now, said registered dietitian Katie Clark, \"caution should be taken not to promote chocolate as a health food,\" even though it's fine in moderation.\nThe health benefit may come from antioxidants called flavonoids that are present in chocolate, Saposnik said.\nSaposnik said more studies will help clarify the association between chocolate and stroke risk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of chocolate is not in question. ", "answer": 2}, {"article": "\"In that population, there is a benefit,\" Coleman said.\nSaid Coleman: \"Zoledronic acid cannot be routinely recommended for prevention of cancer returning, but it remains a very good drug for patients where the cancer has already spread to the bone.\"\nIn one previous study, the use of the drug was linked with a 32 percent improvement in survival and lowered recurrence in younger women with breast cancer.\nBisphosphonates have been used to treat osteoporosis as well as bone complications of breast cancer treatment, she said.\n\"The role of bisphosphonates in preventing cancer recurrence has been less clear,\" she said, noting that multiple studies have had conflicting findings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article did not make it clear that the FDA has not yet approved zoledronic acid as adjunctive treatment for women with early breast cancer.\n\u00a0", "answer": 0}, {"article": "\"The results and especially the rapidity of the effects observed in the gantenerumab trial went beyond our expectations,\" Luca Santarelli, MD, study co-author and Roche senior vice president of neuroscience, writes in an email.\nTherefore, it's not known if reducing the amount of them will slow or stop the disease.\nThe study is published in the online edition of Archives of Neurology.\nWhat is not entirely known at this point, though, is if these plaques cause Alzheimer's or are by-products of the disease.\nThe experimental compound, known as gantenerumab, is being developed by Roche, the Swiss pharmaceutical company.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story ends with an appropriate send-off:\u00a0 \u201cWe need more studies to know if it is safe or effective.\u201d\u00a0 The early, experimental nature of the research is clear.", "answer": 1}, {"article": "she asked.\nHowever, if this test could be done in really young children, it might help identify autism so that treatment can begin early, Lopez-Alberola suggested.\nFor one, this study was done in school-aged children, many of whom were actually teenagers, so it is impossible to know if these differences in neuroimaging would also be found in younger patients, Adesman pointed out.\nAlthough this study was done with school-aged children and teens, the same test can be done with children as young as 18 months, Hirsch noted.\nAnother expert, Dr. Robert F. Lopez-Alberola, chief of pediatric neurology at the University of Miami Miller School of Medicine, said that \"it's nice to have an objective measure, but it doesn't really do much.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that using MRIs to diagnose autism is an uNPRoven approach. The author of the study says, \u201cThis is not the diagnostic that you can package and send to all community health centers in the United States. This is an announcement that this can be done,\u201d she said. The story could have pointed out that the validity of the testing would be dependent on the expertise of the radiologist, as reading functinal MRI is different from traditional MRI.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/15/national/a141001S34.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "\"This can potentially decrease having to go back to the operating room and with no real effect on your [cosmetic] outcome,\" said study leader Dr. Susan Boolbol, chief of breast surgery at Beth Israel Medical Center, in New York City.\nIn June, the radiation-free device won the blessing of a U.S. Food and Drug Administration advisory panel.\nHowever, she thinks more research is needed.\nThe expected cost of the MarginProbe in the United States, if approved, is not yet known, said Michael Graffeo, a spokesman for its maker, Dune Medical Devices.\nThe device is also being studied for use with prostate cancer, the company said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers are told that an FDA advisory panel recommended that the FDA approve the device, which has been used for several years in Europe.", "answer": 1}, {"article": "CNN Films Presents:\" Glen Campbell ...\nThe main goal of the current study, which included 119 patients, was to find out whether high doses of resveratrol could be safe.\n(The current study was a phase 2 trial, typically meant to evaluate safety and get an early look at efficacy of a new drug.)\nThe current study used high doses of resveratrol to increase the chances that enough of the compound got into the brain to have an effect.\nThere is probably little benefit in taking currently available resveratrol supplements, even if they claim to contain levels similar to the ones used in this study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study addresses this specifically: \u201cEven if concentrated forms of resveratrol pills like the kind used in this study were available, it\u2019s too soon to recommend going out and getting some just yet.\u201d", "answer": 1}, {"article": "The Site is down for maintenance.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The experimental nature of the drug was clear in the story.", "answer": 1}, {"article": "The page you are looking for has moved. Please go to the main EurekAlert! homepage to locate the section you are interested in and reset your bookmarks.\n\nFor further assistance, please contact webmaster@eurekalert.org.", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Most readers will know that ibuprofen is a widely available, over-the-counter drug.\nHowever, it\u2019s not made clear how available (or accurate) the saliva test for Abeta42 is.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/01/17/national/a130050S19.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This\nrating does not apply, as the story focuses on watchful waiting and active surveillance in lieu of preventative surgery for\nhernias. Hernia operations are a common procedure and available in most hospitals; the new treatment (no intervention, save\nfor monitoring general health or symptoms typical of a hernia) is also now an evidence-based option for treatment.", "answer": 2}, {"article": "\u201cYou could not have convinced me that I would ever have done this or continued with this,\u201d she said.\nDr. Solomon and other experts cautioned that bigger studies with other masters and approaches were necessary.\n\u201cThe mind-body connections set it apart from other exercises,\u201d she said, adding that doctors are seeking \u201canything we can offer that will make patients say \u2018I can really do this.\u2019 \u201d\nBut not all of these reports have been conclusive, and tai chi is hard to study because there are many styles and approaches.\n\u201cIt\u2019s hard for some patients\u2019 families and their doctors to get their head around what it is and whether it\u2019s real.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story makes it clear that there are multiple versions of tai chi. It could have been more clear about how widely available it might be, especially in sparsely populated areas.", "answer": 0}, {"article": "\"Whereas the typical developing kid will have an explosion of their language ability starting at about 12 months in both comprehension and production, kids in autism delay don't start comprehending or producing until later, and they don't ever have that kind of explosion.\nBefore bringing it to clinics, researchers need to make sure this test isn't detecting other developmental delays such as dyslexia, he noted.\nAnd when it is ready for prime time, it probably won't be applicable to all children with autism.\n\"This provides more evidence for abnormal connectivity in the brain.\"\nRight now, experts have little to go by in detecting autism other than carefully monitoring the regular developmental milestones in children, Young said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear several ways that this is early research and would require further development before a detection protocol was available.", "answer": 1}, {"article": "High blood pressure, or hypertension, is a major risk factor for cardiovascular diseases \u2014 the leading causes of death worldwide.\nThe Cochrane review attracted sharp criticism from nutrition experts.\nWhile previous trials have found there is a blood pressure benefit from cutting salt, research has yet to show if that translates into better overall heart health in the wider population.\nSimon Capewell, a professor of Clinical Epidemiology at Liverpool University, said the review was \u201cdisappointing and inconclusive\u201d and did not change public health consensus that dietary salt raises blood pressure.\nThis gave the researchers enough data to be able to start drawing conclusions, they said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of salt is not in question.", "answer": 2}, {"article": "Glover acknowledges that \"it's not a perfect solution.\nThere are more than a few caveats when it comes to the treatment regimen.\nThough the immunotherapy treatment is simply a matter of gradually increasing your tolerance to peanuts, you could have a severe reaction at home.\nHe added that although the study proved the treatment's effectiveness and safety only in children, adults would probably benefit in the same way.\nEllis is one of the majority of children for whom the treatment works.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the treatment is not yet FDA-approved, and is not currently commercially available.", "answer": 1}, {"article": "Also, scar tissue often builds up around intravenous wires, a process that can make removing and replacing them difficult or dangerous.\nBut Dr. Bardy estimated that the device could work in about 25 percent of patients who now get a defibrillator.\nDr. Bardy said the cost of the new device is about the same as a standard defibrillator.\nDr. Douglas P. Zipes, a professor at the Indiana University School of Medicine in Indianapolis, said the new device could someday displace existing models used in many patients Every month, about 10,000 patients in this country get a defibrillator, either for the first time or as replacements for devices whose batteries have worn out.\nThe device is being developed by Cameron Health, a small company in San Clemente, Calif., that was co-founded by Dr. Bardy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe story points out that the new type of implantable defibrillator is available in some countries in Europe, but that further trials are needed to produce evidence that could be used to apply for FDA approval in the United States.", "answer": 1}, {"article": "-- Icing the bottom of the foot, sometimes using ice to massage the heel area\n\n-- Using cups made of gel in shoes to cushion the heel (and many orthopedic surgeons say expensive custom-made orthotics are not necessary)\n\n-- Wearing a night splint, a simple brace that holds the foot in a flexed position to keep the plantar fascia stretched during sleep\n\n-- Physical therapy, though some studies indicate that some PT practices such as ultrasound and whirlpool are not helpful\n\n-- Use of NSAID (non-steroidal anti-inflammatory) drugs such as ibuprofen and naproxen\n\n-- Corticosteroid injections into the heel, though this is controversial and should not be used repeatedly\n\n-- Backing off activities like running until the pain goes away, and then reinitiating them gradually\n\nAbout 90 percent of sufferers will get better with time.\nDuggal says foot specialists don't really know what causes the pain of plantar fasciitis.\nSo the hope is that platelet injections will stimulate healing without the damaging effects of shock-wave therapy.\nBut while inflammation can be involved in plantar fasciitis, it doesn't seem to be the cause, Duggal says.\nMeanwhile, foot specialists and their patients are left with a smattering of low-tech treatments that they say all plantar fasciitis patients should try, whether or not they eventually go on to shock-wave therapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0says that shockwave therapy is \"beginning to catch on around the U.S.\" While this\u00a0gives readers the accurate impression that the treatment is approved for use and available in some places, it doesn\u2019t really give readers a sense as to how\u00a0likely they are to find it at their local doctor\u2019s\u00a0or orthopedist\u2019s office. Although it earns a satisfactory, the story could have provided a bit more detail on the history of these devices in the U.S. (they were first approved for use in 2000) and how widespread they have become.", "answer": 1}, {"article": "\"We don't want to treat any man unnecessarily with that type of treatment.\nThese findings are good news for some men, since the effects of short term of hormone therapy are reversible, D'Amico said.\nHe noted that the radiation treatments in use today differ from those given in 1994 when the trial began.\nBut when the researchers looked closely at those findings, they found that patients with low-risk prostate cancer did not need hormone therapy because the chance they would survive with radiation alone was already almost 99 percent, Jones said.\nOverall, hormone therapy reduced the risk of dying from prostate cancer over 10 years from 8 percent to 4 percent, Jones said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained about the treatment used in the study reported on as well as how radiation therapy has changed since the men in the study were treated.", "answer": 1}, {"article": "This compared with 1.9 percent using mitoxantrone.\nThe FDA\u2019s review should happen in the third quarter, Sanofi said.\nThe French drugmaker said on Thursday that the combination of the treatments led to an improved median overall survival of 15.1 months against 12.7 months in patients who took a chemotherapy of mitoxantrone with prednisone/prednisolone.\nCabazitaxel won priority review from the U.S. Food and Drug Administration (FDA), meaning the health regulator will take about six months instead of the usual 10 months to assess if a drug is efficient and safe to be marketed.\nThe clinical trial results will be presented at the 2010 American Society of Clinical Oncology (ASCO) on June 6.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story indicated that the drug reported on was not yet approved for use in the EU; it also mentioned that drug is currently scheduled for an expedited review by the US FDA.\u00a0 ", "answer": 1}, {"article": "The drugs are benzodiazepines, which are widely known by their brand names Xanax and Valium and commonly prescribed to help treat anxiety.\nStill, it\u2019s well established that benzodiazepine and opioids compound each other\u2019s overdose risk.\nFinally, since the study looked at correlation (not causation), it\u2019s possible that it missed some other factor driving up overdose deaths among concurrent benzodiazepine and opioid users \u2014 perhaps, for whatever reason, these users may be more likely to misuse their drugs.\nAnd since the research relied on patients who were continuously insured throughout the study period, it\u2019s possible the findings don\u2019t exactly apply to people with spottier coverage.\nBut there\u2019s a catch: Such overdoses seem to be very closely tied to the opioid epidemic, with the majority of benzodiazepine overdose deaths involving both benzodiazepines and opioids.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "On balance the story could have done a better job of exploring what it would take to halt these dangerous drug interactions. The headline describes their elimination as a \u201csimple way to help combat the opioid epidemic,\u201d but the story acknowledges otherwise:\nFor some patients, eliminating these co-prescriptions could involve some tough trade-offs. If someone genuinely suffers from pain and anxiety, doctors and patients will need to work out which condition is more important to treat and which one can be treated with alternatives \u2014 to avoid a potentially deadly overdose.\nThe story also could have addressed the difficulty in changing physicians\u2019 prescribing patterns. If indeed, as the story contends, \u201cit\u2019s well established that benzodiazepine and opioids compound each other\u2019s overdose risk,\u201d why have so many dual prescriptions been written?\u00a0 Are there readily available and affordable alternatives to these two classes of drugs? The story doesn\u2019t say.", "answer": 0}, {"article": "A study shows that not all good fats are the same when it comes to protecting your health\n\nA study shows that not all good fats are the same when it comes to protecting your health.\nRamsden says the findings provide some refined understanding of unsaturated fats, which come in different chemical forms that may have varying benefits or risks.\nReviewing the dietary advice as a whole is important, says Alice Lichtenstein, a spokesperson for the association, since changes in one area could have unexpected, and potentially harmful, effects on other eating habits.\nFor more than three years, researchers at the time followed 458 men aged 30 to 59 years old who had a history of heart disease; about half were told to replace the saturated fats they consumed from animal and dairy sources with omega-6 linoleic acid, which is commonly found in safflower oil or margarines made from it.\nThe AHA further breaks down the unsaturated-fat advice by suggesting that people devote about 5% to 10% of their daily calories to foods containing linoleic acid.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As with the competing HealthDay story, there really wasn\u2019t enough information about the fatty acid composition of different vegetable oils, including\u00a0which ones are rich sources of linoleic acid (e.g. safflower oil and corn oil) and which ones\u00a0have a balance of omega-3 and omega-6 fats (e.g. canola, soy). There\u2019s still good evidence that the latter group are healthier than saturated fats. As with the previous criterion comment, it would have not taken much space to explain this to readers.", "answer": 0}, {"article": "There's no definitive answer to that just yet, Wang said.\nWhile larger studies are needed to confirm the findings, tai chi looks promising as an alternative treatment, Yeh said.\nMost patients, according to background information in the article, remain in pain years after the diagnosis, are aerobically unfit, have poor muscle strength and flexibility, and need medications to control symptoms.\nDoctors will often suggest exercise, sleep hygiene techniques and medications to treat the condition, but often with limited success, said Dr. Gloria Yeh, an assistant professor of medicine at Harvard Medical School, who wrote an accompanying editorial in the journal.\n\"This could represent an ideal exercise for fibromyalgia sufferers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers are left to make their own assumptions about the availability of tai chi classes in their communities. More problematic is that the story does not provide any detail about the style or rigor of the tai chi classes (aside from the fact that the classes last an hour), making it difficult for a patient, or health care advisor, to make an informed decision as to how to proceed.", "answer": 0}, {"article": "\"What we've had available the last 16, 17 years has made a big difference,\" Richert says, \"and what we have coming onboard now, these are going to make even a larger difference.\nThe studies for these drugs, which are not yet on the market, were funded by the drug manufacturers.\nIn light of that experience, federal regulators may go slowly with the two new drugs, called fingolimod and cladribine.\nThe new pills also appear to be more effective than most current drugs.\nThese dangers are nothing new \u2014 the MS drug Tysabri was pulled from the market after some patients came down with rare brain infections.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that the drugs in question are not yet on the market and that \"federal regulators may go slowly with the two new drugs.\"", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story reported on a common dietary component and its association with bone mineral density.", "answer": 1}, {"article": "April 18, 2011 -- The FDA has approved a new noninvasive portable device for the treatment of a deadly type of brain tumor. The device uses electrical fields to slow and possibly reverse tumor growth.\n\nThe device, manufactured by Novocure, is called the NovoTTF-100A System and is meant for adults with glioblastoma multiforme that recurs or progresses after chemotherapy and radiation treatment.\n\nGlioblastoma multiforme is a common type of brain cancer, and the tumor is highly resistant to standard treatments, such as surgery, radiation, and chemotherapy, the FDA says in a statement.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The purpose of the story was to announce FDA approval of the new device, so it\u2019s clear that it\u2019s not widely available yet.", "answer": 1}, {"article": "These plaques, which are caused by blood cholesterol, build up over time and cause arteries to narrow, leading to heart disease as the heart works harder to pump blood through the body.\n\"The best use is in patients who have no symptoms, but the value of the test is not well known.\"\nThey generally cost less than $100, she said.\nThe findings appear in the July 7 issue of Annals of Internal Medicine.\nThis study confirms their usefulness in that regard, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that CAC testing is widely available.", "answer": 1}, {"article": "When his heart disease was first diagnosed four and a half years ago, Mr. Del Sontro, now 50, told his cardiologist he wanted to run one more Bay to Breakers race, a century-old 12-kilometer race in San Francisco.\nThat strategy alone, Dr. Biesecker said, has eliminated the vast majority of candidate genes.\nDr. Biesecker acknowledged that there was no guarantee of success.\nResearchers\u2019 ignorance of these control regions and what many of them do might doom the effort.\nThe researchers are now searching for culprits among genes that remain \u2014 a search that could take years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. Any\u00a0tests or treatments based on this research are many years away.", "answer": 2}, {"article": "\u201cThere\u2019s some danger of kids getting a rash, and it would be inadvisable to give it to women in the early stages of pregnancy,\u201d he said.\nSome might not have a large enough sample to find a small but statistically significant effect.\nThe authors acknowledged certain weaknesses in their study.\n\u201cBut if adults believe in echinacea, they\u2019re going to get benefits \u2014 maybe from placebo \u2014 but they\u2019ll get benefits.\u201d\n\nDr. Coleman, who described himself as \u201cnot much of a pill taker,\u201d hedged a bit when asked if he planned to use echinacea himself.\nThere are more than 200 species of virus that cause colds, Dr. Coleman said, and a study could test one species against which echinacea proves ineffective, while leaving open the question of whether it works for others.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article fails to say\u00a0how widely the herb is used and where it\u2019s available. But it\u2019s probably safe to assume that most Americans know how to find it.\u00a0 ", "answer": 2}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the first sentence that the device is not yet available and that the FDA just approved the device for marketing to breast cancer patients.\nDigniCap wrote on its website: \u201cWe will be finalizing agreements with major cancer centers and community oncology groups across the country so that they will be able to offer DigniCap\u00ae treatments to patients as soon as possible.\u201d", "answer": 1}, {"article": "\"We have no right as parents or as physicians or adults to strap them down and chop off a normal part of their body.\nSome think the academy's position is long overdue, and that the group should have gone even further and more forcefully recommended circumcision.\nChapin and other critics argue that the scientific evidence is questionable.\nBut many experts say the academy is making the right call.\nAt that time, the group, which represents about 60,000 pediatricians nationwide, concluded that there was no clear evidence for or against circumcising newborns.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability is clear in the story, as is the decline in use\u2026and the fact that many state Medicaid programs have stopped covering it.", "answer": 1}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\n\nNew shingles vaccine is highly effective \u2014 and in short supply\n\nResearchers use immune-cell 'army' to battle another tough cancer\nShlomo Shinnar, president of the American Epilepsy Society and a neurologist at Montefiore Medical Center in New York, has said the drug will be \u201ca very valuable addition\u201d to the limited options for treating severe childhood-onset epilepsy.\nFDA Commissioner Scott Gottlieb said the approval was \u201ca reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies.\u201d The medication, tested in three randomized, placebo-controlled trials with more than 500 patients, was effective in reducing seizures, the FDA said.\nHowever, it isn\u2019t clear whether such a reclassification would involve CBD products in general, the CBD formulation used specifically in Epidiolex or something else.\nThe drug is the first treatment approved for Dravet syndrome.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does not state exactly when the drug will be on the U.S. market, but generally, FDA approval coincides with market availability.", "answer": 1}, {"article": "The decrease we saw was larger than is seen with the currently used medications,\" Lanctot said.\nTUESDAY, July 24, 2018 (HealthDay News) -- The active ingredient in pot that gets you high can calm agitation in people with advanced Alzheimer's disease, a small new study suggests.\nMarinol is now being tested for its usefulness in treating Alzheimer's symptoms, Lanctot said.\n\"It's a milder form of TCH\" compared to whole-leaf marijuana, Lanctot said.\nAgitation is a frequent symptom of advanced Alzheimer's, Lanctot explained.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s mentioned that a form of synthetic THC (dronabinol; trade name \u2018Marinol\u2019) also is available in the U.S. (The story makes it sound like Nabilone is only available in Canada, but it does appear to be FDA approved in the US for cancer treatment as side effects, known as Cesamet.)\nGiven the fact that this a Canadian study (where medical marijuana has been legal since 2001), and that the legality of medical marijuana in the US varies by state, it might have helped readers to clarify if a synthetic like nabilone is considered legal, experimental, and/or requires a prescription.", "answer": 1}, {"article": "; Eur Uro 2016 \n\niii Loeb et al.\nThe full paper is accessible via the online edition of The Journal of Urology.\nSince the introduction of the SelectMDx test in mid-2016, over 23,000 patients have been tested and 15 commercial contracts have been signed with US based insurance companies.\nThe test has been included in the 2018 European Association of Urology (EAU) clinical guidelines.\nSelectMDx is available in the US and all EU member states.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the test is already in use.", "answer": 1}, {"article": "(Reuters Health) - When a migraine strikes, patients might one day be able to make the experience less painful by using a smartphone-controlled device to deliver mild electric shocks to their arm, a company-funded experiment suggests.\n\u201cAll stimulation treatments given so far have been in the head,\u201d said lead study author Dr. David Yarnitsky, an advisory board member for Theranica, the company developing the device.\nOne shortcoming of the current study is that researchers didn\u2019t examine how long the pain relief lasts beyond two hours, Schoenen said by email.\nIt\u2019s designed to stimulate nerves under the skin in the arm and block pain signals from reaching the brain.\nResearchers asked participants to put the device on their upper arm as soon as possible after the start of a migraine and use it for 20 minutes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story establishes that TENS was already available for use on the head, but uses a researcher\u2019s words to carefully note that\u00a0it remains to be seen if TENS on the arm is a reliable stand-alone treatment that doesn\u2019t need to be paired with drugs. It also makes it clear that the technology is still being tested.", "answer": 1}, {"article": "The researchers wanted to evaluate whether in a group of women suffering from severe menstrual pain, aged between 18 and 34, self-acupressure would be more effective at achieving a sustained reduction in menstrual pain than usual care alone (e.g.\nAdditionally, the app was used to collect all study-related data.\nThe app Luna has recently been updated and optimized for use with iOS.\nThe app helped participants to apply simple self-acupressure techniques to three different acupressure points.\nIt can also send regular reminders.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release links to a website where the app is available in German and where it can be downloaded for free.", "answer": 1}, {"article": "Prostate cancer cells express up to 100 times more PCA3 RNA than do normal cells.\nThe test, which is approved in some European countries but not in the U.S., detects genetic material -- RNA -- from prostate cancer gene 3 or PCA3.\nThe PCA3 test can do things the PSA test can't, says Jack Groskopf, PhD, of Gen-Probe Inc., which manufactures the test and funded the new research.\nIt showed that the test accurately predicts whether a prostate biopsy will reveal cancer in high-risk men.\nThe PSA test detects prostate-specific antigen, a protein given off by all prostate cells.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story does mention that this test is not approved for use in the US but that is approved for use in several European countries. \u00a0It closes by indicating that the company that makes the test is hoping to file for approval later this year.", "answer": 1}, {"article": "They rated themselves as healthier and were less likely to report problems with mobility, pain, daily activities, social interactions and feelings of depression and anxiety, among other factors that can compromise well-being.\nIn reviewing studies that followed patients for five to 25 years after weight-loss surgery, Dr. Twells and colleagues found major long-lasting benefits to the patients\u2019 health and quality of life.\n\u201cMost say they wish they\u2019d done it 10 years sooner.\u201d She explained that the overwhelming majority of patients who undergo bariatric surgery have spent many years trying \u2014 and failing \u2014 to lose weight and keep it off.\n\u201cI haven\u2019t come across a patient yet who wouldn\u2019t recommend it,\u201d Dr. Twells said in an interview.\n\u201cBariatric surgery is probably the most effective intervention we have in health care,\u201d says Laurie K. Twells, a clinical epidemiologist at Memorial University of Newfoundland.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that bariatric surgeries are common and widely available\u2013if not necessarily covered by one\u2019s insurance plan.", "answer": 1}, {"article": "N-acetylcysteine reduced PTSD symptoms, cravings, and depression in veterans with PTSD and substance use disorder in a randomized controlled pilot trial conducted at the Medical University of South Carolina and the Ralph H. Johnson VA Medical Center\n\nN-acetylcysteine, when combined with group cognitive behavioral therapy (CBT), reduced symptoms of posttraumatic stress disorder (PTSD), cravings, and depression significantly more than CBT alone in veterans with co-occurring PTSD and substance use disorder, a particularly difficult-to-treat population, according to the findings of a randomized controlled pilot trial conducted by researchers at the Medical University of South Carolina (MUSC) and the Ralph H. Johnson VA Medical Center.\nThis trial is the first to use NAC as a pharmacotherapy for PTSD and a broad range of SUDs.\n\"For PTSD, these are some of the best outcomes we have seen in the literature for a medication.\"\n\"This is a tough patient population with SUD to work with.\"\nToday, MUSC continues the tradition of excellence in education, research, and patient care.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We learn it is sold over-the-counter and available everywhere.", "answer": 1}, {"article": "In May, British researchers reported that patients taking them have a higher risks of liver dysfunction, kidney failure, muscle weakness and cataracts.\nThe longer people took the highly popular cholesterol-lowering pills, the lower their risk of later developing colon cancer, the researchers told a meeting of the American College of Gastroenterology.\nAnd U.S. health officials have been watching data that suggests some statins such as Merck & Co\u2019s blockbuster drug Vytorin may actually raise the risk of cancer, although they have saidf this is unlikely.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted,\u201d Samadder added in a statement.\nSamadder\u2019s team did what is known as a meta-analysis, combining the findings of 22 scientific studies with more than 2.5 million volunteers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that statin medications are a popular medication for managing cholesterol levels and so it was clear that they are currently in use.\nIt would have been useful to indicate that these are prescription medications available in both brand name and generic versions.", "answer": 1}, {"article": "On day one, subjects reported to a laboratory after a 10-hour fast, completed a health status report, and had either a high- or low-nitrate breakfast.\nBeet roots contain high concentrations of nitrates, which are converted into nitrites by bacteria in the mouth .\nAn hour later, an MRI scan recorded brain flow in each person\u2019s brain.\nNov. 3, 2010 -- Drinking beet juice increases blood flow to the brain in older people, a finding that suggests the dark red vegetable may fight the progression of dementia , a new study shows.\nOn the third and fourth days, researchers switched diets and repeated the process for each person.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that nitrites are found in high concentrations in beets, celery, cabbage and other leafy green vegetables like spinach.", "answer": 1}, {"article": "To resolve that possibility, a new trial is under way at 20 cancer centers, including M.D.\nAlmost all the patients mounted an immune response.\nHe noted the impressive results could be the result of cherry-picking patients, accepting only those whose tumors had been excised by surgery and radiation.\nGilbert cautioned that the study results are preliminary.\nThe trial's big surprise was that the chemotherapy didn't stop the vaccine from prompting a strong immune response and instead enhanced it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that the treatment described was available only as part of a clinical trial.\nWhile this was accurately reported, the story should have mentioned whether or not patient recruitment for the trial was ongoing and if so, it could have included a link to \u00a0http://clinicaltrials.gov/.", "answer": 1}, {"article": "The average age of people in both groups was 73.\nOther assessments, such as PET scans for plaques of Alzheimer's proteins in the brain, are good at detecting early signs of Alzheimer's disease, but available to few patients.\nWhen the researchers focused on specific parts of the brain most likely to show damage, the accuracy rose to 95 percent.\nOne day, MRI brain scans may help predict whether older people will develop dementia, new research suggests.\nIn a small study, MRI brain scans predicted with 89 percent accuracy who would go on to develop dementia within three years, according to research at Washington University School of Medicine in St. Louis and the University of California San Francisco.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "MRI scans are described as \u201cwidely available.\u201d", "answer": 1}, {"article": "Other times doctors may not realize how many tests involving radiation patients have already undergone -- information that could influence a doctor's decision -- or may order a CT scan when other tests that do not involve radiation, such as a blood test, an MRI or an ultrasound, would suffice.\nThese are X-rays from a CT scan.\nA child's risk may run as high as one case of cancer for every 500 scans, experts say.\nThe upsurge in CT use has fueled a big jump in the annual amount of radiation that each American is receiving from medical procedures of all kinds.\nThere are many reasons for the increase, including improvements in the technology that have speeded the procedure, a growing list of uses and a proliferation of the machines.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly CT scans are available.", "answer": 1}, {"article": "Brown rice is a whole grain \u2014 white rice before it has been refined and polished and stripped of the bran covering, which is high in fiber and nutrients.\nBut, Dr. Sun said, there were many possible explanations for why brown rice eaters are at lower risk for Type 2 diabetes.\nBut the Harvard study is one of the first to distinguish between brown rice and white rice consumption in the United States, where rice is not a staple food and relatively little is eaten overall, said Dr. Qi Sun, an instructor in medicine at Brigham and Women\u2019s Hospital, which is affiliated with Harvard Medical School.\nThe study, which was published in The Archives of Internal Medicine and used data from two Harvard nurses\u2019 health studies and a separate study of health professionals, isn\u2019t the first to point a finger at foods like white rice as a culprit in Type 2 diabetes.\nCorrection: An earlier version of this story misidentified the amount of cooked rice in a serving.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0Both white rice and brown rice are widely available. \u00a0That said \u2013 there are food oases where comprehensive grocery stores are not accessible and where brown rice would be more difficult, though not impossible to come by. \u00a0There was no discussion of this in the story.", "answer": 1}, {"article": "People who experience them see or hear things that are not there (hallucinations) and/or have false beliefs (delusions).\nNo drug in this class is approved to treat patients with dementia-related psychosis.\n\u201cNuplazid represents an important treatment for people with Parkinson\u2019s disease who experience these symptoms.\u201d\n\nAn estimated 50,000 Americans are diagnosed with Parkinson\u2019s disease each year, according to the National Institutes of Health, and about one million Americans have the condition.\nThe U.S. Food and Drug Administration today approved Nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson\u2019s disease.\nThe effectiveness of Nuplazid was shown in a six-week clinical trial of 199 participants.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release is reporting FDA\u2019s recent approval of Nuplazid so it\u2019s understood the drug isn\u2019t available now. Ideally, for patients\u2019 sake, the news release would have mentioned the company\u2019s announced roll-out plans.\nAccording to a company news release, the firm intends to launch the drug in June 2016.", "answer": 1}, {"article": "Everyone loses some bone with aging - women abruptly at menopause when estrogen levels decline, men more slowly as male hormones decline over time.\nBut remember: Not exercising also puts you at risk.\nIf a person simply stands, the muscles accommodate and do most of the work, he said - with no benefit to the bone.\nAnother 34 million are at risk because they have low bone density.\nOther exercises - such as front and lateral raises with free weights - focus on the spine at chest level.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "not applicable in this case", "answer": 2}, {"article": "Allergan Inc. said that two large human tests of its Botox drug, best known for smoothing wrinkles, showed that periodic injections prevent headaches in adults who suffer from chronic migraines.\n\nEven though details of the study weren't released, the announcement, which surprised many physicians and investors, sent Allergan's shares soaring 11%, or $5.95, to $60.53 at 4 p.m. in New York Stock Exchange composite trading. Botox has been used to treat severe headaches for many years, but some researchers have long been skeptical...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that Botox is available and FDA-approved for several other indications.", "answer": 1}, {"article": "\u201cDuchenne muscular dystrophy (DMD) is a progressive and fatal genetic disorder of muscle degeneration.\nTests in mice genetically engineered to have a condition similar to Duchenne muscular dystrophy showed the drug could improve how the heart works, Joseph Beavoa of the University of Washington and colleagues at the University of North Carolina found.\nIt is not clear just how the drug is helping the mice, they reported in the Proceedings of the National Academy of Sciences, but they said it may be worth trying it as a treatment for muscular dystrophy.\n\u201cAlthough PDE5 inhibitors will certainly not cure DMD, the current studies suggest that they could be used in combination with current or future therapies,\u201d the researchers wrote.\nPatients with DMD lack expression of the protein dystrophin as a result of mutations in the X-linked dystrophin gene,\u201d the researchers wrote.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story reports that sildenafil is the drug in Viagra, used to treat erectile dysfunction, and also Revatio, which is used to treat pulmonary hypertension. The story would have been better if it referred to the active ingredient in Viagra, rather than Viagra itself, and had pointed out that to treat heart problems, the drug would be given continually (as it is for pulmonary hypertension) and not just occasionally as it is when used to treat erectile dysfunction.", "answer": 1}, {"article": "According to traditional medicine, specific acupuncture points on the skin are connected to internal pathways that conduct energy, or qi (\u201cchee\u201d), and stimulating these points with a fine needle promotes the healthy flow of qi.\nThe study, which followed 150 pregnant women with major depression, tested \u201cdepression-specific\u201d acupuncture against massage and acupuncture sessions that, according to traditional Chinese medicine, does not specifically target depression.\nIt is unclear, Manber said, why acupuncture might help lessen the severity of depression.\nOverall, Manber\u2019s team notes, the response to acupuncture in this study was comparable to what has been seen in studies of psychotherapy for depression during pregnancy.\nOverall, 63 percent responded to the therapy, versus 37 percent of the \u201ccontrol\u201d acupuncture group and half of the massage group, according to findings published in the medical journal Obstetrics & Gynecology.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t address whether any acupuncture therapists are trained in the \"depression-specific\" acunpuncture methods that were used in one arm of this study.\u00a0 ", "answer": 0}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story notes that the FDA approved this asthma treatment earlier this year and that it is available at about 30 medical centers in the U.S.", "answer": 1}, {"article": "A minimally invasive procedure designed to shrink prostate tissue with a series of nine-second blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates.\n\nThe procedure, called Rez\u016bm (pronounced \u201cresume\u201d) and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016. Thermal energy in the form of steam is applied to the prostate with a needle. As it cools it releases heat energy into the tissue, killing cells and shrinking...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that Rez\u016bm is clinically available.", "answer": 1}, {"article": "There was, however, a 70 percent reduction in chlamydia infections and cases of syphilis decreased by 73 percent.\nLike Molina and his co-authors, they said STI preventive use at this point is premature.\nSpellberg also said people who used the drug this way would be exposing the bacteria they have in their gastro-intestinal tracts \u2014 their own gut flora \u2014 to regular doses of doxycycline.\nMolina noted that antibiotic resistance to doxycycline has not been seen in chlamydia or syphilis, despite the fact that the drug has been used to treat these infections for decades.\nHe noted a recent report in the journal Science revealed that some cancer immunotherapy drugs worked less well in people who had recently taken antibiotics.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that doxycycline is widely available and that it is used to treat other diseases, including acne.", "answer": 1}, {"article": "The GI tract is also home to the intestinal microbiome, a complex population of roughly 100 trillion microorganisms (more than ten times the number of cells that make up the human body) that interacts with the mucosal lining of the GI tract.\nOverall, these results indicate that changes in intestinal inflammation can alter the trajectory of psychiatric mood disorders and that modulating the intestinal microbiota may be a new avenue of treatment for patients suffering from these diseases.\nAnd a new study from Baltimore's Sheppard Pratt Health System, conducted by a research team led by Faith Dickerson, finds that a probiotic supplement may reduce inflammation of the gut, which is known to exacerbate bipolar disorder.\nA group of patients recently hospitalized for mania participated in a 6-month study to track the effects of probiotic treatment on both their mood and the status of their immune system.\nThe beneficial effects were most pronounced in those patients who exhibited abnormally high levels of inflammation at the beginning of the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The dosage and composition of the probiotic mixture used in this study are not clarified. Therefore, readers have no idea if just any probiotic will do. This is worrisome since some readers \u2014 particularly those with bipolar illness \u2014 may extrapolate from the news release headline and start self-medicating based on these preliminary findings that don\u2019t prove probiotics help bipolar illness.", "answer": 0}, {"article": "About the UNM Comprehensive Cancer CenterThe University of New Mexico Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Cancer Center in a 500-mile radius.\nThe international study found that it protects against HPV infection in women older than 26 years.\nNewswise \u2014 WhatA research paper published in The Lancet Infectious Diseases reported that the human papillomavirus (HPV) vaccine is safe and efficacious across a wide age range of women.\nHPV vaccines are expected to prevent most of these cancer cases.\nThe study showed that women in this age group were still protected from HPV infections.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Most readers are probably aware of HPV vaccinations and that the vaccine is widely available. However, the vaccine isn\u2019t affordable to all.", "answer": 2}, {"article": "Like rheumatoid arthritis, osteoarthritis is a chronic, degenerative joint disease.\nStudy researcher Gabriel Chodick, MD, called the risk reduction \"important and meaningful,\" but he says more research is needed to confirm the association.\nThe study appears in the September issue of the journal PLoS Medicine.\nThe regular use of statins was associated with a 42% reduction in rheumatoid arthritis (RA) risk in a newly reported study of patients enrolled in one of Israel's largest health plans .\nBetween 1998 and 2007, 2,578 new cases of rheumatoid arthritis were identified in this group.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story notes that statins are the most commonly prescribed class of drugs in the world, which is an even better description than the one used in the HealthDay story.", "answer": 1}, {"article": "The hope is that our positive surgical experience will help pave the way for future research into DBS and Alzheimer's,\" says Dr. Ponce.\nThe ADvance Trial, using a device from Functional Neuromodulation, Inc., is aimed at evaluating the safety, efficacy and tolerability of DBS in this patient population.\nDuring the trial, 42 patients with mild Alzheimer's disease underwent the surgical procedure and were closely monitored for adverse effects.\nResults from the Phase 2 study, reported in the Journal of Neurosurgery on Dec. 18, 2015, demonstrated the safety of DBS in Alzheimer's patients.\nA neurosurgical procedure in which an implanted neurostimulator delivers electrical signals to specific areas of the brain to help regulate abnormal signals, DBS is currently only approved in the U.S. for the treatment of Parkinson's disease and essential tremor.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that the device is only approved for use in patients with Parkinson\u2019s disease and essential tremor. It\u2019s available to those patients, and only for research in other conditions.", "answer": 1}, {"article": "They then moved each patient's head forward and shook it from side to side for about 15 seconds.\nThirty-five study participants had this form of vertigo.\nThose with the new form of vertigo were also more likely to have severe motion sickness than those with other forms of the condition, the study showed.\nPreventative medication was given to 20 of the 35 people with the newly detected type of vertigo.\nThe researchers noticed that uncontrolled eye movements, called nystagmus, lasted longer in people with this new form of vertigo.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The mechanism for diagnosis of this supposed new form of vertigo is explained by both the news story and the original paper.\u00a0 It requires some sort of audio-visual equipment to record eye movements, and there was discussion of a non-named medication providing relief. There is not enough information to fully inform the reader about the availability of getting screened for this type of vertigo, nor how to treat it.", "answer": 0}, {"article": "Whitcomb, whose research on the determinants of fertility and pregnancy outcomes usually involves studying biomarkers at the molecular level, adds, \"Lifestyle is definitely relevant to these outcomes because it can have an effect at the molecular level.\nThe EAGeR trial focused on women with a history of one or two prior pregnancy losses.\nWhitcomb says another way in which this study is distinct from other work in this area has to do with who was included in the study.\nThe researchers also note that the overall generalizability of this work is limited because the study population may not be representative of the general population with regard to fecundability, and exercise habits may differ in women with prior miscarriage compared to those without.\nFurther study is necessary to clarify possible mechanisms through which walking and vigorous activity might affect time-to-pregnancy.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "As noted above, the release mentions walking as both easily accessible and a potentially modifiable factor for those trying to get pregnant.", "answer": 1}, {"article": "1.\nThe study is published in Annals of Internal Medicine.\nResearchers sought to determine the clinical effectiveness of acupuncture or Alexander Technique lessons compared with usual care for persons with chronic, nonspecific neck pain.\nOver time, both interventions resulted in a greater increase in self-efficacy than did usual care, and these improvements were associated with better NPQ outcomes.\nBoth interventions had a high rate of acceptability, and greater adherence was associated with better pain outcomes.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the release that both of these therapies are widely available.", "answer": 1}, {"article": "\"Just telling people to do things doesn't work,\" says Sean Duffy, CEO of Omada Health.\nAnd he says the convenience of having the program delivered on a smartphone was key, too.\nThere is some evidence that these kinds of programs are working.\nAnd he says he's pleased with the results of the pilot study of Omada's program.\nNot every Omada Health participant makes the progress they're aiming for.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear the Omada program is available and in use around the country and even links to the company website.", "answer": 1}, {"article": "Nothing worked.\nThen she discovered another option: a series of fat-reducing injections intended to slim down a double chin.\nShe stood ramrod-straight, head held high, to make the bulge less apparent.\nBy middle age, Ms. Gallagher, 51, the owner of a pet-sitting business in Torrance, Calif., was avoiding mirrors and considering liposuction, but she worried about the effects of anesthesia and the recovery time.\n\u201cIt was receding.\u201d\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the treatment will be available in late summer after doctors are trained to give the injections.", "answer": 1}, {"article": "Hyperbaric wound treatment, often for diabetics, is booming.\nOften, Efrati and others say, injured brain cells don't die, but may persist for years or decades, alive but hobbled.\nOf course, such anecdotes are not the same as rigorous scientific research.\nOverall, there is relatively little research on hyperbaric treatment for brain injury, in part because pressurized oxygen can't be patented, which limits its potential profitability.\nEfrati agreed that hyperbaric treatment requires more research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of hyperbaric chambers, or rooms, is not discussed.\nAccording to the Undersea & Hyperbaric Medicine Society, there are over 200 accredited facilities in the United States.\nOne thing we wanted to note: The statement from a researcher that there\u2019s no way to patent (and thus, make money from) hyperbaric oxygen therapy as an explanation for why the evidence base is so fragmentary seemed to ring false in the setting of these private clinics that can create frequent return visits for long periods of time.", "answer": 0}, {"article": "As technologies and processes continue improve this is likely to be reduced,\" she continues.\nThese vaccines are not necessarily the future of personalized cancer treatment.\n\u201cIt is still unknown whether these vaccines will extend the survival of cancer patients, or whether they are more effective than other recently developed immunotherapies.\nCornelius Melief, from the Leiden University Medical Center, Netherlands, said in an accompanying News & Views article that controlled, randomized Phase II clinical trials will be needed to work out if the vaccines are effective.\nHe added, however, that the studies confirm the potential of cancer vaccines.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although not explicitly stated, most readers will understand that the vaccines are not currently available and have to undergo a lot more testing before they are available \u2014 if ever.", "answer": 1}, {"article": "[1] Quotes direct from authors and cannot be found in text of Article.\nSurprisingly, the findings also revealed that the standard altona RT-PCR test, under the conditions deployed in the field, was itself an imperfect reference standard.\n[1]\n\nIn this study, the researchers compared the diagnostic accuracy of the new RDT against the benchmark RT-PCR test (altona Diagnostics) being used for clinical diagnosis in the field reference laboratory run by Public Health England at Port Loko in Sierra Leone.\n[1]\n\nWriting in a linked Comment, Dr Nahid Bhadelia from Boston University School of Medicine and Boston Medical Center, Boston, USA says, \"[This study] validates the accuracy of the ReEBOV RDT in patients who are well into their illness...suggesting it could be used to triage this subset of patients if RT-PCR is not available, particularly in those with a high index of clinical suspicion for a differential diagnosis...the data presented provide crucial information about the point of-care function of this rapid diagnostic test, such as ease of use, quality of samples taken at the bedside, and the concordance with venous samples...the results raise caution regarding the performance of the widely used altona RT-PCR assay, which the authors suggest might have underperformed because of laboratory specific technical and performance factors.\"\nThe authors caution that given the limitations of the performance of the altona RT-PCR reference test in patients with low levels of the virus in their blood, more research is needed to assess how the new RDT will perform in patients very early in the course of EVD.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re\u00a0told the following, via a quote from a researcher: \u201cAlthough the RDT requires refrigeration, this is already available in many health centres in endemic areas, particularly those that store vaccines and other medical products.\u201d Although we\u2019d like to know more about the regulatory approval status of the test, we\u2019ll award a Satisfactory here.", "answer": 1}, {"article": "Learn more about Mayo Clinic.\nHowever, it was unclear whether these drugs could be used safely in cancer patients until now.\nDr. McBane noted that cancer and cancer treatment can be associated with kidney injury, which can limit the drug's use further.\nHe says these qualities make this class of drug much easier to use than the traditional blood thinners.\nSAN DIEGO -- Mayo Clinic researchers have found that an oral drug, apixaban, used to treat blood clots in patients undergoing cancer therapy, is safe and effective.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that apixaban, a member of a new class of \u201cblood thinners called \u2018direct oral anticoagulants\u2019 have become available.\u201d Both oral and injectable anti-coagulant medications are now widely available at hospitals and clinics where they are administered to patients.", "answer": 1}, {"article": "(H\u00f6gqvist Tabor says it's tricky because it depends on the individual, and can range from a few beats per minute to 10 beats per minute.)\nBut as Clue\u2019s and Ava\u2019s fertility research indicates, increasingly sophisticated sensors and algorithms could significantly open up wearables\u2019 capabilities \u2014 and make them that much more able to tackle bigger, complicated health issues.\nIf you\u2019re curious exactly what kind of increase in resting heart rate you should look out for, Clue hasn\u2019t revealed that information yet, but says it will publish that and other data in a paper later.\nFitbits aren't the only wearables that can track fertility-related biometrics in the background.\nBy monitoring these multiple biomarkers while a woman is asleep, Ava\u2019s wearable and app can notify her during the five days she\u2019s most fertile, ending in ovulation, according to von Bidder, who says Ava has conducted studies on about 60 people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Fitbits are widely available, though the story seems to take it for granted that readers will know this. Similarly, the story refers to the relevant app, called \u201cClue,\u201d as a \u201cwomen\u2019s health data startup.\u201d It\u2019s not clear from that description whether the relevant app is already available. (It is.) The story does note the availability of other, related technologies.", "answer": 0}, {"article": "\"These days it's possible for a food company to pay just about anybody to conduct a study,\" says Silverglade.\nThat's the paradox of products such as POM, Silverglade says: The health claims on these products strain the imagination, yet studies have repeatedly shown that health claims sell food.\nThe bottom line is that consumers shouldn't believe everything they read on labels.\nProbably not,\" says Dr. Lenard Lesser, M.D., one of the co-authors of that study and a researcher at UCLA.\nMost health beverage drinkers aren't as enthusiastic as the realtor from Alaska who posted the above testimonial.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We know that one company racked up $91 m in sales in one recent year, giving some indication of how widespread is the use of some of these products.", "answer": 1}, {"article": "As they age, people with elevated diastolic blood pressure are at a higher-than-average risk of developing elevated systolic blood pressure.\n\"Heart disease and strokes are a leading cause of death in the United States.\nThese evidence-based data demonstrate the effect of diet on cardiovascular disease outcomes, particularly diastolic blood pressure.\"\nAt the beginning and end of each diet period, participants spent three days undergoing metabolic testing in a clinical research setting.\nThis collaborative research began in 2010.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Whole grain foods are readily available at grocery stores and markets, so availability is not an issue here.", "answer": 2}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nEpclusa also carries a warning not to use with certain drugs that may reduce the amount of Epclusa in the blood which could lead to reduced efficacy of Epclusa.\nKnowing the genotype helps inform treatment recommendations and the duration of treatment.\nEpclusa is a fixed-dose combination tablet containing sofosbuvir, a drug approved in 2013, and velpatasvir, a new drug, and is the first to treat all six major forms of HCV.\nThe safety and efficacy of Epclusa for 12 weeks was evaluated in three Phase III clinical trials of 1,558 subjects without cirrhosis or with compensated cirrhosis (mild cirrhosis).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is announcing the approval of the drug which usually means it will be available in the near future.", "answer": 1}, {"article": "\u2022 Using other options to collect urine, such as bedpans.\nNow, researchers report that a new program shows it might be possible to reduce both catheter use and its associated infections.\nRoughly 250,000 such infections occur in hospitals each year in the United States, costing about $250 million, the researchers pointed out.\nBut there was no drop in infections or catheter use in intensive care units (ICUs), the study findings showed.\n\"This program can reduce urinary infections in hospitals if a team is assembled to ensure adoption of best practices and to rapidly correct reasons for failing to comply with these processes,\" she added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told the procedure is in use at 600 hospitals, though it would have helped to note they\u2019re spread across 32 states, plus Washington D.C. and Puerto Rico. It could have been made clearer that any hospital can use this safety bundle now that the methods are published widely.", "answer": 1}, {"article": "\"It's just like physical exercise -- when we are approaching the new year we will buy a pass for the gym and go fervently in January and then slack off,\" Willis said.\nSherry L. Willis, the lead author of the study and a Pennsylvania State University professor of human development, said those who had the training also reported greater confidence in their ability to solve everyday problems, and this was especially true of the group that got the reasoning training.\nThe researchers also showed that the benefits of the brain exercises extended well beyond the specific skills the volunteers learned.\nIf anything, the study suggests, there is a bigger payoff to mental exercise, because the brief training sessions seemed to confer enormous benefits as many as five years later.\nThe study did not indicate that mental training can hold off all cognitive decline permanently.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story did contain advice (from the lead author of the study) about working on puzzles that are more difficult, something new, and stretch the mind \u2013 the nature of the three distinct interventions used with the ACTIVE study participants was not clear, nor was the\u00a0difficulty of\u00a0finding people to work with on these specific sorts of mental training activities mentioned.\u00a0 How one might access the interventions used in the study was not clarified for the reader.\u00a0 It is also not clear how the study interventions actually relate to the kinds of examples given in the story such as doing puzzles.", "answer": 0}, {"article": "According to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain.\nSo it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\nBut the pain is far more controlled, and I can function much better at my current level of discomfort.\u201d\n\nAs the human and financial costs of the opioid crisis rise, spinal stimulation may become more popular, even though it\u2019s expensive.\n\u201cSince this surgery I\u2019ve actually had another disc herniate, complicating everything.\nThat aching back is hard to fix, but here are a few things to try\n\nThese real-life cyborgs hack their bodies with chips, magnets and other tech\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that these devices are available and in some cases covered by insurance. Though it may have been helpful to note that these devices are usually performed by specialists and particularly in rural areas, access to them may be harder to get.", "answer": 1}, {"article": "We're sorry, but we seem to have lost this page.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is something that the story really should have done high up. Why has it become standard practice to do a CT\u00a0scan and not an MRI? One of the authors says that 40% of his time is spent giving MRIs and 40% doing CT scans. Is that typical? Nonethless, we\u2019ll give it the benefit of the doubt. ", "answer": 1}, {"article": "Psoriasis is a chronic autoimmune-related skin condition in which thick, scaly patches appear on the skin.\nFurther analysis showed those who lost the most excess weight a year after surgery showed the biggest improvements in their disease activity.\nPatients who saw the most improvements had more severe disease at the time of surgery and were of an older age at diagnosis.\nTreatment requires a coordinated effort by dermatologists and rheumatologists to help manage symptoms such as swelling, inflammation and skin changes.\n\"These findings can be used to identify people who may benefit most from this type of intervention.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Bariatric surgery is widely available and most people with internet access (or any access to medical care) can figure that out fairly quickly in their area.", "answer": 1}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that Abraxane is already used to treat advanced breast cancer and non-small-cell lung cancer.", "answer": 1}, {"article": "So does cardiologist Roger Blumenthal, who heads the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins.\nIt's important to note that statin drugs are generally safe, and harms are uncommon.\nAnd it is only useful as a screening test for people who haven't had heart disease.\nThey worry that it will trigger overtreatment of conditions that the scan will pick up, but which don't require urgent attention.\nBut that test, which Grundy says is available for about $100, is controversial among some physicians.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that statins are widely prescribed.", "answer": 1}, {"article": "\"We have been trying as doctors for centuries to find a treatment that actually reverses heart injury,\" Eduardo Marban, MD, PhD, tells WebMD.\nIf so, this could change the nature of medicine.\nIt's the first completed, controlled clinical trial showing that scarred heart tissue can be repaired.\nMarban, director of the Cedars-Sinai Heart Institute in Los Angeles, led the study.\nAll that's needed is a little help from one's own heart stem cells.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the treatment is still in the experimental stage.\n\u00a0", "answer": 1}, {"article": "People with Type 2 diabetes get an earful of grim lectures about their health prospects and endure much hardship to manage their condition well. But new research offers those who do so a rare reward. A glass of wine every day not only won't hurt, says a new study: It can actually improve cardiac health, help manage cholesterol and foster better sleep.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is obvious that red and white wine are readily available to most readers.", "answer": 1}, {"article": "A type of sleeping pill that several major pharmaceutical companies are racing to develop received good news yesterday when Swiss biotech company Actelion Ltd. reported positive clinical data.\n\nSleep experts say the drug class needs further study but could potentially offer some benefits beyond Ambien, the top-selling drug in the $3.8 billion global market for sleeping pills. While Ambien and similar drugs, called nonbenzodiazepine drugs, are effective and easily tolerated by most people, some insomniacs don't respond to the...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story did not explicitly state that this drug is not yet available, the first sentence makes it quite clear this drug is still in development and in the process of undergoing clincial trials.", "answer": 1}, {"article": "She said that, \"though this study includes a small sample size followed for a short period of time, the results are promising in that TAK-875 appears to be effective for glycemic [blood sugar] control without significant risk for hypoglycemia or weight gain.\nAfter 12 weeks, all the patients taking the different doses of TAK-875 had significant drops in their blood sugar levels, the researchers said.\nThe study was funded by Takeda Pharmaceutical (which is developing the drug), and appears online Feb. 26 in The Lancet.\nOther diabetes experts had mixed views on the new findings.\nHowever, like Wissner-Greene, Sood said that \"further investigation is warranted, especially including [heart disease] patients.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Right in the headline, the story shows that the drug is not widely available, calling it \u201cexperimental.\u201d Also, the lead of the story says that the findings are \u201caccording to the results of a phase 2 clinical trial.\u201d However, the story did not specifically clarify that this drug has years to go before it ever reaches the market.", "answer": 1}, {"article": "Coronary heart disease, which causes heart attacks and angina -- chest pain resulting from the heart not getting enough blood -- is the leading cause of death in the United States, with nearly 450,000 in 2005, according to the American Heart Association.\nThis method of intravenous injection means that the procedure theoretically could be performed in a doctor's office or clinic, increasing the accesibility to patients, Karp said.\nThe phase I results from 53 patients are not definitive proof that the treatment is effective, but do suggest so, Hare said.\nMore broadly, besides bone marrow transplantations, there have not been any major successes in the stem cell field in terms of helping large numbers of patients, Karp said.\nThe study is a step forward in a field in which a lot of approaches have been tried in animals and preliminary human trials, but none has been approved for widespread clinical use for heart patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Most of the story makes it clear that the technique is in early trials and not in clinical use. Only the opening line is troubling \u2013 \"If you\u2019ve just had your first heart attack, doctors may one day be able to reverse the damage done with stem cell therapy.\" Due to clumsy wording,\u00a0 this suggests that if you had your first\u00a0 heart attack in late 2009, doctors may someday be able to reverse today\u2019s damage from it \u2013 which is not\u00a0 at all the case. \nBut this misstep is remedied by a later statement that it would take a best-case scenario to have such an approach approved even in five years. \n", "answer": 1}, {"article": "1Wiseman JT, Guzman AM, Fernandes-Taylor S, et al.\nDr. Gunter said they were very successful in giving patients knowledge and access to technology so they could participate in the study.\nThe study results appear as an \"article in press\" on the website of the Journal of the American College of Surgeons ahead of print.\nShe said this is a model easily adaptable to other medical centers, whether through providing participants with a phone, having a rotating supply of phones at the hospitals for patients to borrow, or relying on a patient's personal device.\nThe WiSOR research team addressed this issue by having participants undergo tailored training to learn to use the WoundCheck app.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no discussion of how many hospitals are using this app.\nThe release did discuss some of the practical aspects of implementation but nothing about whether such an app is available or if insurance will pay for any of the costs involved.", "answer": 0}, {"article": "Scientists hypothesize that the electrical currents may disrupt bacteria in two ways: by interrupting the production of chemical messages that instruct bacteria to develop biofilms and by weakening the molecular structure of existing biofilms, potentially making them more susceptible to antibiotics or the body\u2019s natural immune response.\n\u201cThis technology has a long shelf life and is compact enough to be put into any field medical kit.\nGood news for the millions of people who suffer from skin wounds that won\u2019t heal.\nMade of silk and silver, the experimental dressing includes a self-contained battery that delivers a continuous, safe, low-level electrical current to the injury.\nThe team\u2019s next move is to focus on the bioelectric bandage as a treatment for chronic wounds in a patient population; however, the technology could also be used to treat acute injuries.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that this research of an \u201cadvanced\u201d WED is experimental and the technology has not yet been tested in humans. There\u2019s a strong implication that the bandages won\u2019t be available anytime soon.", "answer": 1}, {"article": "\u201cIt\u2019s like you\u2019re possessed,\u201d said Lorie Novak, who has suffered from chronic migraines since childhood.\nBut the companies\u2019 fortunes are intertwined, he said, and \u201cthe class only wins if headache care in America improves.\u201d\n\nAiming to prevent migraines before they start\n\nThere\u2019s plenty of room for improvement.\nThat medication, Topamax, has been dubbed dubbed \u201cSleepomax\u201d by doctors and patients because it\u2019s also a heavy sedative.\nMerck got all the way into late-stage trials with an anti-CGRP tablet, spending more than $1 billion only to find in 2011 that the drug had toxic effects on the liver and thus no future.\nTargeting CGRP is not a particularly new idea.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Yes, and the news is not good: The drugs are moving through the clinical trial process\u00a0and have not yet received FDA approval. The story speculates that \u201cthe first therapy could hit the market in 2018,\u201d a prediction that presumes no glitches will slow the process.", "answer": 1}, {"article": "Research in the Journal of the American College of Nutrition suggests that eating a hearty portion of instant oatmeal for breakfast -- versus a popular oat-based cold cereal -- leads to lower calorie intake at lunch\n\nCHICAGO, IL, August 19, 2015 - A new study revealed that your cereal choice at breakfast might have an impact on how much you eat for lunch.\nNewly published research in the Journal of the American College of Nutrition showed that a hearty bowl of instant oatmeal helped curb food intake at lunch better than a leading oat-based, cold cereal -- even when each bowl provided the same number of calories.\nThe Quaker Oats Center of Excellence is focused on elevating the relevance and benefits of oats through science, agriculture and innovation.\n\"The fact that choosing instant oatmeal over a cold cereal may also help Americans curb their intake at lunch is especially encouraging.\"\nAuthors stated that the processing of the cold cereal might lead to changes in the oat fiber that reduced its ability to enhance satiety.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release, by naming the brand of oatmeal studied, makes it clear that it is available. Few people will not have heard of Quaker instant oatmeal.", "answer": 1}, {"article": "A colonoscopy isn\u2019t something you get just for giggles. Beyond the obvious unpleasantness, there\u2019s the small but real risk of complications that in rare cases can lead to hospitalization or even death.\n\nThat\u2019s why the American Cancer Society and other groups recommend that people screened for colorectal cancer using a colonoscopy wait a decade in between tests if no polyps or other signs of potential cancer are found. Polyps are slow-growing, and the benefits of being screened more frequently than that don\u2019t seem to outweigh the risks \u2026", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of colonoscopies is not in question.", "answer": 2}, {"article": "A new, detailed mammography exam catches more cancers while causing fewer false alarms, according to the company that sells it. The downside, some physicians say, is that it costs more and delivers twice as much radiation as traditional mammograms.\n\nTomosynthesis, or three-dimensional mammography, has been available in the U.S. since February from Hologic Inc., Bedford, Mass. In just a few months, radiologists say they are finding cancers they would have missed with the standard exam.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the article stated the device had been available in the U.S. since February, it was unclear if this was only for people in clinical trials, or if hospitals and cancer centers across the country were currently using it. Nonetheless, we\u2019ll give the story the benefit of the doubt on this one.", "answer": 1}, {"article": "1 Yiou et al.\nPHOENIX, Oct. 19, 2017 /PRNewswire/ -- Creative Medical Technology Holdings (OTCQB \u2013 CELZ) announced today completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company's patented CaverStem\u2122 procedure.\n\"Based on establishment of safety of the CaverStem\u2122 procedure in a formal university-based clinical trial, and independent confirmation of efficacy in an European clinical trial1, we have launched commercialization for the CaverStem\u2122 procedure,\" said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings.\n2013 Jun 9;11:139. https://www.ncbi.nlm.nih.gov/pubmed/23758954\n\nOTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.\nThe trial, sponsored by Creative Medical Technology Holdings, was conducted at the University of California Los Angeles Harbor Hospital/LA Biomed under Institutional Review Board (IRB) approval.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release appears to be overly optimistic in stating when this therapy may be available to patients. Moreover, other than the study site that performed this small trial, there is no mention of where this procedure may be had.\nThe news release did say that they expect \u201cthat the procedure will be available to patients that meet the eligibility criteria within the next 60 days.\u201d Yet this statement raises some red flags. First of all, it does not say what the eligibility criteria are, which may give ineligible patients false hope. Secondly, the 60-day time frame is incredibly quick. Even after promising safety studies, most medications and procedures undergo a third study that looks solely at efficacy (the primary outcome of this study was listed as safety and tolerability).\u00a0 ", "answer": 0}, {"article": "But at this stage, the company itself has been careful not to promote its device directly to consumers since its F.D.A.\nHourlong treatments are best spaced out by two months, said Dr. Dover, who charges $700 per spot.\nDr. Bass was not a clinical investigator for Zeltiq, but he said, \u201cI\u2019m convinced both on the science and clinical experience, it\u2019s able to eliminate fat noninvasively.\u201d\n\nNadine Tosk, a publicist for Zeltiq, explained that the rollout of the device was \u201cvery limited right now.\u201d Dr. Jeffrey Dover, a dermatologist in Chestnut Hill, Mass., who advises Zeltiq and participated in its clinical trial, said a few board-certified plastic surgeons and dermatologists were \u201chandpicked\u201d because \u201cwe know they do good work.\u201d Restraint is key, he said, because a doctor could apply Zeltiq to \u201cthe same spot\u201d in the same day, which isn\u2019t how it\u2019s meant to be used.\nMore than five dozen \u201cZeltiq specialists\u201d can be found by ZIP code at body-contouring.com, which is a patient guide not sponsored by manufacturers of body-slimming devices.\nAfter reviewing Erchonia Medical\u2019s clinical study, Dr. Brian M. Kinney, a plastic surgeon in Los Angeles, said, \u201cI can\u2019t prove that it works.\u201d His concerns are that the tape measure method of gauging circumferential changes \u201cisn\u2019t consistently reliable.\u201d What\u2019s more, study participants and the placebo group were assessed only two weeks after their last treatment, not long enough to measure adequately whether results last.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that Zerona is available nationwide through medical spas, chiropractors, dermatologists and plastic surgeons. Zeltiq, the story says, is available at over five dozen clinics identified on a website. ", "answer": 1}, {"article": "About 8% and 18% of Serada users reported daytime sleepiness and dizziness, respectively, compared to about 3% and 8% of women who took a placebo.\nNAMS founder and former executive director Wulf Utian, MD, says Serada does not appear to be as effective as hormonal therapy, but it may be a useful alternative treatment for women who can\u2019t take hormones or don\u2019t want to.\nMichael Sweeney, MD, who is vice president of research and development for Serada manufacturer Depomed Inc., says the company\u2019s slow-release gabapentin formulation avoids many of these side effects.\nIn a manufacturer-funded study, the drug Serada proved to be more effective than placebo for preventing hot flashes and reducing their severity.\n\u201cThis drug was about 60% to 65% effective, which is about the same efficacy that has been reported with antidepressants [for treatment of hot flashes].\u201d\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The oblique reference to this drug perhaps being \"one step closer to becoming the first approved nonhormonal treatment for menopause-related hot flashes\" is likely to leave many readers unsure about whether this drug is not yet available or whether it is just not approved specifically for treatment of hot flashes.\nThe standard formul gabapentin, which is approved for treatment of seizures and pain,\u00a0can be prescribed off label for treatment of hot flashes even though it isn\u2019t FDA approved for this use. (In fact, Pfizer has recently been slapped with large fines for promoting unapproved off-label uses of the drug.) However, the slow-release form of the drug discussed here is not available commercially. Although it calls the new drug \"experimental,\"\u00a0the story\u00a0doesn\u2019t\u00a0explicitly address\u00a0the\u00a0availability of the immediate-release vs. slow-release forms of the drug.\u00a0The article should have been clearer that the FDA has not approved this new slow release form, and that it is not available.\u00a0\u00a0", "answer": 0}, {"article": ".\nThe authors said now that this has been shown to be effective in a non-academic clinical setting, there also is potential for insurance companies to reimburse CAMBRA and other preventive therapies for adults, thereby lowering patient costs while increasing profits for dental practices.\nThe findings, which support earlier research demonstrating positive results of the assessment and treatment method in a university setting, have the potential to transform dental care for high-risk patients at a lower cost to both patients and dental clinics and practices.\nThe researchers said the risk reduction among the control group may have been caused by the fluoride toothpaste enhancing tooth repair, as well as the mouth rinse enhancing saliva flow and having bactericidal effects.\nFrom this assessment, the dentist utilizes behavioral approaches and chemical treatments to optimize protective factors.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This CAMBRA method is available at about half of US schools and colleges of dentistry according to the release. However, the prescription fluoride toothpaste is available from most pharmacies.", "answer": 1}, {"article": "Nerve cells in the brain die, and in a few short years, children lose the ability to walk or talk.\nOne of medicine\u2019s greatest villains: HIV.\nFor the first time, doctors have used gene therapy to stave off a fatal degenerative brain disease, an achievement that some experts had thought impossible.\nThe patients were children who had inherited a mutated gene causing a rare disorder, adrenoleukodystrophy, or ALD.\nThey usually die within five years of diagnosis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t make clear that this treatment is, at the very least, years away from clinical use. The story notes only that Bluebird Bio is \u201cin hopes of marketing gene therapy for ALD.\u201d This line, found more than halfway through a 1,300 word story, isn\u2019t sufficient. This is an area where the Associated Press story fared better, noting that the FDA \u201crequires gene therapy participants to be monitored for 15 years, so these patients will continue to be studied.\u201d The AP story also notes that Bluebird Bio \u201cplans to seek approval of the therapy in the U.S. and Europe.\u201d The AP was stronger on this criterion.", "answer": 0}, {"article": "Complications can include fluid buildup around the heart, called cardiac tamponade, which makes it difficult for the heart to pump blood.\n\"Of concern is that complication rates are still higher than desirable for this procedure, and there was suboptimal use of stroke-preventing anticoagulation [anti-clotting] therapy after the procedure,\" added Fonarow, who was not involved with the study.\nAblation was successful in 74 percent of patients, Arbelo said.\nCatheter ablation is covered by most insurance, including Medicare, the researchers said.\nAtrial arrhythmias in the first three months after ablation were classified as early recurrences and not considered as failures, Arbelo said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Catheter ablation is available in most medical centers offering broad cardiac services, but the story didn\u2019t explain that.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a180226S32.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "People with cluster headaches can have as many as eight per day in bouts that last for weeks or months.\nTUESDAY, Dec. 8, 2009 (HealthDay News) -- High-flow oxygen appears to be an effective treatment for cluster headaches, British researchers have found.\nHigh-flow oxygen also provided better pain relief at 30 and 60 minutes.\nThe National Pain Foundation has more about cluster headache.\n\"This work paves the way for further studies to optimize the administration of oxygen and its more widespread use as an acute attack treatment in cluster headache, offering an evidence-based alternative to those who cannot take triptan agents,\" they concluded.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says high-flow oxygen is in \"limited use\" to treat cluster headaches. But it fails to say where or how it is available \u2013 or even what \"limited\" really means.\u00a0 Two places in the US?\u00a0 Twenty?\u00a0 ", "answer": 0}, {"article": "It has been 51 years since the first birth-control pill became available in the U.S., bringing dozens of contraceptive options for women in its wake. There are currently two options on the market for men\u2014vasectomy or a condom.\n\nThe research pipeline is full of possibilities, though. Scientists at Columbia University Medical Center have halted sperm production and started it again in mice with no apparent side effects, using a drug that blocks receptors for vitamin A. An injectable synthetic substance, in Phase 3 clinical trials...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We like the left column sidebar that lists 3 \u201cpromising\u201d methods and specifies status and availability.\u00a0 Nice touch.", "answer": 1}, {"article": "Dr. Christopher B. Granger, the study\u2019s lead author and a professor of medicine at Duke University, said, \u201cI think this is a profound trial result that will have a major impact on the practice and management of patients with atrial fibrillation.\nThe study included 18,201 people in 1,034 clinical sites in 39 countries and was consistent worldwide, the sponsors said.\nThe companies\u2019 stock soared after they released a brief statement about the stroke and bleeding benefits in June.\nAlthough the study was financed by the drug makers, which raises the issue of bias, it met the gold standard for medical research as a randomized, double-blinded trial in which doctors and patients did not know who took which pill until the end.\nThe first new drug, Pradaxa, from the German drug maker Boehringer Ingelheim, was introduced in the United States last fall.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story opened by indicating that Eliquis (apixabane) was experimental and closed by indicating the expectation of submission to the FDA for approval.", "answer": 1}, {"article": "\u2022 LPCN 1021 was well tolerated and had a favorable safety profile in the long-term management of hypogonadal patients\n\u2022 No hepatic, cardiac or drug-related serious adverse events were reported\n\u2022 The most common drug-related adverse events for LPCN 1021 and T gel 1.62 percent were acne (2.9 percent vs. 2.9 percent, respectively), headache (0.5 percent vs. 3.8 percent, respectively), weight increase (2.4 percent vs. 0 percent, respectively), hematocrit increase (1.9 percent vs. 0 percent, respectively), liver enzyme level increase (1.4 percent vs. 0 percent, respectively), fatigue (0.5 percent vs. 1.9 percent, respectively), and hypertension (0.5 percent vs. 1.9 percent, respectively)\n\u2022 Lipid parameters (i.e., cholesterol, LDL, HDL, and TG) were comparable between treatment groups at Week 52\n\u2022 Androgenic parameters including hematocrit, hemoglobin, platelet, prothrombin, and prostate-specific antigen (PSA) showed no significant differences in change from baseline to end of study between treatments\n\n\"Based on the results of this study, we might be closer than ever to having an oral form of therapy to treat the millions of men with hypogonadism,\" said Dr. K\u00f6hler.\nFollowing a 13-week efficacy phase, men continued to receive their assigned treatment for up to 52 weeks.\nThe research will be highlighted by study authors during a special press conference to be moderated by Tobias S. K\u00f6hler, MD, MPH, FACS, AUA spokesperson and associate professor of Surgery at Southern Illinois University on May 8, 2016 at 7:30 a.m. PT in the San Diego Convention Center.\nIt is often administered as a gel, patch, injection or implant (pellet).\n\"Making sure an oral treatment is safe and effective for men and for the children and partners at risk for inadvertent testosterone transference is the top priority, and what we've found so far has shown we're on the right track.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states \u201cThere is currently no oral form of testosterone therapy approved for use in the United States by the Federal Drug Agency\u201d and then talks about this new product under development. Readers can assume the product is not yet available.", "answer": 1}, {"article": "Heart disease is still the leading killer of Americans \u2014 790,000 people have heart attacks each year \u2014 and stenting is a mainstay treatment in virtually every hospital.\nMore than 500,000 heart patients worldwide have stents inserted each year to relieve chest pain, according to the researchers.\nSometimes patients get stents when they have no pain at all, just blockages.\nThe devices are lifesaving when used to open arteries in patients in the throes of a heart attack.\nA procedure used to relieve chest pain in hundreds of thousands of heart patients each year is useless for many of them, researchers reported on Wednesday.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Stenting procedures are clearly widely available in the U.S. and across the world. What\u2019s less clear, the story says, is whether guidelines or practice for stenting will change in the U.S.: \u201cThe idea that stenting relieves chest pain is so ingrained that some experts said they expect most doctors will continue with stenting, reasoning that the new research is just one study.\u201d We thought this was an interesting point and are glad it was included.", "answer": 1}, {"article": "In 2015, he was ranked the No.\nAmong elder women, the American Cancer Society and the United States Preventive Services Task Force recommend regular mammography for ages 65 to 74.\nAlthough a number of randomized trials demonstrate the clear benefits of mammography screening in women up to age 74 on reducing mortality, data are sparse in women over the age of 74, especially minorities.\nIn a new study published in the American Journal of Medicine, Charles H. Hennekens, M.D., senior author and first Sir Richard Doll Professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University, indicates that black and white women ages 75 to 84 years who had an annual mammogram had lower 10-year breast cancer mortality than corresponding women who had biennial or no/irregular mammograms.\nThe researchers selected 69 as the lower age limit because Medicare coverage of the general population begins at age 65, and the exposure of interest was regular mammography screening in the four years immediately preceding breast cancer diagnosis.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that mammograms are widely available. However, most current guidelines cap recommended annual or biannual mammograms at age 74. These recommendations have a direct effect on Medicare and private insurance coverage.", "answer": 1}, {"article": "During a salvage radical prostatectomy, the prostate gland and surrounding tissue are surgically removed to keep the cancer from spreading.\n\"However, this study shows that it is a viable treatment option.\n\"By studying a national database of prostate cancer cases, we found that a procedure known as salvage radical prostatectomy can greatly increase a man's chance of survival when traditional radiation therapy has failed to eradicate the cancer.\"\n\"Prostate cancer, unfortunately, is a common cancer, and more than 27,000 men are estimated to have died from the disease in 2015,\" said Naveen Pokala, M.D., an assistant professor in the Division of Urology at the MU School of Medicine and lead author of the study.\nNow, a University of Missouri School of Medicine researcher has found that a complex procedure to remove the prostate achieves excellent long-term survival for men after radiation therapy has failed.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Data analyzed in the release relates to surgeries performed between 1988 and 2010 at many different institutions so we assume it is widely available.", "answer": 2}, {"article": "\"The new study is the first to establish a direct relationship between fish consumption, brain structure, and Alzheimer's risk,\" Raji says.\nSeveral studies have linked a diet rich in certain fish to a reduced risk of Alzheimer's disease.\nRaji presented the findings here at the annual meeting of the Radiological Society of North America.\nThis benefit is thought to come from the omega-3 fatty acids in fish, although studies of fish oil supplements have produced disappointing results in people who already have Alzheimer's.\nNov. 30, 2011 (Chicago) -- Older people who eat baked or broiled fish at least once a week may be boosting their brain health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish is not in question.\n ", "answer": 2}, {"article": "\"One day I turn to my wife and I'm like, 'I feel calm today.\nBut ketamine's story took a surprising turn in 2006, when researchers at the National Institutes of Health showed that an intravenous dose could relieve severe depression in a matter of hours.\nThe fear was \"overwhelming,\" he says.\nAnd that could explain why patients like James usually stop overheating once they are taking ketamine.\nAnd almost from the time it reached the market it has also been used as a mind-bending party drug.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story highlights a patient using a ketamine nasal spray without making it clear that this form of the drug has not been approved by the FDA.", "answer": 0}, {"article": "With knee-replacement surgery on the rise, more patients with two bad knees are opting for a controversial procedure that replaces both at the same time.\n\nSimultaneous bilateral knee replacement, as the surgery is known, is a subject of debate among orthopedic surgeons, with conflicting evidence about the risks and benefits. Proponents say it eliminates the need for a second hospital stay and grueling rehabilitation period, reduces time spent under anesthesia and costs less.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It was made clear that both bilateral and staged knee replacement surgeries are fairly common and widely available. Similarly, it was made clear that some surgeons refuse to perform bilateral surgeries, or will only perform them for patients that meet fairly stringent criteria.", "answer": 1}, {"article": "\"At the end of the day, our findings might modestly over - or under-estimate the health burdens,\" he told us.\nBut, here's the flip side: The researchers also found there's a significant risk in eating too little of certain healthy foods.\nOne challenge: People who have healthy diets often have other healthy habits, too \u2014 such as getting regular exercise.\nNow, the task of estimating death or disease linked to diet is tricky.\nAnd eating more \u2014 or less \u2014 of just 10 types of food can help raise or lower the risk of death from these causes, the researchers found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of the foods discussed in the story is not an issue, which is why we\u2019ll rate this Not Applicable. However, the fact that so many \u201cbad for you\u201d foods are so much more readily available today than they used to be is something the story could have touched on. In addition, such foods are often cheaper\u00a0than more healthy alternatives in many communities.", "answer": 2}, {"article": "But plasma insulin response was sharply lower in fructose drinkers, which may affect what we eat, according to the senior author, Dr. Kathleen A.\nPage said.\n\u201cDon\u2019t stop eating fruit.\n\u201cNo,\u201d Dr.\nThe volunteers drank a 10-ounce glass of cherry-flavored liquid that contained two and a half ounces of fructose or glucose.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not relevant to this story.", "answer": 2}, {"article": "Happiness won\u2019t help you live longer (but unhappiness won\u2019t kill you either)\n\nGuinea is finally declared Ebola-free, but that does not mean the crisis is over\n\nMost popular Washington Post health stories of 2015: A mother tells her story of how she lost her darling daughter a few weeks short of her 29th birthday when she stepped in front of a train in Baltimore.\nBut some doctors and researchers were puzzled by the fact that in head-to-head comparisons between the two classes of drugs they appeared to equally safe and effective.\nNow a large new analysis involving 250,000 patients shows that these medications may be as effective and safe as their older cousins, the angiotensin converting enzyme, or ACE inhibitors.\nThe other piece of good news regarding the medications is that ACE inhibitors, as well as many ARBs, are now generic -- meaning that the cost difference is minimal.\nThat led many doctors and standards groups to conclude that ACE inhibitors were more effective than ARBs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does point out that ACE inhibitor drugs have been available for decades and that ARBs have been available since the year 2000.", "answer": 1}, {"article": "U.S. doctors do at least two stenting procedures these days for every coronary bypass operation.\nNow the biggest collection of cases so far comes out in favor of surgery on the all-important question of mortality.\nBut Dr. Laura Mauri says in an accompanying editorial that the new study can't settle any debates.\nPut another way, 21 percent of stented patients had died after four years compared with 16 percent of surgery patients.\nThe National Heart, Lung and Blood Institute, which funded the study with new \"stimulus\" money from the American Recovery and Reinvestment Act, is more bullish on the implications.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Unlike the Wall Street Journal story and the Associated Press story we reviewed, this story at least mentioned the fact that more people have been opting for stents instead of bypass surgery.", "answer": 1}, {"article": "Not so long ago, in 2000, the American Academy of Pediatrics recommended that allergenic foods be kept away from infants until they were at least a year old, and often older.\nThis is relatively new thinking.\nThat warning was especially strong for those with a family history of allergies.\nEarly introduction didn\u2019t seem to make a difference for autoimmune diseases, at least according to the available evidence; eating gluten young wasn\u2019t associated with the risk of developing celiac disease.\nExactly why is a question researchers are still exploring.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The food items are widely available.", "answer": 2}, {"article": "Guyuron, chair of plastic surgery at University Hospitals Case Medical Center in Cleveland, went on to identify four common \"trigger sites\" and publish studies showing that, in selected patients, surgical decompression of nerves in one or more of these sites provides lasting migraine relief. He has also taught 250 plastic surgeons around the world (none in the Philadelphia area) to perform the outpatient operation, which costs an average of $10,000 and is not covered by many insurers.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does make it clear that this is an experimental approach and that the surgeon in question may be one of the few practicing this technique \u2013 although he claims to have trained 250 surgeons around the world. .", "answer": 1}, {"article": "Hernias occur when part of an internal organ, such as the intestines, bulges out through muscle.\nThe study authors didn't examine a third approach, known as \"patch and plug,\" he said.\nIt was developed in the 1990s, Brunt said.\nThe findings appear in the March issue of the Archives of Surgery.\nAlmost all the patients were men, and their average age was around 55.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both approaches seem to be widely available, so the fact that the story didn\u2019t discuss this shouldn\u2019t be held against it. We\u2019ll rule it not applicable.", "answer": 2}, {"article": "\"When people have serious injuries, whether from accidents or violence, and when they have severe hemorrhage they can bleed to death.\nIn fact, a trial to see whether TXA can reduce postpartum bleeding has started, the team noted.\nThe drug, tranexamic acid (TXA) is cheap, widely available around the world and easily administered, experts said.\nThe researchers believe that TXA could have even wider uses, such as reducing brain bleeds after brain injury.\nCurrently, TXA is not generally used in emergency rooms to treat trauma patients, but Roberts believes that this study could change that.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that TXA is widely available around the world and easily administered.", "answer": 1}, {"article": "Radiation oncologist Dr. Richard Stock, of Mt.\nIt's the most expensive device in medicine today.\nThe technology is two decades old, but Mass.\n\"With four treatments left, I have 98 percent of my vision left,\" Rianta said.\nJust weeks later, Rianta was getting the therapy and the tumor was shrinking.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story describes the limited availability of proton beam therapy.", "answer": 1}, {"article": "The drugs, which include Depakote, Lamictal, Topamax, Keppra, Lyrica and Neurontin, are sometimes prescribed for chronic pain and headaches, as well.\nDrugs for epilepsy, bipolar illness and mood problems double the risks of suicidal thoughts and behavior, and patients taking them should be watched for sudden behavioral changes, drug regulators have said.\nDoctors said Thursday that the increased risk did not outweigh the benefits of the drugs.\nThe increased risks, while double in relative terms, are small.\nThese medications are primarily used to help epileptics control seizures and to calm the surges in energy and mood that, along with bouts of depression, characterize bipolar disorder.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes some pharmacological treatments available for epilepsy.\u00a0 The story notes these same medications may also be used to treat chronic pain, mood disorders and headaches. The risks of suicidality are not as great in non-epileptics. ", "answer": 1}, {"article": "This signal is passed to a computer that decodes it, and the resulting instruction is then sent to a sleeve he wears on his forearm that stimulates the muscles that move his wrist and fingers.\nThat's why the device requires training every time Burkhart uses it.\nThere are still many challenges to be overcome to bring this work out of the lab and into the lives of the millions of people who are paralysed.\nFor starters, the device that records the brain signals will need to be much smaller so it's fully implanted under the paralysed person's skin.\nOur understanding of how brain signals change will also be crucial to making this technology usable on a large scale.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that this device is in laboratory testing. The comments from independent sources at the very end of the story help describe the long and uncertain road ahead for researchers.", "answer": 1}, {"article": "Seventeen percent were having moderate to severe vasomotor symptoms, and 18 percent reported moderate to severe sexual symptoms.\nThere is also, she said, a complete lack of understanding that for most women, these symptoms are not fleeting.\n\u201cWomen and doctors simply are not aware that symptoms can last this long.\u201d\n\nFinally, many women don\u2019t realize that non hormonal options can be safe and effective, she added.\nDr. Wulf H. Utian, medical director of the North American Menopause Society, agrees that many reasons may underlie the lack of treatment.\nThe findings may be applicable to other countries, too, according to senior author Dr. Susan R. Davis from Monash University in Melbourne.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story establishes that all of the treatments discussed \u2014 hormone pills, estrogen creams, and non-hormonal treatments \u2014 are available.", "answer": 1}, {"article": "FcMBL binds to pathogens and pathogen-released fragments, known as Pathogen-Associated Molecular Patterns (PAMPs) by recognizing carbohydrate molecules on their surface.\nNow, a Wyss Institute team led by Donald Ingber reports in eBioMedicine that it has filled this void with a rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.\n\"This assay could become a real game changer in this clinical area, and it also should lead to more judicious use of antibiotics, helping to decrease the worrisome rise we are seeing in antibiotic-resistant organisms.\"\nAs a prerequisite to their clinical study, the Wyss Institute's team had successfully tested the assay in rat and pig models of infection with pathogenic E. coli bacteria.\nTogether, the findings suggest that the FcMBL-based pathogen detection technology with its rapid handling time, high sensitivity and broad specificity towards infection-causing pathogens could provide a real-world advance to diagnose life-threatening infections in both clinical microbiology laboratories and point-of-care settings.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release gets a pass here but just barely. Unless you\u2019re reading carefully you might think the test is already ready for prime-time. Instead, a researcher notes that \u201cWe are currently working to ready it for for high-throughput use in clinical and point of care situations and to accelerate it even further.\u201d", "answer": 1}, {"article": "Jamie Stagl worries that women with breast cancer don\u2019t get enough help coping with their diagnosis.\nWomen may be particularly receptive to these approaches when they\u2019re coping with a cancer diagnosis, said Laura S. Porter, an associate professor at Duke University Medical Center.\nSo Stagl, now a clinical fellow at Massachusetts General Hospital, helped study a University of Miami program that taught 240 breast-cancer patients relaxation techniques and coping strategies.\nStagl doesn\u2019t know whether the women are still using the techniques they were taught \u2014 which include mindfulness, deep breathing, visual imagery, cognitive behavioral therapy, and learning how to ask for help from friends and family.\nAnd researchers want to know whether relaxation actually reduces the recurrence of breast cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Many breast cancer treatment providers can offer patients information about programs to help patients deal with stress, anxiety, and other depressive symptoms associated with a cancer diagnosis. However, the story does not make clear how widely available such programs are, and how much existing programs resemble the study intervention.", "answer": 0}, {"article": "Ductal breast cancer is the most common type of breast cancer and forms in the milk ducts.\nThe use of fish oil was linked to lower risk of invasive ductal breast cancer.\nMany people currently take fish oil supplements to decrease their risk for heart disease.\nOther supplements were not linked to breast cancer risk in the new study, including black cohosh, dong quai, soy, and St. John's wort, which are often taken to relieve some of the symptoms of menopause.\nExactly how fish oil may affect breast cancer risk is not fully understood, but it may be related to its strong anti-inflammatory properties.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish oil supplements is not in question.", "answer": 2}, {"article": "\"If the question were just, 'Does egg freezing and thawing work to achieve a pregnancy?'\nAnd yet, even Widra agrees that egg freezing has appeal if it can help avoid the anguish of infertility.\nThe bigger challenge, Sher and others say, is reaching out to younger women \u2014 getting them to take action before it's too late.\nNow, technology is dangling the possibility that women can stop that clock, at least for a while.\nStill, he says, freezing eggs offers many women the biggest game changer since the birth control pill 50 years ago.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story barely meets this requirement. It describes the procedure as something gaining acceptance, but still \u201cexperimental.\u201d What isn\u2019t emphasized is that this is not offered by many centers that can freeze ooccytes and far from all infertility programs have successful protocols in place.", "answer": 1}, {"article": "But \"that trial is never getting done, nor should it be done,\" Golden said.\nThe findings come as the American Academy of Pediatrics debates updating its recommendations regarding circumcision among newborns.\nNot so, write the Australian researchers, who examined eight studies for a review in the latest issue of the Annals of Family Medicine.\nShe said that circumcision poses problems from a mental point of view, potentially causing \"significant anger or feeling incomplete, hurt, frustrated, abnormal or violated.\"\nParents who think circumcision has medical benefits should be aware that there's \"a lack of consensus and robust evidence\" on that, she added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 2}, {"article": "(image: transmission electron micrograph of Zika virus, NIAID)\n\n\"If we could find a way to specifically target those GSCs that are the source of recurrence, then that might provide an option to prevent recurrence or even a cure,\" says Qin.\nIn addition, the Zika virus was much less efficient at attacking the differentiated, healthy brain cells.\nIn a study published this week in mBio\u00ae, an open-access journal of the American Society for Microbiology, the team shows that a live, attenuated version of the Zika virus could form the basis of a new treatment option for this fatal brain cancer.\nNext, the team will work with clinicians to develop safety tests of the ZIKV-LAV in glioblastoma patients.\nComparing those profiles, the team found that in the treated cells, the virus triggered a strong antiviral response in the cells, which induced inflammation and eventually cell death.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear this treatment isn\u2019t yet available for use in humans. The release could have put the findings into clearer perspective if it noted that availability for human use is years in the future, if ever.", "answer": 2}, {"article": "In 2016, breast cancer accounted for 29 percent of all new cancers identified in the United States and was responsible for 14 percent of all cancer-related deaths.\nThe researchers were able to isolate relevant data to more accurately identify breast cancer biomarkers using two different electronic nose gas sensors for breath, along with gas-chromatography mass spectrometry (GC-MS) to quantify substances found in urine.\n\"Our new approach utilizing urine and exhaled breath samples, analyzed with inexpensive, commercially available processes, is non-invasive, accessible and may be easily implemented in a variety of settings.\"\nThe study reports breast cancer is the most commonly diagnosed malignancy among females and the leading cause of death around the world.\n\"We've now shown that inexpensive, commercial electronic noses are sufficient for classifying cancer patients at early stages,\" says Prof. Zeiri.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release quotes the lead author claiming: \u201cWe\u2019ve now shown that inexpensive, commercial electronic noses are sufficient for classifying cancer patients at early stages.\u201d This implies that such \u201cnoses\u201d are already commercially available for breast cancer detection but we\u2019re not told where they are available and how frequently they\u2019re used.", "answer": 0}, {"article": "Women are considered obese at a BMI of 30 and morbidly obese at 40 (which is typically about 100 pounds over a woman's ideal body weight), yet almost a third of women presenting for bariatric surgery did not identify themselves as obese.\nThe study speaks both to the benefits of bariatric surgery and to the tremendous toll obesity takes on health.\nThe study looked at the effects of bariatric surgery in a relatively short timeframe, one to three years after surgery.\nWhile the study speaks to the transformative effect bariatric surgery can have, Modesitt urged people to avoid gaining weight in the first place and for those seeking to lose weight to exercise and eat more healthily before turning to surgery.\nModesitt, of the UVA's Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology, was most surprised by the dramatic changes seen in the patients' metabolic profiles derived from the gut microbiome, the population of microorganisms living inside us.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the release that the participants underwent a standard bariatric surgery and that these procedures are available. The release could have specified the criteria used to determine who is eligible for such procedures and whether insurance will cover it.", "answer": 1}, {"article": "Researchers from Norway and Harvard University compared the death rates from breast cancer in four groups: one group of women from 1996 through 2005 who were living in Norwegian counties with screening; another group in the same time period who were living in counties without screening; and two similar groups from 1986 through 1995.\nIt concluded the availability of mammography screening corresponded with a reduction in the rate of death from breast cancer, \"but the screening itself accounted for only about a third of the total reduction.\"\n\"Among women in the nonscreening group, there was an 18 percent reduction in the rate of death from breast cancer, as compared with the preceding 10-year period, presumably as a result of increased breast-cancer awareness, improved therapy, and the use of more sensitive diagnostic tools,\" the findings state.\nThe publication notes that in 2002, the World Health Organization concluded that mammography screening for women between ages 50 and 69 reduced the death rate from breast cancer by 25 percent.\nThe study, published in the New England Journal of Medicine, analyzed data from more than 40,000 women with breast cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Sorry. The page you requested is not available", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that the drug is currently on the market and approved for other uses. But it did not state whether Rituxan is, or may become, used off-label for relapsing-remitting MS. And, as noted in our summary comment below, there are issues surrounding off-label use that could have been addressed.", "answer": 0}, {"article": "\"There's no magic in a liter-and-a-half,\" he said.\nWhether the advice would benefit women with normal urine output, however, is unclear, Wessells noted.\nTheir total daily fluid intake, including water and other beverages, averaged nearly 12 cups.\nHalf of the women in the study were asked to consume 1.5 liters of water, or about 6 cups, each day in addition to their usual daily fluid intake.\nDr. Susan Bleasdale, medical director of infection control at the University of Illinois at Chicago, said the study \"may be a game changer\" for antibiotic \"stewardship\" programs aimed at reducing inappropriate antibiotic use.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "For most people in the U.S, water is easily available.", "answer": 2}, {"article": "METs, or metabolic equivalents, are a measure of physiological measure expressing the energy cost of physical activities.\nDr Hupin emphasised that the widespread acceptance of this message would encourage more elderly people to include even \"low doses\" of physical activity in their usual daily activities, without experiencing high levels of fatigue or of pain.\nThese differences in risk were statistically significant.\nThere were other significant findings too - notably that starting or restarting physical activity during retirement reduced the risk of death by two-thirds, but in contrast any reduction, even in low levels of activity, exposed the elderly to a higher risk of death.\nBased on the results, Dr Hupin said that a revision of the recommendations for physical activity in the elderly may thus be warranted and beneficial - low dose physical activity can significantly reduce mortality.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It isn\u2019t a big deal that the news release didn\u2019t discuss the availability of exercise methods, since the elderly can pursue any physical activity for at least 15 minutes a day, five days a week. But we\u2019d note that access to some of the activities mentioned (cycling, swimming, gymnastics) might be limited, and the release could have noted that as well.", "answer": 2}, {"article": "\"We don't yet have a full understanding--nobody does--of how the bile acid actually does what it does in heart cells,\" explains Michalak.\nThe study discovered the specific triggers activating the development of fibrosis which accelerates heart failure.\nThey also aim to gain a better understanding of exactly how bile acids can prevent cardiac fibrosis from occurring.\nThe team is now pushing forward with additional studies to see if the same therapeutic effect can be achieved in humans.\nCurrently patients with heart failure have poor quality of life and a dismal prognosis.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is silent on the availability of\u00a0TUDCA, the bile salt used in the study. As noted above, it is available commercially as a supplement. However, due to the pre-clinical nature of the research it is premature and ill-advised to rely on TUDCA for cardiac fibrosis prevention.", "answer": 0}, {"article": "Reavill says he may be proudest of his intention to hire disabled veterans in southern Illinois, a hard-hit region economically.\nBut because it's self-contained, the catheter theoretically should provide little margin for contamination that can lead to infection.\nHe recently procured a bank loan agreement and is hoping the award recognition and hospitals' willingness to try the catheter will attract a venture capitalist.\nIt remains to be seen whether that saved time will result in saved lives.\nCalled the ReavillMED CV, the Food and Drug Administration-cleared device includes a catheter called a PICC line, IV tubing that sheathes it to provide sterility, and a transducer that can directly measure blood pressure to help determine needed fluid levels.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not clearly explained.\u00a0 Is anyone using this catheter clinically right now?", "answer": 0}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Because this is an announcement from the FDA about approval, the drug will now be marketed for treatment, and the story clearly indicates that the drug combination is distributed by Genentech.\nWe\u2019ll rule this Satisfactory, but we\u2019d caution that\u00a0FDA approval does not necessarily equal availability. The key factor here is the cost and who will pay for it, or not. The story doesn\u2019t address this.", "answer": 1}, {"article": "\u201cIt\u2019s a promising result from an interesting data set,\u201d he said.\nThe program is now incorporated in Posit Science\u2019s BrainHQ.com brain training program.\nThe new analysis was by Dr. Jerri Edwards of the University of South Florida, whose mentor, Dr. Karlene Ball of the University of Alabama at Birmingham, sold her rights to the program to Posit Science.\nThe letter was in response to heavy marketing by companies touting the benefits of their programs based on scant scientific data.\nThe study, known as Active, examined the effects of cognitive training programs on 2,785 healthy older adults.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "According to the article, there already exist companies such as Posit Science who offer these so-called brain games.", "answer": 1}, {"article": "\"They have a lot of promise and are potentially very important,\" said Katherine Hamilton, a headache specialist at Penn Medicine. The drugs, which are injected under the skin, offer hope for patients who have not responded to other treatments, but Hamilton said that what is \"potentially even more clinically relevant is they have a lower side-effect profile\" than other medications commonly used for migraine. She added, though, that it remains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reported that all three drugs have been approved for sale by the FDA and a fourth \u2014 which isn\u2019t named \u2014 is in development.", "answer": 1}, {"article": "Guadecitabine is an experimental drug that has not been approved for use by the U.S. Food and Drug Administration.\nThe drug combination is being tested in an ongoing phase II clinical trial (NCT01896856) in a larger group of metastatic colorectal cancer patients at multiple institutions to determine the effectiveness of the dual therapy compared with chemotherapy regimens that do not include guadecitabine, says Azad.\nAlthough the study's main purpose was to test the safety rather than the effectiveness of guadecitabine doses, \"we were very happy to see some patients who benefited from the combination of the therapies for many months to more than a year,\" says Nilofer Azad, M.D., professor of oncology at the Johns Hopkins University School of Medicine.\nThe current study was based on previous studies in the laboratory of Nita Ahuja, M.D., director of the Sarcoma and Peritoneal Surface Malignancy Program and professor of surgery at the Johns Hopkins University School of Medicine, which showed that guadecitabine limited the growth of colorectal cancer cell lines when combined with irinotecan, says Azad.\n\"We did see that giving a higher dose of the drug seemed to produce a better methylation response among patients,\" says Valerie Lee, M.D., a fellow at the Johns Hopkins Kimmel Cancer Center.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that this was a preliminary trial and that a phase II trial is ongoing. That\u2019s good. In addition, the release states: \u201cGuadecitabine is an experimental drug that has not been approved for use by the U.S. Food and Drug Administration.\u201d That\u2019s great. We wish all releases were this straight-forward about drug/treatment availability.", "answer": 1}, {"article": "This, too, is suggested by sense and common experience, as it is affirmed by the science reported here,\" Katz said.\nThose in the second phase of the trial continued their diet and exercise program.\nLower stress by itself predicted more weight loss during the first phase of the trial, they added.\nThese factors may also have a biological impact, he added.\nThe report, funded by the U.S. National Institutes of Health, is published in the March 29 online edition of the International Journal of Obesity.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.", "answer": 2}, {"article": "In a transvaginal ultrasound (TVU), sound waves emitted from a probe placed in vagina help a physician check if Essure has been placed properly.\nAll physicians who offer Essure are expected to be trained to perform the TVU confirmation test by mid-2016, the company said.\nBut since its approval in 2002, women using the device have sent the FDA more than 5,000 complaints, ranging from pain and menstrual problems to pregnancies and even deaths.\nSome of the complaints related to the placement of the device.\nThe training will start in September, the same month the FDA will hold a public panel meeting to discuss the safety and effectiveness of Essure.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "TVU is an established imaging technique and procedure, carried out by both ob-gyns and by radiologists (and in some cases ultrasound technicians). The requirement for additional training and certification is a bit curious. But since one can gather from the story that the procedure is widely available, we\u2019ll award a Satisfactory rating here.", "answer": 1}, {"article": "General.\nWhile the results, from only nine patients, must be replicated in a larger study, said Dr. Joseph Bellanti of Georgetown University Medical Center, \u201cif what they found is true, they really have something here.\u201d Bellanti, who was not involved in the research, said the study\u2019s eight-year follow-up and use of a placebo control arm made him \u201ccautiously optimistic\u201d that two doses of the BCG vaccine \u201ccan decrease levels of A1c,\u201d a measure of blood glucose that predicts the likelihood of serious complications such as stroke and kidney failure.\nThe new paper describes how the BCG vaccine, which has been used for nearly 100 years against tuberculosis and is considered extremely safe, might affect diabetes.\n\u201cThe clinical effects and the proposed mechanism demonstrated are exciting and add to the emerging consensus that the BCG vaccine can have a lasting and valuable impact on the immune system,\u201d said Dr. Mihai Netea of Radboud University Medical Center in the Netherlands, who was not involved in the study.\nAfter the vaccine showed signs of effectiveness, an additional six patients were vaccinated five years ago, and 111 more recently.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not explicitly address the issue of when, if ever, patients might have access to the BCG vaccine as a treatment for Type 1 diabetes. However, it does state that the treatment is being tested in a Phase 2 clinical trial involving 150 patients with Type 1 diabetes. The story also notes that one barrier to further development of BCG as a diabetes treatment is that it would appear to have little commercial value, meaning that drug manufacturers aren\u2019t interested in it.", "answer": 1}, {"article": "Asthma patients suffer fewer attacks and need fewer hospital visits.\nThe one-time cost of $20,000, they say, is dwarfed by the tens of thousands of dollars in hospital bills and medication costs that a severe asthmatic can easily accumulate in a single year.\nBut the procedure is expensive, costing around $20,000, and insurers have been reluctant to cover it.\nAs a result, many people who need it, doctors say, are forced to go without it.\nEvery year, about 3,400 die because of it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story states that about 650 people have been treated, and although it discusses lack of insurance coverage, it never explicitly explains how widespread is its availability.\u00a0 Do only high-tech teaching hospitals provide it?", "answer": 0}, {"article": "But this study doesn't tell us about long-term outcomes or what transpired over a long period of time,\" he said.\nClearly, the earlier a breast cancer is diagnosed, the less treatment that will be required.\nAnd the women who were screened earlier had smaller tumors.\nBut only 29 women fell into the \"never had a mammogram\" group.\nPort noted that screening guidelines tend to be based on the ability of mammograms to save lives and how often they give a false positive result.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We believe that mammograms are well-known to be widely available. And the earlier and more frequent screening described here is not earlier or more frequent than what many guidelines recommend, so would not be expected to be denied by health insurers.", "answer": 1}, {"article": "\"We were very intrigued by the higher lean mass, the possibility that vitamin D can help infants to not only grow healthy skeletons but also healthy amounts of muscle and less fat,\" said Hope Weiler, one of the study's authors and Director of the Mary Emily Clinical Nutrition Research Unit at McGill University.\nThe new study confirmed the importance for the development of strong bones of a vitamin D supplement of 400 IU/day during a baby's first year.\nThis amount is in line with current Canadian health guidelines.\nThe researchers achieved this by following up on a 2013 study in which 132 infants in Montr\u00e9al, Qu\u00e9bec, were given a vitamin D3 supplement at one of four different dosages between the ages of 1 month and 12 months.\nVitamin D supplementation is routinely recommended for babies until they can get an adequate amount through their diet.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that vitamin D supplementation is already widely recommended for infants.", "answer": 1}, {"article": "\n\u2022 Read this story at www.uab.edu/news\n\u2022 The UAB News Studio is available for live or taped interviews with UAB experts.\nThere are more than 30-plus new dry eye basic, translational and clinical studies being funded by the NEI/National Institutes of Health to further explore these lipids and proteins, with more than 50 papers being published monthly.\nNewswise \u2014 BIRMINGHAM, Ala. \u2013 The Food and Drug Administration recently approved lifitegrast, a new eye drop for treating signs and symptoms of dry eye in adult patients.\nKelly Nichols, O.D., Ph.D., a dry eye expert and dean of the University of Alabama at Birmingham School of Optometry, conducted research studies for the parent drug company to explore the efficacy and safety of lifitegrast in treating this eye condition that affects more than 16 million adults in the United States.\nSpecialty testing for dry eye is performed at the Dry Eye Relief Clinic at UAB Eye Care, in the School of Optometry.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Though the news release does not say anything about availability, it does note that the FDA has approved the product.\u00a0 The drug was approved July\u00a012, 2016.", "answer": 1}, {"article": "Multiple neurological disorders, including Parkinson\u2019s disease and dementia with Lewy bodies, involve the abnormal clumping of a protein called alpha-synuclein into brain deposits called Lewy bodies.\nImportantly, test results were available within two days, compared to related assays that require up to 13 days.\nByron Caughey, Ph.D., a senior investigator in NIAID\u2019s Laboratory of Persistent Viral Diseases, is available to comment on this study.\nThe NIAID group continues to adapt the RT-QuIC assay to detect additional types of neurological diseases with greater accuracy using the least invasive patient sample possible \u2014 whether that is blood, skin, nasal brushings, or other samples.\nThis research was supported in part by NIH funding awards ZIA AI001086-08, AGO5131, and PHS P30-AG010133.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The tentative wording of the lead \u2014 that the test could \u201coffer the possibility of improving early diagnosis\u201d \u2014 raises the question of what needs to happen for this test to become widely available. The release doesn\u2019t answer that question.\nNor does the study discuss improved diagnosis since that\u2019s not the intent of the test\u2019s development \u2014 it\u2019s research to determine who to include in trials and follow their disease progression.", "answer": 0}, {"article": "The average age of children in the study was 7.\nThe findings suggest that a sniff test could be quite useful in the clinic, although the researchers emphasize that their test is in no way ready for that yet.\nIt wasn't clear if this impairment would show up in a test of the sniff response, however.\nThey also want to find out how early in life such a test might be used.\n\"This raises the hope that these findings could form the base for development of a diagnostic tool that can be applied very early on, such as in toddlers only a few months old.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release not only makes clear that a sniff test is \u201cin no way ready\u201d for clinical use, but lays out several questions for relevant future research that needs to be done before such a clinical tool can be developed.", "answer": 1}, {"article": "Mice taking metformin in their drinking water had 34 percent fewer tumors than those not taking metformin.\nThis adds credence to the idea that metformin's value is in its ability to lower overall insulin levels in the body, Cantley said.\nAnd when the drug was administered by injection, the improvement seen was 73 percent.\nAt this point, no one knows if metformin is safe in non-diabetic populations but some clinical trials are starting to look at the issue, Lippman said.\n\"The evidence in diabetic humans is very convincing and very strong,\" added Dr. Phillip Dennis, a senior investigator with the U.S. National Cancer Institute and senior author on the lung cancer paper.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The current widespread use and availability of metformin is clear from the story", "answer": 1}, {"article": "Zinc lozenges appear to influence the common cold through the release of free zinc ions into the oro-pharyngeal region.\nThus, zinc doses of over 100 mg per day do not seem to provide any more benefit.\nAccording to Dr. Hemil\u00e4, there is no justification for the popular phrase that \"there is no cure for the common cold\" because of the strong evidence that zinc lozenges can shorten common cold duration by over 30%.\nHowever, in future studies the optimal composition of zinc lozenges should be investigated.\nNevertheless, he also considers that \"the current evidence of efficacy for zinc lozenges is so strong that common cold patients should be encouraged to try them for treating their colds, but the patients should ascertain that the lozenges do not contain citric acid or its salt citrate.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t talk about the availability of zinc lozenges, but given that a search on Amazon turns up hundreds of sources, and most grocery and drug stores stock zinc, that\u2019s not a significant omission.", "answer": 2}, {"article": "Please visit http://www.\nTo gage the effects of lifestyle habits, the researchers developed a score based on the results of the health professionals survey, then applied it to the physicians' study.\n\"This study underscores the ongoing need for more effective prevention measures and policies to increase exercise, improve diet quality and reduce tobacco use in our population,\" said senior author June M. Chan, ScD, from the departments of Urology, and Epidemiology and Biostatistics at UCSF.\n\"We estimated that 47 percent of lethal prostate cancer cases would be prevented in the United States if men over 60 had five or more of these healthy habits,\" said Kenfield, assistant professor in the Department of Urology at UCSF Medical Center, and formerly of the Department of Medicine at Harvard Medical School in Boston, where the study was initiated.\nIn the study, published today, Nov. 17, 2015, in the Journal of the National Cancer Institute, the researchers analyzed data from two U.S. studies: the Health Professionals Follow-Up Study that tracked more than 42,000 males ages 40 to 75, from 1986 to 2010; and a second, the Physicians' Health Study that followed more than 20,000 males ages 40 to 84, from 1982 to 2010.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The study was limited to a relatively high level income group and the interventions may not be attainable for all men, in all socioeconomic groups. Does partaking of vigorous physical exercise on a regular basis require access to a gym or just a high degree of motivation? Are tomatoes and fish attainable year round for all socioeconomic groups? The study addresses this to some extent when it says, \u201cIt takes co-operation and effort from multiple areas, like insurance companies, employers, policy makers and city planners, to figure out how to creatively support and encourage more exercise into most busy adults\u2019 working day.\u201d We\u2019ll award a Satisfactory here.", "answer": 1}, {"article": "\"This is the holy grail,\" says Suresh S. Ramalingam, MD, associate professor and director of the lung program at Emory University's Winship Cancer Institute in Atlanta.\nBut that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.\nHe was not involved in the research.\n\"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers,\" says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors.\nAug. 17, 2011 -- German researchers say that highly trained dogs are able to reliably sniff out lung cancer in human breath.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that this very preliminary research procedure with dogs is not available yet.", "answer": 1}, {"article": "In 2012, the Food and Drug Administration updated labeling on statins to include warnings about confusion and memory loss, elevated blood sugar leading to Type 2 diabetes, and muscle weakness.\nLimiting factors should be a patient's own preference about taking a daily pill, price and the risk of diabetes, they said.\nOne of the recommendations was that statins should be prescribed to anyone with a 7.5 percent risk or higher of developing heart disease over the next 10 years.\nBut even with those risks, it\u2019s worthwhile, Gaziano\u2019s team found.\nThere\u2019s an online tool that people or their doctors can use to calculate their risk of heart disease, which is based on age, sex, blood pressure and cholesterol levels.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that statins are widely available. They are also paid for by insurance plans.", "answer": 1}, {"article": "The volumetric impedance phase shift spectroscopy (VIPS) device (Cerebrotech VisorTM, Cerebrotech Medical Systems, Pleasanton, CA) works by sending low-energy radio waves through the brain that change frequency when passing through fluids.\nThe researchers hope that the device will save valuable time -- especially important in stroke where time is brain -- when it is deployed with emergency medical personnel in the field.\nThis study was funded by Cerebrotech Medical Systems.\n\"If we can give the information to emergency personnel out in the field that this is a large-vessel occlusion, that should change their thought process in triage as to which hospital they go to.\"\nThe neuroimaging data was needed to teach the VIPS device which radio waves were indicative of stroke.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We learn that this is very preliminary research and that the researchers will do another study to \u201cdetermine if the VIPS device can use complex machine learning algorithms to teach itself how to discriminate between minor and severe stroke without the help of neurologists.\u201d", "answer": 1}, {"article": "The main campus also includes University Hospitals Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; University Hospitals MacDonald Women's Hospital, Ohio's only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center.\nThe majority of women taking either TX004HR or placebo (85.4 - 92.1 percent) found the product easy to use.\n\"We still have to find better ways to educate the millions of women suffering with VVA about the symptoms, however, so that more of them know it is common, decide to discuss treatment with their healthcare professional, and seek symptom relief with appropriate treatment.\"\nPrevious survey research completed by Dr. Kingsberg and others has shown that while 32 million women may be experiencing symptomatic VVA and suffering from related impacts on sexual function, interpersonal relationships, self-esteem and overall quality of life, only 7 percent are currently using a prescription therapy to alleviate symptoms.\nThe new results were part of a multi-center randomized, placebo-controlled phase 3 clinical trial for TX004HR, an investigational bio-identical 17\u03b2-estradiol applicator free vaginal softgel capsule.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release says nothing about when these softgels might be available.", "answer": 0}, {"article": "A diet that includes tomatoes could lower the chance of having a stroke.\n\nA new study shows that men who had the highest levels of lycopene\u2014an antioxidant found in tomatoes\u2014had fewer strokes than men who had the lowest level of lycopene in their blood. Overall, the risk of strokes was reduced by 55%.\n\nThe study, based in Finland, will be published...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of tomatoes is not in question.", "answer": 2}, {"article": "[4] Quotes direct from author and cannot be found in text of Article.\nThe resource has been open to bona fide health researchers for 18 months.\nWe hope that our score might eventually enable doctors to quickly and easily identify their highest risk patients, although more research will be needed to determine whether it can be used in this way in a clinical setting.\n\"This is the first study of its kind which is based on a very large study sample, and is not limited to specific populations, single types of risk, or requiring laboratory testing.\"\nThey used a statistical survival model to assess the probability that 655 specific demographic, lifestyle, and health measurements could predict death from any cause and six specific causes, in men and women separately.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Notes at the end of the news release speak to the availability of the interactive \u201cUbble\u201d website once the research article is published. We could not access the calculator, perhaps due to high traffic levels accompanying the rollout.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly, oophorectomy, surgical removal of the ovaries, is available.", "answer": 1}, {"article": "BRCA mutations cause about 5 to 10 percent of breast cancers and 10 to 15 percent of ovarian cancers among white women in the United States.\n\u201cProphylactic removal of ovaries and fallopian tubes is strongly recommended in women before age 40 in BRCA1 and BRCA2 mutation carriers,\u201d said Dr. Susan Domchek, executive director of the University of Pennsylvania\u2019s Basser Research Center, which specializes in BRCA mutations.\nCancer experts said Tuesday that the actress and filmmaker Angelina Jolie Pitt was wise to have had her ovaries and fallopian tubes removed last week because she carries a genetic mutation, BRCA1, that significantly increases the risk of ovarian cancer, a disease so difficult to detect that it is often found only at an advanced, untreatable stage.\nIt is unclear how common the mutations are in other racial and ethnic groups.\nThey also said Ms. Jolie Pitt\u2019s decision to discuss her own choices so frankly will encourage women in similar situations to consider their own options.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The comments of Drs. Domchek, Offit, and Bakkum-Gamez make it clear that the surgical procedure is widely available.", "answer": 1}, {"article": "Vaginal and vulvar cancers are usually caused by the human papillomavirus, which also causes cervical cancer.\nBut raloxifene's edge in blood-clot and uterine-cancer avoidance was not statistically significant, and tamoxifen proved better at reducing the rate of noninvasive breast cancer.\nRaloxifene, sold by Eli Lilly & Company under the name Evista, is now approved only to prevent bone-thinning.\nThe breast cancer trial, the Study of Tamoxifen and Raloxifene, or STAR, has been a focus of intense debate.\nThe new data are not likely to settle the debate about which drug is better.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that both tamoxifen and raloxifene are currently available, and notes the conditions for which they are approved.", "answer": 1}, {"article": "Melanie Ashton continued, \"We found that people who had a better-quality diet, a diet with anti-inflammatory properties, or a lower BMI, showed better response to add-on nutraceutical treatment than did those who reported a low-quality diet, or a diet including foods that promote inflammation, or who were overweight.\nNow a group of Australian, German and American scientists have shown those who have a high quality diet, a less inflammatory diet, and/or a low BMI (Body Mass Index) may respond better to an add-on nutraceutical treatment provided as part of a clinical trial.\nWhile current medications are useful, they are better at targeting mania symptoms (the 'up' phase), leaving a lack of effective treatment for people experiencing depressive episodes.\nThese are early results, but if replicated may mean that treatment of some mental health problems could benefit from the inclusion of dietary advice.\nThe fact that there are two opposite sets of symptoms means that finding an effective treatment is difficult.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release suggests \u201cnutraceuticals,\u201d including the\u00a0anti-inflammatory amino acid n-acetylcysteine (NAC) are potentially helpful. NAC is widely available in both prescription and over-the-counter formulations.", "answer": 1}, {"article": "\"We're trying to make it simpler, but we don't want to lose the efficacy,\" he said.\nBredesen said that his team has a couple of larger trials planned to confirm or refute the results in the current study and to address key questions about how long results can be maintained and how late in the course of cognitive decline reversal is possible.\nJames E. Galvin, M.D., M.P.H., a professor of clinical biomedical science at FAU's Charles E. Schmidt College of Medicine and a professor in the Christine E. Lynn College of Nursing, who was not involved in the study, agreed that personalized approaches such as the MEND protocol are the types of approaches needed for this disease going forward.\nBredesen noted, too, that the MEND protocol was suitable for patients in the early stages of Alzheimer's.\nBut even if MEND is effective, the program is complex and difficult to follow.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story quotes Bredesen saying \u201chis team has a couple of larger trials planned to confirm or refute the results in the current study and to address key questions about how long results can be maintained and how late in the course of cognitive decline reversal is possible.\u201d\nBut the story could have served readers better if it had pressed Bredesen for specifics about when these trials might occur. The complexity of the protocol, the expense and time involved and questions about insurance coverage all make availability\u00a0a very key question.", "answer": 0}, {"article": "Many pregnant women who have symptoms of depression worry that taking antidepressants might harm their unborn babies -- so they stop taking their medications, say researchers at the Stanford University School of Medicine.\nThe study included 150 pregnant women diagnosed with major depressive disorder.\nSome received depression-specific acupuncture treatments, others had needles inserted in acupuncture points not known to relieve depression, and a third group received massage therapy.\nAcupuncture might be a useful alternative, they say, because a study of pregnant women shows that the procedure works in reducing depressive symptoms better than other non-pharmacological techniques.\n\"I hope that people will respect the rigorous methodology used in this blinded, randomized, controlled trial and accept the result,\" study researcher Deirdre Lyell, MD, assistant professor of obstetrics and gynecology at Stanford University School of Medicine, says in a news release.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The acupuncture treatment appears to have been customized for depression. Depression-specific acupuncture is not likely to be available everywhere. The story didn\u2019t tell us. ", "answer": 0}, {"article": "To find out more about the activities of EULAR, visit: http://www.\n\"Findings from our study have shown that adopting a TNFi dose reduction strategy can still meet this objective, with no compromise on symptom control for the patient and offering a more cost-effective option by substantially reducing the high drug costs associated with TNFi maintenance therapy.\"\nIn some cases however, patients maintained a clinical response after stopping the TNFi altogether.\nOf the 47 patients who reduced, then stopped their TNFi after six months, 45% (21/47) succeeded without flaring, and their final mean DAS28 score after stopping treatment was 2.2, demonstrating low disease activity.\nThe OPTTIRA study is a 12-month multicentre, randomised controlled trial designed to evaluate if reducing TNFi doses (of either etanercept or adalimumab) caused a loss of response in RA patients who were also receiving a synthetic DMARD.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although availability is not explicitly addressed, the release does note that\u00a0biologic drugs are used as an add-on treatment option to methotrexate, which suggests that they are approved and available. This is true in the U.S., and also seems to be true in the UK, where the study originated.", "answer": 1}, {"article": "How (Study Design): This was a randomized clinical trial (RCT).\nAuthors: Andrew K. Chang, M.D., M.S., of Albany Medical College, Albany, New York, and coauthors\n\nResults: After 2 hours pain was less in all participants, without any important difference in effect between the four groups.\nStudy Limitations: The results apply only to pain after two hours.\nAbout 1 in 5 patients required additional medication to control their pain.\nThe following related elements also are available on the For The Media website:\n\nThe editorial, \"Opioid vs Nonopioid Acute Pain Management in the Emergency Department,\" by Demetrios N. Kyriacou, M.D., Ph.D., Senior Editor, JAMA, Chicago; Northwestern University Feinberg School of Medicine, Chicago.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not address this explicitly, but it is fairly clear from the context that all of these painkillers are already clinically available.", "answer": 1}, {"article": "Professor Norman Ratcliffe said, \"There is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.\nThe research team is now looking to fund a full clinical trial.\nOur aim is to create a test that avoids this procedure at initial diagnosis by detecting cancer in a non-invasive way by smelling the disease in men's urine.\nAfter further sample testing the next step is to take this technology and put it into a user friendly format.\nThe research team used a gas chromatography sensor system called Odoreader that was developed by a team led by Professor Probert and Professor Norman Ratcliffe at UWE Bristol.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that this screening tool is still in development and that the developers are seeking funders to expand the testing.", "answer": 1}, {"article": "\"If someone said to my husband, 'I know this has been a rough road for you, and a big impact on your sex life, but if she stays on it another five years.\nThese drugs are slightly more effective than tamoxifen, although they don't work before menopause, Litton says.\nTamoxifen is the only hormonal option for women before menopause, Litton says.\nGray noted that tamoxifen has risks.\nDoctors saw no increase in strokes, which has long been a concern with tamoxifen, Gray says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability is well-established in the story.", "answer": 1}, {"article": "She said: \"My first thought on diagnosis was that I wanted to survive, I gave little thought to long term or late effects of treatment.\nThe results will be crucial to future large scale trials looking at optimum care for anal cancer patients.\nThe study worked with data on more than 10,000 patients, examining whether current methods of checking if anal cancer has spread to lymph nodes are giving experts an accurate picture of survival rates.\nBy identifying a unique phenomenon, these results will be taken into account by future work and ultimately could lead to better diagnosis of tumour stage and thus better treatment.\n\"These findings will help us to better understand how anal cancer patients should be treated, ultimately improving survival rates and quality of life.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that the study is likely to have an impact on treatment plans of future patients, but we never learn what that impact might precisely be, and what next steps might be taken by the oncology treatment community to use the findings and correct misleading statistics on diagnosis and treatment.", "answer": 0}, {"article": "About the Alzheimer's Research and Prevention Foundation\n\nThe Alzheimer's Research and Prevention Foundation is a non-profit organization dedicated to reducing the incidence of Alzheimer's disease by conducting clinical research and providing educational outreach about the lifestyle changes that can help prevent Alzheimer's disease.\nThe full text of \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\" can be accessed at http://content.iospress.com/articles/journal-of-alzheimers-disease/jad142766.\nWhile preliminary studies have suggested a link between meditation, a sense of spirituality or faith and the risk of Alzheimer's disease, the article's author, Dharma Singh Khalsa, M.D., states that a cultivation of higher levels of psycho-social well-being, such as independence, resilience and life purpose represents \"an important new frontier that deserves further research as it is freely available to anyone, anytime, anywhere.\"\nKhalsa's article highlights the principles and practices of this 12-minute meditation, with corresponding SPECT scans showing how it successfully activates the posterior cingulate gyrus, an important region of the brain that helps regulate memory and emotional function.\n\"We've been studying the impact of meditation on memory for more than 20 years, and are as encouraged as we've ever been on its powerful role in maximizing brain health,\" said Khalsa, president and medical director of the Alzheimer's Research and Prevention Foundation and a clinical associate professor of integrative medicine at the University of New Mexico School of Medicine.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release establishes that the Kirtan Kriya meditation technique is currently in use. Instructions can be found on the Alzheimer\u2019s Research and Prevention Foundation\u2019s website.", "answer": 1}, {"article": "In a statement, Dr. Lesley Russell, Cephalon's chief medical officer, said:\n\nThe most common side effects for Nuvigil, include diarrhea, headache, insomnia and nausea, according to Cephalon.\nBut the regulators weren't buying the evidence put forward by the company to prove the medicine's benefits in treating travelers' \"excessive sleepiness\" outweighed its risks.\nThe regulators just gave a second thumbs down to drugmaker Cephalon's application to sell Nuvigil as a remedy for jet lag.\nFinally, it should be said that the Drug Enforcement Administration has made Nuvigil a federally controlled substance because it has the potential for abuse and dependence.\nSo who wouldn't want a pill to fight the doldrums caused by skipping too many time zones too fast?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that Nuvigil is already approved for some uses but not for jet lag.", "answer": 1}, {"article": "Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys.\n\"High-risk neuroblastoma can be resistant to traditional therapy, and survival can be poor.\nThis research is an excellent example of the collaboration between Nemours Children's Hospital and the University of Central Florida.\n\"This shows that nanoparticles can be an effective delivery vehicle for cancer drugs,\" said Professor Sudipta Seal, who directs of UCF's NanoScience Technology Center and Advanced Materials Processing Analysis Center, and is a collaborator on the study.\nOverall, the nano-therapeutic treatments showed a more pronounced effect in MYCN-amplified cells, which are traditionally more resistant to drug therapies.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The beginning of the news release makes it sound like this technology is available at your local hospital. Later in the report, however, the news release makes it clear that this study was conducted in cell lines in a laboratory. Researchers hope to expand this research to animal models and direct the curcumin nanoparticles to tumor sites, the news release adds.\nWe feel this is enough for a Satisfactory rating.", "answer": 1}, {"article": "These studies have been done with people, but other promising research has only been done with lab animals so far. In one 2009 study in the Journal of Medicinal Food, tart cherries helped fat rats. Not our favorite role models perhaps, but the obese beasties' risk of Type 2 diabetes and heart disease were reduced significantly, and parallel studies are now in the works with members of our own species, says lead author E. Mitchell Seymour: \"There are some interesting and potentially exciting results on the horizon. Stay tuned.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of cherries is not in question.", "answer": 2}, {"article": "Dying tumor cells release cell-free DNA (cfDNA) into the blood, where cancer-specific methylation changes can be detected at any disease stage.\nI am therefore very encouraged with the results of this study, showing that EpiCheck has the ability to identify both non-small-cell and small-cell lung cancer at early stages, with a high level of sensitivity and specificity.\nSuch promising results combined with the simplicity of the test, could allow us to detect lung cancer at the early stages and hence improve 5-year survival from about 15% to about 50-70%.\n\"Furthermore, these results were validated prospectively in an independent cohort.\n\"Clearly, we must establish screening programs for lung cancer worldwide.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll give this a marginal satisfactory for giving readers a hint that the test is not yet available when it says the company is \u201clooking forward to begin extensive clinical trials in the US,\u00a0Europe\u00a0and\u00a0China\u00a0next year, in order to get the test to the market as soon as possible at an affordable price.\u201d That tells us that the test is likely years away from being commercialized \u2014 if ever.", "answer": 1}, {"article": "In nonblood-based tumors, such as melanoma, only about one-half of patients have T cells in their tumors that can be harvested, and only about one-half of those harvested cells can be grown.\nFor the clinical trial, the Johns Hopkins team enrolled 25 patients with newly diagnosed or relapsed multiple myeloma, although three of the patients relapsed before they could receive the MILs therapy.\nNoonan says the research team has used these data to guide two other ongoing MILs clinical trials.\nBorrello notes that several U.S. cancer centers have conducted similar experimental treatments, known as adoptive T cell therapy, but says the Johns Hopkins team is believed to be the only one to use MILs.\nThe researchers say the trials also have shed light on new ways to grow the MILs.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release points out that \u201cseveral U.S. cancer centers have conducted similar experimental treatments\u201d but adds that Johns Hopkins is the only one using the MIL cells. It also points to several other ongoing clinical trials at Hopkins that build on the findings of this small study. Using the terms \u201cpilot\u201d and \u201cexperimental,\u201d the release signals that availability is very limited.", "answer": 1}, {"article": "Oxytocin is produced naturally in the bodies of humans and animals.\nResearchers who were not involved in the study praised the work, saying the findings were promising and could lead to the first effective treatment for the central problems affecting people with autism.\nWhile cautioning that more research is needed on children and additional patients to make sure oxytocin is safe and effective, advocates for families with children with autism welcomed the findings.\nAlthough more research is needed to confirm and explore the findings, the results are the latest in a growing body of evidence indicating that the hormone could lead to ways to help people with the often devastating brain disorder function better.\nBecause previous research has indicated that some people with autism might have abnormally low levels of oxytocin, conducting tests to identify those people and administering them the hormone might help as well, said Karen Parker, an assistant professor of psychiatry at Stanford University School of Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The treatment, oxytocin nasal spray, is not commercially available as such and is not approved for this indication. These facts are not explicitly noted in the story. However, the story does note the apparent use of the drug for this purpose by some, without noting the lack of FDA approval of the product. Although this could have been much more clear, the story does make it clear that some people are getting the stuff somehow.\u00a0 It would have been relatively easy to explain how. \n", "answer": 1}, {"article": "Drugs such as aspirin and ibuprofen treat inflammation, the body's immune response to infections or pathogens.\nLooking to the future\n\n\"Evidence at this point suggests that cytokine antagonists -- which are much more specific in their anti-inflammatory effects than drugs like aspirin -- show modest antidepressant effects in individuals with depression and increased inflammation,\" said Raison, who did not participate in in Khandaker's research.\nTheir potential side effects also must be investigated, Khandaker said, adding that \"we and other research groups from both sides of the Atlantic are currently planning and conducting such randomized control trials.\"\nKhandaker said that five of the 20 studies focused on one specific cytokine.\nThese trials form the basis of the Cambridge research that was published Tuesday in the journal Molecular Psychiatry\n\nBased on previous findings about depression, the team looked at the side effects experienced by patients given anti-cytokine drugs in 20 separate studies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that more research needs to be done before the new anti-inflammatories could be prescribed as a direct therapy for depression, and\u00a0one of the researchers notes that it\u2019s too early to prescribe them for depression.\u00a0We\u00a0also liked that the story mentioned other diseases that are treated by anti-inflammatories.", "answer": 1}, {"article": "Dr. Scolnick has not seen the results of the Novartis trial, but was told of them and concluded that if the drugs work in fragile X, \u201cthere\u2019s nothing to say that they won\u2019t work in some cases of broader autism-spectrum disorders.\u201d\n\nThe roots for the Novartis results began in 1982 when Stephen T. Warren, then a graduate student in genetics at Michigan State University, was looking for a job and something to research.\nAnd despite going to some of the best hospitals in the country, four years would pass before Andy\u2019s condition was properly diagnosed.\nSure enough, mice, fish and fruit flies that through genetic engineering were made to have fragile X seemed to become normal when given Dr. Bear\u2019s compound.\nThe discovery was front-page news around the world, and experts predicted that widespread fetal testing and therapies were in the offing.\nThe results of the trial were something of a jumble until Novartis scientists noticed that patients who had a particular, undisclosed biological trait improved far more than others.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no question that the\u00a0drug discussed in the story is years away from being available and may never get approved by the FDA.\u00a0\u00a0", "answer": 1}, {"article": "An electromagnetic wave then agitates water molecules in the surrounding tumor tissue, producing friction and heat that eventually destroy the tumor.\nU.S. researchers say the technique certainly shows promise.\nIn a preliminary study, the technique, called microwave ablation, eliminated lung tumors in 19 of 28 patients.\nThe procedure, which costs about $2,000, takes about an hour, and the patient is typically kept overnight in the hospital for observation.\nBut more patients have to be followed for far longer to see if they stay in remission, they say.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers are really only told that this was a study in Italy and that \u201cUS researchers say the technique certainly shows promise.\u201d The story does not make it clear whether a patient could expect to have this technique performed in a typical hospital or how many clinical trials are currently ongoing involving microwave ablation.", "answer": 0}, {"article": "\u201cIt\u2019s a bit like with mobile phones.\nThe ultimate goal is to create a device that can check patients blood day and night, during and between meals, and deliver insulin as required.\nThe new system, which involves patients wearing a matchbox-sized monitor and a similar-sized pump with a tube to deliver insulin into the body, also halved the amount of time blood sugar dropped to worrying or dangerous levels, they said.\nHe said the results were \u201can important stepping stone\u201d toward bringing an artificial pancreas to the commercial market, but predicted several years yet of refinement before it could be used day and night by patients in normal life.\n\u201cThese devices could transform the management of type 1 diabetes, but it is likely to be a gradual process,\u201d Roman Hovorka of Cambridge, who led the research, said in a telephone interview.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story suggests that it will be several more years before the \"new device\" supposedly tested in this study will be available on the commercial market. But as the competing story in the New York Times makes clear,\u00a0the\u00a0researchers in this study did not test a \"device\"\u00a0per se\u00a0but rather an algorithm that could hypothetically be used to link up a glucose monitor and an insulin pump to create\u00a0a new device for automatically managing blood glucose.\u00a0The\u00a0suggestion that there is a device\u00a0already in testing\u00a0exaggerates the level of progress that\u00a0has been made and will give readers a false sense\u00a0as to\u00a0how close\u00a0this product is to\u00a0becoming a reality.\u00a0 ", "answer": 0}, {"article": "UT Southwestern physicians provide care in about 80 specialties to more than 100,000 hospitalized patients, 600,000 emergency room cases, and oversee approximately 2.2 million outpatient visits a year.\nAnd the exercise needs to be performed four to five times a week.\nThe new study appears in Circulation, a journal of the American Heart Association.\nTwo to three times a week was not enough, the researchers found in an earlier study.\nPrevious studies from Dr. Levine's research program have shown substantial improvements in cardiac compliance in young individuals after a year of training, but surprisingly little change if the training was started after age 65.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The intervention in question here is aerobic exercise. Widely available.", "answer": 2}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nWith the rate of diabetes increasing dramatically worldwide, many individuals will be at risk for vision loss from diabetic eye complications and DME is a major global health concern,\u201d says Jennifer K. Sun, M.D., M.P.H., a member of the study research team and writing committee, and an Investigator in the Section on Vascular Biology, an ophthalmologist in Beetham Eye Institute at Joslin and an Assistant Professor at Harvard Medical School.\nPhysicians now have robust data to help them counsel patients and make informed decisions regarding treatment options,\u201d says study co-author Lloyd P. Aiello, M.D., Ph.D., Professor of Ophthalmology at Harvard Medical School, Director of Joslin\u2019s Beetham Eye Institute, co-head of Joslin's Section of Vascular Cell Biology, and founding chair of the DRCR Network.\nIn light of these positive results, \u201cit is more important than ever for patients with diabetes to be evaluated on a regular basis for eye disease and receive treatment promptly once indicated as we now have excellent success in treating patients with DME,\u201d says Dr. Aiello.\n\u201cThe results clearly remove any doubts about anti-VEGF drugs\u2019 efficacy in treating DME.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Two of these drugs are available specifically for macular edema and the third, although used off label, is also available in proper form and dosage. The story makes this clear. Since\u00a0availability also relates to cost and who will pay for it \u2014 especially this era of high deductible health plans \u2014 some comment about the increased availability of the lower-cost option would not have been inappropriate.", "answer": 1}, {"article": "In addition to Chang, other authors on the all-MD Anderson study include: Stephen Hahn, M.D., Ritsuko Komaki, M.D., Pamela K. Allen, Ph.D., Zhongxing Liao, M.D., Steven H. Lin, M.D., Ph.D., Daniel Gomez, M.D., James Welsh, M.D., Melenda Jeter M.D., James Cox, M.D., Michael O'Reilly, M.D., Ming Li, M.D.\nOf note, said Chang, no patients developed the most severe, or grade five, toxicities, as seen in patients who receive standard of care.\nIn contrast, the historical OS rate with standard of care concurrent chemotherapy and traditional radiation was 16 months at the time when the study was designed.\nWhile the study's survival, recurrence rates and toxic effects are still favorable when compared to rates associated with the most advanced traditional photon radiation therapy, intensity modulated radiation therapy (IMRT), technology to diagnose and stage the disease, as well all treatment modalities have significantly improved.\nToxic effects of treatment in both the acute and late settings also were analyzed.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "How widespread the treatment options are is not clear. The release does clearly state that this was done at a single site. However, it would have been relatively easy to state that there are only a small number of facilities that can deliver proton beam therapy.", "answer": 0}, {"article": "For that reason, UV devices are often used for sterilization \u2014 for medical equipment in hospitals, for example, or drinking water for backcountry campers.\n\u201cThere has been no way of killing viruses in the air in public spaces, and this is an approach that may solve that problem.\u201d\n\u201cSo up until now, they\u2019re only really practical when people aren\u2019t around,\u201d say Brenner.\n\u201cThink about doctor\u2019s waiting rooms, schools, airports and airplanes\u2014any place where there\u2019s a likelihood for airborne viruses.\u201d And unlike the flu vaccine, he says, far-UVC light is likely to be effective against all airborne microbes, including newly emerging virus strains.\n\u201cIf you have a lamp over the surgical site that can sterilize the air, you can prevent the bacteria from floating down and contaminating the wound.\u201d\n\nBrenner can\u2019t predict how long it might take for these lamps to be commercially available, but he says he\u2019s \u201cextremely optimistic\u201d about the technology.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is a just passing satisfactory\u2013it\u2019s implied that the product is not available yet, because the story mentioned the lead author \u201cis working with a company to develop a commercially available version of the lamp.\u201d", "answer": 1}, {"article": "\"So I don't need any chemotherapy, I don't need any radiation.\nThat's because standard chest X-rays too often can't spot it until it's too late, reports.\nIt turned out to be cancer.\nIf Lazarus hadn't had any studies, says Dr. Harvey Pass of the NYU Medical Center in New York, the tumor would have grown causing pain, cough bleeding and maybe not have been able to be surgically removed.\nA chest X-ray showed nothing suspicious.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if lung cancer screening is widely available.", "answer": 0}, {"article": "An analysis of 106 randomized trials involving more than 250,000 patients examined the effects of newer angiotensin receptor blockers (ARBs) and older angiotensin-converting enzyme (ACE) inhibitors.\nAccording to the new analysis, published online Jan. 4 in the Mayo Clinic Proceedings, the only difference between the medications is that ARBs are more easily tolerated.\nHowever, when trials were conducted at similar times, one drug was not more effective than the other, the findings showed.\nAlthough ACE inhibitors were developed 10 years earlier, both types of drugs showed similar effects in the analysis, challenging previous findings that suggest ACE inhibitors have greater benefits.\n\"This is the first time that we have a clear and consistent message from the three buckets of trials of ACE inhibitors and ARBs, all of which show that there is no outcome difference between the two agents, except for better tolerability of ARBs,\" Bangalore said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that both ACE inhibitors and ARBs have been around for years, the latter since the year 2000 and the former for at least a decade earlier, so readers can easily understand this story is about currently available drugs", "answer": 1}, {"article": "MORE: The IUD Answer: Why The Best Form of Birth Control is the One No One Uses\n\nThe researchers followed 237 women who were using an implant like Implanon and Nexplanon and 263 women using the Mirena hormonal IUD.\nThe benefit of being able to use the implant and IUD for a longer period of time is that it could reduce costs for individuals and insurance.\nThe study is still ongoing, and the researchers plan to recruit up to 800 women and ultimately test whether the IUDs and implants were effective for up to three years after their current FDA-approved duration.\nThe study is still continuing, and it could be quite a long time before any changes to clinical recommendations are considered.\nTwo highly effective contraceptives\u2014the intrauterine device (IUD) and the implant\u2014actually last much longer than they are currently recommended, according to new research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that these birth control choices are widely available in the United States. The story could have noted that access to LARCs in developing countries may be limited, and that using these devices longer might help with that problem.", "answer": 1}, {"article": "The found the chronic poor sleepers became sick more often: those who slept for five hours or less each night were 4.5 times more likely to catch the cold than people who slept seven hours or more.\nThe study is unique because it used objective measures to show that poor sleep habits make people more vulnerable to a cold virus, says Badr, who was not involved in the research.\nIn fact, sleep was more important than any other factor, including age, stress or income level, in predicting who would get sick after being exposure to the cold virus, the researchers say.\nThe actigraphy measured sleep in a much more accurate way than information researchers get from self-reports, he says.\nParticipants who slept for six hours each night did only slightly better -- they were 4.2 times more likely to develop a cold than the seven-hour-a-night folks.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Of course, not everyone can find six or more hours in a day to sleep. But the study did not address this.", "answer": 0}, {"article": "A systematic review of C.B.T.\nImprovements like mine and those reported in the study bring sleep statistics for those with insomnia quite close to those without it.\nMy experience is consistent with these averages.\nAnd as studies show, it works better than drugs.\nThis further emphasizes the point that many insomniacs aren\u2019t that different from normal sleepers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We are not given a lot of detail, but consider both CBT and medications to be widely available.\u00a0This is particularly true because the writer makes it clear that an online program was helpful (rather than requiring a specialized clinic or provider).", "answer": 1}, {"article": "To place an electronic embedded link to this study in your story: This link will be live at the embargo time: http://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2016.4219\n\nIn a study published online by JAMA Surgery, Daniel E. Hall, M.D., M.Div., M.H.Sc., of the Veterans Affairs Pittsburgh Healthcare System and University of Pittsburgh, and colleagues examined the effect of a Frailty Screening Initiative (FSI) on death and complications by comparing the surgical outcomes of patients treated before and after implementation of the FSI.\nIt also suggests the potential to improve postoperative survival among the frail through systematic administrative screening, review, and optimization of perioperative plans.\nOn the basis of this review, clinicians from surgery, anesthesia, critical care, and palliative care were notified of the patient\u2019s frailty and associated surgical risks; if indicated, perioperative plans were modified based on team input.\n\u201cThis study reveals the feasibility of facility-wide frailty screening in elective surgical populations.\nThis study included 9,153 patients (average age, 60 years) from a Veterans Affairs medical center who presented for major, elective, noncardiac surgery.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear if the screening index and action plans for surgery among frail patients are readily available for other institutions to use.", "answer": 0}, {"article": "(Adenoids, glands at the roof of the mouth, are often removed along with tonsils.)\nThere aren't strong guidelines regarding the use of tonsillectomy to treat sleep disorders, so the doctors reviewed the evidence to see whether the surgery outperformed so-called watchful waiting -- monitoring the situation.\nTo qualify for the surgery, a child must have many recurring throat infections within a short span of time or severe sleep disturbances, said Dr. Sivakumar Chinnadurai, a co-author of the reviews.\nThe study results showed \"there may be new evidence that supports expanding the criteria and opening up the procedure to more individuals,\" said Dr. Alyssa Hackett, an otolaryngologist with the New York Eye and Ear Infirmary of Mount Sinai in New York City.\nStill, Chinnadurai and Hackett warned against automatically choosing the surgery for every sore throat.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that \u201cTonsillectomy is the third most common surgery performed on U.S. children.\u201d\u00a0 We know tonsillectomies are readily available through the health care system, if needed.", "answer": 1}, {"article": "I was absolutely terrified because I saw my mom go through it, and I saw how much pain she was in,\" Barletta says.\nThat's still the standard procedure for the 50,000 Americans who are operated on each year for this problem.\nLaPook notes that it will be a few more years before this procedure is widely available.\nHe says it's in the final stages of testing at about 30 hospitals around the country.\nDr. Saibal Kar performed the innovative procedure on Barletta at Cedars Sinai Hospital in Los Angeles.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This piece did include a disclaimer at the end that this procedure is done only in a limited number of centers and is investigational at this time.\n\u00a0", "answer": 1}, {"article": "On average, using probiotics reduced a bout of diarrhea by more than a day, and reduced the risk of a prolonged diarrhea episode -- four days or more -- by 59 percent.\nStephen Allen, a pediatrician at Swansea University in the United Kingdom who lead the review, tells Shots that probiotics were effective in almost all the studies, which had more than 8,000 participants total, his team evaluated.\nAllen says that since the original review, there's been increasing interest in probiotics and, therefore, more research.\nEven so, Allen says more research is needed to determine the specific strains of bacteria that are most effective.\nAmong the different bacteria tested were L. acidophilus, S. boulardii, and L. casei, which occur naturally or are added to products like supplements, yogurt, miso, soy milk and some juices.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story listed several different types of products containing \u2018probiotics\u2019, indicating that they may normally be found in some products while others represent supplemented products.", "answer": 1}, {"article": "The average daily dose of insulin dropped almost 39 percent after 12 weeks for the group with some beta cell function and 25 percent in those with no beta cell function, suggesting that the group with no beta cell function now produced insulin.\nBoth experts said the treatment appears safe, with no risk of rejection.\nThis was an initial clinical trial designed to test for safety.\nThis treatment could potentially be useful in other autoimmune diseases, such as lupus and rheumatoid arthritis.\nAlthough the treatment didn't wean anyone off insulin completely, average blood sugar levels dropped significantly, which would reduce the risk of long-term complications.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that this type of treatment is not yet available and no claims were made about a timetable for reaching the market.", "answer": 1}, {"article": "Visit the U.S. Centers for Disease Control and Prevention for more on obesity.\nThe balloon treatment will be available starting in January, but the cost hasn't been announced, Pryor said.\nSix months after the balloons were removed, nearly 90 percent maintained the weight loss they achieved during treatment, Pryor said.\nThe results were also presented at a medical meeting in May.\nThe device, called the Obalon Balloon System, was approved in September by the U.S. Food and Drug Administration.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that the Obalon balloon was approved by the FDA in September and will be available in January 2017.", "answer": 1}, {"article": "They were then followed till they were about 10 years old, according to the study.\n\"We observed that early dietary intervention [with extensively hydrolyzed formula] decreased the frequency of diabetes-associated autoantibodies, which are markers of an ongoing disease process, by about 50 percent by the age of 10 years,\" said the study's lead author, Dr. Michael Knip, a professor of pediatrics at the Hospital for Children and Adolescents in Helsinki, Finland.\nHow the highly hydrolyzed formula might reduce the risk of developing diabetes-predictive antibodies is unknown, but the researchers speculated that it might contribute to reduced gut permeability or changes in gut microflora, among other things.\nAccording to Knip, the take-home message from the study is that \"it is possible to reduce considerably the initiation of the diabetes disease process in at-risk children in a simple and safe way: weaning to an extensively hydrolyzed formula.\"\nPeople who have two or more type 1 antibodies have between a 50 and 100 percent risk of developing type 1 diabetes, according to background information in the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Various infant formulas are available when weaning infants from breast milk, or when breastfeeding is not an option.\u00a0 The story discusses research that compared regular infant formula with a type of extensively hydrolyzed formula that helps break down proteins during digestion.\nThis formula may not be available to some parents due to greater expense.", "answer": 0}, {"article": "Psoriasis is a skin condition that causes patches of skin redness and flaking.\nSiliq is also approved with a Medication Guide to inform patients of the risk of suicidal ideation and behavior, and that because Siliq is a medication that affects the immune system, patients may have a greater risk of getting an infection, or an allergic or autoimmune condition.\nBecause of the observed risk of suicidal ideation and behavior, the labeling for Siliq includes a Boxed Warning and the drug is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Siliq REMS Program.\n\"Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today\u2019s approval provides patients with another treatment option for their psoriasis,\" said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nNotable requirements of the Siliq REMS Program include the following:\n\u2022 Prescribers must be certified with the program and counsel patients about this risk.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since Siliq is a new psoriasis drug that just received FDA approval, it is clear that it is now coming onto the market. The news release states the drug will only be available through a restricted program called the Siliq Risk Evaluation and Mitigation Strategy. The release then lists the requirements of the program, which include patient counseling, signing of a patient-prescriber agreement form and pharmacy certification.\nWe feel this is good enough for a Satisfactory rating here.", "answer": 1}, {"article": "A new study offers a fresh strategy for treating patients suffering from both coronary artery disease and heart failure, afflictions linked to poor quality of life and high risk of death that affect as many as two million Americans.\n\nThe 1,212-patient study calls into question the need for immediate bypass surgery in these patients\u2014an approach commonly recommended by doctors. The study, called Stich, found benefits in treating people with medication only, and in treating people with a combination of bypass surgery and medication....", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the range of treatments studied by the authors are widely available.", "answer": 1}, {"article": "Toxins produced by bacteria, such as salmonella, can severely harm the digestive system by damaging nerves critical to healthy gut function.\nThe new blood tests identify the presence and amount of specific antibodies reacting to the toxins.\nThe tests, created by Mark Pimentel, MD, director of the GI Motility Program and Laboratory, confirm when a patient has developed IBS because of food poisoning, a major cause of the disorder.\n\"With these new blood tests, many patients will now be able to proceed right to therapy for their condition.\"\n\"The fact that we can now confirm the disease through their blood, not their head, is going to end a lot of the emotional suffering I have seen these patients endure.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release clearly states that the tests are already on the market.", "answer": 1}, {"article": "Graphic artist Colleen Kelly decided in 2000 that she had nothing to lose by enrolling in an experimental study of VNS.\nThe device has also attracted attention on Capitol Hill, where the Senate Finance Committee has spent two years looking into decision-making at the FDA.\nThe pocket-watch-sized device is billed as \"a pacemaker for the brain,\" the newest cutting-edge treatment for as many as 4 million adults whose severe depression is not relieved by psychotherapy, drugs or even shock treatments.\nAnother 7,000 people -- aided by a network of nurses hired by Cyberonics, the Houston-based manufacturer of the device -- are seeking approval from their insurance companies for the $25,000 operation.\nA report by Harvard Pilgrim Health Care, an influential mental health insurer in Boston, called it \"experimental, investigational and unproven.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains how many Americans have had the device implanted (more than 550 since FDA approval), how many are waiting insurance company approval (7,000), and how many Washington, DC-area physicians have been trained in the use of the device (more than 3,700). ", "answer": 1}, {"article": "Where did this Ron DeSantis come from? Florida\u0092s governor surprises everyone but himself.\n\nA month into his term, Gov. Ron DeSantis has shattered assumptions that he would govern exclusively from the right. He has drawn unexpected praise from Republicans and Democrats.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discussed several approaches to treatment. \u00a0It focused on liver transplantation and indicated that livers were in short supply. \u00a0It indicated that weight loss was a means to stop progression of the condition and may be an adequate approach. \u00a0It also mentioned that there are a number of clinical trials being conducted for treatment of cirrhosis.", "answer": 1}, {"article": "Individuals with panic chronically hyperventilate, even when not experiencing a panic attack.\nFreespira is both easy to use and effective.\nTheir first product, Freespira, is an FDA-cleared treatment for individuals suffering from panic disorder, panic attacks and other symptoms of panic.\nThis latest study, conducted as part of the VITAL Program at Allegheny Health Network in Pennsylvania, also demonstrated a 50% reduction in healthcare costs in patients with panic symptoms 12 months after being treated with Freespira.\nEarly data from a fifth study reported on Freespira treatment for patients with Post-Traumatic Stress Disorder (PTSD).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The device has apparently been commercially available for many years but this is not specifically addressed in the release.", "answer": 0}, {"article": "[3] Quote direct from author and cannot be found in text of Article.\nBut until now, information on the prognostic value of grip strength was limited, and mainly obtained from select high-income countries.\nThe study, published in The Lancet, also found that grip strength is a stronger predictor of death than systolic blood pressure, and the authors suggest that it could be used as a quick, low-cost screening tool by doctors or other healthcare professionals to identify high-risk patients among people who develop major illnesses such as heart failure and stroke.\nLoss of grip strength is unlikely to lie on a single final common pathway for the adverse effects of ageing, but it might be a particularly good marker of underlying ageing processes, perhaps because of the rarity of muscle-specific diseases contributing to change in muscle function.\"\nFurther research is needed to establish whether efforts to improve muscle strength are likely to reduce an individual's risk of death and cardiovascular disease.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release implies that the type of dynamometer used to assess grip strength in this study is widely available, but a clearer statement about availability, especially in low-income countries, would have made the release better.", "answer": 1}, {"article": ".\nThis new radionuclide drug shows strong binding to the protein PSMA and is readily and safely taken up by malignant PSMA-positive tumors.\nResults of the human study showed that imaging was effective for the evaluation of metastatic prostate cancer, and subsequent therapy resulted in a drop in prostate-specific antigen levels from 38.0 to 4.6 nanograms per milliliter.\nThis phase was followed by a first-in-human clinical trial of both imaging and therapy in a single person.\nOptions for these patients are few, and they come with substantial adverse effects.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This release does eventually make it clear that only one patient has been tested, that this is very preliminary work and that the drug is not available.", "answer": 1}, {"article": "The single-color digital PCR test offers several advantages over other methods of circulating tumor DNA analysis, compared to next-generation targeted sequencing and fluorescent probe-based digital PCR assays.\nAccording to the report in The Journal of Molecular Diagnostics, this highly sensitive test has the potential to be personalized to recognize mutations unique to any individual cancer.\nIn contrast, molecular tests like the one we have developed will enable patients to be monitored at every visit, and thus have the potential for quickly tracking cancer growth and spread.\nThe three patients, whose samples did not show elevated cancer DNA, were undergoing active treatment at the time of collection.\nThe report describes the use of the test to analyze samples from six patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the release that the test is not widely available and is only just now being developed.", "answer": 1}, {"article": ".\nOur mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.\n\"Many would have predicted that tendon healing is inflammation-linked,\" said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal, \"but that the anti-inflammatory roles of TSCs could be so potent, and so amplifiable, is a striking finding.\"\n\"Our findings represent an important foundation for the development of a new treatment that would regulate overwhelmed inflammation for tendon ruptures and tears, tendonitis, tendinopathy, and other tendon injuries and diseases.\"\nSubmit to The FASEB Journal by visiting http://fasebj.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t provide any indication when a therapy might be available \u2014 if ever. This very preliminary basic research has\u00a0a long research path ahead.", "answer": 0}, {"article": "Since 2013, the American Academy of Pediatrics endorses a wait-and-see approach, seeking to let more earaches heal on their own without antibiotics.\nMoms have flooded https://www.facebook.com/ClearPop with glowing testimonials for this simple drug-free solution that:\n\n-can be given along with analgesics or antibiotics.\nCLINICAL TESTS\n\nChildren diagnosed with Acute Otitis Media, or ear infection, consumed the xylitol and Vitamin C-based product in pediatric offices.\nWALNUT CREEK, Calif., Jan. 15, 2016 /PRNewswire/ -- Child screams from the pain of earache; exhausted parent ventures to drugstore in wee hours to find\u2026nothing.\nFounder and Chairman: Dr. Scott Morehouse, scott@clearpop.com\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release\u00a0states clearly where the product is available.", "answer": 1}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the vaccination is already in use for people over age 65.\u00a0 ", "answer": 1}, {"article": "6 Kowdley KV, et al.\nThis ongoing, open-label study enrolled 90 children aged between six and 11 years with chronic HCV, mostly genotype 1 (n=86).\n\"These data establish the use of the oral direct-acting antivirals as an important treatment option in HCV-infected children aged six to 11 years old.\"\nNo children discontinued the study due to side effects or had a severe or life-threatening adverse event related to the study drug.\n\"This study is a breakthrough for the management of children aged six to 11 years old with Hepatitis C, demonstrating that the new DAA regimen is highly efficacious and, more importantly, safe in this group of HCV-infected children\", said Prof Frank Tacke, University Hospital Aachen, Germany, and EASL Governing Board Member.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t explain what hurdles, such as FDA approval, are required to make this therapy available to children.", "answer": 0}, {"article": "The monthly, peer-reviewed Journal of Clinical Sleep Medicine is the official publication of the American Academy of Sleep Medicine, a professional membership society that improves sleep health and promotes high quality, patient-centered care through advocacy, education, strategic research, and practice standards.\nThe improvements were more robust in those who were adherent to PAP therapy.\nResults show that there were significant and clinically meaningful improvements in general quality of life and sleep-related quality of life measures after the initiation of PAP therapy for sleep apnea.\nThe study involved 2,027 patients with sleep apnea who began PAP therapy between Jan. 1, 2010, and Dec. 31, 2014.\nThe American Academy of Sleep Medicine previously identified quality of life as one of three sleep apnea outcome measures that clinicians can track to optimize care for adult patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release made no mention of the availability of CPAP machines, even though they are easy to find. As mentioned above, however, their cost can often be prohibitive. It would have been helpful if the news release discussed low-cost options, especially since they mentioned that the intervention seemed to have less effect for lower socio-economic subgroups.", "answer": 0}, {"article": "\u201cMy nightmare was that nothing would be different from the placebo group, and there would be nothing of interest to talk about,\u201d he says.\nIn what the authors describe as the largest and longest study of resveratrol in people with mild to moderate Alzheimer\u2019s disease, there\u2019s encouraging news that the component, which is found in red wine, grapes and dark chocolate, may keep the disease from progressing.\nTurner says the findings don\u2019t suggest that red wine is a cure for Alzheimer\u2019s.\nI think resveratrol is an engaging target that\u2019s very interesting and could be pharmacologically manipulated to develop a treatment.\u201d\n\nMORE: Red Wine Not That Healthy After All, Study Shows\n\nThe resveratrol group showed no change in the levels of a protein that builds up in the brains of Alzheimer\u2019s patients.\nThe amounts of resveratrol in the purified doses that the participants took were extremely high and beyond those found on the market currently \u2014 around what would be contained in about 1,000 bottles of red wine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does make clear that this study does not mean people should begin drinking red wine or taking resveratrol supplements to combat Alzheimer\u2019s disease, and notes that more studies are needed to determine benefit or to create drugs for clinical use.", "answer": 1}, {"article": "TMS treats conditions by delivering brief, powerful magnetic field pulses that stimulate nerve cells in the brain.\nThe approval was based on a clinical trial of 100 people with obsessive-compulsive disorder, where roughly half received treatment with TMS and the other half had a sham treatment that didn't deliver the electromagnetic pulses.\nOverall, 38% of the people with the real device responded to the treatment compared with 11% of those with the sham device.\nPeople who were taking medication for OCD continued to do so for the trial.\nA response was considered a 30% reduction in the Yale-Brown Obsessive Compulsive Scale (YBOCS) score, which is used to measure the severity of OCD symptoms.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers will understand that the TMS device is now commercially available for OCD, although the article does not offer any information about facilities that offer the treatment.", "answer": 1}, {"article": "\"It was the end of our world and we didn't know why, because this child was a perfectly normal healthy child, Never had a problem,\" Miller says.\nFDA said it asked the company to dig deeper into its data on Singulair for evidence of possible links to suicide.\nTheir labeling does not contain language about suicide.\nThe agency recently began notifying the public earlier about possible safety issues.\nFDA said it is reviewing a handful of reports involving mood changes, suicidal behavior and suicide in patients who have taken the popular allergy and asthma drug.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The segment makes clear that Singulair is widely used. ", "answer": 1}, {"article": "Send your questions to Julia via the submission form or @juliaoftoronto on Twitter.\nAcetaminophen, after all, is the most popular over-the-counter painkiller worldwide.\nThis is why aspirin has its place as a protective agent against strokes and heart attacks for people at a higher risk.\n(Ibuprofen also has potential side effects; more on that below.)\nBetween 1998 and 2003, acetaminophen was the leading cause of acute liver failure in the US.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s obvious from the story that all of the medications profiled have been widely available without a prescription for many decades. Aspirin, a modified version of salicyclic acid, was created by a Bayer chemist in 1897; acetaminophen followed in 1956; and ibuprofen in 1962.", "answer": 1}, {"article": "FDA approves first drug aimed at women with inherited breast cancer\n\nU.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.\n\nThe Food and Drug Administration on Friday approved AstraZeneca PLC\u2019s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the FDA just approved the drug for patients with inherited BRCA gene mutations who have undergone chemotherapy, and that it\u2019s been on the market since 2014 for ovarian cancer. Presumably, that means it\u2019s widely available.\nBut, it then mentions that a \u201ccompanion\u201d blood test was also just approved to look for these genes. It\u2019s not clear if this test specifically will be required before women receive the new drug, and if that test will be available right away.", "answer": 0}, {"article": "\u201cWe still found the same thing,\u201d Brandt said.\nBy 2018, those fats will be nearly eliminated from American diets, they add.\n\u201cHere we find on a population level when we restrict them, it benefits society by reducing heart attacks and strokes.\u201d\n\nThe findings suggest the FDA\u2019s action will lead to health benefits across the country, he added.\nStill, the study can\u2019t say the trans fat restrictions caused fewer admissions in those counties.\nWhile admissions for heart attacks and strokes fell after 2002 in all the counties, the drop was more substantial in those that enacted trans fat restrictions, the authors found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes where trans fats are now restricted (New York City) and explains that restrictions will become nationwide in 2018.\nBy 2018, those fats will be nearly eliminated from American diets, they add.", "answer": 1}, {"article": "\"So we thought, 'What if we change that by injecting the therapy drug into the metastatic lesions and change the microenvironment of the cancer?'\nThe research showed that using the immunotherapy drug pembrolizumab and the experimental agent SD-101, a sequence of nucleic acids that mimics a bacterial infection, altered the microenvironment around the tumor in a way that enabled the immune system to more effectively attack the cancer.\nThe study highlights the need for more research into combination therapies like this one, because many people with cancer do not respond to immunotherapy or experience a reoccurrence of their tumors after treatment.\nThe research was an early-stage study, conducted to test the side effects and best dosage of a potential new combined therapy, and the findings were published today in the journal Cancer Discovery.\nThe results of the study suggest that the combination of pembrolizumab and SD-101 could provide an alternative treatment for people with melanoma whose tumors have not responded or would be unlikely to respond to other therapies.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes clear that this is an experimental therapy that is not yet available. The release could have been improved by noting that Keytruda was approved by the FDA for use in metastatic melanoma in 2015.", "answer": 1}, {"article": "A new study shows women who drank the equivalent of a beer or small glass of wine each day were less likely to develop chronic diseases like heart disease, cancer, and diabetes as they got older compared to nondrinkers or those who drink four or more drinks at one time.\nResearchers then analyzed health status information collected after the women turned 70.\nIn the study, researchers looked at the effects of drinking alcohol at midlife on the risk of diseases commonly associated with aging in a group of 13,894 women enrolled in the Nurses' Health Study.\nSept. 6, 2011 -- \"A drink a day keeps disease away\" may be the new motto for middle-age women hoping to age gracefully.\nAfter taking into account other factors that might affect health and disease risk, like smoking, researchers found women who drank light or moderate amounts of alcohol were less likely to develop chronic diseases as they aged.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of alcoholic drinks is not in question.", "answer": 2}, {"article": "Of those, 2,148 had taken lithium, 1,670 had used valproate, 1,477 had been on olanzapine and 1,376 had taken quetiapine.\nThe researchers\u2019 analysis bore out one of the two main criticisms of lithium, but found the other to be baseless.\n\u201cDifferent people will find that different treatments help with managing their mental health problems.\nIt is seen by patients, and some psychiatrists, as a dangerous drug.\nPeople rightly have suspicions about it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the four drugs studied are indeed available.", "answer": 1}, {"article": "In other words, they are the precursors to muscle, fat, bone, and tendon tissue.\n\u201cThe recovery some patients showed was not just minimal, it was significant,\u201d said Steinberg, who has researched stem cell therapies for more than 15 years.\nAnd in a clinical trial testing the technique, researchers found injections can safely improve patients' motor function.\nRecently, researchers from the Stanford University School of Medicine have made it their mission to improve these outcomes.\nFurthermore, there were no life-threatening effects linked to the procedure used to administer them.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that the investigators are planning a larger trial of the procedure.", "answer": 1}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that bone density screenings are common and done in a variety of ways.", "answer": 1}, {"article": "Migraines are characterised by an intense, throbbing headache, sensitivity to light and noise, nausea, vomiting, low energy, and visual disturbances.\nA new migraine drug that can halve the length of attacks has been hailed as \u201cthe start of real change\u201d in how the condition is treated.\n\u201cThis is probably the first example of a migraine preventing drug that was rationally designed, rather than serendipitously found,\u201d he added.\nLead investigator Prof Peter Goadsby, from King\u2019s College hospital, London, said: \u201cStrive \u2026 represents an incredibly important step forward for migraine understanding and migraine treatment.\u201d\n\nThe findings, reported in the New England Journal of Medicine, clearly showed that blocking the CGRP pathway could reduce the impact of migraine, he said.\nPhase three trial data on nearly 1,000 patients showed that it typically cut between three and four \u201cmigraine days\u201d per month.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of\u00a0erenumab was never clear established. Yes, one could deduce that a Phase III trial was just reported, so it probably isn\u2019t on the market yet. But the story never said that. In addition, there can still be a troubled road between completion of a Phase III trial and approval. For a story that trumpeted \u201cincredibly important step forward\u2026.start of a real change (in treatment)\u2026first drug in 20 years proven to prevent migraine attacks\u201d and other superlatives, the story could have helped readers see through one trial\u2019s optimism to explain what pitfalls might lie ahead.", "answer": 0}, {"article": "After adjusting for non-modifiable stroke risk factors (such as age and family history), researchers found stroke risk among women who breastfed their babies was on average:\n\u2022 19 percent lower in women who had breastfed for up to six months.\nThe Association has strict policies to prevent these relationships from influencing the science content.\nThe WHI was supported by the National Health, Lung, and Blood Institute.\nHowever, because the Women's Health Initiative is large, researchers were able to adjust for many characteristics, and the effects of breastfeeding remained strong, Jacobson said.\nThis is among the first studies to examine breastfeeding and a possible relationship to stroke risk for mothers, as well as how such a relationship might vary by ethnicity.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release requests that pregnant women make breastfeeding part of their \u201cbirthing plan\u201d and to breastfeed for at least six months to receive the most benefits. It\u2019s assumed readers know that breastfeeding is an available option unless there are medical or lifestyle barriers.", "answer": 1}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n\nThe story mentions that chronic fatigue syndrome has \u201cno effective treatment.\" It also states that \"some doctors are already prescribing drugs approved for HIV\u00a0for fatigue patients.\" We\u2019ll give the story a satisfactory score on this criterion, although we have mixed feelings about the message it left with readers. \n", "answer": 1}, {"article": "Imaging equipment makers such as GE Healthcare, Siemens, Philips and Toshiba Medical Systems are working to develop low-dose CT scanners.\nThat is a lot of excess deaths.\u201d\n\nCT scans give doctors a view inside the body, often eliminating the need for exploratory surgery.\nThe findings, published in the Archives of Internal Medicine, add to mounting evidence that Americans are overexposed to radiation from diagnostic tests, especially from a specialized kind of X-ray called a computed tomography, or CT, scan.\nBut CT scans involve much higher radiation dose than conventional X-rays.\nRedberg, who wrote a commentary on the studies, said U.S. doctors\u2019 enthusiasm for the tests has led to an explosion in their use that is putting patients at risk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly CT scans are available. The story does a good job of describing the\u00a0dramatic increase in the use of CT scanning in the past 20 years.", "answer": 1}, {"article": "BLOOMINGTON, Ind.\n\"While concerns about prescribing medications to treat ADHD that have the potential for abuse are understandable, this study provides further evidence that the use of these medications is not associated with increased risk of substance use problems in adolescence or adulthood,\" Quinn said.\nThe results, based upon nearly 3 million people with ADHD in the United States, are reported in the American Journal of Psychiatry.\n\"The results also highlight the importance of careful diagnosis and compliance with treatment.\"\nThis research was supported in part by the National Institutes of Health's National Institute of Mental Health and National Institute on Drug Abuse.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release did not discuss the availability of ADHD medications. However, these are commonly prescribed medications that are widely available in the US and Europe.", "answer": 2}, {"article": "She also said the survival benefit was observed across key subgroups, including those with varying levels of a protein called PD-L1 that can help tumors avoid detection.\nAnalysts from Baader Helvea said its announcement completes an \u201calready robust\u201d set of data for regulators who now must sign off on Tecentriq\u2019s use as an initial treatment of lung cancer.\nWhile Roche did not provide specific overall survival data, the headline result helps its bid to catch up to better-established immunotherapies from Merck and Bristol-Myers Squibb and its shares rose about 1 percent in early trading.\n\u201cWe continue to see Roche efficacy more than sufficiently competitive to grant a 43 percent market share in the indication, translating in 4.9 billion francs Tecentriq peak sales and 1.2 billion francs in 2018,\u201d Baader\u2019s Bruno Bulic said.\nThe Basel-based company, which had previously announced Tecentriq, Avastin and chemotherapy had reduced the risk of disease progression or death, said on Monday it hopes for a quick approval from authorities for the cocktail.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "For better or worse, the story makes clear that Roche intends to submit the new data to regulators right away.", "answer": 1}, {"article": "More than 1 in 20 American, ages 12 and older, are struggling with depression, according to the Centers for Disease Control and Prevention.\nWhile the results are striking, this technology is not a guarantee of complete resolution of depressive symptoms or medication side effects.\nFinally, her psychiatrist, suspicious that her body might process medication differently than most, recommended a genetic test to see why Ellis wasn\u2019t responding to the prescriptions.\n\"We look at it as a tool to help the physician.\nIt's unclear how many patients have had to stop or chosen to stop treatment for depression due to side effects.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It says Avera is \u201coffering\u201d the test and that there are others used in hospitals. It\u2019s pretty clear that they are available, at least to some people. This is sufficient for a Satisfactory rating, though the story would have been stronger if it had explained this more thoroughly.", "answer": 1}, {"article": ".\nThese additional results of the Systolic Blood Pressure Intervention Trial (SPRINT) appear in the current online issue of the Journal of the American Medical Association (JAMA).\nWHO: Lawrence Fine, M.D., chief of the Clinical Applications and Prevention Branch at NHLBI and a co-author of the study, is available to comment on the findings and implications of this research.\nWHAT: NIH-supported researchers are reporting additional details about a widely-publicized study that linked a systolic blood pressure target under 120 mm Hg (millimeters of mercury) with reduced cardiovascular disease and a lower risk of death.\nThe new analysis singles out adults aged 75 and older and confirms that those with high blood pressure also benefit from the lower pressure target similar to the larger group studied in the earlier research: non-diabetic adults aged 50 and older.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Without naming the drugs used in the study, the release leaves us to assume the ready availability of any of the medications. It would have been easy for the news release to indicate that the study did not use any investigational agents \u2014 just widely available blood pressure medicines. Unfortunately, the release doesn\u2019t explain that, thus netting an unsatisfactory rating.", "answer": 0}, {"article": "For older people who fracture a hip, the prognosis is grim: a third or more die within a year and only about 1 in 5 return to their pre-injury level of function.\n\nA new approach to care could mean it doesn\u2019t have to be that way.\n\nMore hospitals are putting hip fracture patients on a fast track from the emergency room to the operating room,...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear how widely available this fast-track surgery option is in general, but this is\u00a0something you\u2019d want to know if you were a patient/caregiver trying to find some place that offers this.", "answer": 0}, {"article": "Error code 404. Something went\n\nwrong and we can't seem to find\n\nthe page you're looking for.\n\n Report a broken link.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says \u201ca small but growing number of hospitals offer microsurgical attempts at relief from lymphedema.\u201d It also mentions that it\u2019s sometimes covered by insurance.", "answer": 1}, {"article": "The Ohio State University, Northern Arizona University and Arizona State University researchers found a parallel between behavioral symptoms of autism and gastrointestinal distress, and improvements to both after fecal transplant.\nChildren without autism were used as a control for the study, the news release reported.\nOne of the study\u2019s limitations is its small size, and researchers cautioned that families should not try to replicate the treatment at home.\nResearchers also asked the children\u2019s doctors to perform pre- and post-diagnostic evaluations, which suggested lasting benefits.\n\u201cWe have to be mindful of the placebo effect, and we have to take [the findings] with a grain of salt,\u201d Matthew Sullivan, an associate professor of microbiology at The Ohio State University, said in the release.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have been more explicit about how this treatment is nowhere ready for widespread use, but it did indicate the study was small, and it included the warning that \u201cresearchers cautioned that families should not try to replicate the treatment at home.\u201d", "answer": 1}, {"article": "\u201cBut we do expect the patients to have significant improvements in mobility.\u201d\n\nNearly 30,000 Asterias\u2019s shares were traded by 12:30 p.m.\nThe therapy, AST OPC-1, is the first product derived from human embryos to be tested on humans.\nMenlo Park, California-based Asterias expects to release complete safety data from the first half of the study later in the year.\nData showed that the severity of the spinal injury was reduced in the first patient and two other patients were able to resume their rehabilitation programs soon after being injected with the stem cells.\nThe early study tested the benefits of a smaller dose of 2 million stem cells that are tuned to develop into nerves.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The Reuters story makes it fairly clear that this therapy is in its early phases. The article describes how Asterias acquired the therapy from another research company in 2013 and how this announcement has been the first about the research in more than two years.", "answer": 1}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article provides no information\u00a0about the availability of the new tests, either temporally or geographically.", "answer": 0}, {"article": "5 Million Have Heart Failure in U.S.\n\nMore than 5 million Americans have heart failure, which occurs when the heart muscle loses its ability to pump enough blood throughout the body.\nThe new device was about that accurate at differentiating between severe and less severe heart failure patients.\nThe device has gas sensors that detect various odorous molecules in sweat.\nThe goal of the project is to develop a simple, accurate, noninvasive, and reproducible method for early identification of chronic heart failure, he tells WebMD.\n\"Still, much more work is needed before we will know if the electronic nose will make it to the clinic,\" says Ruschitzka, who moderated a news briefing to discuss the findings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this device is still in the early phases of testing.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story reported on a new method for detecting clots that can cause cardioembolic strokes and a new method for treating massive deep vein thrombosis in the leg.\u00a0 The story could have emphasized that neither of these is routinely used.\u00a0 Although the story did say that they are new, readers could easily be confused about this application of MRI because they may be familiar with the use of MRI for other diagnostic procedures.\nThe story also included no information about the availability of the Angiojet, the medical device discussed.\u00a0 While the story made it sound like this was something new, this device has had FDA approval since 1999.\u00a0 http://www.fda.gov/cdrh/pdf/P980037b.pdf", "answer": 0}, {"article": "Renal vein surgery can often be managed with minimally invasive laparoscopic techniques, but this is not typically advisable for an IVC thrombus (a fibrous clot), which is surgically far more complex with potentially fatal complications that can occur in the course of removing the thrombus and reconstructing the IVC.\nNone of the operations was converted to open surgery and all but two patients were ambulatory on the day of or day after surgery.\nEach surgeon performed between one and ten procedures for IVC tumor thrombi which ranged from one to 11 cm in length on preoperative imaging.\n\"Using robotic nephrectomy, our complication rate and lack of mortalities compare reasonably with open series with no grade III to V complications, according to the Clavien system, in any patient, including no deaths.\"\nThe first known procedure using robotic surgery of renal tumors with IVC tumor thrombi was performed in 2008.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that robot assisted minimally invasive surgery is available in many institutions and has become the mainstay for prostatic surgery. The news release does point out that the surgeons who participated in the story were experienced with the technique. While implied in some parts of the release and downplayed in others, this is not a surgical procedure that should be undertaken lightly.", "answer": 1}, {"article": "\u201cThe length of statin use, both greater than six months and greater than five years of use was associated with reduction in colorectal cancer risk.\u201d\n\nThe group of statins that showed the greatest effect in reducing risk are classified as lipophilic: atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Altocor, Altoprev, Mevacor), pitavastatin (Livalo), and simvastatin (Zocor),\n\nColorectal cancer is the third most common type of cancer in the U.S.; 102,900 new cases of colon cancer are diagnosed in men and women every year, and about 39,670 new cases of rectal cancer are diagnosed annually.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted.\u201d\n\nThis study was presented at a medical conference.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n\u201cObservational studies have suggested that long-term use of statins is associated with reduced risk of several cancers, including breast, prostate, lung, pancreas and liver,\u201d says Samadder in the news release.\nAlso, the longer patients used statin drugs, the greater their reduction in risk for colorectal cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There isn\u2019t any question about the availability of statins.\u00a0", "answer": 1}, {"article": "Animal studies have suggested that omega-3 fatty acids may have anti-cancer effects, but the results from human epidemiological studies have been inconclusive.\nThe analysis appears online in The American Journal of Clinical Nutrition.\nA new study has found that consumption of omega-3 fatty acids from fish is associated with a reduced risk for one kind of colon polyp, but only in women.\n\u201cThis is more evidence to suggest that omega-3s are beneficial and may have anti-inflammatory action helpful in reducing cancer risk,\u201d said the lead author, Dr. Harvey J. Murff, an associate professor of medicine at Vanderbilt.\nAfter controlling for age, race, body mass index, smoking and other factors, the researchers found that women in the highest fifth for omega-3 consumption \u2014 those who consumed three or more servings of fish a week \u2014 were 33 percent less likely than women in the lowest fifth to have adenomatous polyps, a type likely to become cancerous.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of fish is not currently in question, although its future availability has been questioned considering the rate we are overharvesting wild stocks. Stories that don\u2019t critically evaluate these kinds of studies might conceivably contribute to the problem.", "answer": 2}, {"article": "Those who consumed above the median amount of caffeine for this group (with an average intake of 261 mg per day) were diagnosed at a lower rate than those who fell below the median (with an average intake of 64 mg per day).\nThe findings come from participants in the Women's Health Initiative Memory Study, which is funded by the National Heart, Lung, and Blood Institute.\nIntake was estimated from questions about coffee, tea, and cola beverage intake, including frequency and serving size.\nThe researchers adjusted for risk factors such as hormone therapy, age, race, education, body mass index, sleep quality, depression, hypertension, prior cardiovascular disease, diabetes, smoking, and alcohol consumption.\nDriscoll and her research colleagues used data from 6,467 community-dwelling, postmenopausal women aged 65 and older who reported some level of caffeine consumption.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release quotes the principal investigator saying, essentially, that caffeine is an easy thing to add to the diet and is widely available.\u00a0True enough.", "answer": 1}, {"article": "Jet lag occurs when sleeping and waking patterns are not synchronized to circadian rhythms.\nZeitzer's latest study, published Monday in the Journal of Clinical Investigation , could make treatment easier by providing light exposure during sleep, before the trip, without changing or interrupting your routine.\nThis time around, researchers tried to further optimize the process.\nThe treatment \"exploits biology in the eye\" to speed up the brain's adjustment to time changes, he said.\nThere's still more testing to be done before the technique is available to the public.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that the light therapy wasn\u2019t ready for prime time yet.", "answer": 1}, {"article": "Plaque psoriasis is an autoimmune condition that causes cells to build up on the surface of the skin, forming thick red patches and flaky silver-white scales.\nHe adds that the data on Siliq suggests that it is not only effective in treating psoriasis, but that many patients experience improvement in anxiety and depression, as well.\nThe drug also comes with a more serious warning, as well.\nValeant Pharmaceuticals, Siliq\u2019s manufacturer, says that pricing information is not available at this time, and expects to begin sales and marketing in the second half of 2017.\nBecause of these events, the labeling for Siliq will include a Boxed Warning, and the drug will only be available through a restricted REMS (Risk Evaluation and Mitigation Strategy) program.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story deals with the availability issue by saying it \u201cexpects to begin sales and marketing in the second half of 2017.\u201d", "answer": 1}, {"article": "Personal sound amplification products (PSAPs) are less-expensive, over-the-counter devices not specifically labeled for hearing loss treatment, but some are technologically comparable with hearing aids and may be appropriate for mild to moderate hearing loss.\nAccording to nationally representative estimates, less than 20 percent of adults with hearing loss report hearing aid use.\nNicholas S. Reed, Au.D., of the Johns Hopkins School of Medicine, Baltimore, and colleagues compared five of these devices (costs, approximately $350 to $30) with a conventional hearing aid (cost, $1,910) among 42 adults (average age, 72 years) with mild to moderate hearing loss.\nA limitation of the study was the modest number of participants.\nThe researchers found that the change in accuracy in speech understanding from unaided to aided varied by device.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of both hearing aids (\u201cthrough a licensed professional\u201d) and PSAPs (\u201cover-the-counter\u201d) is clearly established.", "answer": 1}, {"article": "\"Historically, patients with chronic systolic heart failure were considered too frail to exercise and, through the late 1980s, avoidance of physical activity was a standard recommendation,\" the study's authors write.\nThe study authors say there's a usually a strong relationship between depression and heart failure, so the fact that tai chi helped cheer people up was an especially good sign.\nThe movement is tai chi, an ancient martial art turned exercise, and a study out this week in Archives of Internal Medicine says it may help people suffering from heart failure feel better about life.\nIn a quality of life questionnaire the researchers gave out, those who practiced tai chi scored significantly higher than those who hadn't been doing the movement.\nThe researchers recruited 100 people with the chronic condition from heart clinics in Boston.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story suggests that tai chi is widely practiced in China,\u00a0but\u00a0it didn\u2019t discuss the\u00a0availability of classes in the United States. While it isn\u2019t hard to find trained instructors in\u00a0a city such as Boston, where the study being\u00a0covered was conducted, readers from rural areas might find it difficult to locate classes led by someone experienced in this form of therapy.\u00a0\u00a0Someone with\u00a0heart failure may also have trouble finding transportation to a class. The story should have mentioned these issues.", "answer": 0}, {"article": "For further information, please contact:\nThe previously unrecognized PMS/PMDD benefit of PS Plus came about when 2,000 volunteers received and consumed Lipogen's PS Plus for brain health and stress management.\n\"We also have begun an ongoing, double-blind, randomized, placebo-controlled clinical trial with daacro GmbH, Trier, Germany, to learn more how Lipogen's formulation can help alleviate PMS and PMDD symptoms.\n\"Realizing the significance of this discovery, it encouraged us to further explore a product line for women's health utilizing Lipogen's proprietary phospholipid ingredients.\"\nAccording to the Medical University of South Carolina, current available treatments include SSRIs and other drug treatments that treat side effects and can cost from US$60.00 - US$535.00 per month.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t mention when or in which formulation the supplement might be available in the U.S. market, even though the release is introducing the supplement to a U.S. audience.", "answer": 0}, {"article": "\u201cThis is a first step,\u201d he said, \u201cand all these applications will require further work.\u201d But, he added, if the testing is successful, \u201cI think it will be very popular.\u201d\n\nThe idea for second skin originated more than a decade ago when Dr. R. Rox Anderson, a professor of dermatology at Harvard Medical School, was approached by Living Proof, which had been working on a polymer to be used as a hair product.\nOne of the first applications, said Dr. Barbara A. Gilchrest, a dermatology professor who is part of the research team, was on undereye bags, a condition that plagues so many middle-aged and older people.\n\u201cWe were looking for safety, spreadability, adherence, and the right kind of mechanical and optical properties.\u201d\n\nThe \u201cskin\u201d can last for more than a day.\nThe skin still has to be able to breathe through this stuff.\nand a scientific founder of Living Proof, started searching for something that would work.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story establishes\u00a0these as preliminary studies, adding that they haven\u2019t obtained enough data yet to submit the product for FDA approval.", "answer": 1}, {"article": "What does that mean for men today?\nWASHINGTON \u2014 Prostate cancer is more likely to be life-threatening if the man's PSA level rose rapidly during the years before he was diagnosed, says a new study that may help change how PSA tests are used.\nPerhaps more important, it suggests a more in-depth evaluation of the common blood tests could better predict who needs aggressive treatment and who has a slower-growing tumor that may be OK to monitor instead.\nA study with just 20 deaths is far too small to prove the value of PSA velocity, cautioned Dr. Durado Brooks, a prostate specialist with the American Cancer Society.\nThe study is far from proof that making health decisions based on so-called PSA velocity can really save lives.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states this latest study could help change how PSA (or prostate specific antigen) tests are currently used, implying that PSA testing is available.\u00a0 The article also states that many doctors already use PSA velocity to help determine which men need biopsies, also implying that the use of PSA velocity, a particular way to use PSA testing, is available\u00a0although not necessarily used by all at this time.\u00a0 ", "answer": 1}, {"article": "A similar decrease in brain volume was found with some anti-amyloid immunotherapy trials,\" Turner adds.\nTurner, who treats patients at MedStar Georgetown University Hospital, cautions that the findings cannot be used to recommend resveratrol.\nTurner says the study also found that resveratrol was safe and well tolerated.\nAn \"investigational new drug\" application was required by the U.S. Food and Drug Administration to test the pure synthetic (pharmaceutical-grade) resveratrol in the study.\nGUMC was one of 21 participating medical centers across the U.S.\n\nFurther studies, including analysis of frozen blood and cerebrospinal fluid taken from patients, are underway to test possible drug mechanisms.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states resveratrol is not available commercially in the 1-gram oral form.", "answer": 1}, {"article": "It\u2019s quite unusual,\u201d she added.\nIt was of tremendous magnitude in the last [blood] draw.\u201d\n\nThe next step will be to take bone and CT scans to see if the cancer is disappearing internally as well as externally, which Young will receive in a couple of weeks.\n\u201cEven the marks where it was climbing up my neck are all gone.\u201dFurther study needed\n\nWhat Diamond is hoping for now is funding for a full clinical trial so that he can test the combination in advanced triple-negative breast cancer patients who test positive for p53.\nReferred to City of Hope by her physician at Davis, she began responding to the experimental treatment right away, Yuan said, her skin tumors disappearing and the latest biopsies showing no cancer.\nIt\u2019s quite a dramatic response.\u201d\n\nSo dramatic, in fact, that Yuan refers to Young as her \u201cmiracle patient.\u201d\n\n\u201cThis in some ways is pretty unprecedented.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While part of the drug combination (pembrolizumab) mentioned in the release is available, the experimental p53 vaccine appears to only be available through a City of Hope researcher. There was mention of a desire to create clinical trials open to \u201cto women from all over the country\u201d but that\u2019s far from certain.\nIt\u2019s clear from the release that City of Hope is trying to recruit new patients and generate pharmaceutical sponsors. Many patients with this type of breast\u00a0 cancer may get the impression from the release that they, too, can receive this \u201cremarkable\u201d treatment if they make their way to the hospital. But how practical is their open invitation?\u00a0Experimental therapies like the vaccine are not covered by health insurance.", "answer": 0}, {"article": "You've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n\nThe female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\n\n* Dr. Harry Fisch, clinical professor of urology and reproductive medicine at Weill Cornell Medical College, and chief corporate officer of Veru Healthcare, which distributes FC2\n\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job of handling the nuances of availability.", "answer": 1}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story makes it clear that statins are widely available. ", "answer": 1}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the company that makes the Oncotype DX test, Genomic Health, plans to start selling the test early next year. \nBut the reader has no idea how realistic this prediction is. Given the economic self-interest of the source, the story should have indicated what regulatory or commercial barriers the company faces before it can bring the test to market.\u00a0 ", "answer": 0}, {"article": "\u201cThe men in the highest group have a risk of cancer on biopsy of about 70% and those in the lowest group have a risk of cancer of about 20%,\u201d says Tomlins.\nThe company that developed the test, Gen-Probe, helped to pay for the study, and several authors said they had a personal financial interest in the technology.\nThe two tests together appeared to generate both sensitive and specific results.\nSensitive means it\u2019s unlikely that the test would miss a case of cancer.\n\u201cThe real key is using this or any test to help drive decisions,\u201d says Jones, who was not involved in the research, \u201cIf it helps me to know who to biopsy or not biopsy, that\u2019s massively valuable information.\u201d\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that the test was in development.", "answer": 1}, {"article": "\"It wasn't a huge, overwhelming difference,\" O'Neil said.\nO'Neil said because Weight Watchers has centers all over the country, including sites in small towns with limited or no medical facilities, its program could help meet this need if combined with diabetes-specific counseling.\nWhile the Weight Management Center has a high success rate at helping patients lose weight to fight diabetes, many people with the condition don't live near a specialized program and need help that's readily available.\nThe Weight Watchers study is new evidence of what that help might include when it comes to a side effect of weight gain: Type 2 diabetes.\nThat's why he said it was important for MUSC to be involved in the study, which was funded by a grant from the commercial weight loss program, Weight Watchers.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that because Weight Watchers \u201chas centers all over the country, including sites in small towns with limited or no medical facilities, its program could help meet this need if combined with diabetes-specific counseling.\u201d We\u2019ll give this a marginal satisfactory because while there are, indeed, many Weight Watchers centers, the program will be too costly for many.", "answer": 1}, {"article": "But not a whole lot.\nThe review, published by the Cochrane Collaboration, an international organization that evaluates medical research, also shows that people taking the supplements tended to have milder symptoms.\nIn 2009, the U.S. Food and Drug Administration warned Matrixx Initiatives to stop selling its widely used supplement Zicam after more than 130 users reportedly lost their sense of smell.\nAn earlier Cochrane review from 1999 didn\u2019t find any signs that zinc supplements would work.\nThey add it is currently unclear what dose and particular formulation of the supplement will be most helpful.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story, unlike the WebMD story, made it clear exactly what the review looked at and where those supplements could be found. \u201cSingh said the side effects of zinc lozenges, which can be bought for a few dollars in any drug store in the U.S., come down to bad taste and some cases of nausea. The researchers did not study nasal zinc remedies, however.In 2009, the U.S. Food and Drug Administration warned Matrixx Initiatives to stop selling its widely used supplement Zicam after more than 130 users reportedly lost their sense of smell.\u201d", "answer": 1}, {"article": "Curcumin is an ingredient found in the common spice turmeric.\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\nIn this report, use of curcumin after burns and scalds were found to reduce the severity of the injury, lessen pain and inflammation, and improve healing with less than expected scarring, or even no scarring, of the affected skin.\nThis study published reports that topical curcumin gel applied soon after mild to moderate burns and scalds appears to be remarkably effective in relieving symptoms and improved healing of the affected skin.\nBased on studies that she has done both in the laboratory and in patients over 25 years, the key to curcumin's effectiveness on burns and scalds is that it is a natural inhibitor of an enzyme called phosphorylase kinase.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release discusses the uses of curcumin for gastronomical and cosmetic purposes \u2014 many of which go back centuries. It adds that medicinal aspects of curcumin have been studied intensely for various human ailments in recent years.\nIt\u2019s also clear from the news release that patients have the option of taking curcumin tablets orally for \u201cother conditions.\u201d A quick Google search shows that curcumin tablets are available for purchase at health food stores.\nFor these reasons, we give the news release a Satisfactory rating.", "answer": 1}]